Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
APC2	APC2	A120	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
APC	APC	A120	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
tumour	tumour	T560	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
controls	control	C536	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
Wnt	Wnt	W530	NN	I-NP	O
signalling	signalling	S254	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
by	by	B000	IN	B-PP	O
forming	form	F652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
with	with	W300	IN	B-PP	O
glycogen	glycogen	G425	NN	B-NP	O
synthase	synthase	S532	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
3beta	3beta	B300	NN	I-NP	O
(	(	0000	(	O	O
GSK	GSK	G200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3beta	3beta	B300	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
axin	axin	A250	NN	B-NP	O
/	/	0000	SYM	B-NP	O
conductin	conductin	C532	NN	I-NP	O
and	and	A530	CC	I-NP	O
betacatenin	betacatenin	B323	NN	I-NP	O
.	.	0000	.	O	O

Complex	Complex	C514	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
induces	induce	I532	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
degradation	degradation	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
betacatenin	betacatenin	B323	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
colon	colon	C450	NN	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
betacatenin	betacatenin	B323	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
it	it	I300	PRP	B-NP	O
binds	bind	B532	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
and	and	A530	CC	O	O
activates	activate	A231	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
Tcf	Tcf	T210	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
reviewed	review	R130	VBN	B-VP	O
in	in	I500	IN	B-PP	O
[	[	0000	(	B-NP	O
1	1	0000	CD	I-NP	O
]	]	0000	)	O	O
[	[	0000	(	O	O
2	2	0000	CD	B-NP	O
]	]	0000	)	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
and	and	A530	CC	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
homologues	homologue	H542	NNS	I-NP	O
.	.	0000	.	O	O

Mammalian	Mammalian	M545	JJ	B-NP	O
APC2	APC2	A120	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
closely	closely	C424	RB	B-ADVP	O
resembles	resemble	R251	VBZ	B-VP	O
APC	APC	A120	NN	B-NP	O
in	in	I500	IN	B-PP	O
overall	overall	O164	JJ	B-NP	O
domain	domain	D500	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
functionally	functionally	F523	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
two	two	T000	CD	B-NP	O
SAMP	SAMP	S510	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
conductin	conductin	C532	NN	B-NP	O
.	.	0000	.	O	O

Like	Like	L200	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
,	,	0000	,	O	O
APC2	APC2	A120	NN	B-NP	O
regulates	regulate	R243	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
active	active	A231	JJ	B-NP	O
betacatenin	betacatenin	B323	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Tcf	Tcf	T210	NN	I-NP	O
complexes	complex	C514	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
demonstrated	demonstrate	D523	VBN	B-VP	O
using	use	U252	VBG	B-VP	O
transient	transient	T652	JJ	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activation	activation	A231	NN	I-NP	O
assays	assay	A200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
/	/	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
colon	colon	C450	NN	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
APC2	APC2	A120	NN	I-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19p13	19p13	P000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	LS	B-LST	O
.	.	0000	.	O	O

APC	APC	A120	NN	B-NP	O
and	and	A530	CC	I-NP	O
APC2	APC2	A120	NN	I-NP	O
may	may	M000	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
have	have	H100	VB	I-VP	O
comparable	comparable	C516	JJ	B-NP	O
functions	function	F523	NNS	I-NP	O
in	in	I500	IN	B-PP	O
development	development	D141	NN	B-NP	O
and	and	A530	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
English	English	E524	JJ	B-NP	O
and	and	A530	CC	I-NP	O
North	North	N630	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
HNPCC	HNPCC	H512	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
:	:	0000	:	O	O
origin	origin	O625	NN	B-NP	O
,	,	0000	,	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
sex	sex	S200	NN	B-NP	O
specific	specific	S121	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
,	,	0000	,	O	O
origin	origin	O625	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
non	non	N500	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
HNPCC	HNPCC	H512	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
A	A	A000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
at	at	A300	IN	B-PP	O
nt943	nt943	N300	NN	B-NP	O
+	+	0000	SYM	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
disrupts	disrupt	D261	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
from	from	F650	IN	B-PP	O
MSH2	MSH2	M200	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	RB	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
so	so	S000	RB	B-VP	O
far	far	F600	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
initially	initially	I534	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
33	33	0000	CD	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
analysed	analyse	A542	VBN	B-VP	O
from	from	F650	IN	B-PP	O
eastern	eastern	E236	JJ	B-NP	O
England	England	E524	NNP	I-NP	O
,	,	0000	,	O	O
more	more	M600	RBR	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
to	to	T000	TO	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
52	52	0000	CD	B-NP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	I-NP	O
English	English	E524	JJ	I-NP	O
HNPCC	HNPCC	H512	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
analysed	analyse	A542	VBN	B-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
MSH2	MSH2	M200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
(	(	0000	(	O	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
separately	separately	S163	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Newfoundland	Newfoundland	N153	NNP	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
England	England	E524	NNP	B-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Newfoundland	Newfoundland	N153	NNP	B-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	States	S320	NNP	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
haplotype	haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
microsatellite	microsatellite	M262	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
MSH2	MSH2	M200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
.	.	0000	.	O	O

Within	Within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
English	English	E524	NNP	I-NP	O
and	and	A530	CC	I-NP	O
US	US	U200	NNP	I-NP	O
families	family	F542	NNS	I-NP	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
little	little	L340	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MSH2	MSH2	M200	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
flanking	flanking	F452	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
(	(	0000	(	O	O
CA5	CA5	C000	NN	B-NP	O
and	and	A530	CC	O	O
D2S288	D2S288	D200	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Newfoundland	Newfoundland	N153	NNP	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
within	within	W350	IN	B-PP	O
Newfoundland	Newfoundland	N153	NNP	B-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
reported	report	R163	VBN	B-VP	O
by	by	B000	IN	B-PP	O
others	other	O362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
MLH1	MLH1	M400	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Finnish	Finnish	F520	JJ	B-NP	O
HNPCC	HNPCC	H512	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
calculated	calculate	C424	VBD	B-VP	O
age	age	A200	NN	B-NP	O
related	related	R430	JJ	I-NP	O
risks	risk	R200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
,	,	0000	,	O	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
endometrial	endometrial	E535	JJ	I-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
nt943	nt943	N300	NN	B-NP	O
+	+	0000	SYM	O	O
3	3	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
76	76	0000	CD	B-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
men	man	M500	NNS	B-NP	O
and	and	A530	CC	I-NP	O
women	woman	W500	NNS	I-NP	O
separately	separately	S163	RB	B-ADVP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
both	both	B300	DT	B-NP	O
sexes	sex	S200	NNS	I-NP	O
combined	combine	C515	VBN	B-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
penetrances	penetrance	P536	NNS	I-NP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
60	60	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

86	86	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

57	57	0000	CD	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
than	than	T500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
63	63	0000	CD	B-NP	O
v	v	V000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
30	30	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O
84	84	0000	CD	B-NP	O
v	v	V000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
44	44	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
ages	age	A200	NNS	B-NP	O
50	50	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
60	60	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
females	female	F542	NNS	B-NP	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
endometrial	endometrial	E535	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
60	60	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
premenopausal	premenopausal	P651	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
intersex	intersex	I536	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risks	risk	R200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
programmes	programme	P626	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
attempts	attempt	A351	NNS	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
modifiers	modifier	M316	NNS	I-NP	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
in	in	I500	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
sex	sex	S200	NN	B-NP	O
specific	specific	S121	JJ	I-NP	O
influence	influence	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
E	E	E000	NN	I-NP	O
genotype	genotype	G531	NN	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
(	(	0000	(	O	O
AO	AO	A000	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
length	length	L523	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Apolipoprotein	Apolipoprotein	A141	NN	B-NP	O
E	E	E000	NN	I-NP	O
(	(	0000	(	O	O
APOE	APOE	A100	NN	B-NP	O
)	)	0000	)	O	O
genotype	genotype	G531	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
turn	turn	T650	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
influence	influence	I514	VB	I-VP	O
AO	AO	A000	NN	B-NP	O
in	in	I500	IN	B-PP	O
Alzheimer	Alzheimer	A425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
rendering	render	R536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
APOE	APOE	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
a	a	A000	DT	B-NP	O
likely	likely	L240	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
to	to	T000	TO	B-VP	O
affect	affect	A123	VB	I-VP	O
AO	AO	A000	NN	B-NP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
neurological	neurological	N642	JJ	I-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
too	too	T000	RB	B-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
determined	determine	D365	VBD	B-VP	O
APOE	APOE	A100	NN	B-NP	O
genotype	genotype	G531	NN	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
138	138	0000	CD	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
analysed	analyse	A542	VBN	I-VP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
CAG	CAG	C200	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
.	.	0000	.	O	O

Genotyping	Genotype	G531	VBG	B-VP	O
for	for	F600	IN	B-PP	O
APOE	APOE	A100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
blind	blind	B453	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
information	information	I516	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
highlighting	highlight	H242	VBG	B-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
AO	AO	A000	NN	B-NP	O
in	in	I500	IN	B-PP	O
maternally	maternally	M365	RB	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
APOE	APOE	A100	NN	I-NP	O
epsilon2epsilon3	epsilon2epsilon3	E124	NN	I-NP	O
genotype	genotype	G531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
significantly	significantly	S251	RB	B-NP	O
earlier	early	E646	JJR	I-NP	O
AO	AO	A000	NN	I-NP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
.	.	0000	.	O	O

Such	Such	S200	PDT	B-NP	O
a	a	A000	DT	I-NP	O
sex	sex	S200	NN	I-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
AO	AO	A000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
apparent	apparent	A165	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
APOE	APOE	A100	NNP	I-NP	O
genotypes	genotype	G531	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
subtle	subtle	S134	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
course	course	C620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
neurodegeneration	neurodegeneration	N632	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
interacting	interact	I536	VBG	I-VP	O
genes	gene	G520	NNS	B-NP	O
to	to	T000	TO	B-VP	O
exert	exert	E263	VB	I-VP	O
gender	gender	G536	NN	B-NP	O
specific	specific	S121	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
upon	upon	U150	IN	B-PP	O
AO	AO	A000	NN	B-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
bacteremic	bacteremic	B236	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	I-Disease
to	to	T000	TO	B-PP	I-Disease
Neisseria	Neisseria	N260	NNP	B-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
29	29	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	I-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
episode	episode	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
disseminated	disseminate	D253	VBN	B-NP	B-Disease
gonococcal	gonococcal	G524	JJ	I-NP	I-Disease
infection	infection	I512	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
arthritis	arthritis	A636	NN	I-NP	B-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lack	lack	L200	VB	I-VP	O
serum	serum	S650	NN	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seventh	seventh	S153	JJ	I-NP	O
component	component	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
complement	complement	C514	NN	B-NP	O
(	(	0000	(	O	O
C7	C7	C000	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
or	or	O600	CC	I-NP	O
immunochemical	immunochemical	I525	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
other	other	O360	JJ	B-NP	O
components	component	C515	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
and	and	A530	CC	I-NP	O
immunochemical	immunochemical	I525	JJ	I-NP	O
assessment	assessment	A253	NN	I-NP	O
.	.	0000	.	O	O

Her	Her	H600	PRP$	B-NP	O
fresh	fresh	F620	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
lacked	lack	L230	VBD	B-VP	O
complement	complement	C514	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
bactericidal	bactericidal	B236	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
against	against	A252	IN	B-PP	O
Neisseria	Neisseria	N260	NNP	B-NP	O
gonorrhoeae	gonorrhoeae	G560	NNP	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
addition	addition	A350	NN	I-NP	O
of	of	O100	IN	B-PP	O
fresh	fresh	F620	JJ	B-NP	O
normal	normal	N654	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
or	or	O600	CC	O	O
purified	purify	P613	VBN	B-NP	O
C7	C7	C000	NN	I-NP	O
restored	restore	R236	VBD	B-VP	O
bactericidal	bactericidal	B236	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
functional	functional	F523	JJ	B-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
activity	activity	A231	NN	I-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
.	.	0000	.	O	O

Opsonization	Opsonization	O125	NN	B-NP	O
and	and	A530	CC	I-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
chemotactic	chemotactic	C532	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
functioned	function	F523	VBD	B-VP	O
normally	normally	N654	RB	B-ADVP	O
.	.	0000	.	O	O

Complete	Complete	C514	JJ	B-NP	B-Disease
absence	absence	A125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C7	C7	C000	NN	B-NP	I-Disease
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
sibling	sibling	S145	NN	I-NP	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
of	of	O100	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
arthritis	arthritis	A636	NN	I-NP	B-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
clinically	clinically	C452	RB	B-ADVP	O
well	well	W400	RB	B-NP	O
eight	eight	E230	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
old	old	O430	JJ	I-NP	O
son	son	S500	NN	I-NP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
infectious	infectious	I512	JJ	B-NP	O
complications	complication	C514	NNS	I-NP	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
bactericidal	bactericidal	B236	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
host	host	H230	NN	B-NP	O
defense	defense	D152	NN	I-NP	O
against	against	A252	IN	B-PP	O
bacteremic	bacteremic	B236	JJ	B-NP	B-Disease
neisseria	neisseria	N260	NN	I-NP	I-Disease
infections	infection	I512	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
cartilage	cartilage	C634	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
hair	hair	H600	NN	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
Previous	Previous	P612	JJ	I-NP	O
reports	report	R163	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
cartilage	cartilage	C634	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
hair	hair	H600	NN	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
(	(	0000	(	O	O
CHH	CHH	C000	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
to	to	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
evaluate	evaluate	E143	VB	I-VP	O
this	this	T200	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
CHH	CHH	C000	NN	B-NP	B-Disease
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

STUDY	STUDY	S300	NN	B-NP	O
DESIGN	DESIGN	D250	NNP	B-NP	O
One	One	O500	CD	I-NP	O
hundred	hundred	H536	CD	I-NP	O
twenty	twenty	T530	CD	I-NP	O
-	-	0000	HYPH	O	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
CHH	CHH	C000	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
through	through	T620	IN	B-PP	O
2	2	0000	CD	B-NP	O
countrywide	countrywide	C536	JJ	I-NP	O
epidemiologic	epidemiologic	E135	JJ	I-NP	O
surveys	survey	S612	NNS	I-NP	O
in	in	I500	IN	B-PP	O
1974	1974	0000	CD	B-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
1986	1986	0000	CD	B-NP	O
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
nonaffected	nonaffected	N512	JJ	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
Population	Population	P143	NNP	I-NP	O
Register	Register	R236	NNP	I-NP	O
Center	Center	C536	NNP	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
cohort	cohort	C630	NN	I-NP	O
underwent	undergo	U536	VBD	B-VP	O
follow	follow	F400	VB	I-VP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
for	for	F600	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
incidence	incidence	I523	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
Finnish	Finnish	F520	NNP	I-NP	O
Cancer	Cancer	C526	NNP	I-NP	O
Registry	Registry	R236	NNP	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
1995	1995	0000	CD	B-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
A	A	A000	DT	B-NP	O
statistically	statistically	S323	RB	I-NP	O
significant	significant	S251	JJ	I-NP	O
excess	excess	E200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
CHH	CHH	C000	NN	B-NP	B-Disease
(	(	0000	(	O	O
standardized	standardized	S353	JJ	B-NP	O
incidence	incidence	I523	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
16	16	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
mainly	mainly	M540	RB	B-ADJP	O
attributable	attributable	A361	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Hodgkins	Hodgkins	H325	NNP	I-NP	I-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
(	(	0000	(	O	O
standardized	standardized	S353	JJ	B-NP	O
incidence	incidence	I523	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
90	90	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
18	18	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
264	264	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
excess	excess	E200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
basal	basal	B240	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
(	(	0000	(	O	O
standardized	standardized	S353	JJ	B-NP	O
incidence	incidence	I523	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
35	35	0000	CD	I-NP	O
,	,	0000	,	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
102	102	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
incidence	incidence	I523	NN	I-NP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
differ	differ	D160	VB	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
average	average	A162	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
incidence	incidence	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Hodgkins	Hodgkins	H325	NNP	I-NP	I-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
,	,	0000	,	O	O
probably	probably	P614	RB	B-ADVP	O
attributable	attributable	A361	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
defective	defective	D123	JJ	B-NP	O
immunity	immunity	I530	NN	I-NP	O
,	,	0000	,	O	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
CHH	CHH	C000	NN	B-NP	B-Disease
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
and	and	A530	CC	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
dihydropyrimidine	dihydropyrimidine	D361	NN	B-NP	B-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Dihydropyrimidine	Dihydropyrimidine	D361	NN	B-NP	B-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
DPD	DPD	D130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
characterised	characterise	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
thymine	thymine	T500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
uraciluria	uraciluria	U624	NN	I-NP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
DPD	DPD	D130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
reviewed	review	R130	VBN	I-VP	O
17	17	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
presenting	present	P625	VBG	B-VP	O
22	22	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
DPD	DPD	D130	NN	B-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
2	2	0000	CD	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
[	[	0000	(	O	O
295	295	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
298delTCAT	298delTCAT	D432	NN	I-NP	O
,	,	0000	,	I-NP	O
1897delC	1897delC	D420	NN	I-NP	O
]	]	0000	)	O	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
[	[	0000	(	I-NP	O
IVS14	IVS14	I120	NN	I-NP	O
+	+	0000	SYM	I-NP	O
1G	1G	G000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
]	]	0000	)	O	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
85T	85T	T000	NN	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
,	,	0000	,	O	O
703C	703C	C000	NN	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NNP	I-NP	O
,	,	0000	,	O	O
2658G	2658G	G000	NN	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
2983G	2983G	G000	NN	B-NP	O
>	>	0000	SYM	B-VP	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
various	various	V620	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
DPD	DPD	D130	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
invariant	invariant	I516	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
by	by	B000	IN	B-PP	O
far	far	F600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
(	(	0000	(	O	O
52	52	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
six	six	S200	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
less	less	L200	RBR	I-VP	O
frequently	frequently	F625	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variability	variability	V614	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
convulsive	convulsive	C514	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
motor	motor	M360	NN	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
being	be	B520	VBG	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
abundant	abundant	A153	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
clear	clear	C460	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
and	and	A530	CC	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
established	establish	E231	VBN	I-VP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
altered	alter	A436	VBN	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
alanine	alanine	A450	NN	I-NP	O
,	,	0000	,	I-NP	O
uracil	uracil	U624	NN	I-NP	O
and	and	A530	CC	I-NP	O
thymine	thymine	T500	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
might	might	M230	MD	B-VP	O
underlie	underlie	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
various	various	V620	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
encountered	encounter	E525	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DPD	DPD	D130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Fibroblast	Fibroblast	F161	NN	B-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
homologous	homologous	H542	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
2	2	0000	CD	I-NP	O
(	(	0000	(	O	O
FHF2	FHF2	F100	NN	B-NP	O
)	)	0000	)	O	O
:	:	0000	:	O	O
gene	gene	G500	NN	B-NP	O
structure	structure	S362	NN	I-NP	O
,	,	0000	,	O	O
expression	expression	E216	NN	B-NP	O
and	and	A530	CC	O	O
mapping	mapping	M152	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Borjeson	Borjeson	B625	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Forssman	Forssman	F625	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lehmann	Lehmann	L500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
Xq26	Xq26	X200	NN	B-NP	O
delineated	delineate	D453	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
BFLS	BFLS	B142	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Borjeson	Borjeson	B625	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Forssman	Forssman	F625	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lehmann	Lehmann	L500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
BFLS	BFLS	B142	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
syndromal	syndromal	S536	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
mental	mental	M534	JJ	I-NP	I-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
q26	q26	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
BFLS	BFLS	B142	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
,	,	0000	,	O	O
46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
Y	Y	Y000	NN	B-NP	O
,	,	0000	,	O	O
dup	dup	D100	NN	B-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q26q28	q26q28	Q200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
inherited	inherit	I563	VBN	B-VP	O
from	from	F650	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
phenotypically	phenotypically	P531	RB	I-NP	O
normal	normal	N654	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

Fluorescence	Fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridisation	hybridisation	H163	NN	I-NP	O
using	use	U252	VBG	B-VP	O
yeast	yeast	Y230	NN	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Xq26	Xq26	X200	NN	B-NP	O
localised	localise	L242	VBD	B-VP	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
approximately	approximately	A162	RB	I-NP	O
400	400	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Xq26	Xq26	X200	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
region	region	R250	NN	I-NP	O
between	between	B350	IN	B-PP	O
DXS155	DXS155	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS294	DXS294	D200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
DXS730	DXS730	D200	NN	I-NP	O
.	.	0000	.	O	O

Database	Database	D312	NN	B-NP	O
searches	search	S620	NNS	I-NP	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
available	available	A141	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fibroblast	fibroblast	F161	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
homologous	homologous	H542	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
FHF2	FHF2	F100	NN	B-NP	O
,	,	0000	,	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
FHF2	FHF2	F100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
,	,	0000	,	O	O
1B	1B	B000	NN	B-NP	O
.	.	0000	.	O	O

FHF2	FHF2	F100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
over	over	O160	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
200	200	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
in	in	I500	IN	B-PP	O
Xq26	Xq26	X200	NN	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
composed	compose	C512	VBN	I-VP	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
seven	seven	S150	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
shows	show	S200	VBZ	B-VP	O
tissue	tissue	T200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
alternative	alternative	A436	JJ	I-NP	O
splicing	splicing	S142	NN	I-NP	O
and	and	A530	CC	O	O
alternative	alternative	A436	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
starts	start	S363	NNS	I-NP	O
.	.	0000	.	O	O

Northern	Northern	N636	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridisation	hybridisation	H163	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
highest	high	H230	JJS	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
FHF2	FHF2	F100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
localisation	localisation	L242	NN	I-NP	O
and	and	A530	CC	I-NP	O
tissue	tissue	T200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BFLS	BFLS	B142	NN	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
syndromal	syndromal	S536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
mental	mental	M534	JJ	I-NP	I-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
mapping	map	M152	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
E	E	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cadherin	cadherin	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CDH1	CDH1	C300	NN	B-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
predispose	predispose	P632	VBP	B-VP	O
to	to	T000	TO	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
E	E	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cadherin	cadherin	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CDH1	CDH1	C300	NN	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
Maori	Maori	M600	NNP	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
heterogeneous	heterogeneous	H362	JJ	I-ADJP	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
clear	clear	C460	JJ	B-ADJP	O
what	what	W300	WDT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Maori	Maori	M600	NNP	I-NP	O
populations	population	P143	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
germline	germline	G654	NN	B-NP	O
CDH1	CDH1	C300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
eight	eight	E230	CD	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
kindreds	kindred	K536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
British	British	B632	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
CDH1	CDH1	C300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
16	16	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	I-NP	O
flanking	flanking	F452	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
family	family	F540	NN	I-NP	O
contained	contain	C535	VBD	B-VP	O
(	(	0000	(	O	O
i	i	I000	NNS	B-NP	O
)	)	0000	)	O	O
two	two	T000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
first	first	F623	JJ	B-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
affected	affect	A123	VBN	B-VP	O
before	before	B160	IN	B-PP	O
age	age	A200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
;	;	0000	:	O	O
or	or	O600	CC	O	O
(	(	0000	(	O	O
ii	ii	I000	NNS	B-NP	O
)	)	0000	)	O	O
three	three	T600	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
CDH1	CDH1	C300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
25	25	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	B-VP	O
truncate	truncate	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
E	E	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cadherin	cadherin	C365	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
and	and	A530	CC	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
both	both	B300	CC	O	O
gastric	gastric	G236	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
;	;	0000	:	O	O
thus	thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
six	six	S200	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
CDH1	CDH1	C300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
developed	develop	D141	VBD	B-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
30	30	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CDH1	CDH1	C300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Maori	Maori	M600	NNP	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
minority	minority	M563	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
gastric	gastric	G236	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
CDH1	CDH1	C300	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
E	E	E000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cadherin	cadherin	C365	NN	I-NP	O
function	function	F523	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
other	other	O360	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
our	our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
germline	germline	G654	NN	B-NP	O
CDH1	CDH1	C300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
predispose	predispose	P632	VBP	B-VP	O
to	to	T000	TO	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
CDH1	CDH1	C300	NN	B-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
both	both	B300	CC	O	O
gastric	gastric	G236	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
murine	murine	M650	JJ	B-NP	O
WT1	WT1	W300	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
urogenital	urogenital	U625	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
WT1	WT1	W300	NN	B-NP	O
,	,	0000	,	O	O
plays	play	P420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
urogenital	urogenital	U625	JJ	B-NP	O
development	development	D141	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
WT1	WT1	W300	NN	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
neoplastic	neoplastic	N142	JJ	O	B-Disease
(	(	0000	(	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
,	,	0000	,	O	O
mesothelioma	mesothelioma	M234	NN	B-NP	B-Disease
,	,	0000	,	O	O
leukemias	leukemia	L252	NNS	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
nonneoplastic	nonneoplastic	N514	JJ	B-NP	B-Disease
(	(	0000	(	O	O
glomerulosclerosis	glomerulosclerosis	G456	NN	B-NP	B-Disease
)	)	0000	)	O	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
diseases	disease	D200	NNS	B-NP	O
linked	link	L523	VBN	B-VP	O
specifically	specifically	S121	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
Denys	Deny	D520	NNPS	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
DDS	DDS	D320	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
can	can	C500	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
valuable	valuable	V414	JJ	B-NP	O
insight	insight	I523	NN	I-NP	O
concerning	concern	C526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
in	in	I500	IN	B-PP	O
development	development	D141	NN	B-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

DDS	DDS	D320	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
childhood	childhood	C430	NN	I-NP	O
disease	disease	D200	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
nephropathy	nephropathy	N161	NN	I-NP	B-Disease
involving	involve	I514	VBG	B-VP	O
mesangial	mesangial	M252	JJ	B-NP	B-Disease
sclerosis	sclerosis	S246	NN	I-NP	I-Disease
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
pseudohermaphroditism	pseudohermaphroditism	P236	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
(	(	0000	(	O	O
WT	WT	W300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

DDS	DDS	D320	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
constitutionally	constitutionally	C523	RB	B-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
exonic	exonic	E252	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
include	include	I524	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	B-VP	O
truncate	truncate	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
(	(	0000	(	O	O
ZF	ZF	Z100	NN	B-NP	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
targeted	target	T623	VBN	I-NP	O
murine	murine	M650	JJ	I-NP	O
Wt1	Wt1	W300	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
Wt1	Wt1	W300	NN	B-NP	O
(	(	0000	(	O	O
tmT396	tmT396	T530	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
truncates	truncate	T652	VBZ	B-VP	O
ZF3	ZF3	Z100	NN	B-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
396	396	0000	CD	I-NP	O
,	,	0000	,	O	O
induces	induce	I532	VBZ	B-VP	O
mesangial	mesangial	M252	JJ	B-NP	B-Disease
sclerosis	sclerosis	S246	NN	I-NP	I-Disease
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
DDS	DDS	D320	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
and	and	A530	CC	I-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Male	Male	M400	JJ	B-NP	B-Disease
genital	genital	G534	JJ	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
also	also	A420	RB	B-ADVP	O
were	be	W600	VBD	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
transcript	transcript	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nontargeted	nontargeted	N536	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
9	9	0000	CD	I-NP	O
skipping	skipping	S215	NN	I-NP	O
event	event	E153	NN	I-NP	O
,	,	0000	,	O	O
implying	imply	I514	VBG	B-VP	O
a	a	A000	DT	B-NP	O
causal	causal	C240	JJ	I-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
Wt1	Wt1	W300	NN	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumorigenesis	tumorigenesis	T562	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
WT1	WT1	W300	NN	I-NP	O
(	(	0000	(	O	O
tmT396	tmT396	T530	NN	B-NP	O
)	)	0000	)	O	O
protein	protein	P635	NN	B-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
only	only	O540	RB	B-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
WT	WT	W300	NN	I-NP	B-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
has	have	H200	VBZ	B-VP	O
implications	implication	I514	NNS	B-NP	O
regarding	regard	R263	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
by	by	B000	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
exerts	exert	E263	VBZ	B-VP	O
its	its	I320	PRP$	B-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

Mechanism	Mechanism	M252	NN	B-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
iron	iron	I650	NN	I-NP	O
absorption	absorption	A126	NN	I-NP	O
in	in	I500	IN	B-PP	O
murine	murine	M650	JJ	B-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
:	:	0000	:	O	O
increased	increase	I526	VBN	B-NP	O
duodenal	duodenal	D354	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
iron	iron	I650	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
DMT1	DMT1	D530	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HH	HH	H000	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
tissue	tissue	T200	NN	B-NP	O
iron	iron	I650	NN	I-NP	O
deposition	deposition	D123	NN	I-NP	O
secondary	secondary	S253	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
excessive	excessive	E210	JJ	B-NP	O
dietary	dietary	D360	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
absorption	absorption	A126	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
physically	physically	P240	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
TfR	TfR	T160	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
duodenal	duodenal	D354	JJ	B-NP	O
crypt	crypt	C613	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
proposed	propose	P612	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
attenuate	attenuate	A353	VBP	B-VP	O
the	the	T000	DT	B-NP	O
uptake	uptake	U132	NN	I-NP	O
of	of	O100	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
-	-	0000	HYPH	O	O
bound	bind	B530	VBN	B-NP	O
iron	iron	I650	NN	I-NP	O
from	from	F650	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
by	by	B000	IN	B-PP	O
duodenal	duodenal	D354	JJ	B-NP	O
crypt	crypt	C613	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
up	up	U100	RB	B-ADVP	O
-	-	0000	HYPH	O	O
regulation	regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
transporters	transporter	T652	NNS	B-NP	O
for	for	F600	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
tested	test	T230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
HFE	HFE	H100	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
increased	increase	I526	VBN	I-VP	O
duodenal	duodenal	D354	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
divalent	divalent	D145	JJ	I-NP	O
metal	metal	M340	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
(	(	0000	(	O	O
DMT1	DMT1	D530	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
4	4	0000	CD	B-NP	O
weeks	week	W200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
iron	iron	I650	NN	B-NP	O
loading	loading	L352	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
+	+	0000	SYM	B-NP	O
/	/	0000	SYM	B-VP	O
+	+	0000	SYM	B-NP	O
littermates	littermate	L365	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
elevated	elevate	E413	VBN	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturations	saturation	S363	NNS	I-NP	O
(	(	0000	(	O	O
68	68	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
vs	v	V200	NNS	I-NP	O
.	.	0000	.	O	O
49	49	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
elevated	elevated	E413	JJ	B-NP	O
liver	liver	L160	NN	I-NP	O
iron	iron	I650	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
(	(	0000	(	O	O
985	985	0000	CD	B-NP	O
micrograms	microgram	M262	NNS	I-NP	O
vs	vs	V200	CC	O	O
.	.	0000	.	O	O
381	381	0000	CD	B-NP	O
micrograms	microgram	M262	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
Northern	Northern	N636	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
quantitated	quantitate	Q530	VBD	B-VP	O
duodenal	duodenal	D354	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
classes	class	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
one	one	O500	CD	B-NP	O
containing	contain	C535	VBG	B-VP	O
an	an	A500	DT	B-NP	O
iron	iron	I650	NN	I-NP	O
responsive	responsive	R215	JJ	I-NP	O
element	element	E453	NN	I-NP	O
(	(	0000	(	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
called	call	C430	VBN	B-VP	O
DMT1	DMT1	D530	NN	B-NP	O
(	(	0000	(	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
containing	contain	C535	VBG	B-VP	O
no	no	N000	DT	B-NP	O
IRE	IRE	I600	NN	I-NP	O
,	,	0000	,	O	O
called	call	C430	VBN	B-VP	O
DMT1	DMT1	D530	NN	B-NP	O
(	(	0000	(	O	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
positive	positive	P231	JJ	I-NP	O
control	control	C536	NN	I-NP	O
for	for	F600	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
up	up	U100	RB	B-ADVP	O
-	-	0000	HYPH	B-NP	O
regulation	regulation	R243	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	B-Disease
iron	iron	I650	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
greatly	greatly	G634	RB	B-NP	O
increased	increase	I526	VBN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
duodenal	duodenal	D354	JJ	B-NP	O
DMT1	DMT1	D530	NN	I-NP	O
(	(	0000	(	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
mRNA	mRNA	M650	NN	B-NP	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
also	also	A420	RB	B-ADVP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
an	an	A500	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
duodenal	duodenal	D354	JJ	B-NP	O
DMT1	DMT1	D530	NN	I-NP	O
(	(	0000	(	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
mRNA	mRNA	M650	NN	B-NP	O
(	(	0000	(	O	O
average	average	A162	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	B-ADVP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
despite	despite	D213	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
elevated	elevate	E413	VBN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
and	and	A530	CC	O	O
hepatic	hepatic	H132	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
content	content	C535	NN	I-NP	O
.	.	0000	.	O	O

Duodenal	Duodenal	D354	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
(	(	0000	(	O	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	B-NP	O
IRE	IRE	I600	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
,	,	0000	,	O	O
nor	nor	N600	CC	O	O
was	be	W200	VBD	B-VP	O
hepatic	hepatic	H132	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
increased	increase	I526	VBD	B-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
HH	HH	H000	NN	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
HFE	HFE	H100	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
inappropriately	inappropriately	I516	RB	B-NP	O
low	low	L000	JJ	I-NP	O
crypt	crypt	C613	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
iron	iron	I650	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
resultant	resultant	R243	JJ	B-NP	O
stabilization	stabilization	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
(	(	0000	(	O	O
IRE	IRE	I600	NN	B-NP	O
)	)	0000	)	O	O
mRNA	mRNA	M650	NN	B-NP	O
,	,	0000	,	O	O
up	up	U100	RB	B-ADVP	O
-	-	0000	HYPH	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMT1	DMT1	D530	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
increased	increase	I526	VBN	B-NP	O
absorption	absorption	A126	NN	I-NP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
.	.	0000	.	O	O

Neurophysiologic	Neurophysiologic	N612	JJ	B-NP	O
follow	follow	F400	VB	B-VP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
of	of	O100	IN	B-PP	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
term	term	T650	NN	I-NP	O
dietary	dietary	D360	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
in	in	I500	IN	B-PP	O
adult	adult	A343	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
monitor	monitor	M536	VB	I-VP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
in	in	I500	IN	B-PP	O
adult	adult	A343	NN	B-NP	O
-	-	0000	HYPH	O	O
onset	onset	O523	NN	B-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
somatosensory	somatosensory	S532	JJ	B-NP	O
evoked	evoked	E123	JJ	I-NP	O
potentials	potential	P353	NNS	I-NP	O
(	(	0000	(	O	O
SEPs	SEP	S120	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
motor	motor	M360	NN	B-NP	O
evoked	evoke	E123	VBN	I-NP	O
potentials	potential	P353	NNS	I-NP	O
(	(	0000	(	O	O
MEPs	MEP	M120	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
SEPs	SEP	S120	NNS	I-NP	O
and	and	A530	CC	I-NP	O
MEPs	MEP	M120	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
proved	prove	P613	VBN	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
revealing	reveal	R145	VBG	B-VP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
progressively	progressively	P626	RB	B-NP	O
severe	severe	S160	JJ	I-NP	O
,	,	0000	,	I-NP	O
central	central	C536	JJ	I-NP	O
dying	dying	D520	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
back	back	B200	JJ	I-NP	I-Disease
axonopathy	axonopathy	A251	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
stages	stage	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Eight	Eight	E230	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
underwent	undergo	U536	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
,	,	0000	,	I-NP	O
brain	brain	B650	NN	I-NP	O
and	and	A530	CC	I-NP	O
spine	spine	S150	NN	I-NP	O
MRI	MRI	M600	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
SEP	SEP	S100	NN	B-NP	O
and	and	A530	CC	I-NP	O
MEP	MEP	M100	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
before	before	B160	IN	B-PP	O
and	and	A530	CC	I-PP	O
after	after	A136	IN	I-PP	O
3	3	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Lorenzos	Lorenzos	L652	NNP	B-NP	O
oil	oil	O400	NN	I-NP	O
dietary	dietary	D360	JJ	I-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Before	Before	B160	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
MRI	MRI	M600	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
pure	pure	P600	JJ	B-NP	O
spinal	spinal	S154	JJ	I-NP	B-Disease
SEP	SEP	S100	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
two	two	T000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
SEPs	SEP	S120	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
involvement	involvement	I514	NN	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
spinal	spinal	S154	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
somatosensory	somatosensory	S532	JJ	I-NP	O
tracts	tract	T623	NNS	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
pure	pure	P600	JJ	B-NP	O
spinal	spinal	S154	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
showed	show	S300	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
neurophysiologic	neurophysiologic	N612	JJ	I-NP	O
worsening	worsening	W625	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
advanced	advanced	A315	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
(	(	0000	(	O	O
exhibited	exhibit	E213	VBN	B-VP	O
by	by	B000	IN	B-PP	O
SEPs	SEP	S120	NNS	B-NP	O
)	)	0000	)	O	O
showed	show	S300	VBD	B-VP	O
substantially	substantially	S123	RB	B-NP	O
unchanged	unchanged	U525	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
neurophysiologic	neurophysiologic	N612	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
brain	brain	B650	NN	I-NP	O
MRI	MRI	M600	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
neurophysiologic	neurophysiologic	N612	JJ	I-NP	O
worsening	worsening	W625	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
Lorenzos	Lorenzo	L652	NNS	I-NP	O
oil	oil	O400	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
inflammatory	inflammatory	I514	JJ	B-NP	B-Disease
brain	brain	B650	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
without	without	W300	IN	B-PP	O
clear	clear	C460	JJ	B-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
inflammatory	inflammatory	I514	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
modify	modify	M310	VB	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
natural	natural	N364	JJ	I-NP	O
course	course	C620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
because	because	B200	IN	B-SBAR	O
effective	effective	E123	JJ	B-NP	O
treatments	treatment	T635	NNS	I-NP	O
should	should	S430	MD	B-VP	O
begin	begin	B250	VB	I-VP	O
before	before	B160	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
neurologic	neurologic	N642	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
,	,	0000	,	I-NP	O
SEPs	SEP	S120	NNS	I-NP	O
and	and	A530	CC	I-NP	O
MEPs	MEP	M120	NNS	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
the	the	T000	DT	B-NP	O
effectiveness	effectiveness	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
experimental	experimental	E216	JJ	I-NP	O
treatments	treatment	T635	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
brain	brain	B650	NN	I-NP	O
MRI	MRI	M600	NN	I-NP	O
.	.	0000	.	O	O

GCH1	GCH1	G200	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
oromandibular	oromandibular	O653	JJ	I-NP	B-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
GCH1	GCH1	G200	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
oromandibular	oromandibular	O653	JJ	I-NP	B-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystonia	dystonia	D235	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
responded	respond	R215	VBD	B-VP	O
positively	positively	P231	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
treatment	treatment	T635	NN	B-NP	O
with	with	W300	IN	B-PP	O
L	L	L000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dopa	dopa	D100	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
GCH1	GCH1	G200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
must	must	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
considered	consider	C523	VBN	I-VP	O
even	even	E150	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
dystonic	dystonic	D235	JJ	B-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	O
not	not	N300	RB	O	O
typical	typical	T124	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
dopa	dopa	D100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
responsive	responsive	R215	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Korean	Korean	K650	JJ	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
extensively	extensively	E235	RB	B-ADVP	O
analyzed	analyze	A542	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
messenger	messenger	M252	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
(	(	0000	(	O	O
mRNA	mRNA	M650	NN	B-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
62	62	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Korean	Korean	K650	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
adopted	adopt	A313	VBD	B-VP	O
both	both	B300	CC	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
method	method	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
reverse	reverse	R162	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
)	)	0000	)	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
(	(	0000	(	O	O
PTT	PTT	P300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
all	all	A400	DT	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
represented	represent	R162	VBN	B-VP	O
by	by	B000	IN	B-PP	O
aberrant	aberrant	A165	JJ	B-NP	O
bands	band	B532	NNS	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
38	38	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
61	61	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Nineteen	Nineteen	N535	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
detected	detect	D323	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
presumed	presume	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
novel	novel	N140	JJ	B-ADJP	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
emphasizing	emphasize	E512	VBG	B-VP	O
the	the	T000	DT	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
Korean	Korean	K650	JJ	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
48	48	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
followed	follow	F430	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PTT	PTT	P300	NN	B-NP	O
for	for	F600	IN	B-PP	O
those	those	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
for	for	F600	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
combined	combine	C515	VBN	I-NP	O
approach	approach	A162	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
germline	germline	G654	NN	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
29	29	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
48	48	0000	CD	I-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
6	6	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
distinguish	distinguish	D235	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
14	14	0000	CD	I-NP	O
later	later	L360	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
truncating	truncate	T652	VBG	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
9	9	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
64	64	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
using	use	U252	VBG	B-VP	O
PTT	PTT	P300	NN	B-NP	O
only	only	O540	RB	B-ADVP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
confirm	confirm	C516	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
with	with	W300	IN	B-PP	O
PTT	PTT	P300	NN	B-NP	O
was	be	W200	VBD	B-VP	O
superior	superior	S160	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
with	with	W300	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PTT	PTT	P300	NN	B-NP	O
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
practical	practical	P623	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
method	method	M300	NN	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
epidemiology	epidemiology	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
Arg95Stop	Arg95Stop	A623	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C9	C9	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
ninth	ninth	N530	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
human	human	H500	JJ	B-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
(	(	0000	(	O	O
C9	C9	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
complement	complement	C514	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
one	one	O500	CD	I-NP	O
homozygote	homozygote	H523	NN	I-NP	O
in	in	I500	IN	B-PP	O
1000	1000	0000	CD	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
very	very	V600	RB	B-ADJP	O
rare	rare	R600	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
countries	country	C536	NNS	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
TGA	TGA	T200	NN	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
for	for	F600	IN	B-PP	O
Arg95	Arg95	A620	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C9	C9	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Arg95Stop	Arg95Stop	A623	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Arg95Stop	Arg95Stop	A623	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
collected	collect	C423	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
300	300	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
main	main	M500	JJ	I-NP	O
islands	island	I245	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
.	.	0000	.	O	O

Heterozygote	Heterozygote	H362	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
system	system	S235	NN	B-NP	O
designed	design	D253	VBN	B-VP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
confirmation	confirmation	C516	NN	B-NP	O
with	with	W300	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
/	/	0000	SYM	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Arg95Stop	Arg95Stop	A623	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Arg95Stop	Arg95Stop	A623	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
300	300	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
Arg95Stop	Arg95Stop	A623	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
frequencies	frequency	F625	NNS	B-NP	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
serological	serological	S642	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O

The	The	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
specifically	specifically	S121	RB	B-ADVP	O
regulates	regulate	R243	VBZ	B-VP	O
transferrin	transferrin	T652	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
iron	iron	I650	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
in	in	I500	IN	B-PP	O
HeLa	HeLa	H400	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
hereditary	hereditary	H636	JJ	I-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
(	(	0000	(	O	O
Feder	Feder	F360	NNP	B-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	O	O

N	N	N000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Gnirke	Gnirke	G562	NNP	B-NP	O
,	,	0000	,	O	O
A	A	A000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Thomas	Thomas	T520	NNP	B-NP	O
,	,	0000	,	O	O
W	W	W000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Tsuchihashi	Tsuchihashi	T200	NNP	B-NP	O
,	,	0000	,	O	O
Z	Z	Z000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Ruddy	Ruddy	R300	NNP	B-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Basava	Basava	B210	NNP	B-NP	O
,	,	0000	,	O	O
A	A	A000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Dormishian	Dormishian	D652	NNP	B-NP	O
,	,	0000	,	O	O
F	F	F000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Domingo	Domingo	D520	NNP	B-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	O	O

J	J	J000	NNP	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Ellis	Ellis	E420	NNP	B-NP	O
,	,	0000	,	O	O
M	M	M000	NNP	B-NP	O
.	.	0000	.	O	O

C	C	C000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Fullan	Fullan	F450	NNP	B-NP	O
,	,	0000	,	O	O
A	A	A000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Hinton	Hinton	H535	NNP	B-NP	O
,	,	0000	,	O	O
L	L	L000	NNP	B-NP	O
.	.	0000	.	O	O

M	M	M000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Jones	Jones	J520	NNP	B-NP	O
,	,	0000	,	O	O
N	N	N000	NNP	B-NP	O
.	.	0000	.	O	O

L	L	L000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Kimmel	Kimmel	K540	NNP	B-NP	O
,	,	0000	,	O	O
B	B	B000	NNP	B-NP	O
.	.	0000	.	O	O

E	E	E000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Kronmal	Kronmal	K654	NNP	B-NP	O
,	,	0000	,	O	O
G	G	G000	NNP	B-NP	O
.	.	0000	.	O	O

S	S	S000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Lauer	Lauer	L600	NNP	B-NP	O
,	,	0000	,	O	O
P	P	P000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Lee	Lee	L000	NNP	B-NP	O
,	,	0000	,	O	O
V	V	V000	NNP	B-NP	O
.	.	0000	.	O	O

K	K	K000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Loeb	Loeb	L100	NNP	B-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	O	O

B	B	B000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Mapa	Mapa	M100	NNP	B-NP	O
,	,	0000	,	O	O
F	F	F000	NNP	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
McClelland	McClelland	M245	NNP	B-NP	O
,	,	0000	,	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Meyer	Meyer	M600	NNP	B-NP	O
,	,	0000	,	O	O
N	N	N000	NNP	B-NP	O
.	.	0000	.	O	O

C	C	C000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Mintier	Mintier	M536	NNP	B-NP	O
,	,	0000	,	O	O
G	G	G000	NNP	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Moeller	Moeller	M460	NNP	B-NP	O
,	,	0000	,	O	O
N	N	N000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Moore	Moore	M600	NNP	B-NP	O
,	,	0000	,	O	O
T	T	T000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Morikang	Morikang	M625	NNP	B-NP	O
,	,	0000	,	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Prasss	Prasss	P620	NNP	B-NP	O
,	,	0000	,	O	O
C	C	C000	NNP	B-NP	O
.	.	0000	.	O	O

E	E	E000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Quintana	Quintana	Q535	NNP	B-NP	O
,	,	0000	,	O	O
L	L	L000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Starnes	Starnes	S365	NNP	B-NP	O
,	,	0000	,	O	O
S	S	S000	NNP	B-NP	O
.	.	0000	.	O	O

M	M	M000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Schatzman	Schatzman	S232	NNP	B-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	O	O

C	C	C000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Brunke	Brunke	B652	NNP	B-NP	O
,	,	0000	,	O	O
K	K	K000	NNP	B-NP	O
.	.	0000	.	O	O

J	J	J000	NNP	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Drayna	Drayna	D650	NNP	B-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	O	O

T	T	T000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Risch	Risch	R200	NN	B-NP	O
,	,	0000	,	O	O
N	N	N000	NN	B-NP	O
.	.	0000	.	O	O

J	J	J000	NNP	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Bacon	Bacon	B250	NNP	B-NP	O
,	,	0000	,	O	O
B	B	B000	NNP	B-NP	O
.	.	0000	.	O	O

R	R	R000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Wolff	Wolff	W410	NNP	B-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	O	O

R	R	R000	NN	B-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
1996	1996	0000	CD	B-NP	O
)	)	0000	)	O	O
Nat	Nat	N300	NNP	B-NP	O
.	.	0000	.	O	O

Genet	Genet	G530	NNP	B-NP	O
.	.	0000	.	O	O

13	13	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
399	399	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
408	408	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
surface	surface	S612	NN	I-NP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
complexes	complex	C514	NNS	I-NP	O
with	with	W300	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
TfR	TfR	T160	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
increasing	increase	I526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
dissociation	dissociation	D235	NN	I-NP	O
constant	constant	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
(	(	0000	(	O	O
Tf	Tf	T100	NN	B-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
receptor	receptor	R213	NN	I-NP	O
10	10	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	O	O
(	(	0000	(	O	O
Gross	Gross	G620	NNP	B-NP	O
,	,	0000	,	O	O
C	C	C000	NNP	B-NP	O
.	.	0000	.	O	O

N	N	N000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Irrinki	Irrinki	I652	NNP	B-NP	O
,	,	0000	,	O	O
A	A	A000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Feder	Feder	F360	NNP	B-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
N	N	N000	NNP	I-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Enns	Enns	E520	NNP	B-NP	O
,	,	0000	,	O	O
C	C	C000	NNP	B-NP	O
.	.	0000	.	I-NP	O
A	A	A000	NNP	I-NP	O
.	.	0000	.	O	O
(	(	0000	(	O	O
1998	1998	0000	CD	B-NP	O
)	)	0000	)	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Biol	Biol	B400	NNP	I-NP	O
.	.	0000	.	I-NP	O
Chem	Chem	C500	NNP	I-NP	O
.	.	0000	.	I-NP	O
273	273	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
22068	22068	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
22074	22074	0000	CD	I-NP	O
;	;	0000	:	O	O
Feder	Feder	F360	NNP	B-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
N	N	N000	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Penny	Penny	P500	NNP	B-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	I-NP	O
M	M	M000	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Irrinki	Irrinki	I652	NNP	B-NP	O
,	,	0000	,	O	O
A	A	A000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Lee	Lee	L000	NNP	B-NP	O
,	,	0000	,	O	O
V	V	V000	NNP	B-NP	O
.	.	0000	.	I-NP	O
K	K	K000	NNP	I-NP	O
.	.	0000	NNP	I-NP	O
,	,	0000	,	O	O
Lebron	Lebron	L165	NNP	B-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
A	A	A000	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Watson	Watson	W325	NNP	B-NP	O
,	,	0000	,	O	O
N	N	N000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Tsuchihashi	Tsuchihashi	T200	NNP	B-NP	O
,	,	0000	,	O	O
Z	Z	Z000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Sigal	Sigal	S240	NNP	B-NP	O
,	,	0000	,	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Bjorkman	Bjorkman	B262	NNP	B-NP	O
,	,	0000	,	O	O
P	P	P000	NNP	B-NP	O
.	.	0000	.	I-NP	O
J	J	J000	NNP	I-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Schatzman	Schatzman	S232	NNP	B-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	I-NP	O
C	C	C000	NNP	I-NP	O
.	.	0000	.	O	O
(	(	0000	(	O	O
1998	1998	0000	CD	B-NP	O
)	)	0000	)	O	O
Proc	Proc	P620	NNP	B-NP	O
.	.	0000	.	I-NP	O
Natl	Natl	N340	NNP	I-NP	O
.	.	0000	.	O	O

Acad	Acad	A230	NN	B-NP	O
.	.	0000	.	O	O

Sci	Sci	S200	NNS	B-NP	O
.	.	0000	.	O	O

U	U	U000	NNP	B-NP	O
S	S	S000	NNP	I-NP	O
A	A	A000	NNP	I-NP	O
95	95	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1472	1472	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
1477	1477	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
remain	remain	R500	VB	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
surface	surface	S612	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
traffics	traffic	T612	NNS	B-NP	O
with	with	W300	IN	B-PP	O
TfR	TfR	T160	NN	B-NP	O
to	to	T000	TO	B-PP	O
Tf	Tf	T100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
internal	internal	I536	JJ	I-NP	O
compartments	compartment	C516	NNS	I-NP	O
(	(	0000	(	O	O
Gross	Gross	G620	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1998	1998	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
HeLa	HeLa	H400	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
controlled	control	C536	VBN	I-VP	O
by	by	B000	IN	B-PP	O
tetracycline	tetracycline	T362	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
reduces	reduce	R320	VBZ	B-VP	O
55Fe	55Fe	F000	NN	B-NP	O
uptake	uptake	U132	NN	I-NP	O
from	from	F650	IN	B-PP	O
Tf	Tf	T100	NN	B-NP	O
by	by	B000	IN	B-PP	O
33	33	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
but	but	B300	CC	O	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
the	the	T000	DT	B-NP	O
endocytic	endocytic	E532	JJ	I-NP	O
or	or	O600	CC	I-NP	O
exocytic	exocytic	E232	JJ	I-NP	O
rates	rate	R320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
TfR	TfR	T160	NN	B-NP	O
cycling	cycling	C245	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
reduce	reduce	R320	VB	I-VP	O
cellular	cellular	C460	JJ	B-NP	O
acquisition	acquisition	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
from	from	F650	IN	B-PP	O
Tf	Tf	T100	NN	B-NP	O
within	within	W350	IN	B-PP	O
endocytic	endocytic	E532	JJ	B-NP	O
compartments	compartment	C516	NNS	I-NP	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
specifically	specifically	S121	RB	B-ADVP	O
reduces	reduce	R320	VBZ	B-VP	O
iron	iron	I650	NN	B-NP	O
uptake	uptake	U132	NN	I-NP	O
from	from	F650	IN	B-PP	O
Tf	Tf	T100	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	B-NP	O
Tf	Tf	T100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
mediated	mediate	M300	VBN	I-NP	O
iron	iron	I650	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
from	from	F650	IN	B-PP	O
Fe	Fe	F000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
nitrilotriacetic	nitrilotriacetic	N364	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
altered	alter	A436	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
explain	explain	E214	VBP	B-VP	O
the	the	T000	DT	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
HeLa	HeLa	H400	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
system	system	S235	NN	I-NP	O
and	and	A530	CC	O	O
demonstrate	demonstrate	D523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
control	control	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
over	over	O160	IN	B-PP	O
the	the	T000	DT	B-NP	O
Tf	Tf	T100	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
mediated	mediate	M300	VBN	B-NP	O
pathway	pathway	P300	NN	I-NP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
uptake	uptake	U132	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
in	in	I500	IN	B-PP	O
organs	organ	O625	NNS	B-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
,	,	0000	,	O	O
pancreas	pancreas	P526	NN	B-NP	O
,	,	0000	,	O	O
heart	heart	H630	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
spleen	spleen	S145	NN	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
iron	iron	I650	NN	B-NP	O
loaded	load	L300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatotic	hemochromatotic	H526	JJ	I-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
lacking	lack	L252	VBG	B-VP	O
functional	functional	F523	JJ	B-NP	O
HFE	HFE	H100	NN	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
and	and	A530	CC	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
reveal	reveal	R140	VBP	B-VP	O
new	new	N000	JJ	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
relationships	relationship	R435	NNS	I-NP	O
and	and	A530	CC	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
with	with	W300	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
episodes	episode	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
fever	fever	F160	NN	B-NP	O
with	with	W300	IN	B-PP	O
serositis	serositis	S623	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
synovitis	synovitis	S513	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
MEFV	MEFV	M100	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
data	datum	D300	NNS	B-NP	O
from	from	F650	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Arab	Arab	A610	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
we	we	W000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
originally	originally	O625	RB	I-VP	O
found	find	F530	VBN	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
,	,	0000	,	I-NP	O
more	more	M600	RBR	I-NP	O
ethnically	ethnically	E352	RB	I-NP	O
diverse	diverse	D162	JJ	I-NP	O
panel	panel	P540	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
90	90	0000	CD	B-NP	O
symptomatic	symptomatic	S513	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
11	11	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
79	79	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
novel	novel	N140	JJ	B-ADJP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
alters	alter	A436	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
residue	residue	R230	NN	I-NP	O
(	(	0000	(	O	O
680	680	0000	CD	B-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
known	know	K500	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
(	(	0000	(	O	O
P369S	P369S	P200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

Consistent	Consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
another	another	A536	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
E148Q	E148Q	E200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
ethnicities	ethnicity	E352	NNS	I-NP	O
and	and	A530	CC	B-PP	O
on	on	O500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
haplotype	haplotype	H143	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
an	an	A500	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
relationships	relationship	R435	NNS	I-NP	O
between	between	B350	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
Italian	Italian	I345	NNP	I-NP	O
and	and	A530	CC	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
affected	affect	A123	VBN	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
200	200	0000	CD	I-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
MEFV	MEFV	M100	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
was	be	W200	VBD	B-VP	O
21	21	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
E148Q	E148Q	E200	NN	B-NP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
lines	line	L520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
evidence	evidence	E135	NN	B-NP	O
indicate	indicate	I532	VBP	B-VP	O
reduced	reduce	R323	VBN	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
among	among	A520	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
E148Q	E148Q	E200	NN	B-NP	O
,	,	0000	,	O	O
P369S	P369S	P200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
K695R	K695R	K600	NN	B-NP	O
.	.	0000	.	O	O

Nevertheless	Nevertheless	N163	RB	B-ADVP	O
,	,	0000	,	O	O
E148Q	E148Q	E200	NN	B-NP	O
helps	help	H412	VBZ	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
recessive	recessive	R210	JJ	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
family	family	F540	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
dominantly	dominantly	D534	RB	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
MEFV	MEFV	M100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
Mediterranean	Mediterranean	M365	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
strongly	strongly	S365	RB	B-VP	O
suggests	suggest	S232	VBZ	I-VP	O
a	a	A000	DT	B-NP	O
heterozygote	heterozygote	H362	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
geographic	geographic	G261	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Autoimmune	Autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
Fas	Fas	F200	NN	I-NP	O
:	:	0000	:	O	O
genotype	genotype	G531	NN	B-NP	O
influences	influence	I514	VBZ	B-VP	O
penetrance	penetrance	P536	NN	B-NP	O
.	.	0000	.	O	O

Autoimmune	Autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
lymphocyte	lymphocyte	L512	NN	B-NP	I-Disease
homeostasis	homeostasis	H523	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
immunological	immunological	I542	JJ	B-NP	I-Disease
tolerance	tolerance	T465	NN	I-NP	I-Disease
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APT1	APT1	A130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
Fas	Fas	F200	NN	B-NP	O
(	(	0000	(	O	O
CD95	CD95	C300	NN	B-NP	O
,	,	0000	,	O	O
APO	APO	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
mediator	mediator	M360	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
apoptotic	apoptotic	A132	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
crucial	crucial	C624	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
lymphocyte	lymphocyte	L512	NN	B-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
17	17	0000	CD	B-NP	O
unique	unique	U520	JJ	I-NP	O
APT1	APT1	A130	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
unrelated	unrelated	U564	JJ	B-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
(	(	0000	(	O	O
71	71	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
7	7	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encode	encode	E523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
intracellular	intracellular	I536	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
Fas	Fas	F200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
,	,	0000	,	O	O
activated	activate	A231	VBN	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
from	from	F650	IN	B-PP	O
all	all	A400	DT	B-NP	O
17	17	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
apoptotic	apoptotic	A132	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
exposed	expose	E212	VBN	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
anti	anti	A530	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Fas	Fas	F200	NN	I-NP	O
agonist	agonist	A252	NN	I-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
.	.	0000	.	O	O

Similar	Similar	S546	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
negative	negative	N231	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
transfected	transfecte	T652	VBN	B-VP	O
with	with	W300	IN	B-PP	O
cDNAs	cDNA	C352	NNS	B-NP	O
bearing	bear	B652	VBG	B-VP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
cotransfection	cotransfection	C365	NN	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
,	,	0000	,	O	O
Fas	Fas	F200	NN	B-NP	O
constructs	construct	C523	NNS	I-NP	O
with	with	W300	IN	B-PP	O
either	either	E360	CC	O	O
intra	intra	I536	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
or	or	O600	CC	I-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
caused	cause	C230	VBD	B-VP	O
dominant	dominant	D530	JJ	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
mediated	mediate	M300	VBN	B-VP	O
by	by	B000	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Fas	Fas	F200	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
Fas	Fas	F200	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	B-NP	O
not	not	N300	RB	I-NP	O
restricted	restricted	R236	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Variant	Variant	V653	NN	B-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
1	1	0000	CD	O	O
)	)	0000	)	O	O
T	T	T000	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
sequence	sequence	S252	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
mediates	mediate	M320	VBZ	B-VP	O
apoptosis	apoptosis	A132	NN	B-NP	O
less	less	L200	RBR	B-ADVP	O
well	well	W400	RB	I-ADVP	O
than	than	T500	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Fas	Fas	F200	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
partially	partially	P634	RB	B-ADJP	O
inhibitory	inhibitory	I513	JJ	I-ADJP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
African	African	A162	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
Fas	Fas	F200	NN	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
,	,	0000	,	O	O
dominant	dominant	D530	JJ	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
was	be	W200	VBD	B-VP	O
much	much	M200	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
pronounced	pronounced	P652	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
mutants	mutant	M353	NNS	B-NP	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
intracellular	intracellular	I536	JJ	I-NP	O
,	,	0000	,	O	O
versus	versus	V620	IN	B-PP	O
extracellular	extracellular	E236	JJ	B-ADJP	O
,	,	0000	,	O	O
portion	portion	P635	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
causing	cause	C252	VBG	B-VP	O
disruption	disruption	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intracellular	intracellular	I536	JJ	I-NP	O
Fas	Fas	F200	NN	I-NP	O
death	death	D300	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
-	-	0000	HYPH	O	O
bearing	bear	B652	VBG	B-VP	O
relatives	relative	R431	NNS	B-NP	O
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
related	relate	R430	VBN	B-NP	O
morbidity	morbidity	M613	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
44	44	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
with	with	W300	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
versus	versus	V620	IN	B-ADVP	O
0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
with	with	W300	IN	B-PP	O
extracellular	extracellular	E236	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
within	within	W350	IN	B-PP	O
APT1	APT1	A130	NN	B-NP	O
strongly	strongly	S365	RB	B-ADVP	O
influences	influence	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
.	.	0000	.	O	O

Multicentric	Multicentric	M432	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HFE	HFE	H100	NN	B-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
(	(	0000	(	O	O
GH	GH	G000	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
believed	believe	B413	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
restricted	restrict	R236	VBN	B-VP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
northwestern	northwestern	N632	JJ	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
,	,	0000	,	O	O
>	>	0000	SYM	B-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
GH	GH	G000	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
tyrosine	tyrosine	T625	NN	B-NP	O
for	for	F600	IN	B-PP	O
cysteine	cysteine	C235	NN	B-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
282	282	0000	CD	I-NP	O
(	(	0000	(	O	O
C282Y	C282Y	C000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unprocessed	unprocessed	U516	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
GH	GH	G000	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
,	,	0000	,	O	O
C282Y	C282Y	C000	NN	B-NP	O
and	and	A530	CC	I-NP	O
H63D	H63D	H300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
such	such	S200	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
predispose	predispose	P632	VB	I-VP	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
compound	compound	C515	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
to	to	T000	TO	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
differ	differ	D160	VBP	B-VP	O
,	,	0000	,	O	O
C282Y	C282Y	C000	NN	B-NP	O
being	be	B520	VBG	B-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
northwestern	northwestern	N632	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
ancestry	ancestry	A523	NN	I-NP	O
and	and	A530	CC	I-NP	O
H63D	H63D	H300	NN	I-NP	O
being	be	B520	VBG	B-VP	O
found	find	F530	VBN	I-VP	O
at	at	A300	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
>	>	0000	SYM	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
countries	country	C536	NNS	B-NP	O
bordering	border	B636	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Middle	Middle	M340	NNP	I-NP	O
East	East	E230	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Indian	Indian	I535	JJ	I-NP	O
subcontinent	subcontinent	S125	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
that	that	T300	WDT	B-NP	O
extends	extend	E235	VBZ	B-VP	O
<	<	0000	SYM	B-NP	O
/	/	0000	SYM	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
arisen	arise	A625	VBN	I-VP	O
during	during	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
past	past	P230	JJ	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
H63D	H63D	H300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
older	old	O436	JJR	B-ADJP	O
and	and	A530	CC	O	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
occur	occur	O260	VB	I-VP	O
on	on	O500	IN	B-PP	O
such	such	S200	PDT	B-NP	O
a	a	A000	DT	I-NP	O
large	large	L620	JJ	I-NP	O
extended	extend	E235	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
<	<	0000	SYM	B-NP	O
/	/	0000	SYM	B-NP	O
=	=	0000	SYM	B-VP	O
700	700	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
H63D	H63D	H300	NN	I-NP	O
and	and	A530	CC	I-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
on	on	O500	IN	B-PP	O
new	new	N000	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Sri	Sri	S600	NNP	B-NP	O
Lanka	Lanka	L520	NNP	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
H63D	H63D	H300	NN	B-NP	O
on	on	O500	IN	B-PP	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
C282Y	C282Y	C000	NN	B-NP	O
on	on	O500	IN	B-PP	O
one	one	O500	CD	B-NP	O
new	new	N000	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
,	,	0000	,	O	O
demonstrating	demonstrate	D523	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
arisen	arise	A625	VBN	I-VP	O
independently	independently	I531	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
island	island	I245	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
the	the	T000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
selection	selection	S423	NN	B-NP	O
pressure	pressure	P626	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
selection	selection	S423	NN	I-NP	O
pressures	pressure	P626	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
infectious	infectious	I512	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
,	,	0000	,	O	O
environmental	environmental	E516	JJ	B-NP	O
conditions	condition	C535	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
anemia	anemia	A500	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
retrospective	retrospective	R362	JJ	I-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
pilot	pilot	P430	NN	I-NP	O
study	study	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
newborns	newborn	N165	NNS	I-NP	O
for	for	F600	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Scandinavian	Scandinavian	S253	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
retrospectively	retrospectively	R362	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
837	837	0000	CD	B-NP	O
random	random	R535	JJ	I-NP	O
anonymized	anonymize	A523	VBN	B-VP	O
dried	dry	D630	VBD	B-VP	O
blood	blood	B430	NN	B-NP	O
spot	spot	S130	NN	I-NP	O
(	(	0000	(	O	O
DBS	DBS	D120	NN	B-NP	O
)	)	0000	)	O	O
samples	sample	S514	NNS	B-NP	O
from	from	F650	IN	B-PP	O
neonatal	neonatal	N534	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
programs	program	P626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Scandinavia	Scandinavia	S253	NNP	B-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
C282Y	C282Y	C000	NN	B-NP	O
allele	allele	A400	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
3	3	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Greenland	Greenland	G654	NNP	B-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
/	/	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
Iceland	Iceland	I245	NNP	B-NP	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Faeroe	Faeroe	F600	NNP	I-NP	O
Islands	Islands	I245	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
8	8	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
Denmark	Denmark	D562	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Denmark	Denmark	D562	NNP	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
population	population	P143	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
highly	highly	H240	RB	B-ADJP	O
advantageous	advantageous	A315	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
terms	term	T652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
preventive	preventive	P615	JJ	B-NP	O
health	health	H430	NN	I-NP	O
care	care	C600	NN	I-NP	O
.	.	0000	.	O	O

Long	Long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
term	term	T650	NN	I-NP	O
follow	follow	F400	VB	B-VP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
evaluation	evaluation	E143	NN	B-NP	O
of	of	O100	IN	B-PP	O
C282Y	C282Y	C000	NN	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
and	and	A530	CC	O	O
H63D	H63D	H300	NN	B-NP	O
/	/	0000	SYM	I-NP	O
C282Y	C282Y	C000	NN	I-NP	O
compound	compound	C515	NN	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
will	will	W400	MD	B-VP	O
give	give	G100	VB	I-VP	O
an	an	A500	DT	B-NP	O
indication	indication	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
alkaptonuria	alkaptonuria	A421	NN	I-NP	B-Disease
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
.	.	0000	.	O	O

Alkaptonuria	Alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
aku	aku	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
error	error	E600	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
metabolism	metabolism	M314	NN	B-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
homogentisate	homogentisate	H525	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
dioxygenase	dioxygenase	D252	NN	B-NP	O
(	(	0000	(	O	O
HGD	HGD	H230	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
created	create	C630	VBN	B-VP	O
by	by	B000	IN	B-PP	O
ethylnitrosourea	ethylnitrosourea	E345	NN	B-NP	O
mutagenesis	mutagenesis	M325	NN	I-NP	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
to	to	T000	TO	B-VP	O
amplify	amplify	A514	VB	I-VP	O
the	the	T000	DT	B-NP	O
Hgd	Hgd	H230	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
from	from	F650	IN	B-PP	O
Hgd	Hgd	H230	NN	B-NP	O
(	(	0000	(	O	O
aku	aku	A200	NN	B-NP	O
)	)	0000	)	O	O
/	/	0000	SYM	O	O
Hgd	Hgd	H230	NN	B-NP	O
(	(	0000	(	O	O
aku	aku	A200	NN	B-NP	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
products	product	P632	NNS	I-NP	O
shorter	short	S636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
product	product	P632	NN	I-NP	O
were	be	W600	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
were	be	W600	VBD	B-VP	O
then	then	T500	RB	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
Hgd	Hgd	H230	NN	I-NP	O
(	(	0000	(	O	O
aku	aku	A200	NN	B-NP	O
)	)	0000	)	O	O
mouse	mouse	M200	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
,	,	0000	,	O	O
causing	cause	C252	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
and	and	A530	CC	I-NP	O
frame	frame	F650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
shifted	shift	S130	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
base	base	B200	NN	I-NP	O
change	change	C520	NN	I-NP	O
allowed	allow	A430	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
create	create	C630	VB	I-VP	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
radioactive	radioactive	R323	JJ	I-NP	O
genotyping	genotyping	G531	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Non	Non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
enlarged	enlarged	E546	JJ	B-NP	B-Disease
vestibular	vestibular	V231	JJ	I-NP	I-Disease
aqueduct	aqueduct	A232	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Enlarged	Enlarged	E546	JJ	B-NP	B-Disease
vestibular	vestibular	V231	JJ	I-NP	I-Disease
aqueduct	aqueduct	A232	NN	I-NP	I-Disease
(	(	0000	(	O	O
EVA	EVA	E100	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
known	know	K500	VBN	B-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
inner	inner	I560	JJ	B-NP	B-Disease
ear	ear	E600	NN	I-NP	I-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
of	of	O100	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
interest	interest	I536	NN	I-NP	O
because	because	B200	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
anomaly	anomaly	A540	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
sensorineural	sensorineural	S526	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
EVA	EVA	E100	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
7q31	7q31	Q000	CD	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Pendred	Pendred	P536	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
seven	seven	S150	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Pendred	Pendred	P536	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
sensorineural	sensorineural	S526	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
EVA	EVA	E100	NN	B-NP	B-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compound	compound	C515	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
but	but	B300	CC	B-PP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	O
cause	cause	C200	VBP	B-VP	O
both	both	B300	CC	O	O
syndromic	syndromic	S536	JJ	B-ADJP	B-Disease
and	and	A530	CC	O	I-Disease
non	non	N500	AFX	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
29	29	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
neurologic	neurologic	N642	JJ	I-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
,	,	0000	,	O	O
occasionally	occasionally	O254	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
classic	classic	C420	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
usually	usually	U240	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
onset	onset	O523	NN	B-NP	O
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
(	(	0000	(	O	O
childhood	childhood	C430	NN	B-NP	B-Disease
cerebral	cerebral	C616	JJ	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
rapid	rapid	R130	JJ	B-NP	O
neurologic	neurologic	N642	JJ	I-NP	B-Disease
deterioration	deterioration	D363	NN	I-NP	I-Disease
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
vegetative	vegetative	V231	JJ	I-NP	O
state	state	S300	NN	I-NP	O
.	.	0000	.	O	O

Adult	Adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
cerebral	cerebral	C616	JJ	I-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
also	also	A420	RB	B-ADVP	O
presents	present	P625	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
rapidly	rapidly	R134	RB	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
neurologic	neurologic	N642	JJ	I-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
.	.	0000	.	O	O

Milder	Mild	M436	JJR	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
Addison	Addison	A325	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
also	also	A420	RB	I-ADVP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
discovery	discovery	D216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
causative	causative	C231	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
diverse	diverse	D162	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
presentations	presentation	P625	NNS	I-NP	O
remains	remain	R520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
elucidated	elucidate	E423	VBN	I-VP	O
.	.	0000	.	O	O

OBJECTIVES	OBJECTIVES	O123	NNS	B-NP	O
To	To	T000	TO	B-VP	O
conduct	conduct	C532	VB	I-VP	O
mutational	mutational	M354	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
29	29	0000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
from	from	F650	IN	B-PP	O
29	29	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
obtain	obtain	O135	VB	I-VP	O
knowledge	knowledge	K543	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
The	The	T000	DT	B-NP	O
29	29	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
comprised	comprise	C516	VBD	B-VP	O
13	13	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	B-Disease
cerebral	cerebral	C616	JJ	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
,	,	0000	,	O	O
11	11	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
cerebral	cerebral	C616	JJ	I-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conducted	conduct	C532	VBD	B-VP	O
detailed	detailed	D343	JJ	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
29	29	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
by	by	B000	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
Southern	Southern	S365	JJ	I-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
products	product	P632	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
total	total	T340	JJ	B-NP	O
RNA	RNA	R500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
extracted	extract	E236	VBN	I-VP	O
from	from	F650	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Three	Three	T600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
cerebral	cerebral	C616	JJ	I-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
large	large	L620	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
26	26	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
21	21	0000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
12	12	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
small	small	S540	JJ	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Eighteen	Eighteen	E235	CD	B-NP	O
(	(	0000	(	O	O
69	69	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
26	26	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
involved	involve	I514	VBD	B-VP	O
amino	amino	A500	NN	B-NP	O
acids	acid	A232	NNS	I-NP	O
conserved	conserve	C526	VBN	B-VP	O
in	in	I500	IN	B-PP	O
homologous	homologous	H542	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
PMP70	PMP70	P510	NN	B-NP	O
,	,	0000	,	O	O
mALDRP	mALDRP	M436	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Pxa1p	Pxa1p	P210	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
AG	AG	A200	NNP	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
1081	1081	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
1082	1082	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
white	white	W300	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
truncation	truncation	T652	NN	I-NP	O
or	or	O600	CC	O	O
subtle	subtle	S134	JJ	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
expressions	expression	E216	NNS	I-NP	O
between	between	B350	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
involving	involve	I514	VBG	B-VP	O
conserved	conserve	C526	VBN	B-NP	O
amino	amino	A500	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
and	and	A530	CC	O	O
those	those	T200	DT	B-NP	O
involving	involve	I514	VBG	B-VP	O
nonconserved	nonconserved	N525	JJ	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
other	other	O360	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
or	or	O600	CC	I-NP	O
environmental	environmental	E516	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
modify	modify	M310	VBP	B-VP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expressions	expression	E216	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
skin	skin	S250	NN	I-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
activating	activate	A231	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
.	.	0000	.	O	O

WNT	WNT	W530	NN	B-NP	O
signalling	signalling	S254	NN	I-NP	O
orchestrates	orchestrate	O623	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
developmental	developmental	D141	JJ	B-NP	O
programs	program	P626	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
stimulus	stimulus	S354	NN	I-NP	O
,	,	0000	,	O	O
cytoplasmic	cytoplasmic	C314	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
catenin	catenin	C350	NN	I-NP	O
(	(	0000	(	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
CTNNB1	CTNNB1	C351	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
stabilized	stabilize	S314	VBN	I-VP	O
,	,	0000	,	O	O
enabling	enable	E514	VBG	B-VP	O
downstream	downstream	D523	JJ	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activation	activation	A231	NN	I-NP	O
by	by	B000	IN	B-PP	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LEF	LEF	L100	NN	I-NP	O
/	/	0000	SYM	B-NP	O
TCF	TCF	T210	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
target	target	T623	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
/	/	0000	SYM	B-NP	O
TCF	TCF	T210	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
c	c	C000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
MYC	MYC	M200	NN	I-NP	O
,	,	0000	,	O	O
explaining	explain	E214	VBG	B-VP	O
why	why	W000	WRB	B-ADVP	O
constitutive	constitutive	C523	JJ	B-NP	O
activation	activation	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WNT	WNT	W530	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
can	can	C500	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
colon	colon	C450	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
colon	colon	C450	NN	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
arise	arise	A620	VBP	B-VP	O
from	from	F650	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
ubiquitin	ubiquitin	U123	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
degradation	degradation	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	O	O
catenin	catenin	C350	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
colon	colon	C450	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
some	some	S500	DT	B-NP	I-Disease
other	other	O360	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
harbour	harbour	H616	VBP	B-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
-	-	0000	HYPH	O	O
stabilizing	stabilize	S314	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
discovered	discover	D216	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
an	an	A500	DT	B-NP	O
activated	activate	A231	VBN	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
catenin	catenin	C350	NN	I-NP	O
are	be	A600	VBP	B-VP	O
predisposed	predispose	P632	VBN	I-VP	O
to	to	T000	TO	B-PP	O
developing	develop	D141	VBG	B-VP	O
skin	skin	S250	NN	B-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
resembling	resemble	R251	VBG	B-VP	O
pilomatricomas	pilomatricoma	P453	NNS	B-NP	B-Disease
.	.	0000	.	O	O

Given	Give	G150	VBN	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
skin	skin	S250	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
exhibits	exhibit	E213	VBZ	B-VP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
hair	hair	H600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
follicle	follicle	F424	NN	I-NP	O
morphogenesis	morphogenesis	M612	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
wondered	wonder	W536	VBD	B-VP	O
whether	whether	W360	IN	B-SBAR	O
human	human	H500	JJ	B-NP	O
pilomatricomas	pilomatricoma	P453	NNS	I-NP	B-Disease
might	might	M230	MD	B-VP	O
originate	originate	O625	VB	I-VP	O
from	from	F650	IN	B-PP	O
hair	hair	H600	NN	B-NP	O
matrix	matrix	M362	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
whether	whether	W360	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
might	might	M230	MD	B-VP	O
possess	possess	P200	VB	I-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
-	-	0000	HYPH	O	O
stabilizing	stabilize	S314	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
explore	explore	E214	VBP	B-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	I-NP	O
aetiology	aetiology	A342	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
common	common	C500	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
skin	skin	S250	NN	I-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
nuclear	nuclear	N246	JJ	B-NP	O
LEF	LEF	L100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
dividing	divide	D135	VBG	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
providing	provide	P613	VBG	B-VP	O
biochemical	biochemical	B252	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
pilomatricomas	pilomatricoma	P453	NNS	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
derived	derive	D613	VBN	I-VP	O
from	from	F650	IN	B-PP	O
hair	hair	H600	NN	B-NP	O
matrix	matrix	M362	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

At	At	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
75	75	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
possess	possess	P200	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
,	,	0000	,	O	O
normally	normally	N654	RB	B-ADVP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
phosphorylation	phosphorylation	P216	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
,	,	0000	,	I-NP	O
ubiquitin	ubiquitin	U123	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
mediated	mediate	M300	VBN	B-NP	O
degradation	degradation	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTNNB1	CTNNB1	C351	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
greater	great	G636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
other	other	O360	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
examined	examine	E253	VBN	B-VP	O
thus	thus	T200	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
directly	directly	D623	RB	B-VP	O
implicates	implicate	I514	VBZ	I-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
catenin	catenin	C350	NN	I-NP	O
/	/	0000	SYM	I-NP	O
LEF	LEF	L100	NN	I-NP	O
misregulation	misregulation	M262	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hair	hair	H600	NN	B-NP	O
matrix	matrix	M362	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Pendred	Pendred	P536	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
chloride	chloride	C463	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
iodide	iodide	I300	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
syndromic	syndromic	S536	JJ	B-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
and	and	A530	CC	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	O
sensorineural	sensorineural	S526	JJ	I-NP	B-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
goitre	goitre	G360	NN	I-NP	B-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
7	7	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
subsequently	subsequently	S125	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
positional	positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
.	.	0000	.	O	O

PDS	PDS	P320	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
designated	designate	D253	VBN	B-VP	O
pendrin	pendrin	P536	NN	B-NP	O
.	.	0000	.	O	O

Pendrin	Pendrin	P536	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	B-ADJP	O
related	related	R430	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
sulfate	sulfate	S413	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
-	-	0000	HYPH	O	O
anion	anion	A500	NN	B-NP	O
transporter	transporter	T652	NN	I-NP	O
(	(	0000	(	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Sat	Sat	S300	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
;	;	0000	:	O	O
29	29	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
(	(	0000	(	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
DTD	DTD	D300	NN	B-NP	O
;	;	0000	:	O	O
32	32	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
downregulated	downregulate	D562	VBN	B-VP	O
in	in	I500	IN	B-PP	O
adenoma	adenoma	A350	NN	B-NP	B-Disease
(	(	0000	(	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
DRA	DRA	D600	NN	B-NP	O
;	;	0000	:	O	O
45	45	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
homology	homology	H542	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
slightly	slightly	S423	RB	I-NP	O
modified	modify	M313	VBN	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
transporter	transporter	T652	NN	I-NP	O
signature	signature	S253	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
comprising	comprise	C516	VBG	B-VP	O
its	its	I320	PRP$	B-NP	O
putative	putative	P310	JJ	I-NP	O
second	second	S253	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
pendrin	pendrin	P536	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
unable	unable	U514	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
sulfate	sulfate	S413	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
pendrin	pendrin	P536	NN	B-NP	O
in	in	I500	IN	B-PP	O
Xenopus	Xenopus	X512	NNP	B-NP	O
laevis	laevis	L120	NNP	I-NP	O
oocytes	oocyte	O232	NNS	I-NP	O
by	by	B000	IN	B-PP	O
microinjection	microinjection	M265	NN	B-NP	O
of	of	O100	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	O
cRNA	cRNA	C650	NN	I-NP	O
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
Sf9	Sf9	S100	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
following	follow	F452	VBG	B-PP	O
infection	infection	I512	NN	B-NP	O
with	with	W300	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
baculovirus	baculovirus	B241	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rates	rate	R320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
transport	transport	T652	NN	B-NP	O
for	for	F600	IN	B-PP	O
iodide	iodide	I300	NN	B-NP	O
and	and	A530	CC	I-NP	O
chloride	chloride	C463	NN	I-NP	O
were	be	W600	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
following	follow	F452	VBG	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
pendrin	pendrin	P536	NN	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
pendrin	pendrin	P536	NN	B-NP	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
transporter	transporter	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
chloride	chloride	C463	NN	B-NP	O
and	and	A530	CC	I-NP	O
iodide	iodide	I300	NN	I-NP	O
,	,	0000	,	B-NP	O
but	but	B300	CC	I-NP	O
not	not	N300	RB	I-NP	O
sulfate	sulfate	S413	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
insight	insight	I523	NN	B-NP	O
into	into	I530	IN	B-PP	O
thyroid	thyroid	T630	JJ	B-NP	O
physiology	physiology	P242	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
pathophysiology	pathophysiology	P312	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pendred	Pendred	P536	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
711	711	0000	CD	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
:	:	0000	:	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
S65C	S65C	S200	NN	B-NP	O
implication	implication	I514	NN	I-NP	O
in	in	I500	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HH	HH	H000	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
an	an	A500	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
class	class	C420	NN	I-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
1996	1996	0000	CD	B-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
C282Y	C282Y	C000	NN	B-NP	O
,	,	0000	,	O	O
accounting	account	A253	VBG	B-VP	O
for	for	F600	IN	B-PP	O
80	80	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
to	to	T000	TO	B-PP	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
H63D	H63D	H300	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
representing	represent	R162	VBG	B-VP	O
40	40	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
to	to	T000	TO	I-NP	O
70	70	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
C282Y	C282Y	C000	NN	I-NP	O
HH	HH	H000	NN	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
C282Y	C282Y	C000	NN	B-NP	O
,	,	0000	,	O	O
H63D	H63D	H300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
193A	193A	A000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
S65C	S65C	S200	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
and	and	A530	CC	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
confirm	confirm	C516	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
main	main	M500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
,	,	0000	,	O	O
accounting	account	A253	VBG	B-VP	O
for	for	F600	IN	B-PP	O
85	85	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
H63D	H63D	H300	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
represented	represent	R162	VBD	B-VP	O
39	39	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HH	HH	H000	NN	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
carry	carry	C600	VB	I-VP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
screening	screening	S265	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
S65C	S65C	S200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
enriched	enrich	E562	VBN	I-VP	O
in	in	I500	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
without	without	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
assigned	assign	A253	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
neither	neither	N360	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
nor	nor	N600	CC	I-NP	O
H63D	H63D	H300	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
enrichment	enrichment	E562	NN	I-NP	O
of	of	O100	IN	B-PP	O
S65C	S65C	S200	NN	B-NP	O
among	among	A520	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
S65C	S65C	S200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
objective	objective	O123	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
to	to	T000	TO	I-VP	O
provide	provide	P613	VB	I-VP	O
more	more	M600	RBR	B-NP	O
accurate	accurate	A263	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
estimates	estimate	E235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
)	)	0000	)	O	O
germline	germline	G654	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
achieve	achieve	A210	VB	I-VP	O
this	this	T200	DT	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
consecutive	consecutive	C523	JJ	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
study	study	S300	NN	I-NP	O
reporting	report	R163	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
screen	screen	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
hundred	hundred	H536	CD	I-NP	O
and	and	A530	CC	I-NP	O
seven	seven	S150	CD	I-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
RNase	RNase	R520	NN	I-NP	O
mismatch	mismatch	M253	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
truncating	truncate	T652	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
962del4	962del4	D400	CD	B-NP	O
and	and	A530	CC	I-NP	O
3600del11	3600del11	D400	CD	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
novel	novel	N140	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
previously	previously	P612	RB	B-NP	O
reported	report	R163	VBN	I-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
common	common	C500	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
91	91	0000	CD	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
series	series	S620	NN	I-NP	O
and	and	A530	CC	O	O
24	24	0000	CD	B-NP	O
sister	sister	S236	NN	I-NP	O
controls	control	C536	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Q356R	Q356R	Q600	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADVP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
03	03	0000	CD	O	O
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
may	may	M000	MD	B-VP	O
influence	influence	I514	VB	I-VP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
summary	summary	S560	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
some	some	S500	DT	B-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
rare	rare	R600	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
polymorphisms	polymorphism	P456	NNS	B-NP	O
in	in	I500	IN	B-PP	O
determining	determine	D365	VBG	B-VP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
highlight	highlight	H242	VBP	B-VP	O
the	the	T000	DT	B-NP	O
necessity	necessity	N230	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
truncating	truncate	T652	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
related	relate	R430	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
can	can	C500	MD	B-VP	O
compensate	compensate	C515	VB	I-VP	O
functionally	functionally	F523	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
protein	protein	P635	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
therapy	therapy	T610	NN	B-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
ATP	ATP	A310	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
cassette	cassette	C230	NN	B-NP	O
(	(	0000	(	O	O
ABC	ABC	A120	NN	B-NP	O
)	)	0000	)	O	O
transporter	transporter	T652	NN	B-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
ALDP	ALDP	A431	NN	B-NP	O
)	)	0000	)	O	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
lethal	lethal	L340	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
which	which	W200	WDT	B-NP	O
no	no	N000	DT	B-NP	O
efficient	efficient	E125	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
established	establish	E231	VBN	I-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
other	other	O360	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
ABC	ABC	A120	NNP	I-NP	O
transporters	transporter	T652	NNS	I-NP	O
currently	currently	C653	RB	B-ADVP	O
are	be	A600	VBP	B-VP	O
known	know	K500	VBN	I-VP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	O
-	-	0000	HYPH	O	O
related	relate	R430	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
ALDRP	ALDRP	A436	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
70	70	0000	CD	B-NP	O
kDa	kDa	K300	NN	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PMP70	PMP70	P510	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
PMP70	PMP70	P510	NN	B-NP	O
-	-	0000	HYPH	O	O
related	relate	R430	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
transient	transient	T652	JJ	B-NP	O
and	and	A530	CC	I-NP	O
stable	stable	S314	JJ	I-NP	O
overexpression	overexpression	O162	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
ALDP	ALDP	A431	NN	B-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
closest	close	C423	JJS	I-NP	O
relative	relative	R431	JJ	I-NP	O
ALDRP	ALDRP	A436	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
could	could	C430	MD	B-VP	O
restore	restore	R236	VB	I-VP	O
the	the	T000	DT	B-NP	O
impaired	impaired	I516	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
in	in	I500	IN	B-PP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
ALD	ALD	A430	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pathognomonic	pathognomonic	P325	JJ	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
could	could	C430	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
prevented	prevent	P615	VBN	I-VP	O
by	by	B000	IN	B-PP	O
overexpression	overexpression	O162	NN	B-NP	O
of	of	O100	IN	B-PP	O
ALDRP	ALDRP	A436	NN	B-NP	O
in	in	I500	IN	B-PP	O
immortalized	immortalize	I563	VBN	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
ALD	ALD	A430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Immunofluorescence	Immunofluorescence	I514	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
replacement	replacement	R142	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALDP	ALDP	A431	NN	B-NP	O
by	by	B000	IN	B-PP	O
ALDRP	ALDRP	A436	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
stabilization	stabilization	S314	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
ALDP	ALDP	A431	NN	I-NP	O
itself	itself	I324	PRP	B-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
restore	restore	R236	VB	I-VP	O
the	the	T000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALDP	ALDP	A431	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
by	by	B000	IN	B-PP	O
stimulation	stimulation	S354	NN	B-NP	O
of	of	O100	IN	B-PP	O
ALDRP	ALDRP	A436	NN	B-NP	O
and	and	A530	CC	I-NP	O
PMP70	PMP70	P510	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
dietary	dietary	D360	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
peroxisome	peroxisome	P625	NN	I-NP	O
proliferator	proliferator	P641	NN	I-NP	O
fenofibrate	fenofibrate	F516	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
correction	correction	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
ALD	ALD	A430	NN	B-NP	I-Disease
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
possible	possible	P214	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
drug	drug	D620	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
overexpression	overexpression	O162	NN	I-NP	O
or	or	O600	CC	O	O
ectopic	ectopic	E231	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALDRP	ALDRP	A436	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Centrosome	Centrosome	C536	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
G2	G2	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
M	M	M000	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
induce	induce	I532	VBP	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	B-NP	O
isoform	isoform	I216	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Brca1	Brca1	B620	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
predispose	predispose	P632	NN	I-NP	O
women	woman	W500	NNS	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
mechanisms	mechanism	M252	NNS	B-NP	O
underlying	underlie	U536	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
-	-	0000	HYPH	O	O
related	relate	R430	VBN	B-NP	O
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
derived	derive	D613	VBD	B-VP	O
mouse	mouse	M200	NN	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
fibroblast	fibroblast	F161	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
targeted	target	T623	VBN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Brca1	Brca1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
maintain	maintain	M535	VBP	B-VP	O
an	an	A500	DT	B-NP	O
intact	intact	I532	JJ	I-NP	O
G1	G1	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
S	S	S000	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
and	and	A530	CC	O	O
proliferate	proliferate	P641	VBP	B-VP	O
poorly	poorly	P640	RB	B-ADVP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
G2	G2	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
M	M	M000	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
accompanied	accompany	A251	VBN	I-VP	O
by	by	B000	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Mutant	Mutant	M353	JJ	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
contain	contain	C535	VBP	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
,	,	0000	,	I-NP	O
functional	functional	F523	JJ	I-NP	O
centrosomes	centrosome	C536	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
unequal	unequal	U524	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
segregation	segregation	S262	NN	I-NP	O
,	,	0000	,	O	O
abnormal	abnormal	A156	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
division	division	D125	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
aneuploidy	aneuploidy	A514	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
uncover	uncover	U521	VBP	B-VP	O
an	an	A500	DT	B-NP	O
essential	essential	E253	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
maintaining	maintain	M535	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
stability	stability	S314	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
centrosome	centrosome	C536	NN	B-NP	O
duplication	duplication	D142	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
G2	G2	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
M	M	M000	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Defective	Defective	D123	JJ	B-NP	O
CD95	CD95	C300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
APO	APO	A100	NN	I-NP	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
Fas	Fas	F200	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
formation	formation	F653	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
autoimmune	autoimmune	A350	JJ	I-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
type	type	T100	NN	B-NP	I-Disease
Ia	Ia	I000	NN	I-NP	I-Disease
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CD95	CD95	C300	NN	I-NP	O
(	(	0000	(	O	O
APO	APO	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
Fas	Fas	F200	NN	I-NP	O
)	)	0000	)	O	O
receptor	receptor	R213	NN	B-NP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
dominantly	dominantly	D534	RB	B-VP	O
interfere	interfere	I536	VBP	I-VP	O
with	with	W300	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
unknown	unknown	U525	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
local	local	L240	JJ	B-NP	O
or	or	O600	CC	I-NP	O
global	global	G414	JJ	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytoplasmic	cytoplasmic	C314	JJ	I-NP	O
death	death	D300	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
CD95	CD95	C300	NN	I-NP	O
death	death	D300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
domain	domain	D500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
to	to	T000	TO	B-VP	O
bind	bind	B530	VB	I-VP	O
the	the	T000	DT	B-NP	O
FADD	FADD	F300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
MORT1	MORT1	M630	NN	I-NP	O
signaling	signaling	S254	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
from	from	F650	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
FADD	FADD	F300	NN	B-NP	O
association	association	A235	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
caspase	caspase	C212	NN	B-NP	O
recruitment	recruitment	R263	NN	I-NP	O
and	and	A530	CC	O	O
activation	activation	A231	NN	B-NP	O
after	after	A136	IN	B-PP	O
CD95	CD95	C300	NN	B-NP	O
crosslinking	crosslinking	C624	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
intracytoplasmic	intracytoplasmic	I536	JJ	B-NP	O
CD95	CD95	C300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
impair	impair	I516	NN	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
chiefly	chiefly	C140	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
disrupting	disrupt	D261	VBG	B-VP	O
death	death	D300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
domain	domain	D500	NN	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
signaling	signaling	S254	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
FADD	FADD	F300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
MORT1	MORT1	M630	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
and	and	A530	CC	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
CCC	CCC	C200	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homogentisate	homogentisate	H525	NN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
dioxygenase	dioxygenase	D252	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HGO	HGO	H200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homogentisate	homogentisate	H525	NN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
dioxygenase	dioxygenase	D252	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HGO	HGO	H200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Herein	Herein	H650	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
haplotype	haplotype	H143	NN	B-NP	O
and	and	A530	CC	O	O
mutational	mutational	M354	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
new	new	N000	JJ	I-NP	O
AKU	AKU	A200	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
two	two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
INV4	INV4	I510	NN	B-NP	O
+	+	0000	SYM	B-NP	O
31A	31A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
and	and	A530	CC	I-NP	O
INV11	INV11	I510	NN	I-NP	O
+	+	0000	SYM	B-NP	O
18A	18A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
six	six	S200	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
AKU	AKU	A200	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
INV1	INV1	I510	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1G	1G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
W60G	W60G	W200	NN	B-NP	O
,	,	0000	,	O	O
Y62C	Y62C	Y200	NN	B-NP	O
,	,	0000	,	O	O
A122D	A122D	A300	NN	B-NP	O
,	,	0000	,	O	O
P230T	P230T	P300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D291E	D291E	D000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
further	further	F636	RB	B-ADVP	O
illustrates	illustrate	I423	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
remarkable	remarkable	R562	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
AKU	AKU	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Reexamination	Reexamination	R253	NN	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
29	29	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
thus	thus	T200	RB	B-ADVP	O
far	far	F600	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
randomly	randomly	R535	RB	B-VP	O
distributed	distribute	D236	VBN	I-VP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
CCC	CCC	C200	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
inverted	invert	I516	VBN	I-NP	O
complement	complement	C514	NN	I-NP	O
,	,	0000	,	O	O
GGG	GGG	G200	NN	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
involve	involve	I514	VB	I-VP	O
CpG	CpG	C120	NN	B-NP	O
dinucleotides	dinucleotide	D524	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
illustrates	illustrate	I423	VBZ	B-VP	O
important	important	I516	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
between	between	B350	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
at	at	A300	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
short	short	S630	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
sequence	sequence	S252	NN	I-NP	O
motifs	motif	M312	NNS	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
CCC	CCC	C200	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
motifs	motif	M312	NNS	I-NP	O
comprise	comprise	C516	VBP	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
(	(	0000	(	O	O
34	34	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
bases	base	B200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
CCC	CCC	C200	NN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
in	in	I500	IN	B-PP	O
HGO	HGO	H200	NN	B-NP	O
.	.	0000	.	O	O

Fabry	Fabry	F160	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
galactosidase	galactosidase	G423	NN	I-NP	O
A	A	A000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
carrier	carrier	C600	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
fluorescent	fluorescent	F462	JJ	B-NP	O
chemical	chemical	C524	JJ	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
mismatches	mismatch	M253	NNS	B-NP	O
.	.	0000	.	O	O

Fabry	Fabry	F160	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
FD	FD	F300	NN	B-NP	B-Disease
)	)	0000	)	O	O
(	(	0000	(	O	O
angiokeratoma	angiokeratoma	A526	NN	B-NP	B-Disease
corporis	corporis	C616	NN	I-NP	I-Disease
diffusum	diffusum	D125	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
inborn	inborn	I516	JJ	B-NP	I-Disease
error	error	E600	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
glycosphingolipid	glycosphingolipid	G421	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
galactosidase	galactosidase	G423	NN	I-NP	O
A	A	A000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
GLA	GLA	G400	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
systemic	systemic	S235	JJ	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
neutral	neutral	N364	JJ	B-NP	O
glycosphingolipids	glycosphingolipid	G421	NNS	I-NP	O
with	with	W300	IN	B-PP	O
terminal	terminal	T654	JJ	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
galactosyl	galactosyl	G423	NN	I-NP	O
moieties	moiety	M320	NNS	I-NP	O
.	.	0000	.	O	O

Clinically	Clinically	C452	RB	B-ADVP	O
,	,	0000	,	O	O
affected	affect	A123	VBD	B-VP	O
hemizygous	hemizygous	H520	JJ	B-NP	O
males	male	M420	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
angiokeratoma	angiokeratoma	A526	NN	B-NP	B-Disease
,	,	0000	,	O	O
severe	severe	S160	JJ	B-NP	B-Disease
acroparesthesia	acroparesthesia	A261	NN	I-NP	I-Disease
,	,	0000	,	O	O
renal	renal	R540	JJ	B-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
vasculopathy	vasculopathy	V241	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
heart	heart	H630	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
brain	brain	B650	NN	I-NP	I-Disease
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
demonstration	demonstration	D523	NN	B-NP	O
of	of	O100	IN	B-PP	O
alpha	alpha	A410	SYM	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
galactosidase	galactosidase	G423	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
leukocytes	leukocyte	L232	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
diagnostic	diagnostic	D252	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
,	,	0000	,	O	O
enzymatic	enzymatic	E525	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	B-ADVP	O
inconclusive	inconclusive	I525	JJ	B-ADJP	O
,	,	0000	,	O	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
random	random	R535	VB	I-VP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
,	,	0000	,	O	O
underlining	underline	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
need	need	N300	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
investigations	investigation	I512	NNS	I-NP	O
for	for	F600	IN	B-PP	O
accurate	accurate	A263	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
counseling	counseling	C524	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
chemical	chemical	C524	JJ	B-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
mismatches	mismatch	M253	NNS	B-NP	O
adapted	adapt	A313	VBN	B-VP	O
to	to	T000	TO	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
detection	detection	D323	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
alpha	alpha	A410	SYM	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Gal	Gal	G400	NN	I-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
six	six	S200	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FD	FD	F300	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
included	include	I524	VBD	B-VP	O
five	five	F100	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
C202W	C202W	C000	NN	B-NP	O
,	,	0000	,	O	O
C223G	C223G	C200	NN	B-NP	O
,	,	0000	,	O	O
N224D	N224D	N300	NN	B-NP	O
,	,	0000	,	O	O
R301Q	R301Q	R200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Q327K	Q327K	Q200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
[	[	0000	(	I-NP	O
IVS3	IVS3	I120	NN	I-NP	O
G	G	G000	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
level	level	L140	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
altered	altered	A436	JJ	B-NP	O
pre	pre	P600	AFX	I-NP	O
-	-	0000	HYPH	O	O
mRNA	mRNA	M650	NN	B-NP	O
splicing	splicing	S142	NN	I-NP	O
with	with	W300	IN	B-PP	O
consequent	consequent	C525	JJ	B-NP	O
alteration	alteration	A436	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
translational	translational	T652	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
and	and	A530	CC	I-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
translation	translation	T652	NN	B-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
strategy	strategy	S363	NN	I-NP	O
,	,	0000	,	O	O
carrier	carrier	C600	NN	B-NP	O
status	status	S320	NN	I-NP	O
was	be	W200	VBD	B-VP	O
accurately	accurately	A263	RB	I-VP	O
assessed	assess	A230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
at	at	A300	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
risk	risk	R200	NN	I-NP	O
females	female	F542	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
enzymatic	enzymatic	E525	JJ	B-NP	O
dosages	dosage	D200	NNS	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	B-PP	O
diagnose	diagnose	D252	NN	B-NP	O
or	or	O600	CC	O	O
exclude	exclude	E243	VB	B-VP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Prenatal	Prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
by	by	B000	IN	B-PP	O
FISH	FISH	F200	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
duplication	duplication	D142	NN	B-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MIM	MIM	M500	NN	B-NP	O
312080	312080	0000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
made	make	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
young	young	Y520	JJ	I-NP	O
boy	boy	B000	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
boys	boy	B200	VBZ	B-VP	O
maternal	maternal	M365	JJ	B-NP	O
aunt	aunt	A530	NN	I-NP	O
came	come	C500	VBD	B-VP	O
for	for	F600	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
16	16	0000	CD	B-NP	O
+	+	0000	SYM	I-NP	O
weeks	week	W200	NNS	I-NP	O
pregnant	pregnant	P625	JJ	B-ADJP	O
and	and	A530	CC	O	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
fetus	fetus	F320	NN	I-NP	O
.	.	0000	.	O	O

Samples	Sample	S514	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
duplication	duplication	D142	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
interphase	interphase	I536	NN	B-NP	O
FISH	FISH	F200	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
lymphocyte	lymphocyte	L512	NN	B-NP	O
preparations	preparation	P616	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
aunt	aunt	A530	NN	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
amniotic	amniotic	A532	JJ	I-NP	O
fluid	fluid	F430	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
preparation	preparation	P616	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
confirming	confirm	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
neither	neither	N360	CC	O	O
the	the	T000	DT	B-NP	O
aunt	aunt	A530	NN	I-NP	O
nor	nor	N600	CC	O	O
the	the	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Dominant	Dominant	D530	JJ	B-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC1309	APC1309	A120	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
.	.	0000	.	O	O

Inactivation	Inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
product	product	P632	NN	I-NP	O
initiates	initiate	I532	VBZ	B-VP	O
colorectal	colorectal	C462	JJ	B-NP	O
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
APC	APC	A120	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
carry	carry	C600	VBP	B-VP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
develop	develop	D141	VBP	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
subsequent	subsequent	S125	JJ	B-NP	O
carcinomas	carcinoma	C625	NNS	I-NP	B-Disease
early	early	E640	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
life	life	L100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
correlates	correlate	C643	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
and	and	A530	CC	O	O
sporadic	sporadic	S163	JJ	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
cluster	cluster	C423	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
points	point	P532	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutants	mutant	M353	NNS	I-NP	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
function	function	F523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
recently	recently	R253	RB	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
enhanced	enhance	E523	VBN	B-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	B-NP	O
Tcf	Tcf	T210	NN	I-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
colon	colon	C450	NN	B-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
experimental	experimental	E216	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
polyposis	polyposis	P412	NN	I-NP	B-Disease
.	.	0000	.	O	O

Wild	Wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	B-NP	O
Tcf	Tcf	T210	NN	I-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
strongly	strongly	S365	RB	I-VP	O
inhibited	inhibit	I513	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
truncated	truncate	T652	VBN	I-VP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1309	1309	0000	CD	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
mutant	mutant	M353	JJ	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
codon	codon	C350	NN	B-NP	O
386	386	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
1465	1465	0000	CD	I-NP	O
)	)	0000	)	O	O
interfered	interfere	I536	VBD	B-VP	O
only	only	O540	RB	B-ADVP	O
weakly	weakly	W240	RB	I-ADVP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
idea	idea	I300	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
growth	growth	G630	NN	I-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
part	part	P630	NN	B-NP	O
,	,	0000	,	O	O
driven	drive	D615	VBN	B-VP	O
by	by	B000	IN	B-PP	O
selection	selection	S423	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
components	component	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
histone	histone	H235	NN	I-NP	O
deacetylase	deacetylase	D234	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
contains	contain	C535	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
carboxyl	carboxyl	C612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
(	(	0000	(	O	O
BRCT	BRCT	B623	NN	B-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
shared	share	S630	VBN	I-VP	O
with	with	W300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
other	other	O360	JJ	I-NP	O
proteins	protein	P635	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
maintaining	maintain	M535	VBG	B-VP	O
genome	genome	G500	NN	B-NP	O
integrity	integrity	I532	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
effort	effort	E163	NN	I-NP	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
sought	seek	S230	VBD	B-VP	O
to	to	T000	TO	I-VP	O
isolate	isolate	I243	VB	I-VP	O
proteins	protein	P635	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
interact	interact	I536	VBP	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCT	BRCT	B623	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Purified	Purify	P613	VBN	B-NP	O
BRCT	BRCT	B623	NN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
placenta	placenta	P425	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
library	library	L160	NN	I-NP	O
by	by	B000	IN	B-PP	O
Far	Far	F600	NNP	B-NP	O
Western	Western	W236	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Rb	Rb	R100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
binding	bind	B535	VBG	I-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	I-NP	O
RbAp46	RbAp46	R100	NN	I-NP	O
and	and	A530	CC	I-NP	O
RbAp48	RbAp48	R100	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
with	with	W300	IN	B-PP	O
Rb	Rb	R100	NN	B-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
BRCT	BRCT	B623	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
associates	associate	A232	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
histone	histone	H235	NN	I-NP	O
deacetylases	deacetylas	D234	NNS	I-NP	O
HDAC1	HDAC1	H320	NN	I-NP	O
and	and	A530	CC	I-NP	O
HDAC2	HDAC2	H320	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
components	component	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
histone	histone	H235	NN	I-NP	O
deacetylase	deacetylase	D234	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-VP	O
may	may	M000	MD	I-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
processes	process	P620	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
transcription	transcription	T652	NN	B-NP	O
,	,	0000	,	O	O
DNA	DNA	D500	NN	B-NP	O
repair	repair	R160	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
recombination	recombination	R251	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-NP	B-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C6	C6	C000	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
routine	routine	R350	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
sera	serum	S600	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
discovered	discover	D216	VBN	I-VP	O
who	who	W000	WP	B-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
sub	sub	S100	AFX	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
total	total	T340	JJ	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C6	C6	C000	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
C7	C7	C000	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
family	family	F540	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
characteristic	characteristic	C623	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
being	be	B520	VBG	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
silent	silent	S453	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
low	low	L000	JJ	B-NP	O
quantities	quantity	Q532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
C6	C6	C000	NN	I-NP	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
both	both	B300	CC	O	O
antigenically	antigenically	A532	RB	B-ADJP	O
deficient	deficient	D125	JJ	I-ADJP	O
and	and	A530	CC	O	O
smaller	small	S546	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
(	(	0000	(	O	O
110	110	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
daltons	dalton	D435	NNS	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
140	140	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
daltons	dalton	D435	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
small	small	S540	JJ	B-NP	O
quantities	quantity	Q532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
apparently	apparently	A165	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
C7	C7	C000	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
concluded	conclude	C524	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
likely	likely	L240	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
C6	C6	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
produces	produce	P632	VBZ	B-VP	O
hyopsynthesis	hyopsynthesis	H125	NN	B-NP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
of	of	O100	IN	B-PP	O
C6	C6	C000	NN	B-NP	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
C7	C7	C000	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
C6	C6	C000	NN	B-NP	O
and	and	A530	CC	I-NP	O
C7	C7	C000	NN	I-NP	O
may	may	M000	MD	B-VP	O
function	function	F523	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
unit	unit	U530	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
transcript	transcript	T652	NN	I-NP	O
copied	copy	C130	VBD	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
includes	include	I524	VBZ	B-VP	O
information	information	I516	NN	B-NP	O
for	for	F600	IN	B-PP	O
both	both	B300	DT	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Changes	Change	C520	NNS	B-NP	O
at	at	A300	IN	B-PP	O
P183	P183	P000	NN	B-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
weaken	weaken	W250	VBN	B-VP	O
its	its	I320	PRP$	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	O	O
protein	protein	P635	NN	B-NP	O
interactions	interaction	I536	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
early	early	E640	JJ	B-NP	O
contractures	contracture	C536	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
elbows	elbow	E412	NNS	I-NP	I-Disease
,	,	0000	,	O	I-Disease
Achilles	Achilles	A242	NNP	B-NP	I-Disease
tendons	tendon	T535	NNS	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
spine	spine	S150	NN	B-NP	I-Disease
,	,	0000	,	O	O
slowly	slowly	S400	RB	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
wasting	wasting	W235	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
weakness	weakness	W252	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
conduction	conduction	C532	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
and	and	A530	CC	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
34	34	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
serine	serine	S650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
emerin	emerin	E565	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
envelope	envelope	E514	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
spanning	span	S152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
unrelated	unrelated	U564	JJ	B-NP	O
EDMD	EDMD	E353	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
predict	predict	P632	VBP	B-VP	O
the	the	T000	DT	B-NP	O
replacement	replacement	R142	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
proline	proline	P645	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
183	183	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
either	either	E360	CC	O	O
a	a	A000	DT	B-NP	O
histidine	histidine	H235	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
threonine	threonine	T650	NN	I-NP	O
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mobility	mobility	M143	NN	I-NP	O
and	and	A530	CC	I-NP	O
expression	expression	E216	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
are	be	A600	VBP	B-VP	O
indistinguishable	indistinguishable	I532	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
emerin	emerin	E565	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
weakened	weaken	W253	VBN	I-VP	O
interactions	interaction	I536	NNS	B-NP	O
with	with	W300	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
lamina	lamina	L500	NN	I-NP	O
components	component	C515	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
usual	usual	U240	JJ	I-NP	O
EDMD	EDMD	E353	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
P183	P183	P000	NN	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
first	first	F623	JJ	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
,	,	0000	,	O	O
elbow	elbow	E410	NN	B-NP	B-Disease
contractures	contracture	C536	NNS	I-NP	I-Disease
,	,	0000	,	O	O
ankle	ankle	A524	NN	B-NP	B-Disease
contractures	contracture	C536	NNS	I-NP	I-Disease
,	,	0000	,	O	O
upper	upper	U160	JJ	B-NP	B-Disease
limb	limb	L510	NN	I-NP	I-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
and	and	A530	CC	O	O
lower	low	L600	JJR	B-NP	B-Disease
limb	limb	L510	NN	I-NP	I-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
involvement	involvement	I514	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
on	on	O500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
proline	proline	P645	NN	B-NP	O
183	183	0000	CD	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
proper	proper	P616	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
/	/	0000	SYM	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Microdeletions	Microdeletion	M263	NNS	B-NP	O
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
bands	band	B532	NNS	I-NP	O
1q32	1q32	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q41	q41	Q000	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Van	Van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Van	Van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
VWS	VWS	V200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
comprising	comprise	C516	VBG	B-VP	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
cleft	cleft	C413	JJ	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
lip	lip	L100	NN	I-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
reported	report	R163	VBD	B-VP	O
previously	previously	P612	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
500	500	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
800	800	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
localized	localize	L242	VBD	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
bands	band	B532	NNS	I-NP	O
1q32	1q32	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q41	q41	Q000	NN	I-NP	O
[	[	0000	(	O	O
Sander	Sander	S536	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1994	1994	0000	CD	B-NP	O
Hum	Hum	H500	NNP	I-NP	O
Mol	Mol	M400	NNP	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
3	3	0000	CD	I-NP	O
576	576	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
578	578	0000	CD	I-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

Along	Along	A452	IN	B-PP	O
with	with	W300	IN	B-PP	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
palate	palate	P430	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
lip	lip	L100	NN	I-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
,	,	0000	,	O	O
affected	affect	A123	VBN	B-NP	O
relatives	relative	R431	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
developmental	developmental	D141	JJ	B-NP	B-Disease
delays	delay	D420	NNS	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
nearby	nearby	N610	RB	B-ADVP	O
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
disrupted	disrupt	D261	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
localize	localize	L242	VB	I-VP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
we	we	W000	PRP	B-NP	O
searched	search	S623	VBD	B-VP	O
for	for	F600	IN	B-PP	O
other	other	O360	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
VWS	VWS	V200	NNS	B-NP	B-Disease
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
highly	highly	H240	RB	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
D1S3753	D1S3753	D200	NN	B-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
37	37	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
an	an	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
confined	confine	C515	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
cardinal	cardinal	C635	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
mapping	mapping	M152	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
extended	extend	E235	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
Mb	Mb	M100	NN	I-NP	O
beyond	beyond	B530	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
popliteal	popliteal	P143	JJ	B-NP	B-Disease
pterygia	pterygia	P362	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
76	76	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mixed	mixed	M230	JJ	B-NP	O
syndromic	syndromic	S536	JJ	I-NP	B-Disease
forms	form	F652	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
cleft	cleft	C413	NN	B-NP	I-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
palate	palate	P430	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
178	178	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nonsyndromic	nonsyndromic	N525	JJ	B-NP	B-Disease
cleft	cleft	C413	NN	I-NP	I-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
palate	palate	P430	NN	I-NP	I-Disease
.	.	0000	.	O	O

Splicing	Splicing	S142	NN	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
ATM	ATM	A350	NN	B-NP	O
:	:	0000	:	O	O
underlying	underlie	U536	VBG	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	I-NP	O
consequences	consequence	C525	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
constitute	constitute	C523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
(	(	0000	(	O	O
30	30	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
62	62	0000	CD	I-NP	O
[	[	0000	(	O	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
]	]	0000	)	O	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
AT	AT	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
truncation	truncation	T652	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

Fewer	Few	F600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
involved	involve	I514	VBD	B-VP	O
the	the	T000	DT	B-NP	O
canonical	canonical	C524	JJ	I-NP	O
AG	AG	A200	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
or	or	O600	CC	O	O
GT	GT	G300	NN	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
occurred	occur	O263	VBD	B-VP	O
at	at	A300	IN	B-PP	O
less	less	L200	RBR	B-NP	O
stringently	stringently	S365	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
silent	silent	S453	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
nucleotides	nucleotide	N243	NNS	B-NP	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
AG	AG	A200	NN	I-NP	O
and	and	A530	CC	I-NP	O
GT	GT	G300	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
consensus	consensus	C525	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
creation	creation	C635	NN	B-NP	O
of	of	O100	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
or	or	O600	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
donor	donor	D560	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	B-NP	O
introns	intron	I536	NNS	I-NP	O
or	or	O600	CC	I-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
consequences	consequence	C525	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
lesser	less	L260	JJR	I-NP	O
degree	degree	D260	NN	I-NP	O
,	,	0000	,	O	O
intron	intron	I536	NN	B-NP	O
retention	retention	R353	NN	I-NP	O
,	,	0000	,	O	O
activation	activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
cryptic	cryptic	C613	JJ	B-NP	O
splice	splice	S142	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
creation	creation	C635	NN	B-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
splice	splice	S142	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
occurred	occur	O263	VBD	B-VP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
western	western	W236	JJ	B-NP	O
blotting	blotting	B435	NN	I-NP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
AT	AT	A300	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
splicing	splicing	S142	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
normal	normal	N654	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
and	and	A530	CC	O	O
patients	patient	P353	NNS	B-NP	O
for	for	F600	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
no	no	N000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
defect	defect	D123	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
caution	caution	C350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
interpretation	interpretation	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
accompanying	accompany	A251	VBG	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Alpha	Alpha	A410	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
actin	actin	A235	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
hypertrophic	hypertrophic	H163	JJ	I-NP	I-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
actin	actin	A235	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ACTC	ACTC	A232	NN	B-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
suffering	suffer	S165	VBG	B-VP	O
from	from	F650	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
hypertrophic	hypertrophic	H163	JJ	I-NP	I-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
(	(	0000	(	O	O
FHC	FHC	F200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
excluded	exclude	E243	VBD	B-VP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
FHC	FHC	F200	NN	I-NP	B-Disease
loci	locus	L200	NNS	I-NP	O
as	as	A200	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
studied	study	S300	VBN	B-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
lod	lod	L300	NN	B-NP	O
scores	score	S262	NNS	I-NP	O
varying	vary	V652	VBG	B-VP	O
between	between	B350	IN	B-PP	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
and	and	A530	CC	O	O
-	-	0000	SYM	B-NP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
plausible	plausible	P421	JJ	B-NP	O
candidate	candidate	C530	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
highly	highly	H240	RB	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
heart	heart	H630	NN	I-NP	O
identified	identify	I353	VBD	B-VP	O
ACTC	ACTC	A232	NN	B-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
likely	likely	L240	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
maximal	maximal	M254	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
ACTC	ACTC	A232	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
Ala295Ser	Ala295Ser	A426	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
close	close	C420	NN	I-NP	O
to	to	T000	TO	B-PP	O
2	2	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
recently	recently	R253	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
dilated	dilated	D430	JJ	I-NP	I-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
(	(	0000	(	O	O
IDC	IDC	I320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Overgrowth	Overgrowth	O162	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
oral	oral	O640	JJ	B-NP	I-Disease
mucosa	mucosa	M200	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
facial	facial	F240	JJ	B-NP	I-Disease
skin	skin	S250	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
aspartylglucosaminuria	aspartylglucosaminuria	A216	NN	B-NP	B-Disease
.	.	0000	.	O	O

Aspartylglucosaminuria	Aspartylglucosaminuria	A216	NN	B-NP	B-Disease
(	(	0000	(	O	O
AGU	AGU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	B-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
aspartylglucosaminidase	aspartylglucosaminidase	A216	NN	B-NP	I-Disease
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
main	main	M500	JJ	I-NP	O
symptom	symptom	S513	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
progressive	progressive	P626	JJ	B-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
Cys163Ser	Cys163Ser	C260	NN	B-NP	O
)	)	0000	)	O	O
being	be	B520	VBG	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
Finnish	Finnish	F520	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
66	66	0000	CD	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
AGU	AGU	A200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
for	for	F600	IN	B-PP	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
oral	oral	O640	JJ	I-NP	O
mucosa	mucosa	M200	NN	I-NP	O
and	and	A530	CC	O	O
44	44	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
for	for	F600	IN	B-PP	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
facial	facial	F240	JJ	B-NP	O
skin	skin	S250	NN	I-NP	O
.	.	0000	.	O	O

Biopsy	Biopsy	B120	NN	B-NP	O
specimens	specimen	S125	NNS	I-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
oral	oral	O640	JJ	I-NP	O
lesions	lesion	L252	NNS	I-NP	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
teeth	tooth	T300	NNS	I-NP	O
,	,	0000	,	O	O
plus	plus	P420	CC	O	O
two	two	T000	CD	B-NP	O
facial	facial	F240	JJ	I-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
histologically	histologically	H234	RB	B-ADVP	O
.	.	0000	.	O	O

Immunohistochemical	Immunohistochemical	I523	JJ	B-NP	O
staining	staining	S352	NN	I-NP	O
for	for	F600	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
15	15	0000	CD	B-NP	O
oral	oral	O640	JJ	I-NP	O
specimens	specimen	S125	NNS	I-NP	O
.	.	0000	.	O	O

Skin	Skin	S250	NNP	B-NP	O
was	be	W200	VBD	B-VP	O
seborrhoeic	seborrhoeic	S162	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
adolescent	adolescent	A342	JJ	B-NP	O
and	and	A530	CC	I-NP	O
adult	adult	A343	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
erythema	erythema	E635	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
facial	facial	F240	JJ	I-NP	I-Disease
skin	skin	S250	NN	I-NP	I-Disease
already	already	A463	RB	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
44	44	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
nine	nine	N500	CD	B-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
facial	facial	F240	JJ	B-NP	B-Disease
angiofibromas	angiofibroma	A521	NNS	I-NP	I-Disease
,	,	0000	,	O	O
tumours	tumour	T562	NNS	B-NP	B-Disease
primarily	primarily	P656	RB	B-VP	O
occurring	occur	O265	VBG	I-VP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
tuberous	tuberous	T162	JJ	B-NP	B-Disease
sclerosis	sclerosis	S246	NN	I-NP	I-Disease
.	.	0000	.	O	O

Oedemic	Oedemic	O352	JJ	B-NP	B-Disease
buccal	buccal	B240	JJ	I-NP	I-Disease
mucosa	mucosa	M200	NN	I-NP	I-Disease
(	(	0000	(	O	O
leucoedema	leucoedema	L235	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
gingival	gingival	G521	JJ	B-NP	B-Disease
overgrowths	overgrowth	O162	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
AGU	AGU	A200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
oral	oral	O640	JJ	I-NP	B-Disease
mucosal	mucosal	M240	JJ	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
studied	study	S300	VBN	B-VP	O
histologically	histologically	H234	RB	B-ADVP	O
,	,	0000	,	O	O
15	15	0000	CD	B-NP	O
represented	represent	R162	VBD	B-VP	O
fibroepithelial	fibroepithelial	F161	JJ	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
epithelial	epithelial	E134	JJ	I-NP	I-Disease
hyperplasias	hyperplasia	H161	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
reactive	reactive	R231	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
nature	nature	N360	NN	B-NP	O
.	.	0000	.	O	O

Cytoplasmic	Cytoplasmic	C314	JJ	B-NP	O
vacuolisation	vacuolisation	V242	NN	I-NP	O
was	be	W200	VBD	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
.	.	0000	.	O	O

Immunohistochemically	Immunohistochemically	I523	RB	B-ADVP	O
,	,	0000	,	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
in	in	I500	IN	B-PP	O
AGU	AGU	A200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
mucosal	mucosal	M240	JJ	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
differ	differ	D160	VB	I-VP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
corresponding	correspond	C621	VBG	B-VP	O
lesions	lesion	L252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
mucosal	mucosal	M240	JJ	B-NP	B-Disease
overgrowth	overgrowth	O162	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
AGU	AGU	A200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
directly	directly	D623	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
lysosomal	lysosomal	L254	JJ	B-NP	O
storage	storage	S362	NN	I-NP	O
or	or	O600	CC	B-PP	O
with	with	W300	IN	B-PP	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
OCRL1	OCRL1	O264	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
oculocerebrorenal	oculocerebrorenal	O242	JJ	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
Lowe	Lowe	L000	NN	B-NP	I-Disease
(	(	0000	(	O	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
major	major	M260	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
eyes	eye	E200	NNS	B-NP	I-Disease
,	,	0000	,	O	I-Disease
nervous	nervous	N612	JJ	B-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
kidneys	kidney	K352	NNS	B-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
OCRL1	OCRL1	O264	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

OCRL1	OCRL1	O264	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
biphosphate	biphosphate	B121	NN	I-NP	O
(	(	0000	(	O	O
PtdIns	PtdIns	P352	NN	B-NP	O
[	[	0000	(	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
]	]	0000	)	I-NP	O
P2	P2	P000	NN	I-NP	O
)	)	0000	)	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
OCRL1	OCRL1	O264	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
seven	seven	S150	CD	B-NP	O
new	new	N000	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
R317X	R317X	R200	NN	B-NP	O
and	and	A530	CC	O	O
E558X	E558X	E200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
other	other	O360	JJ	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
caused	cause	C230	VBD	B-VP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
R483G	R483G	R200	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
PtdIns	PtdIns	P352	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
)	)	0000	)	O	O
P2	P2	P000	NN	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
2799delC	2799delC	D420	NN	B-NP	O
,	,	0000	,	O	O
modifies	modify	M312	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
OCRL1	OCRL1	O264	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
extension	extension	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

Altogether	Altogether	A432	RB	B-ADVP	O
,	,	0000	,	O	O
70	70	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
52	52	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
cluster	cluster	C423	VBP	B-VP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
11	11	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
OCRL1	OCRL1	O264	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
direct	direct	D623	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
of	of	O100	IN	B-PP	O
Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

MEFV	MEFV	M100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
Gene	Gene	G500	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
armenian	armenian	A650	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
:	:	0000	:	O	O
diagnostic	diagnostic	D252	JJ	B-NP	O
value	value	V400	NN	I-NP	O
and	and	A530	CC	O	O
unfavorable	unfavorable	U516	JJ	B-NP	O
renal	renal	R540	JJ	I-NP	O
prognosis	prognosis	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
M694V	M694V	M100	NN	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
therapeutic	therapeutic	T613	JJ	I-NP	O
implications	implication	I514	NNS	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessively	recessively	R214	RB	I-NP	B-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Armenian	Armenian	A650	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
,	,	0000	,	O	O
its	its	I320	PRP$	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
made	make	M300	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
retrospectively	retrospectively	R362	RB	I-ADVP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
exclusion	exclusion	E242	NN	B-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-VP	O
entirely	entirely	E536	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
nonspecific	nonspecific	N521	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
serosal	serosal	S624	JJ	B-NP	B-Disease
inflammation	inflammation	I514	NN	I-NP	I-Disease
and	and	A530	CC	O	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
unnecessary	unnecessary	U526	JJ	B-NP	O
surgery	surgery	S626	NN	I-NP	O
.	.	0000	.	O	O

Renal	Renal	R540	JJ	B-NP	B-Disease
amyloidosis	amyloidosis	A543	NN	I-NP	I-Disease
,	,	0000	,	O	O
prevented	prevent	P615	VBN	B-VP	O
by	by	B000	IN	B-PP	O
colchicine	colchicine	C425	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
severe	severe	S160	JJ	I-NP	O
complication	complication	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMF	FMF	F510	NNP	B-NP	B-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MEFV	MEFV	M100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
the	the	T000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
and	and	A530	CC	I-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
gene	gene	G500	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
90	90	0000	CD	B-NP	O
Armenian	Armenian	A650	JJ	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
77	77	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
selected	select	S423	VBN	I-VP	O
through	through	T620	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
(	(	0000	(	O	O
R408Q	R408Q	R200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
new	new	N000	JJ	B-ADJP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
93	93	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
163	163	0000	CD	I-NP	O
independent	independent	I531	JJ	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
both	both	B300	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
89	89	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
instances	instance	I523	NNS	I-NP	O
,	,	0000	,	O	O
family	family	F540	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
provided	provide	P613	VBD	B-VP	O
molecular	molecular	M424	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
pseudodominant	pseudodominant	P235	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
and	and	A530	CC	O	O
incomplete	incomplete	I525	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
M694V	M694V	M100	NN	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
amyloidosis	amyloidosis	A543	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
arthritis	arthritis	A636	NN	I-NP	B-Disease
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
0002	0002	0000	CD	B-NP	O
and	and	A530	CC	O	O
P	P	P000	NN	B-NP	O
=	=	0000	JJ	I-NP	O
.	.	0000	.	I-NP	O
006	006	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
demonstration	demonstration	D523	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
and	and	A530	CC	I-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
particular	particular	P632	JJ	B-NP	O
modes	mode	M320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
should	should	S430	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
new	new	N000	JJ	B-NP	O
ways	way	W200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
management	management	M525	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
including	include	I524	VBG	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
and	and	A530	CC	O	O
therapeutic	therapeutic	T613	JJ	B-NP	O
decisions	decision	D252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Noninvasive	Noninvasive	N512	JJ	B-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
hair	hair	H600	NN	B-NP	O
root	root	R300	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
amplification	amplification	A514	NN	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
reliable	reliable	R414	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
methods	method	M320	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
and	and	A530	CC	I-NP	O
PCR	PCR	P260	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
methods	method	M320	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
measure	measure	M260	VB	B-VP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
size	size	S200	NN	I-NP	O
in	in	I500	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
immunocytochemical	immunocytochemical	I523	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
on	on	O500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
smears	smear	S562	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
developed	develop	D141	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
method	method	M300	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-VP	O
called	call	C430	VBN	I-VP	O
"	"	0000	``	O	O
antibody	antibody	A531	NN	B-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
"	"	0000	''	O	O
uses	use	U200	VBZ	B-VP	O
monoclonal	monoclonal	M524	JJ	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
(	(	0000	(	O	O
FMRP	FMRP	F561	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
test	test	T230	NN	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
male	male	M400	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
hair	hair	H600	NN	I-NP	O
roots	root	R320	NNS	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
in	in	I500	IN	B-PP	O
hair	hair	H600	NN	B-NP	O
roots	root	R320	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
FMRP	FMRP	F561	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
-	-	0000	HYPH	O	O
expressing	express	E216	VBG	B-VP	O
hair	hair	H600	NN	B-NP	O
roots	root	R320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
.	.	0000	.	O	O

Control	Control	C536	NN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
clear	clear	C460	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
in	in	I500	IN	B-PP	O
nearly	nearly	N640	RB	B-NP	O
every	every	E160	DT	I-NP	O
hair	hair	H600	NN	I-NP	O
root	root	R300	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
male	male	M400	JJ	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
lacked	lack	L230	VBD	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
in	in	I500	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
their	their	T600	PRP$	I-NP	O
hair	hair	H600	NN	I-NP	O
roots	root	R320	NNS	I-NP	O
.	.	0000	.	O	O

Mentally	Mentally	M534	RB	B-NP	B-Disease
retarded	retard	R363	VBN	I-NP	I-Disease
female	female	F540	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
FMRP	FMRP	F561	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
some	some	S500	DT	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
hair	hair	H600	NN	I-NP	O
roots	root	R320	NNS	I-NP	O
(	(	0000	(	O	O
<	<	0000	SYM	B-NP	O
55	55	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
overlap	overlap	O164	NN	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
female	female	F540	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
advantages	advantage	A315	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
test	test	T230	NN	I-NP	O
are	be	A600	VBP	B-VP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
plucking	plucking	P425	NN	B-NP	O
of	of	O100	IN	B-PP	O
hair	hair	H600	NN	B-NP	O
follicles	follicle	F424	NNS	I-NP	O
does	do	D200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
appreciable	appreciable	A162	JJ	I-NP	O
harm	harm	H650	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
mentally	mentally	M534	RB	I-NP	B-Disease
retarded	retarded	R363	JJ	I-NP	I-Disease
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	O	O
2	2	0000	CD	O	O
)	)	0000	)	O	O
hairs	hair	H620	NNS	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
sent	send	S530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
envelope	envelope	E514	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
center	center	C536	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
test	test	T230	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
available	available	A141	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
5	5	0000	CD	B-NP	O
h	h	H000	NN	I-NP	O
of	of	O100	IN	B-PP	O
plucking	plucking	P425	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
test	test	T230	NN	I-NP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
two	two	T000	CD	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
show	show	S000	VB	I-VP	O
the	the	T000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Swedish	Swedish	S320	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
HPC1	HPC1	H120	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1q24	1q24	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
restricted	restrict	R236	VBN	I-VP	O
to	to	T000	TO	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Prostate	Prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
clusters	cluster	C423	NNS	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
10	10	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
from	from	F650	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	O
cancer	cancer	C526	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
previously	previously	P612	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
1q24	1q24	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
HPC1	HPC1	H120	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
91	91	0000	CD	B-NP	O
North	North	N630	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Swedish	Swedish	S320	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
each	each	E200	DT	B-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
Smith	Smith	S530	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	I-NP	O
1996	1996	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
report	report	R163	NN	I-NP	O
we	we	W000	PRP	B-NP	O
analyze	analyze	A542	VBP	B-VP	O
40	40	0000	CD	B-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
original	original	O625	JJ	I-NP	O
and	and	A530	CC	O	O
28	28	0000	CD	B-NP	O
newly	newly	N400	RB	B-VP	O
identified	identify	I353	VBN	I-VP	O
)	)	0000	)	O	O
Swedish	Swedish	S320	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HPC	HPC	H120	NN	B-NP	B-Disease
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
40	40	0000	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
spanning	span	S152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
within	within	W350	IN	B-PP	O
1q24	1q24	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

10	10	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-PP	O
D1S413	D1S413	D200	NN	B-NP	O
(	(	0000	(	O	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
[	[	0000	(	O	O
theta	theta	T300	NN	B-NP	O
]	]	0000	)	O	O
of	of	O100	IN	B-PP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
NPL	NPL	N140	NN	I-NP	O
(	(	0000	(	O	O
nonparametric	nonparametric	N516	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
)	)	0000	)	O	O
Z	Z	Z000	NN	B-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

64	64	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
D1S202	D1S202	D200	NN	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
05	05	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
originated	originate	O625	VBD	B-VP	O
almost	almost	A452	RB	B-ADVP	O
exclusively	exclusively	E242	RB	I-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
early	early	E640	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
(	(	0000	(	O	O
age	age	A200	NN	B-NP	O
<	<	0000	SYM	O	O
65	65	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
yielded	yield	Y430	VBD	B-VP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

38	38	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
D1S413	D1S413	D200	NN	B-NP	O
(	(	0000	(	O	O
straight	straight	S362	JJ	B-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
NPL	NPL	N140	NN	I-NP	O
Z	Z	Z000	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

95	95	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
D1S422	D1S422	D200	NN	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Estimates	Estimate	E235	NNS	B-NP	O
from	from	F650	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
tests	test	T232	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
within	within	W350	IN	B-PP	O
Sweden	Sweden	S350	NNP	B-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-NP	O
many	many	M500	JJ	I-NP	O
as	as	A200	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
HPC1	HPC1	H120	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
HPC1	HPC1	H120	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
those	those	T200	DT	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
feline	feline	F450	NN	B-NP	O
beta	beta	B300	SYM	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
glucuronidase	glucuronidase	G426	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
mucopolysaccharidosis	mucopolysaccharidosis	M214	NN	B-NP	B-Disease
VII	VII	V000	CD	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
domestic	domestic	D523	JJ	B-NP	O
cats	cat	C320	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
mucopolysaccharidosis	mucopolysaccharidosis	M214	NN	B-NP	B-Disease
VII	VII	V000	CD	I-NP	I-Disease
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
lysosomal	lysosomal	L254	JJ	I-NP	I-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
beta	beta	B300	SYM	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
glucuronidase	glucuronidase	G426	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

beta	beta	B300	SYM	O	O
-	-	0000	HYPH	B-NP	O
Glucuronidase	Glucuronidase	G426	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
cat	cat	C300	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
and	and	A530	CC	O	O
restored	restore	R236	VBN	B-VP	O
by	by	B000	IN	B-PP	O
retroviral	retroviral	R361	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
rat	rat	R300	NN	B-NP	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
glucuronidase	glucuronidase	G426	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
Glucuronidase	Glucuronidase	G426	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
cat	cat	C300	NN	I-NP	O
testis	testis	T232	NN	I-NP	O
by	by	B000	IN	B-PP	O
Northern	Northern	N636	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Normal	Normal	N654	JJ	B-NP	O
feline	feline	F450	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
glucuronidase	glucuronidase	G426	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
characterized	characterize	C623	VBN	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
amplified	amplify	A514	VBN	B-VP	O
from	from	F650	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
cat	cat	C300	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
by	by	B000	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
coupled	couple	C143	VBN	B-VP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
cat	cat	C300	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
predicted	predict	P632	VBD	B-VP	O
an	an	A500	DT	B-NP	O
E351K	E351K	E200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
,	,	0000	,	O	O
destroyed	destroy	D236	VBD	B-VP	O
a	a	A000	DT	B-NP	O
BssSI	BssSI	B200	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
eliminated	eliminate	E453	VBD	B-VP	O
GUSB	GUSB	G210	NN	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

Multiple	Multiple	M431	JJ	B-NP	O
species	specie	S120	NNS	I-NP	O
comparison	comparison	C516	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
crystal	crystal	C623	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
glucuronidase	glucuronidase	G426	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
E351	E351	E000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
residue	residue	R230	NN	I-NP	O
most	most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
essential	essential	E253	JJ	B-NP	O
in	in	I500	IN	B-PP	O
maintenance	maintenance	M535	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
conformation	conformation	C516	NN	I-NP	O
.	.	0000	.	O	O

BssSI	BssSI	B200	NN	B-NP	O
digestion	digestion	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
products	product	P632	NNS	I-NP	O
amplified	amplify	A514	VBN	B-VP	O
from	from	F650	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
affected	affect	A123	VBN	B-NP	O
cats	cat	C320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
and	and	A530	CC	O	O
cats	cat	C320	NNS	B-NP	O
with	with	W300	IN	B-PP	O
half	half	H410	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
glucuronidase	glucuronidase	G426	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Carriers	Carrier	C620	NNS	B-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
manner	manner	M560	NN	I-NP	O
produced	produce	P632	VBD	B-VP	O
affected	affect	A123	VBN	I-VP	O
kittens	kitten	K352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
prospective	prospective	P621	JJ	B-NP	O
breedings	breeding	B635	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
feline	feline	F450	NN	I-NP	O
MPS	MPS	M120	NN	I-NP	B-Disease
VII	VII	V000	CD	I-NP	I-Disease
breeding	breeding	B635	NN	I-NP	O
colony	colony	C450	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
established	establish	E231	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
rearrangement	rearrangement	R652	NN	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22q11	22q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
22q11	22q11	Q000	CD	I-NP	O
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
rearrangements	rearrangement	R652	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
anomaly	anomaly	A540	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
anomaly	anomaly	A540	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
cat	cat	C300	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
der	der	D600	NN	B-NP	B-Disease
(	(	0000	(	O	I-Disease
)	)	0000	)	O	I-Disease
syndrome	syndrome	S536	NN	B-NP	I-Disease
and	and	A530	CC	O	O
velo	velo	V400	AFX	B-VP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cardio	cardio	C630	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
facial	facial	F240	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
/	/	0000	SYM	B-VP	O
DiGeorge	DiGeorge	D262	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
VCFS	VCFS	V212	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
tetrasomy	tetrasomy	T362	NN	B-NP	O
,	,	0000	,	I-NP	O
trisomy	trisomy	T625	NN	I-NP	O
or	or	O600	CC	I-NP	O
monosomy	monosomy	M525	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22q11	22q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

VCFS	VCFS	V212	NN	B-NP	B-Disease
/	/	0000	SYM	I-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
particular	particular	P632	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
on	on	O500	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
prone	prone	P650	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
rearrangements	rearrangement	R652	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
end	end	E530	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
points	point	P532	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
VCFS	VCFS	V212	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
DGS	DGS	D200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
defined	define	D153	VBN	I-VP	O
by	by	B000	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
VCFS	VCFS	V212	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
DGS	DGS	D200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
3	3	0000	CD	I-NP	O
Mb	Mb	M100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
nested	nested	N230	JJ	I-NP	O
distal	distal	D234	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
rare	rare	R600	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
unique	unique	U520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	I-NP	O
translocations	translocation	T652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
occur	occur	O260	VBP	B-VP	O
sporadically	sporadically	S163	RB	B-ADVP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
sequences	sequence	S252	NNS	B-NP	O
at	at	A300	IN	B-PP	O
or	or	O600	CC	I-PP	O
near	near	N600	IN	I-PP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
confer	confer	C516	VBP	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
developed	develop	D141	VBD	B-VP	O
hamster	hamster	H523	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
human	human	H500	JJ	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
from	from	F650	IN	B-PP	O
VCFS	VCFS	V212	NN	B-NP	B-Disease
/	/	0000	SYM	B-VP	O
DGS	DGS	D200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
classes	class	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
occur	occur	O260	VBP	B-VP	O
within	within	W350	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
low	low	L000	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
termed	term	T653	VBN	B-NP	O
LCR22s	LCR22	L262	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
support	support	S163	VB	I-VP	O
this	this	T200	DT	B-NP	O
idea	idea	I300	NN	I-NP	O
further	further	F636	RBR	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
that	that	T300	WDT	B-NP	O
carries	carry	C620	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
3	3	0000	CD	I-NP	O
Mb	Mb	M100	NN	I-NP	O
region	region	R250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
VCFS	VCFS	V212	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
DGS	DGS	D200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
models	model	M342	NNS	B-NP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
how	how	H000	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
LCR22s	LCR22	L262	NNS	I-NP	O
can	can	C500	MD	B-VP	O
mediate	mediate	M300	VB	I-VP	O
different	different	D165	JJ	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
events	event	E153	NNS	I-NP	O
,	,	0000	,	O	O
thereby	thereby	T610	RB	B-VP	O
generating	generate	G563	VBG	I-VP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
rearrangements	rearrangement	R652	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
anomaly	anomaly	A540	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
five	five	F100	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LCR22	LCR22	L260	NN	I-NP	O
on	on	O500	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
mediate	mediate	M300	VB	I-VP	O
other	other	O360	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
consequences	consequence	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
response	response	R215	NN	I-NP	O
2	2	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
EGR2	EGR2	E260	NN	B-NP	O
)	)	0000	)	O	O
correlate	correlate	C643	VBP	B-VP	O
with	with	W300	IN	B-PP	O
severity	severity	S163	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
myelinopathies	myelinopathy	M451	NNS	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
response	response	R215	NN	I-NP	O
2	2	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
EGR2	EGR2	E260	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
Cys2His2zinc	Cys2His2zinc	C252	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
myelination	myelination	M453	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
idea	idea	I300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
based	base	B230	VBN	I-VP	O
partly	partly	P634	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
Krox20	Krox20	K620	NN	I-NP	O
(	(	0000	(	O	O
Egr2	Egr2	E260	NN	B-NP	O
)	)	0000	)	O	O
knockout	knockout	K523	NN	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
display	display	D214	VBP	B-VP	O
hypomyelination	hypomyelination	H154	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
PNS	PNS	P520	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
block	block	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
Schwann	Schwann	S250	NNP	B-NP	O
cells	cell	C420	NNS	I-NP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
differentiation	differentiation	D165	NN	B-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
EGR2	EGR2	E260	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
peripheral	peripheral	P616	JJ	I-NP	I-Disease
neuropathies	neuropathy	N613	NNS	I-NP	I-Disease
Charcot	Charcot	C623	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Marie	Marie	M600	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Tooth	Tooth	T300	NNP	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
,	,	0000	,	O	O
Dejerine	Dejerine	D265	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sottas	Sottas	S320	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
hypomyelinating	hypomyelinate	H154	VBG	I-NP	I-Disease
neuropathy	neuropathy	N613	NN	I-NP	I-Disease
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
EGR2	EGR2	E260	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
dominant	dominant	D530	JJ	B-ADJP	O
and	and	A530	CC	O	O
occur	occur	O260	VBP	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
recessive	recessive	R210	JJ	B-ADJP	O
and	and	A530	CC	O	O
affects	affect	A123	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
inhibitory	inhibitory	I513	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
(	(	0000	(	O	O
R1	R1	R000	NN	B-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
binds	bind	B532	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
NAB	NAB	N100	NN	I-NP	O
transcriptional	transcriptional	T652	JJ	B-ADJP	O
co	co	C000	AFX	O	O
-	-	0000	HYPH	O	O
repressors	repressor	R162	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
assays	assay	A200	NNS	I-NP	O
and	and	A530	CC	O	O
transcriptional	transcriptional	T652	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
consequences	consequence	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
affect	affect	A123	VBP	B-VP	O
DNA	DNA	D500	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
residual	residual	R234	JJ	B-NP	O
binding	binding	B535	NN	I-NP	O
directly	directly	D623	RB	B-ADVP	O
correlates	correlate	C643	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
R1	R1	R000	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
prevents	prevent	P615	VBZ	B-VP	O
interaction	interaction	I536	NN	B-NP	O
of	of	O100	IN	B-PP	O
EGR2	EGR2	E260	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
NAB	NAB	N100	NN	I-NP	O
co	co	C000	AFX	O	O
-	-	0000	HYPH	O	O
repressors	repressor	R162	NNS	B-NP	O
and	and	A530	CC	O	O
thereby	thereby	T610	RB	B-VP	O
increases	increase	I526	VBZ	I-VP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
insight	insight	I523	NN	B-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
EGR2	EGR2	E260	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
reason	reason	R250	NN	I-NP	O
for	for	F600	IN	B-PP	O
varying	vary	V652	VBG	B-VP	O
severity	severity	S163	NN	B-NP	O
and	and	A530	CC	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
familial	familial	F540	JJ	I-NP	I-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
continued	continue	C535	VBN	B-NP	O
secretion	secretion	S263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
weakly	weakly	W240	RB	I-NP	O
active	active	A231	JJ	I-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
post	post	P230	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
natal	natal	N340	JJ	I-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	B-Disease
vasopressin	vasopressin	V216	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
AVP	AVP	A100	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
published	publish	P142	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
affect	affect	A123	VBP	B-VP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
neurophysin	neurophysin	N612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
carrier	carrier	C600	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
presumed	presume	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
interfere	interfere	I536	VB	I-VP	O
with	with	W300	IN	B-PP	O
processing	processing	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
preprohormone	preprohormone	P616	NN	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
neuronal	neuronal	N654	JJ	B-NP	B-Disease
damage	damage	D520	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
Palestinian	Palestinian	P423	JJ	I-NP	O
family	family	F540	NN	I-NP	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
asymptomatic	asymptomatic	A251	JJ	B-NP	O
first	first	F623	JJ	I-NP	O
cousin	cousin	C250	NN	I-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
children	child	C436	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
neurohypophyseal	neurohypophyseal	N612	JJ	B-NP	B-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
autosomal	autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
children	child	C436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
C301	C301	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
replacing	replace	R142	VBG	B-VP	O
Pro7	Pro7	P600	NN	B-NP	O
of	of	O100	IN	B-PP	O
mature	mature	M360	JJ	B-NP	O
AVP	AVP	A100	NN	I-NP	O
with	with	W300	IN	B-PP	O
Leu	Leu	L000	NN	B-NP	O
(	(	0000	(	O	O
Leu	Leu	L000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
AVP	AVP	A100	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Leu	Leu	L000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
AVP	AVP	A100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
weak	weak	W200	JJ	I-NP	O
agonist	agonist	A252	NN	I-NP	O
with	with	W300	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
30	30	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
V2	V2	V000	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
.	.	0000	.	O	O

Measured	Measure	M263	VBN	B-VP	O
by	by	B000	IN	B-PP	O
radioimmunoassay	radioimmunoassay	R352	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
synthetic	synthetic	S532	JJ	I-NP	O
Leu	Leu	L000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AVP	AVP	A100	NN	I-NP	O
standard	standard	S353	NN	I-NP	O
,	,	0000	,	O	O
serum	serum	S650	NN	B-NP	O
Leu	Leu	L000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AVP	AVP	A100	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
elevated	elevate	E413	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
children	child	C436	NNS	I-NP	O
and	and	A530	CC	O	O
further	further	F636	RB	B-VP	O
increased	increase	I526	VBD	I-VP	O
during	during	D652	IN	B-PP	O
water	water	W360	NN	B-NP	O
deprivation	deprivation	D161	NN	I-NP	O
to	to	T000	TO	B-PP	O
as	as	A200	RB	B-ADVP	O
high	high	H200	JJ	I-ADVP	O
as	as	A200	IN	B-PP	O
30	30	0000	CD	B-NP	O
times	time	T520	NNS	I-NP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
youngest	young	Y523	JJS	I-NP	O
child	child	C430	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
old	old	O430	JJ	B-ADJP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
only	only	O540	RB	I-VP	O
mildly	mildly	M434	RB	I-VP	O
affected	affect	A123	VBD	I-VP	O
but	but	B300	CC	I-VP	O
had	have	H300	VBD	I-VP	O
Leu	Leu	L000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
AVP	AVP	A100	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
her	her	H600	PRP	B-NP	O
severely	severely	S164	RB	B-VP	O
affected	affect	A123	VBD	I-VP	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
brother	brother	B636	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
unknown	unknown	U525	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
may	may	M000	MD	B-VP	O
partially	partially	P634	RB	I-VP	O
compensate	compensate	C515	VB	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
active	active	A231	JJ	B-NP	I-Disease
AVP	AVP	A100	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
very	very	V600	RB	B-NP	O
young	young	Y520	JJ	I-NP	O
children	child	C436	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
selection	selection	S423	NN	I-NP	O
rescue	rescue	R200	NN	I-NP	O
female	female	F540	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
Piga	Piga	P200	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
null	null	N400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
linked	link	L523	VBN	I-NP	O
PIGA	PIGA	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
glycosyl	glycosyl	G424	NN	B-NP	I-Disease
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
GPI	GPI	G100	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
anchored	anchor	A526	VBN	I-NP	I-Disease
proteins	protein	P635	NNS	I-NP	I-Disease
on	on	O500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
paroxysmal	paroxysmal	P625	JJ	B-NP	B-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
hemoglobinuria	hemoglobinuria	H524	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
GPI	GPI	G100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
anchor	anchor	A526	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
conventional	conventional	C515	JJ	B-NP	O
Piga	Piga	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	B-Disease
lethality	lethality	L343	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
chimeric	chimeric	C562	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
Cre	Cre	C600	NN	I-NP	O
/	/	0000	SYM	B-NP	O
loxP	loxP	L210	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
mice	mouse	M200	NNS	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
loxP	loxP	L210	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
flank	flank	F452	VBP	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
Piga	Piga	P200	NNP	B-NP	O
exon	exon	E250	NN	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
crossbreeding	crossbreed	C621	VBG	B-VP	O
with	with	W300	IN	B-PP	O
female	female	F540	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
EIIa	EIIa	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cre	cre	C600	NN	I-NP	O
strain	strain	S365	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
floxed	floxed	F423	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
undergoes	undergo	U536	VBZ	B-VP	O
Cre	Cre	C600	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
recombination	recombination	R251	NN	I-NP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
efficiency	efficiency	E125	NN	I-NP	O
during	during	D652	IN	B-PP	O
early	early	E640	JJ	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
X	X	X000	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
,	,	0000	,	O	O
female	female	F540	JJ	B-NP	O
offspring	offspring	O121	NN	I-NP	O
are	be	A600	VBP	B-VP	O
mosaic	mosaic	M200	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
express	express	E216	VBP	B-VP	O
or	or	O600	CC	I-VP	O
lack	lack	L200	VBP	I-VP	O
GPI	GPI	G100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
mosaic	mosaic	M200	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
heart	heart	H630	NN	B-NP	O
,	,	0000	,	O	O
lung	lung	L520	NN	B-NP	O
,	,	0000	,	O	O
kidney	kidney	K350	NN	B-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
liver	liver	L160	NN	B-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Piga	Piga	P200	NNP	I-NP	O
is	be	I200	VBZ	B-VP	O
active	active	A231	JJ	B-ADJP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
require	require	R260	VBP	B-VP	O
GPI	GPI	G100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
salient	salient	S453	JJ	I-NP	O
exceptions	exception	E213	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
spleen	spleen	S145	NN	B-NP	O
,	,	0000	,	O	O
thymus	thymus	T520	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
red	red	R300	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
had	have	H300	VBD	B-VP	O
almost	almost	A452	RB	B-NP	O
equal	equal	E240	JJ	I-NP	O
numbers	number	N516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
recombined	recombined	R251	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
implying	imply	I514	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
GPI	GPI	G100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
derivation	derivation	D613	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

PIGA	PIGA	P200	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
cells	cell	C420	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
advantage	advantage	A315	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
other	other	O360	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
needed	need	N300	VBN	I-VP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
clonal	clonal	C454	JJ	I-NP	O
dominance	dominance	D520	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
paroxysmal	paroxysmal	P625	JJ	B-NP	B-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
hemoglobinuria	hemoglobinuria	H524	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
produce	produce	P632	VB	I-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Targeted	Target	T623	VBN	B-NP	O
mutagenesis	mutagenesis	M325	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Hfe	Hfe	H100	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
deletes	delete	D432	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
,	,	0000	,	O	O
generating	generate	G563	VBG	B-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
introduces	introduce	I536	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
C282Y	C282Y	C000	NN	B-NP	O
)	)	0000	)	O	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
Hfe	Hfe	H100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
otherwise	otherwise	O362	RB	B-VP	O
leaves	leave	L120	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
intact	intact	I532	JJ	B-ADJP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
bred	breed	B630	VBN	I-VP	O
and	and	A530	CC	O	O
analyzed	analyze	A542	VBN	B-VP	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
either	either	E360	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
postnatal	postnatal	P235	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
loading	loading	L352	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	RBR	B-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
either	either	E360	CC	O	O
mutation	mutation	M350	NN	B-NP	O
accumulate	accumulate	A254	VBP	B-VP	O
more	more	M600	JJR	B-NP	O
iron	iron	I650	NN	I-NP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
liver	liver	L160	NN	B-NP	O
iron	iron	I650	NN	I-NP	O
stores	store	S362	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
greatly	greatly	G634	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
,	,	0000	,	O	O
splenic	splenic	S145	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
22	22	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EMD	EMD	E530	NN	B-NP	B-Disease
)	)	0000	)	O	O
revealed	reveal	R143	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
21	21	0000	CD	B-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
EMD	EMD	E530	NN	I-NP	I-Disease
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
emerin	emerin	E565	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
three	three	T600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
Pro183Thr	Pro183Thr	P636	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
removing	remove	R515	VBG	B-VP	O
residues	residue	R232	NNS	B-NP	O
95	95	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
99	99	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
236	236	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
241	241	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
unusual	unusual	U524	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
being	be	B520	VBG	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
compared	compare	C516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
detail	detail	D340	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
null	null	N400	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
was	be	W200	VBD	B-VP	O
milder	mild	M436	JJR	B-ADJP	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
was	be	W200	VBD	B-VP	O
later	later	L360	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
first	first	F623	JJ	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
ankle	ankle	A524	NN	B-NP	B-Disease
contractures	contracture	C536	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
muscle	muscle	M240	NN	B-NP	B-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
diagnostic	diagnostic	D252	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
pointing	point	P535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
functionally	functionally	F523	RB	B-NP	O
important	important	I516	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Severe	Severe	S160	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
rare	rare	R600	JJ	I-NP	O
benign	benign	B525	JJ	I-NP	B-Disease
neuromuscular	neuromuscular	N652	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
vary	vary	V600	VB	I-VP	O
remarkably	remarkably	R562	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
,	,	0000	,	I-NP	O
course	course	C620	NN	I-NP	O
and	and	A530	CC	I-NP	O
severity	severity	S163	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
TCTAC	TCTAC	T232	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
631	631	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
635	635	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
caused	cause	C230	VBD	B-VP	O
an	an	A500	DT	B-NP	O
unusually	unusually	U524	RB	I-NP	O
severe	severe	S160	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
including	include	I524	VBG	B-PP	O
loss	loss	L200	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
ambulation	ambulation	A514	NN	B-NP	I-Disease
and	and	A530	CC	O	O
severe	severe	S160	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
wasting	waste	W235	VBG	B-VP	I-Disease
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
brothers	brother	B636	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
family	family	F540	NN	I-NP	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
significantly	significantly	S251	RB	I-NP	O
milder	mild	M436	JJR	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
interfamilial	interfamilial	I536	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
distribution	distribution	D236	NN	B-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
severity	severity	S163	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
point	point	P530	VBP	B-VP	O
to	to	T000	TO	B-PP	O
environmental	environmental	E516	JJ	B-NP	O
or	or	O600	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
modification	modification	M312	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
in	in	I500	IN	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Common	Common	C500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
early	early	E640	JJ	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
men	man	M500	NNS	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
Families	Family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
subsequently	subsequently	S125	RB	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
terminating	terminate	T653	VBG	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
,	,	0000	,	O	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
among	among	A520	IN	B-PP	O
male	male	M400	JJ	B-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
aimed	aim	A530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
men	man	M500	NNS	I-NP	O
predisposed	predispose	P632	VBD	B-VP	O
them	them	T500	PRP	B-NP	O
to	to	T000	TO	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
We	We	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
83	83	0000	CD	B-NP	O
(	(	0000	(	O	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
82	82	0000	CD	B-NP	O
(	(	0000	(	O	O
for	for	F600	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
6174delT	6174delT	D430	NN	I-NP	O
)	)	0000	)	O	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
were	be	W600	VBD	B-VP	O
treated	treat	T630	VBN	I-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
young	young	Y520	JJ	I-NP	O
age	age	A200	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Our	Our	O600	PRP$	B-NP	O
study	study	S300	NN	I-NP	O
should	should	S430	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
a	a	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
fold	fold	F430	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
6	6	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
only	only	O540	RB	B-NP	O
two	two	T000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
closely	closely	C424	RB	B-ADVP	O
matched	match	M323	VBD	B-VP	O
their	their	T600	PRP$	B-NP	O
incidence	incidence	I523	NN	I-NP	O
(	(	0000	(	O	O
about	about	A130	RB	B-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
unlike	unlike	U542	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
significantly	significantly	S251	RB	I-VP	O
predispose	predispose	P632	VB	I-VP	O
men	man	M500	NNS	B-NP	O
to	to	T000	TO	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease

Beta	Beta	B300	SYM	O	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
and	and	A530	CC	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTNNB1	CTNNB1	C351	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
hepatoblastoma	hepatoblastoma	H131	NN	B-NP	B-Disease
.	.	0000	.	O	O

Hepatoblastoma	Hepatoblastoma	H131	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
malignant	malignant	M425	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
liver	liver	L160	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
average	average	A162	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
3	3	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Epidemiologic	Epidemiologic	E135	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
epidemiologic	epidemiologic	E135	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
,	,	0000	,	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
hepatoblastoma	hepatoblastoma	H131	NN	B-NP	B-Disease
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
downregulation	downregulation	D562	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	O	O
catenin	catenin	C350	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
-	-	0000	HYPH	O	O
activating	activate	A231	VBG	B-VP	O
protein	protein	P635	NN	B-NP	O
with	with	W300	IN	B-PP	O
oncogenic	oncogenic	O525	JJ	B-NP	O
potential	potential	P353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
ongoing	ongoing	O525	JJ	I-NP	O
immunohistochemical	immunohistochemical	I523	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	O	O
catenin	catenin	C350	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
types	type	T120	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	O	O
catenin	catenin	C350	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytoplasm	cytoplasm	C314	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
investigated	investigate	I512	VBN	I-NP	O
hepatoblastomas	hepatoblastoma	H131	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
catenin	catenin	C350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CTNNB1	CTNNB1	C351	NN	B-NP	O
)	)	0000	)	O	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
activating	activate	A231	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
time	time	T500	NN	I-NP	O
that	that	T300	IN	B-ADVP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
hepatoblastoma	hepatoblastoma	H131	NN	B-NP	B-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
activating	activate	A231	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
catenin	catenin	C350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
substitute	substitute	S123	VB	I-VP	O
biallelic	biallelic	B420	JJ	B-NP	O
APC	APC	A120	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

Genes	Genes	G520	NNP	B-NP	O
Chromosomes	Chromosomes	C652	NNP	I-NP	O
Cancer	Cancer	C526	NNP	I-NP	O
25	25	0000	CD	I-NP	O
399	399	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
402	402	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1999	1999	0000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Decrease	Decrease	D262	NN	B-NP	O
in	in	I500	IN	B-PP	O
GTP	GTP	G310	NN	B-NP	O
cyclohydrolase	cyclohydrolase	C243	NN	I-NP	O
I	I	I000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
progressive	progressive	P626	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
diurnal	diurnal	D654	JJ	I-NP	O
fluctuation	fluctuation	F423	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
progressive	progressive	P626	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
diurnal	diurnal	D654	JJ	I-NP	O
fluctuation	fluctuation	F423	NN	I-NP	O
(	(	0000	(	O	O
HPD	HPD	H130	NN	B-NP	B-Disease
;	;	0000	:	O	O
dopa	dopa	D100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
responsive	responsive	R215	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
,	,	0000	,	O	O
DRD	DRD	D630	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
recently	recently	R253	RB	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GTP	GTP	G310	NN	I-NP	O
cyclohydrolase	cyclohydrolase	C243	NN	I-NP	O
I	I	I000	CD	I-NP	O
(	(	0000	(	O	O
GCH1	GCH1	G200	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
quantified	quantify	Q531	VBD	B-VP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
GCH1	GCH1	G200	NN	B-NP	O
in	in	I500	IN	B-PP	O
phytohemagglutinin	phytohemagglutinin	P352	NN	B-NP	O
(	(	0000	(	O	O
PHA	PHA	P000	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
stimulated	stimulate	S354	VBN	B-NP	O
mononuclear	mononuclear	M524	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
one	one	O500	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
that	that	T300	WDT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
or	or	O600	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
junctions	junction	J523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GCH1	GCH1	G200	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
were	be	W600	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
to	to	T000	TO	B-PP	O
about	about	A130	RB	B-NP	O
40	40	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
GCH1	GCH1	G200	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
from	from	F650	IN	B-PP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
inactive	inactive	I523	JJ	I-NP	O
state	state	S300	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
should	should	S430	MD	B-VP	O
exist	exist	E230	VB	I-VP	O
on	on	O500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
unknown	unknown	U525	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GCH1	GCH1	G200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
decrease	decrease	D262	VB	I-VP	O
the	the	T000	DT	B-NP	O
GCH1	GCH1	G200	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
HPD	HPD	H130	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
DRD	DRD	D630	NN	I-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Sulfate	Sulfate	S413	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
impaired	impaired	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
pendred	pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
thyrocytes	thyrocyte	T623	NNS	I-NP	O
.	.	0000	.	O	O

Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
syndromic	syndromic	S536	JJ	B-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
dyshormonogenic	dyshormonogenic	D265	JJ	B-NP	B-Disease
goiter	goiter	G360	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
sensory	sensory	S526	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
neural	neural	N640	JJ	I-NP	I-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
its	its	I320	PRP$	B-NP	O
function	function	F523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
as	as	A200	RB	B-PP	O
yet	yet	Y300	RB	B-ADJP	O
unknown	unknown	U525	JJ	I-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
connection	connection	C523	NN	I-NP	O
between	between	B350	IN	B-PP	O
thyroid	thyroid	T630	JJ	B-NP	B-Disease
goiter	goiter	G360	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
sensory	sensory	S526	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
neural	neural	N640	JJ	I-NP	I-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
remains	remain	R520	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
enigma	enigma	E525	NN	I-NP	O
.	.	0000	.	O	O

PDS	PDS	P320	NN	B-NP	O
codes	cod	C320	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
pendrin	pendrin	P536	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	B-ADJP	O
related	related	R430	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
sufate	sufate	S130	NN	B-NP	O
transporters	transporter	T652	NNS	I-NP	O
.	.	0000	.	O	O

Mechanisms	Mechanism	M252	NNS	B-NP	O
by	by	B000	IN	B-PP	O
which	which	W200	WDT	B-NP	O
abnormal	abnormal	A156	JJ	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
could	could	C430	MD	B-VP	O
deleteriously	deleteriously	D436	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
iodide	iodide	I300	NN	B-NP	O
organification	organification	O625	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
tested	test	T230	VBD	B-VP	O
sulfate	sulfate	S413	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
thyrocytes	thyrocyte	T623	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
defective	defective	D123	JJ	B-ADJP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
pendrin	pendrin	P536	NN	B-NP	O
in	in	I500	IN	B-PP	O
fact	fact	F230	NN	B-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
emphasizes	emphasize	E512	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Small	Small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
triple	triple	T614	JJ	I-NP	O
helix	helix	H420	NN	I-NP	O
produce	produce	P632	VBP	B-VP	O
kniest	kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
moderately	moderately	M363	RB	I-NP	O
severe	severe	S160	JJ	I-NP	O
type	type	T100	NN	I-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
collagenopathy	collagenopathy	C425	NN	I-NP	I-Disease
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
short	short	S630	JJ	B-NP	O
trunk	trunk	T652	NN	I-NP	O
and	and	A530	CC	I-NP	O
limbs	limb	L512	NNS	I-NP	O
,	,	0000	,	O	O
kyphoscoliosis	kyphoscoliosis	K124	NN	B-NP	B-Disease
,	,	0000	,	O	O
midface	midface	M312	NN	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
severe	severe	S160	JJ	B-NP	O
myopia	myopia	M100	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hearing	hearing	H652	NN	B-NP	B-Disease
loss	loss	L200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
type	type	T100	NN	B-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
(	(	0000	(	O	O
COL2A1	COL2A1	C400	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
predominant	predominant	P635	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
cartilage	cartilage	C634	NN	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
but	but	B300	CC	I-NP	O
two	two	T000	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
cause	cause	C200	VBP	B-VP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
,	,	0000	,	O	O
either	either	E360	CC	O	O
by	by	B000	IN	B-PP	O
small	small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
or	or	O600	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
between	between	B350	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
12	12	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
24	24	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL2A1	COL2A1	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
sequence	sequence	S252	NN	B-NP	O
anomalies	anomaly	A542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
index	index	I532	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
identified	identify	I353	VBD	B-VP	O
four	four	F600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
COL2A1	COL2A1	C400	NN	B-NP	O
that	that	T300	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
a	a	A000	DT	B-NP	O
21	21	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
16	16	0000	CD	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
18	18	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
19	19	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
introns	intron	I536	NNS	B-NP	O
14	14	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
20	20	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL2A1	COL2A1	C400	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
12	12	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
intron	intron	I536	NN	I-NP	O
12	12	0000	CD	I-NP	O
junction	junction	J523	NN	I-NP	O
,	,	0000	,	O	O
deleting	delete	D435	VBG	B-VP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fifth	fifth	F130	JJ	I-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
three	three	T600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
encoded	encode	E523	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
shorter	short	S636	JJR	B-NP	O
type	type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
monomers	monomer	M562	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
alteration	alteration	A436	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
COL2A1	COL2A1	C400	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
span	span	S150	VB	I-VP	O
from	from	F650	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
12	12	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
24	24	0000	CD	B-NP	O
,	,	0000	,	O	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Kniest	Kni	K523	JJS	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyl	uridyl	U634	NN	I-NP	O
transferase	transferase	T652	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
activity	activity	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyl	uridyl	U634	NN	I-NP	O
transferase	transferase	T652	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
turn	turn	T650	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
exhibits	exhibit	E213	VBZ	B-VP	O
considerable	considerable	C523	JJ	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
1998	1998	0000	CD	B-NP	O
,	,	0000	,	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
150	150	0000	CD	I-NP	O
different	different	D165	JJ	I-NP	O
base	base	B200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
recorded	record	R263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
24	24	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
and	and	A530	CC	I-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
in	in	I500	IN	B-PP	O
15	15	0000	CD	B-NP	O
countries	country	C536	NNS	I-NP	O
worldwide	worldwide	W643	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
most	most	M230	RBS	B-VP	O
frequently	frequently	F625	RB	I-VP	O
cited	cite	C300	VBN	I-VP	O
are	be	A600	VBP	B-VP	O
Q188R	Q188R	Q600	NN	B-NP	O
,	,	0000	,	O	O
K285N	K285N	K500	NN	B-NP	O
,	,	0000	,	O	O
S135L	S135L	S400	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
N314D	N314D	N300	NN	B-NP	O
.	.	0000	.	O	O

Q188R	Q188R	Q600	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
European	European	E615	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
those	those	T200	DT	B-NP	O
predominantly	predominantly	P635	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
60	60	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
70	70	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
significant	significant	S251	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
relative	relative	R431	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
homoallelic	homoallelic	H542	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Q188R	Q188R	Q600	NN	B-NP	O
tend	tend	T530	VBP	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
keeping	keep	K152	VBG	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
virtually	virtually	V634	RB	I-NP	O
complete	complete	C514	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

Globally	Globally	G414	RB	B-ADVP	O
,	,	0000	,	O	O
K285N	K285N	K500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
rarer	rarer	R600	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
it	it	I300	PRP	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
on	on	O500	IN	B-PP	O
25	25	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
invariably	invariably	I516	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

S135L	S135L	S400	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
almost	almost	A452	RB	B-ADVP	O
exclusively	exclusively	E242	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
African	African	A162	JJ	B-NP	O
Americans	American	A562	NNPS	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
discrepant	discrepant	D261	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
some	some	S500	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
S135L	S135L	S400	NN	B-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
exhibit	exhibit	E213	VB	I-VP	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

Duarte	Duarte	D630	NN	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
Los	Los	L200	NNP	B-NP	O
Angeles	Angeles	A524	NNP	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Duarte	Duarte	D630	NN	B-NP	O
2	2	0000	CD	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
Duarte	Duarte	D630	JJ	B-ADJP	O
)	)	0000	)	O	O
variants	variant	V653	NNS	B-NP	O
carry	carry	C600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
,	,	0000	,	O	O
N314D	N314D	N300	NN	B-NP	O
,	,	0000	,	O	O
even	even	E150	RB	B-SBAR	O
though	though	T200	IN	I-SBAR	O
D1	D1	D000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
erythrocyte	erythrocyte	E636	NN	I-NP	O
GALT	GALT	G430	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
D2	D2	D000	NN	B-NP	O
with	with	W300	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

N314D	N314D	N300	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
base	base	B200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
differ	differ	D160	VBP	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
D1	D1	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
D2	D2	D000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

N314D	N314D	N300	NN	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
impair	impair	I516	VB	I-VP	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
abundance	abundance	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
lines	line	L520	NNS	B-NP	O
from	from	F650	IN	B-PP	O
D2	D2	D000	NN	B-NP	O
and	and	A530	CC	I-NP	O
D1	D1	D000	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
distinguish	distinguish	D235	VBP	B-VP	O
the	the	T000	DT	B-NP	O
D1	D1	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
D2	D2	D000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
activities	activity	A231	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
documented	document	D253	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
undoubtedly	undoubtedly	U531	RB	B-ADVP	O
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nonallelic	nonallelic	N542	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
on	on	O500	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
remain	remain	R500	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
elucidated	elucidate	E423	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
:	:	0000	:	O	O
definition	definition	D153	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
an	an	A500	DT	B-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	O
VHL	VHL	V400	NN	B-NP	B-Disease
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
173	173	0000	CD	B-NP	O
primary	primary	P656	JJ	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
in	in	I500	IN	B-PP	O
73	73	0000	CD	B-NP	O
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
sequencing	sequencing	S252	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
microdeletions	microdeletion	M263	NNS	B-NP	O
in	in	I500	IN	B-PP	O
58	58	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
,	,	0000	,	O	O
microinsertions	microinsertion	M265	NNS	B-NP	O
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
correspond	correspond	C621	VBP	B-VP	O
to	to	T000	TO	B-PP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

VHL	VHL	V400	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
only	only	O540	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
nonpapillary	nonpapillary	N514	JJ	I-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
(	(	0000	(	O	O
RCC	RCC	R200	NN	B-NP	B-Disease
)	)	0000	)	O	O
subtype	subtype	S131	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
previously	previously	P612	RB	B-ADVP	O
reported	report	R163	VBN	B-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
compare	compare	C516	VB	I-VP	O
somatic	somatic	S532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
database	database	D312	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
507	507	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutational	mutational	M354	JJ	B-NP	O
events	event	E153	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
difference	difference	D165	NN	I-NP	O
between	between	B350	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
78	78	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
vs	vs	V200	CC	O	O
only	only	O540	RB	B-NP	O
37	37	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
postulated	postulate	P234	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
RCC	RCC	R200	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
corresponds	correspond	C621	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
with	with	W300	IN	B-PP	O
few	few	F000	JJ	B-NP	O
specific	specific	S121	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
then	then	T500	RB	B-ADVP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
RCC	RCC	R200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
RCC	RCC	R200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
77	77	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
versus	versus	V620	IN	B-PP	O
55	55	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
may	may	M000	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
RCC	RCC	R200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O

Defective	Defective	D123	JJ	B-NP	O
CTLA	CTLA	C340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
cycling	cycling	C245	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
in	in	I500	IN	B-PP	O
Chediak	Chediak	C320	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Higashi	Higashi	H200	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
deregulation	deregulation	D624	NN	B-NP	O
of	of	O100	IN	B-PP	O
T	T	T000	NN	B-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
.	.	0000	.	O	O

Cytotoxic	Cytotoxic	C320	JJ	B-NP	O
T	T	T000	NN	I-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-VP	O
antigen	antigen	A532	NN	B-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
CTLA	CTLA	C340	NN	B-NP	O
-	-	0000	HYPH	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
CD152	CD152	C300	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
T	T	T000	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
.	.	0000	.	O	O

Its	Its	I320	PRP$	B-NP	O
membrane	membrane	M516	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	I-VP	O
regulated	regulate	R243	VBN	I-VP	O
by	by	B000	IN	B-PP	O
endocytosis	endocytosis	E532	NN	B-NP	O
and	and	A530	CC	I-NP	O
trafficking	trafficking	T612	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
secretory	secretory	S263	JJ	I-NP	O
lysosome	lysosome	L250	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

Chediak	Chediak	C320	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Higashi	Higashi	H200	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
CHS	CHS	C200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
trafficking	trafficking	T612	NN	I-NP	O
regulator	regulator	R243	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
LYST	LYST	L230	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
membrane	membrane	M516	NN	I-NP	O
targeting	targeting	T623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteins	protein	P635	NNS	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
secretory	secretory	S263	JJ	B-NP	O
lysosomes	lysosome	L252	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
features	feature	F362	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
hemophagocytosis	hemophagocytosis	H512	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
equivalent	equivalent	E214	NN	I-NP	O
of	of	O100	IN	B-PP	O
CHS	CHS	C200	NNP	B-NP	B-Disease
,	,	0000	,	O	O
beige	beige	B200	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
present	present	P625	JJ	B-NP	O
similar	similar	S546	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
but	but	B300	CC	O	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
develop	develop	D141	VB	I-VP	O
the	the	T000	DT	B-NP	O
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
herein	herein	H650	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
CTLA	CTLA	C340	NN	B-NP	O
-	-	0000	HYPH	O	O
4	4	0000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
enlarged	enlarged	E546	JJ	B-NP	O
,	,	0000	,	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
in	in	I500	IN	B-PP	O
CHS	CHS	C200	NN	B-NP	B-Disease
T	T	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
properly	properly	P616	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
surface	surface	S612	NN	I-NP	O
after	after	A136	IN	B-PP	O
T	T	T000	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
its	its	I320	PRP$	B-NP	O
surface	surface	S612	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
impaired	impaired	I516	JJ	B-ADJP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	I-VP	O
proposed	propose	P612	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
surface	surface	S612	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTLA	CTLA	C340	NN	B-NP	O
-	-	0000	HYPH	O	O
4	4	0000	CD	B-NP	O
by	by	B000	IN	B-PP	O
CHS	CHS	C200	NN	B-NP	B-Disease
T	T	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphoproliferative	lymphoproliferative	L516	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
insight	insight	I523	NN	B-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTLA	CTLA	C340	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Proteolipoprotein	Proteolipoprotein	P634	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
82	82	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
Pelizaeus	Pelizaeus	P420	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
Disease	Disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
duplications	duplication	D142	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
originate	originate	O625	VBP	B-VP	O
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
germ	germ	G650	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Clinical	Clinical	C452	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
Network	Network	N362	NN	I-NP	O
on	on	O500	IN	B-PP	O
Brain	Brain	B650	NNP	B-NP	B-Disease
Dysmyelinating	Dysmyelinating	D254	NNP	I-NP	I-Disease
Disease	Disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
Disease	Disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
developmental	developmental	D141	JJ	B-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
myelination	myelination	M453	NN	B-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
and	and	A530	CC	O	O
segregating	segregate	S262	VBG	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipoprotein	proteolipoprotein	P634	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
.	.	0000	.	O	O

Investigating	Investigate	I512	VBG	B-VP	O
82	82	0000	CD	B-NP	O
strictly	strictly	S362	RB	I-NP	O
selected	select	S423	VBN	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PMD	PMD	P530	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
PLP	PLP	P410	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
77	77	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
complete	complete	C514	JJ	B-NP	O
PLP	PLP	P410	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
gene	gene	G500	NN	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
(	(	0000	(	O	O
62	62	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
coding	coding	C352	NN	B-NP	O
or	or	O600	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
involved	involve	I514	VBN	I-VP	O
less	less	L200	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
(	(	0000	(	O	O
38	38	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
56	56	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
relevant	relevant	R415	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
22	22	0000	CD	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
68	68	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mothers	mother	M362	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
value	value	V400	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
thirds	third	T632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
mothers	mother	M362	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
expected	expect	E212	VBN	I-VP	O
if	if	I100	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
an	an	A500	DT	B-NP	O
equal	equal	E240	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
and	and	A530	CC	I-NP	O
female	female	F540	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
sharp	sharp	S610	JJ	B-NP	O
contrast	contrast	C536	NN	I-NP	O
,	,	0000	,	O	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
34	34	0000	CD	I-NP	O
duplicated	duplicate	D142	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
91	91	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mothers	mother	M362	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
carriers	carrier	C620	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
value	value	V400	NN	I-NP	O
significantly	significantly	S251	RB	B-ADVP	O
(	(	0000	(	O	O
chi2	chi2	C000	NN	B-NP	O
=	=	0000	JJ	B-VP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O
20	20	0000	CD	B-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
favor	favor	F160	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
bias	bias	B200	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
estimation	estimation	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
/	/	0000	SYM	I-NP	O
female	female	F540	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
k	k	K000	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
between	between	B350	IN	B-PP	O
parental	parental	P653	JJ	B-NP	O
and	and	A530	CC	I-NP	O
grandparental	grandparental	G653	JJ	I-NP	O
generations	generation	G563	NNS	I-NP	O
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
three	three	T600	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
generation	generation	G563	NN	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
allowed	allow	A430	VBD	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
estimation	estimation	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
k	k	K000	NN	I-NP	O
value	value	V400	NN	I-NP	O
(	(	0000	(	O	O
k	k	K000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Again	Again	A250	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
male	male	M400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
imbalance	imbalance	I514	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
duplications	duplication	D142	NNS	I-NP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
breakage	breakage	B620	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
Angelman	Angelman	A524	NNP	I-NP	I-Disease
syndromes	syndrome	S536	NNS	I-NP	I-Disease
involves	involve	I514	VBZ	B-VP	O
recombination	recombination	R251	NN	B-NP	O
between	between	B350	IN	B-PP	O
large	large	L620	JJ	B-NP	O
,	,	0000	,	I-NP	O
transcribed	transcribe	T652	VBN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
at	at	A300	IN	B-PP	O
proximal	proximal	P625	JJ	B-NP	O
and	and	A530	CC	I-NP	O
distal	distal	D234	JJ	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Angelman	Angelman	A524	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
distinct	distinct	D235	JJ	B-NP	O
neurobehavioral	neurobehavioral	N616	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
most	most	M230	RBS	B-ADVP	O
often	often	O135	RB	I-ADVP	O
arise	arise	A620	VBP	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
Mb	Mb	M100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
during	during	D652	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
or	or	O600	CC	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
gametogenesis	gametogenesis	G532	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-ADVP	O
.	.	0000	.	O	O

67	67	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
births	birth	B632	NNS	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
these	these	T200	DT	B-NP	O
events	event	E153	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
the	the	T000	DT	B-NP	O
regions	region	R252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contain	contain	C535	VBP	B-VP	O
two	two	T000	CD	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
clusters	cluster	C423	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
cluster	cluster	C423	NN	I-NP	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
potentially	potentially	P353	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
positionally	positionally	P235	RB	I-VP	O
cloned	clone	C453	VBN	I-VP	O
from	from	F650	IN	B-PP	O
YACs	YAC	Y200	NNS	B-NP	O
within	within	W350	IN	B-PP	O
or	or	O600	CC	I-PP	O
near	near	N600	IN	I-PP	O
these	these	T200	DT	B-NP	O
regions	region	R252	NNS	I-NP	O
.	.	0000	.	O	O

Analyses	Analysis	A542	NNS	B-NP	O
of	of	O100	IN	B-PP	O
rodent	rodent	R353	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
human	human	H500	JJ	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
,	,	0000	,	O	O
YAC	YAC	Y200	NN	B-NP	O
contigs	contig	C532	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
FISH	FISH	F200	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
or	or	O600	CC	I-NP	O
rearranged	rearrange	R652	VBN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
15	15	0000	CD	B-NP	O
identified	identify	I353	VBD	B-VP	O
duplicated	duplicate	D142	VBN	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
END	END	E530	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
or	or	O600	CC	I-PP	O
near	near	N600	IN	I-PP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
END	END	E530	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
repeat	repeat	R130	NN	I-NP	O
units	unit	U532	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
derived	derive	D613	VBN	I-VP	O
from	from	F650	IN	B-PP	O
large	large	L620	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HERC2	HERC2	H620	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
many	many	M500	JJ	B-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
transcriptionally	transcriptionally	T652	RB	B-ADJP	O
active	active	A231	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
AS	AS	A200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
identifiable	identifiable	I353	JJ	I-NP	O
,	,	0000	,	I-NP	O
rearranged	rearranged	R652	JJ	I-NP	O
HERC2	HERC2	H620	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
event	event	E153	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
postulate	postulate	P234	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
END	END	E530	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
mediate	mediate	M300	VBP	B-VP	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
active	active	A231	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
and	and	A530	CC	I-NP	O
female	female	F540	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
may	may	M000	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Brazilian	Brazilian	B624	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
van	van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
suggests	suggest	S232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
cleft	cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
17p11	17p11	P000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
-	-	0000	:	O	O
11	11	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

van	van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
VWS	VWS	V200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
1q32	1q32	Q000	CD	B-NP	O
-	-	0000	HYPH	O	O
41	41	0000	CD	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
pits	pit	P320	NNS	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
sinuses	sinus	S520	NNS	B-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
lower	low	L600	JJR	I-NP	I-Disease
lip	lip	L100	NN	I-NP	I-Disease
,	,	0000	,	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
/	/	0000	SYM	O	I-Disease
palate	palate	P430	NN	B-NP	I-Disease
(	(	0000	(	O	O
CL	CL	C400	NN	B-NP	B-Disease
/	/	0000	SYM	O	I-Disease
P	P	P000	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
(	(	0000	(	O	O
CP	CP	C100	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
bifid	bifid	B130	JJ	B-NP	B-Disease
uvula	uvula	U140	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hypodontia	hypodontia	H135	NN	B-NP	B-Disease
(	(	0000	(	O	O
H	H	H000	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
incomplete	incomplete	I525	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	B-ADJP	O
variable	variable	V614	JJ	I-ADJP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
CL	CL	C400	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
P	P	P000	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
CP	CP	C100	NN	I-NP	B-Disease
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
genealogy	genealogy	G542	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
recurrence	recurrence	R265	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
<	<	0000	SYM	O	O
40	40	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
CP	CP	C100	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
descendants	descendant	D253	NNS	B-NP	O
with	with	W300	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
clefts	cleft	C413	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
influenced	influence	I514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
modifying	modify	M315	VBG	B-VP	O
genes	gene	G520	NNS	B-NP	O
at	at	A300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Brazilian	Brazilian	B624	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
,	,	0000	,	O	O
considering	consider	C523	VBG	B-VP	O
as	as	A200	IN	B-SBAR	O
affected	affect	A123	VBN	B-VP	O
the	the	T000	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
CP	CP	C100	NN	B-NP	B-Disease
,	,	0000	,	O	O
regardless	regardless	R263	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
whether	whether	W360	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
17p11	17p11	P000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
11	11	0000	CD	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	:	O	O
11	11	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
1p32	1p32	P000	NN	B-NP	O
-	-	0000	HYPH	O	O
41	41	0000	CD	B-NP	O
,	,	0000	,	O	O
enhances	enhance	E520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
CP	CP	C100	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
at	at	A300	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
risk	risk	R200	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

If	If	I100	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
will	will	W400	MD	B-VP	O
represent	represent	R162	VB	I-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
mapped	map	M130	VBN	B-VP	O
through	through	T620	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
modifies	modify	M312	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

New	New	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
polymorphisms	polymorphism	P456	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
rare	rare	R600	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
SSCP	SSCP	S210	NN	I-NP	O
strategy	strategy	S363	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
,	,	0000	,	O	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
spans	span	S152	NNS	B-NP	O
about	about	A130	IN	B-NP	O
150	150	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
as	as	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
starting	start	S363	VBG	I-NP	O
material	material	M364	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
92	92	0000	CD	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
optimized	optimize	O135	VBN	I-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
technique	technique	T252	NN	B-NP	O
that	that	T300	WDT	B-NP	O
detected	detect	D323	VBD	B-VP	O
all	all	A400	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
known	know	K500	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
segments	segment	S253	NNS	B-NP	O
being	be	B520	VBG	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
expedite	expedite	E213	VB	I-VP	O
screening	screening	S265	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
sequentially	sequentially	S253	RB	B-ADVP	O
loaded	load	L300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
gels	gel	G420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
sets	set	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
pretested	preteste	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
avoid	avoid	A130	VB	I-VP	O
overlapping	overlap	O164	VBG	I-VP	O
patterns	pattern	P365	NNS	B-NP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
were	be	W600	VBD	B-VP	O
intragenic	intragenic	I536	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
expected	expected	E212	JJ	I-NP	O
177	177	0000	CD	I-NP	O
unknown	unknown	U525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
approximately	approximately	A162	RB	B-NP	O
70	70	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
mostly	mostly	M234	RB	B-NP	O
protein	protein	P635	NN	I-NP	O
truncating	truncate	T652	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
(	(	0000	(	O	O
that	that	T300	WDT	B-NP	O
would	would	W430	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
detectable	detectable	D323	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
truncation	truncation	T652	NN	I-NP	O
testing	testing	T235	NN	I-NP	O
if	if	I100	IN	B-SBAR	O
RNA	RNA	R500	NN	B-NP	O
starting	starting	S363	NN	I-NP	O
material	material	M364	NN	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
available	available	A141	JJ	B-ADJP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
defined	define	D153	VBN	I-VP	O
for	for	F600	IN	B-PP	O
every	every	E160	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Herein	Herein	H650	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
35	35	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
34	34	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
or	or	O600	CC	O	O
rare	rare	R600	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
compilation	compilation	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
assembled	assemble	A251	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
.	.	0000	.	O	O

Defining	Define	D152	VBG	B-VP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
sites	site	S320	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
great	great	G630	JJ	B-NP	O
importance	importance	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
designing	design	D252	VBG	B-VP	O
automated	automated	A353	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
for	for	F600	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
McLeod	McLeod	M243	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XK	XK	X200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
XK	XK	X200	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
McLeod	McLeod	M243	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
50	50	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
man	man	M500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
progressive	progressive	P626	JJ	B-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
,	,	0000	,	O	O
choreic	choreic	C620	JJ	B-NP	B-Disease
movement	movement	M153	NN	I-NP	I-Disease
,	,	0000	,	O	O
elevated	elevated	E413	JJ	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
creatinine	creatinine	C635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
acanthocytosis	acanthocytosis	A253	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
Kell	Kell	K400	NNP	I-NP	O
antigens	antigen	A532	NNS	I-NP	O
in	in	I500	IN	B-PP	O
erythrocyte	erythrocyte	E636	NN	B-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
and	and	A530	CC	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
(	(	0000	(	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
deletion	deletion	D435	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
position	position	P235	NN	I-NP	O
1095	1095	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
XK	XK	X200	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
caused	cause	C230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
in	in	I500	IN	B-PP	O
translation	translation	T652	NN	B-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
408	408	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
this	this	T200	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
defective	defective	D123	JJ	B-NP	O
Kx	Kx	K200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
McLeod	McLeod	M243	NNP	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Association	Association	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hRad50	hRad50	H630	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
hMre11	hMre11	H560	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
p95	p95	P000	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
with	with	W300	IN	B-PP	O
hRad50	hRad50	H630	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
forms	form	F652	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
with	with	W300	IN	B-PP	O
hMre11	hMre11	H560	NN	B-NP	O
and	and	A530	CC	I-NP	O
p95	p95	P000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
nibrin	nibrin	N165	NN	I-NP	O
.	.	0000	.	O	O

Upon	Upon	U150	IN	B-PP	O
irradiation	irradiation	I635	NN	B-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
foci	focus	F200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
colocalize	colocalize	C424	VBP	B-VP	O
with	with	W300	IN	B-PP	O
hRad50	hRad50	H630	NN	B-NP	O
.	.	0000	.	O	O

Formation	Formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
irradiation	irradiation	I635	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
foci	focus	F200	NNS	I-NP	O
positive	positive	P231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
hRad50	hRad50	H630	NN	B-NP	O
,	,	0000	,	O	O
hMre11	hMre11	H560	NN	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
p95	p95	P000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
dramatically	dramatically	D653	RB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HCC	HCC	H200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
1937	1937	0000	CD	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
but	but	B300	CC	O	O
was	be	W200	VBD	B-VP	O
restored	restore	R236	VBN	I-VP	O
by	by	B000	IN	B-PP	O
transfection	transfection	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

Ectopic	Ectopic	E231	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
rendered	render	R536	VBD	B-VP	O
them	them	T500	PRP	B-NP	O
less	less	L200	RBR	B-ADJP	O
sensitive	sensitive	S523	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
agent	agent	A253	NN	I-NP	O
,	,	0000	,	O	O
methyl	methyl	M340	NN	B-NP	O
methanesulfonate	methanesulfonate	M352	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
responses	response	R215	NNS	I-NP	O
to	to	T000	TO	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
mediated	mediate	M300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
hRad50	hRad50	H630	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
hMre11	hMre11	H560	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
p95	p95	P000	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Relationship	Relationship	R435	NN	B-NP	O
among	among	A520	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
,	,	0000	,	O	O
biochemical	biochemical	B252	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cognitive	cognitive	C253	JJ	B-NP	O
performance	performance	P616	NN	I-NP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	B-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
report	report	R163	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Maternal	Maternal	M365	NNP	I-NP	B-Disease
Phenylketonuria	Phenylketonuria	P542	NNP	I-NP	I-Disease
Collaborative	Collaborative	C416	NNP	I-NP	O
Study	Study	S300	NNP	I-NP	O
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
genotypes	genotype	G531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
cognitive	cognitive	C253	JJ	B-NP	O
development	development	D141	NN	I-NP	O
in	in	I500	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
phenylketonuria	phenylketonuria	P542	NN	I-NP	I-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

METHODOLOGY	METHODOLOGY	M342	NN	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
in	in	I500	IN	B-PP	O
222	222	0000	CD	B-NP	O
hyperphenylalaninemic	hyperphenylalaninemic	H161	JJ	I-NP	B-Disease
females	female	F542	NNS	I-NP	O
enrolled	enrol	E564	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Maternal	Maternal	M365	JJ	I-NP	B-Disease
PKU	PKU	P200	NN	I-NP	I-Disease
Collaborative	Collaborative	C416	JJ	I-NP	O
Study	Study	S300	NN	I-NP	O
(	(	0000	(	O	O
MPKUCS	MPKUCS	M120	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
84	84	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
complete	complete	C514	JJ	B-NP	O
genotype	genotype	G531	NN	I-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
in	in	I500	IN	B-PP	O
199	199	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Based	Base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
about	about	A130	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
associations	association	A235	NNS	I-NP	O
,	,	0000	,	O	O
78	78	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
classes	class	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
severity	severity	S163	NN	B-NP	O
(	(	0000	(	O	O
severe	severe	S160	JJ	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
,	,	0000	,	O	O
moderate	moderate	M363	JJ	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
,	,	0000	,	O	O
mild	mild	M430	JJ	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	B-Disease
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	I-NP	I-Disease
[	[	0000	(	O	O
MHP	MHP	M100	NN	B-NP	B-Disease
]	]	0000	)	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Then	Then	T500	RB	B-ADVP	O
,	,	0000	,	O	O
189	189	0000	CD	B-NP	O
MPKUCS	MPKUCS	M120	NN	I-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
grouped	group	G613	VBN	I-VP	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
various	various	V620	JJ	I-NP	O
combinations	combination	C515	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
classifications	classification	C421	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
sizes	size	S200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
large	large	L620	JJ	B-ADJP	O
enough	enough	E520	RB	I-ADJP	O
for	for	F600	IN	B-PP	O
statistical	statistical	S323	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
groups	group	G612	NNS	I-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
completely	completely	C514	RB	B-VP	O
abolishes	abolish	A142	VBZ	I-VP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
considered	consider	C523	VBN	I-VP	O
functionally	functionally	F523	RB	B-ADJP	O
hemizygous	hemizygous	H520	JJ	I-ADJP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
The	The	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
predicted	predict	P632	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
in	in	I500	IN	B-PP	O
functionally	functionally	F523	RB	B-NP	O
hemizygous	hemizygous	H520	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
related	relate	R430	VBN	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
assigned	assign	A253	VBN	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

Cognitive	Cognitive	C253	JJ	B-NP	O
performance	performance	P616	NN	I-NP	O
(	(	0000	(	O	O
IQ	IQ	I200	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
significantly	significantly	S251	RB	B-ADJP	O
related	relate	R430	VBN	I-ADJP	O
to	to	T000	TO	B-PP	O
genotype	genotype	G531	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
IQ	IQ	I200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mothers	mother	M362	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
combination	combination	C515	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
MHP	MHP	M100	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
99	99	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
96	96	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
IQ	IQ	I200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
mothers	mother	M362	NNS	I-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
severe	severe	S160	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
or	or	O600	CC	B-PP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
severe	severe	S160	JJ	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
moderate	moderate	M363	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
83	83	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
84	84	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
92	92	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
treated	treat	T630	VBN	I-VP	O
during	during	D652	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

Those	Those	T200	DT	B-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
untreated	untreated	U536	JJ	B-ADJP	O
or	or	O600	CC	O	O
treated	treat	T630	VBN	B-VP	O
late	late	L300	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
lower	low	L600	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
average	average	A162	JJ	B-NP	O
IQ	IQ	I200	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
combinations	combination	C515	NNS	I-NP	O
.	.	0000	.	O	O

Females	Female	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
moderate	moderate	M363	JJ	B-NP	O
or	or	O600	CC	I-NP	O
mild	mild	M430	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
treated	treat	T630	VBN	I-VP	O
early	early	E640	JJ	B-ADVP	O
and	and	A530	CC	O	O
treated	treat	T630	VBN	B-VP	O
for	for	F600	IN	B-PP	O
>	>	0000	JJR	B-NP	O
6	6	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
IQ	IQ	I200	NN	B-NP	O
scores	score	S262	NNS	I-NP	O
10	10	0000	CD	B-NP	O
points	point	P532	NNS	I-NP	O
above	above	A100	IN	B-PP	O
average	average	A162	NN	B-NP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
group	group	G610	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
reproductive	reproductive	R163	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
in	in	I500	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
phenylketonuria	phenylketonuria	P542	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
control	control	C536	NN	I-NP	O
and	and	A530	CC	O	O
postnatal	postnatal	P235	JJ	B-NP	O
environmental	environmental	E516	JJ	I-NP	O
circumstances	circumstance	C625	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
factors	factor	F236	NNS	I-NP	O
depend	depend	D153	VBP	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
intellectual	intellectual	I534	JJ	I-NP	O
resources	resource	R262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
with	with	W300	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
among	among	A520	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
,	,	0000	,	O	O
biochemical	biochemical	B252	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cognitive	cognitive	C253	JJ	B-NP	O
performance	performance	P616	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
importance	importance	I516	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
optimal	optimal	O135	JJ	I-NP	O
strategy	strategy	S363	NN	I-NP	O
for	for	F600	IN	B-PP	O
future	future	F360	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
females	female	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
who	who	W000	WP	B-NP	O
plan	plan	P450	VBP	B-VP	O
pregnancy	pregnancy	P625	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Spinal	Spinal	S154	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
seven	seven	S150	CD	B-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
six	six	S200	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
slowly	slowly	S400	RB	I-NP	O
progressive	progressive	P626	JJ	I-NP	O
,	,	0000	,	I-NP	O
mainly	mainly	M540	RB	I-NP	O
spinal	spinal	S154	JJ	I-NP	B-Disease
cord	cord	C630	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
remained	remain	R530	VBD	B-VP	O
for	for	F600	IN	B-PP	O
many	many	M500	JJ	B-NP	O
years	year	Y620	NNS	I-NP	O
the	the	T000	DT	B-NP	O
sole	sole	S400	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

MRI	MRI	M600	NN	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
white	white	W300	JJ	B-NP	B-Disease
matter	matter	M360	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lateral	lateral	L364	JJ	I-NP	O
and	and	A530	CC	I-NP	O
dorsal	dorsal	D624	JJ	I-NP	O
columns	column	C452	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
spinal	spinal	S154	JJ	I-NP	O
cord	cord	C630	NN	I-NP	O
.	.	0000	.	O	O

Post	Post	P230	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mortem	mortem	M635	NN	I-NP	O
examination	examination	E253	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
extensive	extensive	E235	JJ	B-NP	O
myelin	myelin	M450	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
columns	column	C452	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
array	array	A600	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotypes	genotype	G531	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
spinal	spinal	S154	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
radiological	radiological	R342	JJ	I-NP	O
separate	separate	S163	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
that	that	T300	WDT	B-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
included	include	I524	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
differential	differential	D165	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
myelopathy	myelopathy	M413	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
transgene	transgene	T652	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
creating	create	C635	VBG	B-VP	O
a	a	A000	DT	B-NP	O
heritable	heritable	H631	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
angelman	angelman	A524	NN	B-NP	I-Disease
syndromes	syndrome	S536	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Angelman	Angelman	A524	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
imprinted	imprinted	I516	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15q11	15q11	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q13	q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
7	7	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
conservation	conservation	C526	NN	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
gene	gene	G500	NN	B-NP	O
order	order	O636	NN	I-NP	O
and	and	A530	CC	O	O
imprinted	imprinted	I516	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
transgene	transgene	T652	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
(	(	0000	(	O	O
Epstein	Epstein	E123	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
Barr	Barr	B600	NNP	I-NP	O
virus	virus	V620	NN	I-NP	O
Latent	Latent	L353	JJ	I-NP	O
Membrane	Membrane	M516	NN	I-NP	O
Protein	Protein	P635	NN	I-NP	O
2A	2A	A000	NN	I-NP	O
,	,	0000	,	O	O
LMP2A	LMP2A	L510	NN	B-NP	O
)	)	0000	)	O	O
into	into	I530	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
7C	7C	C000	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
resulted	result	R243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
models	model	M342	NNS	I-NP	O
for	for	F600	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
AS	AS	A200	NN	I-NP	B-Disease
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transmitting	transmitting	T652	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

Epigenotype	Epigenotype	E125	NN	B-NP	O
(	(	0000	(	O	O
allelic	allelic	A420	JJ	B-NP	O
expression	expression	E216	NN	B-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
methylation	methylation	M343	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
transgene	transgene	T652	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
generated	generate	G563	VBN	I-VP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
AS	AS	A200	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
region	region	R250	NN	I-NP	O
but	but	B300	CC	O	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
flanking	flanking	F452	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
intact	intact	I532	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
opposite	opposite	O123	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
,	,	0000	,	O	O
maintains	maintain	M535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
correct	correct	C623	JJ	I-NP	O
imprint	imprint	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
AS	AS	A200	JJ	B-NP	B-Disease
mice	mouse	M200	NNS	I-NP	O
and	and	A530	CC	O	O
establishes	establish	E231	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
correct	correct	C623	JJ	I-NP	O
imprint	imprint	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
and	and	A530	CC	I-NP	O
female	female	F540	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
AS	AS	A200	JJ	B-NP	B-Disease
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
homologous	homologous	H542	JJ	B-NP	O
association	association	A235	NN	I-NP	O
and	and	A530	CC	O	O
replication	replication	R142	NN	B-NP	O
asynchrony	asynchrony	A252	NN	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
heritable	heritable	H631	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
deletion	deletion	D435	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
particularly	particularly	P632	RB	B-ADJP	O
useful	useful	U214	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
etiological	etiological	E342	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
and	and	A530	CC	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
,	,	0000	,	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
investigation	investigation	I512	NN	B-NP	O
of	of	O100	IN	B-PP	O
therapeutic	therapeutic	T613	JJ	B-NP	O
approaches	approach	A162	NNS	I-NP	O
for	for	F600	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
van	van	V500	NNP	I-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
kindreds	kindred	K536	NNS	I-NP	O
to	to	T000	TO	B-PP	O
1q32	1q32	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q41	q41	Q000	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
further	further	F636	RBR	B-ADVP	O
supports	support	S163	VBZ	B-VP	O
locus	locus	L200	NN	B-NP	O
homogeneity	homogeneity	H525	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
trait	trait	T630	NN	I-NP	O
.	.	0000	.	O	O

van	van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
vWS	vWS	V200	NN	B-NP	B-Disease
,	,	0000	,	O	O
MIM	MIM	M500	NN	B-NP	O
119300	119300	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
clefting	clefting	C413	NN	I-NP	I-Disease
condition	condition	C535	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
cardinal	cardinal	C635	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mucous	mucous	M200	JJ	B-NP	B-Disease
cysts	cyst	C232	NNS	I-NP	I-Disease
(	(	0000	(	O	O
lower	low	L600	JJR	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
lip	lip	L100	NN	I-NP	I-Disease
pits	pit	P320	NNS	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
clefts	cleft	C413	NNS	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
palate	palate	P430	NN	B-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
vWS	vWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
1q32	1q32	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q41	q41	Q000	NN	I-NP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
physical	physical	P240	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
5	5	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
vWS	vWS	V200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
through	through	T620	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
attended	attend	A353	VBD	B-VP	O
for	for	F600	IN	B-PP	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
palate	palate	P430	VB	B-VP	I-Disease
repair	repair	R160	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Department	Department	D163	NNP	I-NP	O
of	of	O100	IN	B-PP	O
Maxillofacial	Maxillofacial	M241	NNP	B-NP	O
Surgery	Surgery	S626	NNP	I-NP	O
of	of	O100	IN	B-PP	O
Hopital	Hopital	H134	NNP	B-NP	O
Trousseau	Trousseau	T620	NNP	I-NP	O
,	,	0000	,	O	O
Paris	Paris	P620	NNP	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
tentatively	tentatively	T531	RB	I-VP	O
refine	refine	R150	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWS	vWS	V200	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
1q32	1q32	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q41	q41	Q000	NN	I-NP	O
and	and	A530	CC	O	O
possibly	possibly	P214	RB	B-VP	O
identify	identify	I353	VB	I-VP	O
unlinked	unlinked	U545	JJ	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
6	6	0000	CD	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
(	(	0000	(	O	O
D1S249	D1S249	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S425	D1S425	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S491	D1S491	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S205	D1S205	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S414	D1S414	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S425	D1S425	D200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
yielding	yield	Y435	VBG	B-VP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
cumulative	cumulative	C543	JJ	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

27	27	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
D1S245	D1S245	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
innermost	innermost	I565	JJ	I-NP	O
four	four	F600	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
tightly	tightly	T234	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
one	one	O500	CD	B-NP	O
another	another	A536	DT	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
vWS	vWS	V200	NN	B-NP	B-Disease
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
tightly	tightly	T234	RB	B-NP	O
linked	link	L523	VBN	I-NP	O
markers	marker	M626	NNS	I-NP	O
and	and	A530	CC	O	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
favour	favour	F160	VB	I-VP	O
locus	locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
trait	trait	T630	NN	I-NP	O
.	.	0000	.	O	O

Null	Null	N400	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
(	(	0000	(	O	O
Wilson	Wilson	W425	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	B-Disease
copper	copper	C160	NN	I-NP	I-Disease
accumulation	accumulation	A254	NN	I-NP	I-Disease
and	and	A530	CC	O	O
late	late	L300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
onset	onset	O523	NN	I-NP	I-Disease
hepatic	hepatic	H132	JJ	I-NP	I-Disease
nodular	nodular	N346	JJ	I-NP	I-Disease
transformation	transformation	T652	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Atp7b	Atp7b	A310	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
copper	copper	C160	NN	I-NP	O
-	-	0000	HYPH	O	O
transporting	transport	T652	VBG	B-VP	O
ATPase	ATPase	A312	NN	B-NP	O
expressed	express	E216	VBN	B-VP	O
predominantly	predominantly	P635	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
lesser	less	L260	JJR	I-NP	O
extent	extent	E235	NN	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
other	other	O360	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
copper	copper	C160	NN	I-NP	B-Disease
toxicity	toxicity	T230	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
dramatic	dramatic	D653	JJ	B-NP	O
build	build	B430	VB	I-NP	O
-	-	0000	HYPH	B-VP	O
up	up	U100	RP	B-PRT	O
of	of	O100	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
copper	copper	C160	NN	I-NP	O
with	with	W300	IN	B-PP	O
subsequent	subsequent	S125	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
neuro	neuro	N600	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
logical	logical	L240	JJ	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
to	to	T000	TO	B-VP	O
disrupt	disrupt	D261	VB	I-VP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
translation	translation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATP7B	ATP7B	A310	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
generated	generate	G563	VBN	I-VP	O
a	a	A000	DT	B-NP	O
strain	strain	S365	NN	I-NP	O
of	of	O100	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
(	(	0000	(	O	O
null	null	N400	NN	B-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilson	Wilson	W425	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
null	null	N400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
display	display	D214	VBP	B-VP	O
a	a	A000	DT	B-NP	O
gradual	gradual	G634	JJ	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	O
copper	copper	C160	NN	I-NP	O
that	that	T300	WDT	B-NP	O
increases	increase	I526	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
level	level	L140	NN	I-NP	O
60	60	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	B-ADJP	O
greater	great	G636	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
5	5	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
copper	copper	C160	NN	B-NP	O
concentration	concentration	C525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
kidney	kidney	K350	NN	I-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
placenta	placenta	P425	NN	B-NP	O
and	and	A530	CC	O	O
lactating	lactate	L235	VBG	B-VP	O
mammary	mammary	M560	JJ	B-NP	O
glands	gland	G453	NNS	I-NP	O
of	of	O100	IN	B-PP	O
homo	homo	H500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
zygous	zygous	Z200	JJ	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
milk	milk	M420	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
glands	gland	G453	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
copper	copper	C160	NN	B-NP	B-Disease
deficient	deficient	D125	JJ	B-ADJP	I-Disease
.	.	0000	.	O	O

Morphological	Morphological	M614	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
resembling	resemble	R251	VBG	B-VP	O
cirrhosis	cirrhosis	C620	NN	B-NP	B-Disease
developed	develop	D141	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
livers	liver	L162	NNS	I-NP	O
from	from	F650	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
older	old	O436	JJR	B-NP	O
than	than	T500	IN	I-NP	O
7	7	0000	CD	I-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

Progeny	Progeny	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
females	female	F542	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
neurological	neurological	N642	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
growth	growth	G630	NN	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
copper	copper	C160	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Copper	Copper	C160	NN	B-NP	O
concentration	concentration	C525	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
livers	liver	L162	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
newborn	newborn	N165	JJ	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
null	null	N400	JJ	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
dramatically	dramatically	D653	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
summary	summary	S560	NN	B-NP	O
,	,	0000	,	O	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
cirrhotic	cirrhotic	C632	JJ	B-NP	B-Disease
liver	liver	L160	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
resembles	resemble	R251	VBZ	B-VP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
toxic	toxic	T200	JJ	I-NP	O
milk	milk	M420	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

French	French	F652	JJ	B-NP	O
Machado	Machado	M230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
exhibit	exhibit	E213	VB	I-VP	O
gametic	gametic	G532	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Segregation	Segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	B-Disease
repeat	repeat	R130	NN	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
study	study	S300	NN	I-NP	O
performed	perform	P616	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
disease	disease	D200	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
transmitted	transmit	T652	VBN	I-VP	O
during	during	D652	IN	B-PP	O
meiosis	meiosis	M200	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
of	of	O100	IN	B-PP	O
French	French	F652	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
and	and	A530	CC	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
pooled	pool	P430	VBN	I-NP	O
data	data	D300	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	NN	B-NP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
379	379	0000	CD	B-NP	O
436	436	0000	CD	I-NP	O
(	(	0000	(	O	O
46	46	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
53	53	0000	CD	I-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
support	support	S163	VB	I-VP	O
meiotic	meiotic	M320	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
confirm	confirm	C516	VB	I-VP	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
,	,	0000	,	O	O
sperm	sperm	S165	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
D14S1050	D14S1050	D200	NN	B-NP	O
,	,	0000	,	O	O
closely	closely	C424	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
910	910	0000	CD	B-NP	O
sperm	sperm	S165	NN	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
50	50	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
samples	sample	S514	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
49	49	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
frequency	frequency	F625	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
significant	significant	S251	JJ	B-ADJP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
8423	8423	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Likelihood	Likelihood	L243	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-VP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
sperm	sperm	S165	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
SPERMSEG	SPERMSEG	S165	NN	I-NP	O
program	program	P626	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
support	support	S163	NN	I-NP	O
for	for	F600	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
gamete	gamete	G530	NN	I-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
report	report	R163	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
disease	disease	D200	NN	B-NP	O
allele	allele	A400	NN	I-NP	O
stability	stability	S314	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
influenced	influence	I514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
trans	trans	T652	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
987	987	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
C	C	C000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
variance	variance	V652	NN	I-NP	O
in	in	I500	IN	B-PP	O
repeat	repeat	R130	NN	B-NP	O
number	number	N516	NN	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
overlapped	overlap	O164	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
variance	variance	V652	NN	I-NP	O
in	in	I500	IN	B-PP	O
repeat	repeat	R130	NN	B-NP	O
number	number	N516	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
C	C	C000	NN	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
eye	eye	E000	NN	B-NP	B-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
ocular	ocular	O246	JJ	B-NP	O
morphogenesis	morphogenesis	M612	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ocular	ocular	O246	JJ	B-NP	B-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
corneal	corneal	C654	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
cataract	cataract	C362	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
foveal	foveal	F140	JJ	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
regulator	regulator	R243	NN	I-NP	O
that	that	T300	WDT	B-NP	O
recognizes	recognize	R252	VBZ	B-VP	O
target	target	T623	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
through	through	T620	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
paired	paired	P630	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
composed	compose	C512	VBN	I-VP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
subdomains	subdomain	S135	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
subdomain	subdomain	S135	NN	I-NP	O
(	(	0000	(	O	O
NTS	NTS	N320	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
subdomain	subdomain	S135	NN	I-NP	O
(	(	0000	(	O	O
CTS	CTS	C320	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
bind	bind	B530	VBP	B-VP	O
respective	respective	R212	JJ	B-NP	O
consensus	consensus	C525	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
,	,	0000	,	O	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
NTS	NTS	N320	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
amino	amino	A500	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5a	5a	A000	CD	I-NP	O
abolishes	abolish	A142	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
binding	binding	B535	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
NTS	NTS	N320	NNS	I-NP	O
and	and	A530	CC	O	O
unmasks	unmask	U520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTS	CTS	C320	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
exon	exon	E250	NN	B-NP	O
5a	5a	A000	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
switch	switch	S320	NN	I-NP	O
that	that	T300	WDT	B-NP	O
specifies	specify	S121	VBZ	B-VP	O
target	target	T623	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
ascertained	ascertain	A263	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
cataract	cataract	C362	NN	I-NP	I-Disease
,	,	0000	,	O	O
Axenfeldt	Axenfeldt	A251	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
foveal	foveal	F140	JJ	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
variant	variant	V653	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	B-NP	O
A	A	A000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
20th	20th	T000	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5a	5a	A000	CD	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
>	>	0000	SYM	O	O
Asp	Asp	A210	NN	B-NP	O
(	(	0000	(	O	O
GTC	GTC	G320	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
GAC	GAC	G200	NN	I-NP	O
)	)	0000	)	O	O
substitution	substitution	S123	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
7th	7th	T000	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
V54D	V54D	V300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
slightly	slightly	S423	RB	B-ADVP	O
increased	increase	I526	VBD	B-VP	O
NTS	NTS	N320	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
and	and	A530	CC	O	O
decreased	decrease	D262	VBD	B-VP	O
CTS	CTS	C320	NN	B-NP	O
transactivation	transactivation	T652	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
to	to	T000	TO	B-PP	O
almost	almost	A452	RB	B-NP	O
half	half	H410	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Penetrances	Penetrance	P536	NNS	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
1675delA	1675delA	D400	NN	I-NP	O
and	and	A530	CC	O	O
1135insA	1135insA	I520	NN	B-NP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
and	and	A530	CC	O	O
predictive	predictive	P632	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
penetrances	penetrance	P536	NNS	B-NP	O
and	and	A530	CC	I-NP	O
expressions	expression	E216	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
known	know	K500	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
two	two	T000	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
founder	founder	F536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Norwegian	Norwegian	N625	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Index	Index	I532	NN	B-NP	O
cases	case	C200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
ways	way	W200	NNS	I-NP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
consecutive	consecutive	C523	JJ	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
16	16	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
through	through	T620	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
family	family	F540	NN	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
clinic	clinic	C452	NN	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Altogether	Altogether	A432	RB	B-ADVP	O
,	,	0000	,	O	O
20	20	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
1675delA	1675delA	D400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
10	10	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
1135insA	1135insA	I520	NN	B-NP	O
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
relatives	relative	R431	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
absence	absence	A125	NN	B-NP	O
/	/	0000	SYM	I-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
133	133	0000	CD	B-NP	O
living	live	L152	VBG	B-VP	O
female	female	F540	JJ	B-NP	O
relatives	relative	R431	NNS	I-NP	O
,	,	0000	,	O	O
83	83	0000	CD	B-NP	O
(	(	0000	(	O	O
62	62	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
penetrance	penetrance	P536	NN	B-NP	O
and	and	A530	CC	I-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
differences	difference	D165	NNS	B-NP	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
method	method	M300	NN	B-NP	O
of	of	O100	IN	B-PP	O
ascertainment	ascertainment	A263	NN	B-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
disease	disease	D200	NN	B-NP	O
started	start	S363	VBD	B-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
30	30	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	DT	B-NP	O
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
carrying	carry	C652	VBG	B-NP	O
women	woman	W500	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
experienced	experience	E216	VBN	I-VP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

More	More	M600	RBR	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
than	than	T500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
recorded	record	R263	VBN	I-VP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
penetrance	penetrance	P536	NN	B-NP	O
and	and	A530	CC	O	O
expression	expression	E216	NN	B-NP	O
(	(	0000	(	O	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
vs	v	V200	NNS	I-NP	O
.	.	0000	.	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
reports	report	R163	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
founder	founder	F536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Whether	Whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
differences	difference	D165	NNS	I-NP	O
reflect	reflect	R142	VBP	B-VP	O
true	true	T600	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
methodological	methodological	M342	JJ	B-NP	O
problems	problem	P614	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
discussed	discuss	D230	VBN	I-VP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
methodological	methodological	M342	JJ	B-NP	O
problems	problem	P614	NNS	I-NP	O
;	;	0000	:	O	O
possible	possible	P214	JJ	B-NP	O
explanations	explanation	E214	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
a	a	A000	DT	B-NP	O
"	"	0000	``	I-NP	O
true	true	T600	JJ	I-NP	O
"	"	0000	''	I-NP	O
low	low	L000	JJ	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
or	or	O600	CC	O	O
preferential	preferential	P616	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
dermatofibrosarcoma	dermatofibrosarcoma	D653	NN	I-NP	B-Disease
protuberans	protuberans	P631	AFX	O	I-Disease
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-NP	O
collagen	collagen	C425	NN	I-NP	O
type	type	T100	NN	I-NP	O
Ialpha1	Ialpha1	I410	NN	I-NP	O
/	/	0000	SYM	B-NP	O
platelet	platelet	P434	NN	I-NP	O
-	-	0000	HYPH	O	O
derived	derive	D613	VBN	B-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
PDGF	PDGF	P321	NN	B-NP	O
)	)	0000	)	O	O
B	B	B000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chain	chain	C500	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
generates	generate	G563	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transforming	transform	T652	VBG	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
processed	process	P623	VBN	I-VP	O
to	to	T000	TO	B-PP	O
functional	functional	F523	JJ	B-NP	O
PDGF	PDGF	P321	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
BB	BB	B100	NN	I-NP	O
.	.	0000	.	O	O

Dermatofibrosarcoma	Dermatofibrosarcoma	D653	NN	B-NP	B-Disease
protuberans	protuberan	P631	NNS	I-NP	I-Disease
(	(	0000	(	O	O
DFSP	DFSP	D121	NN	B-NP	B-Disease
)	)	0000	)	O	O
displays	display	D214	VBZ	B-VP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
involving	involve	I514	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
17	17	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
22	22	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
fuse	fuse	F200	VBP	B-VP	O
the	the	T000	DT	B-NP	O
collagen	collagen	C425	NN	I-NP	O
type	type	T100	NN	I-NP	O
Ialpha1	Ialpha1	I410	NN	I-NP	O
(	(	0000	(	O	O
COLIA1	COLIA1	C400	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
platelet	platelet	P434	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
derived	derive	D613	VBN	B-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
PDGF	PDGF	P321	NN	B-NP	O
)	)	0000	)	O	O
B	B	B000	NN	B-NP	O
-	-	0000	HYPH	O	O
chain	chain	C500	NN	B-NP	O
(	(	0000	(	O	O
PDGFB	PDGFB	P321	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
and	and	A530	CC	I-NP	O
structural	structural	S362	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
COLIA1	COLIA1	C400	NN	I-NP	O
/	/	0000	SYM	B-NP	O
PDGFB	PDGFB	P321	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
a	a	A000	DT	B-NP	O
stable	stable	S314	JJ	I-NP	O
NIH3T3	NIH3T3	N300	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
contained	contain	C535	VBD	B-VP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
derived	derive	D613	VBN	B-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
COIA1	COIA1	C000	NN	I-NP	O
intron	intron	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
PDGFB	PDGFB	P321	NN	I-NP	O
intron	intron	I536	NN	I-NP	O
1	1	0000	CD	I-NP	O
fusion	fusion	F250	NN	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
morphological	morphological	M614	JJ	B-NP	O
transformation	transformation	T652	NN	I-NP	O
and	and	A530	CC	O	O
increased	increase	I526	VBN	B-NP	O
growth	growth	G630	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PDGF	PDGF	P321	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
CGP57148B	CGP57148B	C210	NN	I-NP	O
reversed	reverse	R162	VBD	B-VP	O
the	the	T000	DT	B-NP	O
transformed	transform	T652	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
reduced	reduce	R323	VBD	B-VP	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
COLIA1	COLIA1	C400	NN	B-NP	O
/	/	0000	SYM	B-NP	O
PDGFB	PDGFB	P321	NN	I-NP	O
-	-	0000	HYPH	O	O
expressing	express	E216	VBG	B-VP	O
cells	cell	C420	NNS	B-NP	O
but	but	B300	CC	O	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
control	control	C536	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
dimeric	dimeric	D562	JJ	B-NP	O
COLIA1	COLIA1	C400	NN	I-NP	O
/	/	0000	SYM	B-VP	O
PDGFB	PDGFB	P321	NN	B-NP	O
precursors	precursor	P626	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
through	through	T620	IN	B-PP	O
PDGFB	PDGFB	P321	NN	B-NP	O
immunoprecipitations	immunoprecipitation	I516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
metabolically	metabolically	M314	RB	B-NP	O
labeled	label	L143	VBN	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
PDGFB	PDGFB	P321	NN	B-NP	O
immunoprecipitations	immunoprecipitation	I516	NNS	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
immunoblotting	immunoblotte	I514	VBG	B-VP	O
with	with	W300	IN	B-PP	O
COLIA1	COLIA1	C400	NN	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
.	.	0000	.	O	O

Pulse	Pulse	P420	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
chase	chase	C200	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
COLIA1	COLIA1	C400	NN	I-NP	O
/	/	0000	SYM	B-NP	O
PDGFB	PDGFB	P321	NN	I-NP	O
precursor	precursor	P626	NN	I-NP	O
was	be	W200	VBD	B-VP	O
processed	process	P623	VBN	I-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
end	end	E530	NN	I-NP	O
product	product	P632	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
indistinguishable	indistinguishable	I532	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PDGF	PDGF	P321	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
BB	BB	B100	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
COLIA1	COLIA1	C400	NN	B-NP	O
/	/	0000	SYM	B-NP	O
PDGFB	PDGFB	P321	NN	I-NP	O
-	-	0000	HYPH	O	O
expressing	express	E216	VBG	B-NP	O
cells	cell	C420	NNS	I-NP	O
generated	generate	G563	VBD	B-VP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
after	after	A136	IN	B-PP	O
s	s	S000	NNS	B-NP	O
.	.	0000	.	O	O

c	c	C000	NN	B-NP	O
c	c	C000	NN	I-NP	O
.	.	0000	.	I-NP	O
injection	injection	I523	NN	I-NP	O
into	into	I530	IN	B-PP	O
nude	nude	N300	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
tumor	tumor	T560	NN	B-NP	B-Disease
growth	growth	G630	NN	I-NP	O
was	be	W200	VBD	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
with	with	W300	IN	B-PP	O
CGP57148B	CGP57148B	C210	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
COLIA1	COLIA1	C400	NN	I-NP	O
/	/	0000	SYM	B-VP	O
PDGFB	PDGFB	P321	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
DFSP	DFSP	D121	NN	B-NP	B-Disease
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
development	development	D141	NN	I-NP	O
through	through	T620	IN	B-PP	O
ectopic	ectopic	E231	JJ	B-NP	O
production	production	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
PDGF	PDGF	P321	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
BB	BB	B100	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
autocrine	autocrine	A326	JJ	I-NP	O
loop	loop	L100	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PDGF	PDGF	P321	NN	B-NP	O
receptors	receptor	R213	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
target	target	T623	NN	I-NP	O
for	for	F600	IN	B-PP	O
pharmacological	pharmacological	P652	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
DFSP	DFSP	D121	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
giant	giant	G530	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
fibroblastoma	fibroblastoma	F161	NN	I-NP	I-Disease
,	,	0000	,	O	O
e	e	E000	NN	B-NP	O
.	.	0000	.	I-NP	O
g	g	G000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PDGF	PDGF	P321	NN	B-NP	O
receptor	receptor	R213	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
inhibitors	inhibitor	I513	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
CGP57148B	CGP57148B	C210	NN	B-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
PEX1	PEX1	P200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Zellweger	Zellweger	Z426	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Zellweger	Zellweger	Z426	NNP	I-NP	B-Disease
spectrum	spectrum	S123	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
,	,	0000	,	O	O
encompassing	encompass	E525	VBG	B-VP	O
Zellweger	Zellweger	Z426	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
progressively	progressively	P626	RB	I-NP	O
milder	mild	M436	JJR	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
and	and	A530	CC	O	O
infantile	infantile	I515	JJ	B-NP	B-Disease
Refsum	Refsum	R125	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
to	to	T000	TO	B-VP	O
form	form	F650	VB	I-VP	O
functional	functional	F523	JJ	B-NP	O
peroxisomes	peroxisome	P625	NNS	I-NP	O
.	.	0000	.	O	O

Cell	Cell	C400	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
complementation	complementation	C514	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
diseases	disease	D200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
heterogeneous	heterogeneous	H362	JJ	I-ADJP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
thirds	third	T632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
lying	lie	L520	VBG	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
complementation	complementation	C514	NN	I-NP	O
group	group	G610	NN	I-NP	O
,	,	0000	,	O	O
CG1	CG1	C200	NN	B-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
biology	biology	B420	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
PEX1	PEX1	P200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
CG1	CG1	C200	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
previous	previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
focused	focus	F230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
mildly	mildly	M434	RB	B-NP	O
affected	affect	A123	VBN	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
no	no	N000	DT	B-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
PEX1	PEX1	P200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
Zellweger	Zellweger	Z426	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PMP70	PMP70	P510	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Zellweger	Zellweger	Z426	NN	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
CG1	CG1	C200	NN	B-NP	O
,	,	0000	,	O	O
raising	raise	R252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
CG1	CG1	C200	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
may	may	M000	MD	B-VP	O
represent	represent	R162	VB	I-VP	O
a	a	A000	DT	B-NP	O
mixture	mixture	M236	NN	I-NP	O
of	of	O100	IN	B-PP	O
PEX1	PEX1	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
and	and	A530	CC	I-NP	O
PMP70	PMP70	P510	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
address	address	A362	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
in	in	I500	IN	B-PP	O
Zellweger	Zellweger	Z426	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
CG1	CG1	C200	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
all	all	A400	DT	B-NP	O
24	24	0000	CD	I-NP	O
PEX1	PEX1	P200	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
both	both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PMP70	PMP70	P510	NN	B-NP	O
.	.	0000	.	O	O

PEX1	PEX1	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
(	(	0000	(	O	O
c	c	C000	NN	B-NP	O
.	.	0000	.	I-NP	O
2097insT	2097insT	I523	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Subsequent	Subsequent	S125	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
CG1	CG1	C200	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
correlates	correlate	C643	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Zellweger	Zellweger	Z426	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
function	function	F523	NN	I-NP	O
its	its	I320	PRP$	B-NP	O
frequency	frequency	F625	NN	I-NP	O
makes	make	M200	VBZ	B-VP	O
it	it	I300	PRP	B-NP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Zellweger	Zellweger	Z426	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
helping	help	H415	VBG	B-VP	O
to	to	T000	TO	I-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
belong	belong	B452	VBP	B-VP	O
to	to	T000	TO	B-PP	O
CG1	CG1	C200	NN	B-NP	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
,	,	0000	,	I-NP	O
translational	translational	T652	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
immunodeficiency	immunodeficiency	I531	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
,	,	0000	,	O	O
eczema	eczema	E250	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
recurrent	recurrent	R265	JJ	B-NP	O
infections	infection	I512	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

WASP	WASP	W210	NN	B-NP	O
contains	contain	C535	VBZ	B-VP	O
several	several	S164	JJ	B-NP	O
functional	functional	F523	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
through	through	T620	IN	B-PP	O
which	which	W200	WDT	B-NP	O
it	it	I300	PRP	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
signaling	signaling	S254	NN	I-NP	O
and	and	A530	CC	I-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
cytoskeleton	cytoskeleton	C324	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
17	17	0000	CD	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
novel	novel	N140	JJ	B-ADJP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
obligate	obligate	O142	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
PCR	PCR	P260	NN	I-VP	O
amplified	amplify	A514	VBN	I-VP	O
and	and	A530	CC	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
SSCA	SSCA	S200	NN	B-NP	O
,	,	0000	,	O	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
level	level	L140	NN	I-NP	O
were	be	W600	VBD	B-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
by	by	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	O	O
PCR	PCR	P260	NN	B-NP	O
and	and	A530	CC	O	O
Western	Western	W236	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nonsense	nonsense	N525	NN	I-NP	O
,	,	0000	,	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
alter	alter	A436	VBP	B-VP	O
splice	splice	S142	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mRNAs	mRNA	M652	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
represented	represent	R162	VBD	B-VP	O
the	the	T000	DT	B-NP	O
normally	normally	N654	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
normally	normally	N654	RB	B-NP	O
spliced	splice	S142	VBN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
one	one	O500	CD	B-NP	O
such	such	S200	JJ	I-NP	O
case	case	C200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Western	Western	W236	JJ	B-NP	O
blotting	blotting	B435	NN	I-NP	O
,	,	0000	,	O	O
reduced	reduce	R323	VBN	B-VP	O
amounts	amount	A532	NNS	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
size	size	S200	NN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
as	as	A200	RB	B-ADVP	O
well	well	W400	RB	I-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
or	or	O600	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
WASP	WASP	W210	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affected	A123	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
.	.	0000	.	O	O

Reduced	Reduce	R323	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
size	size	S200	NN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
XLT	XLT	X430	NN	B-NP	B-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
concluded	conclude	C524	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
level	level	L140	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
sufficient	sufficient	S125	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
predicting	predict	P632	VBG	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
course	course	C620	NN	I-NP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcript	transcript	T652	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
level	level	L140	NN	I-NP	O
are	be	A600	VBP	B-VP	O
needed	need	N300	VBN	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
better	good	B360	JJR	I-NP	O
assessment	assessment	A253	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Aminoglycoside	Aminoglycoside	A524	NN	B-NP	O
antibiotics	antibiotic	A531	NNS	I-NP	O
restore	restore	R236	VBP	B-VP	O
dystrophin	dystrophin	D236	NN	B-NP	O
function	function	F523	NN	I-NP	O
to	to	T000	TO	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscles	muscle	M242	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mdx	mdx	M320	NN	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
striated	striate	S363	VBN	B-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
premature	premature	P653	JJ	B-NP	O
stop	stop	S310	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
aminoglycoside	aminoglycoside	A524	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
can	can	C500	MD	B-VP	O
suppress	suppress	S162	VB	I-VP	O
stop	stop	S310	NN	B-NP	O
codons	codon	C352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
tested	test	T230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
gentamicin	gentamicin	G535	NN	B-NP	O
on	on	O500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
muscle	muscle	M240	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
-	-	0000	HYPH	O	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
that	that	T300	WDT	B-NP	O
possesses	possess	P200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Exposure	Exposure	E212	NN	B-NP	O
of	of	O100	IN	B-PP	O
mdx	mdx	M320	NN	B-NP	O
myotubes	myotube	M312	NNS	I-NP	O
to	to	T000	TO	B-PP	O
gentamicin	gentamicin	G535	NN	B-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
membrane	membrane	M516	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
then	then	T500	RB	B-ADVP	O
evaluated	evaluate	E143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
differing	differ	D165	VBG	B-VP	O
dosages	dosage	D200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
gentamicin	gentamicin	G535	NN	B-NP	O
on	on	O500	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
and	and	A530	CC	O	O
functional	functional	F523	JJ	B-NP	O
protection	protection	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
muscles	muscle	M242	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mdx	mdx	M320	NN	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
regimen	regimen	R250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
membrane	membrane	M516	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
striated	striate	S363	VBN	I-NP	O
muscles	muscle	M242	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
and	and	A530	CC	O	O
that	that	T300	WDT	B-NP	O
provided	provide	P613	VBD	B-VP	O
functional	functional	F523	JJ	B-NP	O
protection	protection	P632	NN	I-NP	O
against	against	A252	IN	B-PP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
injury	injury	I526	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
to	to	T000	TO	B-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
aminoglycosides	aminoglycoside	A524	NNS	B-NP	O
can	can	C500	MD	B-VP	O
suppress	suppress	S162	VB	I-VP	O
stop	stop	S310	NN	B-NP	O
codons	codon	C352	NNS	I-NP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
raise	raise	R200	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
regimen	regimen	R250	NN	I-NP	O
for	for	F600	IN	B-PP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
diseases	disease	D200	NNS	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
could	could	C430	MD	B-VP	O
prove	prove	P610	VB	I-VP	O
effective	effective	E123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
up	up	U100	IN	B-NP	O
to	to	T000	TO	I-NP	O
15	15	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
oxidative	oxidative	O231	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
in	in	I500	IN	B-PP	O
target	target	T623	NN	B-NP	O
organs	organ	O625	NNS	I-NP	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
markedly	markedly	M623	RB	I-NP	O
increased	increase	I526	VBN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
to	to	T000	TO	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
,	,	0000	,	O	O
increased	increase	I526	VBD	B-VP	O
incidence	incidence	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
neurodegeneration	neurodegeneration	N632	NN	B-NP	B-Disease
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cerebellar	cerebellar	C614	JJ	I-NP	O
Purkinje	Purkinje	P625	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Ionizing	Ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
oxidizes	oxidize	O232	VBZ	B-VP	O
macromolecules	macromolecule	M265	NNS	B-NP	O
and	and	A530	CC	O	O
causes	cause	C200	VBZ	B-VP	O
tissue	tissue	T200	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
reactive	reactive	R231	JJ	B-NP	O
oxygen	oxygen	O250	NN	I-NP	O
species	specie	S120	NNS	I-NP	O
(	(	0000	(	O	O
ROS	ROS	R200	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
hypothesized	hypothesize	H132	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
employed	employ	E514	VBD	B-VP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
disrupted	disrupt	D261	VBN	I-NP	O
Atm	Atm	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
organs	organ	O625	NNS	B-NP	O
which	which	W200	WDT	B-NP	O
develop	develop	D141	VBP	B-VP	O
pathologic	pathologic	P342	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Atm	Atm	A350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
targets	target	T623	NNS	B-NP	O
of	of	O100	IN	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
cerebellar	cerebellar	C614	JJ	B-NP	O
Purkinje	Purkinje	P625	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
particularly	particularly	P632	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
mechanistic	mechanistic	M252	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
lay	lie	L000	VBD	B-VP	O
a	a	A000	DT	B-NP	O
rational	rational	R354	JJ	I-NP	O
foundation	foundation	F535	NN	I-NP	O
for	for	F600	IN	B-PP	O
therapeutic	therapeutic	T613	JJ	B-NP	O
intervention	intervention	I536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Recessively	Recessively	R214	RB	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
multiple	multiple	M431	JJ	I-NP	B-Disease
epiphyseal	epiphyseal	E124	JJ	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
stature	stature	S360	NN	I-NP	O
,	,	0000	,	O	O
club	club	C410	NN	B-NP	B-Disease
foot	foot	F300	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
double	double	D140	JJ	B-NP	B-Disease
layered	layered	L630	JJ	I-NP	I-Disease
patella	patella	P340	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
observed	observe	O126	VBN	I-VP	O
over	over	O160	IN	B-PP	O
25	25	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
sulphate	sulphate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DTDST	DTDST	D323	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
achondrogenesis	achondrogenesis	A253	NN	I-NP	B-Disease
1B	1B	B000	NN	I-NP	I-Disease
,	,	0000	,	O	O
atelosteogenesis	atelosteogenesis	A342	NN	B-NP	B-Disease
2	2	0000	CD	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
c862t	c862t	C300	NN	I-NP	O
(	(	0000	(	O	O
R279W	R279W	R000	NN	B-NP	O
)	)	0000	)	O	O
transition	transition	T652	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Finnish	Finnish	F520	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
usually	usually	U240	RB	I-VP	O
combined	combine	C515	VBN	I-VP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
c862t	c862t	C300	NN	B-NP	O
(	(	0000	(	O	O
R279W	R279W	R000	NN	B-NP	O
)	)	0000	)	O	O
until	until	U534	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
analysed	analyse	A542	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
36	36	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
tall	tall	T400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
stature	stature	S360	NN	I-NP	O
(	(	0000	(	O	O
180	180	0000	CD	B-NP	O
cm	cm	C500	NN	I-NP	O
)	)	0000	)	O	O
who	who	W000	WP	B-NP	O
asked	ask	A230	VBD	B-VP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counselling	counselling	C524	NN	I-NP	O
for	for	F600	IN	B-PP	O
suspected	suspect	S212	VBN	B-NP	O
multiple	multiple	M431	JJ	I-NP	B-Disease
epiphyseal	epiphyseal	E124	JJ	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
treated	treat	T630	VBN	I-VP	O
for	for	F600	IN	B-PP	O
club	club	C410	NN	B-NP	B-Disease
foot	foot	F300	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
hip	hip	H100	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
.	.	0000	.	O	O

Skeletal	Skeletal	S243	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	B-Disease
epiphyseal	epiphyseal	E124	JJ	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
peculiar	peculiar	P246	JJ	I-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
double	double	D140	JJ	I-NP	B-Disease
layered	layered	L630	JJ	I-NP	I-Disease
patella	patella	P340	NN	I-NP	I-Disease
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
recognised	recognise	R252	VBN	I-VP	O
during	during	D652	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

Cleft	Cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
,	,	0000	,	O	O
swelling	swell	S452	VBG	B-VP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
ear	ear	E600	JJ	I-NP	I-Disease
pinna	pinna	P500	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hitch	hitch	H320	NN	B-NP	B-Disease
hiker	hiker	H260	NN	I-NP	I-Disease
thumb	thumb	T510	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
both	both	B300	DT	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
parents	parent	P653	NNS	I-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
R279W	R279W	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
sulphate	sulphate	S413	NN	I-NP	O
incorporation	incorporation	I526	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
typical	typical	T124	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Counselling	Counselling	C524	NN	B-NP	O
was	be	W200	VBD	B-VP	O
given	give	G150	VBN	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
thereby	thereby	T610	RB	B-VP	O
considerably	considerably	C523	RB	I-VP	O
reducing	reduce	R325	VBG	I-VP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

Multiple	Multiple	M431	JJ	B-NP	B-Disease
epiphyseal	epiphyseal	E124	NN	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
more	more	M600	RBR	I-VP	O
frequently	frequently	F625	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
COMP	COMP	C510	NN	I-NP	O
(	(	0000	(	O	O
EDM1	EDM1	E350	NN	B-NP	B-Disease
,	,	0000	,	O	O
McKusick	McKusick	M200	NNP	B-NP	O
132400	132400	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
COL9A2	COL9A2	C400	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
EDM2	EDM2	E350	NN	B-NP	B-Disease
,	,	0000	,	O	O
McKusick	McKusick	M200	NNP	B-NP	O
600204	600204	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
other	other	O360	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
features	feature	F362	NNS	B-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
proband	proband	P615	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
and	and	A530	CC	O	O
considered	consider	C523	VBN	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
autosomal	autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
MED	MED	M300	NN	I-NP	B-Disease
(	(	0000	(	O	O
EDM4	EDM4	E350	NN	B-NP	B-Disease
,	,	0000	,	O	O
McKusick	McKusick	M200	NNP	B-NP	O
226900	226900	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
entity	entity	E530	NN	I-NP	O
and	and	A530	CC	O	O
assigns	assign	A252	VBZ	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
DTDST	DTDST	D323	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
'	'	0000	``	I-NP	O
broad	broad	B630	JJ	I-NP	O
bone	bone	B500	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
platyspondylic	platyspondylic	P432	JJ	I-NP	O
'	'	0000	''	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Atypical	Atypical	A312	JJ	B-NP	O
or	or	O600	CC	I-NP	O
variant	variant	V653	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
well	well	W400	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
known	know	K500	VBN	I-NP	O
chondrodysplasias	chondrodysplasia	C536	NNS	I-NP	B-Disease
may	may	M000	MD	B-VP	O
pose	pose	P200	VB	I-VP	O
diagnostic	diagnostic	D252	JJ	B-NP	O
problems	problem	P614	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
suggesting	suggest	S235	VBG	B-VP	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
but	but	B300	CC	B-PP	O
with	with	W300	IN	B-PP	O
unusual	unusual	U524	JJ	B-NP	O
radiographic	radiographic	R326	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
severe	severe	S160	JJ	B-NP	O
platyspondyly	platyspondyly	P432	NN	I-NP	B-Disease
,	,	0000	,	O	O
wide	wide	W300	JJ	B-NP	O
metaphyses	metaphys	M312	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
fibular	fibular	F146	JJ	B-NP	O
overgrowth	overgrowth	O162	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
partially	partially	P634	RB	B-ADJP	O
reminiscent	reminiscent	R525	JJ	I-ADJP	O
of	of	O100	IN	B-PP	O
metatropic	metatropic	M361	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
was	be	W200	VBD	B-VP	O
clarified	clarify	C461	VBN	I-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
undescribed	undescribed	U532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
Q454P	Q454P	Q100	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
10th	10th	T000	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
value	value	V400	NN	I-NP	O
in	in	I500	IN	B-PP	O
such	such	S200	JJ	B-NP	O
atypical	atypical	A312	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
determined	determine	D365	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
facet	facet	F230	NN	I-NP	O
to	to	T000	TO	B-PP	O
Knudson	Knudson	K532	NNP	B-NP	O
'	'	0000	POS	B-NP	O
s	s	S000	NNS	I-NP	O
'	'	0000	POS	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hit	hit	H300	VBN	I-NP	O
'	'	0000	''	I-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
.	.	0000	.	O	O

APC	APC	A120	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	I-VP	O
cited	cite	C300	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
prime	prime	P650	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Truncating	Truncate	T652	VBG	B-VP	O
germline	germline	G654	NN	B-NP	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
,	,	0000	,	O	O
infrequently	infrequently	I516	RB	B-ADVP	O
,	,	0000	,	O	O
allelic	allelic	A420	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
)	)	0000	)	O	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
(	(	0000	(	O	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	B-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
also	also	A420	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
two	two	T000	CD	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Clues	Clue	C420	NNS	B-NP	O
from	from	F650	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
,	,	0000	,	O	O
missense	missense	M252	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
codons	codon	C352	NNS	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
250	250	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
450	450	0000	CD	I-NP	O
)	)	0000	)	O	O
indicate	indicate	I532	VBP	B-VP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
APC	APC	A120	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
might	might	M230	MD	B-VP	O
not	not	N300	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
simple	simple	S514	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
codons	codon	C352	NNS	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
194	194	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
392	392	0000	CD	I-NP	O
at	at	A300	IN	B-ADVP	O
most	most	M230	JJS	I-ADVP	O
)	)	0000	)	O	O
mainly	mainly	M540	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
whose	whose	W200	WP$	B-NP	O
second	second	S253	JJ	I-NP	O
hits	hit	H320	NNS	I-NP	O
tend	tend	T530	VBP	B-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
by	by	B000	IN	B-PP	O
truncating	truncate	T652	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
different	different	D165	JJ	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
cells	cell	C420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
selective	selective	S423	JJ	I-NP	O
advantages	advantage	A315	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
close	close	C420	RB	B-ADJP	O
to	to	T000	TO	B-PP	O
codon	codon	C350	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
300	300	0000	CD	I-NP	O
providing	provide	P613	VBG	B-VP	O
the	the	T000	DT	B-NP	O
greatest	great	G632	JJS	I-NP	O
advantage	advantage	A315	NN	I-NP	O
.	.	0000	.	O	O

Allelic	Allelic	A420	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
selected	select	S423	VBN	I-VP	O
strongly	strongly	S365	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
near	near	N600	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
300	300	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
association	association	A235	NN	I-NP	O
exists	exist	E232	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
desmoids	desmoid	D253	NNS	I-NP	I-Disease
.	.	0000	.	O	O

APC	APC	A120	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
indicate	indicate	I532	VBP	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
if	if	I100	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
broader	broad	B636	JJR	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
selected	select	S423	VBN	I-VP	O
in	in	I500	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
effectively	effectively	E123	RB	B-NP	O
higher	high	H260	JJR	I-NP	O
and	and	A530	CC	I-NP	O
more	more	M600	JJR	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
grow	grow	G600	VBP	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mxi1	Mxi1	M200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
neurofibrosarcomas	neurofibrosarcoma	N616	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Mxi1	Mxi1	M200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
negatively	negatively	N231	RB	I-VP	O
regulate	regulate	R243	VB	I-VP	O
Myc	Myc	M200	NN	B-NP	O
function	function	F523	NN	I-NP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Little	Little	L340	JJ	B-NP	O
effort	effort	E163	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
made	make	M300	VBN	I-VP	O
to	to	T000	TO	B-VP	O
find	find	F530	VB	I-VP	O
alterations	alteration	A436	NNS	B-NP	O
involving	involve	I514	VBG	B-VP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
solid	solid	S430	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
31	31	0000	CD	B-NP	O
human	human	H500	JJ	I-NP	O
gastric	gastric	G236	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
esophageal	esophageal	E212	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
85	85	0000	CD	B-NP	O
bone	bone	B500	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
soft	soft	S130	JJ	B-NP	I-Disease
tissue	tissue	T200	NN	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	O
various	various	V620	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
4	4	0000	CD	B-NP	O
neurofibrosarcomas	neurofibrosarcoma	N616	NNS	I-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
examined	examine	E253	VBD	B-VP	O
29	29	0000	CD	B-NP	O
human	human	H500	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
esophageal	esophageal	E212	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
glioma	glioma	G450	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
glioblastomas	glioblastoma	G414	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
10	10	0000	CD	B-NP	O
others	other	O362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Mxi1	Mxi1	M200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
HLH	HLH	H400	NN	B-NP	O
domain	domain	D500	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

Polymerase	Polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
subsequent	subsequent	S125	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
three	three	T600	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
boundary	boundary	B536	JJ	B-ADJP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
discovered	discover	D216	VBD	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
GCA	GCA	G200	NN	B-NP	O
to	to	T000	TO	B-PP	O
GTA	GTA	G300	NN	B-NP	O
(	(	0000	(	O	O
Ala	Ala	A400	NN	B-NP	O
54	54	0000	CD	I-NP	O
Val	Val	V400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
neurofibrosarcoma	neurofibrosarcoma	N616	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
case	case	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
AAA	AAA	A000	NN	B-NP	O
to	to	T000	TO	B-PP	O
CAA	CAA	C000	NN	B-NP	O
(	(	0000	(	O	O
Lys	Ly	L200	NNS	B-NP	O
118	118	0000	CD	B-NP	O
Gln	Gln	G450	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
GAA	GAA	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
GGA	GGA	G200	NN	B-NP	O
(	(	0000	(	O	O
Glu	Glu	G400	NN	B-NP	O
154	154	0000	CD	I-NP	O
Gly	Gly	G400	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
neurofibrosarcoma	neurofibrosarcoma	N616	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
case	case	C200	NN	B-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3	3	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
GTG	GTG	G320	NN	B-NP	O
to	to	T000	TO	B-PP	O
GCG	GCG	G200	NN	B-NP	O
(	(	0000	(	O	O
Val	Val	V400	NN	B-NP	O
179	179	0000	CD	I-NP	O
Ala	Ala	A400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
GTT	GTT	G300	NN	B-NP	O
to	to	T000	TO	B-PP	O
GCT	GCT	G230	NN	B-NP	O
(	(	0000	(	O	O
Val	Val	V400	NN	B-NP	O
181	181	0000	CD	I-NP	O
Ala	Ala	A400	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
TTC	TTC	T320	NN	B-NP	O
to	to	T000	TO	B-PP	O
CTC	CTC	C320	NN	B-NP	O
(	(	0000	(	O	O
Phe	Phe	P000	NN	B-NP	O
186	186	0000	CD	I-NP	O
Leu	Leu	L000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
neurofibrosarcoma	neurofibrosarcoma	N616	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
case	case	C200	NN	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
case	case	C200	NN	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
informative	informative	I516	JJ	B-NP	O
(	(	0000	(	O	O
TTC	TTC	T320	NN	B-NP	O
)	)	0000	)	O	O
3	3	0000	CD	B-NP	O
/	/	0000	SYM	B-NP	O
(	(	0000	(	O	O
TTC	TTC	T320	NN	B-NP	O
)	)	0000	)	O	O
2	2	0000	CD	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Mxi1	Mxi1	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
neurofibrosarcoma	neurofibrosarcoma	N616	NN	B-NP	B-Disease
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
Mxi1	Mxi1	M200	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
neurofibrosarcoma	neurofibrosarcoma	N616	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	I-VP	O
study	study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
AND	AND	A530	CC	I-NP	O
METHODS	METHODS	M320	NNS	I-NP	O
Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
(	(	0000	(	O	O
HFE	HFE	H100	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
elevated	elevated	E413	JJ	B-NP	O
serum	serum	S650	NN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
excess	excess	E200	JJ	B-NP	B-Disease
iron	iron	I650	NN	I-NP	I-Disease
deposits	deposit	D123	NNS	I-NP	I-Disease
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
body	body	B300	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
conducted	conduct	C532	VBD	B-VP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
study	study	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
Busselton	Busselton	B243	NNP	B-NP	O
,	,	0000	,	O	O
Australia	Australia	A236	NNP	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
obtained	obtain	O135	VBD	B-VP	O
blood	blood	B430	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
determination	determination	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
and	and	A530	CC	I-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
or	or	O600	CC	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
H63D	H63D	H300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
increased	increase	I526	VBN	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
3011	3011	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
adults	adult	A343	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
evaluated	evaluate	E143	VBD	B-VP	O
all	all	A400	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
persistently	persistently	P623	RB	I-VP	O
elevated	elevate	E413	VBN	I-VP	O
transferrin	transferrin	T652	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
saturation	saturation	S363	NN	I-NP	O
values	value	V420	NNS	I-NP	O
(	(	0000	(	O	O
45	45	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
or	or	O600	CC	O	O
higher	high	H260	JJR	B-ADJP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recommended	recommend	R253	VBD	B-VP	O
liver	liver	L160	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
for	for	F600	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
300	300	0000	CD	B-NP	O
ng	ng	N200	NN	I-NP	O
per	per	P600	IN	B-PP	O
milliliter	millilit	M436	JJR	B-ADJP	O
or	or	O600	CC	I-ADJP	O
higher	high	H260	JJR	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
followed	follow	F430	VBN	I-VP	O
for	for	F600	IN	B-PP	O
up	up	U100	RB	B-NP	O
to	to	T000	TO	I-NP	O
four	four	F600	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Sixteen	Sixteen	S235	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
424	424	0000	CD	B-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
was	be	W200	VBD	B-VP	O
45	45	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
or	or	O600	CC	O	O
higher	high	H260	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
15	15	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
16	16	0000	CD	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
1	1	0000	CD	B-NP	O
subject	subject	S123	NN	I-NP	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
43	43	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
given	give	G150	VBN	I-VP	O
a	a	A000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
12	12	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	O	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
12	12	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
elevated	elevate	E413	VBN	I-VP	O
serum	serum	S650	NN	B-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
;	;	0000	:	O	O
6	6	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
7	7	0000	CD	I-NP	O
had	have	H300	VBD	B-VP	O
further	further	F636	JJ	B-NP	O
increases	increase	I526	NNS	I-NP	O
in	in	I500	IN	B-PP	O
1998	1998	0000	CD	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
decrease	decrease	D262	NN	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
value	value	V400	NN	I-NP	O
remained	remain	R530	VBD	B-VP	O
elevated	elevated	E413	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
other	other	O360	JJ	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
remained	remain	R530	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
.	.	0000	.	O	O

Eleven	Eleven	E415	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
16	16	0000	CD	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
underwent	undergo	U536	VBD	B-VP	O
liver	liver	L160	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
;	;	0000	:	O	O
3	3	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
hepatic	hepatic	H132	JJ	B-NP	B-Disease
fibrosis	fibrosis	F162	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
excessive	excessive	E210	JJ	B-NP	B-Disease
alcohol	alcohol	A424	NN	I-NP	I-Disease
consumption	consumption	C525	NN	I-NP	I-Disease
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
cirrhosis	cirrhosis	C620	NN	B-NP	B-Disease
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	O
microvesicular	microvesicular	M261	JJ	I-NP	B-Disease
steatosis	steatosis	S320	NN	I-NP	I-Disease
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
16	16	0000	CD	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
hepatomegaly	hepatomegaly	H135	NN	B-NP	B-Disease
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	B-Disease
pigmentation	pigmentation	P253	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
arthritis	arthritis	A636	NN	B-NP	B-Disease
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
white	white	W300	JJ	B-NP	O
adults	adult	A343	NNS	I-NP	O
of	of	O100	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
ancestry	ancestry	A523	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
those	those	T200	DT	B-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
had	have	H300	VBD	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
quarter	quarter	Q636	NN	I-NP	O
had	have	H300	VBD	B-VP	O
serum	serum	S650	NN	B-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
remained	remain	R530	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
over	over	O160	IN	B-PP	O
a	a	A000	DT	B-NP	O
four	four	F600	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
period	period	P630	NN	I-NP	O
.	.	0000	.	O	O

Large	Large	L620	JJ	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
masquerading	masquerade	M263	VBG	B-VP	O
as	as	A200	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
pitfall	pitfall	P314	NN	I-NP	O
in	in	I500	IN	B-PP	O
diagnostic	diagnostic	D252	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
recessive	recessive	R210	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
relies	rely	R420	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
exact	exact	E230	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
problematic	problematic	P614	JJ	B-ADJP	O
when	when	W500	WRB	B-ADVP	O
only	only	O540	RB	B-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
examined	examine	E253	VBN	I-VP	O
or	or	O600	CC	O	O
when	when	W500	WRB	B-ADVP	O
relevant	relevant	R415	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
by	by	B000	IN	B-PP	O
standard	standard	S353	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
apparently	apparently	A165	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
E390G	E390G	E200	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
quite	quite	Q300	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
mild	mild	M430	JJ	B-ADJP	O
as	as	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
despite	despite	D213	IN	B-PP	O
confirmed	confirm	C516	VBN	B-NP	O
paternity	paternity	P365	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
unusual	unusual	U524	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Presence	Presence	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
exons	exon	E252	NNS	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
10	10	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
range	range	R520	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
.	.	0000	.	O	O

Diagnostic	Diagnostic	D252	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
should	should	S430	MD	B-VP	O
include	include	I524	VB	I-VP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
examination	examination	E253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
whole	whole	W400	JJ	I-NP	O
relevant	relevant	R415	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	I-NP	O
confirmation	confirmation	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
status	status	S320	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Early	Early	E640	RB	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
developed	develop	D141	VBD	B-VP	O
contractures	contracture	C536	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
Achilles	Achilles	A242	NNP	I-NP	I-Disease
tendons	tendon	T535	NNS	I-NP	I-Disease
at	at	A300	IN	B-PP	O
3	3	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
postcervical	postcervical	P232	JJ	I-NP	O
muscles	muscle	M242	NNS	I-NP	O
at	at	A300	IN	B-PP	O
7	7	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
neither	neither	N360	DT	B-NP	O
contractures	contracture	C536	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
elbows	elbow	E412	NNS	I-NP	I-Disease
nor	nor	N600	CC	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
recognized	recognize	R252	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Muscle	Muscle	M240	NN	B-NP	O
computed	compute	C513	VBD	B-VP	O
tomography	tomography	T526	NN	B-NP	O
scanning	scanning	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
changes	change	C520	NNS	B-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
involvement	involvement	I514	NN	I-NP	O
.	.	0000	.	O	O

Emerin	Emerin	E565	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
biopsied	biopsie	B123	VBN	I-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	I-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
no	no	N000	DT	B-NP	O
amplification	amplification	A514	NN	I-NP	O
product	product	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
reinforce	reinforce	R516	VB	B-VP	O
the	the	T000	DT	B-NP	O
necessity	necessity	N230	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
emerin	emerin	E565	NN	I-NP	O
in	in	I500	IN	B-PP	O
younger	young	Y526	JJR	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
EDMD	EDMD	E353	NN	I-NP	B-Disease
before	before	B160	IN	B-PP	O
appearance	appearance	A165	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
avoid	avoid	A130	VB	I-VP	O
sudden	sudden	S350	JJ	B-NP	B-Disease
cardiac	cardiac	C632	JJ	I-NP	I-Disease
death	death	D300	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Duchenne	Duchenne	D250	NN	B-NP	B-Disease
/	/	0000	SYM	I-NP	I-Disease
Becker	Becker	B260	NN	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
:	:	0000	:	O	O
correlation	correlation	C643	NN	B-NP	O
of	of	O100	IN	B-PP	O
phenotype	phenotype	P531	NN	B-NP	O
by	by	B000	IN	B-PP	O
electroretinography	electroretinography	E423	NN	B-NP	O
with	with	W300	IN	B-PP	O
sites	site	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
dark	dark	D620	NN	I-NP	O
-	-	0000	HYPH	O	O
adapted	adapt	A313	VBN	B-VP	O
electroretinogram	electroretinogram	E423	NN	B-NP	O
(	(	0000	(	O	O
ERG	ERG	E620	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
)	)	0000	)	O	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
marked	marked	M623	JJ	I-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
b	b	B000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
amplitude	amplitude	A514	NN	I-NP	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
models	model	M342	NNS	I-NP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
show	show	S000	VBP	B-VP	O
position	position	P235	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
upon	upon	U150	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
5	5	0000	CD	B-NP	O
defects	defect	D123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
have	have	H100	VBP	B-VP	O
normal	normal	N654	JJ	B-NP	O
ERGs	ERG	E620	NNS	I-NP	O
,	,	0000	,	O	O
those	those	T200	DT	B-NP	O
with	with	W300	IN	B-PP	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
b	b	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
amplitude	amplitude	A514	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
prolonged	prolonged	P645	JJ	B-NP	O
implicit	implicit	I514	JJ	I-NP	O
times	time	T520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
b	b	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
and	and	A530	CC	O	O
oscillatory	oscillatory	O243	JJ	B-NP	O
potentials	potential	P353	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
mice	mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
3	3	0000	CD	B-NP	O
defects	defect	D123	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
BMD	BMD	B530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
carboxyl	carboxyl	C612	NN	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
isoform	isoform	I216	NN	I-NP	O
,	,	0000	,	O	O
Dp260	Dp260	D100	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	O
electrophysiology	electrophysiology	E423	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
a	a	A000	DT	B-NP	O
systematic	systematic	S235	JJ	I-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
through	through	T620	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
and	and	A530	CC	I-NP	O
review	review	R100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
noted	note	N300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
wider	wide	W360	JJR	I-NP	O
variation	variation	V635	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
correlate	correlate	C643	VBP	B-VP	O
with	with	W300	IN	B-PP	O
reductions	reduction	R323	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
b	b	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
amplitude	amplitude	A514	NN	I-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
ERGs	ERG	E620	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
predominantly	predominantly	P635	RB	B-ADJP	O
located	located	L230	JJ	I-ADJP	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcript	transcript	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dp260	Dp260	D100	NN	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
important	important	I516	JJ	I-NP	O
determinant	determinant	D365	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ERG	ERG	E620	NN	I-NP	O
b	b	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
position	position	P235	NN	I-NP	O
,	,	0000	,	O	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
muscle	muscle	M240	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
severity	severity	S163	NN	I-NP	O
.	.	0000	.	O	O

Forty	Forty	F630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
six	six	S200	CD	I-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Dp260	Dp260	D100	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
start	start	S363	NN	I-NP	O
site	site	S300	NN	I-NP	O
have	have	H100	VBP	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
ERGs	ERG	E620	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
opposed	oppose	O123	VBN	B-VP	O
to	to	T000	TO	B-PP	O
94	94	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
with	with	W300	IN	B-PP	O
more	more	M600	RBR	B-NP	O
distal	distal	D234	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
Dp260	Dp260	D100	NN	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
retinal	retinal	R354	JJ	I-NP	O
electrophysiology	electrophysiology	E423	NN	I-NP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
reflect	reflect	R142	VB	I-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
contributions	contribution	C536	NNS	I-NP	O
to	to	T000	TO	B-PP	O
retinal	retinal	R354	JJ	B-NP	O
signal	signal	S254	NN	I-NP	O
transmission	transmission	T652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cis	Cis	C200	NN	B-NP	O
and	and	A530	CC	I-NP	O
trans	trans	T652	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
culture	culture	C436	NN	I-NP	O
model	model	M340	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
pathogenesis	pathogenesis	P325	NN	B-NP	O
remain	remain	R500	VBP	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
using	use	U252	VBG	B-VP	O
DM	DM	D500	NN	B-NP	B-Disease
patient	patient	P353	NN	I-NP	O
materials	material	M364	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
often	often	O135	RB	I-VP	O
produced	produce	P632	VBN	I-VP	O
confusing	confusing	C512	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
controlled	controlled	C536	JJ	I-NP	O
environment	environment	E516	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
established	establish	E231	VBN	I-VP	O
a	a	A000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
culture	culture	C436	NN	I-NP	O
model	model	M340	NN	I-NP	O
system	system	S235	NN	I-NP	O
using	use	U252	VBG	B-VP	O
C2C12	C2C12	C200	NN	B-NP	O
mouse	mouse	M200	NN	I-NP	O
myoblasts	myoblast	M142	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
expressing	express	E216	VBG	B-VP	O
chimeric	chimeric	C562	JJ	B-NP	O
reporter	reporter	R163	NN	I-NP	O
constructs	construct	C523	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
reporter	reporter	R163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
fused	fuse	F230	VBN	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
both	both	B300	CC	O	O
cis	ci	C200	NNS	B-NP	O
and	and	A530	CC	O	O
trans	trans	T652	JJ	B-NP	O
effects	effect	E123	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
mediated	mediate	M300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
as	as	A200	RB	B-ADJP	O
few	few	F000	JJ	I-ADJP	O
as	as	A200	IN	B-PP	O
57	57	0000	CD	B-NP	O
CTGs	CTG	C320	NNS	I-NP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
cis	cis	C200	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
aggregation	aggregation	A262	NN	I-NP	O
of	of	O100	IN	B-PP	O
reporter	reporter	R163	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
into	into	I530	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
by	by	B000	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
that	that	T300	IN	B-NP	O
an	an	A500	DT	B-NP	O
expanded	expanded	E215	JJ	I-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
)	)	0000	)	O	O
tract	tract	T623	NN	B-NP	O
alone	alone	A450	RB	B-ADVP	O
was	be	W200	VBD	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
mediate	mediate	M300	VB	I-VP	O
these	these	T200	DT	B-NP	O
cis	cis	C200	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
with	with	W300	IN	B-PP	O
(	(	0000	(	O	O
CUG	CUG	C200	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
200	200	0000	CD	B-NP	O
)	)	0000	)	O	O
selectively	selectively	S423	RB	B-ADVP	O
inhibited	inhibit	I513	VBD	B-VP	O
myogenic	myogenic	M252	JJ	B-NP	O
differentiation	differentiation	D165	NN	I-NP	O
of	of	O100	IN	B-PP	O
C2C12	C2C12	C200	NN	B-NP	O
myoblasts	myoblast	M142	NNS	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Cre	Cre	C600	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
loxP	loxP	L210	NN	I-NP	O
system	system	S235	NN	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
clearly	clearly	C464	RB	I-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
myoblast	myoblast	M142	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
rescued	rescue	R230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
eliminating	eliminate	E453	VBG	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
spontaneous	spontaneous	S153	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
events	event	E153	NNS	I-NP	O
mapped	map	M130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
inhibitory	inhibitory	I513	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
)	)	0000	)	O	O
expansion	expansion	E215	NN	B-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
acts	act	A232	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
cis	ci	C200	NNS	B-NP	O
to	to	T000	TO	B-VP	O
reduce	reduce	R320	VB	I-VP	O
protein	protein	P635	NN	B-NP	O
production	production	P632	NN	I-NP	O
(	(	0000	(	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	B-Disease
haploinsufficiency	haploinsufficiency	H145	NN	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
trans	tran	T652	NNS	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
riboregulator	riboregulator	R162	NN	I-NP	O
to	to	T000	TO	B-VP	O
inhibit	inhibit	I513	VB	I-VP	O
myogenesis	myogenesis	M252	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Coats	Coat	C320	NNS	B-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retina	retina	R350	NN	I-NP	O
(	(	0000	(	O	O
unilateral	unilateral	U543	JJ	B-NP	B-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
telangiectasis	telangiectasis	T452	NN	I-NP	I-Disease
)	)	0000	)	O	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
norrin	norrin	N650	NN	B-NP	O
in	in	I500	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	O
angiogenesis	angiogenesis	A525	NN	I-NP	O
.	.	0000	.	O	O

Coats	Coat	C320	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	B-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
vascular	vascular	V246	JJ	I-NP	I-Disease
development	development	D141	NN	I-NP	I-Disease
(	(	0000	(	O	O
so	so	S000	RB	O	O
-	-	0000	HYPH	O	O
called	call	C430	VBN	B-VP	O
retinal	retinal	R354	JJ	B-NP	B-Disease
telangiectasis	telangiectasis	T452	NN	I-NP	I-Disease
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
massive	massive	M210	JJ	B-NP	O
intraretinal	intraretinal	I536	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
subretinal	subretinal	S163	JJ	I-NP	I-Disease
lipid	lipid	L130	NN	I-NP	I-Disease
accumulation	accumulation	A254	NN	I-NP	I-Disease
(	(	0000	(	O	O
exudative	exudative	E231	JJ	B-NP	B-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
detachment	detachment	D325	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Coats	Coat	C320	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
almost	almost	A452	RB	I-VP	O
invariably	invariably	I516	RB	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
,	,	0000	,	O	O
unilateral	unilateral	U543	JJ	B-ADJP	O
and	and	A530	CC	O	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
female	female	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
unilateral	unilateral	U543	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
Coats	Coat	C320	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gave	give	G100	VBD	B-VP	O
birth	birth	B630	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
son	son	S500	NN	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

Subsequently	Subsequently	S125	RB	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinas	retina	R352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
enucleated	enucleate	E524	VBN	I-NP	O
eyes	eye	E200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
males	male	M420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Coats	Coat	C320	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
demonstrated	demonstrate	D523	VBD	B-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
a	a	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
present	present	P625	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
retinal	retinal	R354	JJ	I-NP	O
tissue	tissue	T200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Coats	Coat	C320	NNS	B-NP	B-Disease
telangiectasis	telangiectasis	T452	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
secondary	secondary	S253	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
norrin	norrin	N650	NN	B-NP	I-Disease
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
)	)	0000	)	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
developing	develop	D141	VBG	I-NP	O
retina	retina	R350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
supports	support	S163	VBZ	B-VP	O
recent	recent	R253	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
retinal	retinal	R354	JJ	I-NP	O
vasculogenesis	vasculogenesis	V242	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	O
TP53	TP53	T100	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
292	292	0000	CD	I-NP	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
P16INK4A	P16INK4A	P520	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
94	94	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Li	Li	L000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
various	various	V620	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
and	and	A530	CC	O	O
adult	adult	A343	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
hereditary	hereditary	H636	JJ	B-NP	O
TP53	TP53	T100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
very	very	V600	RB	B-ADJP	O
rare	rare	R600	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
frequently	frequently	F625	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
hand	hand	H530	NN	I-NP	O
,	,	0000	,	O	O
hereditary	hereditary	H636	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
TP57KIP2	TP57KIP2	T121	NN	B-NP	O
,	,	0000	,	O	O
P15INK4B	P15INK4B	P521	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
P16INK4A	P16INK4A	P520	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
affect	affect	A123	VBP	B-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
TP53	TP53	T100	NN	B-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
TP53	TP53	T100	NN	B-NP	O
,	,	0000	,	O	O
P57KIP2	P57KIP2	P210	NN	B-NP	O
,	,	0000	,	O	O
P15INK4B	P15INK4B	P521	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
P16INK4A	P16INK4A	P520	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
(	(	0000	(	O	O
homo	homo	H500	NN	B-NP	O
/	/	0000	SYM	O	O
hemizygous	hemizygous	H520	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
)	)	0000	)	O	O
pattern	pattern	P365	NN	B-NP	O
of	of	O100	IN	B-PP	O
TP53	TP53	T100	NN	B-NP	O
and	and	A530	CC	I-NP	O
P15INK4B	P15INK4B	P521	NN	I-NP	O
/	/	0000	SYM	B-NP	O
P16INK4A	P16INK4A	P520	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
seminoma	seminoma	S500	NN	I-NP	B-Disease
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
daughter	daughter	D236	NN	I-NP	O
a	a	A000	DT	B-NP	O
medulloblastoma	medulloblastoma	M341	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
cousins	cousin	C252	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
TP53	TP53	T100	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
292	292	0000	CD	I-NP	O
missense	missense	M252	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
AAA	AAA	A000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
ATA	ATA	A300	NN	I-NP	O
;	;	0000	:	O	O
Lys	Lys	L200	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
Ile	Ile	I400	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Tumor	Tumor	T560	NN	B-NP	O
tissue	tissue	T200	NN	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
seminoma	seminoma	S500	NN	I-NP	B-Disease
revealed	reveal	R143	VBD	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
TP53	TP53	T100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
tissues	tissue	T200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
daughter	daughter	D236	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
P16INK4A	P16INK4A	P520	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
94	94	0000	CD	I-NP	O
missense	missense	M252	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
GCG	GCG	G200	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
GAG	GAG	G200	NN	B-NP	O
;	;	0000	:	O	O
Ala	Ala	A400	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Glu	Glu	G400	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
TP53	TP53	T100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

P16INK4A	P16INK4A	P520	NN	B-NP	O
codon	codon	C350	NN	I-NP	O
94	94	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Li	Li	L000	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Fraumeni	Fraumeni	F650	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
alteration	alteration	A436	NN	I-NP	O
in	in	I500	IN	B-PP	O
TP53	TP53	T100	NN	B-NP	O
,	,	0000	,	O	O
P57KIP2	P57KIP2	P210	NN	B-NP	O
,	,	0000	,	O	O
P15INK4B	P15INK4B	P521	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
P16INK4A	P16INK4A	P520	NN	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

Existence	Existence	E235	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
P16INK4A	P16INK4A	P520	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
TP53	TP53	T100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
with	with	W300	IN	B-PP	O
or	or	O600	CC	B-PP	O
without	without	W300	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
TP53	TP53	T100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
seminoma	seminoma	S500	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
medulloblastoma	medulloblastoma	M341	NN	I-NP	B-Disease
)	)	0000	)	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
tumorogenesis	tumorogenesis	T562	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
TP53	TP53	T100	NN	B-NP	O
and	and	A530	CC	I-NP	O
P16INK4A	P16INK4A	P520	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sodium	sodium	S350	NN	I-NP	O
/	/	0000	SYM	B-NP	O
iodide	iodide	I300	NN	I-NP	O
symporter	symporter	S516	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
largest	large	L623	JJS	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
iodide	iodide	I300	NN	B-NP	B-Disease
transport	transport	T652	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
previously	previously	P612	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
nine	nine	N500	CD	B-NP	O
children	child	C436	NNS	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomally	autosomally	A325	RB	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hypothyroidism	hypothyroidism	H136	NN	I-NP	I-Disease
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
iodide	iodide	I300	NN	I-NP	B-Disease
transport	transport	T652	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Hutterite	Hutterite	H363	NNP	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
consanguinity	consanguinity	C525	NN	I-NP	O
living	live	L152	VBG	B-VP	O
in	in	I500	IN	B-PP	O
central	central	C536	JJ	B-NP	O
Canada	Canada	C530	NNP	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hypothyroidism	hypothyroidism	H136	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
newborn	newborn	N165	JJ	B-NP	O
TSH	TSH	T200	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
in	in	I500	IN	B-PP	O
9	9	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
children	child	C436	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
products	product	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
NIS	NIS	N200	NN	I-NP	O
(	(	0000	(	O	O
sodium	sodium	S350	NN	B-NP	O
/	/	0000	SYM	O	O
iodide	iodide	I300	NN	B-NP	O
symporter	symporter	S516	NN	I-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
exon	exon	E250	NN	I-NP	O
with	with	W300	IN	B-PP	O
flanking	flank	F452	VBG	B-VP	O
introns	intron	I536	NNS	B-NP	O
amplified	amplify	A514	VBN	B-VP	O
from	from	F650	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
extracted	extract	E236	VBN	B-VP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
NIS	NIS	N200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
G395R	G395R	G600	NN	B-NP	O
(	(	0000	(	O	O
Gly395	Gly395	G400	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
Arg	Arg	A620	NN	B-NP	O
;	;	0000	:	O	O
GGA	GGA	G200	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
AGA	AGA	A200	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
10th	10th	T000	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
helix	helix	H420	NN	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
by	by	B000	IN	B-PP	O
transfection	transfection	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
NIS	NIS	N200	NN	I-NP	O
complimentary	complimentary	C514	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
into	into	I530	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
7	7	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
perchlorate	perchlorate	P624	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
iodide	iodide	I300	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
iodide	iodide	I300	NN	I-NP	B-Disease
transport	transport	T652	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
who	who	W000	WP	B-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
saliva	saliva	S410	NN	I-NP	O
/	/	0000	SYM	B-VP	O
serum	serum	S650	NN	B-NP	O
technetium	technetium	T253	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	O	O
0	0	0000	CD	B-NP	O
;	;	0000	:	O	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
>	>	0000	SYM	B-NP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
or	or	O600	CC	I-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
report	report	R163	NN	I-NP	O
(	(	0000	(	O	O
IX	IX	I200	CD	B-NP	O
-	-	0000	HYPH	O	O
24	24	0000	CD	B-NP	O
)	)	0000	)	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
NIS	NIS	N200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
now	now	N000	RB	B-ADVP	O
possible	possible	P214	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
use	use	U200	VB	I-VP	O
gene	gene	G500	NN	B-NP	O
diagnostics	diagnostic	D252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
NIS	NIS	N200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hypothyroidism	hypothyroidism	H136	NN	I-NP	I-Disease
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
iodide	iodide	I300	NN	I-NP	B-Disease
transport	transport	T652	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
state	state	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
potential	potential	P353	JJ	B-NP	O
parents	parent	P653	NNS	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
and	and	A530	CC	O	O
arranging	arrange	A652	VBG	B-VP	O
rapid	rapid	R130	JJ	B-NP	O
and	and	A530	CC	I-NP	O
early	early	E640	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
infants	infant	I515	NNS	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
:	:	0000	:	O	O
early	early	E640	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
(	(	0000	(	O	O
FNDI	FNDI	F530	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
hormone	hormone	H650	NN	I-NP	I-Disease
arginine	arginine	A625	NN	I-NP	I-Disease
vasopressin	vasopressin	V216	NN	I-NP	I-Disease
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
neurophysin	neurophysin	N612	NN	B-NP	O
II	II	I000	CD	I-NP	O
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
NPII	NPII	N100	NN	I-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
four	four	F600	CD	B-NP	O
clinically	clinically	C452	RB	I-NP	O
affected	affect	A123	VBN	I-VP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Hospital	Hospital	H213	NNP	I-NP	O
Universitario	Universitario	U516	NNP	I-NP	O
Gregorio	Gregorio	G626	NNP	I-NP	O
Maranon	Maranon	M650	NNP	I-NP	O
(	(	0000	(	O	O
Madrid	Madrid	M363	NNP	B-NP	O
,	,	0000	,	O	O
Spain	Spain	S150	NNP	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
NPII	NPII	N100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
presented	present	P625	VBD	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
G1757	G1757	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
replaces	replace	R142	VBZ	B-VP	O
glycine	glycine	G425	NN	B-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
23	23	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
NPII	NPII	N100	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
heterozygosis	heterozygosis	H362	NN	B-NP	O
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
relatives	relative	R431	NNS	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
8	8	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
old	old	O430	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
study	study	S300	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
developed	develop	D141	VBD	B-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
3	3	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
later	later	L360	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
alteration	alteration	A436	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
harboring	harbor	H616	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
or	or	O600	CC	O	O
have	have	H100	VB	B-VP	O
eventually	eventually	E153	RB	I-VP	O
developed	develop	D141	VBN	I-VP	O
FNDI	FNDI	F530	NNP	B-NP	B-Disease
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
FNDI	FNDI	F530	NNP	B-NP	B-Disease
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
families	family	F542	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
powerful	powerful	P614	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
early	early	E640	JJ	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
in	in	I500	IN	B-PP	O
infants	infant	I515	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Deficit	Deficit	D123	NN	B-NP	O
of	of	O100	IN	B-PP	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
ATP	ATP	A310	NN	I-NP	O
production	production	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Friedreich	Friedreich	F636	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NN	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
ataxias	ataxia	A320	NNS	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
degenerative	degenerative	D256	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
clinically	clinically	C452	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
before	before	B160	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
25	25	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	B-Disease
gait	gait	G300	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
limb	limb	L510	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
,	,	0000	,	O	O
absence	absence	A125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
deep	deep	D100	JJ	B-NP	I-Disease
tendon	tendon	T535	NN	I-NP	I-Disease
reflexes	reflex	R142	NNS	I-NP	I-Disease
,	,	0000	,	O	O
extensor	extensor	E235	NN	B-NP	B-Disease
plantar	plantar	P453	NN	I-NP	I-Disease
responses	response	R215	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
loss	loss	L200	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
position	position	P235	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
vibration	vibration	V163	NN	I-NP	I-Disease
sense	sense	S520	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
limbs	limb	L512	NNS	I-NP	O
.	.	0000	.	O	O

FRDA	FRDA	F630	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
intron	intron	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
9q13	9q13	Q000	CD	I-NP	O
in	in	I500	IN	B-PP	O
97	97	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
widely	widely	W340	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
210	210	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
aa	aa	A000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
frataxin	frataxin	F632	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mitochondria	mitochondrion	M325	NNS	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
severely	severely	S164	RB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Frataxin	Frataxin	F632	NN	B-NP	O
function	function	F523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
unknown	unknown	U525	JJ	B-ADJP	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
knockout	knockout	K523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
frataxin	frataxin	F632	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
YFH1	YFH1	Y100	NN	B-NP	O
)	)	0000	)	O	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
respiration	respiration	R216	NN	I-NP	O
and	and	A530	CC	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mtDNA	mtDNA	M350	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
elevated	elevated	E413	JJ	B-NP	O
intramitochondrial	intramitochondrial	I536	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
impaired	impaired	I516	JJ	B-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
respiration	respiration	R216	NN	I-NP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
phosphorus	phosphorus	P216	JJ	B-NP	O
magnetic	magnetic	M253	JJ	I-NP	O
resonance	resonance	R252	NN	I-NP	O
spectroscopy	spectroscopy	S123	NN	I-NP	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
ATP	ATP	A310	NN	I-NP	O
production	production	P632	NN	I-NP	O
(	(	0000	(	O	O
V	V	V000	NN	B-NP	O
(	(	0000	(	O	O
max	max	M200	NN	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
below	below	B400	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
12	12	0000	CD	I-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
V	V	V000	NN	I-NP	O
(	(	0000	(	O	O
max	max	M200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
GAA	GAA	G000	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
smaller	small	S546	JJR	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
encoded	encode	E523	VBN	I-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
oxidative	oxidative	O231	JJ	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
and	and	A530	CC	O	O
give	give	G100	VB	B-VP	O
a	a	A000	DT	B-NP	O
rationale	rationale	R354	NN	I-NP	O
for	for	F600	IN	B-PP	O
treatments	treatment	T635	NNS	B-NP	O
aimed	aim	A530	VBN	B-VP	O
to	to	T000	TO	B-VP	O
improve	improve	I516	VB	I-VP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
R21X	R21X	R200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
arginase	arginase	A625	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ARG1	ARG1	A620	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
Portuguese	Portuguese	P632	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
argininemia	argininemia	A625	NN	B-NP	B-Disease
.	.	0000	.	O	O

Argininemia	Argininemia	A625	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autossomal	autossomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
cytosolic	cytosolic	C324	JJ	I-NP	I-Disease
liver	liver	L160	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
arginase	arginase	A625	NN	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
(	(	0000	(	O	O
L	L	L000	NN	B-NP	O
-	-	0000	HYPH	O	O
arginine	arginine	A625	NN	B-NP	O
urea	urea	U600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
hydrolase	hydrolase	H364	NN	I-NP	O
;	;	0000	:	O	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
argininemia	argininemia	A625	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Portuguese	Portuguese	P632	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
two	two	T000	CD	B-NP	O
from	from	F650	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
Portugal	Portugal	P632	NNP	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
from	from	F650	IN	B-PP	O
Madeira	Madeira	M360	NNP	B-NP	O
Island	Island	I245	NNP	I-NP	O
)	)	0000	)	O	O
we	we	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	I-NP	O
exon	exon	E250	NN	I-NP	O
/	/	0000	SYM	B-NP	O
intron	intron	I536	NN	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
arginase	arginase	A625	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ARG1	ARG1	A620	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	B-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
21	21	0000	CD	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
substituting	substitute	S123	VBG	B-VP	O
arginine	arginine	A625	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
(	(	0000	(	O	O
R21X	R21X	R200	NN	B-NP	O
CGA	CGA	C200	NN	I-NP	O
to	to	T000	TO	B-PP	O
TGA	TGA	T200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
generating	generate	G563	VBG	B-VP	O
a	a	A000	DT	B-NP	O
NlaIII	NlaIII	N400	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
digestion	digestion	D235	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
PCR	PCR	P260	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARG1	ARG1	A620	NN	B-NP	O
exon	exon	E250	NN	I-NP	O
2	2	0000	CD	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sterol	sterol	S364	NN	I-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP27	CYP27	C100	NN	B-NP	O
)	)	0000	)	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
truncation	truncation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
leucocytes	leucocyte	L232	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
.	.	0000	.	O	O

OBJECTIVES	OBJECTIVES	O123	NNS	B-NP	O
A	A	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
alteration	alteration	A436	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sterol	sterol	S364	NN	I-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP27	CYP27	C100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
CYP27	CYP27	C100	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mostly	mostly	M234	RB	I-VP	O
explored	explore	E214	VBN	I-VP	O
using	use	U252	VBG	I-VP	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
prompting	prompt	P651	VBG	B-VP	O
the	the	T000	DT	B-NP	O
examination	examination	E253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
from	from	F650	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
leucocytes	leucocyte	L232	NNS	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
and	and	A530	CC	I-NP	O
rapid	rapid	R130	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
An	An	A500	DT	B-NP	O
alteration	alteration	A436	NN	I-NP	O
in	in	I500	IN	B-PP	O
CYP27	CYP27	C100	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
was	be	W200	VBD	B-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
single	single	S524	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
and	and	A530	CC	O	O
subsequent	subsequent	S125	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Samples	Sample	S514	NNS	B-NP	O
of	of	O100	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
were	be	W600	VBD	B-VP	O
subjected	subject	S123	VBN	I-VP	O
to	to	T000	TO	B-VP	O
reverse	reverse	R162	VB	I-VP	O
transcription	transcription	T652	NN	B-NP	O
PCR	PCR	P260	NN	I-NP	O
(	(	0000	(	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
was	be	W200	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
with	with	W300	IN	B-PP	O
nested	nested	N230	JJ	B-NP	O
primers	primer	P656	NNS	I-NP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
A	A	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
7	7	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
truncated	truncate	T652	VBN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	B-PP	O
both	both	B300	CC	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
truncated	truncate	T652	VBN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
disclosed	disclose	D242	VBD	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
conjuction	conjuction	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
and	and	A530	CC	O	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

CONCLUSION	CONCLUSION	C524	NN	B-NP	O
The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
truncation	truncation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
were	be	W600	VBD	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
Italian	Italian	I345	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
different	different	D165	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
symptomatology	symptomatology	S513	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
application	application	A142	NN	I-NP	O
of	of	O100	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
leucocytes	leucocyte	L232	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
on	on	O500	IN	B-PP	O
analysing	analyse	A542	VBG	B-VP	O
a	a	A000	DT	B-NP	O
constructive	constructive	C523	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
CYP27	CYP27	C100	NN	B-NP	I-Disease
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
19	19	0000	CD	B-NP	O
Wolfram	Wolfram	W416	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
kindreds	kindred	K536	NNS	I-NP	O
demonstrating	demonstrate	D523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
WFS1	WFS1	W120	NN	B-NP	O
.	.	0000	.	O	O

Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
neurodegenerative	neurodegenerative	N632	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
juvenile	juvenile	J154	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
onset	onset	O523	NN	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
and	and	A530	CC	O	O
progressive	progressive	P626	JJ	B-NP	O
optic	optic	O132	JJ	I-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
.	.	0000	.	O	O

mtDNA	mtDNA	M350	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WFS1	WFS1	W120	NN	B-NP	O
)	)	0000	)	O	O
recently	recently	R253	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4p16	4p16	P000	CD	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
890	890	0000	CD	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
was	be	W200	VBD	B-VP	O
done	do	D500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
screen	screen	S265	VB	I-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WFS1	WFS1	W120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
19	19	0000	CD	B-NP	O
British	British	B632	JJ	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
structural	structural	S362	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
(	(	0000	(	O	O
deletions	deletion	D435	NNS	B-NP	O
and	and	A530	CC	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mtDNA	mtDNA	M350	NN	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
pathogenic	pathogenic	P325	JJ	I-NP	O
mtDNA	mtDNA	M350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
cohort	cohort	C630	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
24	24	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WFS1	WFS1	W120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
8	8	0000	CD	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
8	8	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
,	,	0000	,	O	O
23	23	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
novel	novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
most	most	M230	JJS	B-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
compound	compound	C515	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
relationships	relationship	R435	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
interesting	interesting	I536	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
,	,	0000	,	O	O
consideration	consideration	C523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
size	size	S200	NN	I-NP	O
and	and	A530	CC	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
no	no	N000	DT	B-NP	O
clear	clear	C460	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
cut	cut	C300	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
between	between	B350	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
hot	hot	H300	JJ	I-NP	O
spots	spot	S132	NNS	I-NP	O
or	or	O600	CC	I-NP	O
clusters	cluster	C423	NNS	I-NP	O
.	.	0000	.	O	O

Hence	Hence	H520	RB	B-ADVP	O
,	,	0000	,	O	O
molecular	molecular	M424	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	O
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
psychiatric	psychiatric	P236	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
or	or	O600	CC	O	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
will	will	W400	MD	B-VP	O
require	require	R260	VB	I-VP	O
complete	complete	C514	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
and	and	A530	CC	O	O
upstream	upstream	U123	JJ	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Late	Late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
with	with	W300	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
,	,	0000	,	I-NP	O
demographic	demographic	D526	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
and	and	A530	CC	O	O
characterize	characterize	C623	VB	B-VP	O
demographic	demographic	D526	JJ	B-ADJP	O
,	,	0000	,	O	O
clinical	clinical	C452	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
late	late	L300	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
experiencing	experience	E216	VBG	B-VP	O
their	their	T600	PRP$	B-NP	O
first	first	F623	JJ	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
attack	attack	A320	NN	I-NP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
40	40	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
computerized	computerized	C513	JJ	I-NP	O
registry	registry	R236	NN	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
clinic	clinic	C452	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
then	then	T500	RB	B-VP	O
thoroughly	thoroughly	T624	RB	I-VP	O
interviewed	interview	I536	VBN	I-VP	O
and	and	A530	CC	I-VP	O
examined	examine	E253	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
control	control	C536	NN	I-NP	O
group	group	G610	NN	I-NP	O
consisted	consist	C523	VBD	B-VP	O
of	of	O100	IN	B-PP	O
40	40	0000	CD	B-NP	O
consecutive	consecutive	C523	JJ	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
arrived	arrive	A613	VBD	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
clinic	clinic	C452	NN	I-NP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
regular	regular	R246	JJ	I-NP	O
follow	follow	F400	VB	I-NP	O
-	-	0000	HYPH	B-VP	O
up	up	U100	RP	B-PRT	O
visit	visit	V230	NN	B-NP	O
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
40	40	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
or	or	O600	CC	O	O
older	old	O436	JJR	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
examination	examination	E253	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
and	and	A530	CC	I-NP	O
controls	control	C536	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
using	use	U252	VBG	I-VP	O
a	a	A000	DT	B-NP	O
modified	modify	M313	VBN	I-NP	O
score	score	S260	NN	I-NP	O
,	,	0000	,	O	O
developed	develop	D141	VBN	B-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
commercial	commercial	C562	JJ	I-NP	O
kit	kit	K300	NN	I-NP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
20	20	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
4000	4000	0000	CD	B-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
late	late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
mostly	mostly	M234	RB	B-NP	O
men	man	M500	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
North	North	N630	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
compared	compare	C516	VBN	B-PP	O
to	to	T000	TO	B-PP	O
controls	control	C536	NNS	B-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
had	have	H300	VBD	B-VP	O
abdominal	abdominal	A135	JJ	B-NP	O
attacks	attack	A320	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
these	these	T200	DT	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

001	001	0000	CD	B-NP	O
001	001	0000	CD	I-NP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
had	have	H300	VBD	B-VP	O
chronic	chronic	C652	JJ	B-NP	O
or	or	O600	CC	I-NP	O
prolonged	prolonged	P645	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
example	example	E251	NN	B-NP	O
,	,	0000	,	O	O
amyloidosis	amyloidosis	A543	NN	B-NP	B-Disease
,	,	0000	,	O	O
chronic	chronic	C652	JJ	B-NP	B-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
protracted	protract	P636	VBD	B-VP	O
myalgia	myalgia	M420	NN	B-NP	B-Disease
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

001	001	0000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
treatment	treatment	T635	NN	B-NP	O
was	be	W200	VBD	B-VP	O
good	good	G300	JJ	B-ADJP	O
despite	despite	D213	IN	B-PP	O
using	use	U252	VBG	B-VP	O
low	low	L000	JJ	B-NP	O
colchicine	colchicine	C425	NN	I-NP	O
dose	dose	D200	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
severity	severity	S163	NN	I-NP	O
score	score	S260	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

001	001	0000	CD	B-NP	O
.	.	0000	.	O	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
M694V	M694V	M100	NN	B-NP	O
homozygosity	homozygosity	H523	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

01	01	0000	CD	B-NP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
regular	regular	R246	JJ	I-NP	O
FMF	FMF	F510	NNP	I-NP	B-Disease
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
age	age	A200	NN	I-NP	O
defines	define	D152	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
,	,	0000	,	I-NP	O
demographic	demographic	D526	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O

A	A	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
accurate	accurate	A263	JJ	I-NP	O
,	,	0000	,	I-NP	O
low	low	L000	JJ	I-NP	O
cost	cost	C230	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
widespread	widespread	W321	JJ	I-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
testing	testing	T235	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
by	by	B000	IN	B-PP	O
three	three	T600	CD	B-NP	O
principal	principal	P652	JJ	I-NP	O
concerns	concern	C526	NNS	I-NP	O
the	the	T000	DT	B-NP	O
fear	fear	F600	NN	I-NP	O
of	of	O100	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
health	health	H430	NN	B-NP	O
and	and	A530	CC	I-NP	O
life	life	L100	NN	I-NP	O
insurance	insurance	I526	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
uncertain	uncertain	U526	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
positive	positive	P231	JJ	I-NP	O
test	test	T230	NN	I-NP	O
result	result	R243	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inexpensive	inexpensive	I521	JJ	I-NP	O
and	and	A530	CC	I-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
an	an	A500	DT	B-NP	O
inexpensive	inexpensive	I521	JJ	I-NP	O
system	system	S235	NN	I-NP	O
for	for	F600	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
scanning	scanning	S252	NN	I-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
multiplex	multiplex	M431	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
amplification	amplification	A514	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
dimensional	dimensional	D525	JJ	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
efficiency	efficiency	E125	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
60	60	0000	CD	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
high	high	H200	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
women	woman	W500	NNS	I-NP	O
,	,	0000	,	O	O
14	14	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
contained	contain	C535	VBD	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
14	14	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
five	five	F100	CD	I-NP	O
that	that	T300	WDT	B-NP	O
had	have	H300	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
escaped	escape	E213	VBN	I-VP	O
detection	detection	D323	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
19	19	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
scored	score	S263	VBN	I-VP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
recurring	recur	R265	VBG	I-VP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
were	be	W600	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cost	cost	C230	NN	I-NP	O
of	of	O100	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
per	per	P600	IN	B-PP	O
sample	sample	S514	NN	B-NP	O
was	be	W200	VBD	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
approximately	approximately	A162	RB	B-ADVP	O
US	US	U200	VBZ	B-VP	O
$	$	0000	$	B-NP	O
70	70	0000	CD	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
manual	manual	M540	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
used	use	U230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
to	to	T000	TO	B-PP	O
approximately	approximately	A162	RB	B-VP	O
US	US	U200	VBZ	I-VP	O
$	$	0000	$	B-NP	O
10	10	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
introduction	introduction	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
commercially	commercially	C562	RB	B-NP	O
available	available	A141	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
robotics	robotic	R132	NNS	I-NP	O
and	and	A530	CC	O	O
fluorescent	fluorescent	F462	JJ	B-NP	O
imaging	imaging	I525	NN	I-NP	O
.	.	0000	.	O	O

Implementation	Implementation	I514	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
method	method	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
research	research	R262	NN	I-NP	O
and	and	A530	CC	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
setting	setting	S352	NN	I-NP	O
should	should	S430	MD	B-VP	O
permit	permit	P653	VB	I-VP	O
rapid	rapid	R130	JJ	B-NP	O
accrual	accrual	A264	NN	I-NP	O
of	of	O100	IN	B-PP	O
quantitative	quantitative	Q531	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
on	on	O500	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
associations	association	A235	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
diagnostic	diagnostic	D252	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Maternal	Maternal	M365	JJ	B-NP	B-Disease
uniparental	uniparental	U516	JJ	I-NP	I-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	I-Disease
chromosome	chromosome	C652	NN	B-NP	I-Disease
14	14	0000	CD	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
karyotype	karyotype	K631	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	B-Disease
uniparental	uniparental	U516	JJ	I-NP	I-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	I-Disease
chromosome	chromosome	C652	NN	B-NP	I-Disease
14	14	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
UPD	UPD	U130	NN	B-NP	B-Disease
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
7	7	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
he	he	H000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
referred	refer	R163	VBN	I-VP	O
to	to	T000	TO	B-PP	O
us	us	U200	PRP	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
paediatrician	paediatrician	P362	NN	I-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
symptoms	symptom	S513	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
showed	show	S300	VBD	B-VP	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
,	,	0000	,	O	O
obesity	obesity	O123	NN	B-NP	B-Disease
,	,	0000	,	O	O
mild	mild	M430	JJ	B-NP	O
developmental	developmental	D141	JJ	I-NP	B-Disease
delay	delay	D400	NN	I-NP	I-Disease
,	,	0000	,	O	O
cryptorchidism	cryptorchidism	C613	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
some	some	S500	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
dysmorphic	dysmorphic	D256	JJ	I-NP	B-Disease
features	feature	F362	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
history	history	H236	NN	I-NP	O
further	further	F636	RB	B-ADVP	O
indicated	indicate	I532	VBD	B-VP	O
intrauterine	intrauterine	I536	JJ	B-NP	B-Disease
growth	growth	G630	NN	I-NP	I-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
pregnancy	pregnancy	P625	NN	I-NP	O
.	.	0000	.	O	O

His	His	H200	PRP$	B-NP	O
mother	mother	M360	NN	I-NP	O
was	be	W200	VBD	B-VP	O
44	44	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
birth	birth	B630	NN	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
he	he	H000	PRP	B-NP	O
showed	show	S300	VBD	B-VP	O
hypotonia	hypotonia	H135	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
poor	poor	P600	JJ	B-NP	O
sucking	sucking	S252	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
which	which	W200	WDT	B-NP	O
gavage	gavage	G120	NN	B-NP	O
feeding	feeding	F352	NN	I-NP	O
was	be	W200	VBD	B-VP	O
needed	need	N300	VBN	I-VP	O
.	.	0000	.	O	O

Motor	Motor	M360	NN	B-NP	O
development	development	D141	NN	I-NP	O
was	be	W200	VBD	B-VP	O
delayed	delay	D430	VBN	I-VP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
1	1	0000	CD	B-NP	O
year	year	Y600	NN	I-NP	O
he	he	H000	PRP	B-NP	O
became	become	B250	VBD	B-VP	O
obese	obese	O120	JJ	B-ADJP	B-Disease
despite	despite	D213	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
appetite	appetite	A130	NN	I-NP	O
.	.	0000	.	O	O

Recurrent	Recurrent	R265	JJ	B-NP	O
middle	middle	M340	JJ	I-NP	B-Disease
ear	ear	E600	NN	I-NP	I-Disease
infections	infection	I512	NNS	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
pain	pain	P500	NN	I-NP	O
threshold	threshold	T624	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
great	great	G630	JJ	I-NP	O
skill	skill	S240	NN	I-NP	O
with	with	W300	IN	B-PP	O
jigsaw	jigsaw	J200	NN	B-NP	O
puzzles	puzzle	P242	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
behavioural	behavioural	B164	JJ	I-NP	O
problems	problem	P614	NNS	I-NP	O
or	or	O600	CC	O	O
sleep	sleep	S410	VB	B-VP	O
disturbance	disturbance	D236	NN	B-NP	O
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
(	(	0000	(	O	O
46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
for	for	F600	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
showed	show	S300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
later	later	L360	RB	B-ADVP	O
he	he	H000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
re	re	R000	AFX	B-ADJP	O
-	-	0000	HYPH	O	O
examined	examine	E253	VBN	B-VP	O
because	because	B200	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
thought	think	T230	VBD	B-VP	O
his	his	H200	PRP$	B-NP	O
features	feature	F362	NNS	I-NP	O
fitted	fit	F300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
like	like	L200	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
UPD	UPD	U130	NN	I-NP	B-Disease
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
that	that	T300	DT	B-NP	O
time	time	T500	NN	I-NP	O
precocious	precocious	P620	JJ	B-NP	O
puberty	puberty	P163	NN	I-NP	O
was	be	W200	VBD	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
heterodisomy	heterodisomy	H363	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
11	11	0000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
UPD	UPD	U130	NN	I-NP	B-Disease
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
Robertsonian	Robertsonian	R163	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
cytogenetically	cytogenetically	C325	RB	B-ADVP	O
before	before	B160	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
of	of	O100	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
UPD	UPD	U130	NN	I-NP	B-Disease
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
underlines	underline	U536	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
for	for	F600	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
UPD	UPD	U130	NN	I-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
even	even	E150	RB	B-ADVP	O
without	without	W300	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
Robertsonian	Robertsonian	R163	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Australian	Australian	A236	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
210	210	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
called	call	C430	VBN	B-VP	O
frataxin	frataxin	F632	NN	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
95	95	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
83	83	0000	CD	I-NP	O
people	people	P140	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	O
,	,	0000	,	O	O
78	78	0000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
GAA	GAA	G000	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
five	five	F100	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
51	51	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
smaller	small	S546	JJR	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
expanded	expand	E215	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
and	and	A530	CC	O	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
,	,	0000	,	O	O
age	age	A200	NN	B-NP	O
into	into	I530	IN	B-PP	O
wheelchair	wheelchair	W426	NN	B-NP	O
,	,	0000	,	O	O
scoliosis	scoliosis	S242	NN	B-NP	B-Disease
,	,	0000	,	O	O
impaired	impaired	I516	JJ	B-NP	O
vibration	vibration	V163	NN	I-NP	O
sense	sense	S520	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
foot	foot	F300	NN	B-NP	B-Disease
deformity	deformity	D165	NN	I-NP	I-Disease
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
smaller	small	S546	JJR	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	I-NP	O
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	B-Disease
,	,	0000	,	O	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
proprioception	proprioception	P616	NN	B-NP	I-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
bladder	bladder	B436	NN	B-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
larger	large	L626	JJR	I-NP	O
allele	allele	A400	NN	I-NP	O
size	size	S200	NN	I-NP	O
correlated	correlate	C643	VBD	B-VP	O
with	with	W300	IN	B-PP	O
bladder	bladder	B436	NN	B-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
foot	foot	F300	NN	B-NP	B-Disease
deformity	deformity	D165	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
duration	duration	D635	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
wheelchair	wheelchair	W426	NN	B-NP	O
use	use	U200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
,	,	0000	,	O	O
scoliosis	scoliosis	S242	NN	B-NP	B-Disease
,	,	0000	,	O	O
bladder	bladder	B436	NN	B-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
impaired	impaired	I516	JJ	B-NP	B-Disease
proprioception	proprioception	P616	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
vibration	vibration	V163	NN	B-NP	O
sense	sense	S520	NN	I-NP	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
complications	complication	C514	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
XLRS1	XLRS1	X462	NN	B-NP	O
causing	cause	C252	VBG	B-VP	O
retinoschisis	retinoschisis	R352	NN	B-NP	B-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
first	first	F623	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
putative	putative	P310	JJ	B-NP	O
leader	leader	L360	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
change	change	C520	NN	I-NP	O
.	.	0000	.	O	O

Juvenile	Juvenile	J154	JJ	B-NP	B-Disease
retinoschisis	retinoschisis	R352	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
31	31	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	I-NP	O
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
XLRS1	XLRS1	X462	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
previously	previously	P612	RB	B-NP	O
reported	report	R163	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
for	for	F600	IN	B-PP	O
60	60	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
Retinoschisis	Retinoschisis	R352	NNP	B-NP	B-Disease
Consortium	Consortium	C526	NNP	I-NP	O
,	,	0000	,	O	O
Hum	Hum	H500	NNP	B-NP	O
Mol	Mol	M400	NNP	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
1998	1998	0000	CD	I-NP	O
;	;	0000	:	O	O
7	7	0000	CD	B-NP	O
1185	1185	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1192	1192	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
three	three	T600	CD	I-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
12	12	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
ones	one	O520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
28	28	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
include	include	I524	VBP	B-VP	O
19	19	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
microdeletions	microdeletion	M263	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
insertion	insertion	I526	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
c	c	C000	NN	B-NP	O
.	.	0000	.	O	O

38T	38T	T000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
>	>	0000	SYM	O	O
C	C	C000	NN	B-NP	O
(	(	0000	(	O	O
L13P	L13P	L100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
c	c	C000	NN	B-NP	O
.	.	0000	.	O	O

667T	667T	T000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
>	>	0000	SYM	O	O
C	C	C000	NN	B-NP	O
(	(	0000	(	O	O
C223R	C223R	C600	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
present	present	P625	VBP	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
leader	leader	L360	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
carboxyl	carboxyl	C612	NN	I-NP	O
terminal	terminal	T654	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
beyond	beyond	B530	IN	B-PP	O
the	the	T000	DT	B-NP	O
discoidin	discoidin	D235	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
25	25	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
exons	exon	E252	NNS	B-NP	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
emphasizing	emphasize	E512	VBG	B-VP	O
the	the	T000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
functional	functional	F523	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
discoidin	discoidin	D235	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
protein	protein	P635	NN	I-NP	O

Growth	Growth	G630	NN	B-NP	O
hormone	hormone	H650	NN	I-NP	O
treatment	treatment	T635	NN	I-NP	O
increases	increase	I526	VBZ	B-VP	O
CO	CO	C000	NN	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
response	response	R215	NN	B-NP	O
,	,	0000	,	O	O
ventilation	ventilation	V534	NN	B-NP	O
and	and	A530	CC	O	O
central	central	C536	JJ	B-NP	O
inspiratory	inspiratory	I521	JJ	I-NP	O
drive	drive	D610	NN	I-NP	O
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
beneficial	beneficial	B512	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
hormone	hormone	H650	NN	I-NP	O
(	(	0000	(	O	O
GH	GH	G000	NN	B-NP	O
)	)	0000	)	O	O
treatment	treatment	T635	NN	B-NP	O
on	on	O500	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
and	and	A530	CC	I-NP	O
body	body	B300	NN	I-NP	O
composition	composition	C512	NN	I-NP	O
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
accompanied	accompany	A251	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
improvement	improvement	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
respiratory	respiratory	R216	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
measured	measure	M263	VBD	B-VP	O
resting	rest	R235	VBG	I-VP	O
ventilation	ventilation	V534	NN	B-NP	O
,	,	0000	,	O	O
airway	airway	A600	NN	B-NP	O
occlusion	occlusion	O242	NN	I-NP	O
pressure	pressure	P626	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
ventilatory	ventilatory	V534	JJ	B-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
CO	CO	C000	NN	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
children	child	C436	NNS	I-NP	O
,	,	0000	,	O	O
aged	age	A230	VBN	B-VP	O
7	7	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
before	before	B160	IN	B-PP	O
and	and	A530	CC	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
9	9	0000	CD	I-NP	O
months	month	M532	NNS	I-NP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
start	start	S363	NN	I-NP	O
of	of	O100	IN	B-PP	O
GH	GH	G000	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
.	.	0000	.	O	O

During	During	D652	IN	B-PP	O
GH	GH	G000	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
,	,	0000	,	O	O
resting	rest	R235	VBG	B-NP	O
ventilation	ventilation	V534	NN	I-NP	O
increased	increase	I526	VBD	B-VP	O
by	by	B000	IN	B-PP	O
26	26	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
72	72	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
CO	CO	C000	NN	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
65	65	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
002	002	0000	CD	I-NP	O
,	,	0000	,	O	O
<	<	0000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
04	04	0000	CD	I-NP	O
and	and	A530	CC	O	O
<	<	0000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
02	02	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
ventilatory	ventilatory	V534	JJ	B-NP	O
output	output	O313	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
to	to	T000	TO	B-PP	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
body	body	B300	NN	B-NP	O
mass	mass	M200	NN	I-NP	O
index	index	I532	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSION	CONCLUSION	C524	NN	B-NP	O
Treatment	Treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
children	child	C436	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
stimulatory	stimulatory	S354	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
central	central	C536	JJ	B-NP	O
respiratory	respiratory	R216	JJ	I-NP	O
structures	structure	S362	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
ventilation	ventilation	V534	NN	B-NP	O
and	and	A530	CC	O	O
inspiratory	inspiratory	I521	JJ	B-NP	O
drive	drive	D610	NN	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
improved	improved	I516	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
level	level	L140	NN	I-NP	O
reported	report	R163	VBN	B-VP	O
by	by	B000	IN	B-PP	O
parents	parent	P653	NNS	B-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
children	child	C436	NNS	I-NP	O
during	during	D652	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
hormone	hormone	H650	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O

G130V	G130V	G100	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
arisen	arise	A625	VBN	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NN	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

About	About	A130	RB	B-NP	O
98	98	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
FRDA	FRDA	F630	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
are	be	A600	VBP	B-VP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
17	17	0000	CD	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
so	so	S000	RB	B-VP	O
far	far	F600	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
more	more	M600	RBR	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
G130V	G130V	G100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	O
.	.	0000	.	O	O

G130V	G130V	G100	NN	B-NP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
GAA	GAA	G000	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
atypical	atypical	A312	JJ	I-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
marked	marked	M623	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
extragenic	extragenic	E236	JJ	B-NP	O
marker	marker	M626	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
haplotyping	haplotyping	H143	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
founder	founder	F536	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
differences	difference	D165	NNS	I-NP	O
explicable	explicable	E214	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
recombination	recombination	R251	NN	I-NP	O
events	event	E153	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Synergistic	Synergistic	S562	JJ	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
histone	histone	H235	NN	B-NP	O
hyperacetylation	hyperacetylation	H162	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
demethylation	demethylation	D534	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
reactivation	reactivation	R231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	O	O
CGG	CGG	C200	NN	O	O
)	)	0000	)	O	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
)	)	0000	)	O	O
sequence	sequence	S252	NN	B-NP	O
with	with	W300	IN	B-PP	O
>	>	0000	SYM	B-NP	O
200	200	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
full	full	F400	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
.	.	0000	.	O	O

Hypermethylation	Hypermethylation	H165	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
almost	almost	A452	RB	B-ADJP	O
always	always	A420	RB	I-ADJP	O
present	present	P625	JJ	I-ADJP	O
and	and	A530	CC	O	O
apparently	apparently	A165	RB	B-VP	O
suppresses	suppress	S162	VBZ	I-VP	O
transcription	transcription	T652	NN	B-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
transcriptional	transcriptional	T652	JJ	B-NP	O
reactivation	reactivation	R231	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
full	full	F400	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
achieved	achieve	A213	VBN	I-VP	O
by	by	B000	IN	B-PP	O
inducing	induce	I532	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
demethylation	demethylation	D534	NN	I-NP	O
with	with	W300	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azadeoxycytidine	azadeoxycytidine	A232	NN	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azadC	azadC	A232	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
histone	histone	H235	NN	B-NP	O
acetylation	acetylation	A234	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
another	another	A536	DT	B-NP	O
important	important	I516	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
in	in	I500	IN	B-PP	O
regulating	regulate	R243	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
;	;	0000	:	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
treated	treat	T630	VBD	B-VP	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mosaic	mosaic	M200	JJ	I-NP	O
full	full	F400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
three	three	T600	CD	B-NP	O
drugs	drug	D620	NNS	I-NP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
inducing	induce	I532	VBG	B-VP	O
histone	histone	H235	NN	B-NP	O
hyperacetylation	hyperacetylation	H162	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
a	a	A000	DT	B-NP	O
consistent	consistent	C523	JJ	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
modest	modest	M323	JJ	B-ADJP	O
,	,	0000	,	O	O
reactivation	reactivation	R231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phenylbutyrate	phenylbutyrate	P541	NN	I-NP	O
,	,	0000	,	O	O
sodium	sodium	S350	NN	B-NP	O
butyrate	butyrate	B363	NN	I-NP	O
and	and	A530	CC	O	O
trichostatin	trichostatin	T623	NN	B-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
shown	show	S500	VBN	B-VP	O
by	by	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
combining	combine	C515	VBG	B-VP	O
these	these	T200	DT	B-NP	O
drugs	drug	D620	NNS	I-NP	O
with	with	W300	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azadC	azadC	A232	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
to	to	T000	TO	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
fold	fold	F430	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
with	with	W300	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azadC	azadC	A232	NN	I-NP	O
alone	alone	A450	RB	B-ADVP	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
marked	marked	M623	JJ	I-NP	O
synergistic	synergistic	S562	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
histone	histone	H235	NN	B-NP	O
hyperacetylation	hyperacetylation	H162	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
demethylation	demethylation	D534	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
reactivation	reactivation	R231	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
full	full	F400	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Constitutional	Constitutional	C523	NNP	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	O
VHL	VHL	V400	NNP	O	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
by	by	B000	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

von	von	V500	IN	B-PP	B-Disease
Hippel	Hippel	H140	NNP	B-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
Lindau	Lindau	L530	NNP	B-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominantly	dominantly	D534	RB	I-NP	I-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
predisposing	predispose	P632	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
types	type	T120	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
include	include	I524	VBP	B-VP	O
retinal	retinal	R354	JJ	B-NP	O
hemangioblastomas	hemangioblastoma	H521	NNS	I-NP	B-Disease
,	,	0000	,	O	O
hemangioblastomas	hemangioblastoma	H521	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cysts	cyst	C232	NNS	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
pheochromocytomas	pheochromocytoma	P265	NNS	B-NP	B-Disease
,	,	0000	,	O	O
endolymphatic	endolymphatic	E534	JJ	B-NP	B-Disease
sac	sac	S200	NN	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
epididymal	epididymal	E135	JJ	B-NP	B-Disease
cystadenomas	cystadenoma	C235	NNS	I-NP	I-Disease
[	[	0000	(	O	O
W	W	W000	NNP	B-NP	O
.	.	0000	.	O	O

M	M	M000	NN	B-NP	O
.	.	0000	.	O	O

Linehan	Linehan	L500	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	O	O

Am	Am	A500	NNP	B-NP	O
.	.	0000	.	I-NP	O
Med	Med	M300	NNP	I-NP	O
.	.	0000	.	I-NP	O
Assoc	Assoc	A200	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
273	273	0000	CD	B-NP	O
564	564	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
570	570	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1995	1995	0000	CD	I-NP	O
;	;	0000	:	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	I-NP	O
A	A	A000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Maher	Maher	M600	NNP	I-NP	O
and	and	A530	CC	I-NP	O
W	W	W000	NNP	I-NP	O
.	.	0000	.	I-NP	O
G	G	G000	NNP	I-NP	O
.	.	0000	NNP	I-NP	O
Kaelin	Kaelin	K450	NNP	I-NP	O
,	,	0000	,	O	O
Jr	Jr	J600	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Medicine	Medicine	M325	NN	B-NP	O
(	(	0000	(	O	O
Baltimore	Baltimore	B435	NNP	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
76	76	0000	CD	B-NP	O
381	381	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
391	391	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1997	1997	0000	CD	I-NP	O
;	;	0000	:	O	O
W	W	W000	NNP	B-NP	O
.	.	0000	.	I-NP	O
M	M	M000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Linehan	Linehan	L500	NNP	I-NP	O
and	and	A530	CC	I-NP	O
R	R	R000	NNP	I-NP	O
.	.	0000	.	I-NP	O
D	D	D000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Klausner	Klausner	K425	NNP	I-NP	O
,	,	0000	,	O	O
In	In	I500	IN	B-PP	O
B	B	B000	NN	B-NP	O
.	.	0000	.	O	O
Vogelstein	Vogelstein	V242	NN	B-NP	O
and	and	A530	CC	I-NP	O
K	K	K000	NN	I-NP	O
.	.	0000	.	O	O
Kinzler	Kinzler	K524	NNP	B-NP	O
(	(	0000	(	O	O
eds	ed	E320	NNS	B-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
,	,	0000	,	O	O
The	The	T000	DT	B-NP	O
Genetic	Genetic	G532	JJ	I-NP	O
Basis	Basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Human	Human	H500	NNP	B-NP	O
Cancer	Cancer	C526	NNP	I-NP	O
,	,	0000	,	O	O
pp	pp	P100	NN	B-NP	O
.	.	0000	.	O	O

455	455	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
473	473	0000	CD	I-NP	O
,	,	0000	,	O	O
McGraw	McGraw	M260	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Hill	Hill	H400	NNP	I-NP	O
,	,	0000	,	O	O
1998	1998	0000	CD	B-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3p25	3p25	P000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
26	26	0000	CD	I-NP	O
and	and	A530	CC	O	O
cloned	clone	C453	VBN	B-VP	O
[	[	0000	(	O	O
F	F	F000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Latif	Latif	L310	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
Science	Science	S252	NN	B-NP	O
(	(	0000	(	O	O
Washington	Washington	W252	NNP	B-NP	O
DC	DC	D200	NNP	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
260	260	0000	CD	B-NP	O
1317	1317	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1320	1320	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1993	1993	0000	CD	I-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
varied	vary	V630	VBN	I-VP	O
from	from	F650	IN	B-PP	O
39	39	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
M	M	M000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Whaley	Whaley	W400	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
Am	Am	A500	NNP	B-NP	O
.	.	0000	.	I-NP	O
J	J	J000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Hum	Hum	H500	NNP	I-NP	O
.	.	0000	.	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
55	55	0000	CD	B-NP	O
1092	1092	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1102	1102	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1994	1994	0000	CD	I-NP	O
;	;	0000	:	O	O
Clinical	Clinical	C452	NNP	B-NP	O
Research	Research	R262	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
for	for	F600	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
,	,	0000	,	O	O
Hum	Hum	H500	NNP	B-NP	O
.	.	0000	.	I-NP	O
Mol	Mol	M400	NNP	I-NP	O
.	.	0000	.	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
2233	2233	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
2237	2237	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1995	1995	0000	CD	I-NP	O
;	;	0000	:	O	O
F	F	F000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Chen	Chen	C500	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
Hum	Hum	H500	NNP	B-NP	O
.	.	0000	.	I-NP	O
Mutat	Mutat	M300	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
66	66	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
75	75	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1995	1995	0000	CD	I-NP	O
;	;	0000	:	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	I-NP	O
R	R	R000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Maher	Maher	M600	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Med	Med	M300	NNP	I-NP	O
.	.	0000	.	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
33	33	0000	CD	B-NP	O
328	328	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
332	332	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1996	1996	0000	CD	I-NP	O
;	;	0000	:	O	O
B	B	B000	NN	B-NP	O
.	.	0000	.	O	O
Zbar	Zbar	Z160	NNP	B-NP	O
,	,	0000	,	O	O
Cancer	Cancer	C526	NNP	B-NP	O
Surv	Surv	S610	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
25	25	0000	CD	B-NP	O
219	219	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
232	232	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1995	1995	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
Southern	Southern	S365	JJ	I-NP	O
blotting	blotting	B435	NN	I-NP	O
procedure	procedure	P623	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
improve	improve	I516	VB	I-VP	O
this	this	T200	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
Stolle	Stolle	S340	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
Hum	Hum	H500	NNP	B-NP	O
.	.	0000	.	I-NP	O
Mutat	Mutat	M300	NNP	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
417	417	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
423	423	0000	CD	I-NP	O
,	,	0000	,	O	O
1998	1998	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
method	method	M300	NN	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
and	and	A530	CC	I-VP	O
characterize	characterize	C623	VB	I-VP	O
VHL	VHL	V400	NN	B-NP	B-Disease
germline	germline	G654	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
reexamined	reexamine	R253	VBD	B-VP	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
shown	show	S500	VBN	B-VP	O
previously	previously	P612	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
and	and	A530	CC	O	O
sequencing	sequencing	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
not	not	N300	RB	O	O
to	to	T000	TO	B-VP	O
harbor	harbor	H616	VB	I-VP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
constitutional	constitutional	C523	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
29	29	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
using	use	U252	VBG	B-VP	O
cosmid	cosmid	C253	NN	B-NP	O
and	and	A530	CC	I-NP	O
P1	P1	P000	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cover	cover	C160	VBP	B-VP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
then	then	T500	RB	B-ADVP	O
tested	test	T230	VBD	B-VP	O
six	six	S200	CD	B-NP	O
phenotypically	phenotypically	P531	RB	I-NP	O
normal	normal	N654	JJ	I-NP	O
offspring	offspring	O121	NN	I-NP	O
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
two	two	T000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
four	four	F600	CD	I-NP	O
were	be	W600	VBD	B-VP	O
deletion	deletion	D435	NN	B-NP	O
-	-	0000	HYPH	B-ADJP	O
free	free	F600	JJ	I-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
germline	germline	G654	NN	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
sum	sum	S500	NN	B-NP	O
,	,	0000	,	O	O
FISH	FISH	F200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
and	and	A530	CC	I-NP	O
reliable	reliable	R414	JJ	I-NP	O
method	method	M300	NN	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
VHL	VHL	V400	NN	B-NP	B-Disease
germline	germline	G654	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	O	O
practically	practically	P623	RB	B-ADJP	O
useful	useful	U214	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
where	where	W600	WRB	B-ADVP	O
other	other	O360	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
have	have	H100	VBP	B-VP	O
failed	fail	F430	VBN	I-VP	O
to	to	T000	TO	I-VP	O
detect	detect	D323	VB	I-VP	O
a	a	A000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease

Spectrum	Spectrum	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
hSNF5	hSNF5	H251	NN	B-NP	O
/	/	0000	SYM	B-NP	O
INI1	INI1	I500	NN	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hSNF5	hSNF5	H251	NN	I-NP	O
/	/	0000	SYM	I-NP	O
INI1	INI1	I500	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SWI	SWI	S000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
SNF	SNF	S510	NN	I-NP	O
chromatin	chromatin	C653	NN	I-NP	O
ATP	ATP	A310	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
remodeling	remodeling	R534	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
localized	localize	L242	VBN	B-VP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22q11	22q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
and	and	A530	CC	O	O
recently	recently	R253	RB	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
malignant	malignant	M425	JJ	B-NP	B-Disease
rhabdoid	rhabdoid	R130	JJ	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
hSNF5	hSNF5	H251	NN	B-NP	O
/	/	0000	SYM	B-VP	O
INI1	INI1	I500	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
229	229	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	O
various	various	V620	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
method	method	M300	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
denaturing	denature	D536	VBG	B-VP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
performance	performance	P616	NN	I-NP	O
liquid	liquid	L230	NN	I-NP	O
chromatography	chromatography	C653	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
31	31	0000	CD	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	O	O
36	36	0000	CD	B-NP	O
point	point	P530	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Point	Point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
scattered	scatter	S236	VBN	I-VP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
included	include	I524	VBD	B-VP	O
15	15	0000	CD	B-NP	O
nonsense	nonsense	N525	NN	I-NP	O
,	,	0000	,	O	O
15	15	0000	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
editing	editing	E352	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
retrieved	retrieve	R361	VBN	I-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
rhabdoid	rhabdoid	R130	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
whatever	whatever	W316	WDT	B-NP	O
their	their	T600	PRP$	B-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
occurrence	occurrence	O265	NN	B-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
pathogenetic	pathogenetic	P325	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Recurrent	Recurrent	R265	JJ	B-NP	O
hSNF5	hSNF5	H251	NN	I-NP	O
/	/	0000	SYM	B-VP	O
INI1	INI1	I500	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
choroid	choroid	C630	JJ	B-NP	B-Disease
plexus	plexus	P420	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
central	central	C536	JJ	B-NP	O
primitive	primitive	P653	JJ	I-NP	O
neuroectodermal	neuroectodermal	N623	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
(	(	0000	(	O	O
cPNETs	cPNET	C153	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
medulloblastomas	medulloblastoma	M341	NNS	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
hSNF5	hSNF5	H251	NN	B-NP	O
/	/	0000	SYM	I-NP	O
INI1	INI1	I500	NN	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
gliomas	glioma	G452	NNS	B-NP	B-Disease
,	,	0000	,	O	O
ependymomas	ependymoma	E153	NNS	B-NP	B-Disease
,	,	0000	,	O	O
sarcomas	sarcoma	S625	NNS	B-NP	B-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
types	type	T120	NNS	I-NP	O
,	,	0000	,	O	O
even	even	E150	RB	B-SBAR	O
though	though	T200	IN	I-SBAR	O
most	most	M230	JJS	B-NP	O
analyzed	analyze	A542	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
harbored	harbor	H616	VBD	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
at	at	A300	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
rhabdoid	rhabdoid	R130	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
choroid	choroid	C630	JJ	B-NP	B-Disease
plexus	plexus	P420	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
medulloblastomas	medulloblastoma	M341	NNS	B-NP	B-Disease
and	and	A530	CC	I-NP	O
cPNETs	cPNET	C153	NNS	I-NP	O
share	share	S600	VBP	B-VP	O
common	common	C500	JJ	B-NP	O
pathways	pathway	P320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
oncogenesis	oncogenesis	O525	NN	B-NP	O
related	relate	R430	VBN	B-VP	O
to	to	T000	TO	B-PP	O
hSNF5	hSNF5	H251	NN	B-NP	O
/	/	0000	SYM	O	O
INI1	INI1	I500	NN	B-NP	O
alteration	alteration	A436	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
hSNF5	hSNF5	H251	NN	B-NP	O
/	/	0000	SYM	B-VP	O
INI1	INI1	I500	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
define	define	D150	VBP	B-VP	O
a	a	A000	DT	B-NP	O
genetically	genetically	G532	RB	I-NP	O
homogeneous	homogeneous	H525	JJ	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
aggressive	aggressive	A262	JJ	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
mainly	mainly	M540	RB	B-VP	O
occurring	occur	O265	VBG	I-VP	O
in	in	I500	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
children	child	C436	NNS	I-NP	O
and	and	A530	CC	O	O
frequently	frequently	F625	RB	B-ADVP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-ADVP	O
always	always	A420	RB	I-ADVP	O
,	,	0000	,	O	O
exhibiting	exhibit	E213	VBG	B-VP	O
a	a	A000	DT	B-NP	O
rhabdoid	rhabdoid	R130	JJ	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O

Ataxin	Ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
conformation	conformation	C516	NN	I-NP	O
that	that	T300	WDT	B-NP	O
exposes	expose	E212	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
matrix	matrix	M362	NN	I-NP	O
.	.	0000	.	O	O

Spinocerebellar	Spinocerebellar	S152	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
3	3	0000	CD	I-NP	I-Disease
or	or	O600	CC	O	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Joseph	Joseph	J210	NNP	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
polyglutamine	polyglutamine	P424	NN	I-NP	I-Disease
repeat	repeat	R130	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
disorders	disorder	D263	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
normally	normally	N654	RB	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
becomes	become	B252	VBZ	B-VP	O
expanded	expand	E215	VBN	I-VP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

Experimental	Experimental	E216	JJ	B-NP	O
models	model	M342	NNS	I-NP	O
of	of	O100	IN	B-PP	O
polyglutamine	polyglutamine	P424	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
implicate	implicate	I514	VBP	B-VP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
in	in	I500	IN	B-PP	O
pathogenesis	pathogenesis	P325	NN	B-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
intranuclear	intranuclear	I536	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
expanded	expand	E215	VBN	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
and	and	A530	CC	O	O
neuronal	neuronal	N654	JJ	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
remains	remain	R520	VBZ	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
ataxin	ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
,	,	0000	,	O	O
adopts	adopt	A313	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
conformation	conformation	C516	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
expressed	express	E216	VBN	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
of	of	O100	IN	B-PP	O
transfected	transfecte	T652	VBN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
1C2	1C2	C000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
preferentially	preferentially	P616	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
bind	bind	B530	VB	I-VP	O
expanded	expand	E215	VBN	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
we	we	W000	PRP	B-NP	O
find	find	F530	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
binds	bind	B532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ataxin	ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
glutamine	glutamine	G435	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
ataxin	ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
exposes	expose	E212	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
glutamine	glutamine	G435	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
pathological	pathological	P342	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
allowing	allow	A452	VBG	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-VP	O
bind	bind	B530	VB	I-VP	O
the	the	T000	DT	B-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
1C2	1C2	C000	NN	I-NP	O
.	.	0000	.	O	O

Fractionation	Fractionation	F623	NN	B-NP	O
and	and	A530	CC	O	O
immunochemical	immunochemical	I525	JJ	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
conformation	conformation	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
intranuclear	intranuclear	I536	JJ	B-NP	O
ataxin	ataxin	A325	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
proteolysis	proteolysis	P634	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
instead	instead	I523	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
alters	alter	A436	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
ataxin	ataxin	A325	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
which	which	W200	WDT	B-NP	O
exposes	expose	E212	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
conformationally	conformationally	C516	RB	I-NP	O
altered	alter	A436	VBN	I-NP	O
ataxin	ataxin	A325	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
bound	bind	B530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
matrix	matrix	M362	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pathological	pathological	P342	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
ataxin	ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
associates	associate	A232	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
matrix	matrix	M362	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
event	event	E153	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
conformation	conformation	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
ataxin	ataxin	A325	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
that	that	T300	WDT	B-NP	O
exposes	expose	E212	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
MAGEL2	MAGEL2	M240	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
are	be	A600	VBP	B-VP	O
paternally	paternally	P365	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
and	and	A530	CC	O	O
mapped	map	M130	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
neurogenetic	neurogenetic	N625	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
contiguous	contiguous	C532	JJ	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
involving	involve	I514	VBG	B-VP	O
genes	gene	G520	NNS	B-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
paternally	paternally	P365	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
,	,	0000	,	O	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
mouse	mouse	M200	NN	I-NP	O
models	model	M342	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
but	but	B300	CC	O	O
these	these	T200	DT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
definitively	definitively	D153	RB	I-VP	O
allow	allow	A400	VB	I-VP	O
the	the	T000	DT	B-NP	O
delineation	delineation	D453	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
associated	associated	A230	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
aetiology	aetiology	A342	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
targeted	target	T623	VBN	B-NP	O
mutagenesis	mutagenesis	M325	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
homologues	homologue	H542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
genes	gene	G520	NNS	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
crucial	crucial	C624	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
better	good	B360	JJR	I-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
manuscript	manuscript	M526	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
Magel2	Magel2	M240	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
and	and	A530	CC	I-NP	O
mouse	mouse	M200	NN	I-NP	O
7C	7C	C000	NN	I-NP	O
regions	region	R252	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
close	close	C420	JJ	B-NP	O
proximity	proximity	P625	NN	I-NP	O
to	to	T000	TO	B-PP	O
NDN	NDN	N350	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Ndn	Ndn	N350	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
we	we	W000	PRP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detect	detect	D323	VB	I-VP	O
any	any	A500	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Magel2	Magel2	M240	NN	I-NP	O
but	but	B300	CC	B-PP	O
by	by	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
specific	specific	S121	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
fetal	fetal	F340	JJ	B-NP	O
and	and	A530	CC	I-NP	O
adult	adult	A343	JJ	I-NP	O
brain	brain	B650	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
placenta	placenta	P425	NN	B-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
intronless	intronless	I536	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
tandem	tandem	T535	JJ	B-NP	O
direct	direct	D623	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
contained	contain	C535	VBD	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
CpG	CpG	C120	NN	I-NP	O
island	island	I245	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranscribed	untranscribed	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
encode	encode	E523	VBP	B-VP	O
putative	putative	P310	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
MAGE	MAGE	M200	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
and	and	A530	CC	I-NP	O
NDN	NDN	N350	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
/	/	0000	SYM	I-NP	O
Magel2	Magel2	M240	NN	I-NP	O
are	be	A600	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
aetiology	aetiology	A342	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

cDNA	cDNA	C350	NN	B-NP	O
microarrays	microarray	M262	NNS	I-NP	O
detect	detect	D323	VBP	B-VP	O
activation	activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
myogenic	myogenic	M252	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
program	program	P626	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
.	.	0000	.	O	O

Alveolar	Alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
aggressive	aggressive	A262	JJ	I-NP	O
pediatric	pediatric	P362	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
striated	striate	S363	VBN	B-NP	I-Disease
muscle	muscle	M240	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
in	in	I500	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
;	;	0000	:	O	O
13	13	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q35	q35	Q000	NN	B-NP	O
;	;	0000	:	O	O
q14	q14	Q000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fusion	fusion	F250	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX3	PAX3	P200	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
developmental	developmental	D141	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
limb	limb	L510	NN	B-NP	O
myogenesis	myogenesis	M252	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
FKHR	FKHR	F260	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
forkhead	forkhead	F623	NN	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
factors	factor	F236	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
resultant	resultant	R243	JJ	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
possesses	possess	P200	VBZ	B-VP	O
transforming	transform	T652	VBG	B-VP	O
properties	property	P616	NNS	B-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
on	on	O500	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
are	be	A600	VBP	B-VP	O
largely	largely	L624	RB	B-ADJP	O
unknown	unknown	U525	JJ	I-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
actions	action	A235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	CC	O	O
Pax3	Pax3	P200	NN	B-NP	O
and	and	A530	CC	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
were	be	W600	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
into	into	I530	IN	B-PP	O
NIH	NIH	N000	NN	B-NP	O
3T3	3T3	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
resultant	resultant	R243	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
microarray	microarray	M260	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
225	225	0000	CD	B-NP	O
elements	element	E453	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
but	but	B300	CC	B-NP	O
not	not	N300	RB	I-NP	O
PAX3	PAX3	P200	NN	B-NP	O
activated	activate	A231	VBD	B-VP	O
a	a	A000	DT	B-NP	O
myogenic	myogenic	M252	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
program	program	P626	NN	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
induction	induction	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
factors	factor	F236	NNS	I-NP	O
MyoD	MyoD	M300	NN	B-NP	O
,	,	0000	,	O	O
Myogenin	Myogenin	M250	NN	B-NP	O
,	,	0000	,	O	O
Six1	Six1	S200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Slug	Slug	S420	NN	B-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
battery	battery	B360	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
aspects	aspect	A212	NNS	I-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Notable	Notable	N314	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
Igf2	Igf2	I210	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
binding	bind	B535	VBG	I-NP	O
protein	protein	P635	NN	I-NP	O
Igfbp5	Igfbp5	I210	NN	I-NP	O
.	.	0000	.	O	O

Relevance	Relevance	R415	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
model	model	M340	NN	I-NP	O
was	be	W200	VBD	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
verification	verification	V612	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
IGFBP5	IGFBP5	I210	NN	B-NP	O
,	,	0000	,	O	O
HSIX1	HSIX1	H200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Slug	Slug	S420	NN	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
alveolar	alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
utilizes	utilize	U342	VBZ	B-VP	O
cDNA	cDNA	C350	NN	B-NP	O
microarrays	microarray	M262	NNS	I-NP	O
to	to	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
oncogenic	oncogenic	O525	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
and	and	A530	CC	O	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
profound	profound	P615	JJ	I-NP	O
myogenic	myogenic	M252	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PAX3	PAX3	P200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
in	in	I500	IN	B-PP	O
NIH	NIH	N000	NN	B-NP	O
3T3	3T3	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Experimental	Experimental	E216	JJ	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
MHC	MHC	M200	NN	B-NP	O
class	class	C420	NN	I-NP	O
I	I	I000	CD	I-NP	O
HFE	HFE	H100	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
immune	immune	I500	JJ	B-NP	O
status	status	S320	NN	I-NP	O
and	and	A530	CC	O	O
iron	iron	I650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
puzzling	puzzling	P245	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
became	become	B250	VBD	B-VP	O
even	even	E150	RB	B-ADVP	O
more	more	M600	RBR	I-ADVP	O
so	so	S000	RB	I-ADVP	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Indeed	Indeed	I530	RB	B-ADVP	O
,	,	0000	,	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
well	well	W400	RB	I-NP	O
defined	define	D153	VBN	I-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-NP	O
peptide	peptide	P130	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	binding	B535	NN	B-NP	O
,	,	0000	,	O	O
MHC	MHC	M200	NN	B-NP	O
class	class	C420	NN	I-NP	O
I	I	I000	CD	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecules	molecule	M424	NNS	B-NP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
perform	perform	P616	VB	I-VP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
yet	yet	Y300	RB	I-NP	O
essential	essential	E253	JJ	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
yet	yet	Y300	RB	B-ADVP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
only	only	O540	RB	B-ADJP	O
partial	partial	P634	JJ	I-ADJP	O
;	;	0000	:	O	O
an	an	A500	DT	B-NP	O
even	even	E150	RB	I-NP	O
more	more	M600	RBR	I-NP	O
open	open	O150	JJ	I-NP	O
question	question	Q235	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
its	its	I320	PRP$	B-NP	O
possible	possible	P214	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
immune	immune	I500	JJ	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
advance	advance	A315	VB	I-VP	O
on	on	O500	IN	B-PP	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
avenues	avenue	A152	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
alpha1	alpha1	A410	NN	I-NP	O
and	and	A530	CC	O	O
alpha2	alpha2	A410	NN	B-NP	O
putative	putative	P310	JJ	I-NP	O
ligand	ligand	L253	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
animals	animal	A542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
metabolic	metabolic	M314	JJ	B-NP	O
and	and	A530	CC	I-NP	O
immune	immune	I500	JJ	I-NP	O
parameters	parameter	P653	NNS	I-NP	O
.	.	0000	.	O	O

Faithfully	Faithfully	F314	RB	B-ADVP	O
mimicking	mimic	M525	VBG	B-VP	O
human	human	H500	JJ	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
,	,	0000	,	O	O
mice	mouse	M200	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
develop	develop	D141	NN	I-NP	O
iron	iron	I650	NN	I-NP	O
overload	overload	O164	NN	I-NP	O
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
plasma	plasma	P425	NN	I-NP	O
iron	iron	I650	NN	I-NP	O
content	content	C535	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
raised	raise	R230	VBN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
an	an	A500	DT	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
load	load	L300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
could	could	C430	MD	B-VP	O
,	,	0000	,	O	O
indeed	indeed	I530	RB	B-ADVP	O
,	,	0000	,	O	O
be	be	B000	VB	B-VP	O
traced	trace	T623	VBN	I-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
augmented	augmented	A253	JJ	I-NP	O
duodenal	duodenal	D354	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
absorption	absorption	A126	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
parallel	parallel	P640	NN	B-NP	O
,	,	0000	,	O	O
measurement	measurement	M265	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gut	gut	G300	NN	I-NP	O
mucosal	mucosal	M240	JJ	I-NP	O
iron	iron	I650	NN	I-NP	O
content	content	C535	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
iron	iron	I650	NN	B-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
proteins	protein	P635	NNS	I-NP	O
allows	allow	A420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
informed	informed	I516	JJ	I-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
various	various	V620	JJ	B-NP	O
hypotheses	hypothesis	H132	NNS	I-NP	O
regarding	regard	R263	VBG	B-VP	O
the	the	T000	DT	B-NP	O
precise	precise	P620	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
in	in	I500	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
phenotyping	phenotyping	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	O
and	and	A530	CC	I-NP	O
secondary	secondary	S253	JJ	I-NP	O
lymphoid	lymphoid	L513	JJ	I-NP	O
organs	organ	O625	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
gut	gut	G300	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
compelling	compelling	C514	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
immune	immune	I500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
linked	link	L523	VBN	I-NP	O
function	function	F523	NN	I-NP	O
for	for	F600	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
immune	immune	I500	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
chromosome	chromosome	C652	NN	B-NP	B-Disease
instability	instability	I523	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
lymphoid	lymphoid	L513	JJ	B-NP	B-Disease
malignancy	malignancy	M425	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
detected	detect	D323	VBN	I-VP	O
chromosomally	chromosomally	C652	RB	B-NP	O
anomalous	anomalous	A542	JJ	I-NP	O
clones	clone	C452	NNS	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
banding	banding	B535	NN	I-NP	O
disclosed	disclose	D242	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
clones	clone	C452	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistently	consistently	C523	RB	I-VP	O
marked	mark	M623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
structural	structural	S362	JJ	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
(	(	0000	(	O	O
q	q	Q000	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
14q	14q	Q000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
clones	clone	C452	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
whereas	whereas	W620	IN	B-PP	O
a	a	A000	DT	B-NP	O
ring	ring	R520	NN	I-NP	O
14	14	0000	CD	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
clone	clone	C450	NN	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
data	datum	D300	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
by	by	B000	IN	B-PP	O
others	other	O362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
structural	structural	S362	JJ	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
of	of	O100	IN	B-PP	O
14q	14q	Q000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphocyte	lymphocyte	L512	NN	B-NP	O
clones	clone	C452	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O

Chromosomes	Chromosome	C652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
from	from	F650	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
before	before	B160	IN	B-PP	O
and	and	A530	CC	I-PP	O
after	after	A136	IN	I-PP	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
lymphocytic	lymphocytic	L512	JJ	I-NP	I-Disease
leukemia	leukemia	L250	NN	I-NP	I-Disease
.	.	0000	.	O	O

Before	Before	B160	IN	B-SBAR	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
14q	14q	Q000	NN	I-NP	O
translocation	translocation	T652	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
clone	clone	C450	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
given	give	G150	VBN	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
leukemic	leukemic	L252	JJ	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
structural	structural	S362	JJ	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
of	of	O100	IN	B-PP	O
14q	14q	Q000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
directly	directly	D623	RB	B-ADJP	O
related	relate	R430	VBN	I-ADJP	O
to	to	T000	TO	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
step	step	S310	NN	I-NP	O
toward	toward	T630	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphoid	lymphoid	L513	JJ	B-NP	B-Disease
malignancies	malignancy	M425	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Increasing	Increase	I526	VBG	B-NP	O
evidence	evidence	E135	NN	I-NP	O
,	,	0000	,	O	O
provided	provide	P613	VBN	B-PP	O
by	by	B000	IN	B-PP	O
others	other	O362	NNS	B-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
nonrandom	nonrandom	N565	JJ	I-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
14q	14q	Q000	NN	B-NP	O
in	in	I500	IN	B-PP	O
African	African	A162	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Burkitts	Burkitt	B623	NNS	I-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
lymphoid	lymphoid	L513	JJ	I-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
further	further	F636	JJ	B-NP	O
strengthens	strengthen	S365	NNS	I-NP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Exon	Exon	E250	NN	B-NP	O
9	9	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
influencing	influence	I514	VBG	B-VP	O
KTS	KTS	K320	NN	B-NP	O
splice	splice	S142	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
also	also	A420	RB	B-ADVP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Frasier	Frasi	F626	JJR	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
alter	alter	A436	VB	I-VP	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
+	+	0000	SYM	B-NP	O
/	/	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
KTS	KTS	K320	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Frasier	Frasi	F626	JJR	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
FS	FS	F200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
9	9	0000	CD	I-NP	O
inducing	induce	I532	VBG	B-VP	O
defective	defective	D123	JJ	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
splicing	splicing	S142	NN	I-NP	O
was	be	W200	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
cases	case	C200	NNS	I-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
DDS	DDS	D320	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
proposed	propose	P612	VBN	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
syndromes	syndrome	S536	NNS	I-NP	O
originate	originate	O625	VBP	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
WT1	WT1	W300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
biological	biological	B424	JJ	I-NP	O
point	point	P530	NN	I-NP	O
of	of	O100	IN	B-PP	O
view	view	V000	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
concluded	conclude	C524	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
diseases	disease	D200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	O	O
separable	separable	S161	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
FS	FS	F200	NN	B-NP	B-Disease
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
included	include	I524	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
atypical	atypical	A312	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
DDS	DDS	D320	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Splice	Splice	S142	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
intrafamilial	intrafamilial	I536	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
for	for	F600	IN	B-PP	O
deafness	deafness	D152	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Pendred	Pendred	P536	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
developmental	developmental	D141	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
cochlea	cochlea	C240	NN	I-NP	I-Disease
,	,	0000	,	O	O
sensorineural	sensorineural	S526	JJ	B-NP	B-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
diffuse	diffuse	D120	JJ	B-NP	B-Disease
thyroid	thyroid	T630	NN	I-NP	I-Disease
enlargement	enlargement	E546	NN	I-NP	I-Disease
(	(	0000	(	O	O
goiter	goiter	G360	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
may	may	M000	MD	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
up	up	U100	RB	B-NP	O
to	to	T000	TO	I-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
7q22	7q22	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q31	q31	Q000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
chloride	chloride	C463	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
iodide	iodide	I300	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
that	that	T300	WDT	B-NP	O
shows	show	S200	VBZ	B-VP	O
intrafamilial	intrafamilial	I536	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deafness	deafness	D152	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
(	(	0000	(	O	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
profound	profound	P615	JJ	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
moderate	moderate	M363	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
severe	severe	S160	JJ	I-NP	O
deafness	deafness	D152	NN	I-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
affecting	affect	A123	VBG	B-VP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
639	639	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

RNA	RNA	R500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
from	from	F650	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
639	639	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
7A	7A	A000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
G	G	G000	NN	B-NP	O
generates	generate	G563	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
from	from	F650	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
created	create	C630	VBN	I-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
compete	compete	C513	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
one	one	O500	CD	I-NP	O
,	,	0000	,	O	O
variations	variation	V635	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
aberrant	aberrant	A165	JJ	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cochlea	cochlea	C240	NN	I-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
variability	variability	V614	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deafness	deafness	D152	NN	I-NP	B-Disease
presentation	presentation	P625	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Sjogren	Sjogren	S265	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Larsson	Larsson	L625	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
aldehyde	aldehyde	A430	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Sjogren	Sjogren	S265	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Larsson	Larsson	L625	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
SLS	SLS	S420	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
ichthyosis	ichthyosis	I232	NN	B-NP	B-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
spasticity	spasticity	S123	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
deficient	deficient	D125	JJ	B-NP	B-Disease
activity	activity	A231	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
fatty	fatty	F300	JJ	B-NP	I-Disease
aldehyde	aldehyde	A430	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	O
FALDH	FALDH	F430	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
SLS	SLS	S420	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FALDH	FALDH	F430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
from	from	F650	IN	B-PP	O
63	63	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
49	49	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
-	-	0000	HYPH	B-PP	O
including	include	I524	VBG	B-PP	O
10	10	0000	CD	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
insertions	insertion	I526	NNS	I-NP	O
,	,	0000	,	O	O
22	22	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
9	9	0000	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3	3	0000	CD	B-NP	O
complex	complex	C514	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
-	-	0000	:	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Nineteen	Nineteen	N535	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
reduction	reduction	R323	NN	I-NP	O
of	of	O100	IN	B-PP	O
FALDH	FALDH	F430	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
mammalian	mammalian	M545	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
one	one	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
798G	798G	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
C	C	C000	NN	B-NP	O
[	[	0000	(	O	O
K266N	K266N	K500	NN	B-NP	O
]	]	0000	)	O	O
)	)	0000	)	O	O
seemed	seem	S530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
greater	great	G636	JJR	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
stability	stability	S314	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	I-VP	O
exon	exon	E250	VB	I-VP	O
skipping	skipping	S215	NN	B-NP	O
or	or	O600	CC	I-NP	O
utilization	utilization	U342	NN	I-NP	O
of	of	O100	IN	B-PP	O
cryptic	cryptic	C613	JJ	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
splice	splice	S142	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

Thirty	Thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
seven	seven	S150	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
private	private	P613	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
12	12	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
probands	proband	P615	NNS	I-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
or	or	O600	CC	I-NP	O
Middle	Middle	M340	NNP	I-NP	O
Eastern	Eastern	E236	NNP	I-NP	O
descent	descent	D253	NNP	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
SNPs	SNP	S512	NNS	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FALDH	FALDH	F430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

At	At	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
551C	551C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NNP	I-NP	O
,	,	0000	,	I-NP	O
682C	682C	C000	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NNP	I-NP	O
,	,	0000	,	I-NP	O
733G	733G	G000	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
798	798	0000	CD	B-NP	O
+	+	0000	SYM	I-NP	O
1delG	1delG	D420	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
SNP	SNP	S510	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
originated	originate	O625	VBD	B-VP	O
independently	independently	I531	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
one	one	O500	CD	I-NP	O
occasion	occasion	O250	NN	I-NP	O
or	or	O600	CC	O	O
were	be	W600	VBD	B-VP	O
ancient	ancient	A525	JJ	B-NP	O
SLS	SLS	S420	NN	I-NP	B-Disease
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
had	have	H300	VBD	B-VP	O
undergone	undergo	U536	VBN	I-VP	O
intragenic	intragenic	I536	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
SLS	SLS	S420	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
strikingly	strikingly	S362	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FALDH	FALDH	F430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
framework	framework	F656	NN	I-NP	O
for	for	F600	IN	B-PP	O
understanding	understand	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
tests	test	T232	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
periodontal	periodontal	P635	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
palmoplantar	palmoplantar	P451	JJ	B-NP	B-Disease
keratosis	keratosis	K632	NN	I-NP	I-Disease
.	.	0000	.	O	O

Papillon	Papillon	P145	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lefevre	Lefevre	L160	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
keratosis	keratosis	K632	NN	B-NP	B-Disease
palmoplantaris	palmoplantaris	P451	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
periodontopathia	periodontopathia	P635	NN	B-NP	B-Disease
(	(	0000	(	O	O
PLS	PLS	P420	NN	B-NP	B-Disease
,	,	0000	,	O	O
MIM	MIM	M500	NN	B-NP	O
245000	245000	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
mainly	mainly	M540	RB	I-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
by	by	B000	IN	B-PP	O
dentists	dentist	D532	NNS	B-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
that	that	T300	WDT	B-NP	O
afflicts	afflict	A142	VBZ	B-VP	O
patients	patient	P353	NNS	B-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
the	the	T000	DT	B-NP	O
deciduous	deciduous	D232	JJ	I-NP	O
and	and	A530	CC	I-NP	O
permanent	permanent	P653	JJ	I-NP	O
dentitions	dentition	D535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
affected	affect	A123	VBN	I-VP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
tooth	tooth	T300	JJ	I-NP	B-Disease
loss	loss	L200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Palmoplantar	Palmoplantar	P451	NNP	B-NP	B-Disease
keratosis	keratosis	K632	NN	I-NP	I-Disease
,	,	0000	,	O	O
varying	vary	V652	VBG	B-VP	O
from	from	F650	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
psoriasiform	psoriasiform	P262	NN	I-NP	O
scaly	scaly	S240	RB	B-ADVP	O
skin	skin	S250	NN	B-NP	O
to	to	T000	TO	B-PP	O
overt	overt	O163	JJ	B-NP	O
hyperkeratosis	hyperkeratosis	H162	NN	I-NP	B-Disease
,	,	0000	,	O	O
typically	typically	T124	RB	B-ADVP	O
develops	develop	D141	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
three	three	T600	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
life	life	L100	NN	B-NP	O
.	.	0000	.	O	O

Keratosis	Keratosis	K632	NNP	B-NP	B-Disease
also	also	A420	RB	B-ADVP	O
affects	affect	A123	VBZ	B-VP	O
other	other	O360	JJ	B-NP	O
sites	site	S320	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
elbows	elbow	E412	NNS	B-NP	O
and	and	A530	CC	I-NP	O
knees	knee	K520	NNS	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
PLS	PLS	P420	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
display	display	D214	VBP	B-VP	O
both	both	B300	CC	O	O
periodontitis	periodontitis	P635	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
hyperkeratosis	hyperkeratosis	H162	NN	I-NP	B-Disease
.	.	0000	.	O	O

Some	Some	S500	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
only	only	O540	RB	B-NP	O
palmoplantar	palmoplantar	P451	JJ	I-NP	B-Disease
keratosis	keratosis	K632	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
the	the	T000	DT	B-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
mild	mild	M430	JJ	B-ADJP	O
and	and	A530	CC	O	O
of	of	O100	IN	B-PP	O
late	late	L300	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PLS	PLS	P420	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11q14	11q14	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q21	q21	Q000	NN	I-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
9	9	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
homozygosity	homozygosity	H523	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
small	small	S540	JJ	I-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
narrowed	narrow	N630	VBN	I-VP	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
region	region	R250	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
between	between	B350	IN	B-PP	O
D11S4082	D11S4082	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D11S931	D11S931	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CTSC	CTSC	C320	NN	B-NP	O
)	)	0000	)	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
protease	protease	P632	NN	I-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
dipeptidyl	dipeptidyl	D134	NN	B-NP	O
aminopeptidase	aminopeptidase	A513	NN	I-NP	O
I	I	I000	CD	I-NP	O
)	)	0000	)	O	O
lies	lie	L200	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
defined	define	D153	VBD	B-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTSC	CTSC	C320	NN	B-NP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
assay	assay	A200	NN	I-NP	O
to	to	T000	TO	B-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
an	an	A500	DT	B-NP	O
almost	almost	A452	RB	I-NP	O
total	total	T340	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
reduced	reduced	R323	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
obligate	obligate	O142	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

Confirmation	Confirmation	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
Van	Van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1q32	1q32	Q000	NN	I-NP	O
:	:	0000	:	O	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
STR	STR	S360	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
possible	possible	P214	JJ	B-NP	O
unique	unique	U520	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Van	Van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
VWS	VWS	V200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
craniofacial	craniofacial	C651	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
and	and	A530	CC	O	O
variable	variable	V614	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Its	Its	I320	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
variably	variably	V614	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
include	include	I524	VBP	B-VP	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
,	,	0000	,	O	O
lip	lip	L100	NN	B-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
hypodontia	hypodontia	H135	NN	B-NP	B-Disease
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
map	map	M100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
<	<	0000	JJR	I-NP	O
2	2	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1q32	1q32	Q000	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
locus	locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
aim	aim	A500	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
to	to	T000	TO	B-VP	O
refine	refine	R150	VB	I-VP	O
the	the	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
assess	assess	A200	VB	I-VP	O
possible	possible	P214	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
four	four	F600	CD	B-NP	O
multiplex	multiplex	M431	JJ	I-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
available	available	A141	JJ	I-NP	O
members	member	M516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
clinically	clinically	C452	RB	I-VP	O
assessed	assess	A230	VBN	I-VP	O
and	and	A530	CC	I-VP	O
genotyped	genotype	G531	VBN	I-VP	O
for	for	F600	IN	B-PP	O
19	19	0000	CD	B-NP	O
short	short	S630	JJ	I-NP	O
tandem	tandem	T535	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
and	and	A530	CC	O	O
multipoint	multipoint	M431	JJ	B-NP	O
limit	limit	L530	NN	I-NP	O
of	of	O100	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
(	(	0000	(	O	O
LOD	LOD	L300	NN	B-NP	O
)	)	0000	)	O	O
score	score	S260	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
model	model	M340	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
positive	positive	P231	JJ	B-NP	O
LOD	LOD	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
without	without	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
largest	large	L623	JJS	I-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
was	be	W200	VBD	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

87	87	0000	CD	B-NP	O
87	87	0000	CD	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
assay	assay	A200	NN	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
short	short	S630	JJ	B-NP	O
tandem	tandem	T535	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
(	(	0000	(	O	O
STR	STR	S360	NN	B-NP	O
)	)	0000	)	O	O
markers	marker	M626	NNS	B-NP	O
provided	provide	P613	VBD	B-VP	O
highly	highly	H240	RB	B-NP	O
accurate	accurate	A263	JJ	I-NP	O
size	size	S200	NN	I-NP	O
estimation	estimation	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
allele	allele	A400	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
sizes	size	S200	VBZ	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-ADVP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
four	four	F600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
a	a	A000	DT	B-NP	O
striking	striking	S362	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
STR	STR	S360	NN	B-NP	O
allele	allele	A400	NN	I-NP	O
sharing	share	S652	VBG	B-VP	O
at	at	A300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
loci	locus	L200	NNS	I-NP	O
among	among	A520	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
four	four	F600	CD	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
recruited	recruit	R263	VBN	B-VP	O
at	at	A300	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
locations	location	L235	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
US	US	U200	NNP	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
many	many	M500	JJ	B-NP	O
or	or	O600	CC	I-NP	O
most	most	M230	JJS	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
Thr	Thr	T600	NN	I-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
Met	Met	M300	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
integrin	integrin	I532	NN	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
platelet	platelet	P434	NN	I-NP	O
alloantigen	alloantigen	A453	NN	I-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
affects	affect	A123	VBZ	B-VP	O
collagen	collagen	C425	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
aggregation	aggregation	A262	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
platelet	platelet	P434	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
alloantigen	alloantigen	A453	NN	I-NP	O
,	,	0000	,	O	O
termed	term	T653	VBN	B-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
alloimmune	alloimmune	A450	JJ	I-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	B-LST	O
a	a	A000	LS	I-LST	O
)	)	0000	)	O	O
alloantigen	alloantigen	A453	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	B-NP	O
400	400	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
German	German	G650	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Immunochemical	Immunochemical	I525	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	NN	B-NP	O
)	)	0000	)	O	O
epitopes	epitope	E131	VBZ	B-VP	O
reside	reside	R230	NN	B-NP	O
on	on	O500	IN	B-PP	O
platelet	platelet	P434	NN	B-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
(	(	0000	(	O	O
GP	GP	G100	NN	B-NP	O
)	)	0000	)	O	O
Ia	Ia	I000	NN	B-NP	O
.	.	0000	.	O	O

Nucleotide	Nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
GPIa	GPIa	G100	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
Sit	Sit	S300	NN	B-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
C	C	C000	NN	B-NP	O
(	(	0000	(	O	O
2531	2531	0000	CD	B-NP	O
)	)	0000	)	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
2531	2531	0000	CD	B-NP	O
)	)	0000	)	O	O
point	point	P530	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
Thr	Thr	T600	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
Met	Met	M300	NN	B-NP	O
dimorphism	dimorphism	D561	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
22	22	0000	CD	B-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
negative	negative	N231	JJ	I-NP	O
normal	normal	N654	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Thr	Thr	T600	NN	I-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
encoded	encode	E523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
ACG	ACG	A200	NN	B-NP	O
(	(	0000	(	O	O
2532	2532	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
90	90	0000	CD	B-NP	O
.	.	0000	.	O	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
ACA	ACA	A200	NN	B-NP	O
(	(	0000	(	O	O
2532	2532	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
establish	establish	E231	VB	I-VP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
technique	technique	T252	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
elucidated	elucidate	E423	VBD	B-VP	O
the	the	T000	DT	B-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GPIa	GPIa	G100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
adjacent	adjacent	A325	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
bases	base	B200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
introns	intron	I536	NNS	I-NP	O
(	(	0000	(	O	O
421	421	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
)	)	0000	)	O	O
encompass	encompass	E525	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
142	142	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
bases	base	B200	NNS	I-NP	O
2531	2531	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
2532	2532	0000	CD	I-NP	O
.	.	0000	.	O	O

Polymerase	Polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
on	on	O500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
100	100	0000	CD	B-NP	O
donors	donor	D562	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
Mae	Mae	M000	NN	I-NP	O
III	III	I000	CD	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Met	Met	M300	NN	I-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
form	form	F650	NN	B-NP	O
of	of	O100	IN	B-PP	O
GPIa	GPIa	G100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
restricted	restricted	R236	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
Sit	Sit	S300	NN	B-NP	O
(	(	0000	(	O	O
a	a	A000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
phenotype	phenotype	P531	NN	B-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
stable	stable	S314	JJ	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
hamster	hamster	H523	NN	I-NP	O
ovary	ovary	O160	NN	I-NP	O
transfectants	transfectant	T652	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
GPIa	GPIa	G100	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
exclusively	exclusively	E242	RB	B-ADVP	O
reacted	react	R230	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Glu	Glu	G400	NN	I-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Met	Met	M300	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Glu	Glu	G400	NN	I-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Thr	Thr	T600	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Lys	Ly	L200	NNPS	I-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Thr	Thr	T600	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
isoforms	isoform	I216	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
anti	anti	A530	AFX	O	O
-	-	0000	HYPH	O	O
Br	Br	B600	NNP	B-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
(	(	0000	(	O	O
HPA	HPA	H100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
5b	5b	B000	NN	I-NP	O
)	)	0000	)	O	O
only	only	O540	RB	B-ADVP	O
recognized	recognize	R252	VBD	B-VP	O
the	the	T000	DT	B-NP	O
Lys	Ly	L200	NNPS	I-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Thr	Thr	T600	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
form	form	F650	NN	B-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
anti	anti	A530	AFX	O	O
-	-	0000	HYPH	O	O
Br	Br	B600	NN	B-NP	O
(	(	0000	(	O	O
b	b	B000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
HPA	HPA	H100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
5a	5a	A000	NN	I-NP	O
)	)	0000	)	O	O
reacted	react	R230	VBD	B-VP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
Glu	Glu	G400	NN	B-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Thr	Thr	T600	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Glu	Glu	G400	NN	B-NP	O
(	(	0000	(	O	O
505	505	0000	CD	B-NP	O
)	)	0000	)	O	O
Met	Met	M300	NN	B-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
isoforms	isoform	I216	NNS	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Met	Met	M300	NN	I-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
formation	formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Sit	Sit	S300	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
alloantigenic	alloantigenic	A453	JJ	B-NP	O
determinants	determinant	D365	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
505	505	0000	CD	I-NP	O
(	(	0000	(	O	O
Lys	Lys	L200	NN	B-NP	O
or	or	O600	CC	O	O
Glu	Glu	G400	NN	B-NP	O
)	)	0000	)	O	O
specifically	specifically	S121	RB	B-ADVP	O
controls	control	C536	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
Br	Br	B600	NNP	B-NP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Br	Br	B600	NN	B-NP	O
(	(	0000	(	O	O
b	b	B000	NN	B-NP	O
)	)	0000	)	O	O
epitopes	epitope	E131	NNS	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Platelet	Platelet	P434	NN	B-NP	O
aggregation	aggregation	A262	NN	I-NP	O
responses	response	R215	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Sit	Sit	S300	NN	B-NP	O
(	(	0000	(	O	O
a	a	A000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
individuals	individual	I531	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
diminished	diminish	D523	VBN	I-VP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
collagen	collagen	C425	NN	B-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Thr	Thr	T600	NN	I-NP	O
(	(	0000	(	O	O
799	799	0000	CD	B-NP	O
)	)	0000	)	O	O
Met	Met	M300	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
affects	affect	A123	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GPIa	GPIa	G100	NN	I-NP	O
/	/	0000	SYM	B-VP	O
IIa	IIa	I000	NN	B-NP	O
complex	complex	C514	NN	I-NP	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Papillon	Papillon	P145	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lefevre	Lefevre	L160	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Papillon	Papillon	P145	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lefevre	Lefevre	L160	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PLS	PLS	P420	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterised	characterise	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
palmoplantar	palmoplantar	P451	JJ	B-NP	B-Disease
hyperkeratosis	hyperkeratosis	H162	NN	I-NP	I-Disease
and	and	A530	CC	O	O
severe	severe	S160	JJ	B-NP	O
early	early	E640	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
and	and	A530	CC	I-NP	O
secondary	secondary	S253	JJ	I-NP	O
dentitions	dentition	D535	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11q14	11q14	Q000	NN	I-NP	O
.	.	0000	.	O	O

Correlation	Correlation	C643	NN	B-NP	O
of	of	O100	IN	B-PP	O
physical	physical	P240	JJ	B-NP	O
and	and	A530	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
maps	map	M120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
it	it	I300	PRP	B-NP	O
includes	include	I524	VBZ	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
40	40	0000	CD	I-NP	O
ESTs	EST	E232	NNS	I-NP	O
and	and	A530	CC	O	O
six	six	S200	CD	B-NP	O
known	know	K500	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
protease	protease	P632	NN	I-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CTSC	CTSC	C320	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
CTSC	CTSC	C320	NNP	I-NP	O
message	message	M200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
immune	immune	I500	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
polymorphonuclear	polymorphonuclear	P456	JJ	B-NP	O
leucocytes	leucocyte	L232	NNS	I-NP	O
,	,	0000	,	O	O
macrophages	macrophage	M261	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
precursors	precursor	P626	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
CTSC	CTSC	C320	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
epithelial	epithelial	E134	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
commonly	commonly	C540	RB	B-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
palms	palm	P452	NNS	I-NP	O
,	,	0000	,	O	O
soles	sol	S420	NNS	B-NP	O
,	,	0000	,	O	O
knees	knee	K520	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
oral	oral	O640	JJ	B-NP	O
keratinised	keratinise	K635	VBN	I-NP	O
gingiva	gingiva	G521	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
CTSC	CTSC	C320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTSC	CTSC	C320	NN	B-NP	O
from	from	F650	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
four	four	F600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
1	1	0000	CD	I-NP	O
nonsense	nonsense	N525	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
856C	856C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
introduces	introduce	I536	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
286	286	0000	CD	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
exon	exon	E250	NN	I-NP	O
2	2	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
2692delA	2692delA	D400	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
349	349	0000	CD	I-NP	O
introducing	introduce	I536	VBG	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	I-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
2673	2673	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
2674delCT	2674delCT	D423	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
introduction	introduction	I536	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
343	343	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
429	429	0000	CD	I-NP	O
(	(	0000	(	O	O
2931G	2931G	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
introducing	introduce	I536	VBG	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
PLS	PLS	P420	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
inherited	inherit	I563	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
.	.	0000	.	O	O

Parents	Parent	P653	NNS	B-NP	O
and	and	A530	CC	I-NP	O
sibs	sib	S120	NNS	I-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
show	show	S000	VB	I-VP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
palmoplantar	palmoplantar	P451	NN	I-NP	B-Disease
hyperkeratosis	hyperkeratosis	H162	NN	I-NP	I-Disease
or	or	O600	CC	O	O
severe	severe	S160	JJ	B-NP	O
early	early	E640	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
complete	complete	C514	JJ	I-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
physiology	physiology	P242	NN	I-NP	O
of	of	O100	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
carries	carry	C620	VBZ	B-VP	O
significant	significant	S251	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
understanding	understand	U536	VBG	B-VP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
skin	skin	S250	NN	I-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
periodontal	periodontal	P635	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HGO	HGO	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Finnish	Finnish	F520	JJ	B-NP	O
alkaptonuria	alkaptonuria	A421	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Alkaptonuria	Alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
prototypic	prototypic	P631	JJ	I-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
error	error	E600	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
metabolism	metabolism	M314	NN	B-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homogentisate	homogentisate	H525	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
dioxygenase	dioxygenase	D252	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HGO	HGO	H200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

So	So	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
17	17	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterised	characterise	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
AKU	AKU	A200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
three	three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
R58fs	R58f	R120	NNS	B-NP	O
,	,	0000	,	O	O
R330S	R330S	R200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
H371R	H371R	H600	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
common	common	C500	JJ	I-NP	O
AKU	AKU	A200	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
M368V	M368V	M100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutational	mutational	M354	JJ	B-NP	O
and	and	A530	CC	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HGO	HGO	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
AKU	AKU	A200	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
novel	novel	N140	JJ	I-NP	O
AKU	AKU	A200	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
most	most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
specific	specific	S121	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
originated	originate	O625	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
5	5	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
attenuated	attenuate	A353	VBD	B-VP	B-Disease
APC	APC	A120	NN	B-NP	I-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Newfoundland	Newfoundland	N153	NNP	B-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
predispose	predispose	P632	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
to	to	T000	TO	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
colon	colon	C450	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
rectum	rectum	R235	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
located	locate	L230	VBN	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
extreme	extreme	E236	JJ	I-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
known	know	K500	VBN	B-VP	O
as	as	A200	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
develop	develop	D141	VBP	B-VP	O
relatively	relatively	R431	RB	B-NP	O
few	few	F000	JJ	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
but	but	B300	CC	O	O
are	be	A600	VBP	B-VP	O
still	still	S340	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
separately	separately	S163	RB	I-NP	O
ascertained	ascertain	A263	VBN	I-NP	O
AAPC	AAPC	A120	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Newfoundland	Newfoundland	N153	NNP	B-NP	O
,	,	0000	,	O	O
Canada	Canada	C530	NNP	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
basepair	basepair	B216	NN	I-NP	O
change	change	C520	NN	I-NP	O
(	(	0000	(	O	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
intron	intron	I536	NN	I-NP	O
3	3	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
without	without	W300	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
geographic	geographic	G261	JJ	I-NP	O
area	area	A600	NN	I-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
strengthens	strengthen	S365	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
attenuated	attenuate	A353	VBN	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Alstrom	Alstrom	A423	IN	B-PP	B-Disease
syndrome	syndrome	S536	NN	B-NP	I-Disease
:	:	0000	:	O	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
2p13	2p13	P000	NN	I-NP	O
.	.	0000	.	O	O

Alstrom	Alstrom	A423	IN	B-PP	B-Disease
syndrome	syndrome	S536	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
,	,	0000	,	O	O
sensorineural	sensorineural	S526	JJ	B-NP	B-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
,	,	0000	,	O	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
non	non	N500	AFX	O	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
insulin	insulin	I524	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
dependent	dependent	D153	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Alstrom	Alstrom	A423	IN	B-PP	B-Disease
syndrome	syndrome	S536	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALMS1	ALMS1	A452	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	B-ADJP	O
localized	localized	L242	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
2p13	2p13	P000	NN	I-NP	O
by	by	B000	IN	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
isolated	isolate	I243	VBN	I-NP	O
populations	population	P143	NNS	I-NP	O
-	-	0000	HYPH	B-NP	O
French	French	F652	JJ	I-NP	O
Acadian	Acadian	A235	NNP	I-NP	O
and	and	A530	CC	I-NP	O
North	North	N630	NNP	I-NP	O
African	African	A162	NNP	I-NP	O
.	.	0000	.	O	O

Pair	Pair	P600	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
wise	wise	W200	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
maximum	maximum	M250	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
(	(	0000	(	O	O
logarithm	logarithm	L263	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
odds	odd	O320	NNS	I-NP	O
ratio	ratio	R300	NN	I-NP	O
)	)	0000	)	O	O
scores	score	S262	NNS	B-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

84	84	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
confirm	confirm	C516	VB	I-VP	O
these	these	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
twelve	twelve	T410	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
Alstrom	Alstrom	A423	IN	B-PP	B-Disease
syndrome	syndrome	S536	NN	B-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

13	13	0000	CD	B-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
D2S2110	D2S2110	D200	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
cumulative	cumulative	C543	JJ	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O

16	16	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
D2S2110	D2S2110	D200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
further	further	F636	RBR	B-VP	O
supporting	support	S163	VBG	I-VP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
2p13	2p13	P000	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Meiotic	Meiotic	M320	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
events	event	E153	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
localized	localize	L242	VBN	I-VP	O
the	the	T000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
ALMS1	ALMS1	A452	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
flanked	flank	F452	VBN	B-VP	O
by	by	B000	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
D2S327	D2S327	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
D2S286	D2S286	D200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
fine	fine	F500	JJ	I-NP	O
resolution	resolution	R243	NN	I-NP	O
radiation	radiation	R350	NN	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
31	31	0000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
and	and	A530	CC	I-NP	O
markers	marker	M626	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
constructed	construct	C523	VBN	I-VP	O
.	.	0000	.	O	O

Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
comprises	comprise	C516	VBZ	B-VP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
sensorineural	sensorineural	S526	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
,	,	0000	,	O	O
thyroid	thyroid	T630	JJ	B-NP	B-Disease
goiter	goiter	G360	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
positive	positive	P231	JJ	B-NP	O
perchlorate	perchlorate	P624	NN	I-NP	O
discharge	discharge	D262	NN	I-NP	O
test	test	T230	NN	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
anion	anion	A500	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
called	call	C430	VBN	B-VP	O
pendrin	pendrin	P536	NN	B-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
large	large	L620	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Southern	Southern	S365	NNP	B-NP	O
Tunisia	Tunisia	T520	NNP	I-NP	O
comprising	comprise	C516	VBG	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
23	23	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
profound	profound	P615	JJ	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
L445W	L445W	L000	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
widened	widen	W353	VBN	I-NP	B-Disease
vestibular	vestibular	V231	JJ	I-NP	I-Disease
aqueduct	aqueduct	A232	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
underwent	undergo	U536	VBD	B-VP	O
computed	compute	C513	VBN	I-VP	O
tomography	tomography	T526	NN	B-NP	O
(	(	0000	(	O	O
CT	CT	C300	NN	B-NP	O
)	)	0000	)	O	O
scan	scan	S250	NN	B-NP	O
exploration	exploration	E214	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
ear	ear	E600	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
goiter	goiter	G360	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
11	11	0000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
interestingly	interestingly	I536	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
perchlorate	perchlorate	P624	NN	I-NP	O
discharge	discharge	D262	NN	I-NP	O
test	test	T230	NN	I-NP	O
whenever	whenever	W516	WRB	B-ADVP	O
performed	perform	P616	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
results	result	R243	NNS	I-NP	O
question	question	Q235	VBP	B-VP	O
the	the	T000	DT	B-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
perchlorate	perchlorate	P624	JJ	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
assessment	assessment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
profound	profound	P615	JJ	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
inner	inner	I560	JJ	B-NP	B-Disease
ear	ear	E600	NN	I-NP	I-Disease
morphological	morphological	M614	JJ	B-ADJP	I-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
even	even	E150	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
thyroid	thyroid	T630	JJ	I-NP	B-Disease
goiter	goiter	G360	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Knobloch	Knobloch	K514	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
involving	involve	I514	VBG	B-VP	O
midline	midline	M345	NN	B-NP	B-Disease
scalp	scalp	S241	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
frontal	frontal	F653	JJ	I-NP	I-Disease
region	region	R250	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
Knobloch	Knobloch	K514	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
vitreoretinal	vitreoretinal	V363	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
,	,	0000	,	O	O
high	high	H200	JJ	B-NP	B-Disease
myopia	myopia	M100	NN	I-NP	I-Disease
,	,	0000	,	O	O
cataract	cataract	C362	NN	B-NP	B-Disease
,	,	0000	,	O	O
telecanthus	telecanthus	T425	NN	B-NP	B-Disease
,	,	0000	,	O	O
hypertelorism	hypertelorism	H163	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
arched	arched	A623	JJ	I-NP	I-Disease
palate	palate	P430	NN	I-NP	I-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
defect	defect	D123	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
anterior	anterior	A536	JJ	I-NP	I-Disease
midline	midline	M345	NN	I-NP	I-Disease
scalp	scalp	S241	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
involvement	involvement	I514	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
frontal	frontal	F653	JJ	I-NP	O
bone	bone	B500	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
documented	document	D253	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
computed	compute	C513	VBN	I-NP	O
tomography	tomography	T526	NN	I-NP	O
(	(	0000	(	O	O
CT	CT	C300	NN	B-NP	O
)	)	0000	)	O	O
scan	scan	S250	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
CT	CT	C300	NN	B-NP	O
scan	scan	S250	NN	I-NP	O
and	and	A530	CC	O	O
magnetic	magnetic	M253	JJ	B-NP	O
resonance	resonance	R252	NN	I-NP	O
imaging	imaging	I525	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
review	review	R100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
23	23	0000	CD	I-NP	O
published	publish	P142	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
patient	patient	P353	NN	I-NP	O
illustrates	illustrate	I423	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
investigating	investigate	I512	VBG	B-VP	O
for	for	F600	IN	B-PP	O
underlying	underlie	U536	VBG	B-VP	O
ocular	ocular	O246	JJ	B-NP	O
and	and	A530	CC	I-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
pathology	pathology	P342	NN	I-NP	O
whenever	whenever	W516	WRB	B-ADVP	O
midline	midline	M345	NN	B-NP	B-Disease
scalp	scalp	S241	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
double	double	D140	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
break	break	B620	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
hMRE11	hMRE11	H560	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
like	like	L200	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
hypomorphic	hypomorphic	H156	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hMRE11	hMRE11	H560	NN	B-NP	O
,	,	0000	,	B-PP	O
but	but	B300	CC	I-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
like	like	L200	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
(	(	0000	(	O	O
ATLD	ATLD	A343	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
hMRE11	hMRE11	H560	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
NBS	NBS	N120	NNP	B-NP	B-Disease
and	and	A530	CC	O	O
include	include	I524	VBP	B-VP	O
hypersensitivity	hypersensitivity	H162	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
ionizing	ionize	I525	VBG	B-VP	I-Disease
radiation	radiation	R350	NN	B-NP	I-Disease
,	,	0000	,	O	O
radioresistant	radioresistant	R362	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
abrogation	abrogation	A162	NN	B-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
activation	activation	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
Jun	Jun	J500	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
exposure	exposure	E212	NN	B-NP	O
to	to	T000	TO	B-PP	O
gamma	gamma	G500	NN	B-NP	O
irradiation	irradiation	I635	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
hMre11	hMre11	H560	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
retain	retain	R350	VBP	B-VP	O
some	some	S500	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
interact	interact	I536	VB	I-VP	O
with	with	W300	IN	B-PP	O
hRad50	hRad50	H630	NN	B-NP	O
and	and	A530	CC	I-NP	O
Nbs1	Nbs1	N120	NN	I-NP	O
,	,	0000	,	O	O
formation	formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
hMre11	hMre11	H560	NN	I-NP	O
and	and	A530	CC	I-NP	O
Nbs1	Nbs1	N120	NN	I-NP	O
foci	focus	F200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
hMRE11	hMRE11	H560	NN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
hMre11	hMre11	H560	NN	I-NP	O
/	/	0000	SYM	B-NP	O
hRad50	hRad50	H630	NN	I-NP	O
/	/	0000	SYM	I-NP	O
Nbs1	Nbs1	N120	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
act	act	A230	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
and	and	A530	CC	I-NP	O
link	link	L520	NN	I-NP	O
hMre11	hMre11	H560	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
pathology	pathology	P342	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
TNFRSF11A	TNFRSF11A	T516	NN	B-NP	O
,	,	0000	,	O	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
of	of	O100	IN	B-PP	O
RANK	RANK	R520	NN	B-NP	O
,	,	0000	,	O	O
cause	cause	C200	VBP	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
expansile	expansile	E215	NN	I-NP	I-Disease
osteolysis	osteolysis	O234	NN	I-NP	I-Disease
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
expansile	expansile	E215	NN	I-NP	I-Disease
osteolysis	osteolysis	O234	NN	I-NP	I-Disease
(	(	0000	(	O	O
FEO	FEO	F000	NN	B-NP	B-Disease
,	,	0000	,	O	O
MIM	MIM	M500	NN	B-NP	O
174810	174810	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
,	,	0000	,	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
bone	bone	B500	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
focal	focal	F240	JJ	B-NP	O
areas	area	A620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	B-Disease
bone	bone	B500	NN	I-NP	I-Disease
remodelling	remodelling	R534	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
osteolytic	osteolytic	O234	JJ	I-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
develop	develop	D141	VBP	B-VP	O
usually	usually	U240	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
bones	bone	B520	NNS	I-NP	O
during	during	D652	IN	B-PP	O
early	early	E640	JJ	B-NP	O
adulthood	adulthood	A343	NN	I-NP	O
,	,	0000	,	O	O
show	show	S000	VBP	B-VP	O
increased	increase	I526	VBN	I-VP	O
osteoblast	osteoblast	O231	NN	B-NP	O
and	and	A530	CC	I-NP	O
osteoclast	osteoclast	O232	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
previous	previous	P612	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
mapped	map	M130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
FEO	FEO	F000	NNP	B-NP	B-Disease
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
5	5	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
between	between	B350	IN	B-PP	O
D18S64	D18S64	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D18S51	D18S51	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
18q21	18q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	O	O
-	-	0000	HYPH	O	O
21	21	0000	CD	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	:	O	O
21	21	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Northern	Northern	N636	JJ	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encoding	E523	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
activator	activator	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
factor	factor	F236	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
kappa	kappa	K100	NN	I-NP	O
B	B	B000	NN	I-NP	O
(	(	0000	(	O	O
RANK	RANK	R520	NN	B-NP	O
;	;	0000	:	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
TNFRSF11A	TNFRSF11A	T516	NN	B-NP	O
,	,	0000	,	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

RANK	RANK	R520	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
osteoclast	osteoclast	O232	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
two	two	T000	CD	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
TNFRSF11A	TNFRSF11A	T516	NN	B-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FEO	FEO	F000	NN	B-NP	B-Disease
or	or	O600	CC	O	O
familial	familial	F540	JJ	B-NP	B-Disease
Paget	Paget	P230	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
bone	bone	B500	NN	B-NP	I-Disease
(	(	0000	(	O	O
PDB	PDB	P310	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
18	18	0000	CD	B-NP	O
bases	base	B200	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
bases	base	B200	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
affected	affect	A123	VBD	B-VP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RANK	RANK	R520	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
RANK	RANK	R520	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
perturbations	perturbation	P636	NNS	B-NP	O
in	in	I500	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
caused	cause	C230	VBD	B-VP	O
an	an	A500	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
RANK	RANK	R520	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-VP	O
nuclear	nuclear	N246	JJ	B-NP	O
factor	factor	F236	NN	I-NP	O
-	-	0000	HYPH	O	O
kappaB	kappaB	K100	NN	B-NP	O
(	(	0000	(	O	O
NF	NF	N100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
kappaB	kappaB	K100	NN	I-NP	O
)	)	0000	)	O	O
signalling	signalling	S254	NN	B-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
activating	activate	A231	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Cardiac	Cardiac	C632	JJ	B-NP	O
Na	Na	N000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
channel	channel	C540	NN	B-NP	O
dysfunction	dysfunction	D215	NN	I-NP	O
in	in	I500	IN	B-PP	O
Brugada	Brugada	B623	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
aggravated	aggravate	A261	VBN	I-VP	O
by	by	B000	IN	B-PP	O
beta	beta	B300	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
Mutations	Mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
Na	Na	N000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
channel	channel	C540	NN	B-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
(	(	0000	(	O	O
hH1	hH1	H000	NN	B-NP	O
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-VP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
long	long	L520	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
QT	QT	Q300	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
LQT3	LQT3	L230	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
ventricular	ventricular	V536	JJ	I-NP	I-Disease
fibrillation	fibrillation	F164	NN	I-NP	I-Disease
(	(	0000	(	O	O
IVF	IVF	I100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
auxiliary	auxiliary	A246	JJ	I-NP	O
beta	beta	B300	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
,	,	0000	,	O	O
widely	widely	W340	RB	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
excitable	excitable	E231	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
shifts	shift	S132	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
voltage	voltage	V432	NN	I-NP	O
dependence	dependence	D153	NN	I-NP	O
of	of	O100	IN	B-PP	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
toward	toward	T630	IN	B-PP	O
more	more	M600	RBR	B-NP	O
negative	negative	N231	JJ	I-NP	O
potentials	potential	P353	NNS	I-NP	O
and	and	A530	CC	O	O
restores	restore	R236	VBZ	B-VP	O
normal	normal	N654	JJ	B-NP	O
gating	gate	G352	VBG	I-NP	O
kinetics	kinetic	K532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
Na	Na	N000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
channels	channel	C542	NNS	B-NP	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Xenopus	Xenopus	X512	NNP	B-NP	O
oocytes	oocyte	O232	NNS	I-NP	O
but	but	B300	CC	O	O
has	have	H200	VBZ	B-VP	O
little	little	L340	JJ	B-NP	O
if	if	I100	IN	B-SBAR	O
any	any	A500	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
isoform	isoform	I216	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
characterize	characterize	C623	VBP	B-VP	O
the	the	T000	DT	B-NP	O
altered	alter	A436	VBN	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
beta	beta	B300	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
(	(	0000	(	O	O
hbeta	hbeta	H130	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterologously	heterologously	H364	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
hH1	hH1	H000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
T1620M	T1620M	T500	NN	B-NP	O
)	)	0000	)	O	O
previously	previously	P612	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
IVF	IVF	I100	NN	B-NP	B-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
AND	AND	A530	CC	I-NP	O
RESULTS	RESULTS	R243	NNS	I-NP	O
When	When	W500	WRB	B-ADVP	O
expressed	express	E216	VBN	B-VP	O
alone	alone	A450	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
Xenopus	Xenopus	X512	NNP	B-NP	O
oocytes	oocyte	O232	NNS	I-NP	O
,	,	0000	,	O	O
T1620M	T1620M	T500	NN	B-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
no	no	N000	DT	B-NP	O
persistent	persistent	P623	JJ	I-NP	O
currents	current	C653	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
LQT3	LQT3	L230	NN	I-NP	B-Disease
mutant	mutant	M353	JJ	I-NP	O
channels	channel	C542	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
midpoint	midpoint	M315	NN	I-NP	O
of	of	O100	IN	B-PP	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
(	(	0000	(	O	O
V	V	V000	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	O	O
2	2	0000	CD	O	O
)	)	0000	)	O	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
shifted	shift	S130	VBN	I-VP	O
toward	toward	T630	IN	B-PP	O
more	more	M600	RBR	B-NP	O
positive	positive	P231	JJ	I-NP	O
potentials	potential	P353	NNS	I-NP	O
than	than	T500	IN	B-PP	O
for	for	F600	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
hH1	hH1	H000	NN	I-NP	O
.	.	0000	.	O	O

Coexpression	Coexpression	C216	NN	B-NP	O
of	of	O100	IN	B-PP	O
hbeta	hbeta	H130	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
significantly	significantly	S251	RB	I-VP	O
alter	alter	A436	VB	I-VP	O
current	current	C653	JJ	B-NP	O
decay	decay	D200	NN	I-NP	O
or	or	O600	CC	I-NP	O
recovery	recovery	R216	NN	I-NP	O
from	from	F650	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
hH1	hH1	H000	NN	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
further	further	F636	RB	B-ADVP	O
shifted	shift	S130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
V	V	V000	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	O	O
2	2	0000	CD	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
accelerated	accelerate	A246	VBD	B-VP	O
the	the	T000	DT	B-NP	O
recovery	recovery	R216	NN	I-NP	O
from	from	F650	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
T1620M	T1620M	T500	NN	B-NP	O
.	.	0000	.	O	O

Oocyte	Oocyte	O230	NN	B-NP	O
macropatch	macropatch	M261	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
activation	activation	A231	NN	I-NP	O
kinetics	kinetic	K532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
T1620M	T1620M	T500	NN	B-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
coexpression	coexpression	C216	NN	B-NP	O
of	of	O100	IN	B-PP	O
hbeta	hbeta	H130	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
exposes	expose	E212	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
functional	functional	F523	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
greater	great	G636	JJR	I-NP	O
overlap	overlap	O164	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
channel	channel	C540	NN	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
and	and	A530	CC	O	O
activation	activation	A231	NN	B-NP	O
(	(	0000	(	O	O
window	window	W530	NN	B-NP	O
current	current	C653	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
T1620M	T1620M	T500	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
proposed	propose	P612	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
pathophysiological	pathophysiological	P312	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
IVF	IVF	I100	NN	B-NP	B-Disease
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
possible	possible	P214	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
finding	finding	F535	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
/	/	0000	SYM	I-NP	O
beta	beta	B300	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
association	association	A235	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Meiotic	Meiotic	M320	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
,	,	0000	,	O	O
different	different	D165	JJ	B-NP	O
epidemiological	epidemiological	E135	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
indicated	indicate	I532	VBN	I-VP	O
a	a	A000	DT	B-NP	O
preferential	preferential	P616	JJ	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
to	to	T000	TO	B-PP	O
offspring	offspring	O121	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
drive	drive	D610	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
this	this	T200	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
sperm	sperm	S165	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
six	six	S200	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

Single	Single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sperm	sperm	S165	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
techniques	technique	T252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
for	for	F600	IN	B-PP	O
each	each	E200	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
by	by	B000	IN	B-PP	O
study	study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
short	short	S630	JJ	I-NP	O
tandem	tandem	T535	JJ	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
located	locate	L230	VBN	B-VP	O
either	either	E360	CC	B-PP	O
in	in	I500	IN	I-PP	O
or	or	O600	CC	O	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
segregation	segregation	S262	NN	I-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
RB1	RB1	R100	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SPERMSEG	SPERMSEG	S165	NN	I-NP	O
program	program	P626	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
experimental	experimental	E216	JJ	B-NP	O
parameters	parameter	P653	NNS	I-NP	O
,	,	0000	,	O	O
recombination	recombination	R251	NN	B-NP	O
fractions	fraction	F623	NNS	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
segregation	segregation	S262	NN	B-NP	O
parameters	parameter	P653	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
952	952	0000	CD	I-NP	O
single	single	S524	JJ	I-NP	O
sperm	sperm	S165	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
donors	donor	D562	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
whole	whole	W400	JJ	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
0099	0099	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
segregation	segregation	S262	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
across	across	A262	IN	B-PP	O
donors	donor	D562	NNS	B-NP	O
(	(	0000	(	O	O
.	.	0000	.	O	O
0092	0092	0000	CD	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
result	result	R243	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
favor	favor	F160	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
donor	donor	D560	NN	I-NP	O
only	only	O540	RB	B-ADVP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
provide	provide	P613	VB	I-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
donors	donor	D562	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
segregation	segregation	S262	NN	I-NP	O
distortion	distortion	D236	NN	I-NP	O
favoring	favor	F165	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
seem	seem	S500	VB	I-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
during	during	D652	IN	B-PP	O
spermatogenesis	spermatogenesis	S165	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
thus	thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
meiotic	meiotic	M320	JJ	B-NP	O
drive	drive	D610	NN	I-NP	O
may	may	M000	MD	B-VP	O
result	result	R243	VB	I-VP	O
either	either	E360	CC	O	O
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
fertilization	fertilization	F634	NN	I-NP	O
advantage	advantage	A315	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
better	good	B360	JJR	I-NP	O
mobility	mobility	M143	NN	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
bearing	bear	B652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
defectively	defectively	D123	RB	I-NP	O
imprinted	imprint	I516	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
located	locate	L230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
overview	overview	O161	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
neurodegenerative	neurodegenerative	N632	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
ataxias	ataxia	A320	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
,	,	0000	,	O	O
FRDA	FRDA	F630	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
rapid	rapid	R130	JJ	B-NP	O
advances	advance	A315	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

About	About	A130	RB	B-NP	O
98	98	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
frataxin	frataxin	F632	NN	B-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
mounting	mount	M535	VBG	B-NP	O
evidence	evidence	E135	NN	I-NP	O
to	to	T000	TO	B-VP	O
suggest	suggest	S230	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
accumulation	accumulation	A254	NN	B-NP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
in	in	I500	IN	B-PP	O
mitochondria	mitochondrion	M325	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
excess	excess	E200	JJ	B-NP	O
production	production	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
free	free	F600	JJ	B-NP	O
radicals	radical	R324	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
then	then	T500	RB	B-ADVP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
and	and	A530	CC	I-NP	O
death	death	D300	NN	I-NP	O
.	.	0000	.	O	O

Currently	Currently	C653	RB	B-ADVP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
known	know	K500	VBN	I-NP	O
treatment	treatment	T635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
alters	alter	A436	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
natural	natural	N364	JJ	I-NP	O
course	course	C620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
possible	possible	P214	JJ	I-NP	O
function	function	F523	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
raised	raise	R230	VBN	I-VP	O
hope	hope	H100	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
rational	rational	R354	JJ	B-NP	O
therapeutic	therapeutic	T613	JJ	I-NP	O
strategies	strategy	S363	NNS	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
developed	develop	D141	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-PP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
retinoschisis	retinoschisis	R352	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
retinoschisis	retinoschisis	R352	NN	B-NP	I-Disease
(	(	0000	(	O	O
XLRS	XLRS	X462	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
rare	rare	R600	JJ	I-NP	O
vitreoretinal	vitreoretinal	V363	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
visual	visual	V240	JJ	B-NP	B-Disease
loss	loss	L200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
men	man	M500	NNS	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
XLRS1	XLRS1	X462	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
deleterious	deleterious	D436	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
analyze	analyze	A542	VB	I-VP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
clinically	clinically	C452	RB	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
XLRS	XLRS	X462	NN	B-NP	B-Disease
formutational	formutational	F653	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Ten	Ten	T500	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
XLRS	XLRS	X462	NNS	B-NP	B-Disease
underwent	undergo	U536	VBD	B-VP	O
full	full	F400	JJ	B-NP	O
ophthalmologic	ophthalmologic	O134	JJ	I-NP	O
examination	examination	E253	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
slitlamp	slitlamp	S434	JJ	B-NP	O
biomicroscopy	biomicroscopy	B526	NN	I-NP	O
and	and	A530	CC	O	O
dilated	dilated	D430	JJ	B-NP	O
funduscopy	funduscopy	F532	NN	I-NP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
leukocytes	leukocyte	L232	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
and	and	A530	CC	O	O
analyzed	analyze	A542	VBN	B-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
method	method	M300	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Point	Point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
10	10	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
pairs	pair	P620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
brothers	brother	B636	NNS	B-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
represented	represent	R162	VBD	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
newly	newly	N400	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
herein	herein	H650	RB	B-ADVP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
increases	increase	I526	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
available	available	A141	JJ	I-NP	O
information	information	I516	NN	I-NP	O
regarding	regard	R263	VBG	B-VP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
XLRS	XLRS	X462	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
limited	limited	L530	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
reveal	reveal	R140	VB	I-VP	O
a	a	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

CLINICAL	CLINICAL	C452	JJ	B-NP	O
RELEVANCE	RELEVANCE	R415	NN	I-NP	O
Identification	Identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLRS1	XLRS1	X462	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
expanded	expand	E215	VBN	B-NP	O
information	information	I516	NN	I-NP	O
on	on	O500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
early	early	E640	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
appropriate	appropriate	A161	JJ	B-NP	O
early	early	E640	JJ	I-NP	O
therapy	therapy	T610	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
regarding	regard	R263	VBG	B-VP	O
the	the	T000	DT	B-NP	O
prognosis	prognosis	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
XLRS	XLRS	X462	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
Bax	Bax	B200	NN	I-NP	O
cooperate	cooperate	C163	VBP	B-VP	O
in	in	I500	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
-	-	0000	HYPH	O	O
induced	induce	I532	VBN	B-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
multisystemic	multisystemic	M432	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
,	,	0000	,	O	O
mutated	mutate	M300	VBN	B-VP	O
(	(	0000	(	O	O
ATM	ATM	A350	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
neurodegeneration	neurodegeneration	N632	NN	B-NP	B-Disease
,	,	0000	,	O	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
immune	immune	I500	JJ	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hypersensitivity	hypersensitivity	H162	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
ionizing	ionize	I525	VBG	B-VP	I-Disease
radiation	radiation	R350	NN	B-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
details	detail	D342	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
are	be	A600	VBP	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
neurological	neurological	N642	JJ	I-NP	B-Disease
lesion	lesion	L250	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
becomes	become	B252	VBZ	B-VP	O
apparent	apparent	A165	JJ	B-ADJP	O
early	early	E640	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
life	life	L100	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
developmental	developmental	D141	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
(	(	0000	(	O	O
CNS	CNS	C520	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
null	null	N400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
pronounced	pronounced	P652	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
genotoxic	genotoxic	G532	JJ	B-NP	O
stress	stress	S362	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
ATM	ATM	A350	NN	B-NP	O
functions	function	F523	NNS	I-NP	O
to	to	T000	TO	B-VP	O
eliminate	eliminate	E453	VB	I-VP	O
neurons	neuron	N652	NNS	B-NP	O
with	with	W300	IN	B-PP	O
excessive	excessive	E210	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
death	death	D300	NN	I-NP	O
effector	effector	E123	NN	I-NP	O
Bax	Bax	B200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
developing	develop	D141	VBG	I-NP	O
CNS	CNS	C520	NN	I-NP	O
after	after	A136	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
(	(	0000	(	O	O
IR	IR	I600	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CNS	CNS	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
Bax	Bax	B200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
/	/	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
Atm	Atm	A350	NN	I-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
radioresistant	radioresistant	R362	JJ	B-ADJP	O
,	,	0000	,	O	O
mice	mouse	M200	NNS	B-NP	O
nullizygous	nullizygous	N420	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
Bax	Bax	B200	NN	B-NP	O
and	and	A530	CC	O	O
Atm	Atm	A350	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
additional	additional	A354	JJ	B-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
IR	IR	I600	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CNS	CNS	C520	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
IR	IR	I600	NN	I-NP	O
-	-	0000	HYPH	O	O
induced	induce	I532	VBN	B-NP	O
apoptotic	apoptotic	A132	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CNS	CNS	C520	NN	I-NP	O
requires	require	R262	VBZ	B-VP	O
Atm	Atm	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
Bax	Bax	B200	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
p53	p53	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
collateral	collateral	C436	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
exists	exist	E232	VBZ	B-VP	O
that	that	T300	DT	B-NP	O
has	have	H200	VBZ	B-VP	O
both	both	B300	CC	I-VP	O
Atm	Atm	A350	NN	I-VP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
Bax	Bax	B200	NN	I-NP	O
-	-	0000	HYPH	O	O
independent	independent	I531	JJ	B-NP	O
branches	branch	B652	NNS	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	RB	B-ADVP	O
,	,	0000	,	O	O
Atm	Atm	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
Bax	Bax	B200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CNS	CNS	C520	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
required	require	R263	VBD	B-VP	O
caspase	caspase	C212	NN	B-NP	O
-	-	0000	HYPH	O	O
3	3	0000	CD	B-NP	O
activation	activation	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
implicate	implicate	I514	VBP	B-VP	O
Bax	Bax	B200	NN	B-NP	O
and	and	A530	CC	I-NP	O
caspase	caspase	C212	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
as	as	A200	IN	B-SBAR	O
death	death	D300	NN	B-NP	O
effectors	effector	E123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
neurodegenerative	neurodegenerative	N632	JJ	B-NP	O
pathways	pathway	P320	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Haim	Haim	H500	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Munk	Munk	M520	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Papillon	Papillon	P145	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lefevre	Lefevre	L160	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
many	many	M500	JJ	I-NP	O
palmoplantar	palmoplantar	P451	JJ	I-NP	B-Disease
keratoderma	keratoderma	K636	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
PPK	PPK	P120	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
conditions	condition	C535	NNS	B-NP	I-Disease
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
Papillon	Papillon	P145	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lefevre	Lefevre	L160	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PLS	PLS	P420	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Haim	Haim	H500	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Munk	Munk	M520	NN	B-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
HMS	HMS	H520	NN	B-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
periodontal	periodontal	P635	JJ	I-NP	O
destruction	destruction	D236	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
both	both	B300	CC	O	O
PLS	PLS	P420	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
HMS	HMS	H520	NN	I-NP	B-Disease
share	share	S600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
cardinal	cardinal	C635	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PPK	PPK	P120	NN	B-NP	B-Disease
and	and	A530	CC	O	O
severe	severe	S160	JJ	B-NP	O
periodontitis	periodontitis	P635	NN	I-NP	B-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HMS	HMS	H520	NN	B-NP	B-Disease
including	include	I524	VBG	B-PP	O
arachnodactyly	arachnodactyly	A625	RB	B-ADVP	B-Disease
,	,	0000	,	O	O
acro	acro	A260	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
osteolysis	osteolysis	O234	NN	I-NP	I-Disease
,	,	0000	,	O	O
atrophic	atrophic	A361	JJ	B-NP	B-Disease
changes	change	C520	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
nails	nail	N420	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
radiographic	radiographic	R326	JJ	I-NP	B-Disease
deformity	deformity	D165	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fingers	finger	F526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
PLS	PLS	P420	NN	B-NP	B-Disease
cases	case	C200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
,	,	0000	,	O	O
HMS	HMS	H520	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
only	only	O540	RB	I-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
among	among	A520	IN	B-PP	O
descendants	descendant	D253	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
religious	religious	R420	JJ	I-NP	O
isolate	isolate	I243	NN	I-NP	O
originally	originally	O625	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
Cochin	Cochin	C250	NNP	B-NP	O
,	,	0000	,	O	O
India	India	I530	NNP	B-NP	O
.	.	0000	.	O	O

Parental	Parental	P653	JJ	B-NP	O
consanguinity	consanguinity	C525	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
characteristic	characteristic	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
many	many	M500	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
conditions	condition	C535	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
autosomal	autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
,	,	0000	,	O	O
a	a	A000	DT	O	O
more	more	M600	RBR	B-NP	O
"	"	0000	``	I-NP	O
complex	complex	C514	JJ	I-NP	O
"	"	0000	''	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
with	with	W300	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
influences	influence	I514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
modifying	modify	M315	VBG	I-NP	O
locus	locus	L200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
hypothesised	hypothesise	H132	VBN	I-VP	O
for	for	F600	IN	B-PP	O
HMS	HMS	H520	NN	B-NP	B-Disease
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
PLS	PLS	P420	NN	B-NP	B-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
if	if	I100	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
HMS	HMS	H520	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
sequenced	sequence	S252	VBD	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
and	and	A530	CC	I-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cochin	Cochin	C250	NN	I-NP	O
isolate	isolate	I243	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
PLS	PLS	P420	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
HMS	HMS	H520	NN	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
2127A	2127A	A000	NN	B-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
changes	change	C520	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
segregates	segregate	S262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
HMS	HMS	H520	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
shared	shared	S630	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
cathepsin	cathepsin	C312	NN	I-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
affected	affected	A123	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
descended	descend	D253	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cochin	Cochin	C250	NN	I-NP	O
isolate	isolate	I243	NN	I-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
inherited	inherit	I563	VBN	B-VP	O
"	"	0000	''	O	O
identical	identical	I353	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
descent	descent	D253	JJ	B-ADJP	O
"	"	0000	''	O	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
simple	simple	S514	JJ	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
for	for	F600	IN	B-PP	O
HMS	HMS	H520	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
6	6	0000	CD	I-NP	O
CTSC	CTSC	C320	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
(	(	0000	(	O	O
2126C	2126C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
PLS	PLS	P420	NN	I-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
PLS	PLS	P420	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
HMS	HMS	H520	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cathepsin	cathepsin	C312	NN	B-NP	O
C	C	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
.	.	0000	.	O	O

Approximately	Approximately	A162	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
(	(	0000	(	O	O
MIM	MIM	M500	NN	B-NP	O
208900	208900	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	O	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
supported	support	S163	VBN	I-VP	O
by	by	B000	IN	B-PP	O
some	some	S500	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
but	but	B300	CC	O	O
not	not	N300	RB	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
others	other	O362	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
view	view	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
discrepancy	discrepancy	D261	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
selected	select	S423	VBN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dutch	Dutch	D320	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
ATM	ATM	A350	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
82	82	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
included	include	I524	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
had	have	H300	VBD	B-VP	O
developed	develop	D141	VBN	I-VP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
<	<	0000	SYM	B-NP	O
45	45	0000	CD	I-NP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
survived	survive	S613	VBN	I-VP	O
>	>	0000	SYM	B-NP	O
/	/	0000	SYM	B-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
(	(	0000	(	O	O
mean	mean	M500	NN	B-NP	O
15	15	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
33	33	0000	CD	B-NP	O
(	(	0000	(	O	O
40	40	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
a	a	A000	DT	B-NP	O
contralateral	contralateral	C536	JJ	I-NP	O
breast	breast	B623	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
seven	seven	S150	CD	B-NP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
ATM	ATM	A350	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
five	five	F100	CD	B-NP	O
are	be	A600	VBP	B-VP	O
distinct	distinct	D235	JJ	B-ADJP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	O	O
site	site	S300	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
IVS10	IVS10	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6T	6T	T000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
three	three	T600	CD	B-NP	O
times	time	T520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
series	series	S620	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-NP	O
breast	breast	B623	NN	I-NP	O
cancer	cancer	C526	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
are	be	A600	VBP	B-VP	O
"	"	0000	``	O	O
A	A	A000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
"	"	0000	''	O	O
mutations	mutation	M352	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
cancer	cancer	C526	NN	I-NP	O
in	in	I500	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
approximately	approximately	A162	RB	I-NP	O
ninefold	ninefold	N514	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
increased	increase	I526	VBN	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
a	a	A000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
cancer	cancer	C526	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
frequent	frequent	F625	JJ	B-NP	O
bilateral	bilateral	B436	JJ	I-NP	O
occurrence	occurrence	O265	NN	I-NP	O
,	,	0000	,	O	O
early	early	E640	JJ	B-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
term	term	T650	NN	I-NP	O
survival	survival	S614	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
why	why	W000	WRB	B-ADVP	O
such	such	S200	JJ	B-NP	O
a	a	A000	DT	I-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
series	series	S620	NN	I-NP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
reflect	reflect	R142	VBP	B-VP	O
evolutionary	evolutionary	E143	JJ	B-NP	O
history	history	H236	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
cytosolic	cytosolic	C324	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
housekeeping	housekeeping	H215	NN	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
gene	gene	G500	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
main	main	M500	JJ	I-NP	O
function	function	F523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
NADPH	NADPH	N310	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
electron	electron	E423	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
defense	defense	D152	NN	I-NP	O
against	against	A252	IN	B-PP	O
oxidizing	oxidize	O232	VBG	B-NP	O
agents	agent	A253	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
reductive	reductive	R323	JJ	B-NP	O
biosynthetic	biosynthetic	B253	JJ	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
either	either	E360	CC	B-NP	O
episodic	episodic	E123	JJ	I-NP	B-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
(	(	0000	(	O	O
triggered	trigger	T626	VBN	B-VP	O
by	by	B000	IN	B-PP	O
fava	fava	F100	NN	B-NP	O
beans	bean	B520	NNS	I-NP	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
agents	agent	A253	NNS	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
life	life	L100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
an	an	A500	DT	B-NP	O
evolutionary	evolutionary	E143	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	NN	I-NP	O
to	to	T000	TO	B-PP	O
understanding	understand	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
biology	biology	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
housekeeping	housekeeping	H215	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
alignment	alignment	A425	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
(	(	0000	(	O	O
aa	aa	A000	NN	B-NP	O
)	)	0000	)	O	O
sequence	sequence	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
52	52	0000	CD	B-NP	O
glucose	glucose	G420	NN	I-NP	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
species	specie	S120	NNS	B-NP	O
from	from	F650	IN	B-PP	O
42	42	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
organisms	organism	O625	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
striking	striking	S362	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
aa	aa	A000	NN	I-NP	O
replacements	replacement	R142	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
conservation	conservation	C526	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
thirds	third	T632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
such	such	S200	JJ	B-NP	O
replacements	replacement	R142	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
in	in	I500	IN	B-PP	O
highly	highly	H240	RB	B-ADVP	O
and	and	A530	CC	I-ADVP	O
moderately	moderately	M363	RB	B-VP	O
conserved	conserve	C526	VBN	I-VP	O
(	(	0000	(	O	O
50	50	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
99	99	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
aa	aa	A000	NN	B-NP	O
;	;	0000	:	O	O
relatively	relatively	R431	RB	B-NP	O
few	few	F000	JJ	I-NP	O
are	be	A600	VBP	B-VP	O
in	in	I500	IN	B-PP	O
fully	fully	F400	RB	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
aa	aa	A000	NN	I-NP	O
(	(	0000	(	O	O
where	where	W600	WRB	B-ADVP	O
they	they	T000	PRP	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
lethal	lethal	L340	JJ	B-ADJP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
in	in	I500	IN	B-PP	O
poorly	poorly	P640	RB	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
aa	aa	A000	NN	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
presumably	presumably	P625	RB	O	O
they	they	T000	PRP	B-NP	O
simply	simply	S514	RB	B-ADVP	O
would	would	W430	MD	B-VP	O
not	not	N300	RB	I-VP	O
cause	cause	C200	VB	I-VP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
human	human	H500	JJ	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
residual	residual	R234	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
null	null	N400	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
lethal	lethal	L340	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
some	some	S500	DT	B-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
development	development	D141	NN	B-NP	O
.	.	0000	.	O	O

Comparing	Compare	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
housekeeping	housekeeping	H215	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
evolutionary	evolutionary	E143	JJ	B-NP	O
conservation	conservation	C526	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
pinpointing	pinpoint	P515	VBG	B-VP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
residues	residue	R232	NNS	I-NP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
stability	stability	S314	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	corresponding	C621	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
view	view	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
explosive	explosive	E214	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
full	full	F400	JJ	B-NP	O
genome	genome	G500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
projects	project	P623	NNS	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
tool	tool	T400	NN	I-NP	O
will	will	W400	MD	B-VP	O
become	become	B250	VB	I-VP	O
rapidly	rapidly	R134	RB	B-ADJP	O
available	available	A141	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
numerous	numerous	N562	JJ	B-NP	O
other	other	O360	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Constitutive	Constitutive	C523	JJ	B-NP	O
and	and	A530	CC	I-NP	O
regulated	regulate	R243	VBN	I-NP	O
modes	mode	M320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
splicing	splicing	S142	NN	B-NP	O
produce	produce	P632	VBP	B-VP	O
six	six	S200	CD	B-NP	O
major	major	M260	JJ	I-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
isoforms	isoform	I216	NNS	B-NP	O
with	with	W300	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
properties	property	P616	NNS	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
neuromuscular	neuromuscular	N652	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
adults	adult	A343	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
overexpressor	overexpressor	O162	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
endogenous	endogenous	E532	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
produce	produce	P632	VBP	B-VP	O
six	six	S200	CD	B-NP	O
major	major	M260	JJ	I-NP	O
alternatively	alternatively	A436	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
mRNAs	mRNA	M652	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
almost	almost	A452	RB	B-NP	O
identical	identical	I353	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
type	type	T100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
and	and	A530	CC	O	O
expression	expression	E216	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
.	.	0000	.	O	O

Use	Use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
or	or	O600	CC	I-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
specifying	specify	S121	VBG	B-VP	O
a	a	A000	DT	B-NP	O
VSGGG	VSGGG	V200	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
3	3	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
14	14	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
,	,	0000	,	O	O
occur	occur	O260	VBP	B-VP	O
as	as	A200	IN	B-PP	O
independent	independent	I531	JJ	B-NP	O
stochastic	stochastic	S323	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
excision	excision	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
13	13	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
14	14	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	O	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
terminally	terminally	T654	RB	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
clearly	clearly	C464	RB	B-ADVP	O
cell	cell	C400	NN	B-NP	O
type	type	T100	NN	I-NP	O
dependent	dependent	D153	JJ	B-ADJP	O
and	and	A530	CC	O	O
occurs	occur	O262	VBZ	B-VP	O
predominantly	predominantly	P635	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
smooth	smooth	S530	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
all	all	A400	DT	B-NP	O
six	six	S200	CD	I-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
combinations	combination	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
major	major	M260	JJ	I-NP	O
splicing	splicing	S142	NN	I-NP	O
events	event	E153	NNS	I-NP	O
and	and	A530	CC	O	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
their	their	T600	PRP$	B-NP	O
transfection	transfection	T652	NN	I-NP	O
into	into	I530	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
production	production	P632	NN	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
approximately	approximately	A162	RB	I-NP	O
74	74	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
full	full	F400	JJ	B-ADJP	O
-	-	0000	HYPH	O	O
length	length	L523	NN	B-NP	O
(	(	0000	(	O	O
heart	heart	H630	NN	B-NP	O
-	-	0000	HYPH	B-ADJP	O
,	,	0000	,	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
or	or	O600	CC	I-NP	O
brain	brain	B650	NN	I-NP	O
-	-	0000	HYPH	O	O
specific	specific	S121	JJ	B-ADJP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
C	C	C000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminally	terminally	T654	RB	B-VP	O
truncated	truncate	T652	VBN	I-VP	O
approximately	approximately	A162	RB	B-NP	O
68	68	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
(	(	0000	(	O	O
smooth	smooth	S530	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
)	)	0000	)	O	O
isoforms	isoform	I216	NNS	B-NP	O
.	.	0000	.	O	O

Information	Information	I516	NN	B-NP	O
on	on	O500	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
protein	protein	P635	NN	B-NP	O
isoform	isoform	I216	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
recognizing	recognize	R252	VBG	B-VP	O
differential	differential	D165	JJ	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
)	)	0000	)	O	O
expansion	expansion	E215	NN	B-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
manifestation	manifestation	M512	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
risk	risk	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
venous	venous	V520	JJ	B-NP	B-Disease
thrombosis	thrombosis	T651	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
deficiencies	deficiency	D125	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
protein	protein	P635	NN	B-NP	I-Disease
S	S	S000	NN	I-NP	I-Disease
.	.	0000	.	O	O

Protein	Protein	P635	NN	B-NP	B-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recognized	recognize	R252	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
venous	venous	V520	JJ	B-NP	B-Disease
thrombosis	thrombosis	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
thrombophilic	thrombophilic	T651	JJ	I-NP	B-Disease
conditions	condition	C535	NNS	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
remains	remain	R520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
difficult	difficult	D124	JJ	I-NP	O
to	to	T000	TO	B-VP	O
diagnose	diagnose	D252	VB	I-VP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
variability	variability	V614	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
inconclusive	inconclusive	I525	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
overcome	overcome	O162	VBN	I-VP	O
this	this	T200	DT	B-NP	O
problem	problem	P614	NN	I-NP	O
by	by	B000	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
a	a	A000	DT	B-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
center	center	C536	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
eight	eight	E230	CD	I-NP	O
index	index	I532	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
protein	protein	P635	NN	B-NP	B-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
PROS1	PROS1	P620	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
109	109	0000	CD	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
avoid	avoid	A130	VB	I-VP	O
selection	selection	S423	NN	B-NP	O
bias	bias	B200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
confined	confine	C515	VBD	B-VP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
and	and	A530	CC	I-NP	O
free	free	F600	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
thrombotic	thrombotic	T651	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
free	free	F600	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
level	level	L140	NN	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
reliable	reliable	R414	JJ	I-NP	O
predictor	predictor	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
PROS1	PROS1	P620	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
(	(	0000	(	O	O
sensitivity	sensitivity	S523	NN	B-NP	O
97	97	0000	CD	I-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
specificity	specificity	S121	NN	B-NP	O
100	100	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

First	First	F623	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
PROS1	PROS1	P620	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
-	-	0000	HYPH	B-ADJP	O
fold	fold	F430	RB	B-NP	O
higher	high	H260	JJR	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
thrombosis	thrombosis	T651	NN	B-NP	B-Disease
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
PROS1	PROS1	P620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
recognized	recognize	R252	VBN	I-NP	O
thrombophilic	thrombophilic	T651	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
pregnancy	pregnancy	P625	NN	B-NP	O
/	/	0000	SYM	B-NP	O
puerperium	puerperium	P616	NN	I-NP	O
and	and	A530	CC	I-NP	O
immobility	immobility	I514	NN	I-NP	O
/	/	0000	SYM	B-NP	O
trauma	trauma	T650	NN	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
important	important	I516	JJ	B-NP	O
precipitating	precipitate	P621	VBG	I-NP	O
factors	factor	F236	NNS	I-NP	O
for	for	F600	IN	B-PP	O
thrombosis	thrombosis	T651	NN	B-NP	B-Disease
,	,	0000	,	O	O
almost	almost	A452	RB	B-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
events	event	E153	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
spontaneous	spontaneous	S153	JJ	B-ADJP	O
.	.	0000	.	O	O

Relatives	Relative	R431	NNS	B-NP	O
with	with	W300	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
-	-	0000	HYPH	O	O
site	site	S300	NN	B-NP	O
or	or	O600	CC	O	O
major	major	M260	JJ	B-NP	O
structural	structural	S362	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
PROS1	PROS1	P620	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
had	have	H300	VBN	I-VP	O
a	a	A000	DT	B-NP	O
thrombotic	thrombotic	T651	JJ	I-NP	O
event	event	E153	NN	I-NP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
significantly	significantly	S251	RB	B-NP	O
lower	low	L600	JJR	I-NP	O
total	total	T340	JJ	I-NP	O
and	and	A530	CC	I-NP	O
free	free	F600	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
relatives	relative	R431	NNS	I-NP	O
having	have	H152	VBG	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
persons	person	P625	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PROS1	PROS1	P620	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
protein	protein	P635	NN	B-NP	B-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
at	at	A300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
thrombosis	thrombosis	T651	NN	B-NP	B-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
free	free	F600	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
estimation	estimation	E235	NN	I-NP	O
offers	offer	O162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
reliable	reliable	R414	JJ	I-NP	O
way	way	W000	NN	I-NP	O
of	of	O100	IN	B-PP	O
diagnosing	diagnose	D252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
Blood	Blood	B430	NNP	B-NP	O
.	.	0000	.	I-NP	O
2000	2000	0000	CD	I-NP	O
;	;	0000	:	O	O
95	95	0000	CD	B-NP	O
1935	1935	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1941	1941	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Autoimmune	Autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
from	from	F650	IN	B-PP	O
consanguineous	consanguineous	C525	JJ	B-NP	O
parents	parent	P653	NNS	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
or	or	O600	CC	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
?	?	0000	.	O	O

Autoimmune	Autoimmune	A350	JJ	B-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
and	and	A530	CC	I-NP	O
lymphoproliferations	lymphoproliferation	L516	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
generally	generally	G564	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
Fas	Fas	F200	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
mediated	mediate	M300	VBN	B-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
describes	describe	D261	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ALPS	ALPS	A412	NN	B-NP	B-Disease
without	without	W300	IN	B-PP	O
detectable	detectable	D323	JJ	B-NP	O
Fas	Fas	F200	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
on	on	O500	IN	B-PP	O
freshly	freshly	F624	RB	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
FAS	FAS	F200	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
via	via	V000	IN	B-PP	O
real	real	R400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
time	time	T500	NN	I-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
made	make	M300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
unlikely	unlikely	U542	JJ	B-ADJP	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FAS	FAS	F200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
duplication	duplication	D142	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
cytoplasmic	cytoplasmic	C314	JJ	I-NP	O
signaling	signaling	S254	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
reported	report	R163	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fas	Fas	F200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
null	null	N400	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
,	,	0000	,	O	O
inasmuch	inasmuch	I525	RB	B-ADVP	O
as	as	A200	IN	B-SBAR	O
she	she	S000	PRP	B-NP	O
carries	carry	C620	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FAS	FAS	F200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
she	she	S000	PRP	B-NP	O
shows	show	S200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
and	and	A530	CC	I-NP	O
accelerated	accelerate	A246	VBN	I-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
ALPS	ALPS	A412	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
FAS	FAS	F200	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
autosomal	autosomal	A325	JJ	B-ADJP	O
recessive	recessive	R210	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
imprinted	imprinted	I516	JJ	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Angelman	Angelman	A524	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
deletion	deletion	D435	NN	I-NP	O
region	region	R250	NN	I-NP	O
:	:	0000	:	O	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
regional	regional	R254	JJ	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
control	control	C536	NN	I-NP	O
.	.	0000	.	O	O

Deletions	Deletion	D435	NNS	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15q11	15q11	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q13	q13	Q000	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
developmental	developmental	D141	JJ	I-NP	O
disorders	disorder	D263	NNS	I-NP	O
,	,	0000	,	O	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Angelman	Angelman	A524	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
imprinted	imprint	I516	VBN	O	O
,	,	0000	,	O	O
paternally	paternally	P365	RB	B-NP	O
expressed	express	E216	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
imprinted	imprinted	I516	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
range	range	R520	NN	I-NP	O
over	over	O160	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
acts	act	A232	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
silence	silence	S452	VB	I-VP	O
one	one	O500	CD	B-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
origin	origin	O625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
additional	additional	A354	JJ	B-NP	O
imprinted	imprinted	I516	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
could	could	C430	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
regional	regional	R254	JJ	I-NP	O
control	control	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
imprinting	imprinting	I516	NN	B-NP	O
in	in	I500	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
constructed	construct	C523	VBN	I-VP	O
an	an	A500	DT	B-NP	O
imprinted	imprinted	I516	JJ	I-NP	O
transcript	transcript	T652	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AS	AS	A200	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
22	22	0000	CD	B-NP	O
expressed	express	E216	VBD	B-VP	O
sequence	sequence	S252	NN	B-NP	O
tags	tag	T200	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
radiation	radiation	R350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
hybrid	hybrid	H163	NN	I-NP	O
human	human	H500	JJ	I-NP	O
transcript	transcript	T652	NN	I-NP	O
maps	map	M120	NNS	I-NP	O
or	or	O600	CC	O	O
physical	physical	P240	JJ	B-NP	O
maps	map	M120	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
reverse	reverse	R162	JJ	I-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
and	and	A530	CC	O	O
correlated	correlate	C643	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
map	map	M100	NN	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
new	new	N000	JJ	I-NP	O
paternally	paternally	P365	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
localize	localize	L242	VBP	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
approximately	approximately	A162	RB	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
Mb	Mb	M100	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
SNRPN	SNRPN	S561	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
center	center	C536	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
already	already	A463	RB	B-ADVP	O
includes	include	I524	VBZ	B-VP	O
four	four	F600	CD	B-NP	O
imprinted	imprint	I516	VBN	B-VP	O
,	,	0000	,	O	O
paternally	paternally	P365	RB	B-NP	O
expressed	express	E216	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
other	other	O360	JJ	I-NP	O
tested	test	T230	VBD	B-VP	O
new	new	N000	JJ	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
from	from	F650	IN	B-PP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
exclusive	exclusive	E242	JJ	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
center	center	C536	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
strong	strong	S365	JJ	B-NP	O
regional	regional	R254	JJ	I-NP	O
control	control	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
means	mean	M520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
further	further	F636	JJ	B-NP	O
investigation	investigation	I512	NN	I-NP	O
of	of	O100	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
or	or	O600	CC	O	O
modify	modify	M310	VB	B-VP	O
the	the	T000	DT	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
rearrangements	rearrangement	R652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
1q24	1q24	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
:	:	0000	:	O	O
results	result	R243	NNS	B-NP	O
from	from	F650	IN	B-PP	O
772	772	0000	CD	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
International	International	I536	NNP	I-NP	O
Consortium	Consortium	C526	NNP	I-NP	O
for	for	F600	IN	B-PP	O
Prostate	Prostate	P623	NNP	B-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Genetics	Genetics	G532	NNP	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
provided	provide	P613	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
at	at	A300	IN	B-PP	O
1q24	1q24	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
.	.	0000	.	O	O

Subsequent	Subsequent	S125	JJ	B-NP	O
reports	report	R163	NNS	I-NP	O
in	in	I500	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
collections	collection	C423	NNS	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
yielded	yield	Y430	VBN	I-VP	O
conflicting	conflict	C514	VBG	I-VP	O
results	result	R243	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
locus	locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
provided	provide	P613	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
putative	putative	P310	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
loci	locus	L200	NNS	I-NP	O
on	on	O500	IN	B-PP	O
Xq27	Xq27	X200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
28	28	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1q42	1q42	Q000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
43	43	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1p36	1p36	P000	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
describes	describe	D261	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
combined	combined	C515	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
for	for	F600	IN	B-PP	O
six	six	S200	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
1q24	1q24	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
772	772	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ascertained	ascertain	A263	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
International	International	I536	NNP	I-NP	O
Consortium	Consortium	C526	NNP	I-NP	O
for	for	F600	IN	B-PP	O
Prostate	Prostate	P623	NNP	B-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Genetics	Genetics	G532	NNP	I-NP	O
(	(	0000	(	O	O
ICPCG	ICPCG	I212	NN	B-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
North	North	N630	NNP	B-NP	O
America	America	A562	NNP	I-NP	O
,	,	0000	,	O	O
Australia	Australia	A236	NNP	B-NP	O
,	,	0000	,	O	O
Finland	Finland	F545	NNP	B-NP	O
,	,	0000	,	O	O
Norway	Norway	N600	NNP	B-NP	O
,	,	0000	,	O	O
Sweden	Sweden	S350	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
Kingdom	Kingdom	K523	NNP	I-NP	O
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
some	some	S500	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
peak	peak	P200	NN	I-NP	O
parametric	parametric	P653	JJ	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
assuming	assume	A252	VBG	B-VP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
(	(	0000	(	O	O
HLOD	HLOD	H430	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

40	40	0000	CD	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
D1S212	D1S212	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
(	(	0000	(	O	O
alpha	alpha	A410	NN	B-NP	O
)	)	0000	)	O	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
.	.	0000	.	O	O

06	06	0000	CD	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
LOD	LOD	L300	NN	I-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O
01	01	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
.	.	0000	.	I-NP	O
12	12	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonparametric	nonparametric	N516	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
,	,	0000	,	O	O
presumably	presumably	P625	RB	B-ADVP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
parametric	parametric	P653	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	NN	B-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
male	male	M400	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
transmission	transmission	T652	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
491	491	0000	CD	B-NP	O
such	such	S200	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
HLOD	HLOD	H430	NN	I-NP	O
was	be	W200	VBD	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
491	491	0000	CD	B-NP	O
such	such	S200	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
HLOD	HLOD	H430	NN	I-NP	O
was	be	W200	VBD	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

56	56	0000	CD	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
0006	0006	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
alpha	alpha	A410	NN	B-NP	O
=	=	0000	SYM	B-NP	O
.	.	0000	.	O	O

11	11	0000	CD	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
LOD	LOD	L300	NN	I-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O
04	04	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
.	.	0000	SYM	I-NP	O
19	19	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
HLODs	HLOD	H432	NNS	B-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
281	281	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Within	Within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
male	male	M400	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
transmission	transmission	T652	NN	I-NP	O
,	,	0000	,	O	O
alpha	alpha	A410	NN	B-NP	O
increased	increase	I526	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
mean	mean	M500	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
(	(	0000	(	O	O
<	<	0000	SYM	B-NP	O
65	65	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
alpha	alpha	A410	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
19	19	0000	CD	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
LOD	LOD	L300	NN	I-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O
06	06	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
.	.	0000	.	I-NP	O
34	34	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
five	five	F100	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
alpha	alpha	A410	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
15	15	0000	CD	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
LOD	LOD	L300	NN	I-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O
04	04	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
.	.	0000	.	I-NP	O
28	28	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
alpha	alpha	A410	NN	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
48	48	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
met	meet	M300	VBD	B-VP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
criteria	criterion	C636	NNS	I-NP	O
(	(	0000	(	O	O
peak	peak	P200	JJ	B-NP	O
HLOD	HLOD	H430	NN	I-NP	O
=	=	0000	SYM	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
001	001	0000	CD	B-NP	O
,	,	0000	,	O	O
alpha	alpha	A410	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
29	29	0000	CD	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
LOD	LOD	L300	NN	I-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O
08	08	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
.	.	0000	.	I-NP	O
53	53	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
1q24	1q24	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
,	,	0000	,	O	O
albeit	albeit	A413	IN	B-ADVP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
defined	define	D153	VBN	I-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
prostate	prostate	P623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
HPC1	HPC1	H120	NN	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
small	small	S540	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
prominent	prominent	P653	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
members	member	M516	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
male	male	M400	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
transmission	transmission	T652	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
with	with	W300	IN	B-PP	O
36	36	0000	CD	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
causes	cause	C200	VBZ	B-VP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
sisters	sister	S236	NNS	I-NP	O
.	.	0000	.	O	O

Large	Large	L620	JJ	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
well	well	W400	RB	I-VP	O
documented	document	D253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
large	large	L620	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
with	with	W300	IN	B-PP	O
36	36	0000	CD	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
to	to	T000	TO	B-PP	O
66	66	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
57	57	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
daughters	daughter	D236	NNS	I-NP	O
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
and	and	A530	CC	I-NP	O
third	third	T630	JJ	I-NP	O
decade	decade	D230	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
without	without	W300	IN	B-PP	O
history	history	H236	NN	B-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
give	give	G100	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gonadal	gonadal	G534	JJ	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
large	large	L620	JJ	B-NP	O
expansions	expansion	E215	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
selection	selection	S423	NN	I-NP	O
of	of	O100	IN	B-PP	O
oocytes	oocyte	O232	NNS	B-NP	O
with	with	W300	IN	B-PP	O
long	long	L520	JJ	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
might	might	M230	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
behavior	behavior	B160	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
germlines	germline	G654	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
Purkinje	Purkinje	P625	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Motor	Motor	M360	NNP	B-NP	B-Disease
incoordination	incoordination	I526	NN	I-NP	I-Disease
,	,	0000	,	O	O
immune	immune	I500	JJ	B-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Through	Through	T620	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
targeting	targeting	T623	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
generated	generate	G563	VBN	I-VP	O
a	a	A000	DT	B-NP	O
line	line	L500	NN	I-NP	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
Atm	Atm	A350	NN	B-NP	O
(	(	0000	(	O	O
y	y	Y000	NN	B-NP	O
/	/	0000	SYM	O	O
y	y	Y000	NN	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
Atm	Atm	A350	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
Atm	Atm	A350	NN	B-NP	O
(	(	0000	(	O	O
y	y	Y000	NN	B-NP	O
/	/	0000	SYM	O	O
y	y	Y000	NN	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
show	show	S000	VBP	B-VP	O
a	a	A000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
thymic	thymic	T520	JJ	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
and	and	A530	CC	O	O
survive	survive	S610	VB	B-VP	O
beyond	beyond	B530	IN	B-PP	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

Atm	Atm	A350	NN	B-NP	O
(	(	0000	(	O	O
y	y	Y000	NN	B-NP	O
/	/	0000	SYM	O	O
y	y	Y000	NN	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
deficits	deficit	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
motor	motor	M360	NN	B-NP	O
learning	learning	L652	NN	I-NP	O
indicative	indicative	I532	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
.	.	0000	.	O	O

Even	Even	E150	RB	B-SBAR	O
though	though	T200	IN	I-SBAR	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
no	no	N000	DT	B-NP	O
gross	gross	G620	JJ	I-NP	O
cerebellar	cerebellar	C614	JJ	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
older	old	O436	JJR	B-NP	O
Atm	Atm	A350	NN	I-NP	O
(	(	0000	(	O	O
y	y	Y000	NN	B-NP	O
/	/	0000	SYM	O	O
y	y	Y000	NN	O	O
)	)	0000	)	O	O
animals	animal	A542	NNS	B-NP	O
,	,	0000	,	O	O
ectopic	ectopic	E231	JJ	B-NP	O
and	and	A530	CC	I-NP	O
abnormally	abnormally	A156	RB	I-NP	O
differentiated	differentiate	D165	VBN	I-NP	O
Purkinje	Purkinje	P625	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
apparent	apparent	A165	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
ages	age	A200	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
establish	establish	E231	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
neuropathological	neuropathological	N613	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
unrecognized	unrecognized	U562	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Atm	Atm	A350	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
on	on	O500	IN	B-PP	O
development	development	D141	NN	B-NP	O
or	or	O600	CC	I-NP	O
maintenance	maintenance	M535	NN	I-NP	O
of	of	O100	IN	B-PP	O
CD4	CD4	C300	NN	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
)	)	0000	)	O	O
8	8	0000	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
thymocytes	thymocyte	T523	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
discuss	discuss	D200	VBP	B-VP	O
these	these	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
context	context	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
abnormal	abnormal	A156	JJ	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
Purkinje	Purkinje	P625	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Wilson	Wilson	W425	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
WD	WD	W300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
copper	copper	C160	NN	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
liver	liver	L160	NN	I-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
kidneys	kidney	K352	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
corneas	corneas	C652	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
culminating	culminate	C453	VBG	B-VP	O
in	in	I500	IN	B-PP	O
copper	copper	C160	NN	B-NP	O
toxication	toxication	T235	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
organs	organ	O625	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
responsible	responsible	R215	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
ATP7B	ATP7B	A310	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
WD	WD	W300	NN	B-NP	B-Disease
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
five	five	F100	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
novel	novel	N140	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
16	16	0000	CD	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
6	6	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
novel	novel	N140	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
2871delC	2871delC	D420	NN	I-NP	O
and	and	A530	CC	I-NP	O
2513delA	2513delA	D400	NN	I-NP	O
shift	shift	S130	NN	I-NP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
so	so	S000	IN	B-SBAR	O
that	that	T300	IN	I-SBAR	O
truncated	truncate	T652	VBN	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expected	expect	E212	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
A874V	A874V	A100	NN	I-NP	O
,	,	0000	,	O	O
R778L	R778L	R400	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3892delGTC	3892delGTC	D423	NN	B-NP	O
were	be	W600	VBD	B-VP	O
either	either	E360	CC	O	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
frame	frame	F650	NN	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hepato	hepato	H130	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
neurologic	neurologic	N642	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
late	late	L300	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
2871delC	2871delC	D420	NN	I-NP	O
and	and	A530	CC	I-NP	O
R778L	R778L	R400	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
large	large	L620	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
,	,	0000	,	O	O
R778L	R778L	R400	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
more	more	M600	RBR	B-ADJP	O
prevalent	prevalent	P614	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
Asian	Asian	A250	JJ	B-NP	O
countries	country	C536	NNS	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
countries	country	C536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
tend	tend	T530	VBP	B-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
WD	WD	W300	NN	B-NP	B-Disease
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
fast	fast	F230	JJ	I-NP	O
and	and	A530	CC	I-NP	O
effective	effective	E123	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
WD	WD	W300	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Autoinhibition	Autoinhibition	A351	NN	B-NP	O
and	and	A530	CC	I-NP	O
activation	activation	A231	NN	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Rho	Rho	R000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
family	family	F540	NN	I-NP	O
GTPase	GTPase	G312	NN	I-NP	O
,	,	0000	,	O	O
Cdc42	Cdc42	C320	NN	B-NP	O
,	,	0000	,	O	O
can	can	C500	MD	B-VP	O
regulate	regulate	R243	VB	I-VP	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
cytoskeleton	cytoskeleton	C324	NN	I-NP	O
through	through	T620	IN	B-PP	O
activation	activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
.	.	0000	.	O	O

Activation	Activation	A231	NN	B-NP	O
relieves	relieve	R412	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autoinhibitory	autoinhibitory	A351	JJ	I-NP	O
contact	contact	C532	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
autoinhibited	autoinhibite	A351	VBN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
induced	induce	I532	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
or	or	O600	CC	B-PP	O
by	by	B000	IN	B-PP	O
organic	organic	O625	JJ	B-NP	O
co	co	C000	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
solvents	solvent	S415	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
autoinhibited	autoinhibited	A351	JJ	I-NP	O
complex	complex	C514	NN	I-NP	O
,	,	0000	,	O	O
intramolecular	intramolecular	I536	JJ	B-NP	O
interactions	interaction	I536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
occlude	occlude	O243	VBP	B-VP	O
residues	residue	R232	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
terminus	terminus	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
regulate	regulate	R243	VBP	B-VP	O
the	the	T000	DT	B-NP	O
Arp2	Arp2	A610	NN	I-NP	O
/	/	0000	SYM	O	O
3	3	0000	CD	B-NP	O
actin	actin	A235	NN	I-NP	O
-	-	0000	HYPH	O	O
nucleating	nucleate	N243	VBG	B-VP	O
complex	complex	C514	NN	B-NP	O
.	.	0000	.	O	O

Binding	Binding	B535	NN	B-NP	O
of	of	O100	IN	B-PP	O
Cdc42	Cdc42	C320	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dramatic	dramatic	D653	JJ	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
change	change	C520	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
disruption	disruption	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hydrophobic	hydrophobic	H361	JJ	I-NP	O
core	core	C600	NN	I-NP	O
and	and	A530	CC	I-NP	O
release	release	R420	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
terminus	terminus	T652	NN	I-NP	O
,	,	0000	,	O	O
enabling	enable	E514	VBG	B-VP	O
its	its	I320	PRP$	B-NP	O
interaction	interaction	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
machinery	machinery	M256	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
intrinsically	intrinsically	I536	RB	B-NP	O
unstructured	unstructured	U523	JJ	I-NP	O
peptides	peptide	P132	NNS	I-NP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
GTPase	GTPase	G312	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
induced	induce	I532	VBN	I-VP	O
into	into	I530	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
structural	structural	S362	JJ	I-NP	O
and	and	A530	CC	I-NP	O
functional	functional	F523	JJ	I-NP	O
states	state	S320	NNS	I-NP	O
depending	depend	D153	VBG	B-PP	O
on	on	O500	IN	B-PP	O
context	context	C532	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

hCds1	hCds1	H232	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
mediated	mediate	M300	VBN	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
regulates	regulate	R243	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	O	O
)	)	0000	)	O	O
tumour	tumour	T560	NN	B-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
about	about	A130	IN	B-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
only	only	O540	RB	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
well	well	W400	RB	B-VP	O
understood	understand	U536	VBN	I-VP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
exists	exist	E232	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
foci	focus	F200	NNS	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
hyperphosphorylated	hyperphosphorylate	H161	VBN	I-VP	O
and	and	A530	CC	O	O
disperses	dispers	D216	NNS	B-NP	O
after	after	A136	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
known	know	K500	VBN	I-VP	O
whether	whether	W360	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
and	and	A530	CC	I-NP	O
dispersion	dispersion	D216	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
are	be	A600	VBP	B-VP	O
related	relate	R430	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
response	response	R215	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
replication	replication	R142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
block	block	B420	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
are	be	A600	VBP	B-VP	O
mediated	mediate	M300	VBN	I-VP	O
partly	partly	P634	RB	B-ADVP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cds1	Cds1	C320	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Cds1	Cds1	C320	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
hCds1	hCds1	H232	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Chk2	Chk2	C200	NN	I-NP	O
)	)	0000	)	O	O
regulates	regulate	R243	VBZ	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
function	function	F523	NN	I-NP	O
after	after	A136	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
by	by	B000	IN	B-PP	O
phosphorylating	phosphorylate	P216	VBG	B-VP	O
serine	serine	S650	NN	B-NP	O
988	988	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
hCds1	hCds1	H232	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
interact	interact	I536	VBP	B-VP	O
and	and	A530	CC	O	O
co	co	C000	AFX	O	O
-	-	0000	HYPH	O	O
localize	localize	L242	VB	B-VP	O
within	within	W350	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
but	but	B300	CC	O	O
separate	separate	S163	JJ	B-ADJP	O
after	after	A136	IN	B-PP	O
gamma	gamma	G500	NN	B-NP	O
irradiation	irradiation	I635	NN	I-NP	O
.	.	0000	.	O	O

Phosphorylation	Phosphorylation	P216	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
at	at	A300	IN	B-PP	O
serine	serine	S650	NN	B-NP	O
988	988	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
release	release	R420	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
from	from	F650	IN	B-PP	O
hCds1	hCds1	H232	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
to	to	T000	TO	B-VP	O
restore	restore	R236	VB	I-VP	O
survival	survival	S614	NN	B-NP	O
after	after	A136	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
HCC1937	HCC1937	H200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
spinocerebellar	spinocerebellar	S152	JJ	I-NP	O
ataxia	ataxia	A320	NN	I-NP	O
type	type	T100	NN	I-NP	O
3	3	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
belongs	belong	B452	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinically	clinically	C452	RB	B-NP	O
and	and	A530	CC	I-NP	O
genetically	genetically	G532	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
neurodegenerative	neurodegenerative	N632	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
and	and	A530	CC	I-NP	O
expanded	expand	E215	VBN	I-NP	O
(	(	0000	(	O	O
CAG	CAG	C200	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
,	,	0000	,	O	O
repeat	repeat	R130	NN	B-NP	O
expansions	expansion	E215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
distinct	distinct	D235	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
spinocerebellar	spinocerebellar	S152	JJ	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
3	3	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
gain	gain	G500	VB	I-VP	O
insight	insight	I523	NN	B-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
biology	biology	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
/	/	0000	SYM	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
we	we	W000	PRP	B-NP	O
cloned	clone	C453	VBD	B-VP	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
and	and	A530	CC	O	O
studied	study	S300	VBN	B-VP	O
its	its	I320	PRP$	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
ataxin	ataxin	A325	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
highly	highly	H240	RB	B-ADJP	O
homologous	homologous	H542	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
88	88	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
differs	differ	D162	VBZ	B-VP	O
strongly	strongly	S365	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
published	publish	P142	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
(	(	0000	(	O	O
CAG	CAG	C200	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
block	block	B420	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
just	just	J230	RB	B-NP	O
three	three	T600	CD	I-NP	O
interrupted	interrupt	I536	VBD	B-VP	O
units	unit	U532	NNS	B-NP	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
polyglutamine	polyglutamine	P424	NN	I-NP	O
stretch	stretch	S363	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxin	ataxin	A325	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
rodents	rodent	R353	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
rat	rat	R300	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Northern	Northern	N636	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
transcript	transcript	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
approximately	approximately	A162	RB	B-NP	O
6	6	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
in	in	I500	IN	B-PP	O
length	length	L523	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
rat	rat	R300	NN	B-NP	O
testis	testis	T232	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
smaller	small	S546	JJR	I-NP	O
transcript	transcript	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Transcription	Transcription	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
rsca3	rsca3	R200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
rat	rat	R300	NN	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
brain	brain	B650	NN	B-NP	O
.	.	0000	.	O	O

Analyzing	Analyze	A542	VBG	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
brain	brain	B650	NN	I-NP	O
sections	section	S235	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
higher	high	H260	JJR	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
regions	region	R252	NNS	B-NP	O
predominantly	predominantly	P635	RB	B-VP	O
affected	affect	A123	VBN	I-VP	O
in	in	I500	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-NP	O
additional	additional	A354	JJ	I-NP	O
molecules	molecule	M424	NNS	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
regulatory	regulatory	R243	JJ	B-NP	O
events	event	E153	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
exclusive	exclusive	E242	JJ	I-NP	O
degeneration	degeneration	D256	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
certain	certain	C635	JJ	B-NP	I-Disease
brain	brain	B650	NN	I-NP	I-Disease
areas	area	A620	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Emerin	Emerin	E565	NN	B-NP	B-Disease
,	,	0000	,	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
localized	localize	L242	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
Emery	Emery	E560	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
muscle	muscle	M240	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
triad	triad	T630	NN	I-NP	O
of	of	O100	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
wasting	wasting	W235	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
humero	humero	H560	AFX	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
peroneal	peroneal	P654	JJ	I-NP	I-Disease
muscles	muscle	M242	NNS	I-NP	I-Disease
,	,	0000	,	O	O
early	early	E640	JJ	B-NP	O
contractures	contracture	C536	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
elbows	elbow	E412	NNS	I-NP	I-Disease
,	,	0000	,	O	I-Disease
Achilles	Achilles	A242	NNP	B-NP	I-Disease
tendons	tendon	T535	NNS	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
postcervical	postcervical	P232	JJ	B-NP	I-Disease
muscles	muscle	M242	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
conduction	conduction	C532	NN	I-NP	I-Disease
block	block	B420	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
sudden	sudden	S350	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
on	on	O500	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
named	name	N530	VBN	B-VP	O
emerin	emerin	E565	NN	B-NP	O
that	that	T300	WDT	B-NP	O
localizes	localize	L242	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
,	,	0000	,	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
and	and	A530	CC	I-NP	O
smooth	smooth	S530	JJ	I-NP	O
muscles	muscle	M242	NNS	I-NP	O
and	and	A530	CC	O	O
some	some	S500	DT	B-NP	O
other	other	O360	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
muscle	muscle	M240	NN	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
physiological	physiological	P242	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
the	the	T000	DT	B-NP	O
ultrastructural	ultrastructural	U436	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
and	and	A530	CC	I-NP	O
HeLa	HeLa	H400	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
ultrathin	ultrathin	U436	JJ	B-NP	O
cryosections	cryosection	C623	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
immune	immune	I500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
labeled	label	L143	VBN	B-VP	O
colloidal	colloidal	C434	JJ	B-NP	O
gold	gold	G430	NN	I-NP	O
particles	particle	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
localized	localize	L242	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleoplasmic	nucleoplasmic	N241	JJ	I-NP	O
surface	surface	S612	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	I-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
pore	pore	P600	NN	I-NP	O
.	.	0000	.	O	O

Emerin	Emerin	E565	NN	B-NP	O
stayed	stay	S300	VBD	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytoplasmic	cytoplasmic	C314	JJ	I-NP	O
surface	surface	S612	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
lamina	lamina	L500	NN	I-NP	O
,	,	0000	,	O	O
even	even	E150	RB	B-ADVP	O
after	after	A136	IN	B-PP	O
detergent	detergent	D362	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
solubilizes	solubilize	S414	VBZ	B-VP	O
membrane	membrane	M516	NN	B-NP	O
lipids	lipid	L132	NNS	I-NP	O
and	and	A530	CC	O	O
washes	wash	W200	VBZ	B-VP	O
out	out	O300	RP	B-PRT	O
membrane	membrane	M516	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
anchors	anchor	A526	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
hydrophobic	hydrophobic	H361	JJ	I-NP	O
stretch	stretch	S363	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
protrudes	protrude	P636	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
hydrophilic	hydrophilic	H361	JJ	I-NP	O
region	region	R250	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nucleoplasm	nucleoplasm	N241	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
it	it	I300	PRP	B-NP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
lamina	lamina	L500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
speculate	speculate	S124	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
maintain	maintain	M535	VB	I-VP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
and	and	A530	CC	I-NP	O
stability	stability	S314	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
nuclear	nuclear	N246	JJ	B-NP	O
functions	function	F523	NNS	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
severe	severe	S160	JJ	B-NP	O
stress	stress	S362	NN	I-NP	O
with	with	W300	IN	B-PP	O
rigorous	rigorous	R262	JJ	B-NP	O
contraction	contraction	C536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
relaxation	relaxation	R423	NN	I-NP	O
movements	movement	M153	NNS	I-NP	O
and	and	A530	CC	O	O
calcium	calcium	C425	NN	B-NP	O
flux	flux	F420	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Locus	Locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NN	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
9	9	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
STM7	STM7	S350	NN	B-NP	O
/	/	0000	SYM	B-NP	O
X25	X25	X000	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
date	date	D300	VB	I-VP	O
most	most	M230	JJS	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
locus	locus	L200	NN	B-NP	O
homogeneity	homogeneity	H525	NN	I-NP	O
in	in	I500	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
provide	provide	P613	VBP	B-VP	O
strong	strong	S365	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Studying	Study	S352	VBG	B-VP	O
two	two	T000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detect	detect	D323	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
STM7	STM7	S350	NN	B-NP	O
/	/	0000	SYM	B-NP	O
X25	X25	X000	NN	I-NP	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
STM7	STM7	S350	NN	I-NP	O
/	/	0000	SYM	B-NP	O
X25	X25	X000	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
9	9	0000	CD	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
relevant	relevant	R415	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
9	9	0000	CD	I-NP	O
differs	differ	D162	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
had	have	H300	VBD	B-VP	O
typical	typical	T124	JJ	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
sibpair	sibpair	S160	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
uncommon	uncommon	U525	JJ	I-NP	O
symptom	symptom	S513	NN	I-NP	O
of	of	O100	IN	B-PP	O
retained	retain	R353	VBN	B-NP	O
tendon	tendon	T535	NN	I-NP	O
reflexes	reflex	R142	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
retained	retain	R353	VBN	B-NP	O
tendon	tendon	T535	NN	I-NP	O
reflexes	reflex	R142	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
FRDA2	FRDA2	F630	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
retained	retain	R353	VBN	B-NP	O
tendon	tendon	T535	NN	I-NP	O
reflexes	reflex	R142	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
of	of	O100	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
STM7	STM7	S350	NN	B-NP	O
/	/	0000	SYM	O	O
X25	X25	X000	NN	B-NP	O
(	(	0000	(	O	O
GAA	GAA	G000	NN	B-NP	O
expansions	expansion	E215	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
genetically	genetically	G532	RB	I-NP	O
different	different	D165	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
distinguished	distinguish	D235	VBN	I-VP	O
clinically	clinically	C452	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Glycerol	Glycerol	G426	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
correlate	correlate	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
impaired	impaired	I516	JJ	B-NP	B-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
tolerance	tolerance	T465	NN	I-NP	I-Disease
:	:	0000	:	O	O
dissection	dissection	D235	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
system	system	S235	NN	I-NP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
.	.	0000	.	O	O

Glycerol	Glycerol	G426	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
GK	GK	G200	NN	B-NP	O
)	)	0000	)	O	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
entry	entry	E536	NN	I-NP	O
of	of	O100	IN	B-PP	O
glycerol	glycerol	G426	NN	B-NP	O
into	into	I530	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
and	and	A530	CC	I-NP	O
triglyceride	triglyceride	T624	NN	I-NP	O
metabolism	metabolism	M314	NN	I-NP	O
.	.	0000	.	O	O

Impaired	Impaired	I516	JJ	B-NP	B-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
tolerance	tolerance	T465	NN	I-NP	I-Disease
(	(	0000	(	O	O
IGT	IGT	I230	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
hypertriglyceridemia	hypertriglyceridemia	H163	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
and	and	A530	CC	O	O
cardiovascular	cardiovascular	C631	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
glycerol	glycerol	G426	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
IGT	IGT	I230	NN	B-NP	B-Disease
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
poorly	poorly	P640	RB	B-ADJP	O
understood	understand	U536	VBN	I-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
undertook	undertake	U536	VBD	B-VP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
fasting	fast	F235	VBG	B-VP	O
plasma	plasma	P425	NN	B-NP	O
glycerol	glycerol	G426	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
056	056	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
men	man	M500	NNS	I-NP	O
and	and	A530	CC	I-NP	O
women	woman	W500	NNS	I-NP	O
of	of	O100	IN	B-PP	O
French	French	F652	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
descent	descent	D253	NN	I-NP	O
.	.	0000	.	O	O

Family	Family	F540	RB	B-NP	O
screening	screening	S265	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
cohort	cohort	C630	JJ	I-NP	O
identified	identify	I353	VBN	B-VP	O
18	18	0000	CD	B-NP	O
men	man	M500	NNS	I-NP	O
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
hyperglycerolemia	hyperglycerolemia	H162	NN	I-NP	B-Disease
(	(	0000	(	O	O
values	value	V420	NNS	B-NP	O
above	above	A100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
0	0	0000	CD	B-NP	O
mmol	mmol	M540	NN	I-NP	O
/	/	0000	SYM	B-NP	O
liter	liter	L360	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
demonstrated	demonstrate	D523	VBD	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
from	from	F650	IN	B-PP	O
12	12	0000	CD	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Xp21	Xp21	X100	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
GK	GK	G200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
centered	center	C536	VBN	B-ADJP	O
around	around	A653	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
DXS8039	DXS8039	D200	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
originated	originate	O625	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
proven	proven	P615	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
-	-	0000	HYPH	O	O
the	the	T000	DT	B-NP	O
Saguenay	Saguenay	S250	NNP	I-NP	O
Lac	Lac	L200	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
St	St	S300	NNP	I-NP	O
.	.	0000	.	O	O

-	-	0000	HYPH	B-NP	O
Jean	Jean	J500	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Quebec	Quebec	Q120	NNP	B-NP	O
-	-	0000	:	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
was	be	W200	VBD	B-VP	O
sought	seek	S230	VBN	I-VP	O
.	.	0000	.	O	O

Indeed	Indeed	I530	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
six	six	S200	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
marker	marker	M626	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
over	over	O160	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Resequencing	Resequencing	R252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GK	GK	G200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
N288D	N288D	N300	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
asparagine	asparagine	A216	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
negatively	negatively	N231	RB	I-NP	O
charged	charge	C623	VBN	I-NP	O
aspartic	aspartic	A216	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	B-Disease
dystonias	dystonia	D235	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Primary	Primary	P656	JJ	B-NP	B-Disease
dystonias	dystonia	D235	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
movement	movement	M153	NN	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
dystonia	dystonia	D235	NN	B-NP	B-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
symptom	symptom	S513	NN	I-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
frequently	frequently	F625	RB	I-VP	O
inherited	inherit	I563	VBN	I-VP	O
as	as	A200	IN	B-PP	O
Mendelian	Mendelian	M534	JJ	B-NP	O
traits	trait	T632	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
eight	eight	E230	CD	I-NP	O
clinically	clinically	C452	RB	I-NP	O
distinct	distinct	D235	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
and	and	A530	CC	I-NP	O
two	two	T000	CD	I-NP	O
X	X	X000	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
pedigree	pedigree	P326	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
classification	classification	C421	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
increasingly	increasingly	I526	RB	I-VP	O
being	be	B520	VBG	I-VP	O
replaced	replace	R142	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
one	one	O500	CD	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
six	six	S200	CD	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
,	,	0000	,	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	I-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
torsion	torsion	T625	NN	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
(	(	0000	(	O	O
9q34	9q34	Q000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
focal	focal	F240	JJ	B-NP	B-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
(	(	0000	(	O	O
18p	18p	P000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
idiopathic	idiopathic	I313	JJ	I-NP	B-Disease
torsion	torsion	T625	NN	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
mixed	mix	M230	VBN	B-NP	O
type	type	T100	NN	I-NP	O
(	(	0000	(	O	O
8p21	8p21	P000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
q22	q22	Q000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
dopa	dopa	D100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
responsive	responsive	R215	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
(	(	0000	(	O	O
14q22	14q22	Q000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q22	q22	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
paroxysmal	paroxysmal	P625	JJ	B-NP	B-Disease
dystonic	dystonic	D235	JJ	I-NP	I-Disease
choreoathetosis	choreoathetosis	C632	NN	I-NP	I-Disease
(	(	0000	(	O	O
2q25	2q25	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q33	q33	Q000	NN	I-NP	O
;	;	0000	:	O	O
1p21	1p21	P000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
p13	p13	P000	NN	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	I-VP	O
recessive	recessive	R210	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Xq13	Xq13	X200	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
parkinsonism	parkinsonism	P625	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
Xq22	Xq22	X200	NN	B-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
sensorineural	sensorineural	S526	JJ	B-NP	I-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
,	,	0000	,	O	O
dystonia	dystonia	D235	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
X	X	X000	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
form	form	F650	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
ATP	ATP	A310	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
protein	protein	P635	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
torsion	torsion	T625	NN	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
(	(	0000	(	O	O
DYT1	DYT1	D300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
GTP	GTP	G310	NN	I-NP	O
cyclohydrolase	cyclohydrolase	C243	NN	I-NP	O
1	1	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
dopa	dopa	D100	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
responsive	responsive	R215	JJ	I-NP	I-Disease
dystonia	dystonia	D235	NN	I-NP	I-Disease
(	(	0000	(	O	O
DYT5	DYT5	D300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
sensorineural	sensorineural	S526	JJ	B-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
,	,	0000	,	O	O
dystonia	dystonia	D235	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
DDP	DDP	D310	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
article	article	A632	NN	I-NP	O
reviews	review	R120	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	B-Disease
dystonias	dystonia	D235	NNS	I-NP	I-Disease
,	,	0000	,	O	O
critically	critically	C632	RB	B-VP	O
discusses	discuss	D200	VBZ	I-VP	O
present	present	P625	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
proposes	propose	P612	VBZ	B-VP	O
referring	refer	R165	VBG	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
known	known	K500	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
distinguished	distinguish	D235	VBN	I-VP	O
by	by	B000	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
criteria	criterion	C636	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
dystonias	dystonia	D235	NNS	B-NP	B-Disease
1	1	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
12	12	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

Determination	Determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
X	X	X000	SYM	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
15	15	0000	CD	B-NP	O
not	not	N300	RB	B-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
mainly	mainly	M540	RB	B-ADVP	O
involves	involve	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
white	white	W300	JJ	I-NP	O
matter	matter	M360	NN	I-NP	O
,	,	0000	,	O	O
adrenal	adrenal	A365	JJ	B-NP	O
cortex	cortex	C632	NN	I-NP	O
and	and	A530	CC	I-NP	O
testes	testis	T232	NNS	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
known	know	K500	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
principal	principal	P652	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
saturated	saturate	S363	VBN	B-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
VLCFAs	VLCFA	V421	NNS	B-NP	O
>	>	0000	SYM	O	O
C22	C22	C000	NN	B-NP	O
0	0	0000	CD	I-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-ADVP	O
C26	C26	C000	NN	B-NP	O
0	0	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
impaired	impair	I516	VBN	B-NP	O
capacity	capacity	C123	NN	I-NP	O
for	for	F600	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
oxidation	oxidation	O235	NN	B-NP	O
in	in	I500	IN	B-PP	O
peroxisomes	peroxisome	P625	NNS	B-NP	O
.	.	0000	.	O	O

Diagnosis	Diagnosis	D252	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
usually	usually	U240	RB	I-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
VLCFA	VLCFA	V421	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
or	or	O600	CC	O	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
C26	C26	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
level	level	L140	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
borderline	borderline	B636	JJ	B-ADJP	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
obligate	obligate	O142	JJ	B-NP	O
female	female	F540	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
normal	normal	N654	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
.	.	0000	.	O	O

Effective	Effective	E123	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	B-ADVP	O
fundamental	fundamental	F535	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
unambiguously	unambiguously	U512	RB	I-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
concern	concern	C526	NN	I-NP	O
are	be	A600	VBP	B-VP	O
female	female	F540	JJ	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
kindreds	kindred	K536	NNS	B-NP	O
segregating	segregate	S262	VBG	B-VP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
because	because	B200	IN	B-SBAR	O
normal	normal	N654	JJ	B-NP	O
VLCFA	VLCFA	V421	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
guarantee	guarantee	G653	VB	I-VP	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
status	status	S320	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
fast	fast	F230	JJ	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
method	method	M300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
nested	nested	N230	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
determination	determination	D365	NN	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
methodology	methodology	M342	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
15	15	0000	CD	B-NP	O
not	not	N300	RB	O	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

beta	beta	B300	SYM	O	O
-	-	0000	HYPH	B-NP	O
galactosidase	galactosidase	G423	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
elastin	elastin	E423	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
GM1	GM1	G500	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
gangliosidosis	gangliosidosis	G524	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
involvement	involvement	I514	NN	I-NP	I-Disease
.	.	0000	.	O	O

GM1	GM1	G500	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
gangliosidosis	gangliosidosis	G524	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	B-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
acid	acid	A230	NN	B-NP	I-Disease
beta	beta	B300	SYM	O	I-Disease
-	-	0000	HYPH	O	I-Disease
galactosidase	galactosidase	G423	NN	B-NP	I-Disease
(	(	0000	(	O	O
GLB1	GLB1	G410	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
five	five	F100	CD	B-NP	O
new	new	N000	JJ	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
galactosidase	galactosidase	G423	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
fetus	fetus	F320	NN	I-NP	O
,	,	0000	,	O	O
segregating	segregate	S262	VBG	B-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
,	,	0000	,	I-NP	O
severe	severe	S160	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
presented	present	P625	VBD	B-VP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
involvement	involvement	I514	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
feature	feature	F360	NN	I-NP	O
rarely	rarely	R640	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
GM1	GM1	G500	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
gangliosidosis	gangliosidosis	G524	NN	I-NP	I-Disease
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
RNA	RNA	R500	NN	I-NP	O
and	and	A530	CC	I-NP	O
DNA	DNA	D500	NN	I-NP	O
identified	identify	I353	VBD	B-VP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
and	and	A530	CC	I-NP	O
three	three	T600	CD	I-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
involvement	involvement	I514	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
R59H	R59H	R000	NN	I-NP	O
,	,	0000	,	O	O
Y591C	Y591C	Y200	NN	B-NP	O
,	,	0000	,	O	O
Y591N	Y591N	Y500	NN	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
IVS14	IVS14	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
2A	2A	A000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
other	other	O360	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
compound	compound	C515	NN	B-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
following	follow	F452	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
R201H	R201H	R000	NN	I-NP	O
,	,	0000	,	O	O
R482H	R482H	R000	NN	B-NP	O
,	,	0000	,	O	O
G579D	G579D	G300	NN	B-NP	O
,	,	0000	,	O	O
IVS8	IVS8	I120	NN	B-NP	O
+	+	0000	SYM	B-NP	O
2T	2T	T000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
directly	directly	D623	RB	I-VP	O
correlate	correlate	C643	VB	I-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
fell	fall	F400	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GLB1	GLB1	G410	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
region	region	R250	NN	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Hbeta	Hbeta	H130	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Gal	Gal	G400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
elastin	elastin	E423	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
EBP	EBP	E100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
molecules	molecule	M424	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
they	they	T000	PRP	B-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
differently	differently	D165	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
modulation	modulation	M343	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hmgic	Hmgic	H520	NN	B-NP	O
reduces	reduce	R320	VBZ	B-VP	O
obesity	obesity	O123	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
HMGI	HMGI	H520	NN	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
HMGIC	HMGIC	H520	NN	B-NP	O
,	,	0000	,	O	O
HMGI	HMGI	H520	NN	B-NP	O
and	and	A530	CC	O	O
HMGI	HMGI	H520	NN	B-NP	O
(	(	0000	(	O	O
Y	Y	Y000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
function	function	F523	VBP	B-VP	O
as	as	A200	IN	B-PP	O
architectural	architectural	A623	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
essential	essential	E253	JJ	B-NP	O
components	component	C515	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enhancesome	enhancesome	E525	NN	I-NP	O
.	.	0000	.	O	O

HMGIC	HMGIC	H520	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
predominantly	predominantly	P635	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
proliferating	proliferate	P641	VBG	B-VP	O
,	,	0000	,	O	O
undifferentiated	undifferentiated	U531	JJ	B-NP	O
mesenchymal	mesenchymal	M252	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
disrupted	disrupt	D261	VBN	I-VP	O
and	and	A530	CC	I-VP	O
misexpressed	misexpresse	M216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
mesenchymal	mesenchymal	M252	JJ	B-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
types	type	T120	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
fat	fat	F300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
(	(	0000	(	O	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
Hmgic	Hmgic	H520	JJ	B-ADJP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
fat	fat	F300	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
adipogenesis	adipogenesis	A312	NN	B-NP	O
and	and	A530	CC	I-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
Hmgic	Hmgic	H520	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adipose	adipose	A312	NN	I-NP	O
tissue	tissue	T200	NN	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
,	,	0000	,	I-NP	O
obese	obese	O120	JJ	I-NP	B-Disease
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
complete	complete	C514	JJ	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
Hmgic	Hmgic	H520	JJ	B-NP	I-Disease
resisted	resist	R230	VBD	B-VP	O
diet	diet	D300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
.	.	0000	.	O	O

Disruption	Disruption	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
Hmgic	Hmgic	H520	NNP	B-NP	O
caused	cause	C230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
leptin	leptin	L135	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
Lepob	Lepob	L100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Lepob	Lepob	L100	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dose	dose	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
studies	study	S320	NNS	I-NP	O
implicate	implicate	I514	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
HMGIC	HMGIC	H520	NN	B-NP	O
in	in	I500	IN	B-PP	O
fat	fat	F300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
adipose	adipose	A312	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
target	target	T623	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
obesity	obesity	O123	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
relationship	relationship	R435	NN	I-NP	O
in	in	I500	IN	B-PP	O
factor	factor	F236	NN	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Factor	Factor	F236	NN	B-NP	B-Disease
X	X	X000	SYM	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
haemorrhagic	haemorrhagic	H562	JJ	I-NP	B-Disease
condition	condition	C535	NN	I-NP	I-Disease
,	,	0000	,	O	O
normally	normally	N654	RB	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
a	a	A000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
presentation	presentation	P625	NN	I-NP	O
correlates	correlate	C643	VBZ	B-VP	O
poorly	poorly	P640	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
laboratory	laboratory	L163	NN	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
factor	factor	F236	NN	I-NP	O
X	X	X000	NN	I-NP	O
(	(	0000	(	O	O
F10	F10	F000	NN	B-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
factor	factor	F236	NN	B-NP	B-Disease
X	X	X000	SYM	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
familial	familial	F540	JJ	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
yielding	yield	Y435	VBG	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Family	Family	F540	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
the	the	T000	DT	B-NP	O
contributions	contribution	C536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
F10	F10	F000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
laboratory	laboratory	L163	NN	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
modelling	modelling	M345	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
single	single	S524	JJ	B-NP	O
basepair	basepair	B216	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
flanking	flanking	F452	NN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
splicing	splicing	S142	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
and	and	A530	CC	O	O
luciferase	luciferase	L216	NN	B-NP	O
reporter	reporter	R163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
hexanucleotide	hexanucleotide	H252	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
/	/	0000	SYM	B-NP	O
deletion	deletion	D435	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
F10	F10	F000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
by	by	B000	IN	B-PP	O
reporter	reporter	R163	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
reduce	reduce	R320	VB	I-VP	O
promoter	promoter	P653	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
by	by	B000	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
20	20	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
manifesting	manifest	M512	VBG	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
possessed	possess	P230	VBD	B-VP	O
three	three	T600	CD	B-NP	O
clinically	clinically	C452	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
production	production	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
which	which	W200	WDT	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
lesion	lesion	L250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
presented	present	P625	VBN	I-VP	O
.	.	0000	.	O	O

Variation	Variation	V635	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
antigen	antigen	A532	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
relatives	relative	R431	NNS	I-NP	O
of	of	O100	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
significantly	significantly	S251	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
between	between	B350	IN	B-PP	O
families	family	F542	NNS	B-NP	O
than	than	T500	IN	B-PP	O
within	within	W350	IN	B-PP	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
view	view	V000	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
F10	F10	F000	NN	I-NP	O
lesion	lesion	L250	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
segregating	segregate	S262	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
given	give	G150	VBN	I-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
prime	prime	P650	JJ	I-NP	O
determinant	determinant	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
laboratory	laboratory	L163	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
such	such	S200	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
discerned	discern	D265	VBN	I-VP	O
between	between	B350	IN	B-PP	O
laboratory	laboratory	L163	NN	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
polymorphism	polymorphism	P456	NN	B-NP	O
genotype	genotype	G531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Transgenic	Transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
group	group	G610	NN	I-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
develop	develop	D141	VBP	B-VP	O
adiposity	adiposity	A312	NN	B-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
abnormally	abnormally	A156	RB	I-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
lipomas	lipoma	L152	NNS	I-NP	B-Disease
frequently	frequently	F625	RB	B-ADVP	O
create	create	C630	VBP	B-VP	O
fusion	fusion	F250	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
high	high	H200	JJ	B-NP	O
mobility	mobility	M143	NN	I-NP	O
group	group	G610	NN	I-NP	O
(	(	0000	(	O	O
HMG	HMG	H520	NN	B-NP	O
)	)	0000	)	O	O
I	I	I000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
domains	domain	D520	NNS	B-NP	O
and	and	A530	CC	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
different	different	D165	JJ	B-NP	O
presumed	presume	P625	VBN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
HMG	HMG	H520	NN	B-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HMG	HMG	H520	NN	I-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
component	component	C515	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
domains	domain	D520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
HMG	HMG	H520	NN	B-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
the	the	T000	DT	B-NP	O
ubiquitous	ubiquitous	U123	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
HMG	HMG	H520	NN	I-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
develop	develop	D141	VBP	B-VP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
abundance	abundance	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
fat	fat	F300	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
early	early	E640	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
life	life	L100	NN	B-NP	O
,	,	0000	,	O	O
show	show	S000	VBP	B-VP	O
marked	marked	M623	JJ	B-NP	O
adipose	adipose	A312	NN	I-NP	B-Disease
tissue	tissue	T200	NN	I-NP	I-Disease
inflammation	inflammation	I514	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
abnormally	abnormally	A156	RB	I-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
domains	domain	D520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
HMG	HMG	H520	NN	B-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
fusion	fusion	F250	NN	I-NP	O
partner	partner	P635	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
perturb	perturb	P636	VB	I-VP	O
adipogenesis	adipogenesis	A312	NN	B-NP	O
and	and	A530	CC	O	O
predispose	predispose	P632	VB	B-VP	O
to	to	T000	TO	B-PP	O
lipomas	lipoma	L152	NNS	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
data	datum	D300	NNS	B-NP	O
supporting	support	S163	VBG	B-VP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
utility	utility	U343	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tool	tool	T400	NN	I-NP	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
kind	kind	K530	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
benign	benign	B525	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
phosphorylates	phosphorylate	P216	VBZ	B-VP	O
p95	p95	P000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
nbs1	nbs1	N120	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
S	S	S000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phase	phase	P200	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
AT	AT	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Nijmegen	Nijmegen	N252	NN	B-NP	B-Disease
breakage	breakage	B620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
NBS	NBS	N120	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
p95	p95	P000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
share	share	S600	VBP	B-VP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	B-Disease
instability	instability	I523	NN	I-NP	I-Disease
,	,	0000	,	O	O
radiation	radiation	R350	NN	B-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
and	and	A530	CC	O	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoints	checkpoint	C215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
activated	activate	A231	VBN	I-VP	O
by	by	B000	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
or	or	O600	CC	O	O
radiomimetic	radiomimetic	R353	JJ	B-NP	O
drugs	drug	D620	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
p95	p95	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
responses	response	R215	NNS	B-NP	O
to	to	T000	TO	B-PP	O
DNA	DNA	D500	NN	B-NP	O
double	double	D140	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
breaks	break	B620	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
similarities	similarity	S546	NNS	I-NP	O
between	between	B350	IN	B-PP	O
AT	AT	A300	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
NBS	NBS	N120	NN	I-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
evaluated	evaluate	E143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
between	between	B350	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
p95	p95	P000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
.	.	0000	.	O	O

Activation	Activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
by	by	B000	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
and	and	A530	CC	I-NP	O
induction	induction	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
responses	response	R215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
NBS	NBS	N120	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
p95	p95	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
signalling	signalling	S254	NN	B-NP	O
to	to	T000	TO	B-PP	O
ATM	ATM	A350	NN	B-NP	O
after	after	A136	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
p95	p95	P000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
nbs1	nbs1	N120	NN	I-NP	O
was	be	W200	VBD	B-VP	O
phosphorylated	phosphorylate	P216	VBN	I-VP	O
on	on	O500	IN	B-PP	O
serine	serine	S650	NN	B-NP	O
343	343	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
after	after	A136	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
p95	p95	P000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
construct	construct	C523	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
site	site	S300	NN	I-NP	O
abrogated	abrogate	A162	VBD	B-VP	O
an	an	A500	DT	B-NP	O
S	S	S000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phase	phase	P200	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
compensate	compensate	C515	VB	I-VP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
NBS	NBS	N120	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
link	link	L520	VBP	B-VP	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
p95	p95	P000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
nbs1	nbs1	N120	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
signalling	signalling	S254	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
an	an	A500	DT	B-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
similarities	similarity	S546	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
diseases	disease	D200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Understanding	Understand	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Fragile	Fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
mental	mental	M534	JJ	I-NP	I-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
mainly	mainly	M540	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
massive	massive	M210	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
CGG	CGG	C200	NN	B-NP	O
triplet	triplet	T614	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
mental	mental	M534	JJ	I-NP	I-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
FMR1	FMR1	F560	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CGG	CGG	C200	NN	I-NP	O
triplet	triplet	T614	JJ	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
hypermethylated	hypermethylate	H165	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
repressed	repress	R162	VBN	I-VP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
FMRP	FMRP	F561	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
subsequent	subsequent	S125	JJ	B-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
.	.	0000	.	O	O

FMRP	FMRP	F561	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
shuttles	shuttle	S342	VBZ	B-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
and	and	A530	CC	I-NP	O
cytoplasm	cytoplasm	C314	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
translation	translation	T652	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
polyribosomes	polyribosome	P461	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
rough	rough	R200	JJ	I-NP	O
endoplasmic	endoplasmic	E531	JJ	I-NP	O
reticulum	reticulum	R324	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
discuss	discuss	D200	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
progress	progress	P626	NN	I-NP	O
made	make	M300	VBN	B-VP	O
towards	towards	T632	IN	B-PP	O
understanding	understand	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
CGG	CGG	C200	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
and	and	A530	CC	O	O
physiological	physiological	P242	JJ	B-NP	O
function	function	F523	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
FMRP	FMRP	F561	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
will	will	W400	MD	B-VP	O
not	not	N300	RB	I-VP	O
only	only	O540	RB	I-VP	O
help	help	H410	VB	I-VP	O
to	to	T000	TO	I-VP	O
illuminate	illuminate	I453	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
class	class	C420	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
diseases	disease	D200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
trinucleotide	trinucleotide	T652	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
provide	provide	P613	VBP	B-VP	O
an	an	A500	DT	B-NP	O
avenue	avenue	A150	NN	I-NP	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
aspects	aspect	A212	NNS	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
cognition	cognition	C253	NN	I-NP	O
and	and	A530	CC	I-NP	O
intelligence	intelligence	I534	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Haploinsufficiency	Haploinsufficiency	H145	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
transcription	transcription	T652	NN	I-NP	I-Disease
factors	factor	F236	NNS	I-NP	I-Disease
FOXC1	FOXC1	F200	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
FOXC2	FOXC2	F200	NN	I-NP	I-Disease
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
aberrant	aberrant	A165	JJ	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Anterior	Anterior	A536	JJ	B-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
developmental	developmental	D141	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
Axenfeld	Axenfeld	A251	NNP	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Rieger	Rieger	R260	NNP	B-NP	I-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
(	(	0000	(	O	O
ARA	ARA	A600	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
variably	variably	V614	RB	B-ADVP	O
associate	associate	A230	VBP	B-VP	O
with	with	W300	IN	B-PP	O
harmfully	harmfully	H651	RB	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
intraocular	intraocular	I536	JJ	I-NP	O
pressure	pressure	P626	NN	I-NP	O
(	(	0000	(	O	O
IOP	IOP	I100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
glaucoma	glaucoma	G425	NN	B-NP	B-Disease
.	.	0000	.	O	O

Clinically	Clinically	C452	RB	B-NP	O
observed	observe	O126	VBN	I-NP	O
dysgenesis	dysgenesis	D252	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
correlate	correlate	C643	VB	I-VP	O
with	with	W300	IN	B-PP	O
IOP	IOP	I100	NN	B-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
etiology	etiology	E342	NN	I-NP	O
of	of	O100	IN	B-PP	O
glaucoma	glaucoma	G425	NN	B-NP	B-Disease
development	development	D141	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
understood	understand	U536	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
forkhead	forkhead	F623	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
Foxc1	Foxc1	F200	NN	I-NP	O
(	(	0000	(	O	O
formerly	formerly	F656	RB	B-ADVP	O
Mf1	Mf1	M100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Foxc2	Foxc2	F200	NN	B-NP	O
(	(	0000	(	O	O
formerly	formerly	F656	RB	B-NP	O
Mfh1	Mfh1	M100	NN	I-NP	O
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mesenchyme	mesenchyme	M252	NN	I-NP	O
from	from	F650	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
drainage	drainage	D652	NN	I-NP	O
structures	structure	S362	NNS	I-NP	O
derive	derive	D610	VBP	B-VP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
Foxc1	Foxc1	F200	NN	B-NP	O
,	,	0000	,	O	O
FKHL7	FKHL7	F240	NN	B-NP	O
,	,	0000	,	O	O
cause	cause	C200	VBP	B-VP	O
dominant	dominant	D530	JJ	B-NP	O
anterior	anterior	A536	JJ	I-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
glaucoma	glaucoma	G425	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Foxc1	Foxc1	F200	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
anterior	anterior	A536	JJ	B-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
reported	report	R163	VBN	B-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
include	include	I524	VBP	B-VP	O
small	small	S540	JJ	B-NP	O
or	or	O600	CC	I-NP	O
absent	absent	A125	JJ	I-NP	O
Schlemms	Schlemms	S245	NNP	I-NP	O
canal	canal	C540	NN	I-NP	O
,	,	0000	,	O	O
aberrantly	aberrantly	A165	RB	B-ADVP	O
developed	develop	D141	VBD	B-VP	O
trabecular	trabecular	T612	JJ	B-NP	O
meshwork	meshwork	M262	NN	I-NP	O
,	,	0000	,	O	O
iris	iris	I620	NN	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
severely	severely	S164	RB	B-NP	O
eccentric	eccentric	E253	JJ	I-NP	O
pupils	pupil	P142	NNS	I-NP	O
and	and	A530	CC	O	O
displaced	displace	D214	VBD	B-VP	O
Schwalbes	Schwalbes	S241	NNP	B-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinically	clinically	C452	RB	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
varies	vary	V620	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
background	background	B265	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
eyes	eye	E200	NNS	I-NP	O
,	,	0000	,	O	O
collagen	collagen	C425	NN	B-NP	O
bundles	bundle	B534	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
half	half	H410	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
diameter	diameter	D536	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
collagen	collagen	C425	NN	B-NP	O
and	and	A530	CC	O	O
elastic	elastic	E423	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
very	very	V600	RB	B-ADJP	O
sparse	sparse	S162	JJ	I-ADJP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
abnormalities	abnormality	A156	NNS	B-NP	O
in	in	I500	IN	B-PP	O
extracellular	extracellular	E236	JJ	B-NP	O
matrix	matrix	M362	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
or	or	O600	CC	I-NP	O
organization	organization	O625	NN	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
the	the	T000	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ocular	ocular	O246	JJ	B-NP	O
drainage	drainage	D652	NN	I-NP	O
structures	structure	S362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Foxc1	Foxc1	F200	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
,	,	0000	,	O	O
IOP	IOP	I100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
mice	mouse	M200	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
all	all	A400	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
backgrounds	background	B265	NNS	I-NP	O
and	and	A530	CC	B-PP	O
at	at	A300	IN	B-PP	O
all	all	A400	DT	B-NP	O
ages	age	A200	NNS	I-NP	O
.	.	0000	.	O	O

Similar	Similar	S546	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Foxc2	Foxc2	F200	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
FKHL14	FKHL14	F240	NN	I-NP	O
in	in	I500	IN	B-PP	O
32	32	0000	CD	B-NP	O
ARA	ARA	A600	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Foxc1	Foxc1	F200	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Foxc2	Foxc2	F200	CD	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
mice	mouse	M200	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
useful	useful	U214	JJ	B-NP	O
models	model	M342	NNS	I-NP	O
for	for	F600	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
anterior	anterior	A536	JJ	B-NP	O
segment	segment	S253	NN	I-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
anomalies	anomaly	A542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
interact	interact	I536	VBP	B-VP	O
with	with	W300	IN	B-PP	O
Foxc1	Foxc1	F200	NN	B-NP	O
and	and	A530	CC	I-NP	O
Foxc2	Foxc2	F200	NN	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
FKHL7	FKHL7	F240	NN	B-NP	O
and	and	A530	CC	O	O
FKHL14	FKHL14	F240	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
a	a	A000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
elevated	elevated	E413	JJ	B-NP	O
IOP	IOP	I100	NN	I-NP	O
and	and	A530	CC	I-NP	O
glaucoma	glaucoma	G425	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

(	(	0000	(	O	O
Over	Over	O160	IN	B-PP	O
)	)	0000	)	O	O
correction	correction	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
YAC	YAC	Y200	NN	B-NP	O
transgenics	transgenic	T652	NNS	I-NP	O
:	:	0000	:	O	O
behavioral	behavioral	B164	JJ	B-NP	O
and	and	A530	CC	I-NP	O
physical	physical	P240	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

Fragile	Fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
involving	involve	I514	VBG	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
remains	remain	R520	VBZ	B-VP	O
undetermined	undetermined	U536	JJ	B-ADJP	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
.	.	0000	.	O	O

Fmr1	Fmr1	F560	NN	B-NP	O
knockout	knockout	K523	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
a	a	A000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
some	some	S500	DT	B-NP	O
similarities	similarity	S546	NNS	I-NP	O
to	to	T000	TO	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
macroorchidism	macroorchidism	M262	NN	B-NP	B-Disease
and	and	A530	CC	O	O
behavioral	behavioral	B164	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
step	step	S310	NN	I-NP	O
toward	toward	T630	IN	B-PP	O
understanding	understand	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
FMR1	FMR1	F560	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
determination	determination	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	NN	I-NP	O
for	for	F600	IN	B-PP	O
therapeutic	therapeutic	T613	JJ	B-NP	O
approaches	approach	A162	NNS	I-NP	O
to	to	T000	TO	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
yeast	yeast	Y230	NN	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
YAC	YAC	Y200	NN	B-NP	O
)	)	0000	)	O	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
generated	generate	G563	VBN	I-VP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Fmr1	Fmr1	F560	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
rescued	rescue	R230	VBN	I-VP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
lines	line	L520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
generated	generate	G563	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
carried	carry	C630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
FMR1	FMR1	F560	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
with	with	W300	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
flanking	flanking	F452	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
supported	support	S163	VBD	B-VP	O
production	production	P632	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
FMRP	FMRP	F561	NN	B-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
levels	level	L142	NNS	B-NP	O
10	10	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
15	15	0000	CD	I-NP	O
times	time	T520	NNS	I-NP	O
that	that	T300	IN	I-NP	O
of	of	O100	IN	B-PP	O
endogenous	endogenous	E532	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
tissue	tissue	T200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

Macro	Macro	M260	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
orchidism	orchidism	O623	NN	B-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
knockout	knockout	K523	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
indicating	indicate	I532	VBG	B-VP	O
functional	functional	F523	JJ	B-NP	O
rescue	rescue	R200	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Given	Give	G150	VBN	B-PP	O
the	the	T000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
behavioral	behavioral	B164	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fmr1	Fmr1	F560	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
thorough	thorough	T620	JJ	I-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Fmr1	Fmr1	F560	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
using	use	U252	VBG	B-VP	O
additional	additional	A354	JJ	B-NP	O
behavioral	behavioral	B164	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
displayed	display	D214	VBD	B-VP	O
reduced	reduce	R323	VBN	B-NP	O
anxiety	anxiety	A523	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
responses	response	R215	NNS	I-NP	O
with	with	W300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
exploratory	exploratory	E214	JJ	I-NP	O
behavior	behavior	B160	NN	I-NP	O
.	.	0000	.	O	O

FMR1	FMR1	F560	NN	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
transgenic	transgenic	T652	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
overexpressing	overexpresse	O162	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
did	do	D300	VBD	B-VP	O
produce	produce	P632	VB	I-VP	O
opposing	oppose	O125	VBG	I-VP	O
behavioral	behavioral	B164	JJ	B-NP	O
responses	response	R215	NNS	I-NP	O
and	and	A530	CC	O	O
additional	additional	A354	JJ	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
behaviors	behavior	B162	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
significant	significant	S251	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
for	for	F600	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
since	since	S520	IN	B-PP	O
overexpression	overexpression	O162	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
harbor	harbor	H616	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
own	own	O500	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Transgenic	Transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
large	large	L620	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
expanded	expand	E215	VBN	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
mimic	mimic	M520	VBP	B-VP	O
closely	closely	C424	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3UTR	3UTR	U360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
high	high	H200	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
instability	instability	I523	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
observed	observe	O126	VBN	I-VP	O
through	through	T620	IN	B-PP	O
successive	successive	S210	JJ	B-NP	O
generations	generation	G563	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
generally	generally	G564	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
tissues	tissue	T200	NNS	B-NP	O
from	from	F650	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
increases	increase	I526	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
large	large	L620	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
20	20	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
55	55	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
>	>	0000	JJR	I-NP	O
300	300	0000	CD	I-NP	O
CTG	CTG	C320	NN	I-NP	O
,	,	0000	,	O	O
cloned	clone	C453	VBN	B-VP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
affected	affect	A123	VBN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
large	large	L620	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
flanking	flanking	F452	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
reproduced	reproduce	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
bias	bias	B200	NN	I-NP	O
towards	towards	T632	IN	B-PP	O
expansions	expansion	E215	NNS	B-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
size	size	S200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
instability	instability	I523	NN	B-NP	O
,	,	0000	,	O	O
increasing	increase	I526	VBG	B-VP	O
with	with	W300	IN	B-PP	O
age	age	A200	NN	B-NP	O
,	,	0000	,	O	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
observe	observe	O126	VB	I-VP	O
dramatic	dramatic	D653	JJ	B-NP	O
expansions	expansion	E215	NNS	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
big	big	B200	JJ	B-NP	O
jumps	jump	J512	NNS	I-NP	O
over	over	O160	IN	B-PP	O
several	several	S164	JJ	B-NP	O
hundred	hundred	H536	CD	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
model	model	M340	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
>	>	0000	SYM	B-ADVP	O
300	300	0000	CD	B-NP	O
CTG	CTG	C320	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
to	to	T000	TO	B-VP	O
show	show	S000	VB	I-VP	O
instability	instability	I523	NN	B-NP	O
so	so	S000	RB	B-VP	O
close	close	C420	RB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
situation	situation	S350	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
three	three	T600	CD	I-NP	O
models	model	M342	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
different	different	D165	JJ	B-NP	O
sizes	size	S200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
provide	provide	P613	VBP	B-VP	O
insight	insight	I523	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
modulating	modulate	M343	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Inactivation	Inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Friedreich	Friedreich	F636	NNP	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
early	early	E640	JJ	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	B-Disease
lethality	lethality	L343	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NN	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
cases	case	C200	NNS	I-NP	O
by	by	B000	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
frataxin	frataxin	F632	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
conserved	conserve	C526	VBN	B-VP	O
through	through	T620	IN	B-PP	O
evolution	evolution	E143	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
.	.	0000	.	O	O

Yeast	Yeast	Y230	NN	B-NP	O
knockout	knockout	K523	NN	I-NP	O
models	model	M342	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
histological	histological	H234	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
heart	heart	H630	NN	I-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
or	or	O600	CC	I-NP	O
autopsies	autopsy	A312	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
frataxin	frataxin	F632	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
iron	iron	I650	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
sulfur	sulfur	S416	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
pathological	pathological	P342	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
.	.	0000	.	O	O

Affected	Affect	A123	VBN	B-NP	O
human	human	H500	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
rarely	rarely	R640	RB	B-ADVP	O
available	available	A141	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
examine	examine	E250	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
by	by	B000	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Frda	Frda	F630	NNP	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
homozygous	homozygous	H520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
cause	cause	C200	VBP	B-VP	O
embryonic	embryonic	E516	JJ	B-NP	B-Disease
lethality	lethality	L343	NN	I-NP	I-Disease
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
days	day	D200	NNS	I-NP	O
after	after	A136	IN	B-PP	O
implantation	implantation	I514	NN	B-NP	O
,	,	0000	,	O	O
demonstrating	demonstrate	D523	VBG	B-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
frataxin	frataxin	F632	NN	B-NP	O
during	during	D652	IN	B-PP	O
early	early	E640	JJ	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
residual	residual	R234	JJ	B-NP	O
frataxin	frataxin	F632	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
frataxin	frataxin	F632	NN	I-NP	O
knockout	knockout	K523	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
iron	iron	I650	NN	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
during	during	D652	IN	B-PP	O
embryonic	embryonic	E516	JJ	B-NP	O
resorption	resorption	R261	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
cell	cell	C400	NN	B-NP	O
death	death	D300	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
independent	independent	I531	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Gaucher	Gaucher	G260	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
the	the	T000	DT	B-NP	O
origins	origin	O625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
N370S	N370S	N200	NN	I-NP	O
and	and	A530	CC	I-NP	O
84GG	84GG	G200	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
glucosidase	glucosidase	G423	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	O
1	1	0000	CD	I-NP	O
Gaucher	Gaucher	G260	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
GD	GD	G300	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
neuronopathic	neuronopathic	N651	JJ	I-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	B-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
glucosidase	glucosidase	G423	NN	B-NP	O
(	(	0000	(	O	O
GBA	GBA	G100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	O
1	1	0000	CD	I-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
panethnic	panethnic	P535	JJ	B-ADJP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
more	more	M600	RBR	B-ADJP	O
prevalent	prevalent	P614	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
(	(	0000	(	O	O
AJ	AJ	A200	NN	B-NP	O
)	)	0000	)	O	O
descent	descent	D253	NN	B-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
causative	causative	C231	JJ	I-NP	O
GBA	GBA	G100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
N370S	N370S	N200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
particularly	particularly	P632	RB	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	O	O
q	q	Q000	NN	B-NP	O
approximately	approximately	A162	RB	B-NP	O
.	.	0000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
84GG	84GG	G200	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
(	(	0000	(	O	O
q	q	Q000	NN	B-NP	O
approximately	approximately	A162	RB	B-NP	O
.	.	0000	.	I-NP	O
003	003	0000	CD	I-NP	O
)	)	0000	)	O	O
occurs	occur	O262	VBZ	B-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazim	Ashkenazim	A252	NNP	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
short	short	S630	JJ	B-NP	O
tandem	tandem	T535	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
(	(	0000	(	O	O
STR	STR	S360	NN	B-NP	O
)	)	0000	)	O	O
markers	marker	M626	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
map	map	M100	VB	I-VP	O
a	a	A000	DT	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
GBA	GBA	G100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
genotype	genotype	G531	NN	B-NP	O
261	261	0000	CD	I-NP	O
AJ	AJ	A200	NN	I-NP	O
N370S	N370S	N200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
60	60	0000	CD	B-NP	O
European	European	E615	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
N370S	N370S	N200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
62	62	0000	CD	B-NP	O
AJ	AJ	A200	NN	I-NP	O
84GG	84GG	G200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
four	four	F600	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
GBA	GBA	G100	NN	B-NP	O
(	(	0000	(	O	O
PKLR	PKLR	P246	NN	B-NP	O
,	,	0000	,	O	O
D1S1595	D1S1595	D200	NN	B-NP	O
,	,	0000	,	O	O
D1S2721	D1S2721	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D1S2777	D1S2777	D200	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
on	on	O500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
N370S	N370S	N200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
both	both	B300	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
note	note	N300	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
divergent	divergent	D162	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
,	,	0000	,	O	O
recurrent	recurrent	R265	JJ	B-NP	O
N370S	N370S	N200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
84GG	84GG	G200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
(	(	0000	(	O	O
LD	LD	L300	NN	B-NP	O
)	)	0000	)	O	O
delta	delta	D430	NN	B-NP	O
values	value	V420	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
N370S	N370S	N200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
greater	great	G636	JJR	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
diversity	diversity	D162	NN	I-NP	O
and	and	A530	CC	O	O
less	less	L200	JJR	B-NP	O
LD	LD	L300	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
than	than	T500	IN	B-SBAR	O
did	do	D300	VBD	O	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NN	I-NP	O
N370S	N370S	N200	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
N370S	N370S	N200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
population	population	P143	NN	I-NP	O
prior	prior	P600	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
founding	founding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Coalescence	Coalescence	C425	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
N370S	N370S	N200	NN	I-NP	O
and	and	A530	CC	I-NP	O
84GG	84GG	G200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
estimated	estimate	E235	VBD	B-VP	O
similar	similar	S546	JJ	B-NP	O
coalescence	coalescence	C425	NN	I-NP	O
times	time	T520	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
48	48	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
55	55	0000	CD	I-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
bottleneck	bottleneck	B345	NN	I-NP	O
occurring	occur	O265	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
AJ	AJ	A200	NN	I-NP	O
population	population	P143	NN	I-NP	O
during	during	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
millennium	millennium	M450	NN	I-NP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
became	become	B250	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
B27	B27	B000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
hundred	hundred	H536	CD	I-NP	O
and	and	A530	CC	I-NP	O
twenty	twenty	T530	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
eight	eight	E230	CD	I-NP	O
of	of	O100	IN	B-PP	O
145	145	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
HLA	HLA	H400	NN	B-NP	O
B27	B27	B000	NN	I-NP	O
positive	positive	P231	JJ	B-ADJP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
sero	sero	S600	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	B-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
resembling	resemble	R251	VBG	B-VP	O
peripheral	peripheral	P616	JJ	B-NP	B-Disease
psoriatic	psoriatic	P263	JJ	I-NP	I-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
and	and	A530	CC	O	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
were	be	W600	VBD	B-VP	O
B27	B27	B000	NN	B-ADJP	O
negative	negative	N231	JJ	I-ADJP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
further	further	F636	JJ	I-NP	O
B27	B27	B000	NN	I-NP	O
negative	negative	N231	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
with	with	W300	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
and	and	A530	CC	O	O
ulcerative	ulcerative	U426	JJ	B-NP	B-Disease
colitis	colitis	C432	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
with	with	W300	IN	B-PP	O
ulcerative	ulcerative	U426	JJ	B-NP	B-Disease
colitis	colitis	C432	NN	I-NP	I-Disease
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
somewhat	somewhat	S530	RB	I-NP	O
later	later	L360	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
symptoms	symptom	S513	NNS	B-NP	O
in	in	I500	IN	B-PP	O
B27	B27	B000	NN	B-NP	O
negative	negative	N231	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
interpreted	interpret	I536	VBN	I-VP	O
as	as	A200	IN	B-PP	O
suggesting	suggest	S235	VBG	B-VP	O
some	some	S500	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
with	with	W300	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
for	for	F600	IN	B-PP	O
psoriasis	psoriasis	P262	NN	B-NP	B-Disease
and	and	A530	CC	O	O
inflammatory	inflammatory	I514	JJ	B-NP	B-Disease
bowel	bowel	B400	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
being	be	B520	VBG	B-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
those	those	T200	DT	B-NP	O
who	who	W000	WP	B-NP	O
are	be	A600	VBP	B-VP	O
B27	B27	B000	NN	B-NP	O
negative	negative	N231	JJ	B-ADJP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
five	five	F100	CD	I-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-NP	B-Disease
spondylitis	spondylitis	S153	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
all	all	A400	DT	B-NP	O
B27	B27	B000	NN	I-NP	O
positive	positive	P231	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
instance	instance	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
disassociation	disassociation	D235	NN	B-NP	O
of	of	O100	IN	B-PP	O
B27	B27	B000	NN	B-NP	O
and	and	A530	CC	I-NP	O
spondylitis	spondylitis	S153	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
was	be	W200	VBD	B-VP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
had	have	H300	VBD	B-VP	O
ulcerative	ulcerative	U426	JJ	B-NP	B-Disease
colitis	colitis	C432	NN	I-NP	I-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
spondylitis	spondylitis	S153	NN	B-NP	B-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
B27	B27	B000	NN	I-NP	O
positive	positive	P231	JJ	I-NP	O
fathers	father	F362	NNS	I-NP	O
3	3	0000	CD	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
definite	definite	D153	JJ	B-NP	O
ankylosing	ankylose	A524	VBG	I-NP	B-Disease
spondylitis	spondylitis	S153	NN	I-NP	I-Disease
(	(	0000	(	O	O
23	23	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
provide	provide	P613	VB	I-VP	O
evidence	evidence	E135	NN	B-NP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
concept	concept	C521	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
B27	B27	B000	NN	B-NP	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
favour	favour	F160	VBP	B-VP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
environmental	environmental	E516	JJ	I-NP	O
event	event	E153	NN	I-NP	O
affecting	affect	A123	VBG	B-VP	O
approximately	approximately	A162	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
fifth	fifth	F130	NN	I-NP	O
of	of	O100	IN	B-PP	O
B27	B27	B000	NN	B-NP	O
positive	positive	P231	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
to	to	T000	TO	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Founder	Founder	F536	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Polish	Polish	P420	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
a	a	A000	DT	B-NP	O
hospital	hospital	H213	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
possible	possible	P214	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
founder	founder	F536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Polish	Polish	P420	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
group	group	G610	NN	I-NP	O
consisted	consist	C523	VBD	B-VP	O
of	of	O100	IN	B-PP	O
66	66	0000	CD	B-NP	O
Polish	Polish	P420	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
related	related	R430	JJ	I-NP	O
females	female	F542	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
cancer	cancer	C526	NN	I-VP	B-Disease
diagnosed	diagnose	D252	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
females	female	F542	NNS	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
<	<	0000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
26	26	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
36	36	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
breast	breast	B623	NN	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
prepared	prepare	P616	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
affected	affect	A123	VBD	B-VP	O
woman	woman	W500	NN	B-NP	O
from	from	F650	IN	B-PP	O
each	each	E200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
observed	observe	O126	VBN	B-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
35	35	0000	CD	B-NP	O
(	(	0000	(	O	O
53	53	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
66	66	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
67	67	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
34	34	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
35	35	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
;	;	0000	:	O	O
five	five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
total	total	T340	JJ	B-NP	O
,	,	0000	,	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
33	33	0000	CD	B-NP	O
(	(	0000	(	O	O
94	94	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
35	35	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
detected	detect	D323	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
-	-	0000	HYPH	O	O
5382insC	5382insC	I520	NN	B-NP	O
,	,	0000	,	O	O
C61G	C61G	C200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
4153delA	4153delA	D400	NN	B-NP	O
-	-	0000	HYPH	O	O
accounted	account	A253	VBN	B-VP	O
for	for	F600	IN	B-PP	O
51	51	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
20	20	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
11	11	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	B-Disease
long	long	L520	JJ	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
CoA	CoA	C000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
Israeli	Israeli	I264	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
:	:	0000	:	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
with	with	W300	IN	B-PP	O
P65L	P65L	P400	NN	B-NP	O
and	and	A530	CC	I-NP	O
K247Q	K247Q	K200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
former	former	F656	JJ	I-NP	O
being	be	B520	VBG	B-VP	O
an	an	A500	DT	B-NP	O
exonic	exonic	E252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
skipping	skipping	S215	NN	I-NP	O
.	.	0000	.	O	O

Very	Very	V600	JJ	B-NP	B-Disease
long	long	L520	JJ	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
CoA	CoA	C000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VLCAD	VLCAD	V423	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
life	life	L100	NN	I-NP	O
-	-	0000	HYPH	O	O
threatening	threaten	T635	VBG	B-VP	O
disorder	disorder	D263	NN	B-NP	O
of	of	O100	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-VP	O
-	-	0000	HYPH	O	O
oxidation	oxidation	O235	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
four	four	F600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
childhood	childhood	C430	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
and	and	A530	CC	O	O
high	high	H200	JJ	B-NP	O
mortality	mortality	M634	NN	I-NP	O
.	.	0000	.	O	O

Immunoblot	Immunoblot	I514	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
VLCAD	VLCAD	V423	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
size	size	S200	NN	I-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
aberrant	aberrant	A165	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
(	(	0000	(	O	O
4kDa	4kDa	K300	NN	B-NP	O
smaller	small	S546	JJR	B-ADJP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
,	,	0000	,	O	O
null	null	N400	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
patient	patient	P353	NN	I-NP	O
2	2	0000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
del	del	D400	NN	B-NP	O
4	4	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
at	at	A300	IN	B-PP	O
798	798	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
801	801	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
patient	patient	P353	NN	B-NP	O
3	3	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
65C	65C	C000	NN	I-NP	O
>	>	0000	SYM	O	O
A	A	A000	NN	B-NP	O
(	(	0000	(	O	O
S22X	S22X	S200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Patient	Patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
two	two	T000	CD	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
194C	194C	C000	NN	I-NP	O
>	>	0000	JJ	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
(	(	0000	(	O	O
P65L	P65L	P400	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
739A	739A	A000	NN	B-NP	O
>	>	0000	SYM	O	O
C	C	C000	NN	B-NP	O
transversion	transversion	T652	NN	I-NP	O
(	(	0000	(	O	O
K247Q	K247Q	K200	NN	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
P65L	P65L	P400	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
change	change	C520	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
reduce	reduce	R320	VB	I-VP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
change	change	C520	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
skipping	skipping	S215	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
K247Q	K247Q	K200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
drastic	drastic	D623	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
verified	verify	V613	VBD	B-VP	O
these	these	T200	DT	B-NP	O
events	event	E153	NNS	I-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
splicing	splicing	S142	NN	I-NP	O
experiments	experiment	E216	NNS	I-NP	O
and	and	A530	CC	O	O
transient	transient	T652	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
P65L	P65L	P400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
locates	locate	L232	VBZ	B-VP	O
11	11	0000	CD	B-NP	O
bases	base	B200	NNS	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
exonic	exonic	E252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
which	which	W200	WDT	B-NP	O
affects	affect	A123	VBZ	B-VP	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
splicing	splicing	S142	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Submicroscopic	Submicroscopic	S152	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
cousins	cousin	C252	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
grandmatrilineal	grandmatrilineal	G653	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
:	:	0000	:	O	O
effects	effect	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
imprinting	imprinting	I516	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
critical	critical	C632	JJ	B-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
15q11	15q11	Q000	NN	B-NP	O
-	-	0000	HYPH	O	O
q13	q13	Q000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
subject	subject	S123	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
imprinting	imprinting	I516	NN	B-NP	O
.	.	0000	.	O	O

PWS	PWS	P200	NN	B-NP	B-Disease
becomes	become	B252	VBZ	B-VP	O
apparent	apparent	A165	JJ	B-ADJP	O
when	when	W500	WRB	B-ADVP	O
genes	gene	G520	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternally	paternally	P365	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
PWS	PWS	P200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
first	first	F623	JJ	I-NP	O
cousin	cousin	C250	NN	I-NP	O
both	both	B300	DT	B-NP	O
have	have	H100	VBP	B-VP	O
PWS	PWS	P200	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
cytogenetically	cytogenetically	C325	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
karyotypes	karyotype	K631	NNS	I-NP	O
.	.	0000	.	O	O

Fluorescence	Fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
,	,	0000	,	B-NP	O
but	but	B300	CC	I-NP	O
not	not	N300	RB	I-NP	O
the	the	T000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
associated	associate	A230	VBN	I-NP	O
loci	locus	L200	NNS	I-NP	O
D15S10	D15S10	D200	NN	I-NP	O
,	,	0000	,	O	O
D15S11	D15S11	D200	NN	B-NP	O
,	,	0000	,	O	O
D15S63	D15S63	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
GABRB3	GABRB3	G161	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cousins	cousin	C252	NNS	I-NP	O
fathers	father	F362	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
aunts	aunt	A532	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
clinically	clinically	C452	RB	B-ADJP	O
normal	normal	N654	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
grandmother	grandmother	G653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cousins	cousin	C252	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
deceased	decease	D230	VBN	I-VP	O
and	and	A530	CC	O	O
not	not	N300	RB	B-ADJP	O
available	available	A141	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
study	study	S300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
grandfather	grandfather	G653	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
for	for	F600	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
methylation	methylation	M343	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
D15S63	D15S63	D200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
abnormality	abnormality	A156	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
center	center	C536	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

"	"	0000	``	B-NP	O
Grandmatrilineal	Grandmatrilineal	G653	JJ	I-NP	O
"	"	0000	''	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
when	when	W500	WRB	B-ADVP	O
a	a	A000	DT	B-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
imprinted	imprint	I516	VBN	I-NP	O
,	,	0000	,	I-NP	O
paternally	paternally	P365	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
having	have	H152	VBG	B-VP	O
affected	affect	A123	VBN	I-VP	O
grandchildren	grandchild	G653	NNS	B-NP	O
through	through	T620	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
sons	son	S520	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
,	,	0000	,	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
become	become	B250	VB	I-VP	O
evident	evident	E135	JJ	B-ADJP	O
as	as	A200	RB	B-ADVP	O
long	long	L520	RB	I-ADVP	O
as	as	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
passed	pass	P230	VBN	I-VP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
matrilineal	matrilineal	M364	JJ	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
imprinting	imprinting	I516	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
glycine	glycine	G425	NN	I-NP	O
decarboxylase	decarboxylase	D261	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
GLDC	GLDC	G432	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
processed	process	P623	VBN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
(	(	0000	(	O	O
psiGLDC	psiGLDC	P243	NN	B-NP	O
)	)	0000	)	O	O
:	:	0000	:	O	O
their	their	T600	PRP$	B-NP	O
structure	structure	S362	NN	I-NP	O
and	and	A530	CC	I-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
nonketotic	nonketotic	N523	JJ	B-NP	B-Disease
hyperglycinemia	hyperglycinemia	H162	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
decarboxylase	decarboxylase	D261	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
GLDC	GLDC	G432	NN	B-NP	O
)	)	0000	)	O	O
cause	cause	C200	VBP	B-VP	O
nonketotic	nonketotic	N523	JJ	B-NP	B-Disease
hyperglycinemia	hyperglycinemia	H162	NN	I-NP	I-Disease
(	(	0000	(	O	O
NKH	NKH	N200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
in	in	I500	IN	B-PP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
born	bear	B650	VBN	I-NP	I-Disease
error	error	E600	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
metabolism	metabolism	M314	NN	B-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
neurological	neurological	N642	JJ	I-NP	B-Disease
disturbance	disturbance	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
GLDC	GLDC	G432	NN	B-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
(	(	0000	(	O	O
psiGLDC	psiGLDC	P243	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
studied	study	S300	VBD	B-VP	O
their	their	T600	PRP$	B-NP	O
expression	expression	E216	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
NKH	NKH	N200	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
GLDC	GLDC	G432	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
spans	span	S152	NNS	I-NP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
135	135	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
25	25	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
and	and	A530	CC	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
adhere	adhere	A360	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
canonical	canonical	C524	JJ	I-NP	O
GT	GT	G300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AG	AG	A200	NN	I-NP	O
rule	rule	R400	NN	I-NP	O
,	,	0000	,	O	O
except	except	E213	IN	B-PP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
21	21	0000	CD	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	JJ	I-NP	O
form	form	F650	NN	I-NP	O
GC	GC	G200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
used	use	U230	VBN	I-VP	O
instead	instead	I523	RB	B-PP	O
of	of	O100	IN	I-PP	O
GT	GT	G300	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
site	site	S300	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
residue	residue	R230	NN	I-NP	O
163	163	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
translation	translation	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
triplet	triplet	T614	VBN	B-VP	O
by	by	B000	IN	B-PP	O
primer	primer	P656	NN	B-NP	O
extension	extension	E235	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
psiGLDC	psiGLDC	P243	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
and	and	A530	CC	I-NP	O
shares	share	S620	NNS	I-NP	O
97	97	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
GLDC	GLDC	G432	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
psiGLDC	psiGLDC	P243	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
processed	process	P623	VBN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
that	that	T300	WDT	B-NP	O
arose	arise	A620	VBD	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
GLDC	GLDC	G432	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
about	about	A130	RB	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
8	8	0000	CD	I-NP	O
million	million	M450	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
.	.	0000	.	O	O

RNA	RNA	R500	NN	B-NP	O
blotting	blotting	B435	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
GLDC	GLDC	G432	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
liver	liver	L160	NN	I-NP	O
,	,	0000	,	O	O
kidney	kidney	K350	NN	B-NP	O
,	,	0000	,	O	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
placenta	placenta	P425	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
examined	examine	E253	VBN	I-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
NKH	NKH	N200	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
GLDC	GLDC	G432	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
lymphoblasts	lymphoblast	L514	NNS	I-NP	O
.	.	0000	.	O	O

Exons	Exon	E252	NNS	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
GLDC	GLDC	G432	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
those	those	T200	DT	B-NP	O
from	from	F650	IN	B-PP	O
control	control	C536	NN	B-NP	O
subjects	subject	S123	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
30	30	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
devised	devise	D123	VBN	I-VP	O
a	a	A000	DT	B-NP	O
semi	semi	S500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
to	to	T000	TO	B-VP	O
estimate	estimate	E235	VB	I-VP	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
GLDC	GLDC	G432	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
psiGLDC	psiGLDC	P243	NN	B-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
internal	internal	I536	JJ	I-NP	O
control	control	C536	NN	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
the	the	T000	DT	B-NP	O
homozygosity	homozygosity	H523	NN	I-NP	O
and	and	A530	CC	I-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Structural	Structural	S362	JJ	B-NP	O
information	information	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
GLDC	GLDC	G432	NN	B-NP	O
and	and	A530	CC	I-NP	O
psiGLDC	psiGLDC	P243	NN	I-NP	O
should	should	S430	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
NKH	NKH	N200	NN	B-NP	B-Disease
.	.	0000	.	O	O

De	De	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
exon	exon	E250	NN	I-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mouse	mouse	M200	NN	I-NP	O
embryos	embryo	E516	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
to	to	T000	TO	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
imprint	imprint	I516	NN	I-NP	O
switch	switch	S320	NN	I-NP	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
neurogenetic	neurogenetic	N625	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
infantile	infantile	I515	JJ	B-NP	B-Disease
hypotonia	hypotonia	H135	NN	I-NP	I-Disease
,	,	0000	,	O	O
gonadal	gonadal	G534	JJ	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
obsessive	obsessive	O121	JJ	B-NP	O
behaviour	behaviour	B160	NN	I-NP	O
and	and	A530	CC	O	O
neonatal	neonatal	N534	JJ	B-NP	O
feeding	feeding	F352	NN	I-NP	O
difficulties	difficulty	D124	NNS	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
hyperphagia	hyperphagia	H161	NN	B-NP	B-Disease
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
profound	profound	P615	JJ	B-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
.	.	0000	.	O	O

PWS	PWS	P200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
information	information	I516	NN	I-NP	O
at	at	A300	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
imprinted	imprint	I516	VBN	B-VP	O
,	,	0000	,	O	O
paternally	paternally	P365	RB	B-NP	O
expressed	express	E216	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
MKRN3	MKRN3	M265	NN	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
NDN	NDN	N350	NN	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
NDNL1	NDNL1	N354	NN	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
IPW	IPW	I100	NN	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
9	9	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
two	two	T000	CD	B-NP	O
poorly	poorly	P640	RB	I-NP	O
characterized	characterize	C623	VBN	I-NP	O
framents	frament	F653	NNS	I-NP	O
designated	designate	D253	VBN	B-VP	O
PAR	PAR	P600	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
PAR	PAR	P600	NN	I-NP	O
-	-	0000	HYPH	O	O
5	5	0000	CD	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	I-NP	O
10	10	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Imprinting	Imprinting	I516	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
involves	involve	I514	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
bipartite	bipartite	B163	JJ	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
centre	centre	C536	NN	I-NP	O
(	(	0000	(	O	O
IC	IC	I200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
overlaps	overlap	O164	VBZ	B-VP	O
SNRPN	SNRPN	S561	NN	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
11	11	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SNRPN	SNRPN	S561	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
/	/	0000	SYM	B-VP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
IC	IC	I200	NN	I-NP	O
element	element	E453	NN	I-NP	O
)	)	0000	)	O	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
impair	impair	I516	VB	I-VP	O
the	the	T000	DT	B-NP	O
establishment	establishment	E231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
imprint	imprint	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
and	and	A530	CC	O	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mosaic	mosaic	M200	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
IC	IC	I200	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
on	on	O500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
acquired	acquire	A263	VBN	I-VP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
methylation	methylation	M343	NN	I-NP	O
imprint	imprint	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
made	make	M300	VBN	I-VP	O
identical	identical	I353	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
chimaeric	chimaeric	C562	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
generated	generate	G563	VBN	B-VP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
(	(	0000	(	O	O
ES	ES	E200	NN	B-NP	O
)	)	0000	)	O	O
cell	cell	C400	NN	B-NP	O
lines	line	L520	NNS	I-NP	O
harbouring	harbour	H616	VBG	B-VP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
IC	IC	I200	NN	I-NP	O
element	element	E453	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
only	only	O540	RB	O	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
establishment	establishment	E231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
imprint	imprint	I516	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
postzygotic	postzygotic	P232	JJ	I-NP	O
maintenance	maintenance	M535	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
deficient	deficient	D125	JJ	B-ADJP	B-Disease
in	in	I500	IN	B-PP	I-Disease
Six5	Six5	S200	CD	B-NP	I-Disease
develop	develop	D141	JJ	I-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Expansion	Expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
UTR	UTR	U360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM1	DM1	D500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19	19	0000	CD	I-NP	O
causes	cause	C200	VBZ	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
dominantly	dominantly	D534	RB	I-NP	B-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
myotonia	myotonia	M350	NN	I-NP	B-Disease
,	,	0000	,	O	O
cataracts	cataract	C362	NNS	B-NP	B-Disease
and	and	A530	CC	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
conduction	conduction	C532	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Targeted	Target	T623	VBN	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dm15	Dm15	D500	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
orthologue	orthologue	O634	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
,	,	0000	,	O	O
produced	produce	P632	VBD	B-VP	O
mice	mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
myopathy	myopathy	M130	NN	I-NP	B-Disease
and	and	A530	CC	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
conduction	conduction	C532	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
without	without	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
myotonia	myotonia	M350	NNS	B-NP	B-Disease
and	and	A530	CC	I-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
others	other	O362	NNS	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
repeat	repeat	R130	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
decreases	decrease	D262	VBZ	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
SIX5	SIX5	S200	NN	I-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
7	7	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
SIX5	SIX5	S200	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
disrupted	disrupt	D261	VBD	B-VP	O
mouse	mouse	M200	NN	B-NP	O
Six5	Six5	S200	CD	I-NP	O
by	by	B000	IN	B-PP	O
replacing	replace	R142	VBG	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
galactosidase	galactosidase	G423	NN	I-NP	O
reporter	reporter	R163	NN	I-NP	O
.	.	0000	.	O	O

Six5	Six5	S200	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
reporter	reporter	R163	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
developing	develop	D141	VBG	I-NP	O
lens	lens	L520	NN	I-NP	O
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
abnormalities	abnormality	A156	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
skeletal	skeletal	S243	JJ	B-NP	I-Disease
muscle	muscle	M240	NN	I-NP	I-Disease
function	function	F523	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
developed	develop	D141	VBD	B-VP	O
lenticular	lenticular	L532	JJ	B-NP	B-Disease
opacities	opacity	O123	NNS	I-NP	I-Disease
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
rate	rate	R300	NN	I-NP	O
than	than	T500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
SIX5	SIX5	S200	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
contributes	contribute	C536	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
cataract	cataract	C362	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
multigenic	multigenic	M432	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Six5	Six5	S200	CD	B-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
ocular	ocular	O246	JJ	B-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
wasting	wasting	W235	NN	I-NP	I-Disease
,	,	0000	,	O	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
,	,	0000	,	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
arrhythmia	arrhythmia	A635	NN	I-NP	I-Disease
,	,	0000	,	O	O
hyperinsulinaemia	hyperinsulinaemia	H165	NN	B-NP	B-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ocular	ocular	O246	JJ	B-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
-	-	0000	HYPH	O	O
encoding	encode	E523	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
SIX5	SIX5	S200	NN	B-NP	O
(	(	0000	(	O	O
formerly	formerly	F656	RB	B-NP	O
DMAHP	DMAHP	D510	NN	I-NP	O
;	;	0000	:	O	O
refs	ref	R120	NNS	B-NP	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
three	three	T600	CD	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
by	by	B000	IN	B-PP	O
which	which	W200	WDT	B-NP	O
CTG	CTG	C320	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
can	can	C500	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

First	First	F623	RB	B-ADVP	O
,	,	0000	,	O	O
repeat	repeat	R130	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
may	may	M000	MD	B-VP	O
alter	alter	A436	VB	I-VP	O
the	the	T000	DT	B-NP	O
processing	processing	P625	NN	I-NP	O
or	or	O600	CC	I-NP	O
transport	transport	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
consequently	consequently	C525	RB	B-VP	O
reduce	reduce	R320	VB	I-VP	O
DMPK	DMPK	D512	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Second	Second	S253	RB	B-ADVP	O
,	,	0000	,	O	O
CTG	CTG	C320	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
may	may	M000	MD	B-VP	O
establish	establish	E231	VB	I-VP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterochromatin	heterochromatin	H362	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
decrease	decrease	D262	VB	B-VP	O
SIX5	SIX5	S200	NN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
.	.	0000	.	O	O

Third	Third	T630	JJ	B-NP	O
,	,	0000	,	I-NP	O
toxic	toxic	T200	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
intrinsic	intrinsic	I536	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
repeated	repeat	R130	VBN	I-NP	O
elements	element	E453	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
or	or	O600	CC	I-NP	O
RNA	RNA	R500	NN	I-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
11	11	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
dose	dose	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dm15	Dm15	D500	NN	B-NP	O
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
force	force	F620	NN	I-NP	O
and	and	A530	CC	O	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
conduction	conduction	C532	NN	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
Six5	Six5	S200	CD	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
a	a	A000	DT	B-NP	O
strain	strain	S365	NN	I-NP	O
of	of	O100	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
Six5	Six5	S200	CD	B-NP	O
was	be	W200	VBD	B-VP	O
deleted	delete	D430	VBN	I-VP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
and	and	A530	CC	I-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
cataract	cataract	C362	NN	B-NP	B-Disease
formation	formation	F653	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
inversely	inversely	I516	RB	I-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Six5	Six5	S200	CD	B-NP	O
dosage	dosage	D200	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
temporally	temporally	T516	RB	B-ADJP	O
progressive	progressive	P626	JJ	I-ADJP	O
.	.	0000	.	O	O

Six5	Six5	S200	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
and	and	A530	CC	O	O
Six5	Six5	S200	CD	B-NP	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
mice	mouse	M200	NNS	B-NP	O
show	show	S000	VBP	B-VP	O
increased	increase	I526	VBN	I-VP	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	B-VP	O
/	/	0000	SYM	B-NP	O
K	K	K000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
ATPase	ATPase	A312	NN	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
1	1	0000	CD	B-NP	O
subunit	subunit	S153	NN	I-NP	O
and	and	A530	CC	O	O
decreased	decrease	D262	VBD	B-VP	O
Dm15	Dm15	D500	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
altered	alter	A436	VBN	B-NP	O
ion	ion	I500	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
lens	lens	L520	NN	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	I-VP	O
cataract	cataract	C362	VB	I-VP	B-Disease
formation	formation	F653	NN	B-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
ocular	ocular	O246	JJ	B-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
a	a	A000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
decreased	decrease	D262	VBN	B-NP	O
SIX5	SIX5	S200	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
aetiology	aetiology	A342	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
contiguous	contiguous	C532	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
DMPK	DMPK	D512	NN	B-NP	O
and	and	A530	CC	I-NP	O
SIX5	SIX5	S200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
of	of	O100	IN	B-PP	O
nibrin	nibrin	N165	NN	B-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	I-PP	O
to	to	T000	TO	I-PP	O
radiation	radiation	R350	NN	B-NP	O
exposure	exposure	E212	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
ATM	ATM	A350	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
,	,	0000	,	O	O
radiosensitivity	radiosensitivity	R325	NN	B-NP	O
,	,	0000	,	O	O
chromosomal	chromosomal	C652	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
and	and	A530	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
predisposition	predisposition	P632	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
similarity	similarity	S546	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
damage	damage	D520	NN	I-NP	O
sensors	sensor	S526	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
in	in	I500	IN	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
pathways	pathway	P320	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
recognition	recognition	R253	NN	I-NP	O
,	,	0000	,	I-NP	O
signalling	signalling	S254	NN	I-NP	O
and	and	A530	CC	I-NP	O
repair	repair	R160	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
double	double	D140	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
breaks	break	B620	NNS	I-NP	O
(	(	0000	(	O	O
DSBs	DSB	D212	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
strong	strong	S365	JJ	B-NP	O
parallels	parallel	P642	NNS	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
radiosensitivity	radiosensitivity	R325	NN	B-NP	O
,	,	0000	,	O	O
chromosomal	chromosomal	C652	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
and	and	A530	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
predisposition	predisposition	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Nijmegen	Nijmegen	N252	NN	B-NP	B-Disease
breakage	breakage	B620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
NBS	NBS	N120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
NBS	NBS	N120	NN	B-NP	B-Disease
,	,	0000	,	O	O
nibrin	nibrin	N165	NN	B-NP	O
(	(	0000	(	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
NBS1	NBS1	N120	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
forms	form	F652	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
with	with	W300	IN	B-PP	O
MRE11	MRE11	M600	NN	B-NP	O
and	and	A530	CC	O	O
RAD50	RAD50	R300	NN	B-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
localizes	localize	L242	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
DSBs	DSB	D212	NNS	B-NP	O
within	within	W350	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	M532	NNS	I-NP	O
after	after	A136	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
exposure	exposure	E212	NN	I-NP	O
to	to	T000	TO	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
(	(	0000	(	O	O
IR	IR	I600	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
brightly	brightly	B623	RB	B-ADVP	O
staining	stain	S352	VBG	B-VP	O
nuclear	nuclear	N246	JJ	B-NP	O
foci	focus	F200	NNS	I-NP	O
after	after	A136	IN	B-PP	O
a	a	A000	DT	B-NP	O
longer	long	L526	JJR	I-NP	O
period	period	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
time	time	T500	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overlap	overlap	O164	NN	I-NP	O
between	between	B350	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cellular	cellular	C460	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
and	and	A530	CC	O	O
NBS	NBS	N120	NNP	B-NP	B-Disease
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
nibrin	nibrin	N165	NN	I-NP	O
may	may	M000	MD	B-VP	O
function	function	F523	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
nibrin	nibrin	N165	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
phosphorylated	phosphorylate	P216	VBN	I-VP	O
within	within	W350	IN	B-PP	O
one	one	O500	CD	B-NP	O
hour	hour	H600	NN	I-NP	O
of	of	O100	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
IR	IR	I600	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
response	response	R215	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
abrogated	abrogate	A162	VBN	I-VP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
either	either	E360	CC	O	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
express	express	E216	VB	I-VP	O
ATM	ATM	A350	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
or	or	O600	CC	I-NP	O
express	express	E216	NN	I-NP	O
near	near	N600	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
physically	physically	P240	RB	B-ADVP	O
interacts	interact	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
and	and	A530	CC	O	O
phosphorylates	phosphorylate	P216	VBZ	B-VP	O
nibrin	nibrin	N165	NN	B-NP	O
on	on	O500	IN	B-PP	O
serine	serine	S650	NN	B-NP	O
343	343	0000	CD	I-NP	O
both	both	B300	CC	O	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

Phosphorylation	Phosphorylation	P216	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
site	site	S300	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
functionally	functionally	F523	RB	B-ADJP	O
important	important	I516	JJ	I-ADJP	O
because	because	B200	IN	B-SBAR	O
mutated	mutate	M300	VBN	B-NP	O
nibrin	nibrin	N165	NN	I-NP	O
(	(	0000	(	O	O
S343A	S343A	S000	NN	B-NP	O
)	)	0000	)	O	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
completely	completely	C514	RB	I-VP	O
complement	complement	C514	NN	B-NP	O
radiosensitivity	radiosensitivity	R325	NN	I-NP	O
in	in	I500	IN	B-PP	O
NBS	NBS	N120	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
of	of	O100	IN	B-PP	O
nibrin	nibrin	N165	NN	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
nibrin	nibrin	N165	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
MRE11	MRE11	M600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
RAD50	RAD50	R300	NN	I-NP	O
association	association	A235	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
revealed	reveal	R143	VBN	B-VP	O
by	by	B000	IN	B-PP	O
radiation	radiation	R350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
foci	focus	F200	NNS	I-NP	O
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
similarity	similarity	S546	NN	I-NP	O
in	in	I500	IN	B-PP	O
phenotype	phenotype	P531	NN	B-NP	O
between	between	B350	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
NBS	NBS	N120	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Clinicopathologic	Clinicopathologic	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA	BRCA	B620	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

CONTEXT	CONTEXT	C532	NN	B-NP	O
Most	Most	M230	JJS	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

Attempts	Attempt	A351	NNS	B-NP	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA	BRCA	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
status	status	S320	NN	I-NP	O
in	in	I500	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
produced	produce	P632	VBN	I-VP	O
conflicting	conflict	C514	VBG	I-VP	O
results	result	R243	NNS	B-NP	O
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
regarding	regard	R263	VBG	B-VP	O
survival	survival	S614	NN	B-NP	O
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
distinct	distinct	D235	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	O	B-Disease
(	(	0000	(	O	I-Disease
nonhereditary	nonhereditary	N563	JJ	B-ADJP	I-Disease
)	)	0000	)	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

DESIGN	DESIGN	D250	NN	B-NP	O
AND	AND	A530	CC	O	O
SETTING	SETTING	S352	VBG	B-VP	O
Retrospective	Retrospective	R362	JJ	B-NP	O
cohort	cohort	C630	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
consecutive	consecutive	C523	JJ	I-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
933	933	0000	CD	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
diagnosed	diagnose	D252	VBN	B-VP	O
and	and	A530	CC	I-VP	O
treated	treat	T630	VBN	I-VP	O
at	at	A300	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
institution	institution	I523	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
center	center	C536	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
designated	designate	D253	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
National	National	N354	NNP	I-NP	O
Cancer	Cancer	C526	NNP	I-NP	B-Disease
Institute	Institute	I523	NNP	I-NP	O
,	,	0000	,	O	O
over	over	O160	IN	B-PP	O
a	a	A000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
period	period	P630	NN	I-NP	O
(	(	0000	(	O	O
December	December	D251	NNP	B-NP	O
1986	1986	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
August	August	A230	NNP	B-NP	O
1998	1998	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

PATIENTS	PATIENTS	P353	NNS	B-NP	O
The	The	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
restricted	restricted	R236	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
ease	ease	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
genotyping	genotyping	G531	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
group	group	G610	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
189	189	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
identified	identify	I353	VBD	B-VP	O
themselves	themselves	T524	PRP	B-NP	O
as	as	A200	IN	B-PP	O
Jewish	Jewish	J200	NN	B-NP	O
,	,	0000	,	O	O
88	88	0000	CD	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
101	101	0000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
series	series	S620	NN	I-NP	O
not	not	N300	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
BRCA	BRCA	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
(	(	0000	(	O	O
Gynecologic	Gynecologic	G524	NNP	B-NP	O
Oncology	Oncology	O524	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
protocols	protocol	P632	NNS	I-NP	O
52	52	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
111	111	0000	CD	I-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
trials	trial	T642	NNS	I-NP	O
(	(	0000	(	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
survival	survival	S614	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
included	include	I524	VBN	I-VP	O
for	for	F600	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
.	.	0000	.	O	O

MAIN	MAIN	M500	NNP	B-NP	O
OUTCOME	OUTCOME	O325	NNP	I-NP	O
MEASURES	MEASURES	M262	NNP	I-NP	O
Age	Age	A200	NNP	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
,	,	0000	,	O	O
surgical	surgical	S624	JJ	B-NP	O
stage	stage	S320	NN	I-NP	O
,	,	0000	,	O	O
histologic	histologic	H234	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
type	type	T100	NN	I-NP	O
and	and	A530	CC	I-NP	O
grade	grade	G630	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
surgical	surgical	S624	JJ	B-NP	O
outcome	outcome	O325	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
chemotherapy	chemotherapy	C536	NN	B-NP	O
and	and	A530	CC	I-NP	O
survival	survival	S614	NN	I-NP	O
for	for	F600	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	O
-	-	0000	HYPH	I-NP	O
stage	stage	S320	NN	B-NP	O
(	(	0000	(	O	O
II	II	I000	CD	B-NP	O
and	and	A530	CC	I-NP	O
IV	IV	I100	CD	I-NP	O
)	)	0000	)	O	O
cases	case	C200	NNS	B-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Hereditary	Hereditary	H636	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
rarely	rarely	R640	RB	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
before	before	B160	IN	B-PP	O
age	age	A200	NN	B-NP	O
40	40	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
common	common	C500	JJ	B-ADJP	O
after	after	A136	IN	B-PP	O
age	age	A200	NN	B-NP	O
60	60	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
mean	mean	M500	JJ	B-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
being	be	B520	VBG	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
younger	young	Y526	JJR	I-ADJP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
vs	vs	V200	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
54	54	0000	CD	B-NP	O
vs	vs	V200	IN	I-NP	O
62	62	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
;	;	0000	:	O	O
P	P	P000	NN	B-NP	O
=	=	0000	JJ	I-NP	O
.	.	0000	.	I-NP	O
04	04	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Histology	Histology	H234	NN	B-NP	O
,	,	0000	,	O	O
grade	grade	G630	NN	B-NP	O
,	,	0000	,	O	O
stage	stage	S320	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
success	success	S200	NN	B-NP	O
of	of	O100	IN	B-PP	O
cytoreductive	cytoreductive	C363	JJ	B-NP	O
surgery	surgery	S626	NN	I-NP	O
were	be	W600	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	O
and	and	A530	CC	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
group	group	G610	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
longer	long	L526	JJR	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
free	free	F600	JJ	B-NP	O
interval	interval	I536	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
primary	primary	P656	JJ	B-NP	O
chemotherapy	chemotherapy	C536	NN	I-NP	O
in	in	I500	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nonhereditary	nonhereditary	N563	JJ	I-NP	O
group	group	G610	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
median	median	M350	JJ	I-NP	O
time	time	T500	NN	I-NP	O
to	to	T000	TO	B-PP	O
recurrence	recurrence	R265	NN	B-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
and	and	A530	CC	O	O
7	7	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Those	Those	T200	DT	B-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
improved	improve	I516	VBN	I-VP	O
survival	survival	S614	NN	B-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nonhereditary	nonhereditary	N563	JJ	I-NP	O
group	group	G610	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
004	004	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
stage	stage	S320	NN	B-NP	B-Disease
III	III	I000	CD	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
BRCA	BRCA	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
status	status	S320	NN	I-NP	O
was	be	W200	VBD	B-VP	O
an	an	A500	DT	B-NP	O
independent	independent	I531	JJ	I-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
variable	variable	V614	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
Although	Although	A432	IN	B-PP	O
BRCA	BRCA	B620	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
associated	associate	A230	VBN	B-VP	I-Disease
hereditary	hereditary	H636	JJ	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
have	have	H100	VBP	B-VP	O
surgical	surgical	S624	JJ	B-NP	O
and	and	A530	CC	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
advanced	advance	A315	VBN	B-VP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
stage	stage	S320	NN	I-NP	I-Disease
hereditary	hereditary	H636	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
survive	survive	S610	VBP	B-VP	O
longer	longer	L526	RBR	B-ADVP	O
than	than	T500	IN	B-PP	O
nonhereditary	nonhereditary	N563	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
greater	great	G636	JJR	B-ADJP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
than	than	T500	IN	B-PP	I-Disease
for	for	F600	IN	B-PP	I-Disease
BRCA2	BRCA2	B620	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
,	,	0000	,	O	O
MEFV	MEFV	M100	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
leukocyte	leukocyte	L230	NN	I-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
regulated	regulate	R243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
inflammatory	inflammatory	I514	JJ	B-NP	O
mediators	mediator	M362	NNS	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
episodes	episode	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
neutrophil	neutrophil	N361	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
mediated	mediate	M300	VBN	B-NP	I-Disease
serosal	serosal	S624	JJ	I-NP	I-Disease
inflammation	inflammation	I514	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
FMF	FMF	F510	NNP	B-NP	B-Disease
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
MEFV	MEFV	M100	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mature	mature	M360	JJ	B-NP	O
neutrophils	neutrophil	N361	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
inflammatory	inflammatory	I514	JJ	I-NP	O
regulator	regulator	R243	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
our	our	O600	PRP$	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
extended	extend	E235	VBD	B-VP	O
our	our	O600	PRP$	B-NP	O
previous	previous	P612	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

MEFV	MEFV	M100	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
in	in	I500	IN	B-PP	O
bone	bone	B500	NN	B-NP	O
marrow	marrow	M600	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
differential	differential	D165	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
among	among	A520	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

CD34	CD34	C300	NN	B-NP	O
hematopoietic	hematopoietic	H531	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
cultures	culture	C436	NNS	I-NP	O
induced	induce	I532	VBN	B-VP	O
toward	toward	T630	IN	B-PP	O
the	the	T000	DT	B-NP	O
granulocytic	granulocytic	G654	JJ	I-NP	O
lineage	lineage	L520	NN	I-NP	O
expressed	express	E216	VBD	B-VP	O
MEFV	MEFV	M100	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myelocyte	myelocyte	M423	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
,	,	0000	,	O	O
concurrently	concurrently	C526	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
lineage	lineage	L520	NN	B-NP	O
commitment	commitment	C535	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
prepromyelocytic	prepromyelocytic	P616	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
HL60	HL60	H400	NN	I-NP	O
expressed	express	E216	VBD	B-VP	O
MEFV	MEFV	M100	NN	B-NP	O
only	only	O540	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
granulocytic	granulocytic	G654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
monocytic	monocytic	M523	JJ	I-NP	O
differentiation	differentiation	D165	NN	I-NP	O
.	.	0000	.	O	O

MEFV	MEFV	M100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
monocytic	monocytic	M523	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
U937	U937	U000	NN	I-NP	O
and	and	A530	CC	I-NP	O
THP	THP	T100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
,	,	0000	,	O	O
MEFV	MEFV	M100	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
neutrophils	neutrophil	N361	NNS	B-NP	O
,	,	0000	,	O	O
eosinophils	eosinophil	E251	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
to	to	T000	TO	B-PP	O
varying	vary	V652	VBG	B-NP	O
degrees	degree	D262	NNS	I-NP	O
,	,	0000	,	O	O
monocytes	monocyte	M523	NNS	B-NP	O
.	.	0000	.	O	O

Consistent	Consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
tissue	tissue	T200	NN	I-NP	O
specificity	specificity	S121	NN	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
,	,	0000	,	O	O
complete	complete	C514	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
upstream	upstream	U123	JJ	B-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
homology	homology	H542	NN	B-NP	O
to	to	T000	TO	B-PP	O
myeloid	myeloid	M430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
promoters	promoter	P653	NNS	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
more	more	M600	RBR	I-VP	O
broadly	broadly	B634	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
inflammatory	inflammatory	I514	JJ	B-NP	O
promoter	promoter	P653	NN	I-NP	O
elements	element	E453	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
stimulation	stimulation	S354	NN	I-NP	O
of	of	O100	IN	B-PP	O
monocytes	monocyte	M523	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
proinflammatory	proinflammatory	P651	JJ	I-NP	O
agents	agent	A253	NNS	I-NP	O
interferon	interferon	I536	NN	I-NP	O
(	(	0000	(	O	O
IFN	IFN	I150	NN	B-NP	O
)	)	0000	)	O	O
gamma	gamma	G500	NN	B-NP	O
,	,	0000	,	O	O
tumor	tumor	T560	NN	B-NP	B-Disease
necrosis	necrosis	N262	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
lipopolysaccharide	lipopolysaccharide	L142	NN	B-NP	O
induced	induce	I532	VBD	B-VP	O
MEFV	MEFV	M100	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
antiinflammatory	antiinflammatory	A535	JJ	I-NP	O
cytokines	cytokine	C325	NNS	I-NP	O
interleukin	interleukin	I536	NN	I-NP	O
(	(	0000	(	O	O
IL	IL	I400	NN	B-NP	O
)	)	0000	)	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	O	O
IL	IL	I400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
transforming	transform	T652	VBG	B-VP	O
growth	growth	G630	NN	B-NP	O
factor	factor	F236	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
inhibited	inhibit	I513	VBD	B-VP	O
such	such	S200	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Induction	Induction	I532	NN	B-NP	O
by	by	B000	IN	B-PP	O
IFN	IFN	I150	NN	B-NP	O
-	-	0000	HYPH	O	O
gamma	gamma	G500	SYM	B-NP	O
occurred	occur	O263	VBD	B-VP	O
rapidly	rapidly	R134	RB	B-ADVP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
resistant	resistant	R235	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
cycloheximide	cycloheximide	C242	NN	B-NP	O
.	.	0000	.	O	O

IFN	IFN	I150	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
alpha	alpha	A410	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
induced	induce	I532	VBD	B-VP	O
MEFV	MEFV	M100	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
granulocytes	granulocyte	G654	NNS	B-NP	O
,	,	0000	,	O	O
MEFV	MEFV	M100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
up	up	U100	RB	B-ADVP	O
-	-	0000	HYPH	B-NP	O
regulated	regulate	R243	VBN	B-VP	O
by	by	B000	IN	B-PP	O
IFN	IFN	I150	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
gamma	gamma	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
IFN	IFN	I150	NN	B-NP	O
-	-	0000	HYPH	O	O
alpha	alpha	A410	SYM	B-NP	O
and	and	A530	CC	O	O
colchicine	colchicine	C425	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
refine	refine	R150	VBP	B-VP	O
understanding	understanding	U536	NN	B-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
by	by	B000	IN	B-PP	O
placing	place	P425	VBG	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
myelomonocytic	myelomonocytic	M452	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
proinflammatory	proinflammatory	P651	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
and	and	A530	CC	O	O
identifying	identify	I353	VBG	B-VP	O
it	it	I300	PRP	B-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
IFN	IFN	I150	NN	I-NP	O
-	-	0000	HYPH	O	O
gamma	gamma	G500	SYM	B-NP	O
immediate	immediate	I530	JJ	I-NP	O
early	early	E640	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
and	and	A530	CC	I-NP	O
structural	structural	S362	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
mucopolysaccharidosis	mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Mucopolysaccharidosis	Mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
(	(	0000	(	O	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
;	;	0000	:	O	O
OMIM	OMIM	O500	NN	B-NP	O
#	#	0000	#	B-NP	O
253000	253000	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	B-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
N	N	N000	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
sulfate	sulfate	S413	NN	I-NP	I-Disease
sulfatase	sulfatase	S413	NN	I-NP	I-Disease
(	(	0000	(	O	O
GALNS	GALNS	G452	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
variable	variable	V614	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
65	65	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
and	and	A530	CC	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
remained	remain	R530	VBN	I-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
17	17	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
biochemical	biochemical	B252	JJ	B-NP	O
approaches	approach	A162	NNS	I-NP	O
and	and	A530	CC	O	O
32	32	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
structural	structural	S362	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

Fifteen	Fifteen	F135	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
newly	newly	N400	RB	I-NP	O
engineered	engineer	E525	VBN	I-NP	O
active	active	A231	JJ	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
C79S	C79S	C200	NN	B-NP	O
,	,	0000	,	I-NP	O
C79T	C79T	C300	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
transient	transient	T652	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Mutant	Mutant	M353	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	O	O
except	except	E213	IN	B-PP	O
for	for	F600	IN	B-PP	O
C79S	C79S	C200	NN	B-NP	O
and	and	A530	CC	I-NP	O
C79T	C79T	C300	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
destabilized	destabilize	D231	VBN	I-VP	O
and	and	A530	CC	O	O
detected	detect	D323	VBN	B-VP	O
as	as	A200	IN	B-PP	O
insoluble	insoluble	I524	JJ	B-NP	O
precursor	precursor	P626	NN	I-NP	O
forms	form	F652	NNS	I-NP	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
C79S	C79S	C200	NN	I-NP	O
and	and	A530	CC	I-NP	O
C79T	C79T	C300	NN	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
soluble	soluble	S414	JJ	I-NP	O
mature	mature	M360	JJ	I-NP	O
size	size	S200	NN	I-NP	O
.	.	0000	.	O	O

Mutants	Mutant	M353	NNS	B-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Mutants	Mutant	M353	NNS	B-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
residual	residual	R234	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
GALNS	GALNS	G452	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Sulfatases	Sulfatas	S413	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
GALNS	GALNS	G452	NN	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
family	family	F540	NN	I-NP	O
sharing	share	S652	VBG	B-VP	O
an	an	A500	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
tertiary	tertiary	T636	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
was	be	W200	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ray	ray	R000	NN	I-NP	O
crystal	crystal	C623	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	O	O
acetylgalacto	acetylgalacto	A234	AFX	O	O
-	-	0000	HYPH	B-NP	O
samine	samine	S500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
and	and	A530	CC	I-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
homology	homology	H542	NN	B-NP	O
modeling	modeling	M345	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
32	32	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
different	different	D165	JJ	I-NP	O
reasons	reason	R252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
(	(	0000	(	O	O
i	i	I000	NN	B-NP	O
)	)	0000	)	O	O
destruction	destruction	D236	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hydrophobic	hydrophobic	H361	JJ	I-NP	O
core	core	C600	NN	I-NP	O
or	or	O600	CC	I-NP	O
modification	modification	M312	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
packing	packing	P252	NN	I-NP	O
;	;	0000	:	O	O
(	(	0000	(	B-LST	O
ii	ii	I000	LS	I-LST	O
)	)	0000	)	O	O
removal	removal	R514	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
salt	salt	S430	NN	I-NP	O
bridge	bridge	B632	NN	I-NP	O
to	to	T000	TO	B-VP	O
destabilize	destabilize	D231	VB	I-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
conformation	conformation	C516	NN	I-NP	O
;	;	0000	:	O	O
(	(	0000	(	B-LST	O
iii	iii	I000	LS	I-LST	O
)	)	0000	)	O	O
modification	modification	M312	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
active	active	A231	JJ	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
mild	mild	M430	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
mostly	mostly	M234	RB	B-ADJP	O
located	located	L230	JJ	I-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
surface	surface	S612	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
shed	shed	S300	VBD	B-VP	O
further	further	F636	JJ	B-NP	O
light	light	L230	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
structure	structure	S362	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
relationship	relationship	R435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
band	band	B530	NN	I-NP	O
11q22	11q22	Q000	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
a	a	A000	DT	B-NP	O
distinctive	distinctive	D235	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
homozygotes	homozygote	H523	NNS	B-NP	O
and	and	A530	CC	O	O
predispose	predispose	P632	VB	B-VP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
ischemic	ischemic	I252	JJ	B-NP	B-Disease
heart	heart	H630	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
early	early	E640	JJ	B-NP	O
mortality	mortality	M634	NN	I-NP	O
.	.	0000	.	O	O

PCR	PCR	P260	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
from	from	F650	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
automated	automate	A353	VBN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
66	66	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
splice	splice	S142	NN	B-NP	O
junctions	junction	J523	NNS	I-NP	O
detected	detect	D323	VBD	B-VP	O
77	77	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
85	85	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
90	90	0000	CD	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

Heteroduplex	Heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
detected	detect	D323	VBD	B-VP	O
another	another	A536	DT	B-NP	O
42	42	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Out	Out	O300	IN	B-PP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
71	71	0000	CD	B-NP	O
unique	unique	U520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
50	50	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
only	only	O540	RB	B-PP	O
in	in	I500	IN	I-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
51	51	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
(	(	0000	(	O	O
58	58	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
71	71	0000	CD	I-NP	O
,	,	0000	,	O	O
82	82	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
frameshift	frameshift	F652	NN	B-NP	O
and	and	A530	CC	O	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
truncation	truncation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
types	type	T120	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
missense	missense	M252	JJ	B-ADJP	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
/	/	0000	SYM	O	O
71	71	0000	CD	B-NP	O
,	,	0000	,	O	O
13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
splicing	splicing	S142	NN	B-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
/	/	0000	SYM	O	O
71	71	0000	CD	B-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
2546	2546	0000	CD	B-NP	O
3	3	0000	CD	I-NP	O
(	(	0000	NN	I-NP	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
71	71	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mean	mean	M500	JJ	I-NP	O
survival	survival	S614	NN	I-NP	O
and	and	A530	CC	I-NP	O
height	height	H230	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
134	134	0000	CD	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
correlated	correlate	C643	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
truncating	truncate	T652	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
typically	typically	T124	RB	B-ADVP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
2546	2546	0000	CD	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
shorter	short	S636	JJR	B-ADJP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
significantly	significantly	S251	RB	B-NP	O
shorter	short	S636	JJR	I-NP	O
survival	survival	S614	NN	I-NP	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
or	or	O600	CC	O	O
missense	missense	M252	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
truncating	truncate	T652	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Alterations	Alteration	A436	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
length	length	L523	NN	I-NP	O
or	or	O600	CC	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
composition	composition	C512	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
affect	affect	A123	VBP	B-VP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
ways	way	W200	NNS	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
may	may	M000	MD	B-VP	O
help	help	H410	VB	I-VP	O
estimate	estimate	E235	VB	I-VP	O
the	the	T000	DT	B-NP	O
prognosis	prognosis	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Isolation	Isolation	I243	NN	B-NP	O
,	,	0000	,	O	O
genomic	genomic	G520	JJ	B-NP	O
organization	organization	O625	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
expression	expression	E216	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
rat	rat	R300	NN	I-NP	O
homologs	homolog	H542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
mediterranean	mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
episodes	episode	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
serositis	serositis	S623	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
synovitis	synovitis	S513	NN	I-NP	B-Disease
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
MEFV	MEFV	M100	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
pyrin	pyrin	P650	NN	B-NP	O
/	/	0000	SYM	B-NP	O
marenostrin	marenostrin	M652	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
regulate	regulate	R243	VB	I-VP	O
inflammation	inflammation	I514	NN	B-NP	O
in	in	I500	IN	B-PP	O
myeloid	myeloid	M430	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
manuscript	manuscript	M526	NN	I-NP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
rat	rat	R300	NN	I-NP	O
homologs	homolog	H542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
MEFV	MEFV	M100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
ten	ten	T500	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
2304	2304	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
homolog	homolog	H542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
nine	nine	N500	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
2253	2253	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-ADJP	O
(	(	0000	(	O	O
47	47	0000	CD	B-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
and	and	A530	CC	O	O
65	65	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
similarity	similarity	S546	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
rat	rat	R300	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
73	73	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
and	and	A530	CC	O	O
82	82	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
similarity	similarity	S546	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
rodent	rodent	R353	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
several	several	S164	JJ	B-NP	O
important	important	I516	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
and	and	A530	CC	I-NP	O
signals	signal	S254	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
pyrin	pyrin	P650	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
B	B	B000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
box	box	B200	NN	I-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
Robbins	Robbins	R152	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Dingwall	Dingwall	D524	NNP	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
coiled	coil	C430	VBN	B-VP	O
-	-	0000	HYPH	B-NP	O
coil	coil	C400	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
perhaps	perhaps	P612	RB	B-ADVP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
an	an	A500	DT	B-NP	O
ancient	ancient	A525	JJ	I-NP	O
frame	frame	F650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
shift	shift	S130	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
neither	neither	N360	CC	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
nor	nor	N600	CC	O	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
intact	intact	I532	JJ	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
B30	B30	B000	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
most	most	M230	JJS	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
MEFV	MEFV	M100	NN	I-NP	O
.	.	0000	.	O	O

Nevertheless	Nevertheless	N163	RB	B-ADVP	O
,	,	0000	,	O	O
like	like	L200	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
mouse	mouse	M200	NN	B-NP	O
Mefv	Mefv	M100	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
granulocytes	granulocyte	G654	NNS	I-NP	O
but	but	B300	CC	B-NP	O
not	not	N300	RB	I-NP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
.	.	0000	.	O	O

Consistent	Consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
granulocytes	granulocyte	G654	NNS	B-NP	O
,	,	0000	,	O	O
Mefv	Mefv	M100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
follicles	follicle	F424	NNS	I-NP	O
and	and	A530	CC	O	O
marginal	marginal	M625	JJ	B-NP	O
zones	zone	Z520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
splenic	splenic	S145	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
pulp	pulp	P410	NN	I-NP	O
.	.	0000	.	O	O

Mefv	Mefv	M100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
localized	localize	L242	VBN	I-VP	O
on	on	O500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
Chromosome	Chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
Chr	Chr	C600	NN	B-NP	O
)	)	0000	)	O	O
16	16	0000	CD	B-NP	O
,	,	0000	,	O	O
region	region	R250	NN	B-NP	O
A3	A3	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
B1	B1	B000	NN	I-NP	O
,	,	0000	,	O	O
extending	extend	E235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
synteny	synteny	S535	NN	B-NP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
Chr	Chr	C600	NN	I-NP	O
16p13	16p13	P000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	LS	B-LST	O
.	.	0000	.	O	O

Development	Development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
knockout	knockout	K523	NN	B-NP	O
and	and	A530	CC	I-NP	O
knockin	knockin	K525	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
models	model	M342	NNS	I-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
further	further	F636	JJ	B-NP	O
insights	insight	I523	NNS	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
evolution	evolution	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
arise	arise	A620	NN	I-NP	O
by	by	B000	IN	B-PP	O
separate	separate	S163	JJ	B-NP	O
integration	integration	I532	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
normally	normally	N654	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
Xq22	Xq22	X200	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
and	and	A530	CC	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
males	male	M420	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
PMD	PMD	P530	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
on	on	O500	IN	B-PP	O
Xq22	Xq22	X200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
extra	extra	E236	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
first	first	F623	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AhaII	AhaII	A000	NN	I-NP	O
dimorphism	dimorphism	D561	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
FISH	FISH	F200	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
in	in	I500	IN	B-PP	O
Xp22	Xp22	X100	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
no	no	N000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
standard	standard	S353	JJ	B-NP	O
karyotype	karyotype	K631	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
three	three	T600	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
had	have	H300	VBD	B-VP	O
similar	similar	S546	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
PMD	PMD	P530	NN	B-NP	B-Disease
,	,	0000	,	O	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
pericentric	pericentric	P625	JJ	I-NP	O
inversion	inversion	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
inv	inv	I510	NN	I-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
carried	carry	C630	VBN	B-VP	O
by	by	B000	IN	B-PP	O
several	several	S164	JJ	B-NP	O
affected	affect	A123	VBN	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
FISH	FISH	F200	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
PLP	PLP	P410	NN	B-NP	O
signals	signal	S254	NNS	I-NP	O
at	at	A300	IN	B-PP	O
Xp11	Xp11	X100	NN	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
Xq22	Xq22	X200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
family	family	F540	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
affected	affect	A123	VBD	B-VP	O
members	member	M516	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
extra	extra	E236	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
at	at	A300	IN	B-PP	O
Xq26	Xq26	X200	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
otherwise	otherwise	O362	RB	I-NP	O
normal	normal	N654	JJ	I-NP	O
banding	banding	B535	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
separate	separate	S163	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
PLP	PLP	P410	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
duplicated	duplicate	D142	VBN	I-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
noncontiguous	noncontiguous	N525	JJ	I-NP	O
site	site	S300	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
such	such	S200	JJ	B-NP	O
duplications	duplication	D142	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
common	common	C500	JJ	I-NP	O
but	but	B300	CC	O	O
previously	previously	P612	RB	B-NP	O
undetected	undetected	U532	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
13	13	0000	CD	I-NP	O
duplication	duplication	D142	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
geographically	geographically	G261	RB	B-NP	O
diverse	diverse	D162	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
Exon	Exon	E250	NNP	B-NP	O
13	13	0000	CD	I-NP	O
Duplication	Duplication	D142	NNP	I-NP	O
Screening	Screening	S265	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
U	U	U000	NN	I-NP	O
.	.	0000	.	O	O

S	S	S000	NNP	B-NP	O
S	S	S000	NNP	I-NP	O
.	.	0000	.	I-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
Portuguese	Portuguese	P632	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
goal	goal	G400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
to	to	T000	TO	B-VP	O
estimate	estimate	E235	VB	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
and	and	A530	CC	I-NP	O
geographic	geographic	G261	JJ	I-NP	O
diversity	diversity	D162	NN	I-NP	O
of	of	O100	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
do	do	D000	VB	I-VP	O
this	this	T200	DT	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
collaborative	collaborative	C416	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
set	set	S300	VBN	I-VP	O
up	up	U100	RP	B-PRT	O
that	that	T300	WDT	B-NP	O
involved	involve	I514	VBD	B-VP	O
39	39	0000	CD	B-NP	O
institutions	institution	I523	NNS	I-NP	O
from	from	F650	IN	B-PP	O
19	19	0000	CD	B-NP	O
countries	country	C536	NNS	I-NP	O
and	and	A530	CC	O	O
included	include	I524	VBD	B-VP	O
3	3	0000	CD	B-NP	O
,	,	0000	,	O	O
580	580	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
and	and	A530	CC	O	O
934	934	0000	CD	B-NP	O
early	early	E640	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
11	11	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Belgium	Belgium	B425	NN	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Canada	Canada	C530	NNP	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Great	Great	G630	JJ	B-NP	O
Britain	Britain	B635	NNP	I-NP	O
(	(	0000	(	O	O
6	6	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	State	S320	NNPS	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Haplotyping	Haplotyping	H143	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
derive	derive	D610	VB	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
British	British	B632	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
strongly	strongly	S365	RB	B-ADJP	O
advisable	advisable	A312	JJ	I-ADJP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
laboratories	laboratory	L163	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
out	out	O300	RP	B-PRT	O
screening	screen	S265	VBG	B-VP	O
either	either	E360	CC	O	O
in	in	I500	IN	B-PP	O
English	English	E524	NNP	B-NP	O
-	-	0000	HYPH	B-VP	O
speaking	speak	S125	VBG	B-NP	O
countries	country	C536	NNS	I-NP	O
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
countries	country	C536	NNS	B-NP	O
with	with	W300	IN	B-PP	O
historical	historical	H236	JJ	B-NP	O
links	link	L520	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Britain	Britain	B635	NNP	B-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
include	include	I524	VB	I-VP	O
within	within	W350	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
protocols	protocol	P632	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
based	base	B230	VBN	I-NP	O
assay	assay	A200	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	O
VHL	VHL	V400	NNP	O	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Von	Von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
predisposition	predisposition	P632	NN	B-NP	O
for	for	F600	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-ADJP	B-Disease
and	and	A530	CC	O	I-Disease
multi	multi	M430	AFX	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
centric	centric	C536	JJ	I-NP	I-Disease
hemangioblastoma	hemangioblastoma	H521	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retina	retina	R350	NN	I-NP	O
and	and	A530	CC	I-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
pheochromocytoma	pheochromocytoma	P265	NN	B-NP	B-Disease
,	,	0000	,	O	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
cysts	cyst	C232	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
pancreas	pancreas	P526	NN	B-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
epididymis	epididymis	E135	NN	B-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
which	which	W200	WDT	B-NP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
had	have	H300	VBD	B-VP	O
failed	fail	F430	VBN	I-VP	O
to	to	T000	TO	I-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
partial	partial	P634	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
exons	exon	E252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fifth	fifth	F130	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
FISH	FISH	F200	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
(	(	0000	(	O	O
quantitative	quantitative	Q531	JJ	B-ADJP	O
)	)	0000	)	O	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
germline	germline	G654	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
implemented	implement	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
routine	routine	R350	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
for	for	F600	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
established	establish	E231	VBN	I-NP	O
observation	observation	O126	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
pheochromocytoma	pheochromocytoma	P265	NN	B-NP	B-Disease
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
unraveling	unraveling	U561	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
or	or	O600	CC	I-NP	O
partial	partial	P634	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
a	a	A000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
preponderance	preponderance	P615	NN	I-NP	O
of	of	O100	IN	B-PP	O
central	central	C536	JJ	B-NP	B-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
hemangioblastoma	hemangioblastoma	H521	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
GAA	GAA	G000	NN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

Friedreich	Friedreich	F636	NN	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequently	frequently	F625	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
vast	vast	V230	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
GAA	GAA	G000	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
close	close	C420	RB	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
frataxin	frataxin	F632	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
founding	found	F535	VBG	B-VP	O
mutational	mutational	M354	JJ	B-NP	O
event	event	E153	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
682	682	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
203	203	0000	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
564	564	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
801	801	0000	CD	I-NP	O
g	g	G000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
dating	dating	D352	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
little	little	L340	JJ	B-NP	O
or	or	O600	CC	I-NP	O
no	no	N000	DT	I-NP	O
negative	negative	N231	JJ	I-NP	O
selection	selection	S423	NN	I-NP	O
and	and	A530	CC	O	O
provides	provide	P613	VBZ	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
ancient	ancient	A525	JJ	I-NP	O
spread	spread	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
pre	pre	P600	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
at	at	A300	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
risk	risk	R200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
western	western	W236	JJ	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
Nijmegen	Nijmegen	N252	NN	I-NP	B-Disease
breakage	breakage	B620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Nijmegen	Nijmegen	N252	NN	B-NP	B-Disease
breakage	breakage	B620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
NBS	NBS	N120	NN	B-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
recessive	recessive	R210	JJ	B-NP	B-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
and	and	A530	CC	O	O
similar	similar	S546	JJ	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
kinases	kinase	K520	NNS	B-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kinase	kinase	K520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
NBS1	NBS1	N120	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
specifically	specifically	S121	RB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Nijmegen	Nijmegen	N252	NN	B-NP	B-Disease
breakage	breakage	B620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
forms	form	F652	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
Rad50	Rad50	R300	NN	I-NP	O
and	and	A530	CC	I-NP	O
Mrel1	Mrel1	M640	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
phosphorylation	phosphorylation	P216	NN	B-NP	O
of	of	O100	IN	B-PP	O
NBS1	NBS1	N120	NN	B-NP	O
,	,	0000	,	O	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
,	,	0000	,	O	O
requires	require	R262	VBZ	B-VP	O
catalytically	catalytically	C343	RB	B-NP	O
active	active	A231	JJ	I-NP	O
ATM	ATM	A350	NN	I-NP	O
.	.	0000	.	O	O

Complexes	Complex	C514	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
NBS1	NBS1	N120	NN	I-NP	O
exist	exist	E230	VBP	B-VP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
untreated	untreated	U536	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
cells	cell	C420	NNS	B-NP	O
treated	treat	T630	VBN	B-VP	O
with	with	W300	IN	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
two	two	T000	CD	B-NP	O
residues	residue	R232	NNS	I-NP	O
of	of	O100	IN	B-PP	O
NBS1	NBS1	N120	NN	B-NP	O
,	,	0000	,	O	O
Ser	Ser	S600	NN	B-NP	O
278	278	0000	CD	I-NP	O
and	and	A530	CC	O	O
Ser	Ser	S600	NN	B-NP	O
343	343	0000	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
phosphorylated	phosphorylate	P216	VBN	I-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
by	by	B000	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
and	and	A530	CC	O	O
whose	whose	W200	WP$	B-NP	O
modification	modification	M312	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
response	response	R215	NN	I-NP	O
includes	include	I524	VBZ	B-VP	O
S	S	S000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phase	phase	P200	NN	I-NP	O
checkpoint	checkpoint	C215	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
,	,	0000	,	O	O
formation	formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
NBS1	NBS1	N120	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Mrel1	Mrel1	M640	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Rad50	Rad50	R300	NN	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
and	and	A530	CC	O	O
rescue	rescue	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
hypersensitivity	hypersensitivity	H162	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
ionizing	ionize	I525	VBG	B-VP	I-Disease
radiation	radiation	R350	NN	B-NP	I-Disease
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
cycle	cycle	C240	NN	I-NP	O
checkpoints	checkpoint	C215	NNS	I-NP	O
activated	activate	A231	VBN	B-VP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
and	and	A530	CC	I-NP	O
DNA	DNA	D500	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
overlapping	overlap	O164	VBG	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
microcephaly	microcephaly	M262	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
Cohen	Cohen	C500	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
8q21	8q21	Q000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
8q22	8q22	Q000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
:	:	0000	:	O	O
redefining	redefine	R315	VBG	B-VP	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
of	of	O100	IN	B-PP	O
microcephaly	microcephaly	M262	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	O
progressive	progressive	P626	JJ	I-NP	O
postnatal	postnatal	P235	JJ	I-NP	B-Disease
growth	growth	G630	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
cousin	cousin	C250	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
multiply	multiply	M431	JJ	I-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
of	of	O100	IN	B-PP	O
Lebanese	Lebanese	L152	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
.	.	0000	.	O	O

Hypotonia	Hypotonia	H135	NNP	B-NP	B-Disease
,	,	0000	,	O	O
chorioretinal	chorioretinal	C635	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
myopia	myopia	M100	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
varied	vary	V630	VBD	B-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
related	related	R430	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
distinctive	distinctive	D235	JJ	I-NP	O
facial	facial	F240	JJ	I-NP	O
appearance	appearance	A165	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
initially	initially	I534	RB	I-NP	O
considered	consider	C523	VBN	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Cohen	Cohen	C500	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
withdrawn	withdraw	W365	VBN	I-VP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
was	be	W200	VBD	B-VP	O
assumed	assume	A253	VBN	I-VP	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
assigned	assign	A253	VBD	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
26	26	0000	CD	I-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
band	band	B530	NN	I-NP	O
8q21	8q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
22	22	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
microsatellites	microsatellite	M262	NNS	I-NP	O
at	at	A300	IN	B-PP	O
D8S270	D8S270	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D8S514	D8S514	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
for	for	F600	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
at	at	A300	IN	B-PP	O
D8S267	D8S267	D200	NN	B-NP	O
(	(	0000	(	O	O
Zmax	Zmax	Z520	NN	B-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O
237	237	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
Omax	Omax	O520	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Intriguingly	Intriguingly	I536	RB	B-ADVP	O
enough	enough	E520	RB	I-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
overlaps	overlap	O164	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
refined	refine	R153	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
for	for	F600	IN	B-PP	O
Cohen	Cohen	C500	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
COH1	COH1	C000	NN	B-NP	O
)	)	0000	)	O	O
[	[	0000	(	O	O
Kolehmainen	Kolehmainen	K450	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1997	1997	0000	CD	B-NP	O
Euro	Euro	E600	NNP	I-NP	O
J	J	J000	NNP	I-NP	O
Hum	Hum	H500	NNP	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
5	5	0000	CD	I-NP	O
206	206	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
213	213	0000	CD	I-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
encourages	encourage	E526	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
described	describe	D261	VBN	I-NP	O
kindred	kindred	K536	NN	I-NP	O
segregates	segregate	S262	NNS	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
Cohen	Cohen	C500	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
redefinition	redefinition	R315	NN	I-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O

Polymorphisms	Polymorphism	P456	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CYP2D6	CYP2D6	C130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
increase	increase	I526	VBP	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
.	.	0000	.	O	O

Ankylosing	Ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
and	and	A530	CC	I-NP	O
highly	highly	H240	RB	I-NP	O
familial	familial	F540	JJ	I-NP	O
rheumatic	rheumatic	R532	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sibling	sibling	S145	NN	I-NP	O
recurrence	recurrence	R265	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
63	63	0000	CD	B-NP	O
and	and	A530	CC	O	O
heritability	heritability	H631	NN	B-NP	O
assessed	assess	A230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
twins	twin	T520	NNS	B-NP	O
>	>	0000	SYM	O	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
MHC	MHC	M200	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	O	O
B27	B27	B000	NN	B-NP	O
,	,	0000	,	O	O
contribute	contribute	C536	VBP	B-VP	O
only	only	O540	RB	B-NP	O
20	20	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
MHC	MHC	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
convincingly	convincingly	C515	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
influence	influence	I514	VB	I-VP	O
either	either	E360	CC	O	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
or	or	O600	CC	O	O
its	its	I320	PRP$	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
and	and	A530	CC	I-NP	O
association	association	A235	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
close	close	C420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
within	within	W350	IN	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
cytochrome	cytochrome	C326	NN	I-NP	O
P450	P450	P000	NN	I-NP	O
2D6	2D6	D000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP2D6	CYP2D6	C130	NN	B-NP	O
,	,	0000	,	O	O
debrisoquine	debrisoquine	D162	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
)	)	0000	)	O	O
located	located	L230	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22q13	22q13	Q000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22	22	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
200	200	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
affected	affect	A123	VBD	B-VP	O
sibling	sibling	S145	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
pairs	pair	P620	NNS	I-NP	O
.	.	0000	.	O	O

Association	Association	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
alleles	allele	A420	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CYP2D6	CYP2D6	C130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
both	both	B300	CC	O	O
case	case	C200	NN	O	O
-	-	0000	HYPH	O	O
control	control	C536	NN	B-NP	O
and	and	A530	CC	O	O
within	within	W350	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
family	family	F540	NN	I-NP	O
means	mean	M520	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-SBAR	O
case	case	C200	NN	O	O
-	-	0000	HYPH	O	O
control	control	C536	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
617	617	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
(	(	0000	(	O	O
361	361	0000	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
from	from	F650	IN	B-PP	O
sibling	sibling	S145	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
pair	pair	P600	NN	I-NP	O
and	and	A530	CC	I-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
case	case	C200	NN	I-NP	O
trio	trio	T600	NN	I-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
256	256	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
familial	familial	F540	JJ	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
402	402	0000	CD	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
ethnically	ethnically	E352	RB	I-NP	O
matched	match	M323	VBN	I-NP	O
controls	control	C536	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
employed	employ	E514	VBN	I-VP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
within	within	W350	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
family	family	F540	NN	I-NP	O
association	association	A235	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
361	361	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
161	161	0000	CD	B-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
case	case	C200	NN	I-NP	O
trios	trio	T620	NNS	I-NP	O
and	and	A530	CC	O	O
200	200	0000	CD	B-NP	O
affected	affect	A123	VBD	B-VP	O
sibling	sibling	S145	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
pair	pair	P600	NN	I-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
employed	employ	E514	VBN	I-VP	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
poor	poor	P600	JJ	B-NP	O
metabolizer	metabolizer	M314	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Heterozygosity	Heterozygosity	H362	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
poor	poor	P600	JJ	I-NP	O
metabolizer	metabolizer	M314	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
CYP2D6	CYP2D6	C130	NN	B-NP	O
*	*	0000	SYM	B-NP	O
4	4	0000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
family	family	F540	NN	I-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
CYP2D6	CYP2D6	C130	NN	B-NP	O
*	*	0000	SYM	O	O
4	4	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
and	and	A530	CC	I-NP	O
AS	AS	A200	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
.	.	0000	.	O	O

Weak	Weak	W200	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
between	between	B350	IN	B-PP	O
CYP2D6	CYP2D6	C130	NN	B-NP	O
and	and	A530	CC	I-NP	O
AS	AS	A200	NN	I-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
postulate	postulate	P234	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
altered	alter	A436	VBN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
natural	natural	N364	JJ	I-NP	O
toxin	toxin	T250	NN	I-NP	O
or	or	O600	CC	O	O
antigen	antigen	A532	NN	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
CYP2D6	CYP2D6	C130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
increase	increase	I526	VB	I-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
(	(	0000	(	O	O
DFNB4	DFNB4	D151	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
known	know	K500	VBN	B-VP	O
as	as	A200	IN	B-PP	O
pendrin	pendrin	P536	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
transporter	transporter	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
iodide	iodide	I300	NN	B-NP	O
and	and	A530	CC	I-NP	O
chloride	chloride	C463	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
non	non	N500	AFX	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DFNB4	DFNB4	D151	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
7q31	7q31	Q000	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
screen	screen	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
midwestern	midwestern	M323	JJ	I-NP	O
USA	USA	U200	NN	I-NP	O
with	with	W300	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
dilated	dilated	D430	JJ	B-NP	O
vestibular	vestibular	V231	JJ	I-NP	O
aqueducts	aqueduct	A232	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
three	three	T600	CD	B-NP	O
people	people	P140	NNS	I-NP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
PDS	PDS	P320	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
differ	differ	D160	VBP	B-VP	O
functionally	functionally	F523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
PDS	PDS	P320	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
three	three	T600	CD	B-NP	O
common	common	C500	JJ	I-NP	O
Pendred	Pendred	P536	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
allele	allele	A400	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
(	(	0000	(	O	O
L236P	L236P	L100	NN	B-NP	O
,	,	0000	,	O	O
T416P	T416P	T100	NN	B-NP	O
and	and	A530	CC	O	O
E384G	E384G	E200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
three	three	T600	CD	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
reported	report	R163	VBN	B-VP	O
only	only	O540	RB	B-PP	O
in	in	I500	IN	I-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
syndromic	syndromic	S536	JJ	I-NP	I-Disease
hearing	hearing	H652	NN	I-NP	I-Disease
loss	loss	L200	NN	I-NP	I-Disease
(	(	0000	(	O	O
V480D	V480D	V300	NN	B-NP	O
,	,	0000	,	I-NP	O
V653A	V653A	V000	NN	I-NP	O
and	and	A530	CC	I-NP	O
I490L	I490L	I400	NN	I-NP	O
/	/	0000	SYM	B-NP	O
G497S	G497S	G200	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
complete	complete	C514	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
pendrin	pendrin	P536	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
chloride	chloride	C463	NN	I-NP	O
and	and	A530	CC	I-NP	O
iodide	iodide	I300	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
alleles	allele	A420	NNS	B-NP	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
people	people	P140	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DFNB4	DFNB4	D151	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
transport	transport	T652	VB	I-VP	O
both	both	B300	CC	O	O
iodide	iodide	I300	NN	B-NP	O
and	and	A530	CC	I-NP	O
chloride	chloride	C463	NN	I-NP	O
,	,	0000	,	O	O
albeit	albeit	A413	IN	B-ADVP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
much	much	M200	RB	I-NP	O
lower	low	L600	JJR	I-NP	O
level	level	L140	NN	I-NP	O
than	than	T500	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
pendrin	pendrin	P536	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
anion	anion	A500	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
eliminate	eliminate	E453	VB	I-VP	O
or	or	O600	CC	I-VP	O
postpone	postpone	P231	VB	I-VP	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
goiter	goiter	G360	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DFNB4	DFNB4	D151	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
a	a	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
pendrin	pendrin	P536	NN	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
thyroid	thyroid	T630	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
pendrin	pendrin	P536	NN	B-NP	O
transports	transport	T652	VBZ	B-VP	O
iodide	iodide	I300	NN	B-NP	O
across	across	A262	IN	B-PP	O
the	the	T000	DT	B-NP	O
apical	apical	A124	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
thyrocyte	thyrocyte	T623	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
colloid	colloid	C430	JJ	I-NP	O
space	space	S120	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
IX	IX	I200	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
as	as	A200	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutagen	mutagen	M325	NN	I-NP	O
test	test	T230	NN	I-NP	O
:	:	0000	:	O	O
samples	sample	S514	NNS	B-NP	O
from	from	F650	IN	B-PP	O
Mainland	Mainland	M545	NNP	B-NP	O
China	China	C500	NNP	I-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
putatively	putatively	P314	RB	I-NP	O
endogenous	endogenous	E532	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
source	source	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
allows	allow	A420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
species	species	S120	NN	I-NP	O
to	to	T000	TO	B-VP	O
evolve	evolve	E141	VB	I-VP	O
over	over	O160	IN	B-PP	O
time	time	T500	NN	B-NP	O
but	but	B300	CC	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cost	cost	C230	NN	I-NP	O
of	of	O100	IN	B-PP	O
Mendelian	Mendelian	M534	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
multifactorial	multifactorial	M431	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
factor	factor	F236	NN	I-NP	O
IX	IX	I200	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
F9	F9	F000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
ethnically	ethnically	E352	RB	B-NP	O
and	and	A530	CC	I-NP	O
geographically	geographically	G261	RB	I-NP	O
diverse	diverse	D162	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
and	and	A530	CC	O	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
ancient	ancient	A525	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
shaped	shape	S130	VBN	I-VP	O
the	the	T000	DT	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
compare	compare	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemophilia	hemophilia	H514	NN	B-NP	B-Disease
B	B	B000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Mainland	Mainland	M545	NNP	B-NP	O
China	China	C500	NNP	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
66	66	0000	CD	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
U	U	U000	NN	B-NP	O
.	.	0000	.	O	O

S	S	S000	NN	B-NP	O
.	.	0000	.	O	O

Caucasians	Caucasian	C252	NNS	B-NP	O
,	,	0000	,	O	O
Blacks	Black	B420	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Mexican	Mexican	M250	NNP	B-NP	O
Hispanics	Hispanic	H215	NNPS	I-NP	O
and	and	A530	CC	O	O
stratify	stratify	S363	VB	B-VP	O
by	by	B000	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
and	and	A530	CC	I-NP	O
ethnicity	ethnicity	E352	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
provides	provide	P613	VBZ	B-VP	O
additional	additional	A354	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
inference	inference	I516	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
endogenous	endogenous	E532	JJ	B-NP	O
processes	process	P620	NNS	I-NP	O
predominate	predominate	P635	VBP	B-VP	O
in	in	I500	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Fas	Fas	F200	NN	B-NP	O
preassociation	preassociation	P623	NN	I-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
apoptosis	apoptosis	A132	NN	B-NP	O
signaling	signaling	S254	NN	I-NP	O
and	and	A530	CC	O	O
dominant	dominant	D530	JJ	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
by	by	B000	IN	B-PP	O
pathogenic	pathogenic	P325	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
death	death	D300	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
Fas	Fas	F200	NN	I-NP	O
dominantly	dominantly	D534	RB	B-ADVP	O
interfere	interfere	I536	VBP	B-VP	O
with	with	W300	IN	B-PP	O
Fas	Fas	F200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
autoimmune	autoimmune	A350	JJ	I-NP	B-Disease
lymphoproliferative	lymphoproliferative	L516	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
,	,	0000	,	O	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
depending	depend	D153	VBG	B-VP	O
on	on	O500	IN	B-PP	O
ligand	ligand	L253	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
oligomerization	oligomerization	O425	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
stem	stem	S350	VB	I-VP	O
from	from	F650	IN	B-PP	O
ligand	ligand	L253	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
independent	independent	I531	JJ	I-NP	O
interaction	interaction	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
Fas	Fas	F200	NN	I-NP	O
receptors	receptor	R213	NNS	I-NP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Preassociated	Preassociate	P623	VBN	B-NP	O
Fas	Fas	F200	NN	I-NP	O
complexes	complex	C514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
living	live	L152	VBG	B-VP	O
cells	cell	C420	NNS	B-NP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
resonance	resonance	R252	NN	I-NP	O
energy	energy	E562	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
between	between	B350	IN	B-PP	O
variants	variant	V653	NNS	B-NP	O
of	of	O100	IN	B-PP	O
green	green	G650	JJ	B-NP	O
fluorescent	fluorescent	F462	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
formation	formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
preassociated	preassociated	P623	JJ	B-NP	O
receptor	receptor	R213	NN	I-NP	O
complexes	complex	C514	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Fas	Fas	F200	NN	B-NP	O
signaling	signaling	S254	NN	I-NP	O
and	and	A530	CC	O	O
dominant	dominant	D530	JJ	B-NP	O
interference	interference	I536	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Determination	Determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
status	status	S320	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
flow	flow	F400	NN	B-NP	O
cytometric	cytometric	C353	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
mononuclear	mononuclear	M524	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
WASP	WASP	W210	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
study	study	S300	NN	I-NP	O
disclosed	disclose	D242	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
flow	flow	F400	NN	B-NP	O
cytometric	cytometric	C353	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
WASP	WASP	W210	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
(	(	0000	(	O	O
FCM	FCM	F250	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
WASP	WASP	W210	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
useful	useful	U214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Lymphocytes	Lymphocyte	L512	NNS	B-NP	O
from	from	F650	IN	B-PP	O
all	all	A400	DT	B-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
WASPdim	WASPdim	W213	NNP	B-NP	O
instead	instead	I523	RB	B-PP	O
of	of	O100	IN	I-PP	O
WASPbright	WASPbright	W216	NNP	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
FCM	FCM	F250	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
WASP	WASP	W210	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
monocytes	monocyte	M523	NNS	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

Monocytes	Monocyte	M523	NNS	B-NP	O
from	from	F650	IN	B-PP	O
all	all	A400	DT	B-NP	O
nine	nine	N500	CD	I-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
varied	varied	V630	JJ	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASPdim	WASPdim	W213	NNP	B-NP	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
WASPbright	WASPbright	W216	NNP	B-NP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
control	control	C536	NN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
possessed	possess	P230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
WASPdim	WASPdim	W213	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
from	from	F650	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
except	except	E213	IN	B-PP	O
two	two	T000	CD	B-NP	O
lacked	lack	L230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
WASPdim	WASPdim	W213	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WASPdim	WASPdim	W213	NNP	I-NP	O
population	population	P143	NN	I-NP	O
in	in	I500	IN	B-PP	O
monocytes	monocyte	M523	NNS	B-NP	O
and	and	A530	CC	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
WASP	WASP	W210	NN	B-NP	O
plays	play	P420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
monocytes	monocyte	M523	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
skewed	skewed	S230	JJ	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
fixed	fix	F230	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemopoietic	hemopoietic	H513	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
level	level	L140	NN	I-NP	O
but	but	B300	CC	O	O
progresses	progress	P626	VBZ	B-VP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
lineage	lineage	L520	NN	I-NP	O
commitment	commitment	C535	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Restoration	Restoration	R236	NN	B-NP	O
of	of	O100	IN	B-PP	O
photoreceptor	photoreceptor	P362	NN	B-NP	O
ultrastructure	ultrastructure	U436	NN	I-NP	O
and	and	A530	CC	I-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
slow	slow	S400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
by	by	B000	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
Prph2	Prph2	P610	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
,	,	0000	,	O	O
peripherin	peripherin	P616	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
2	2	0000	CD	I-NP	O
(	(	0000	(	O	O
also	also	A420	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
peripherin	peripherin	P616	NN	B-NP	O
/	/	0000	SYM	B-NP	O
rds	rd	R320	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
inserted	insert	I526	VBN	I-VP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
rims	rim	R520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
photoreceptor	photoreceptor	P362	NN	B-NP	O
outer	outer	O360	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
discs	disc	D200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
with	with	W300	IN	B-PP	O
rom	rom	R500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
stabilization	stabilization	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
discs	disc	D200	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
renewed	renew	R530	VBN	I-VP	O
constantly	constantly	C523	RB	B-ADVP	O
throughout	throughout	T623	IN	B-PP	O
life	life	L100	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
which	which	W200	WDT	B-NP	O
contain	contain	C535	VBP	B-VP	O
the	the	T000	DT	B-NP	O
visual	visual	V240	JJ	I-NP	O
pigments	pigment	P253	NNS	I-NP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
photon	photon	P350	NN	B-NP	O
capture	capture	C136	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Prph2	Prph2	P610	NN	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
photoreceptor	photoreceptor	P362	NN	B-NP	B-Disease
dystrophies	dystrophy	D236	NNS	I-NP	I-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
retinitis	retinitis	R353	NN	I-NP	I-Disease
pigmentosa	pigmentosa	P253	NN	I-NP	I-Disease
and	and	A530	CC	O	O
macular	macular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
diseases	disease	D200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
photoreceptor	photoreceptor	P362	NN	B-NP	O
function	function	F523	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinal	retinal	R354	JJ	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
slow	slow	S400	JJ	B-ADJP	O
(	(	0000	(	O	O
rds	rd	R320	NNS	B-NP	O
or	or	O600	CC	O	O
Prph2	Prph2	P610	NN	B-NP	O
Rd2	Rd2	R300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Rd2	Rd2	R300	NN	I-NP	O
)	)	0000	)	O	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Prph2	Prph2	P610	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
failure	failure	F460	NN	I-NP	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
photoreceptor	photoreceptor	P362	NN	B-NP	O
discs	disc	D200	NNS	I-NP	O
and	and	A530	CC	O	O
outer	outer	O360	JJ	B-NP	O
segments	segment	S253	NNS	I-NP	O
,	,	0000	,	O	O
downregulation	downregulation	D562	NN	B-NP	O
of	of	O100	IN	B-PP	O
rhodopsin	rhodopsin	R312	NN	B-NP	O
and	and	A530	CC	O	O
apoptotic	apoptotic	A132	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
photoreceptor	photoreceptor	P362	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
electroretinograms	electroretinogram	E423	NNS	I-NP	O
(	(	0000	(	O	O
ERGs	ERG	E620	NNS	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
Prph2Rd2	Prph2Rd2	P616	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Rd2	Rd2	R300	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
greatly	greatly	G634	RB	I-VP	O
diminished	diminish	D523	VBN	I-VP	O
a	a	A000	DT	B-NP	O
-	-	0000	HYPH	I-NP	O
wave	wave	W100	NN	I-NP	O
and	and	A530	CC	I-NP	O
b	b	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wave	wave	W100	NN	I-NP	O
amplitudes	amplitude	A514	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
decline	decline	D245	VBP	B-VP	O
to	to	T000	TO	B-PP	O
virtually	virtually	V634	RB	B-NP	O
undetectable	undetectable	U532	JJ	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
.	.	0000	.	O	O

Subretinal	Subretinal	S163	JJ	B-NP	O
injection	injection	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
adeno	adeno	A350	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
associated	associate	A230	VBN	B-NP	O
virus	virus	V620	NN	I-NP	O
(	(	0000	(	O	O
AAV	AAV	A100	NN	B-NP	O
)	)	0000	)	O	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
Prph2	Prph2	P610	NN	I-NP	O
transgene	transgene	T652	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
stable	stable	S314	JJ	B-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
outer	outer	O360	JJ	B-NP	O
segment	segment	S253	NN	I-NP	O
structures	structure	S362	NNS	I-NP	O
and	and	A530	CC	O	O
formation	formation	F653	NN	B-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
stacks	stack	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
discs	disc	D200	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
both	both	B300	CC	O	O
perpherin	perpherin	P616	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	O	O
rhodopsin	rhodopsin	R312	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
morphologically	morphologically	M614	RB	B-ADJP	O
similar	similar	S546	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
outer	outer	O360	JJ	I-NP	O
segments	segment	S253	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
re	re	R000	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
establishment	establishment	E231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
integrity	integrity	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
layer	layer	L600	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
electrophysiological	electrophysiological	E423	JJ	B-NP	O
correction	correction	C623	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
time	time	T500	NN	I-NP	O
that	that	T300	IN	B-ADVP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
ultrastructural	ultrastructural	U436	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
corrected	correct	C623	VBN	I-VP	O
both	both	B300	CC	O	O
morphologically	morphologically	M614	RB	B-ADVP	O
and	and	A530	CC	I-ADVP	O
functionally	functionally	F523	RB	I-ADVP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
gene	gene	G500	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fibrinogen	fibrinogen	F165	NN	I-NP	O
aalpha	aalpha	A410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
account	account	A253	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
afibrinogenemia	afibrinogenemia	A165	NN	I-NP	I-Disease
.	.	0000	.	O	O

Congenital	Congenital	C525	JJ	B-NP	B-Disease
afibrinogenemia	afibrinogenemia	A165	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
,	,	0000	,	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
detectable	detectable	D323	JJ	B-NP	O
fibrinogen	fibrinogen	F165	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
previously	previously	P612	RB	B-ADVP	O
identified	identify	I353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
causative	causative	C231	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonconsanguineous	nonconsanguineous	N525	JJ	I-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
4	4	0000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
persons	person	P625	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
11	11	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fibrinogen	fibrinogen	F165	NN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
(	(	0000	(	O	O
FGA	FGA	F200	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
implied	imply	I514	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
occurred	occur	O263	VBD	B-VP	O
on	on	O500	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
deletion	deletion	D435	NN	B-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
subsequently	subsequently	S125	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
and	and	A530	CC	O	O
probably	probably	P614	RB	B-VP	O
resulted	result	R243	VBD	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonhomologous	nonhomologous	N542	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
mediated	mediate	M300	VBN	B-VP	O
by	by	B000	IN	B-PP	O
7	7	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
direct	direct	D623	JJ	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
collected	collect	C423	VBN	I-VP	O
data	datum	D300	NNS	B-NP	O
on	on	O500	IN	B-PP	O
13	13	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
causative	causative	C231	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
FGA	FGA	F200	NN	B-NP	O
intron	intron	I536	NN	I-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
IVS4	IVS4	I120	NN	B-NP	O
+	+	0000	SYM	O	O
1	1	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
14	14	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
26	26	0000	CD	I-NP	O
(	(	0000	(	O	O
54	54	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
alleles	allele	A420	NNS	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
more	more	M600	JJR	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
86	86	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
afibrinogenemia	afibrinogenemia	A165	NN	B-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
have	have	H100	VBP	B-VP	O
truncating	truncate	T652	VBG	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
FGA	FGA	F200	NN	B-NP	O
,	,	0000	,	O	O
though	though	T200	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
3	3	0000	CD	I-NP	O
fibrinogen	fibrinogen	F165	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
FGG	FGG	F200	NN	B-NP	O
,	,	0000	,	O	O
FGA	FGA	F200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
FGB	FGB	F210	NN	B-NP	O
,	,	0000	,	O	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
afibrinogenemia	afibrinogenemia	A165	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
:	:	0000	:	O	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CUG	CUG	C200	NN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
splicing	splicing	S142	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
and	and	A530	CC	O	O
altered	alter	A436	VBD	B-VP	O
cytoplasmic	cytoplasmic	C314	JJ	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
isoform	isoform	I216	NN	I-NP	O
ratios	ratio	R320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
by	by	B000	IN	B-PP	O
which	which	W200	WDT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
UTR	UTR	U360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
four	four	F600	CD	B-NP	O
RNA	RNA	R500	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
hnRNP	hnRNP	H565	NN	I-NP	O
C	C	C000	NN	I-NP	O
,	,	0000	,	O	O
U2AF	U2AF	U100	NN	B-NP	O
(	(	0000	(	O	O
U2	U2	U000	NN	B-NP	O
auxiliary	auxiliary	A246	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
PTB	PTB	P310	NN	B-NP	O
(	(	0000	(	O	O
polypyrimidine	polypyrimidine	P416	NN	B-NP	O
tract	tract	T623	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
PSF	PSF	P210	NN	B-NP	O
(	(	0000	(	O	O
PTB	PTB	P310	NN	B-NP	O
associated	associate	A230	VBN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
that	that	T300	WDT	B-NP	O
bind	bind	B530	VBP	B-VP	O
to	to	T000	TO	B-PP	O
two	two	T000	CD	B-NP	O
short	short	S630	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CUG	CUG	C200	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
3	3	0000	CD	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
lacking	lack	L252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CUG	CUG	C200	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
essential	essential	E253	JJ	I-NP	O
cis	cis	C200	NN	I-NP	O
acting	act	A235	VBG	B-VP	O
element	element	E453	NN	B-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
event	event	E153	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
(	(	0000	(	B-NP	O
CUG	CUG	C200	NN	I-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
containing	contain	C535	VBG	B-VP	O
mRNAs	mRNA	M652	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
isoform	isoform	I216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
retained	retain	R353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
imbalances	imbalance	I514	NNS	B-NP	O
in	in	I500	IN	B-PP	O
relative	relative	R431	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cytoplasmic	cytoplasmic	C314	JJ	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
on	on	O500	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
and	and	A530	CC	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
Prader	Prader	P636	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
willi	willi	W400	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
murine	murine	M650	JJ	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
imprinted	imprinted	I516	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

Affected	Affected	A123	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
hypotonia	hypotonia	H135	NN	I-NP	I-Disease
,	,	0000	,	O	O
developmental	developmental	D141	JJ	B-NP	B-Disease
delay	delay	D400	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
childhood	childhood	C430	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
onset	onset	O523	NN	I-NP	I-Disease
obesity	obesity	O123	NN	I-NP	I-Disease
.	.	0000	.	O	O

Necdin	Necdin	N235	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
implicated	implicate	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
differentiation	differentiation	D165	NN	I-NP	O
of	of	O100	IN	B-PP	O
neurons	neuron	N652	NNS	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-VP	O
reduce	reduce	R320	VB	I-VP	O
viability	viability	V143	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
disrupted	disrupt	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
(	(	0000	(	O	O
also	also	A420	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
NDNL1	NDNL1	N354	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
51	51	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
similarity	similarity	S546	NN	I-NP	O
to	to	T000	TO	B-PP	O
necdin	necdin	N235	NN	B-NP	O
and	and	A530	CC	O	O
located	located	L230	JJ	B-NP	O
41	41	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
NDN	NDN	N350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
deletion	deletion	D435	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

MAGEL2	MAGEL2	M240	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
predominantly	predominantly	P635	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
tissue	tissue	T200	NN	I-NP	O
affected	affect	A123	VBN	B-VP	O
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
fetal	fetal	F340	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
shown	show	S500	VBN	B-VP	O
by	by	B000	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

MAGEL2	MAGEL2	M240	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
imprinted	imprint	I516	VBN	I-VP	O
with	with	W300	IN	B-PP	O
monoallelic	monoallelic	M542	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
control	control	C536	NN	B-NP	O
brain	brain	B650	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
paternal	paternal	P365	JJ	B-ADJP	O
-	-	0000	HYPH	O	O
only	only	O540	RB	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
demonstrated	demonstrate	D523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
affected	affect	A123	VBN	I-VP	O
individual	individual	I531	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
orthologous	orthologous	O634	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Magel2	Magel2	M240	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
150	150	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
NDN	NDN	N350	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
imprinted	imprint	I516	VBN	I-VP	O
with	with	W300	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
only	only	O540	RB	I-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
predominantly	predominantly	P635	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
late	late	L300	JJ	B-NP	O
developmental	developmental	D141	JJ	I-NP	O
stages	stage	S320	NNS	I-NP	O
and	and	A530	CC	O	O
adult	adult	A343	JJ	B-NP	O
brain	brain	B650	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
shown	show	S500	VBN	B-VP	O
by	by	B000	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
blotting	blotting	B435	NN	I-NP	O
,	,	0000	,	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	O	O
whole	whole	W400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
mount	mount	M530	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

Magel2	Magel2	M240	NN	B-NP	O
distribution	distribution	D236	NN	I-NP	O
partially	partially	P634	RB	B-ADVP	O
overlaps	overlap	O164	VBZ	B-VP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
NDN	NDN	N350	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
strong	strong	S365	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
being	be	B520	VBG	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
in	in	I500	IN	B-PP	O
mid	mid	M300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
gestation	gestation	G235	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
embryos	embryo	E516	NNS	I-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesize	hypothesize	H132	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
necdin	necdin	N235	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
neonatal	neonatal	N534	JJ	I-NP	O
presentation	presentation	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
MAGEL2	MAGEL2	M240	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
critical	critical	C632	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
abnormalities	abnormality	A156	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
brain	brain	B650	NN	B-NP	I-Disease
development	development	D141	NN	I-NP	I-Disease
and	and	A530	CC	O	O
dysmorphic	dysmorphic	D256	JJ	B-NP	B-Disease
features	feature	F362	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Retinoschisin	Retinoschisin	R352	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
retinoschisis	retinoschisis	R352	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
secreted	secrete	S263	VBN	I-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
and	and	A530	CC	I-VP	O
released	release	R423	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Weri	Weri	W600	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Rb1	Rb1	R100	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-PP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
retinoschisis	retinoschisis	R352	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
microcystic	microcystic	M262	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
like	like	L200	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
macular	macular	M246	JJ	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	I-NP	O
schisis	schisis	S200	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
retinal	retinal	R354	JJ	I-NP	O
layers	layer	L620	NNS	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
visual	visual	V240	JJ	B-NP	B-Disease
deterioration	deterioration	D363	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
missense	missense	M252	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	O	O
truncating	truncate	T652	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
causative	causative	C231	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
RS1	RS1	R200	NN	I-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
inactivating	inactivate	I523	VBG	I-VP	O
.	.	0000	.	O	O

RS1	RS1	R200	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
224	224	0000	CD	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
discoidin	discoidin	D235	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
generated	generate	G563	VBN	I-VP	O
a	a	A000	DT	B-NP	O
polyclonal	polyclonal	P424	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
against	against	A252	IN	B-PP	O
a	a	A000	DT	B-NP	O
peptide	peptide	P130	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
within	within	W350	IN	B-PP	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
detects	detect	D323	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
28	28	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
in	in	I500	IN	B-PP	O
retinal	retinal	R354	JJ	B-NP	O
samples	sample	S514	NNS	I-NP	O
reduced	reduce	R323	VBN	B-VP	O
with	with	W300	IN	B-PP	O
dithiothreitol	dithiothreitol	D363	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
multimers	multimer	M435	NNS	B-NP	O
sized	size	S230	VBD	B-VP	O
>	>	0000	SYM	B-NP	O
40	40	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
under	under	U536	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
reducing	reduce	R325	VBG	B-VP	O
conditions	condition	C535	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
screen	screen	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
antibody	antibody	A531	NN	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
retina	retina	R350	NN	B-NP	O
specific	specific	S121	JJ	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
antibody	antibody	A531	NN	I-NP	O
detects	detect	D323	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
size	size	S200	NN	I-NP	O
in	in	I500	IN	B-PP	O
bovine	bovine	B150	JJ	B-NP	O
and	and	A530	CC	I-NP	O
murine	murine	M650	JJ	I-NP	O
retinae	retina	R350	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retina	retina	R350	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
RS1	RS1	R200	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
(	(	0000	(	O	O
using	use	U252	VBG	B-VP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
with	with	W300	IN	B-PP	O
riboprobes	riboprobe	R161	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
(	(	0000	(	O	O
using	use	U252	VBG	B-VP	O
immunohistochemistry	immunohistochemistry	I523	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
antisense	antisense	A532	JJ	I-NP	O
riboprobe	riboprobe	R161	NN	I-NP	O
detected	detect	D323	VBD	B-VP	O
RS1	RS1	R200	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
only	only	O540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
layer	layer	L600	NN	I-NP	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
both	both	B300	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
photoreceptors	photoreceptor	P362	NNS	I-NP	O
and	and	A530	CC	B-PP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
portions	portion	P635	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retina	retina	R350	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
differentiated	differentiate	D165	VBN	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
(	(	0000	(	O	O
Weri	Weri	W600	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Rb1	Rb1	R100	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
express	express	E216	VB	I-VP	O
RS1	RS1	R200	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
release	release	R420	VB	I-VP	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
retinoschisin	retinoschisin	R352	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
released	release	R423	VBN	I-VP	O
by	by	B000	IN	B-PP	O
photo	photo	P300	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
receptors	receptor	R213	NNS	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
functions	function	F523	NNS	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
inner	inner	I560	JJ	I-NP	O
retinal	retinal	R354	JJ	I-NP	O
layers	layer	L620	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
retinoschisis	retinoschisis	R352	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
abnormalities	abnormality	A156	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
secreted	secrete	S263	VBN	I-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
secreted	secrete	S263	VBN	I-NP	O
photo	photo	P300	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
receptor	receptor	R213	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
retinal	retinal	R354	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
voltage	voltage	V432	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
gated	gate	G300	VBN	B-NP	O
sodium	sodium	S350	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
1	1	0000	CD	I-NP	O
subunit	subunit	S153	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
SCN1B	SCN1B	S251	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
benign	benign	B525	JJ	I-NP	B-Disease
familial	familial	F540	JJ	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
convulsions	convulsion	C514	NNS	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
BFIC	BFIC	B120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Benign	Benign	B525	JJ	B-NP	B-Disease
familial	familial	F540	JJ	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
convulsions	convulsion	C514	NNS	I-NP	I-Disease
(	(	0000	(	O	O
BFIC	BFIC	B120	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
epilepsy	epilepsy	E141	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
recently	recently	R253	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Italian	Italian	I345	JJ	B-NP	O
and	and	A530	CC	I-NP	O
French	French	F652	JJ	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
present	present	P625	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
partial	partial	P634	JJ	B-NP	O
,	,	0000	,	I-NP	O
then	then	T500	RB	I-NP	O
generalized	generalize	G564	VBN	I-NP	O
seizures	seizure	S262	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
three	three	T600	CD	B-NP	O
months	month	M532	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seizures	seizure	S262	NNS	I-NP	O
usually	usually	U240	RB	B-ADVP	O
spontaneously	spontaneously	S153	RB	B-NP	O
cease	cease	C200	NN	I-NP	O
after	after	A136	IN	B-PP	O
one	one	O500	CD	B-NP	O
year	year	Y600	NN	I-NP	O
without	without	W300	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
,	,	0000	,	O	O
leaving	leave	L152	VBG	B-VP	O
no	no	N000	DT	B-NP	O
neurological	neurological	N642	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
BFIC	BFIC	B120	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19q	19q	Q000	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sodium	sodium	S350	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
beta1	beta1	B300	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
SCN1B	SCN1B	S251	NN	B-NP	O
)	)	0000	)	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
Australian	Australian	A236	JJ	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	B-Disease
epilepsy	epilepsy	E141	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
febrile	febrile	F164	NN	I-NP	I-Disease
seizures	seizure	S262	NNS	I-NP	I-Disease
"	"	0000	''	O	I-Disease
plus	plus	P420	CC	O	I-Disease
"	"	0000	''	O	I-Disease
(	(	0000	(	O	O
GEFS	GEFS	G120	NN	B-NP	O
+	+	0000	SYM	B-ADJP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
SCN1B	SCN1B	S251	NN	B-NP	O
cosegregates	cosegregate	C262	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
GEFS	GEFS	G120	NN	I-NP	O
+	+	0000	SYM	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

BFIC	BFIC	B120	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
GEFS	GEFS	G120	NN	I-NP	O
+	+	0000	SYM	B-NP	O
have	have	H100	VBP	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
common	common	C500	JJ	B-NP	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
SCN1B	SCN1B	S251	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
BFIC	BFIC	B120	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
SCN1B	SCN1B	S251	NN	B-NP	O
exons	exon	E252	NNS	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
four	four	F600	CD	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
methods	method	M320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
BFIC	BFIC	B120	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Western	Western	W236	NNP	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
no	no	N000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
IVS5	IVS5	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
10C	10C	C000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
segregate	segregate	S262	VB	I-VP	O
with	with	W300	IN	B-PP	O
BFIC	BFIC	B120	NN	B-NP	B-Disease
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
5	5	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
(	(	0000	(	O	O
IVS5	IVS5	I120	NN	B-NP	O
+	+	0000	SYM	B-NP	O
30G	30G	G000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
not	not	N300	RB	O	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
segregating	segregate	S262	VBG	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BFIC	BFIC	B120	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Inactivation	Inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
familial	familial	F540	JJ	I-NP	I-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
APC	APC	A120	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
tumor	tumor	T560	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
typically	typically	T124	RB	B-ADVP	O
develop	develop	D141	VBP	B-VP	O
hundreds	hundred	H536	NNS	B-NP	O
to	to	T000	TO	B-PP	O
thousands	thousand	T253	NNS	B-NP	O
of	of	O100	IN	B-PP	O
benign	benign	B525	JJ	B-NP	B-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
attenuated	attenuate	A353	VBN	I-NP	B-Disease
FAP	FAP	F100	NN	I-NP	I-Disease
(	(	0000	(	O	O
AFAP	AFAP	A100	NN	B-NP	B-Disease
)	)	0000	)	O	O
phenotype	phenotype	P531	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
patients	patient	P353	NNS	B-NP	O
develop	develop	D141	VBP	B-VP	O
fewer	few	F600	JJR	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
develop	develop	D141	VB	B-VP	O
them	them	T500	PRP	B-NP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
older	old	O436	JJR	I-NP	O
age	age	A200	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
AFAP	AFAP	A100	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
well	well	W400	RB	I-VP	O
documented	document	D253	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
AFAP	AFAP	A100	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
well	well	W400	RB	B-ADJP	O
defined	define	D153	VBN	I-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
AFAP	AFAP	A100	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
alternatively	alternatively	A436	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
down	down	D500	RB	B-VP	O
-	-	0000	HYPH	I-VP	O
regulate	regulate	R243	VB	I-VP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
catenin	catenin	C350	NN	I-NP	O
-	-	0000	HYPH	O	O
regulated	regulate	R243	VBN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	O
suppressor	suppressor	S162	NN	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
did	do	D300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
somatically	somatically	S532	RB	B-ADJP	O
mutated	mutated	M300	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
4666insA	4666insA	I520	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
inactivate	inactivate	I523	VB	I-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
develop	develop	D141	VBP	B-VP	O
fewer	few	F600	JJR	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
than	than	T500	IN	B-SBAR	O
do	do	D000	VBP	B-VP	O
typical	typical	T124	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
because	because	B200	IN	B-SBAR	O
somatic	somatic	S532	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	O
tumorigenesis	tumorigenesis	T562	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
develop	develop	D141	VBP	B-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
than	than	T500	IN	B-SBAR	O
does	do	D200	VBZ	O	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
because	because	B200	IN	B-SBAR	O
APC	APC	A120	NN	B-NP	O
(	(	0000	(	O	O
AS9	AS9	A200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
inactivated	inactivate	I523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
inactivate	inactivate	I523	VB	I-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Iron	Iron	I650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
self	self	S410	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
assembly	assembly	A251	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
frataxin	frataxin	F632	NN	I-NP	O
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

Frataxin	Frataxin	F632	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
cardiodegenerative	cardiodegenerative	C632	JJ	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
neurodegenerative	neurodegenerative	N632	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Frataxin	Frataxin	F632	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
encoded	encode	E523	VBN	I-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
widely	widely	W340	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
among	among	A520	IN	B-PP	O
eukaryotes	eukaryote	E263	NNS	B-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
frataxin	frataxin	F632	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
(	(	0000	(	O	O
Yfh1p	Yfh1p	Y100	NN	B-NP	O
)	)	0000	)	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	B-Disease
iron	iron	I650	NN	I-NP	I-Disease
accumulation	accumulation	A254	NN	I-NP	I-Disease
and	and	A530	CC	O	O
hypersensitivity	hypersensitivity	H162	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
oxidative	oxidative	O231	JJ	B-NP	I-Disease
stress	stress	S362	NN	I-NP	I-Disease
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
iron	iron	I650	NN	I-NP	O
deposition	deposition	D123	NN	I-NP	O
and	and	A530	CC	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
damage	damage	D520	NN	I-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
and	and	A530	CC	O	O
cultured	culture	C436	VBN	B-VP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
frataxin	frataxin	F632	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
and	and	A530	CC	I-NP	O
protection	protection	P632	NN	I-NP	O
from	from	F650	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
free	free	F600	JJ	B-NP	O
radicals	radical	R324	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
frataxin	frataxin	F632	NN	B-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Yfh1p	Yfh1p	Y100	NN	B-NP	O
(	(	0000	(	O	O
mYfh1p	mYfh1p	M100	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Escherichia	Escherichia	E262	FW	B-NP	O
coli	coli	C400	FW	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
its	its	I320	PRP$	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

Isolated	Isolate	I243	VBN	B-NP	O
mYfh1p	mYfh1p	M100	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
soluble	soluble	S414	JJ	I-NP	O
monomer	monomer	M560	NN	I-NP	O
(	(	0000	(	O	O
13	13	0000	CD	B-NP	O
,	,	0000	,	O	O
783	783	0000	CD	B-NP	O
Da	Da	D000	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
iron	iron	I650	NN	I-NP	O
and	and	A530	CC	O	O
shows	show	S200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
tendency	tendency	T535	NN	I-NP	O
to	to	T000	TO	B-PP	O
self	self	S410	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
associate	associate	A230	NN	I-NP	O
.	.	0000	.	O	O

Aerobic	Aerobic	A612	JJ	B-NP	O
addition	addition	A350	NN	I-NP	O
of	of	O100	IN	B-PP	O
ferrous	ferrous	F620	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
to	to	T000	TO	B-PP	O
mYfh1p	mYfh1p	M100	NN	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
assembly	assembly	A251	NN	B-NP	O
of	of	O100	IN	B-PP	O
regular	regular	R246	JJ	B-NP	O
spherical	spherical	S162	JJ	I-NP	O
multimers	multimer	M435	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mass	mass	M200	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
MDa	MDa	M300	NN	I-NP	O
(	(	0000	(	O	O
megadaltons	megadalton	M234	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
diameter	diameter	D536	NN	I-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
2	2	0000	CD	B-NP	O
nm	nm	N500	NN	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
multimer	multimer	M435	NN	I-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
60	60	0000	CD	I-NP	O
subunits	subunit	S153	NNS	I-NP	O
and	and	A530	CC	O	O
can	can	C500	MD	B-VP	O
sequester	sequester	S236	VB	I-VP	O
>	>	0000	JJR	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
atoms	atom	A352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
.	.	0000	.	O	O

Titration	Titration	T363	NN	B-NP	O
of	of	O100	IN	B-PP	O
mYfh1p	mYfh1p	M100	NN	B-NP	O
with	with	W300	IN	B-PP	O
increasing	increase	I526	VBG	B-NP	O
iron	iron	I650	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
supports	support	S163	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
stepwise	stepwise	S312	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
multimer	multimer	M435	NN	B-NP	O
assembly	assembly	A251	NN	I-NP	O
.	.	0000	.	O	O

Sequential	Sequential	S253	JJ	B-NP	O
addition	addition	A350	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
iron	iron	I650	NN	I-NP	O
chelator	chelator	C436	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
reducing	reduce	R325	VBG	I-NP	O
agent	agent	A253	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
quantitative	quantitative	Q531	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
release	release	R420	NN	I-NP	O
with	with	W300	IN	B-PP	O
concomitant	concomitant	C525	JJ	B-NP	O
disassembly	disassembly	D251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
multimer	multimer	M435	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
mYfh1p	mYfh1p	M100	NN	B-NP	O
sequesters	sequester	S236	NNS	I-NP	O
iron	iron	I650	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
available	available	A141	JJ	I-NP	O
form	form	F650	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
mitochondria	mitochondrion	M325	NNS	I-NP	O
,	,	0000	,	O	O
native	native	N310	JJ	B-NP	O
mYfh1p	mYfh1p	M100	NN	I-NP	O
exists	exist	E232	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
monomer	monomer	M560	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
-	-	0000	HYPH	I-NP	O
order	order	O636	NN	I-NP	O
species	specie	S120	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
>	>	0000	JJR	I-NP	O
600	600	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
(	(	0000	(	O	O
55	55	0000	CD	B-NP	O
)	)	0000	)	O	O
Fe	Fe	F000	NNP	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
medium	medium	M350	NN	I-NP	O
,	,	0000	,	O	O
immunoprecipitates	immunoprecipitate	I516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
species	specie	S120	NNS	I-NP	O
contain	contain	C535	VBP	B-VP	O
>	>	0000	JJR	B-NP	O
16	16	0000	CD	I-NP	O
atoms	atom	A352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
(	(	0000	(	O	O
55	55	0000	CD	B-NP	O
)	)	0000	)	O	O
Fe	Fe	F000	NN	B-NP	O
per	per	P600	IN	B-PP	O
molecule	molecule	M424	NN	B-NP	O
of	of	O100	IN	B-PP	O
mYfh1p	mYfh1p	M100	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
iron	iron	I650	NN	B-NP	O
-	-	0000	HYPH	O	O
dependent	dependent	D153	JJ	B-NP	O
self	self	S410	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
assembly	assembly	A251	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
mYfh1p	mYfh1p	M100	NN	I-NP	O
reflects	reflect	R142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
physiological	physiological	P242	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
frataxin	frataxin	F632	NN	B-NP	O
in	in	I500	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
sequestration	sequestration	S236	NN	I-NP	O
and	and	A530	CC	I-NP	O
bioavailability	bioavailability	B141	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pleckstrin	pleckstrin	P423	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
(	(	0000	(	O	O
PH	PH	P000	NN	B-NP	O
)	)	0000	)	O	O
domain	domain	D500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
faciogenital	faciogenital	F253	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
(	(	0000	(	O	O
Aarskog	Aarskog	A620	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Scott	Scott	S230	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Aarskog	Aarskog	A620	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Scott	Scott	S230	NN	I-NP	I-Disease
Syndrome	Syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AAS	AAS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterised	characterise	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
short	short	S630	JJ	B-NP	B-Disease
stature	stature	S360	NN	I-NP	I-Disease
and	and	A530	CC	O	O
multiple	multiple	M431	JJ	B-NP	O
facial	facial	F240	JJ	I-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
limb	limb	L510	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
genital	genital	G534	JJ	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
FGD1	FGD1	F230	NN	B-NP	O
,	,	0000	,	O	O
altered	alter	A436	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
AAS	AAS	A200	NN	B-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
homology	homology	H542	NN	B-NP	O
to	to	T000	TO	B-PP	O
Rho	Rho	R000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Rac	Rac	R200	NN	I-NP	O
guanine	guanine	G500	NN	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
exchange	exchange	E252	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
(	(	0000	(	O	O
Rho	Rho	R000	NN	B-NP	O
/	/	0000	SYM	O	O
Rac	Rac	R200	NN	B-NP	O
GEF	GEF	G100	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
original	original	O625	JJ	I-NP	O
report	report	R163	NN	I-NP	O
on	on	O500	IN	B-PP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
AAS	AAS	A200	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analysed	analyse	A542	VBD	B-VP	O
13	13	0000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
AAS	AAS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
presented	present	P625	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
10	10	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
G2559	G2559	G000	NN	B-NP	O
>	>	0000	SYM	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
substituting	substitute	S123	VBG	B-VP	O
a	a	A000	DT	B-NP	O
Gln	Gln	G450	NN	I-NP	O
for	for	F600	IN	B-PP	O
Arg	Arg	A620	NN	B-NP	O
in	in	I500	IN	B-PP	O
position	position	P235	NN	B-NP	O
610	610	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
segregate	segregate	S262	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
AAS	AAS	A200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
carrier	carrier	C600	NN	B-NP	O
females	female	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
Arg	Arg	A620	NN	B-NP	O
-	-	0000	HYPH	O	O
610	610	0000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
pleckstrin	pleckstrin	P423	NN	I-NP	O
homology	homology	H542	NN	I-NP	O
(	(	0000	(	O	O
PH	PH	P000	NN	B-NP	O
)	)	0000	)	O	O
domains	domain	D520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
corresponds	correspond	C621	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
residue	residue	R230	NN	I-NP	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
InsP	InsP	I521	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
in	in	I500	IN	B-PP	O
PH	PH	P000	NN	B-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
residue	residue	R230	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	B-ADVP	O
mutated	mutated	M300	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Brutons	Brutons	B635	NNP	I-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
Btk	Btk	B320	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
agammaglobulinemia	agammaglobulinemia	A252	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Arg610Gln	Arg610Gln	A624	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PH	PH	P000	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FGD1	FGD1	F230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
additional	additional	A354	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PH	PH	P000	NN	B-NP	O
domains	domain	D520	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
diseases	disease	D200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Amino	Amino	A500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
show	show	S000	VBP	B-VP	O
selective	selective	S423	JJ	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
in	in	I500	IN	B-PP	O
striatal	striatal	S363	JJ	B-NP	O
neurons	neuron	N652	NNS	I-NP	O
and	and	A530	CC	O	O
synaptic	synaptic	S513	JJ	B-NP	O
toxicity	toxicity	T230	NN	I-NP	O
.	.	0000	.	O	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
glutamine	glutamine	G435	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
huntingtin	huntingtin	H535	NN	B-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
widespread	widespread	W321	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
mutant	mutant	M353	JJ	B-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
induces	induce	I532	VBZ	B-VP	O
selective	selective	S423	JJ	B-NP	O
neuronal	neuronal	N654	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
striatal	striatal	S363	JJ	B-NP	O
neurons	neuron	N652	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
HD	HD	H300	NN	B-NP	B-Disease
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
production	production	P632	NN	I-NP	O
and	and	A530	CC	I-NP	O
aggregation	aggregation	A262	NN	I-NP	O
of	of	O100	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
preferentially	preferentially	P616	RB	B-ADVP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
-	-	0000	HYPH	O	O
affected	affect	A123	VBN	B-NP	O
neurons	neuron	N652	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
processes	process	P620	NNS	I-NP	O
and	and	A530	CC	O	O
axonal	axonal	A254	JJ	B-NP	O
terminals	terminal	T654	NNS	I-NP	O
.	.	0000	.	O	O

N	N	N000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
form	form	F650	NN	I-NP	O
aggregates	aggregate	A262	NNS	I-NP	O
and	and	A530	CC	O	O
induce	induce	I532	VB	B-VP	O
neuritic	neuritic	N632	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
striatal	striatal	S363	JJ	I-NP	O
neurons	neuron	N652	NNS	I-NP	O
.	.	0000	.	O	O

N	N	N000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
binds	bind	B532	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
synaptic	synaptic	S513	JJ	B-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
and	and	A530	CC	O	O
inhibits	inhibit	I513	VBZ	B-VP	O
their	their	T600	PRP$	B-NP	O
glutamate	glutamate	G435	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
processing	processing	P625	NN	I-NP	O
and	and	A530	CC	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
toxic	toxic	T200	JJ	B-NP	O
fragments	fragment	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	O
affected	affect	A123	VBN	I-VP	O
striatal	striatal	S363	JJ	B-NP	O
neurons	neuron	N652	NNS	I-NP	O
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
neuronal	neuronal	N654	JJ	I-NP	O
processes	process	P620	NNS	I-NP	O
and	and	A530	CC	O	O
axonal	axonal	A254	JJ	B-NP	O
terminals	terminal	T654	NNS	I-NP	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
neuropathology	neuropathology	N613	NN	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
SWI	SWI	S000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
SNF	SNF	S510	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
complex	complex	C514	NN	I-NP	O
:	:	0000	:	O	O
linking	link	L525	VBG	B-VP	O
chromatin	chromatin	C653	NN	B-NP	O
remodeling	remodeling	R534	NN	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
predispose	predispose	P632	VB	B-VP	O
individuals	individual	I531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
affinity	affinity	A153	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
conventional	conventional	C515	JJ	I-NP	O
chromatographic	chromatographic	C653	JJ	I-NP	O
techniques	technique	T252	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
a	a	A000	DT	B-NP	O
predominant	predominant	P635	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
multiprotein	multiprotein	M431	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
complex	complex	C514	NN	B-NP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
displaying	display	D214	VBG	B-VP	O
chromatin	chromatin	C653	NN	B-NP	O
-	-	0000	HYPH	O	O
remodeling	remodel	R534	VBG	B-VP	O
activity	activity	A231	NN	B-NP	O
.	.	0000	.	O	O

Mass	Mass	M200	NNP	B-NP	O
spectrometric	spectrometric	S123	JJ	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
components	component	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
complex	complex	C514	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
SWI	SWI	S000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
SNF	SNF	S510	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
can	can	C500	MD	B-VP	O
directly	directly	D623	RB	I-VP	O
interact	interact	I536	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRG1	BRG1	B620	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SWI	SWI	S000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
SNF	SNF	S510	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
p53	p53	P000	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
mediated	mediate	M300	VBN	B-NP	O
stimulation	stimulation	S354	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
completely	completely	C514	RB	I-VP	O
abrogated	abrogate	A162	VBN	I-VP	O
by	by	B000	IN	B-PP	O
either	either	E360	CC	O	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
mutant	mutant	M353	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRG1	BRG1	B620	NN	B-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
deletion	deletion	D435	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
reveal	reveal	R140	VBP	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
function	function	F523	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
control	control	C536	NN	I-NP	O
through	through	T620	IN	B-PP	O
modulation	modulation	M343	NN	B-NP	O
of	of	O100	IN	B-PP	O
chromatin	chromatin	C653	NN	B-NP	O
structure	structure	S362	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Asef	Asef	A210	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
and	and	A530	CC	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
protein	protein	P635	NN	I-NP	O
signaling	signaling	S254	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
bind	bind	B530	VB	I-VP	O
through	through	T620	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
armadillo	armadillo	A653	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
Rac	Rac	R200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
guanine	guanine	G500	NN	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
exchange	exchange	E252	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
GEF	GEF	G100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
termed	term	T653	VBN	B-NP	O
Asef	Asef	A210	NN	I-NP	O
.	.	0000	.	O	O

Endogenous	Endogenous	E532	JJ	B-NP	O
APC	APC	A120	NN	I-NP	O
colocalized	colocalize	C424	VBD	B-VP	O
with	with	W300	IN	B-PP	O
Asef	Asef	A210	NN	B-NP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
colon	colon	C450	NN	I-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
neuronal	neuronal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
APC	APC	A120	NN	B-NP	O
enhanced	enhance	E523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
GEF	GEF	G100	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
Asef	Asef	A210	NN	B-NP	O
and	and	A530	CC	O	O
stimulated	stimulate	S354	VBD	B-VP	O
Asef	Asef	A210	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
flattening	flattening	F435	NN	I-NP	O
,	,	0000	,	O	O
membrane	membrane	M516	NN	B-NP	O
ruffling	ruffling	R145	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
lamellipodia	lamellipodia	L541	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
in	in	I500	IN	B-PP	O
MDCK	MDCK	M320	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Asef	Asef	A210	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
may	may	M000	MD	B-VP	O
regulate	regulate	R243	VB	I-VP	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
cytoskeletal	cytoskeletal	C324	JJ	I-NP	O
network	network	N362	NN	I-NP	O
,	,	0000	,	O	O
cell	cell	C400	NN	B-NP	O
morphology	morphology	M614	NN	I-NP	O
and	and	A530	CC	I-NP	O
migration	migration	M263	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
neuronal	neuronal	N654	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Function	Function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
axonal	axonal	A254	JJ	I-NP	O
chemoattractant	chemoattractant	C536	NN	I-NP	O
modulated	modulate	M343	VBN	B-VP	O
by	by	B000	IN	B-PP	O
metalloprotease	metalloprotease	M341	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
axonal	axonal	A254	JJ	I-NP	O
chemoattractant	chemoattractant	C536	NN	I-NP	O
netrin	netrin	N365	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
guides	guide	G320	NNS	I-NP	O
spinal	spinal	S154	JJ	B-NP	O
commissural	commissural	C526	JJ	I-NP	O
axons	axon	A252	NNS	I-NP	O
by	by	B000	IN	B-PP	O
activating	activate	A231	VBG	B-VP	O
its	its	I320	PRP$	B-NP	O
receptor	receptor	R213	NN	I-NP	O
DCC	DCC	D200	NN	I-NP	O
(	(	0000	(	O	O
Deleted	Delete	D430	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Colorectal	Colorectal	C462	JJ	B-NP	B-Disease
Cancer	Cancer	C526	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
chemical	chemical	C524	JJ	B-NP	O
inhibitors	inhibitor	I513	NNS	I-NP	O
of	of	O100	IN	B-PP	O
metalloproteases	metalloproteas	M341	NNS	B-NP	O
potentiate	potentiate	P353	VBP	B-VP	O
netrin	netrin	N365	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
mediated	mediate	M300	VBN	B-NP	O
axon	axon	A250	NN	I-NP	O
outgrowth	outgrowth	O326	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
DCC	DCC	D200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
substrate	substrate	S123	NN	I-NP	O
for	for	F600	IN	B-PP	O
metalloprotease	metalloprotease	M341	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
ectodomain	ectodomain	E235	NN	I-NP	O
shedding	shedding	S352	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
inhibitors	inhibitor	I513	NNS	I-NP	O
block	block	B420	VBP	B-VP	O
proteolytic	proteolytic	P634	JJ	B-NP	O
processing	processing	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
and	and	A530	CC	O	O
cause	cause	C200	VB	B-VP	O
an	an	A500	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
on	on	O500	IN	B-PP	O
axons	axon	A252	NNS	B-NP	O
within	within	W350	IN	B-PP	O
spinal	spinal	S154	JJ	B-NP	O
cord	cord	C630	NN	I-NP	O
explants	explant	E214	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
potentiation	potentiation	P353	NN	B-NP	O
of	of	O100	IN	B-PP	O
netrin	netrin	N365	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
by	by	B000	IN	B-PP	O
inhibitors	inhibitor	I513	NNS	B-NP	O
may	may	M000	MD	B-VP	O
result	result	R243	VB	I-VP	O
from	from	F650	IN	B-PP	O
stabilization	stabilization	S314	NN	B-NP	O
of	of	O100	IN	B-PP	O
DCC	DCC	D200	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
axons	axon	A252	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
proteolytic	proteolytic	P634	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
may	may	M000	MD	B-VP	O
regulate	regulate	R243	VB	I-VP	O
axon	axon	A250	NN	B-NP	O
migration	migration	M263	NN	I-NP	O
by	by	B000	IN	B-PP	O
controlling	control	C536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
axon	axon	A250	NN	I-NP	O
guidance	guidance	G352	NN	I-NP	O
receptors	receptor	R213	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CUG	CUG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
humans	human	H520	NNS	I-NP	O
,	,	0000	,	O	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
(	(	0000	(	O	O
mRNA	mRNA	M650	NN	B-NP	O
)	)	0000	)	O	O
contains	contain	C535	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CUG	CUG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
retained	retain	R353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
an	an	A500	DT	B-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
CUG	CUG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
expressed	express	E216	VBD	B-VP	O
expanded	expand	E215	VBN	I-VP	O
CUG	CUG	C200	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
developed	develop	D141	VBD	B-VP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
myopathy	myopathy	M130	NN	I-NP	B-Disease
,	,	0000	,	O	O
whereas	whereas	W620	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
a	a	A000	DT	B-NP	O
nonexpanded	nonexpanded	N521	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	O	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
transcripts	transcript	T652	NNS	B-NP	O
with	with	W300	IN	B-PP	O
expanded	expand	E215	VBN	B-NP	O
CUG	CUG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
a	a	A000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
result	result	R243	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
gain	gain	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
in	in	I500	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
APC	APC	A120	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
tumor	tumor	T560	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
familial	familial	F540	JJ	I-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Almost	Almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
are	be	A600	VBP	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
,	,	0000	,	O	O
small	small	S540	JJ	B-NP	O
insertions	insertion	I526	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
small	small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
would	would	W430	MD	B-VP	O
truncate	truncate	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
well	well	W400	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
characterized	characterize	C623	VBN	I-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
clear	clear	C460	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
49	49	0000	CD	B-NP	O
potential	potential	P353	JJ	I-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
26	26	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
homologous	homologous	H542	JJ	B-NP	O
and	and	A530	CC	I-NP	O
nonhomologous	nonhomologous	N542	JJ	I-NP	O
recombinations	recombination	R251	NNS	I-NP	O
mediated	mediate	M300	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Alu	Alu	A400	NN	B-NP	O
elements	element	E453	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
four	four	F600	CD	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
complex	complex	C514	JJ	B-ADJP	O
,	,	0000	,	O	O
involving	involve	I514	VBG	B-VP	O
deletion	deletion	D435	NN	B-NP	O
and	and	A530	CC	I-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
nucleotides	nucleotide	N243	NNS	B-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
four	four	F600	CD	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
11	11	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
12	12	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
two	two	T000	CD	I-NP	O
others	other	O362	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	B-NP	O
complete	complete	C514	JJ	I-NP	O
or	or	O600	CC	I-NP	O
partial	partial	P634	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
grossly	grossly	G624	RB	B-ADVP	O
altered	alter	A436	VBD	B-VP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
within	within	W350	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
any	any	A500	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
level	level	L140	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
caused	cause	C230	VBD	B-VP	O
inappropriate	inappropriate	I516	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
initially	initially	I534	RB	I-VP	O
revealed	reveal	R143	VBN	I-VP	O
by	by	B000	IN	B-PP	O
analyzing	analyze	A542	VBG	B-VP	O
cDNAs	cDNA	C352	NNS	B-NP	O
and	and	A530	CC	O	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
methods	method	M320	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
screened	screen	S265	VBD	B-VP	O
each	each	E200	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
individually	individually	I531	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
alter	alter	A436	VB	I-VP	O
any	any	A500	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
exons	exon	E252	NNS	I-NP	O
yet	yet	Y300	RB	B-VP	O
affected	affect	A123	VBD	I-VP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
further	further	F636	RBR	B-ADVP	O
underscores	underscore	U536	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
using	use	U252	VBG	B-VP	O
cDNA	cDNA	C350	NN	B-NP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
among	among	A520	IN	B-PP	O
30	30	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
genomic	genomic	G520	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
frequent	frequent	F625	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
second	second	S253	JJ	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CACNA1A	CACNA1A	C250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
EA	EA	E000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
and	and	A530	CC	O	O
FHM	FHM	F500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
specific	specific	S121	JJ	I-NP	O
P	P	P000	NN	I-NP	O
/	/	0000	SYM	I-NP	O
Q	Q	Q000	NN	I-NP	O
type	type	T100	NN	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
channel	channel	C540	NN	I-NP	O
alpha1	alpha1	A410	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
CACNA1A	CACNA1A	C250	NN	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
clinically	clinically	C452	RB	I-NP	O
distinct	distinct	D235	JJ	I-NP	O
disorders	disorder	D263	NNS	I-NP	O
,	,	0000	,	O	O
viz	viz	V200	NN	B-NP	O
.	.	0000	.	O	O
episodic	episodic	E123	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
EA	EA	E000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
2	2	0000	CD	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
familial	familial	F540	JJ	B-NP	B-Disease
hemiplegic	hemiplegic	H514	JJ	I-NP	I-Disease
migraine	migraine	M265	NN	I-NP	I-Disease
(	(	0000	(	O	O
FHM	FHM	F500	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
spinocerebellar	spinocerebellar	S152	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
SCA6	SCA6	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
EA	EA	E000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
2	2	0000	CD	B-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
described	describe	D261	VBN	B-VP	O
thus	thus	T200	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
are	be	A600	VBP	B-VP	O
presumed	presume	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
different	different	D165	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
FHM	FHM	F500	NN	B-NP	B-Disease
.	.	0000	.	O	O

At	At	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
two	two	T000	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
on	on	O500	IN	B-PP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
19p13	19p13	P000	CD	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
and	and	A530	CC	O	O
thus	thus	T200	RB	B-VP	O
represent	represent	R162	VBP	I-VP	O
recurrent	recurrent	R265	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
screened	screen	S265	VBN	I-VP	O
several	several	S164	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
47	47	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CACNA1A	CACNA1A	C250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
characterised	characterise	C623	VBN	I-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
G5260A	G5260A	G000	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
32	32	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
EA	EA	E000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
position	position	P235	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
CACNA1A	CACNA1A	C250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
not	not	N300	RB	B-VP	O
resulting	result	R243	VBG	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
proposed	propose	P612	VBN	I-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
member	member	M516	NN	I-NP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
only	only	O540	JJ	B-NP	O
migraine	migraine	M265	NN	I-NP	B-Disease
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
previously	previously	P612	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
muta	muta	M300	NN	I-NP	O
tion	tion	T500	NN	I-NP	O
,	,	0000	,	O	O
C2272T	C2272T	C300	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
16	16	0000	CD	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
discovered	discover	D216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
FHM	FHM	F500	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Analbuminemia	Analbuminemia	A541	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
neonate	neonate	N530	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
for	for	F600	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
gestational	gestational	G235	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
age	age	A200	NN	I-NP	O
infant	infant	I515	NN	I-NP	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
analbuminemia	analbuminemia	A541	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
neonatal	neonatal	N534	JJ	I-NP	O
period	period	P630	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
twelve	twelve	T410	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
recorded	record	R263	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
literature	literature	L363	NN	I-NP	O
are	be	A600	VBP	B-VP	O
reviewed	review	R130	VBN	I-VP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
lacking	lack	L252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
are	be	A600	VBP	B-VP	O
essentially	essentially	E253	RB	B-ADJP	O
asymptomatic	asymptomatic	A251	JJ	I-ADJP	O
,	,	0000	,	O	O
apart	apart	A163	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
minimal	minimal	M540	JJ	B-NP	O
ankle	ankle	A524	NN	I-NP	B-Disease
edema	edema	E350	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ease	ease	E200	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
fatigue	fatigue	F320	NN	B-NP	I-Disease
.	.	0000	.	O	O

Apparent	Apparent	A165	JJ	B-NP	O
compensatory	compensatory	C515	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
come	come	C500	VBP	B-VP	O
into	into	I530	IN	B-PP	O
play	play	P400	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
serum	serum	S650	NN	B-NP	O
albumin	albumin	A415	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
low	low	L000	JJ	B-NP	O
include	include	I524	NN	I-NP	O
prolonged	prolong	P645	VBN	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
life	life	L100	NN	I-NP	O
of	of	O100	IN	B-PP	O
albumin	albumin	A415	NN	B-NP	O
and	and	A530	CC	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
globulins	globulin	G414	NNS	I-NP	O
,	,	0000	,	O	O
beta	beta	B300	NN	B-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
glycoproteins	glycoprotein	G421	NNS	B-NP	O
,	,	0000	,	O	O
arterial	arterial	A636	JJ	B-NP	B-Disease
hypotension	hypotension	H135	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
capillary	capillary	C146	JJ	I-NP	O
hydrostatic	hydrostatic	H362	JJ	I-NP	O
pressure	pressure	P626	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
respond	respond	R215	VB	I-VP	O
with	with	W300	IN	B-PP	O
rapid	rapid	R130	JJ	B-NP	O
sodium	sodium	S350	NN	I-NP	O
and	and	A530	CC	I-NP	O
chloride	chloride	C463	NN	I-NP	O
diuresis	diuresis	D620	NN	I-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
small	small	S540	JJ	B-NP	O
volume	volume	V450	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
.	.	0000	.	O	O

Examination	Examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
amino	amino	A500	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
investigation	investigation	I512	NN	I-NP	O
not	not	N300	RB	B-VP	O
previously	previously	P612	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
,	,	0000	,	O	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
low	low	L000	JJ	I-NP	O
plasma	plasma	P425	NN	I-NP	O
tryptophan	tryptophan	T613	NN	I-NP	O
level	level	L140	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
view	view	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
tryptophan	tryptophan	T613	NN	B-NP	O
in	in	I500	IN	B-PP	O
albumin	albumin	A415	NN	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Histidinemia	Histidinemia	H235	NNP	B-NP	B-Disease
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	O
and	and	A530	CC	I-NP	O
atypical	atypical	A312	JJ	I-NP	O
form	form	F650	NN	I-NP	O
in	in	I500	IN	B-PP	O
siblings	sibling	S145	NNS	B-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
,	,	0000	,	O	O
6	6	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
13	13	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
old	old	O430	JJ	B-ADJP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
histidinemia	histidinemia	H235	NN	B-NP	B-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
observations	observation	O126	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
younger	young	Y526	JJR	I-NP	O
boy	boy	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
older	old	O436	JJR	I-NP	O
boy	boy	B000	NN	I-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
atypical	atypical	A312	JJ	I-NP	O
form	form	F650	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
partial	partial	P634	JJ	B-NP	O
impairment	impairment	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
skin	skin	S250	NN	I-NP	O
histidase	histidase	H232	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
moderately	moderately	M363	RB	I-NP	O
prolonged	prolonged	P645	JJ	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
life	life	L100	NN	I-NP	O
of	of	O100	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
histidine	histidine	H235	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	I-NP	O
sister	sister	S236	NN	I-NP	O
seem	seem	S500	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Carrier	Carri	C600	JJR	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
pyruvate	pyruvate	P613	NN	B-NP	B-Disease
carboxylase	carboxylase	C612	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
and	and	A530	CC	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

Pyruvate	Pyruvate	P613	NN	B-NP	O
carboxylase	carboxylase	C612	NN	I-NP	O
(	(	0000	(	O	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
1	1	0000	CD	O	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
circulating	circulate	C624	VBG	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
and	and	A530	CC	O	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	O
,	,	0000	,	I-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
,	,	0000	,	I-NP	O
renal	renal	R540	JJ	I-NP	O
cortical	cortical	C632	JJ	I-NP	O
,	,	0000	,	I-NP	O
leukocyte	leukocyte	L230	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
fibroblast	fibroblast	F161	NN	B-NP	O
pyruvate	pyruvate	P613	VBP	B-VP	B-Disease
carboxylase	carboxylase	C612	NN	B-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
PC	PC	P200	NN	B-NP	B-Disease
Portland	Portland	P634	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Lymphocyte	Lymphocyte	L512	NN	B-NP	O
activities	activity	A231	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
mother	mother	M360	NN	B-NP	O
,	,	0000	,	O	O
33	33	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
39	39	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
father	father	F360	NN	B-NP	O
,	,	0000	,	O	O
11	11	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
29	29	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
brother	brother	B636	NN	B-NP	O
,	,	0000	,	O	O
82	82	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	SYM	I-NP	O
103	103	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
sister	sister	S236	NN	B-NP	O
,	,	0000	,	O	O
38	38	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
lowest	low	L230	JJS	I-NP	O
normal	normal	N654	JJ	I-NP	O
.	.	0000	.	O	O

Fibroblasts	Fibroblast	F161	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
mother	mother	M360	NN	I-NP	O
and	and	A530	CC	O	O
father	father	F360	NN	B-NP	O
had	have	H300	VBD	B-VP	O
42	42	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
34	34	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
lowest	low	L230	JJS	I-NP	O
normal	normal	N654	JJ	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
and	and	A530	CC	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
carriers	carrier	C620	NNS	B-NP	O
.	.	0000	.	O	O

Neither	Neither	N360	CC	O	O
pyruvate	pyruvate	P613	NN	B-NP	O
carboxylase	carboxylase	C612	NN	I-NP	O
nor	nor	N600	CC	O	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
PEPCK	PEPCK	P120	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
21	21	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hr	hr	H600	NN	I-NP	O
fast	fast	F230	RB	B-ADVP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Italian	Italian	I345	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	B-Disease
neonatal	neonatal	N534	JJ	I-NP	I-Disease
jaundice	jaundice	J532	NN	I-NP	I-Disease
.	.	0000	.	O	O

Screening	Screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Maternity	Maternity	M365	NNP	I-NP	O
Division	Division	D125	NNP	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Galliera	Galliera	G460	NNP	I-NP	O
Hospital	Hospital	H213	NNP	I-NP	O
in	in	I500	IN	B-PP	O
Genoa	Genoa	G500	NNP	B-NP	O
,	,	0000	,	O	O
Italy	Italy	I340	NNP	B-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
groups	group	G612	NNS	I-NP	O
of	of	O100	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
hyperbilirubinaemia	hyperbilirubinaemia	H161	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
immunological	immunological	I542	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
(	(	0000	(	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
302	302	0000	CD	B-NP	O
newborn	newborn	N165	JJ	I-NP	O
babies	baby	B120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Sardinian	Sardinian	S635	JJ	B-NP	O
extraction	extraction	E236	NN	I-NP	O
(	(	0000	(	O	O
on	on	O500	IN	B-PP	O
cord	cord	C630	NN	B-NP	O
blood	blood	B430	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
(	(	0000	(	O	O
b	b	B000	NN	B-NP	O
)	)	0000	)	O	O
201	201	0000	CD	B-NP	O
newborn	newborn	N165	JJ	I-NP	O
babies	baby	B120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
south	south	S300	JJ	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
ancestry	ancestry	A523	NN	I-NP	O
(	(	0000	(	O	O
on	on	O500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
503	503	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
,	,	0000	,	O	O
43	43	0000	CD	B-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
39	39	0000	CD	B-NP	O
the	the	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Mediterranean	Mediterranean	M365	JJ	I-NP	O
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
,	,	0000	,	O	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
cases	case	C200	NNS	I-NP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
work	work	W620	NN	I-NP	O
these	these	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	B-Disease
neonatal	neonatal	N534	JJ	I-NP	I-Disease
jaundice	jaundice	J532	NN	I-NP	I-Disease
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
originated	originate	O625	VBN	B-VP	O
from	from	F650	IN	B-PP	O
Calabria	Calabria	C416	NNP	B-NP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
Sicily	Sicily	S240	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
respectively	respectively	R212	RB	I-VP	O
designated	designate	D253	VBN	I-VP	O
as	as	A200	IN	B-PP	O
GdDcbrousse	GdDcbrousse	G321	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
,	,	0000	,	I-NP	O
GdGallura	GdGallura	G324	NNP	I-NP	O
and	and	A530	CC	I-NP	O
GdAgrigento	GdAgrigento	G326	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cytogenetic	Cytogenetic	C325	JJ	B-NP	O
investigations	investigation	I512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
.	.	0000	.	O	O

Chromosomal	Chromosomal	C652	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
and	and	A530	CC	O	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
Israeli	Israeli	I264	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
Moroccan	Moroccan	M625	NNP	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
24	24	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
seven	seven	S150	CD	B-NP	O
propositi	propositus	P612	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
,	,	0000	,	O	O
significantly	significantly	S251	RB	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
rates	rate	R320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
blood	blood	B430	NN	B-NP	O
and	and	A530	CC	I-NP	O
skin	skin	S250	NN	I-NP	O
.	.	0000	.	O	O

Skin	Skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
several	several	S164	JJ	B-NP	O
orders	order	O636	NNS	I-NP	O
of	of	O100	IN	B-PP	O
magnitude	magnitude	M253	NN	B-NP	O
more	more	M600	JJR	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
breakage	breakage	B620	NN	I-NP	O
than	than	T500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
rates	rate	R320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
damage	damage	D520	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
phenotypically	phenotypically	P531	RB	I-NP	O
normal	normal	N654	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
obligate	obligate	O142	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
and	and	A530	CC	I-NP	O
sibs	sib	S120	NNS	I-NP	O
)	)	0000	)	O	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
clone	clone	C450	NN	I-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
,	,	0000	,	O	O
possessing	possess	P252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
acrocentric	acrocentric	A262	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
14q	14q	Q000	NN	B-NP	O
+	+	0000	SYM	B-ADJP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
varying	vary	V652	VBG	B-NP	O
proportions	proportion	P616	NNS	I-NP	O
among	among	A520	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
propositi	propositi	P612	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
;	;	0000	:	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
9	9	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Prenatal	Prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wolman	Wolman	W450	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
pregnancies	pregnancy	P625	NNS	I-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
for	for	F600	IN	B-PP	O
Wolman	Wolman	W450	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
monitored	monitor	M536	VBN	I-VP	O
by	by	B000	IN	B-PP	O
assay	assay	A200	NN	B-NP	O
and	and	A530	CC	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
amniotic	amniotic	A532	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
fluid	fluid	F430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Cells	Cell	C420	NNS	B-NP	O
from	from	F650	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
had	have	H300	VBD	B-VP	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
control	control	C536	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
14C	14C	C000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
triolein	triolein	T645	NN	I-NP	O
as	as	A200	IN	B-PP	O
substrate	substrate	S123	NN	B-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
artificial	artificial	A631	JJ	B-NP	O
substrates	substrate	S123	NNS	I-NP	O
(	(	0000	(	O	O
esters	ester	E236	NNS	B-NP	O
of	of	O100	IN	B-PP	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
methylumbelliferone	methylumbelliferone	M345	NN	I-NP	O
and	and	A530	CC	I-NP	O
p	p	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
nitrophenol	nitrophenol	N361	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
measure	measure	M260	VB	I-VP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
30	30	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
control	control	C536	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Electrophoresis	Electrophoresis	E423	NN	B-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
extracts	extract	E236	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wolman	Wolman	W450	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
fetal	fetal	F340	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
following	follow	F452	VBG	B-PP	O
prostaglandin	prostaglandin	P623	NN	B-NP	O
termination	termination	T653	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
pregnancy	pregnancy	P625	NN	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

Assay	Assay	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
fetal	fetal	F340	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
with	with	W300	IN	B-PP	O
14C	14C	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
triolein	triolein	T645	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
with	with	W300	IN	B-PP	O
artificial	artificial	A631	JJ	B-NP	O
substrates	substrate	S123	NNS	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
marked	marked	M623	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Electrophoresis	Electrophoresis	E423	NN	B-NP	O
of	of	O100	IN	B-PP	O
fetal	fetal	F340	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
tissue	tissue	T200	NN	I-NP	O
extracts	extract	E236	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
.	.	0000	.	O	O

Amniotic	Amniotic	A532	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
fluid	fluid	F430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
2	2	0000	CD	I-NP	O
showed	show	S300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
with	with	W300	IN	B-PP	O
all	all	A400	DT	B-NP	O
substrates	substrate	S123	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wolman	Wolman	W450	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
be	be	B000	VB	B-VP	O
made	make	M300	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
radioassay	radioassay	R320	NN	I-NP	O
of	of	O100	IN	B-PP	O
acid	acid	A230	NN	B-NP	O
lipase	lipase	L120	NN	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
electrophoresis	electrophoresis	E423	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Malignant	Malignant	M425	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
greatly	greatly	G634	RB	I-NP	O
increased	increase	I526	VBN	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
malignant	malignant	M425	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
affected	affected	A123	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Heterozygotes	Heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
are	be	A600	VBP	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
comprise	comprise	C516	VB	I-VP	O
about	about	A130	IN	B-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
know	know	K500	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
predisposes	predispose	P632	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
to	to	T000	TO	B-PP	O
cancers	cancer	C526	NNS	B-NP	B-Disease
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
common	common	C500	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
close	close	C420	JJ	I-NP	O
relatives	relative	R431	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
individual	individual	I531	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
any	any	A500	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
criterion	criterion	C636	NN	I-NP	O
or	or	O600	CC	I-NP	O
laboratory	laboratory	L163	NN	I-NP	O
test	test	T230	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
reason	reason	R250	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
death	death	D300	NN	B-NP	O
from	from	F650	IN	B-PP	O
malignant	malignant	M425	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
expected	expect	E212	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
random	random	R535	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
59	59	0000	CD	B-NP	O
deaths	death	D320	NNS	I-NP	O
from	from	F650	IN	B-PP	O
malignant	malignant	M425	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
dying	die	D520	VBG	B-VP	O
before	before	B160	IN	B-PP	O
age	age	A200	NN	B-NP	O
75	75	0000	CD	I-NP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
42	42	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
expected	expect	E212	VBN	B-VP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
younger	young	Y526	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
age	age	A200	NN	B-NP	O
45	45	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
dying	die	D520	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
malignant	malignant	M425	JJ	I-NP	B-Disease
neoplasm	neoplasm	N142	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
greater	great	G636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
5	5	0000	CD	B-NP	O
times	time	T520	NNS	I-NP	O
the	the	T000	DT	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
may	may	M000	MD	B-VP	O
comprise	comprise	C516	VB	I-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
persons	person	P625	NNS	I-NP	O
dying	die	D520	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
before	before	B160	IN	B-PP	O
age	age	A200	NN	B-NP	O
45	45	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
gastric	gastric	G236	JJ	I-NP	I-Disease
,	,	0000	,	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
biliary	biliary	B460	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
lymphoma	lymphoma	L515	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
neoplasms	neoplasm	N142	NNS	I-NP	B-Disease
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
include	include	I524	VBP	B-VP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
basal	basal	B240	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
colonic	colonic	C452	JJ	B-NP	I-Disease
,	,	0000	,	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
cervical	cervical	C612	JJ	B-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Striking	Strike	S362	VBG	B-VP	O
prevalence	prevalence	P614	NN	B-NP	O
of	of	O100	IN	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
"	"	0000	``	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
"	"	0000	''	I-NP	O
w27	w27	W000	NN	I-NP	O
positive	positive	P231	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	I-NP	O
females	female	F542	NNS	I-NP	O
.	.	0000	.	O	O

Ankylosing	Ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
once	once	O520	RB	B-ADVP	O
or	or	O600	CC	I-ADVP	O
twice	twice	T200	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
1000	1000	0000	CD	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
tenth	tenth	T530	NN	I-NP	O
as	as	A200	RB	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
true	true	T600	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Indentification	Indentification	I535	NN	B-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
HL	HL	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
W27	W27	W000	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
susceptible	susceptible	S213	JJ	B-NP	O
persons	person	P625	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
provided	provide	P613	VBN	I-VP	O
a	a	A000	DT	B-NP	O
tool	tool	T400	NN	I-NP	O
facilitating	facilitate	F243	VBG	B-VP	O
epidemiologic	epidemiologic	E135	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
and	and	A530	CC	O	O
allowing	allow	A452	VBG	B-VP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
"	"	0000	``	B-NP	O
control	control	C536	NN	I-NP	O
"	"	0000	''	I-NP	O
populations	population	P143	NNS	I-NP	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
.	.	0000	.	O	O

Evaluation	Evaluation	E143	NN	B-NP	O
by	by	B000	IN	B-PP	O
postal	postal	P234	JJ	B-NP	O
questionnaires	questionnaire	Q235	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
pelvic	pelvic	P412	JJ	B-NP	O
radiography	radiography	R326	NN	I-NP	O
of	of	O100	IN	B-PP	O
78	78	0000	CD	B-NP	O
HL	HL	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
A	A	A000	DT	B-NP	O
27W	27W	W000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
donors	donor	D562	NNS	I-NP	O
selected	select	S423	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
apparently	apparently	A165	RB	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
14	14	0000	CD	B-NP	O
who	who	W000	WP	B-NP	O
satisfied	satisfy	S321	VBD	B-VP	O
the	the	T000	DT	B-NP	O
criteria	criterion	C636	NNS	I-NP	O
for	for	F600	IN	B-PP	O
definite	definite	D153	JJ	B-NP	O
ankylosing	ankylosing	A524	NN	I-NP	B-Disease
spondylitis	spondylitis	S153	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
sexes	sex	S200	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
hundred	hundred	H536	CD	I-NP	O
and	and	A530	CC	I-NP	O
twenty	twenty	T530	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
six	six	S200	CD	I-NP	O
W27	W27	W000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
matched	match	M323	VBN	B-VP	O
for	for	F600	IN	B-PP	O
race	race	R200	NN	B-NP	O
,	,	0000	,	O	O
sex	sex	S200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
age	age	A200	NN	B-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
yield	yield	Y430	VB	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
person	person	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	O	O
sex	sex	S200	NN	B-NP	O
with	with	W300	IN	B-PP	O
HL	HL	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
W27	W27	W000	NN	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
about	about	A130	IN	B-PP	O
a	a	A000	DT	B-NP	O
20	20	0000	CD	I-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
chance	chance	C520	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
will	will	W400	MD	B-VP	O
develop	develop	D141	VB	I-VP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
15	15	0000	CD	B-NP	O
per	per	P600	IN	B-PP	O
thousand	thousand	T253	CD	B-NP	O
.	.	0000	.	O	O

Hitherto	Hitherto	H363	NNP	B-NP	O
accepted	accept	A213	VBD	B-VP	O
figures	figure	F262	NNS	B-NP	O
may	may	M000	MD	B-VP	O
underestimate	underestimate	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
factor	factor	F236	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
20	20	0000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Analbuminemia	Analbuminemia	A541	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
American	American	A562	JJ	I-NP	O
Indian	Indian	I535	JJ	I-NP	O
girl	girl	G640	NN	I-NP	O
.	.	0000	.	O	O

Analbuminemia	Analbuminemia	A541	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
fortuitously	fortuitously	F632	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonedematous	nonedematous	N535	JJ	I-NP	O
12	12	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
Indian	Indian	I535	JJ	I-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
atopic	atopic	A312	JJ	B-NP	B-Disease
dermatitis	dermatitis	D653	NN	I-NP	I-Disease
,	,	0000	,	O	O
mild	mild	M430	JJ	B-NP	O
bronchial	bronchial	B652	JJ	I-NP	B-Disease
asthma	asthma	A235	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
seizure	seizure	S260	NN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hyperlipoproteinemia	hyperlipoproteinemia	H164	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
corneal	corneal	C654	JJ	I-NP	B-Disease
arcus	arcus	A620	NN	I-NP	I-Disease
.	.	0000	.	O	O

Immunologic	Immunologic	I542	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
trace	trace	T620	NN	B-NP	O
amounts	amount	A532	NNS	I-NP	O
(	(	0000	(	O	O
17	17	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
ml	ml	M400	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
apparently	apparently	A165	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
albumin	albumin	A415	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
parents	parent	P653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
remotely	remotely	R534	RB	B-ADJP	O
related	relate	R430	VBN	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
analbuminemia	analbuminemia	A541	NN	B-NP	B-Disease
.	.	0000	.	O	O

Heterozygotes	Heterozygote	H362	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
subnormal	subnormal	S156	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
albumin	albumin	A415	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Gc	Gc	G200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
locus	locus	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
albumin	albumin	A415	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Gc	Gc	G200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
protein	protein	P635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
banding	banding	B535	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
make	make	M200	VBP	B-VP	O
it	it	I300	PRP	B-NP	O
unlikely	unlikely	U542	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
caused	cause	C230	VBD	B-VP	O
analbuminemia	analbuminemia	A541	NN	B-NP	B-Disease
.	.	0000	.	O	O

Gc	Gc	G200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
types	type	T120	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
were	be	W600	VBD	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
prove	prove	P610	VB	I-VP	O
,	,	0000	,	O	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
analbuminemia	analbuminemia	A541	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Gc	Gc	G200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
"	"	0000	``	I-NP	O
thalassemia	thalassemia	T425	NN	I-NP	B-Disease
"	"	0000	''	O	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
and	and	A530	CC	I-NP	O
PDGFRA	PDGFRA	P321	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
piebaldism	piebaldism	P143	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
human	human	H500	JJ	B-NP	O
piebaldism	piebaldism	P143	NN	I-NP	B-Disease
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
receptor	receptor	R213	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mast	mast	M230	NN	I-NP	O
/	/	0000	SYM	B-NP	O
stem	stem	S350	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
segment	segment	S253	NN	I-NP	O
4q12	4q12	Q000	CD	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
piebaldism	piebaldism	P143	NN	B-NP	B-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
multiple	multiple	M431	JJ	B-NP	B-Disease
congenital	congenital	C525	JJ	I-NP	I-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
46	46	0000	CD	I-NP	O
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
,	,	0000	,	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q12q21	q12q21	Q200	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	O	O
)	)	0000	)	O	O
karyotype	karyotype	K631	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
carried	carry	C630	VBD	B-VP	O
out	out	O300	RP	B-PRT	O
quantitative	quantitative	Q531	JJ	B-NP	O
Southern	Southern	S365	JJ	I-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
PDGFRA	PDGFRA	P321	NN	I-NP	O
(	(	0000	(	O	O
platelet	platelet	P434	NN	B-NP	O
-	-	0000	HYPH	O	O
derived	derive	D613	VBN	B-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
hemizygous	hemizygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
and	and	A530	CC	I-NP	O
PDGFRA	PDGFRA	P321	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
included	include	I524	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
and	and	A530	CC	I-NP	O
PDGFRA	PDGFRA	P321	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
piebald	piebald	P143	JJ	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphoribosyl	phosphoribosyl	P216	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
pyrophosphate	pyrophosphate	P612	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	O
-	-	0000	HYPH	O	O
guanine	guanine	G500	NN	B-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patient	patient	P353	NN	I-NP	O
:	:	0000	:	O	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
functionally	functionally	F523	RB	I-NP	O
important	important	I516	JJ	I-NP	O
region	region	R250	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
cause	cause	C200	VBP	B-VP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
hypoxanthine	hypoxanthine	H125	NN	B-NP	I-Disease
guanine	guanine	G500	NN	I-NP	I-Disease
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	I-Disease
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
valuable	valuable	V414	JJ	B-NP	O
information	information	I516	NN	I-NP	O
as	as	A200	IN	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
that	that	T300	WDT	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
spontaneously	spontaneously	S153	RB	B-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
HPRT	HPRT	H163	NNP	B-NP	O
Tokyo	Tokyo	T200	NNP	I-NP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
change	change	C520	NN	I-NP	O
from	from	F650	IN	B-PP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
identified	identify	I353	VBN	B-VP	O
by	by	B000	IN	B-PP	O
sequencing	sequencing	S252	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
amplified	amplify	A514	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
amplified	amplify	A514	VBN	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
would	would	W430	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Asp	Asp	A210	NN	B-NP	O
for	for	F600	IN	B-PP	O
Gly	Gly	G400	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
140	140	0000	CD	I-NP	O
located	located	L230	JJ	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphoribosyl	phosphoribosyl	P216	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
pyrophosphate	pyrophosphate	P612	NN	I-NP	O
(	(	0000	(	O	O
PRPP	PRPP	P610	NN	B-NP	O
)	)	0000	)	O	O
binding	binding	B535	NN	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
HPRT	HPRT	H163	NN	I-NP	B-Disease
deficient	deficient	D125	JJ	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
thus	thus	T200	RB	B-ADVP	O
far	far	F600	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
tend	tend	T530	NN	B-NP	O
to	to	T000	TO	B-VP	O
accumulate	accumulate	A254	VB	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
functionally	functionally	F523	RB	I-NP	O
active	active	A231	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	B-NP	O
missense	missense	M252	JJ	I-NP	O
and	and	A530	CC	I-NP	O
synonymous	synonymous	S520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
can	can	C500	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
at	at	A300	IN	B-PP	O
any	any	A500	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
limited	limited	L530	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
cause	cause	C200	VBP	B-VP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
will	will	W400	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
disease	disease	D200	NN	B-NP	O
tends	tend	T532	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
higher	high	H260	JJR	B-ADJP	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
functionally	functionally	F523	RB	I-NP	O
important	important	I516	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Characterisation	Characterisation	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
rare	rare	R600	JJ	I-NP	O
fragile	fragile	F624	JJ	I-NP	O
site	site	S300	NN	I-NP	O
easily	easily	E240	RB	B-VP	O
confused	confuse	C512	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
fragile	fragile	F624	JJ	I-NP	O
site	site	S300	NN	I-NP	O
(	(	0000	(	O	O
FRAXE	FRAXE	F620	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
folate	folate	F430	NN	I-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
fragile	fragile	F624	JJ	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	O
site	site	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
give	give	G100	VB	I-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
subjected	subject	S123	VBN	B-VP	O
to	to	T000	TO	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
probe	probe	P610	NN	B-NP	O
pfxa3	pfxa3	P120	NN	I-NP	O
which	which	W200	WDT	B-NP	O
detects	detect	D323	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
locates	locate	L232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	O
site	site	S300	NN	I-NP	O
between	between	B350	IN	B-PP	O
150	150	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
600	600	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
FRAXA	FRAXA	F620	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
distinction	distinction	D235	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
fragile	fragile	F624	JJ	I-NP	O
sites	site	S320	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
clinically	clinically	C452	RB	B-ADVP	O
since	since	S520	IN	B-PP	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
FRAXE	FRAXE	F620	NN	B-NP	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
could	could	C430	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
misdiagnosis	misdiagnosis	M232	NN	B-NP	O
of	of	O100	IN	B-PP	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
150	150	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

Norrie	Norrie	N600	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
etiology	etiology	E342	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
blindness	blindness	B453	NN	I-NP	I-Disease
,	,	0000	,	O	O
sensory	sensory	S526	JJ	B-NP	B-Disease
neural	neural	N640	JJ	I-NP	I-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
(	(	0000	(	O	O
L1	L1	L000	NN	B-NP	O
.	.	0000	.	O	O
28	28	0000	CD	O	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
MAO	MAO	M000	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
band	band	B530	NN	B-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
fine	fine	F500	JJ	B-NP	O
physical	physical	P240	JJ	I-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
NDP	NDP	N310	NN	B-NP	O
)	)	0000	)	O	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
smallest	small	S542	JJS	I-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
identified	identify	I353	VBD	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
two	two	T000	CD	I-NP	O
overlapping	overlap	O164	VBG	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
allowed	allow	A430	VBD	B-VP	O
orientation	orientation	O653	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MAOA	MAOA	M000	NN	I-NP	O
and	and	A530	CC	I-NP	O
MAOB	MAOB	M100	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
configuration	configuration	C512	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
event	event	E153	NN	I-NP	O
between	between	B350	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	I-NP	O
GT	GT	G300	NN	I-NP	O
)	)	0000	)	I-NP	O
n	n	N000	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
2	2	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MAOB	MAOB	M100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
between	between	B350	IN	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
NDP	NDP	N310	NN	I-NP	O
,	,	0000	,	O	O
delineates	delineate	D453	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
flanking	flanking	F452	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
telomeric	telomeric	T456	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
,	,	0000	,	O	O
dc12	dc12	D200	NN	B-NP	O
,	,	0000	,	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YACs	YAC	Y200	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
which	which	W200	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
MAOA	MAOA	M000	NN	B-NP	O
and	and	A530	CC	I-NP	O
MAOB	MAOB	M100	NN	I-NP	O
but	but	B300	CC	B-NP	O
not	not	N300	RB	I-NP	O
L1	L1	L000	NN	B-NP	O
.	.	0000	.	O	O

28	28	0000	CD	B-NP	O
,	,	0000	,	O	O
serves	serve	S612	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
flanking	flanking	F452	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
centromeric	centromeric	C536	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
Alu	Alu	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
right	right	R230	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MAO	MAO	M000	NN	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
(	(	0000	(	O	O
YMAO	YMAO	Y500	NN	B-NP	O
.	.	0000	.	I-NP	O
AluR	AluR	A460	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
also	also	A420	RB	B-VP	O
delineates	delineate	D453	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
centromeric	centromeric	C536	JJ	I-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
telomere	telomere	T456	JJ	B-ADJP	O
.	.	0000	.	O	O

DXS7	DXS7	D200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
MAOA	MAOA	M000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
MAOB	MAOB	M100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
NDP	NDP	N310	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dc12	dc12	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
YMAO	YMAO	Y500	NN	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
MAOA	MAOA	M000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
MAOB	MAOB	M100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
NDP	NDP	N310	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dc12	dc12	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
YMAO	YMAO	Y500	NN	I-NP	O
.	.	0000	.	O	O

AluR	AluR	A460	NN	B-NP	O
.	.	0000	.	I-NP	O
centromere	centromere	C536	NNP	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
define	define	D150	VBP	B-VP	O
the	the	T000	DT	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
150	150	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
and	and	A530	CC	O	O
related	related	R430	JJ	B-NP	O
hyperphenylalaninemias	hyperphenylalaninemia	H161	NNS	I-NP	B-Disease
:	:	0000	:	O	O
mutations	mutation	M352	NNS	B-NP	O
and	and	A530	CC	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
producing	produce	P632	VBG	B-VP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	I-NP	B-Disease
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
all	all	A400	DT	B-ADVP	O
exhibit	exhibit	E213	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

About	About	A130	IN	B-NP	O
50	50	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
single	single	S524	JJ	B-ADJP	O
-	-	0000	HYPH	B-NP	O
base	base	B200	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
six	six	S200	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
eight	eight	E230	CD	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
remainder	remainder	R536	NN	I-NP	O
being	be	B520	VBG	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
3	3	0000	CD	I-NP	O
large	large	L620	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
single	single	S524	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
apparently	apparently	A165	RB	B-ADVP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
methylation	methylation	M343	NN	I-NP	O
and	and	A530	CC	I-NP	O
subsequent	subsequent	S125	JJ	I-NP	O
deamination	deamination	D535	NN	I-NP	O
of	of	O100	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
mutagenic	mutagenic	M325	JJ	I-NP	O
CpG	CpG	C120	NN	I-NP	O
dinucleotides	dinucleotide	D524	NNS	I-NP	O
.	.	0000	.	O	O

Recurrent	Recurrent	R265	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
producing	produce	P632	VBG	B-VP	O
associations	association	A235	NNS	B-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

About	About	A130	IN	B-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
residual	residual	R234	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
disease	disease	D200	NN	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-PP	O
continuing	continue	C535	VBG	B-NP	O
advances	advance	A315	NNS	I-NP	O
in	in	I500	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
methodologies	methodology	M342	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
dramatically	dramatically	D653	RB	I-VP	O
accelerated	accelerate	A246	VBN	I-VP	O
the	the	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
being	be	B520	VBG	I-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
register	register	R236	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
updated	update	U130	VBN	I-VP	O
periodically	periodically	P632	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
glycine250	glycine250	G425	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
aspartate	aspartate	A216	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
hexosaminidase	hexosaminidase	H253	NN	B-NP	O
A	A	A000	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
juvenile	juvenile	J154	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Lebanese	Lebanese	L152	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
juvenile	juvenile	J154	JJ	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
sibs	sib	S120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Lebanese	Lebanese	L152	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Maronite	Maronite	M653	NN	I-NP	O
origin	origin	O625	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
extract	extract	E236	NN	B-NP	O
of	of	O100	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
template	template	T514	NN	I-NP	O
to	to	T000	TO	B-VP	O
amplify	amplify	A514	VB	I-VP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
amplified	amplify	A514	VBN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
alteration	alteration	A436	NN	I-NP	O
,	,	0000	,	O	O
guanine	guanine	G500	NN	B-NP	O
to	to	T000	TO	B-PP	O
adenine	adenine	A350	NN	B-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
749	749	0000	CD	I-NP	O
creating	create	C635	VBG	B-VP	O
a	a	A000	DT	B-NP	O
G250D	G250D	G300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
introduces	introduce	I536	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
recognition	recognition	R253	NN	I-NP	O
site	site	S300	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
Eco	Eco	E200	NNP	I-NP	O
RV	RV	R100	NNP	I-NP	O
,	,	0000	,	O	O
permitting	permit	P653	VBG	B-VP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
PCR	PCR	P260	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
and	and	A530	CC	O	O
Eco	Eco	E200	NNP	B-NP	O
RV	RV	R100	NN	I-NP	O
digestion	digestion	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
templates	template	T514	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
in	in	I500	FW	I-NP	O
vitro	vitro	V360	FW	I-NP	O
mutagenized	mutagenize	M325	VBN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
construct	construct	C523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
into	into	I530	IN	B-PP	O
a	a	A000	DT	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
vector	vector	V236	NN	I-NP	O
and	and	A530	CC	O	O
transfected	transfecte	T652	VBN	B-VP	O
into	into	I530	IN	B-PP	O
monkey	monkey	M520	NN	B-NP	O
Cos	Cos	C200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
separately	separately	S163	RB	B-ADVP	O
or	or	O600	CC	I-ADVP	O
along	along	A452	RB	I-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
vector	vector	V236	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
cDNA	cDNA	C350	NN	B-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
introduced	introduce	I536	VBN	B-VP	O
into	into	I530	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
no	no	N000	DT	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
above	above	A100	IN	B-PP	O
endogenous	endogenous	E532	JJ	B-NP	O
COS	COS	C200	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Cotransfection	Cotransfection	C365	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	O	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
cDNA	cDNA	C350	NN	B-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
immunoprecipitation	immunoprecipitation	I516	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
Hex	Hex	H200	NN	I-NP	O
A	A	A000	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
20	20	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
fold	fold	F430	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
between	between	B350	IN	B-PP	O
positive	positive	P231	JJ	B-NP	O
and	and	A530	CC	I-NP	O
negative	negative	N231	JJ	I-NP	O
(	(	0000	(	O	O
mock	mock	M200	JJ	B-NP	O
transfection	transfection	T652	NN	I-NP	O
)	)	0000	)	O	O
control	control	C536	NN	B-NP	O
values	value	V420	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
allowed	allow	A430	VBD	B-VP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
positive	positive	P231	JJ	I-NP	O
control	control	C536	NN	I-NP	O
)	)	0000	)	O	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
cDNA	cDNA	C350	NN	B-NP	O
replaced	replace	R142	VBD	B-VP	O
its	its	I320	PRP$	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
counterpart	counterpart	C536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
environment	environment	E516	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
is	be	I200	VBZ	B-VP	O
compared	compare	C516	VBN	I-VP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
Gly269	Gly269	G400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
Ser	Ser	S600	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
ABSTRACT	ABSTRACT	A123	NN	B-NP	O
TRUNCATED	TRUNCATED	T652	VBN	B-VP	O
AT	AT	A300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	W632	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Novel	Novel	N140	NNP	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
from	from	F650	IN	B-PP	O
China	China	C500	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
three	three	T600	CD	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
infantile	infantile	I515	JJ	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
nonconsanguineous	nonconsanguineous	N525	JJ	I-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
G	G	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1444	1444	0000	CD	I-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
Nakano	Nakano	N250	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1988	1988	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
after	after	A136	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
547	547	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
family	family	F540	NN	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
change	change	C520	NN	I-NP	O
generates	generate	G563	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
6	6	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
homozygosity	homozygosity	H523	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O

Single	Single	S524	JJ	B-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
amplified	amplify	A514	VBN	B-NP	O
exon	exon	E250	NN	I-NP	O
13	13	0000	CD	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1453	1453	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
W485R	W485R	W600	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
creates	create	C632	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
Fnu4HI	Fnu4HI	F500	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
mutagenized	mutagenize	M325	VBN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1453	1453	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
S	S	S000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
detectable	detectable	D323	JJ	B-ADJP	O
above	above	A100	IN	B-PP	O
background	background	B265	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1444	1444	0000	CD	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
)	)	0000	)	O	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
E482K	E482K	E200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
CpG	CpG	C120	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
proband	proband	P615	NN	I-NP	O
and	and	A530	CC	O	O
causes	cause	C200	VBZ	B-VP	O
defective	defective	D123	JJ	B-NP	O
intracellular	intracellular	I536	JJ	I-NP	O
transport	transport	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
rough	rough	R200	JJ	I-NP	O
endoplasmic	endoplasmic	E531	JJ	I-NP	O
reticulum	reticulum	R324	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Golgi	Golgi	G420	NNP	I-NP	O
apparatus	apparatus	A163	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
mild	mild	M430	JJ	B-NP	O
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	I-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	B-NP	B-Disease
(	(	0000	(	O	O
HPA	HPA	H100	NN	B-NP	B-Disease
)	)	0000	)	O	O
cases	case	C200	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Approximately	Approximately	A162	RB	B-NP	O
50	50	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNS	B-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
reflected	reflect	R142	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
severities	severity	S163	NNS	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
specific	specific	S121	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
hypothesized	hypothesize	H132	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
mild	mild	M430	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
12	12	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Swedish	Swedish	S320	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
HPA	HPA	H100	NN	I-NP	B-Disease
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
haplotype	haplotype	H143	NN	B-NP	O
12	12	0000	CD	I-NP	O
had	have	H300	VBD	B-VP	O
mild	mild	M430	JJ	B-NP	O
HPA	HPA	H100	NN	I-NP	B-Disease
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
G	G	G000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
base	base	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
322	322	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
glycine	glycine	G425	NN	B-NP	O
for	for	F600	IN	B-PP	O
alanine	alanine	A450	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
12	12	0000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
base	base	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
408	408	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
glutamine	glutamine	G435	NN	B-NP	O
for	for	F600	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
three	three	T600	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
12	12	0000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
segregated	segregate	S262	VBD	B-VP	O
with	with	W300	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
12	12	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
but	but	B300	CC	O	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	O	O
present	present	P625	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
or	or	O600	CC	I-NP	O
other	other	O360	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
eukaryotic	eukaryotic	E263	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
system	system	S235	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
enzyme	enzyme	E525	NN	B-NP	O
activities	activity	A231	NNS	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
reflect	reflect	R142	VBP	B-VP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
severities	severity	S163	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
in	in	I500	FW	I-NP	O
vitro	vitro	V360	FW	I-NP	O
activities	activity	A231	NNS	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
translated	translate	T652	VBN	I-VP	O
directly	directly	D623	RB	B-ADVP	O
into	into	I530	IN	B-PP	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
activities	activity	A231	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
A322G	A322G	A200	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
had	have	H300	VBD	B-VP	O
about	about	A130	RB	B-NP	O
75	75	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
R408Q	R408Q	R200	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
about	about	A130	RB	B-NP	O
55	55	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PAH	PAH	P000	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
in	in	I500	FW	I-NP	O
vitro	vitro	V360	FW	I-NP	O
activities	activity	A231	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
reported	report	R163	VBN	B-VP	O
for	for	F600	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
produced	produce	P632	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
ABSTRACT	ABSTRACT	A123	NN	B-NP	O
TRUNCATED	TRUNCATED	T652	VBN	B-VP	O
AT	AT	A300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	W632	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-NP	O
vivo	vivo	V100	FW	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
for	for	F600	IN	B-PP	O
I65T	I65T	I300	NN	B-NP	O
and	and	A530	CC	I-NP	O
M1V	M1V	M100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
four	four	F600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
M1V	M1V	M100	NN	B-NP	O
,	,	0000	,	O	O
IVS12nt1	IVS12nt1	I125	NN	B-NP	O
,	,	0000	,	O	O
R408W	R408W	R000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
S349P	S349P	S100	NN	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
French	French	F652	JJ	B-NP	O
Canadians	Canadian	C535	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ancestry	ancestry	A523	NN	B-NP	O
in	in	I500	IN	B-PP	O
eastern	eastern	E236	JJ	B-NP	O
Quebec	Quebec	Q120	NNP	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
9	9	0000	CD	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
converts	convert	C516	VBZ	B-VP	O
codon	codon	C350	NN	B-NP	O
65	65	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
isoleucine	isoleucine	I242	NN	B-NP	O
(	(	0000	(	O	O
ATT	ATT	A300	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
threonine	threonine	T650	NN	B-NP	O
(	(	0000	(	O	O
ACT	ACT	A230	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
expression	expression	E216	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
I65T	I65T	I300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
demonstrating	demonstrate	D523	VBG	B-VP	O
75	75	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	B-NP	O
immunoreactive	immunoreactive	I562	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
expression	expression	E216	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
M1V	M1V	M100	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
eastern	eastern	E236	JJ	B-NP	O
Quebec	Quebec	Q120	NNP	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
nondetectable	nondetectable	N532	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
translation	translation	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

Homozygosity	Homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
M1V	M1V	M100	NN	B-NP	O
and	and	A530	CC	O	O
codominant	codominant	C353	JJ	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
I65T	I65T	I300	NN	B-NP	O
/	/	0000	SYM	B-NP	O
R408W	R408W	R000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
both	both	B300	DT	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
classical	classical	C424	JJ	B-NP	B-Disease
phenylketonuria	phenylketonuria	P542	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hexosaminidase	hexosaminidase	H253	NN	B-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
pseudodeficiency	pseudodeficiency	P231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Berks	Berks	B620	NNP	I-NP	O
County	County	C530	NNP	I-NP	O
Pennsylvania	Pennsylvania	P524	NNP	I-NP	O
Dutch	Dutch	D320	NNP	I-NP	O
.	.	0000	.	O	O

Following	Follow	F452	VBG	B-PP	O
the	the	T000	DT	B-NP	O
birth	birth	B630	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
infants	infant	I515	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
,	,	0000	,	O	O
Pennsylvania	Pennsylvania	P524	NNP	B-NP	O
Dutch	Dutch	D320	NNP	I-NP	O
kindred	kindred	K536	NN	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
assay	assay	A200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
TSD	TSD	T230	NN	B-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
(	(	0000	(	O	O
Kelly	Kelly	K400	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1975	1975	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
was	be	W200	VBD	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
two	two	T000	CD	I-NP	O
altered	alter	A436	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
report	report	R163	VBP	B-VP	O
two	two	T000	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
Pennsylvania	Pennsylvania	P524	NNP	I-NP	O
Dutch	Dutch	D320	NNP	I-NP	O
kindred	kindred	K536	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
reported	report	R163	VBN	B-VP	O
originally	originally	O625	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
Akli	Akli	A240	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1991	1991	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
GT	GT	G300	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
AT	AT	A300	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
739	739	0000	CD	I-NP	O
(	(	0000	(	O	O
Arg247Trp	Arg247Trp	A623	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Triggs	Triggs	T620	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Raine	Raine	R500	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
1992	1992	0000	CD	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
benign	benign	B525	JJ	I-NP	O
"	"	0000	``	I-NP	O
pseudodeficient	pseudodeficient	P231	JJ	I-NP	O
"	"	0000	''	I-NP	O
allele	allele	A400	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
against	against	A252	IN	B-PP	O
artificial	artificial	A631	JJ	B-NP	O
substrate	substrate	S123	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
[	[	0000	(	O	O
G	G	G000	NN	B-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
759	759	0000	CD	B-NP	O
)	)	0000	)	O	O
]	]	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
leaves	leave	L120	VBZ	B-VP	O
valine	valine	V450	NN	B-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
253	253	0000	CD	I-NP	O
unchanged	unchanged	U525	JJ	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
frequency	frequency	F625	NN	B-NP	O
and	and	A530	CC	I-NP	O
RNA	RNA	R500	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	O	O
acetylhexosaminidase	acetylhexosaminidase	A234	NN	B-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
discovered	discover	D216	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
IVS	IVS	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
9	9	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
first	first	F623	RB	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Akli	Akli	A240	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
Genomics	Genomic	G520	NNS	B-NP	O
11	11	0000	CD	B-NP	O
124	124	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
134	134	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1991	1991	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
Caucasians	Caucasian	C252	NNPS	I-NP	O
(	(	0000	(	O	O
10	10	0000	CD	B-NP	O
/	/	0000	SYM	O	O
58	58	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	I-VP	O
diagnostic	diagnostic	D252	JJ	B-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
detects	detect	D323	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
NlaIII	NlaIII	N400	NN	I-NP	O
site	site	S300	NN	I-NP	O
generated	generate	G563	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
among	among	A520	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
defined	define	D153	VBN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
64	64	0000	CD	I-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
those	those	T200	DT	B-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
trace	trace	T620	VBP	B-VP	O
their	their	T600	PRP$	B-NP	O
origins	origin	O625	NNS	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
Kingdom	Kingdom	K523	NNP	I-NP	O
,	,	0000	,	O	O
Ireland	Ireland	I645	NNP	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
Western	Western	W236	NNP	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
among	among	A520	IN	B-PP	O
12	12	0000	CD	B-NP	O
Black	Black	B420	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
or	or	O600	CC	B-PP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
18	18	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
,	,	0000	,	O	O
enzyme	enzyme	E525	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
defined	define	D153	VBN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
who	who	W000	WP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
carry	carry	C600	VB	I-VP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
normally	normally	N654	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
generated	generate	G563	VBN	B-VP	O
from	from	F650	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
IVS	IVS	I120	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Instead	Instead	I523	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
were	be	W600	VBD	B-VP	O
comprised	comprise	C516	VBN	I-VP	O
of	of	O100	IN	B-PP	O
aberrant	aberrant	A165	JJ	B-NP	O
species	specie	S120	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	DT	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
donor	donor	D560	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
truncating	truncate	T652	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
within	within	W350	IN	B-PP	O
IVS	IVS	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
spliced	splice	S142	VBN	B-VP	O
to	to	T000	TO	B-PP	O
exon	exon	E250	NN	B-NP	O
10	10	0000	CD	I-NP	O
.	.	0000	.	O	O

Numerous	Numerous	N562	JJ	B-NP	O
additional	additional	A354	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
products	product	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
most	most	M230	JJS	B-NP	O
involving	involve	I514	VBG	I-NP	O
skipping	skipping	S215	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
surrounding	surrounding	S653	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
pseudodeficiency	pseudodeficiency	P231	NN	I-NP	O
(	(	0000	(	O	O
Triggs	Triggs	T620	NNP	B-NP	O
-	-	0000	HYPH	O	O
Raine	Raine	R500	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
Am	Am	A500	NNP	B-NP	O
J	J	J000	NNP	I-NP	O
Hum	Hum	H500	NNP	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
,	,	0000	,	O	O
1992	1992	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
29	29	0000	CD	B-NP	O
/	/	0000	SYM	O	O
64	64	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	O
carrier	carrier	C600	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
ascertained	ascertain	A263	VBN	B-VP	O
by	by	B000	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
tests	test	T232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	NNPS	I-NP	O
Caucasians	Caucasian	C252	NNPS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Aberrant	Aberrant	A165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
.	.	0000	.	O	O

Choroideremia	Choroideremia	C636	NN	B-NP	B-Disease
(	(	0000	(	O	O
CHM	CHM	C500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
progressive	progressive	P626	JJ	B-NP	I-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
choroid	choroid	C630	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
retina	retina	R350	NN	I-NP	I-Disease
.	.	0000	.	O	O

12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
unrelated	unrelated	U564	JJ	B-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
carry	carry	C600	VBP	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
partially	partially	P634	RB	I-NP	O
cloned	clone	C453	VBN	I-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Finland	Finland	F545	NNP	B-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
120	120	0000	CD	I-NP	O
living	living	L152	NN	I-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
eight	eight	E230	CD	B-NP	O
apparently	apparently	A165	RB	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
screened	screen	S265	VBN	I-VP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
five	five	F100	CD	I-NP	O
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
large	large	L620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
(	(	0000	(	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
insertion	insertion	I526	NN	B-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
C	C	C000	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
two	two	T000	CD	B-NP	O
aberrantly	aberrantly	A165	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
mRNAs	mRNA	M652	NNS	I-NP	O
both	both	B300	CC	O	O
producing	produce	P632	VBG	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
assayed	assay	A230	VBN	I-VP	O
easily	easily	E240	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
amplification	amplification	A514	NN	B-NP	O
and	and	A530	CC	I-NP	O
digestion	digestion	D235	NN	I-NP	O
with	with	W300	IN	B-PP	O
Msel	Msel	M240	NNP	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
additional	additional	A354	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenetic	pathogenetic	P325	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
CHM	CHM	C500	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VB	B-VP	O
a	a	A000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
fifth	fifth	F130	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
worlds	world	W643	NNS	I-NP	O
known	know	K500	VBN	B-VP	O
CHM	CHM	C500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
exonic	exonic	E252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WT1	WT1	W300	NN	B-NP	O
)	)	0000	)	O	O
affecting	affect	A123	VBG	B-VP	O
urogenital	urogenital	U625	JJ	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Denys	Denys	D520	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
developmental	developmental	D141	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
urogenital	urogenital	U625	JJ	I-NP	O
system	system	S235	NN	I-NP	O
and	and	A530	CC	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
,	,	0000	,	O	O
intersex	intersex	I536	NN	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
carrying	carry	C652	VBG	I-VP	O
germline	germline	G654	NN	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
WT1	WT1	W300	NN	B-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
occurred	occur	O263	VBD	B-VP	O
within	within	W350	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
preventing	prevent	P615	VBG	B-VP	O
splicing	splicing	S142	NN	B-NP	O
at	at	A300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alternatively	alternatively	A436	RB	I-NP	O
chosen	choose	C250	VBN	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
when	when	W500	WRB	B-ADVP	O
assayed	assay	A230	VBN	B-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
functional	functional	F523	JJ	I-NP	O
roles	role	R420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
in	in	I500	IN	B-PP	O
urogenital	urogenital	U625	JJ	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
isoform	isoform	I216	NN	I-NP	O
-	-	0000	HYPH	O	O
encoding	encode	E523	VBG	B-VP	O
mRNAs	mRNA	M652	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
protein	protein	P635	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Brain	Brain	B650	NN	B-NP	O
and	and	A530	CC	I-NP	O
heart	heart	H630	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
kinase	kinase	K520	NN	B-NP	O
(	(	0000	(	O	O
DMR	DMR	D560	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
B15	B15	B000	NN	I-NP	O
)	)	0000	)	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
subject	subject	S123	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
RNA	RNA	R500	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
human	human	H500	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
[	[	0000	(	I-NP	O
CTG	CTG	C320	NN	I-NP	O
]	]	0000	)	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
motif	motif	M310	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
uniquely	uniquely	U524	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
flanking	flanking	F452	NN	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
also	also	A420	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
species	specie	S120	NNS	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
another	another	A536	DT	B-NP	O
active	active	A231	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DMR	DMR	D560	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
N9	N9	N000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
close	close	C420	JJ	B-NP	O
proximity	proximity	P625	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

DMR	DMR	D560	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
N9	N9	N000	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	I-NP	O
testis	testis	T232	NN	I-NP	O
,	,	0000	,	O	O
possess	possess	P200	VBP	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
,	,	0000	,	I-NP	O
large	large	L620	JJ	I-NP	O
open	open	O150	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CTG	CTG	C320	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
repeat	repeat	R130	NN	I-NP	O
compromising	compromise	C516	VBG	B-VP	O
the	the	T000	DT	O	O
(	(	0000	(	O	O
alternative	alternative	A436	JJ	O	O
)	)	0000	)	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
kinase	kinase	K520	NN	I-NP	O
or	or	O600	CC	I-NP	O
DMR	DMR	D560	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
N9	N9	N000	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Fragile	Fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
CCG	CCG	C200	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
FMR1	FMR1	F560	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
without	without	W300	IN	B-PP	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
or	or	O600	CC	O	O
an	an	A500	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
CCG	CCG	C200	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CCG	CCG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
FMR1	FMR1	F560	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
about	about	A130	IN	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
megabases	megabas	M212	NNS	I-NP	O
of	of	O100	IN	B-PP	O
flanking	flank	F452	VBG	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
can	can	C500	MD	B-VP	O
exist	exist	E230	VB	I-VP	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
amplification	amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CCG	CCG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
or	or	O600	CC	O	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragile	fragile	F624	JJ	I-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
fragile	fragile	F624	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
genetically	genetically	G532	RB	I-NP	O
homogeneous	homogeneous	H525	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
FMR1	FMR1	F560	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
found	find	F530	VBD	B-VP	O
random	random	R535	JJ	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
who	who	W000	WP	B-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
million	million	M450	CD	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
(	(	0000	(	O	O
Mb	Mb	M100	NN	B-NP	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
D4S10	D4S10	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
D4S168	D4S168	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
strategy	strategy	S363	NN	I-NP	O
to	to	T000	TO	B-VP	O
clone	clone	C450	VB	I-VP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
location	location	L235	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
isolated	isolate	I243	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
overlapping	overlap	O164	VBG	B-VP	O
yeast	yeast	Y230	NN	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
YAC	YAC	Y200	NN	B-NP	O
)	)	0000	)	O	O
clones	clone	C452	NNS	B-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
eight	eight	E230	CD	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
human	human	H500	JJ	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
libraries	library	L162	NNS	I-NP	O
with	with	W300	IN	B-PP	O
twelve	twelve	T410	CD	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
-	-	0000	HYPH	O	O
tagged	tag	T230	VBN	B-NP	O
sites	site	S320	NNS	I-NP	O
(	(	0000	(	O	O
STSs	STS	S320	NNS	B-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
assembled	assemble	A251	VBD	B-VP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
into	into	I530	IN	B-PP	O
overlapping	overlap	O164	VBG	B-VP	O
sets	set	S320	NNS	B-NP	O
by	by	B000	IN	B-PP	O
hybridizing	hybridize	H163	VBG	B-VP	O
them	them	T500	PRP	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
probes	probe	P612	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
STSs	STS	S320	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
isolated	isolate	I243	VBD	B-VP	O
the	the	T000	DT	B-NP	O
ends	end	E532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
inserts	insert	I526	NNS	I-NP	O
of	of	O100	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
to	to	T000	TO	B-VP	O
assist	assist	A230	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
construction	construction	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
contig	contig	C532	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
almost	almost	A452	RB	B-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YACs	YAC	Y200	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
chimeric	chimeric	C562	JJ	B-NP	O
inserts	insert	I526	NNS	I-NP	O
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
contain	contain	C535	VBP	B-VP	O
internal	internal	I536	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
obtain	obtain	O135	VB	I-VP	O
over	over	O160	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
YACs	YAC	Y200	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
one	one	O500	CD	B-NP	O
continuous	continuous	C535	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
covering	cover	C165	VBG	B-VP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
that	that	T300	IN	B-NP	O
most	most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Ten	Ten	T500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
twenty	twenty	T530	CD	I-NP	O
eight	eight	E230	CD	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
comprise	comprise	C516	VBP	B-VP	O
a	a	A000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
set	set	S300	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
clones	clone	C452	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
reagents	reagent	R253	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
eventual	eventual	E153	JJ	I-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Characterization	Characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
part	part	P630	NN	B-NP	O
or	or	O600	CC	I-NP	O
all	all	A400	DT	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
from	from	F650	IN	B-PP	O
pulsed	pulse	P423	VBN	B-NP	O
-	-	0000	HYPH	I-NP	O
field	field	F430	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
PFGE	PFGE	P120	NN	B-NP	O
)	)	0000	)	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
monoamine	monoamine	M500	NN	I-NP	O
oxidase	oxidase	O232	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
B	B	B000	NN	B-NP	O
(	(	0000	(	O	O
MAOA	MAOA	M000	NN	B-NP	O
&	&	0000	CC	I-NP	O
MAOB	MAOB	M100	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
DXS7	DXS7	D200	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
physically	physically	P240	RB	B-ADVP	O
very	very	V600	RB	B-ADJP	O
close	close	C420	JJ	I-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
therefore	therefore	T616	RB	I-VP	O
extended	extend	E235	VBN	I-VP	O
studies	study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
relationship	relationship	R435	NN	I-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
characterisation	characterisation	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
650	650	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
using	use	U252	VBG	B-VP	O
L1	L1	L000	NN	B-NP	O
.	.	0000	.	O	O

28	28	0000	CD	B-NP	O
(	(	0000	(	O	O
recognising	recognise	R252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
contains	contain	C535	VBZ	B-VP	O
both	both	B300	CC	O	O
MAOA	MAOA	M000	NN	B-NP	O
and	and	A530	CC	I-NP	O
MAOB	MAOB	M100	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
YL1	YL1	Y400	NN	I-NP	O
.	.	0000	.	O	O

28	28	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
both	both	B300	DT	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
independently	independently	I531	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
MAOA	MAOA	M000	NN	B-NP	O
and	and	A530	CC	I-NP	O
B	B	B000	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
range	range	R520	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
map	map	M100	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
subclones	subclone	S124	NNS	B-NP	O
prepared	prepare	P616	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
phage	phage	P200	NN	I-NP	O
library	library	L160	NN	I-NP	O
(	(	0000	(	O	O
lambda	lambda	L513	SYM	B-NP	O
DASH	DASH	D200	NN	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterised	characterise	C623	VBN	I-VP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
employed	employ	E514	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
end	end	E530	NN	I-NP	O
point	point	P530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
NDP	NDP	N310	NN	B-NP	B-Disease
)	)	0000	)	O	O
patient	patient	P353	NN	B-NP	O
who	who	W000	WP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lack	lack	L200	VB	I-VP	O
both	both	B300	CC	O	O
DXS7	DXS7	D200	NN	B-NP	O
and	and	A530	CC	O	O
MAO	MAO	M000	NN	B-NP	O
coding	coding	C352	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
retention	retention	R353	NN	B-NP	O
of	of	O100	IN	B-PP	O
subclones	subclone	S124	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
patient	patient	P353	NN	I-NP	O
place	place	P420	VBP	B-VP	O
the	the	T000	DT	B-NP	O
end	end	E530	NN	I-NP	O
point	point	P530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
within	within	W350	IN	B-PP	O
30	30	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
130	130	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
combining	combine	C515	VBG	B-VP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
with	with	W300	IN	B-PP	O
established	establish	E231	VBN	B-NP	O
recombination	recombination	R251	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
or	or	O600	CC	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
250kb	250kb	K100	JJ	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
are	be	A600	VBP	B-VP	O
necessary	necessary	N260	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
African	African	A162	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
almost	almost	A452	RB	B-ADVP	O
entirely	entirely	E536	RB	I-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
differs	differ	D162	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
B	B	B000	NN	I-NP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
replacements	replacement	R142	NNS	I-NP	O
,	,	0000	,	O	O
68	68	0000	CD	B-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
and	and	A530	CC	O	O
126	126	0000	CD	B-NP	O
Asn	Asn	A250	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Asp	Asp	A210	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variant	variant	V653	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
mutation	mutation	M350	NN	I-NP	O
126	126	0000	CD	I-NP	O
Asn	Asn	A250	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Asp	Asp	A210	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
genes	gene	G520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
parts	part	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
are	be	A600	VBP	B-VP	O
both	both	B300	DT	O	O
about	about	A130	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	LS	B-LST	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
68	68	0000	CD	I-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
B	B	B000	NN	I-NP	O
background	background	B265	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
because	because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
68	68	0000	CD	I-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
happened	happen	H153	VBD	B-VP	O
to	to	T000	TO	I-VP	O
arise	arise	A620	VB	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
instance	instance	I523	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
because	because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
68	68	0000	CD	I-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
alone	alone	A450	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
approached	approach	A162	VBN	I-VP	O
this	this	T200	DT	B-NP	O
question	question	Q235	NN	I-NP	O
by	by	B000	IN	B-PP	O
producing	produce	P632	VBG	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
B	B	B000	NN	I-NP	O
,	,	0000	,	O	O
A	A	A000	NN	B-NP	O
,	,	0000	,	O	O
A	A	A000	NN	B-NP	O
-	-	0000	HYPH	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
68	68	0000	CD	I-NP	O
Val	Val	V400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
bacterial	bacterial	B236	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
system	system	S235	NN	I-NP	O
and	and	A530	CC	O	O
analysing	analyse	A542	VBG	B-VP	O
their	their	T600	PRP$	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
each	each	E200	DT	B-NP	O
single	single	S524	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
slight	slight	S423	JJ	I-NP	O
decrease	decrease	D262	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
the	the	T000	DT	I-NP	O
specific	specific	S121	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
yield	yield	Y430	NN	I-NP	O
of	of	O100	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
B	B	B000	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
together	together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
roughly	roughly	R240	RB	I-NP	O
additive	additive	A310	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
a	a	A000	DT	O	O
much	much	M200	RB	B-ADVP	O
more	more	M600	RBR	I-ADVP	O
drastic	drastic	D623	JJ	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
yield	yield	Y430	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
synergistic	synergistic	S562	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
on	on	O500	IN	B-PP	O
thermal	thermal	T654	JJ	B-NP	O
stability	stability	S314	NN	I-NP	O
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
NADP	NADP	N310	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
.	.	0000	.	O	O

Comparable	Comparable	C516	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
produced	produce	P632	VBN	I-VP	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
replacement	replacement	R142	NN	I-NP	O
119	119	0000	CD	I-NP	O
Gln	Gln	G450	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Glu	Glu	G400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
instead	instead	I523	RB	B-PP	O
of	of	O100	IN	I-PP	O
126	126	0000	CD	B-NP	O
Asn	Asn	A250	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Asp	Asp	A210	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
infer	infer	I516	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
coexistence	coexistence	C235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	O
-	-	0000	:	O	O
because	because	B200	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
act	act	A230	VBP	B-VP	O
synergistically	synergistically	S562	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
causing	cause	C252	VBG	B-VP	O
instability	instability	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

Small	Small	S540	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
ribonucleoprotein	ribonucleoprotein	R152	NN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
N	N	N000	NN	I-NP	O
(	(	0000	(	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
expressed	express	E216	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
paternally	paternally	P365	RB	B-NP	O
derived	derive	D613	VBN	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
region	region	R250	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
or	or	O600	CC	B-PP	O
with	with	W300	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	I-Disease
chromosome	chromosome	C652	NN	B-NP	I-Disease
15	15	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expressed	express	E216	VBN	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
maternally	maternally	M365	RB	B-NP	O
imprinted	imprinted	I516	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
must	must	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
associated	associate	A230	VBN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
SmN	SmN	S500	NN	I-NP	O
(	(	0000	(	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15q12	15q12	Q000	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
processed	process	P623	VBN	I-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
SNRPNP1	SNRPNP1	S561	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
region	region	R250	NN	I-NP	O
6pter	6pter	P360	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
p21	p21	P000	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Snrpn	Snrpn	S561	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
maternally	maternally	M365	RB	I-VP	O
imprinted	imprint	I516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternally	paternally	P365	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
SNRPN	SNRPN	S561	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Cajun	Cajun	C250	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
to	to	T000	TO	I-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Cajun	Cajun	C250	NNP	I-NP	O
population	population	P143	NN	I-NP	O
in	in	I500	IN	B-PP	O
southwest	southwest	S323	JJ	B-NP	O
Louisiana	Louisiana	L250	NNP	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
origins	origin	O625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Eleven	Eleven	E415	CD	B-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
insertion	insertion	I526	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
70	70	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
origins	origin	O625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cajun	Cajun	C250	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
was	be	W200	VBD	B-VP	O
enzymatically	enzymatically	E525	RB	I-VP	O
determined	determine	D365	VBN	I-VP	O
for	for	F600	IN	B-PP	O
90	90	0000	CD	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
extensive	extensive	E235	JJ	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
couple	couple	C140	NN	I-NP	O
from	from	F650	IN	B-PP	O
France	France	F652	NNP	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
insertion	insertion	I526	NN	I-NP	O
.	.	0000	.	O	O

Pedigree	Pedigree	P326	NNP	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cajun	Cajun	C250	NNP	I-NP	O
population	population	P143	NN	I-NP	O
since	since	S520	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
founding	founding	F535	NN	I-NP	O
over	over	O160	IN	B-PP	O
2	2	0000	CD	B-NP	O
centuries	century	C536	NNS	I-NP	O
ago	ago	A200	IN	B-ADVP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
widely	widely	W340	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
apparently	apparently	A165	RB	B-ADVP	O
was	be	W200	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
century	century	C536	NN	I-NP	O
and	and	A530	CC	O	O
probably	probably	P614	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
Louisiana	Louisiana	L250	NNP	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
and	and	A530	CC	I-NP	O
others	other	O362	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
linked	link	L523	VBN	B-VP	I-Disease
Norrie	Norrie	N600	NNP	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
ND	ND	N300	NN	B-NP	B-Disease
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
or	or	O600	CC	I-VP	O
disrupted	disrupt	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
prerequisite	prerequisite	P623	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
established	establish	E231	VBN	I-VP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
intron	intron	I536	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
,	,	0000	,	O	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
exons	exon	E252	NNS	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	O	O
2	2	0000	CD	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
technique	technique	T252	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
altered	alter	A436	VBD	B-VP	O
PCR	PCR	P260	NN	B-NP	O
fragments	fragment	F625	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
detail	detail	D340	NN	B-NP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Eleven	Eleven	E415	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	O	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
are	be	A600	VBP	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
give	give	G100	VB	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
significant	significant	S251	JJ	B-NP	O
structural	structural	S362	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
functionally	functionally	F523	RB	B-NP	O
relevant	relevant	R415	JJ	I-NP	O
base	base	B200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
healthy	healthy	H430	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
,	,	0000	,	O	O
emphasize	emphasize	E512	VBP	B-VP	O
the	the	T000	DT	B-NP	O
causal	causal	C240	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
pave	pave	P100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
way	way	W000	NN	I-NP	O
for	for	F600	IN	B-PP	O
reliable	reliable	R414	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
and	and	A530	CC	I-NP	O
carrier	carrier	C600	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
by	by	B000	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
multiplex	multiplex	M431	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
technique	technique	T252	NN	B-NP	O
was	be	W200	VBD	B-VP	O
employed	employ	E514	VBN	I-VP	O
to	to	T000	TO	I-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Co	Co	C000	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
amplification	amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
11	11	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
or	or	O600	CC	I-NP	O
duplication	duplication	D142	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
samples	sample	S514	NNS	I-NP	O
subjected	subject	S123	VBN	B-VP	O
to	to	T000	TO	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Duchenne	Duchenne	D250	JJ	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
introduces	introduce	I536	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
within	within	W350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
a	a	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
premature	premature	P653	JJ	I-NP	O
translational	translational	T652	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
accounting	account	A253	VBG	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
inherited	inherit	I563	VBD	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
from	from	F650	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
the	the	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
5	5	0000	CD	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
useful	useful	U214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
internal	internal	I536	JJ	B-NP	O
control	control	C536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Proliferation	Proliferation	P641	NN	B-NP	O
-	-	0000	HYPH	O	O
related	relate	R430	VBN	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
nucleoside	nucleoside	N242	NN	I-NP	O
diphosphate	diphosphate	D121	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
.	.	0000	.	O	O

High	High	H200	JJ	B-NP	O
level	level	L140	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nm23	nm23	N500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
H1	H1	H000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
nucleoside	nucleoside	N242	NN	I-NP	O
diphosphate	diphosphate	D121	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
correlate	correlate	C643	VB	I-VP	O
with	with	W300	IN	B-PP	O
diminished	diminish	D523	VBN	B-NP	O
metastasis	metastasis	M323	NN	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
others	other	O362	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nm23	nm23	N500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
H1	H1	H000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
dimensional	dimensional	D525	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
gels	gel	G420	NNS	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
designated	designate	D253	VBN	I-VP	O
it	it	I300	PRP	B-NP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
neuroblastoma	neuroblastoma	N614	NN	B-NP	B-Disease
,	,	0000	,	O	O
higher	high	H260	JJR	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
amplification	amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
myc	myc	M200	NN	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
,	,	0000	,	O	O
large	large	L620	JJ	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
mass	mass	M200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
metastasis	metastasis	M323	NN	B-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	O
stage	stage	S320	NN	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
limited	limited	L530	JJ	B-NP	O
stage	stage	S320	NN	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
nm23	nm23	N500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
H1	H1	H000	NN	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
amounts	amount	A532	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
compared	compare	C516	VBN	I-VP	O
between	between	B350	IN	B-PP	O
resting	rest	R235	VBG	B-NP	O
and	and	A530	CC	I-NP	O
mitotically	mitotically	M324	RB	I-NP	O
stimulated	stimulate	S354	VBN	I-NP	O
normal	normal	N654	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
PBLs	PBL	P142	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
increased	increase	I526	VBD	B-VP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
mitotic	mitotic	M320	JJ	B-NP	O
stimulation	stimulation	S354	NN	I-NP	O
and	and	A530	CC	O	O
paralleled	parallel	P643	VBD	B-VP	O
the	the	T000	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
subtypes	subtype	S131	NNS	I-NP	O
of	of	O100	IN	B-PP	O
acute	acute	A230	JJ	B-NP	B-Disease
leukemia	leukemia	L250	NN	I-NP	I-Disease
,	,	0000	,	O	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
nm23	nm23	N500	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
relative	relative	R431	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
resting	rest	R235	VBG	B-NP	O
normal	normal	N654	JJ	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

Treatment	Treatment	T635	NN	B-NP	O
of	of	O100	IN	B-PP	O
mitotically	mitotically	M324	RB	B-NP	O
stimulated	stimulate	S354	VBN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cyclosporin	cyclosporin	C242	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
inhibits	inhibit	I513	VBZ	B-VP	O
proliferation	proliferation	P641	NN	B-NP	O
,	,	0000	,	O	O
blocked	block	B423	VBD	B-VP	O
the	the	T000	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	O	O
nm23	nm23	N500	NN	B-NP	O
;	;	0000	:	O	O
treatment	treatment	T635	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
leukemia	leukemia	L250	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
HL	HL	H400	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
60	60	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
dimethylsulfoxide	dimethylsulfoxide	D534	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
induces	induce	I532	VBZ	B-VP	O
terminal	terminal	T654	JJ	B-NP	O
differentiation	differentiation	D165	NN	I-NP	O
,	,	0000	,	O	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
diminished	diminish	D523	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
p19	p19	P000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
nm23	nm23	N500	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
therefore	therefore	T616	RB	B-ADVP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
nm23	nm23	N500	NN	B-NP	O
-	-	0000	HYPH	O	O
H1	H1	H000	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
cell	cell	C400	NN	B-NP	O
proliferative	proliferative	P641	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
intrachromosomal	intrachromosomal	I536	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
5q22	5q22	Q000	NN	B-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAPC	FAPC	F120	NN	B-NP	B-Disease
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
epidermoid	epidermoid	E136	JJ	B-NP	B-Disease
cysts	cyst	C232	NNS	I-NP	I-Disease
,	,	0000	,	O	O
osteomata	osteoma	O235	NNS	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
areas	area	A620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	H163	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
pigment	pigment	P253	NN	I-NP	I-Disease
epithelium	epithelium	E134	NN	I-NP	I-Disease
(	(	0000	(	O	O
CHRPEs	CHRPE	C612	NNS	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
aunt	aunt	A530	NN	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
suffered	suffer	S163	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
to	to	T000	TO	I-NP	O
moderate	moderate	M363	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
mental	mental	M534	JJ	B-NP	B-Disease
handicap	handicap	H532	NN	I-NP	I-Disease
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q22q23	q22q23	Q200	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	O	O
)	)	0000	)	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
normal	normal	N654	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
direct	direct	D623	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
dir	dir	D600	NN	B-NP	O
ins	in	I520	NNS	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q31	q31	Q000	NN	B-NP	O
.	.	0000	.	O	O
3q22q23	3q22q23	Q200	CD	B-NP	O
3q22q23	3q22q23	Q200	NN	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	O	O
)	)	0000	)	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
fluorescent	fluorescent	F462	JJ	I-NP	O
hybridisation	hybridisation	H163	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
loci	locus	L200	NNS	B-NP	O
D5S37	D5S37	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
D5S98	D5S98	D200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
outside	outside	O323	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
whereas	whereas	W620	IN	B-PP	O
loci	locus	L200	NNS	B-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
probes	probe	P612	NNS	B-NP	O
EF5	EF5	E100	NN	I-NP	O
.	.	0000	.	O	O

44	44	0000	CD	B-NP	O
and	and	A530	CC	O	O
YN5	YN5	Y500	NN	B-NP	O
.	.	0000	.	O	O

48	48	0000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
lost	lose	L230	VBN	I-VP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
MCC	MCC	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
band	band	B530	NN	B-NP	O
5q22	5q22	Q000	NN	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	O
direct	direct	D623	JJ	I-NP	O
insertions	insertion	I526	NNS	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
considered	consider	C523	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
microdeletion	microdeletion	M263	NN	I-NP	O
syndromes	syndrome	S536	NNS	I-NP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rod	rod	R300	NN	I-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
cGMP	cGMP	C251	NN	I-NP	O
phosphodiesterase	phosphodiesterase	P213	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-ADJP	O
:	:	0000	:	O	O
tight	tight	T230	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
4p16	4p16	P000	CD	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
retinal	retinal	R354	JJ	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
mouse	mouse	M200	NN	I-NP	O
(	(	0000	(	O	O
gene	gene	G500	NN	B-NP	O
symbol	symbol	S514	NN	I-NP	O
,	,	0000	,	O	O
rd	rd	R300	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
retinopathies	retinopathy	R351	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
rd	rd	R300	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
PDE	PDE	P300	NN	I-NP	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Pdeb	Pdeb	P310	NN	B-NP	O
)	)	0000	)	O	O
prompted	prompt	P651	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
utilized	utilize	U342	VBN	I-VP	O
backcross	backcross	B262	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
to	to	T000	TO	B-VP	O
verify	verify	V610	VB	I-VP	O
and	and	A530	CC	I-VP	O
define	define	D150	VB	I-VP	O
more	more	M600	RBR	B-ADVP	O
precisely	precisely	P624	RB	I-ADVP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Pdeb	Pdeb	P310	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
Mgsa	Mgsa	M200	NN	B-NP	O
on	on	O500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PDEB	PDEB	P310	NN	B-NP	O
)	)	0000	)	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
4p16	4p16	P000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
,	,	0000	,	O	O
very	very	V600	RB	B-ADVP	O
close	close	C420	RB	I-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
comparative	comparative	C516	JJ	I-NP	O
map	map	M100	NN	I-NP	O
for	for	F600	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
and	and	A530	CC	I-NP	O
humans	human	H520	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
will	will	W400	MD	B-VP	O
reside	reside	R230	VB	I-VP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Pdeb	Pdeb	P310	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
homologues	homologue	H542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
4p16	4p16	P000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
maintained	maintain	M535	VBN	I-VP	O
but	but	B300	CC	O	O
gene	gene	G500	NN	B-NP	O
order	order	O636	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
possible	possible	P214	JJ	I-NP	O
sites	site	S320	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
mouse	mouse	M200	NN	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Coincident	Coincident	C523	JJ	B-NP	O
Kaposi	Kaposi	K120	NNP	I-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
T	T	T000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
24	24	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
eczema	eczema	E250	NN	B-NP	B-Disease
,	,	0000	,	O	O
recurrent	recurrent	R265	JJ	B-NP	O
mild	mild	M430	JJ	I-NP	O
infections	infection	I512	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mediastinal	mediastinal	M323	JJ	I-NP	O
mass	mass	M200	NN	I-NP	O
,	,	0000	,	O	O
generalized	generalize	G564	VBN	B-VP	O
lymphadenopathy	lymphadenopathy	L513	NN	B-NP	B-Disease
,	,	0000	,	O	O
splenomegaly	splenomegaly	S145	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
severe	severe	S160	JJ	B-NP	O
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	B-Disease
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
immune	immune	I500	JJ	B-NP	O
function	function	F523	NN	I-NP	O
including	include	I524	VBG	B-PP	O
immunoglobulin	immunoglobulin	I524	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
T	T	T000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
subsets	subset	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
proliferated	proliferate	P641	VBD	B-VP	O
normally	normally	N654	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
phytohemagglutinin	phytohemagglutinin	P352	NN	B-NP	O
,	,	0000	,	O	O
concanavalin	concanavalin	C525	NN	B-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
neuraminidase	neuraminidase	N653	NN	B-NP	O
/	/	0000	SYM	I-NP	O
galactose	galactose	G423	NN	I-NP	O
oxidase	oxidase	O232	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
their	their	T600	PRP$	B-NP	O
proliferative	proliferative	P641	JJ	I-NP	O
responses	response	R215	NNS	I-NP	O
to	to	T000	TO	B-PP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
CD43	CD43	C300	NN	I-NP	O
antibody	antibody	A531	NN	I-NP	O
and	and	A530	CC	I-NP	O
periodate	periodate	P630	NN	I-NP	O
were	be	W600	VBD	B-VP	O
diminished	diminish	D523	VBN	I-VP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
inguinal	inguinal	I525	JJ	I-NP	O
lymph	lymph	L510	NN	I-NP	O
node	node	N300	NN	I-NP	O
biopsy	biopsy	B120	NN	I-NP	O
surprisingly	surprisingly	S616	RB	B-ADVP	O
revealed	reveal	R143	VBD	B-VP	O
Kaposi	Kaposi	K120	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
following	follow	F452	VBG	B-PP	O
splenectomy	splenectomy	S145	NN	B-NP	O
to	to	T000	TO	B-VP	O
increase	increase	I526	VB	I-VP	O
the	the	T000	DT	B-NP	O
platelet	platelet	P434	NN	I-NP	O
count	count	C530	NN	I-NP	O
,	,	0000	,	O	O
biopsy	biopsy	B120	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mediastinal	mediastinal	M323	JJ	I-NP	O
mass	mass	M200	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
T	T	T000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
large	large	L620	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
biopsied	biopsied	B123	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
Epstein	Epstein	E123	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Barr	Barr	B600	NNP	I-NP	I-Disease
virus	virus	V620	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
cytomegalovirus	cytomegalovirus	C352	NN	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
negative	negative	N231	JJ	B-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
were	be	W600	VBD	B-VP	O
studies	study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	B-Disease
immunodeficiency	immunodeficiency	I531	NN	I-NP	I-Disease
virus	virus	V620	NN	I-NP	I-Disease
(	(	0000	(	O	O
HIV	HIV	H100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
Kaposi	Kaposi	K120	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
arising	arise	A625	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
immunodeficiency	immunodeficiency	I531	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
Kaposi	Kaposi	K120	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
can	can	C500	MD	B-VP	O
arise	arise	A620	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
face	face	F200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
immunosuppression	immunosuppression	I521	NN	I-NP	O
that	that	T300	WDT	B-NP	O
follows	follow	F420	VBZ	B-VP	O
allograft	allograft	A426	NN	B-NP	O
transplantation	transplantation	T652	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
infected	infect	I512	VBN	B-VP	O
with	with	W300	IN	B-PP	O
HIV	HIV	H100	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
postulate	postulate	P234	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
longevity	longevity	L521	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
face	face	F200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
immunosuppression	immunosuppression	I521	NN	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
Kaposi	Kaposi	K120	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
gastric	gastric	G236	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
,	,	0000	,	O	O
genetic	genetic	G532	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
during	during	D652	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
well	well	W400	RB	B-ADJP	O
understood	understand	U536	VBN	I-ADJP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
gastric	gastric	G236	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
originate	originate	O625	VB	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
metaplasia	metaplasia	M314	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
colon	colon	C450	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
carcinogenesis	carcinogenesis	C625	NN	B-NP	O
of	of	O100	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Based	Base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
idea	idea	I300	NN	I-NP	O
,	,	0000	,	O	O
DNAs	DNA	D520	NNS	B-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
gastric	gastric	G236	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
RNase	RNase	R520	NN	I-NP	O
protection	protection	P632	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
sequencing	sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
products	product	P632	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
nearly	nearly	N640	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
44	44	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
frame	frame	F650	NN	I-NP	O
shift	shift	S130	NN	I-NP	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
truncation	truncation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
plays	play	P420	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
role	role	R400	NN	I-NP	O
during	during	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
some	some	S500	DT	B-NP	O
gastric	gastric	G236	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
71	71	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kilodalton	kilodalton	K434	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
nonmuscle	nonmuscle	N524	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
known	known	K500	JJ	I-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
brain	brain	B650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
427	427	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
translated	translate	T652	VBN	B-VP	O
from	from	F650	IN	B-PP	O
14	14	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kilobase	kilobase	K412	NN	I-NP	O
(	(	0000	(	O	O
kb	kb	K100	NN	B-NP	O
)	)	0000	)	O	O
mRNAs	mRNA	M652	NNS	B-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
described	describe	D261	VBD	B-VP	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
that	that	T300	WDT	B-NP	O
also	also	A420	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
and	and	A530	CC	O	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
transcription	transcription	T652	NN	I-NP	O
and	and	A530	CC	I-NP	O
translation	translation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
70	70	0000	CD	I-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
terminal	terminal	T654	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
cysteine	cysteine	C235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
,	,	0000	,	O	O
seven	seven	S150	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
terminus	terminus	T652	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
some	some	S500	DT	B-NP	O
modifications	modification	M312	NNS	I-NP	O
formed	form	F653	VBN	B-VP	O
by	by	B000	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
lacks	lack	L200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
large	large	L620	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
spectrin	spectrin	S123	NN	B-NP	O
-	-	0000	HYPH	B-ADVP	O
like	like	L200	JJ	B-PP	O
repeats	repeat	R132	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
actin	actin	A235	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
nonmuscle	nonmuscle	N524	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
extracts	extract	E236	NNS	I-NP	O
.	.	0000	.	O	O

Correlation	Correlation	C643	NN	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
information	information	I516	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
22	22	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
developed	develop	D141	VBN	B-VP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
;	;	0000	:	O	O
17	17	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
sparse	sparse	S162	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
were	be	W600	VBD	B-VP	O
profuse	profuse	P612	NN	B-NP	O
types	type	T120	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
truncation	truncation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
by	by	B000	IN	B-PP	O
frame	frame	F650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
shift	shift	S130	NN	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
deletion	deletion	D435	NN	B-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
nonsense	nonsense	N525	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
seven	seven	S150	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
correlate	correlate	C643	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
;	;	0000	:	O	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
profuse	profuse	P612	NN	B-NP	O
polyps	polyp	P412	NNS	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1250	1250	0000	CD	I-NP	O
and	and	A530	CC	O	O
codon	codon	C350	NN	B-NP	O
1464	1464	0000	CD	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
fewer	few	F600	JJR	B-NP	O
polyps	polyp	P412	NNS	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
stability	stability	S314	NN	I-NP	O
or	or	O600	CC	I-NP	O
biological	biological	B424	JJ	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	O	O
rapid	rapid	R130	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Moroccan	Moroccan	M625	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Infantile	Infantile	I515	JJ	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
well	well	W400	RB	I-VP	O
known	know	K500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
an	an	A500	DT	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
exists	exist	E232	VBZ	B-VP	O
among	among	A520	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
.	.	0000	.	O	O

More	More	M600	RBR	B-ADVP	O
recently	recently	R253	RB	I-ADVP	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
become	become	B250	VBN	I-VP	O
apparent	apparent	A165	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
elevated	elevated	E413	JJ	B-NP	O
carrier	carrier	C600	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
for	for	F600	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
also	also	A420	RB	B-ADVP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
other	other	O360	JJ	I-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
Moroccan	Moroccan	M625	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
subgroup	subgroup	S126	NN	I-NP	O
of	of	O100	IN	B-PP	O
Sephardic	Sephardic	S163	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
.	.	0000	.	O	O

Elsewhere	Elsewhere	E426	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
reported	report	R163	VBD	B-VP	O
an	an	A500	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
304	304	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
305	305	0000	CD	I-NP	O
(	(	0000	(	O	O
delta	delta	D430	SYM	O	O
F304	F304	F000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
305	305	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
Moroccan	Moroccan	M625	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
from	from	F650	IN	B-PP	O
six	six	S200	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Moroccan	Moroccan	M625	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
two	two	T000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
G	G	G000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
replacement	replacement	R142	NN	I-NP	O
of	of	O100	IN	B-PP	O
Tyr180	Tyr180	T600	NN	B-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Arg170	Arg170	A620	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
Gln	Gln	G450	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
CpG	CpG	C120	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
infant	infant	I515	NN	I-NP	O
with	with	W300	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
four	four	F600	CD	B-NP	O
harbor	harbor	H616	VBP	B-VP	O
the	the	T000	DT	B-NP	O
delta	delta	D430	SYM	I-NP	O
F304	F304	F000	NN	I-NP	O
/	/	0000	SYM	O	O
305	305	0000	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
the	the	T000	DT	B-NP	O
Arg170	Arg170	A620	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
Gln	Gln	G450	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
the	the	T000	DT	B-NP	O
Tyr180	Tyr180	T600	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
Stop	Stop	S310	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
rapid	rapid	R130	JJ	B-NP	O
,	,	0000	,	I-NP	O
nonradioactive	nonradioactive	N563	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
helpful	helpful	H414	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
by	by	B000	IN	B-PP	O
natural	natural	N364	JJ	B-NP	O
and	and	A530	CC	I-NP	O
amplification	amplification	A514	NN	I-NP	O
created	create	C630	VBD	B-VP	O
restriction	restriction	R236	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
:	:	0000	:	O	O
five	five	F100	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
a	a	A000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
and	and	A530	CC	I-NP	O
simple	simple	S514	JJ	I-NP	O
method	method	M300	NN	I-NP	O
to	to	T000	TO	B-VP	O
diagnose	diagnose	D252	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
Chinese	Chinese	C520	NNP	B-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
method	method	M300	NN	I-NP	O
involves	involve	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
primers	primer	P656	NNS	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
digestion	digestion	D235	NN	B-NP	O
with	with	W300	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
recognize	recognize	R252	VBP	B-VP	O
artificially	artificially	A631	RB	I-VP	O
created	create	C630	VBN	I-VP	O
or	or	O600	CC	O	O
naturally	naturally	N364	RB	B-VP	O
occurring	occur	O265	VBG	I-VP	O
restriction	restriction	R236	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

Ninety	Ninety	N530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
four	four	F600	CD	I-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
47	47	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
(	(	0000	(	O	O
nt	nt	N300	NN	B-NP	O
)	)	0000	)	O	O
1376	1376	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
21	21	0000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1388	1388	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
A	A	A000	NN	B-NP	O
to	to	T000	TO	B-PP	O
G	G	G000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
493	493	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
A	A	A000	NN	B-NP	O
to	to	T000	TO	B-PP	O
G	G	G000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
95	95	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
C	C	C000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1024	1024	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
392	392	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
94	94	0000	CD	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
487	487	0000	CD	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
former	former	F656	JJ	I-NP	O
five	five	F100	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

Aside	Aside	A230	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
showing	show	S520	VBG	B-VP	O
that	that	T300	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nt	nt	N300	NN	B-NP	O
1376	1376	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
research	research	R262	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
nt	nt	N300	NN	B-NP	O
493	493	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
among	among	A520	IN	B-PP	O
Chinese	Chinese	C520	NNP	B-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
among	among	A520	IN	B-PP	O
different	different	D165	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
discovering	discover	D216	VBG	B-VP	O
significant	significant	S251	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
between	between	B350	IN	B-PP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
inactivating	inactivate	I523	VBG	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
by	by	B000	IN	B-PP	O
denaturing	denature	D536	VBG	B-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dominantly	dominantly	D534	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
condition	condition	C535	NN	I-NP	O
predisposing	predispose	P632	VBG	B-VP	O
to	to	T000	TO	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
responsible	responsible	R215	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
or	or	O600	CC	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
facilitated	facilitate	F243	VBN	I-VP	O
the	the	T000	DT	B-NP	O
search	search	S620	NN	I-NP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
authors	author	A362	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
RNase	RNase	R520	NN	I-NP	O
protection	protection	P632	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
procedure	procedure	P623	VBP	B-VP	O
to	to	T000	TO	I-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
denaturing	denature	D536	VBG	I-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
DGGE	DGGE	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

DGGE	DGGE	D200	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
exons	exon	E252	NNS	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
13	13	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
14	14	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
33	33	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
stop	stop	S310	NN	B-NP	O
codons	codon	C352	NNS	I-NP	O
or	or	O600	CC	I-NP	O
frameshifts	frameshift	F652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
reported	report	R163	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
;	;	0000	:	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
are	be	A600	VBP	B-VP	O
chain	chain	C500	NN	B-NP	O
terminating	terminating	T653	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
DGGE	DGGE	D200	NN	B-NP	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
and	and	A530	CC	I-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unusually	unusually	U524	RB	I-NP	O
large	large	L620	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
extension	extension	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DGGE	DGGE	D200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sufficient	sufficient	S125	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinically	clinically	C452	RB	B-NP	O
well	well	W400	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
,	,	0000	,	O	O
unrelated	unrelated	U564	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
establishment	establishment	E231	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
hand	hand	H530	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
spread	spread	S163	VBN	B-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
length	length	L523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
presymptomatic	presymptomatic	P625	JJ	I-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
procedure	procedure	P623	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
routine	routine	R350	JJ	I-NP	O
laboratory	laboratory	L163	NN	I-NP	O
.	.	0000	.	O	O

Nevertheless	Nevertheless	N163	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
above	above	A100	JJ	I-NP	O
DGGE	DGGE	D200	NN	I-NP	O
approach	approach	A162	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
incidentally	incidentally	I523	RB	I-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O

Such	Such	S200	JJ	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
offer	offer	O160	VBP	B-VP	O
a	a	A000	DT	B-NP	O
practical	practical	P623	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
rapid	rapid	R130	JJ	I-NP	O
procedure	procedure	P623	NN	I-NP	O
for	for	F600	IN	B-PP	O
presymptomatic	presymptomatic	P625	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
informative	informative	I516	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Yeast	Yeast	Y230	JJ	B-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
APC	APC	A120	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
(	(	0000	(	O	O
YACs	YAC	Y200	NNS	B-NP	O
)	)	0000	)	O	O
spanning	span	S152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	JJ	I-NP	O
distance	distance	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
megabase	megabase	M212	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
MCC	MCC	M200	NN	I-NP	O
(	(	0000	(	O	O
for	for	F600	IN	B-PP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
APC	APC	A120	NN	B-NP	B-Disease
(	(	0000	(	O	O
for	for	F600	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
at	at	A300	IN	B-PP	O
5q21	5q21	Q000	NN	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
and	and	A530	CC	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
.	.	0000	.	O	O

Starting	Start	S363	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
MCC	MCC	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
strategy	strategy	S363	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undertaken	undertake	U536	VBN	I-VP	O
to	to	T000	TO	I-VP	O
identify	identify	I353	VB	I-VP	O
constitutional	constitutional	C523	JJ	B-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
might	might	M230	MD	B-VP	O
considerably	considerably	C523	RB	I-VP	O
narrow	narrow	N600	VB	I-VP	O
down	down	D500	RP	B-PRT	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
end	end	E530	NN	I-NP	O
,	,	0000	,	O	O
YACs	YAC	Y200	NNS	B-NP	O
identified	identify	I353	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
MCC	MCC	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
across	across	A262	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
cosmid	cosmid	C253	NN	I-NP	O
library	library	L160	NN	I-NP	O
to	to	T000	TO	B-VP	O
provide	provide	P613	VB	I-VP	O
a	a	A000	DT	B-NP	O
source	source	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
probes	probe	P612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
scanning	scanning	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cosmids	cosmid	C253	NNS	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
segregated	segregate	S262	VBD	B-VP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
suspected	suspect	S212	VBN	B-VP	O
to	to	T000	TO	B-VP	O
carry	carry	C600	VB	I-VP	O
putative	putative	P310	JJ	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
approach	approach	A162	NN	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
confirmation	confirmation	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
polyposis	polyposis	P412	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
that	that	T300	WDT	B-NP	O
overlaps	overlap	O164	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
isolated	isolate	I243	VBN	I-NP	O
YACs	YAC	Y200	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
YAC	YAC	Y200	NNP	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
prove	prove	P610	VB	I-VP	O
a	a	A000	DT	B-NP	O
valuable	valuable	V414	JJ	I-NP	O
resource	resource	R262	NN	I-NP	O
for	for	F600	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
by	by	B000	IN	B-PP	O
transfer	transfer	T652	NN	B-NP	O
to	to	T000	TO	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
-	-	0000	HYPH	B-VP	O
derived	derive	D613	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Denys	Deny	D520	NNPS	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
,	,	0000	,	O	O
genital	genital	G534	JJ	B-NP	B-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
nephropathy	nephropathy	N161	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11p13	11p13	P000	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
WT1	WT1	W300	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
WT1	WT1	W300	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
8	8	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
unlike	unlike	U542	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
reports	report	R163	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
three	three	T600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
inherited	inherit	I563	VBD	B-VP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
from	from	F650	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
phenotypically	phenotypically	P531	RB	I-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
father	father	F360	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
affecting	affect	A123	VBG	I-NP	O
394Arg	394Arg	A620	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
in	in	I500	IN	B-PP	O
over	over	O160	IN	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Denys	Deny	D520	NNPS	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
exhibit	exhibit	E213	VB	I-VP	O
incomplete	incomplete	I525	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
familial	familial	F540	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
are	be	A600	VBP	B-VP	O
recommended	recommend	R253	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Submicroscopic	Submicroscopic	S152	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAGR	WAGR	W260	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
revealed	reveal	R143	VBN	B-VP	O
by	by	B000	IN	B-PP	O
nonradioactive	nonradioactive	N563	JJ	B-NP	O
in	in	I500	FW	I-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

Fluorescence	Fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
biotin	biotin	B350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
labeled	label	L143	VBN	I-NP	O
probes	probe	P612	NNS	I-NP	O
mapping	map	M152	VBG	B-VP	O
to	to	T000	TO	B-PP	O
11p13	11p13	P000	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAGR	WAGR	W260	NN	I-NP	B-Disease
(	(	0000	(	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
,	,	0000	,	O	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
genitourinary	genitourinary	G536	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
detected	detect	D323	VBN	I-VP	O
a	a	A000	DT	B-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
11p13	11p13	P000	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
who	who	W000	WP	B-NP	O
subsequently	subsequently	S125	RB	B-VP	O
presented	present	P625	VBD	I-VP	O
with	with	W300	IN	B-PP	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
horseshoe	horseshoe	H620	NN	I-NP	O
kidney	kidney	K350	NN	I-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-ADVP	O
revealed	reveal	R143	VBD	B-VP	O
at	at	A300	IN	B-PP	O
surgery	surgery	S626	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
has	have	H200	VBZ	B-VP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
including	include	I524	VBG	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
AN2	AN2	A500	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
predisposition	predisposition	P632	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WT1	WT1	W300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
WAGR	WAGR	W260	NN	I-NP	B-Disease
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
only	only	O540	RB	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Pax	Pax	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
lines	line	L520	NNS	I-NP	O
from	from	F650	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
previously	previously	P612	RB	B-NP	O
characterized	characterize	C623	VBN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
at	at	A300	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
another	another	A536	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
mapping	map	M152	VBG	B-VP	O
between	between	B350	IN	B-PP	O
two	two	T000	CD	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-NP	O
translocation	translocation	T652	NN	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
(	(	0000	(	O	O
and	and	A530	CC	O	O
hence	hence	H520	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
both	both	B300	DT	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
Pax	Pax	P200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
homologue	homologue	H542	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

FISH	FISH	F200	NN	B-NP	O
with	with	W300	IN	B-PP	O
cosmid	cosmid	C253	NN	B-NP	O
probes	probe	P612	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
proved	prove	P613	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
fast	fast	F230	JJ	I-NP	O
and	and	A530	CC	I-NP	O
reliable	reliable	R414	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
limited	limit	L530	VBN	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
material	material	M364	NN	B-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
strong	strong	S365	JJ	B-NP	O
potential	potential	P353	NN	I-NP	O
for	for	F600	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
applications	application	A142	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
for	for	F600	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
MHC	MHC	M200	NN	I-NP	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

Family	Family	F540	RB	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

Close	Close	C420	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
HL	HL	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
first	first	F623	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
by	by	B000	IN	B-PP	O
FU	FU	F000	NN	B-NP	O
and	and	A530	CC	O	O
co	co	C000	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
workers	worker	W626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
1974	1974	0000	CD	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
31	31	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Hodgkins	Hodgkins	H325	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
following	follow	F452	VBG	I-NP	O
markers	marker	M626	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
C2	C2	C000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
factor	factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
blood	blood	B430	NN	B-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
enzyme	enzyme	E525	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-VP	O
close	close	C420	VB	I-VP	O
linkage	linkage	L520	NN	B-NP	O
between	between	B350	IN	B-PP	O
HL	HL	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Bf	Bf	B100	NN	B-NP	O
(	(	0000	(	O	O
HL	HL	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
,	,	0000	,	O	O
electrophoretic	electrophoretic	E423	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
of	of	O100	IN	B-PP	O
B	B	B000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
HL	HL	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
A	A	A000	DT	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
closely	closely	C424	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
different	different	D165	JJ	B-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
W18	W18	W000	NN	I-NP	O
and	and	A530	CC	I-NP	O
W24	W24	W000	NN	I-NP	O
,	,	0000	,	O	O
W18	W18	W000	NN	B-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
share	share	S600	VBP	B-VP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
SD2	SD2	S300	NN	I-NP	O
antigen	antigen	A532	NN	I-NP	O
W18	W18	W000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
LD	LD	L300	NN	I-NP	O
type	type	T100	NN	I-NP	O
7a	7a	A000	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Screening	Screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
:	:	0000	:	O	O
61	61	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
summary	summary	S560	NN	I-NP	O
of	of	O100	IN	B-PP	O
150	150	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
61	61	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
summary	summary	S560	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
150	150	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Examination	Examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
ribonuclease	ribonuclease	R152	NN	I-NP	O
protection	protection	P632	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
disclosed	disclose	D242	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
significant	significant	S251	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
product	product	P632	NN	I-NP	O
in	in	I500	IN	B-PP	O
97	97	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
150	150	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
following	follow	F452	VBG	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
great	great	G630	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
truncate	truncate	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
product	product	P632	NN	I-NP	O
;	;	0000	:	O	O
2	2	0000	LS	B-LST	O
)	)	0000	)	O	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
;	;	0000	:	O	O
3	3	0000	LS	B-LST	O
)	)	0000	)	O	O
no	no	N000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
extracolonic	extracolonic	E236	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
;	;	0000	:	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
more	more	M600	RBR	B-NP	O
than	than	T500	IN	I-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
base	base	B200	NN	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
from	from	F650	IN	B-PP	O
cytosine	cytosine	C325	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
,	,	0000	,	O	O
nearly	nearly	N640	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
third	third	T630	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
GpG	GpG	G120	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
information	information	I516	NN	B-NP	O
helpful	helpful	H414	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
will	will	W400	MD	B-VP	O
also	also	A420	RB	I-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
presymptomatic	presymptomatic	P625	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
members	member	M516	NNS	B-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
:	:	0000	:	O	O
mutation	mutation	M350	NN	B-NP	O
cluster	cluster	C423	NN	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
63	63	0000	CD	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
(	(	0000	(	O	O
16	16	0000	CD	B-NP	O
adenomas	adenoma	A352	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
47	47	0000	CD	B-NP	O
carcinomas	carcinoma	C625	NNS	I-NP	B-Disease
)	)	0000	)	O	O
developed	develop	D141	VBN	B-VP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
FAP	FAP	F100	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
(	(	0000	(	O	O
LOH	LOH	L000	NN	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
43	43	0000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
;	;	0000	:	O	O
16	16	0000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
introns	intron	I536	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
two	two	T000	CD	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
had	have	H300	VBD	B-VP	O
frameshift	frameshift	F652	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
deletion	deletion	D435	NN	B-NP	O
or	or	O600	CC	I-NP	O
insertion	insertion	I526	NN	I-NP	O
;	;	0000	:	O	O
nineteen	nineteen	N535	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
to	to	T000	TO	I-NP	O
31	31	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
were	be	W600	VBD	B-VP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Hence	Hence	H520	RB	B-ADVP	O
,	,	0000	,	O	O
41	41	0000	CD	B-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
43	43	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
truncation	truncation	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Over	Over	O160	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
clustered	cluster	C423	VBN	I-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
as	as	A200	IN	B-PP	O
MCR	MCR	M260	NN	B-NP	O
(	(	0000	(	O	O
mutation	mutation	M350	NN	B-NP	O
cluster	cluster	C423	NN	I-NP	O
region	region	R250	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Combining	Combine	C515	VBG	B-VP	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
,	,	0000	,	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
adenomas	adenoma	A352	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
39	39	0000	CD	B-NP	O
carcinomas	carcinoma	C625	NNS	I-NP	B-Disease
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
60	60	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
adenomas	adenoma	A352	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
23	23	0000	CD	B-NP	O
carcinomas	carcinoma	C625	NNS	I-NP	B-Disease
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
strongly	strongly	S365	RB	B-VP	O
suggest	suggest	S230	VBP	I-VP	O
that	that	T300	IN	B-SBAR	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
great	great	G630	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Constitutional	Constitutional	C523	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Denys	Deny	D520	NNPS	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterised	characterise	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
nephropathy	nephropathy	N161	NN	I-NP	B-Disease
,	,	0000	,	O	O
genital	genital	G534	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
also	also	A420	RB	B-VP	O
predisposes	predispose	P632	VBZ	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
eventually	eventually	E153	RB	B-ADVP	O
go	go	G000	VBP	B-VP	O
into	into	I530	IN	B-PP	O
end	end	E530	NN	B-NP	O
stage	stage	S320	NN	I-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
WT1	WT1	W300	NN	B-NP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
11p13	11p13	P000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
constitutional	constitutional	C523	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
were	be	W600	VBD	B-VP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
1180	1180	0000	CD	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
arg	arg	A620	NN	I-NP	O
>	>	0000	SYM	B-NP	O
trp	trp	T610	NN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
change	change	C520	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
was	be	W200	VBD	B-VP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
1186	1186	0000	CD	I-NP	O
converting	convert	C516	VBG	B-VP	O
an	an	A500	DT	B-NP	O
asp	asp	A210	NN	I-NP	O
>	>	0000	SYM	B-NP	O
asn	asn	A250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
resultant	resultant	R243	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	O	O
converting	convert	C516	VBG	B-VP	O
an	an	A500	DT	B-NP	O
arg	arg	A620	NN	I-NP	O
>	>	0000	SYM	B-VP	O
his	his	H200	PRP$	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
821	821	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
unable	unable	U514	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
find	find	F530	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
despite	despite	D213	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
11p13	11p13	P000	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
and	and	A530	CC	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
further	further	F636	RB	B-ADVP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
kidney	kidney	K350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
genito	genito	G530	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
urinary	urinary	U656	JJ	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
founder	founder	F536	NN	I-NP	O
populations	population	P143	NNS	I-NP	O
:	:	0000	:	O	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Finland	Finland	F545	NNP	B-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
populations	population	P143	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
powerful	powerful	P614	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
fine	fine	F500	JJ	B-NP	O
structure	structure	S362	NN	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
Luria	Luria	L600	NNP	B-NP	O
and	and	A530	CC	I-NP	O
Delbrucks	Delbrucks	D416	NNP	I-NP	O
classical	classical	C424	JJ	I-NP	O
methods	method	M320	NNS	I-NP	O
for	for	F600	IN	B-PP	O
analysing	analyse	A542	VBG	B-VP	O
bacterial	bacterial	B236	JJ	B-NP	O
cultures	culture	C436	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
adapted	adapt	A313	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
founder	founder	F536	NN	I-NP	O
populations	population	P143	NNS	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
estimate	estimate	E235	VB	I-VP	O
(	(	0000	(	B-LST	O
i	i	I000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
between	between	B350	IN	B-PP	O
a	a	A000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
;	;	0000	:	O	O
(	(	0000	(	B-LST	O
ii	ii	I000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
expected	expect	E212	VBN	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
allelic	allelic	A420	JJ	B-NP	O
homogeneity	homogeneity	H525	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
iii	iii	I000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
these	these	T200	DT	B-NP	O
methods	method	M320	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
striking	striking	S362	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
for	for	F600	IN	B-PP	O
diastrophic	diastrophic	D236	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
(	(	0000	(	O	O
DTD	DTD	D300	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Finland	Finland	F545	NNP	B-NP	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DTD	DTD	D300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
should	should	S430	MD	B-VP	O
lie	lie	L000	VB	I-VP	O
within	within	W350	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

06	06	0000	CD	B-NP	O
centimorgans	centimorgan	C535	NNS	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
about	about	A130	IN	B-NP	O
60	60	0000	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CSF1R	CSF1R	C216	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Predictions	Prediction	P632	NNS	B-NP	O
about	about	A130	IN	B-PP	O
allelic	allelic	A420	JJ	B-NP	O
homogeneity	homogeneity	H525	NN	I-NP	O
in	in	I500	IN	B-PP	O
Finland	Finland	F545	NNP	B-NP	O
and	and	A530	CC	O	O
mutation	mutation	M350	NN	B-NP	O
rates	rate	R320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
simple	simple	S514	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
independent	independent	I531	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
refinement	refinement	R153	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
on	on	O500	IN	B-PP	O
Xp	Xp	X100	NN	B-NP	O
and	and	A530	CC	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
marker	marker	M626	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
OATL1	OATL1	O340	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DXS14	DXS14	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
DXS7	DXS7	D200	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
further	further	F636	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
,	,	0000	,	O	O
HOATL1	HOATL1	H340	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
close	close	C420	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
OATL1	OATL1	O340	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
(	(	0000	(	O	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
localize	localize	L242	VBP	B-VP	O
the	the	T000	DT	B-NP	O
TIMP	TIMP	T510	NN	I-NP	O
,	,	0000	,	O	O
OATL1	OATL1	O340	NN	B-NP	O
,	,	0000	,	O	O
DXS255	DXS255	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
loci	locus	L200	NNS	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS146	DXS146	D200	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
OATL1	OATL1	O340	NN	I-NP	O
and	and	A530	CC	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
loci	locus	L200	NNS	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
TIMP	TIMP	T510	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
narrow	narrow	N600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
within	within	W350	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
region	region	R250	NN	I-NP	O
bracketed	bracket	B623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
TIMP	TIMP	T510	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS146	DXS146	D200	NN	I-NP	O
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
order	order	O636	NN	I-NP	O
Xpter	Xpter	X136	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
TIMP	TIMP	T510	NN	I-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
OATL1	OATL1	O340	NN	B-NP	O
,	,	0000	,	O	O
WAS	WAS	W200	NN	B-NP	O
,	,	0000	,	O	O
DXS255	DXS255	D200	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
DXS146	DXS146	D200	NN	I-NP	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
specific	specific	S121	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
per	per	P600	IN	B-PP	O
100	100	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
and	and	A530	CC	O	O
sustained	sustain	S235	VBN	B-NP	B-Disease
muscle	muscle	M240	NN	I-NP	I-Disease
contraction	contraction	C536	NN	I-NP	I-Disease
,	,	0000	,	O	O
often	often	O135	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
accompanying	accompany	A251	VBG	B-VP	O
symptoms	symptom	S513	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
and	and	A530	CC	I-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
show	show	S000	VBP	B-VP	O
extreme	extreme	E236	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
,	,	0000	,	O	O
both	both	B300	CC	B-PP	O
within	within	W350	IN	I-PP	O
and	and	A530	CC	I-PP	O
between	between	B350	IN	I-PP	O
families	family	F542	NNS	B-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
variability	variability	V614	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
condition	condition	C535	NN	I-NP	O
segregates	segregate	S262	NNS	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19q13	19q13	Q000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
every	every	E160	DT	B-NP	O
population	population	P143	NN	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
flanked	flank	F452	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
tightly	tightly	T234	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
ERCC1	ERCC1	E620	NN	I-NP	O
proximally	proximally	P625	RB	B-ADVP	O
and	and	A530	CC	O	O
D19S51	D19S51	D200	NN	B-NP	O
distally	distally	D234	RB	B-ADVP	O
;	;	0000	:	O	O
these	these	T200	DT	B-NP	O
define	define	D150	NN	I-NP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
expressed	express	E216	VBN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
which	which	W200	WDT	B-NP	O
detects	detect	D323	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
larger	large	L626	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
or	or	O600	CC	O	O
unaffected	unaffected	U512	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
fragment	fragment	F625	NN	I-NP	O
varies	vary	V620	VBZ	B-VP	O
between	between	B350	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
increases	increase	I526	NNS	B-NP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
through	through	T620	IN	B-PP	O
generations	generation	G563	NNS	B-NP	O
in	in	I500	IN	B-PP	O
parallel	parallel	P640	NN	B-NP	O
with	with	W300	IN	B-PP	O
increasing	increase	I526	VBG	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
postulate	postulate	P234	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
that	that	T300	WDT	B-NP	O
underlies	underlie	U536	VBZ	B-VP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Common	Common	C500	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
motifs	motif	M312	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
X	X	X000	NN	I-NP	O
/	/	0000	SYM	B-VP	O
autosome	autosome	A325	NN	B-NP	O
translocation	translocation	T652	NN	I-NP	O
and	and	A530	CC	O	O
associated	associate	A230	VBN	B-VP	O
deletion	deletion	D435	NN	B-NP	O
.	.	0000	.	O	O

Reciprocal	Reciprocal	R216	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
translocations	translocation	T652	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
common	common	C500	JJ	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
occur	occur	O260	VBP	B-VP	O
randomly	randomly	R535	RB	B-ADVP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
learn	learn	L650	VB	I-VP	O
about	about	A130	IN	B-PP	O
causative	causative	C231	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cytologically	cytologically	C342	RB	I-NP	O
balanced	balanced	B452	JJ	I-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
reciprocal	reciprocal	R216	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
,	,	0000	,	O	O
t	t	T000	NN	B-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
;	;	0000	:	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
p21	p21	P000	NN	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
;	;	0000	:	O	O
q31	q31	Q000	CD	B-NP	O
.	.	0000	.	O	O
22	22	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Physical	Physical	P240	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
after	after	A136	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
separation	separation	S163	NN	I-NP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
,	,	0000	,	O	O
reveals	reveal	R142	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
disrupts	disrupt	D261	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Xp21	Xp21	X100	NN	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
18	18	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
intron	intron	I536	NN	I-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
clones	clone	C452	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
span	span	S150	VBP	B-VP	O
both	both	B300	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
normal	normal	N654	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
5	5	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
deleted	delete	D430	VBN	B-VP	O
from	from	F650	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

RFLP	RFLP	R141	NN	B-NP	O
and	and	A530	CC	O	O
Southern	Southern	S365	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
translocation	translocation	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
fathers	father	F362	NNS	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
X	X	X000	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
,	,	0000	,	O	O
deletion	deletion	D435	NN	B-NP	O
and	and	A530	CC	I-NP	O
translation	translation	T652	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
simultaneously	simultaneously	S543	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
event	event	E153	NN	I-NP	O
that	that	T300	WDT	B-NP	O
involves	involve	I514	VBZ	B-VP	O
three	three	T600	CD	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
.	.	0000	.	O	O

Short	Short	S630	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
homology	homology	H542	NN	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
,	,	0000	,	O	O
GGAAT	GGAAT	G230	NN	B-NP	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
exactly	exactly	E234	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
on	on	O500	IN	B-PP	O
both	both	B300	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
X	X	X000	NN	I-NP	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
preserved	preserve	P626	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
der	der	D600	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
chromosome	chromosome	C652	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
derived	derive	D613	VBN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
GGAATCA	GGAATCA	G232	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
lost	lose	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
der	der	D600	NN	I-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
chromosome	chromosome	C652	NN	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
matches	match	M320	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inverted	invert	I516	VBN	I-NP	O
GAATCA	GAATCA	G320	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
opposite	opposite	O123	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
exactly	exactly	E234	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
etiology	etiology	E342	NN	I-NP	O
for	for	F600	IN	B-PP	O
DiGeorge	DiGeorge	D262	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
consistent	consistent	C523	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	I-NP	O
microdeletions	microdeletion	M263	NNS	I-NP	O
of	of	O100	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
.	.	0000	.	O	O

DiGeorge	DiGeorge	D262	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
DGS	DGS	D200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
developmental	developmental	D141	JJ	I-NP	O
field	field	F430	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
and	and	A530	CC	I-NP	O
fourth	fourth	F630	JJ	I-NP	O
pharyngeal	pharyngeal	P652	JJ	I-NP	O
pouches	pouch	P200	NNS	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
aplasia	aplasia	A142	NN	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
thymus	thymus	T520	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
parathyroid	parathyroid	P636	JJ	B-NP	I-Disease
glands	gland	G453	NNS	I-NP	I-Disease
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
conotruncal	conotruncal	C536	JJ	B-NP	B-Disease
cardiac	cardiac	C632	JJ	I-NP	I-Disease
malformations	malformation	M416	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Cytogenetic	Cytogenetic	C325	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
band	band	B530	NN	B-NP	O
22q11	22q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
,	,	0000	,	I-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
DGS	DGS	D200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
utilizing	utilize	U342	VBG	B-VP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
banding	banding	B535	NN	I-NP	O
techniques	technique	T252	NNS	I-NP	O
,	,	0000	,	O	O
detected	detect	D323	VBD	B-VP	O
interstitial	interstitial	I536	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
inconclusive	inconclusive	I525	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
six	six	S200	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
karyotypes	karyotype	K631	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
detected	detect	D323	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
14	14	0000	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	I-NP	O
10	10	0000	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
,	,	0000	,	O	O
D22S75	D22S75	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D22S259	D22S259	D200	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
14	14	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
D22S66	D22S66	D200	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
.	.	0000	.	O	O

Physical	Physical	P240	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
using	use	U252	VBG	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
places	place	P420	VBZ	B-VP	O
D22S66	D22S66	D200	NN	B-NP	O
between	between	B350	IN	B-PP	O
D22S75	D22S75	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D22S259	D22S259	D200	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
six	six	S200	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Parent	Parent	P653	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
origin	origin	O625	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
inherit	inherit	I563	VB	I-VP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
inherit	inherit	I563	VB	I-VP	O
a	a	A000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
maternally	maternally	M365	RB	I-NP	O
and	and	A530	CC	I-NP	O
five	five	F100	CD	I-NP	O
paternally	paternally	P365	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
unbalanced	unbalanced	U514	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
translocation	translocation	T652	NN	I-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
,	,	0000	,	O	O
parent	parent	P653	NN	B-NP	O
of	of	O100	IN	B-PP	O
origin	origin	O625	NN	B-NP	O
or	or	O600	CC	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
play	play	P400	VB	I-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
DGS	DGS	D200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
three	three	T600	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
14	14	0000	CD	I-NP	O
DGS	DGS	D200	NN	I-NP	B-Disease
probands	proband	P615	NNS	I-NP	O
begins	begin	B252	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
delineate	delineate	D453	VB	I-VP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22	22	0000	CD	I-NP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
DGS	DGS	D200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
confirms	confirm	C516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
submicroscopic	submicroscopic	S152	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
etiologic	etiologic	E342	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
vast	vast	V230	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
adrenocortical	adrenocortical	A365	JJ	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
.	.	0000	.	O	O

Endocrine	Endocrine	E532	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
occasionally	occasionally	O254	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
adrenocorotical	adrenocorotical	A365	JJ	I-NP	B-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
(	(	0000	(	O	O
LOH	LOH	L000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
close	close	C420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
carcinoma	carcinoma	C625	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
evidence	evidence	E135	NN	B-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
demonstration	demonstration	D523	NN	I-NP	O
of	of	O100	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
adrenocortical	adrenocortical	A365	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
results	result	R243	NNS	I-NP	O
and	and	A530	CC	O	O
our	our	O600	PRP$	B-NP	O
previous	previous	P612	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
on	on	O500	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
recurring	recur	R265	VBG	I-NP	O
desmoid	desmoid	D253	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutant	mutant	M353	NN	I-NP	O
/	/	0000	SYM	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
condition	condition	C535	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
give	give	G100	VB	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
benign	benign	B525	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
functional	functional	F523	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
colon	colon	C450	NN	I-NP	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
various	various	V620	JJ	I-NP	O
parts	part	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
body	body	B300	NN	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Oncogenic	Oncogenic	O525	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
20	20	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
showing	show	S520	VBG	B-VP	O
incomplete	incomplete	I525	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
RB1	RB1	R100	NN	B-NP	O
,	,	0000	,	O	O
segregates	segregate	S262	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
(	(	0000	(	O	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
penetrance	penetrance	P536	NN	B-NP	O
.	.	0000	.	O	O

Certain	Certain	C635	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
show	show	S000	VBP	B-VP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
many	many	M500	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
being	be	B520	VBG	B-VP	O
unaffected	unaffected	U512	JJ	B-ADJP	O
,	,	0000	,	O	O
unilaterally	unilaterally	U543	RB	B-VP	O
affected	affect	A123	VBN	I-VP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
with	with	W300	IN	B-PP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
spontaneously	spontaneously	S153	RB	B-NP	O
regressed	regress	R262	VBN	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
PCR	PCR	P260	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
two	two	T000	CD	B-NP	O
such	such	S200	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
20	20	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
661	661	0000	CD	I-NP	O
converts	convert	C516	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
(	(	0000	(	O	O
CGG	CGG	C200	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
tryptophan	tryptophan	T613	NN	I-NP	O
(	(	0000	(	O	O
TGG	TGG	T200	NN	B-NP	O
)	)	0000	)	O	O
codon	codon	C350	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
incomplete	incomplete	I525	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
virtually	virtually	V634	RB	B-NP	O
all	all	A400	DT	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-VP	O
indicating	indicate	I532	VBG	I-VP	O
that	that	T300	IN	B-SBAR	O
single	single	S524	JJ	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
modify	modify	M310	VB	I-VP	O
protein	protein	P635	NN	B-NP	O
structure	structure	S362	NN	I-NP	O
/	/	0000	SYM	B-NP	O
function	function	F523	NN	I-NP	O
such	such	S200	JJ	B-NP	O
that	that	T300	IN	I-NP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
inevitable	inevitable	I513	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
675	675	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
converts	convert	C516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
glutamine	glutamine	G435	NN	I-NP	O
(	(	0000	(	O	O
GAA	GAA	G000	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
(	(	0000	(	O	O
TAA	TAA	T000	NN	B-NP	O
)	)	0000	)	O	O
codon	codon	C350	NN	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
occurs	occur	O262	VBZ	B-VP	O
near	near	N600	IN	B-PP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
raising	raise	R252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	O	O
less	less	L200	RBR	B-ADVP	O
severely	severely	S164	RB	I-ADVP	O
disrupted	disrupt	D261	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Late	Late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
:	:	0000	:	O	O
molecular	molecular	M424	JJ	B-NP	O
pathology	pathology	P342	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
causing	cause	C252	VBG	B-VP	O
late	late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
that	that	T300	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
arginine84	arginine84	A625	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
residue	residue	R230	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
replaced	replace	R142	VBN	I-VP	O
by	by	B000	IN	B-PP	O
glutamine	glutamine	G435	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
alleles	allele	A420	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
arginine84	arginine84	A625	NN	I-NP	O
to	to	T000	TO	B-PP	O
glutamine	glutamine	G435	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
some	some	S500	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotypes	genotype	G531	NNS	B-NP	O
,	,	0000	,	O	O
ARSA	ARSA	A620	NN	B-NP	O
activities	activity	A231	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
on	on	O500	IN	B-PP	O
4	4	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
81	81	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
examined	examine	E253	VBN	B-VP	O
,	,	0000	,	O	O
further	further	F636	RBR	B-ADVP	O
validates	validate	V432	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
concept	concept	C521	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
different	different	D165	JJ	B-NP	O
degrees	degree	D262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
residual	residual	R234	JJ	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypical	phenotypical	P531	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
in	in	I500	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Trisomy	Trisomy	T625	NN	B-NP	B-Disease
15	15	0000	CD	I-NP	I-Disease
with	with	W300	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
15	15	0000	CD	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
.	.	0000	.	O	O

Uniparental	Uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
human	human	H500	JJ	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
particularly	particularly	P632	RB	I-NP	O
instructive	instructive	I523	JJ	I-NP	O
case	case	C200	NN	I-NP	O
which	which	W200	WDT	B-NP	O
raises	raise	R200	VBZ	B-VP	O
important	important	I516	JJ	B-NP	O
issues	issue	I200	NNS	I-NP	O
concerning	concern	C526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
producing	produce	P632	VBG	B-VP	O
uniparental	uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
and	and	A530	CC	O	O
whose	whose	W200	WP$	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
trisomy	trisomy	T625	NN	B-NP	O
may	may	M000	MD	B-VP	O
precede	precede	P623	VB	I-VP	O
uniparental	uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
.	.	0000	.	O	O

Chorionic	Chorionic	C652	JJ	B-NP	O
villus	villus	V420	NN	I-NP	O
sampling	sampling	S514	NN	I-NP	O
performed	perform	P616	VBN	B-VP	O
for	for	F600	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
age	age	A200	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
trisomy	trisomy	T625	NN	B-NP	B-Disease
15	15	0000	CD	I-NP	I-Disease
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cultured	culture	C436	VBN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
though	though	T200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
amniocytes	amniocyte	A523	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
at	at	A300	IN	B-PP	O
15	15	0000	CD	B-NP	O
wk	wk	W200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
over	over	O160	IN	B-NP	O
100	100	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
child	child	C430	NN	I-NP	O
was	be	W200	VBD	B-VP	O
hypotonic	hypotonic	H135	JJ	B-ADJP	B-Disease
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
banding	banding	B535	NN	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
reveal	reveal	R140	VB	I-VP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
70	70	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Over	Over	O160	IN	B-PP	O
time	time	T500	NN	B-NP	O
,	,	0000	,	O	O
typical	typical	T124	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
developed	develop	D141	VBD	B-VP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
probes	probe	P612	NNS	B-NP	O
for	for	F600	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
maternal	maternal	M365	JJ	B-NP	O
disomy	disomy	D250	NN	I-NP	O
.	.	0000	.	O	O

Maternal	Maternal	M365	JJ	B-NP	O
nondisjunction	nondisjunction	N532	NN	I-NP	O
with	with	W300	IN	B-PP	O
fertilization	fertilization	F634	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
disomic	disomic	D252	JJ	I-NP	O
egg	egg	E200	NN	I-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
sperm	sperm	S165	NN	I-NP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
likely	likely	L240	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
confined	confine	C515	VBN	B-NP	O
placental	placental	P425	JJ	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
and	and	A530	CC	O	O
uniparental	uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
advanced	advance	A315	VBN	B-VP	O
maternal	maternal	M365	JJ	B-NP	O
age	age	A200	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
predisposing	predispose	P632	VBG	I-NP	O
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
amelogenesis	amelogenesis	A542	NN	I-NP	I-Disease
imperfecta	imperfecta	I516	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
AMELX	AMELX	A542	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
located	locate	L230	VBN	B-VP	O
at	at	A300	IN	B-PP	O
Xp22	Xp22	X100	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
p22	p22	P000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
enamel	enamel	E540	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
amelogenin	amelogenin	A542	NN	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
dental	dental	D534	JJ	I-NP	I-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
amelogenesis	amelogenesis	A542	NN	I-NP	I-Disease
imperfecta	imperfecta	I516	NN	I-NP	I-Disease
(	(	0000	(	O	O
XAI	XAI	X000	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
XAI	XAI	X000	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
AMELX	AMELX	A542	NN	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
linkage	linkage	L520	NN	B-NP	O
was	be	W200	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
between	between	B350	IN	B-PP	O
XAI	XAI	X000	NN	B-NP	B-Disease
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
combined	combined	C515	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
DXS16	DXS16	D200	NN	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

04	04	0000	CD	B-NP	O
04	04	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
AMELX	AMELX	A542	NN	B-NP	O
,	,	0000	,	O	O
located	located	L230	JJ	B-ADJP	O
close	close	C420	RB	I-ADJP	O
to	to	T000	TO	B-PP	O
DXS16	DXS16	D200	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
XAI	XAI	X000	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
process	process	P620	NN	I-NP	O
(	(	0000	(	O	O
AIH1	AIH1	A000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
those	those	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
multipoint	multipoint	M431	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
combined	combined	C515	JJ	I-NP	O
maximum	maximum	M250	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
for	for	F600	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

30	30	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
AIH1	AIH1	A000	NN	B-NP	O
at	at	A300	IN	B-PP	O
2	2	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS16	DXS16	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
around	around	A653	IN	B-PP	O
this	this	T200	DT	B-NP	O
location	location	L235	NN	I-NP	O
extended	extend	E235	VBD	B-VP	O
about	about	A130	IN	B-NP	O
8	8	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS92	DXS92	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
AIH1	AIH1	A000	NN	I-NP	O
location	location	L235	NN	I-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
precisely	precisely	P624	RB	I-VP	O
defined	define	D153	VBN	I-VP	O
by	by	B000	IN	B-PP	O
multipoint	multipoint	M431	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
events	event	E153	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
AIH1	AIH1	A000	NN	B-NP	O
lies	lie	L200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
between	between	B350	IN	B-PP	O
DXS143	DXS143	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS85	DXS85	D200	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
significant	significant	S251	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
against	against	A252	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
locus	locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
XAI	XAI	X000	NN	B-NP	B-Disease
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
DXS144E	DXS144E	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
F9	F9	F000	NN	I-NP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
with	with	W300	IN	B-PP	O
either	either	E360	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
gave	give	G100	VBD	B-VP	O
a	a	A000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
at	at	A300	IN	B-PP	O
DXS144E	DXS144E	D200	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

83	83	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
in	in	I500	IN	B-PP	O
multipoint	multipoint	M431	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

84	84	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
support	support	S163	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
extended	extend	E235	VBD	B-VP	O
9	9	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS144E	DXS144E	D200	NN	B-NP	O
and	and	A530	CC	O	O
14	14	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
F9	F9	F000	NN	B-NP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
ABSTRACT	ABSTRACT	A123	NN	B-NP	O
TRUNCATED	TRUNCATED	T652	VBN	B-VP	O
AT	AT	A300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	W632	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Multiple	Multiple	M431	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
for	for	F600	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
amino	amino	A500	JJ	B-NP	I-Disease
acid	acid	A230	NN	I-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
prevalent	prevalent	P614	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
primarily	primarily	P656	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
hepatic	hepatic	H132	JJ	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

PKU	PKU	P200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
60	60	0000	CD	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
lesions	lesion	L252	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
associations	association	A235	NNS	I-NP	O
,	,	0000	,	O	O
relative	relative	R431	JJ	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
distributions	distribution	D236	NNS	B-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
R158Q	R158Q	R200	NN	B-NP	O
,	,	0000	,	O	O
R261Q	R261Q	R200	NN	B-NP	O
,	,	0000	,	O	O
IVS10nt546	IVS10nt546	I125	NN	B-NP	O
,	,	0000	,	O	O
R408W	R408W	R000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
IVS12n1	IVS12n1	I125	NN	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
subsequently	subsequently	S125	RB	B-ADVP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
roles	role	R420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
explaining	explain	E214	VBG	B-VP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
five	five	F100	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
strongly	strongly	S365	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
more	more	M600	JJR	I-NP	O
than	than	T500	IN	I-NP	O
70	70	0000	CD	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
in	in	I500	IN	B-PP	O
or	or	O600	CC	I-PP	O
near	near	N600	IN	I-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
arose	arise	A620	VBD	B-VP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
founding	founding	F535	JJ	I-NP	O
event	event	E153	NN	I-NP	O
that	that	T300	WDT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
within	within	W350	IN	B-PP	O
time	time	T500	NN	B-NP	O
periods	period	P632	NNS	I-NP	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
several	several	S164	JJ	B-NP	O
hundred	hundred	H536	CD	I-NP	O
to	to	T000	TO	B-PP	O
several	several	S164	JJ	B-NP	O
thousand	thousand	T253	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
and	and	A530	CC	I-NP	O
distributions	distribution	D236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
five	five	F100	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
throughout	throughout	T623	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
founding	founding	F535	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
specific	specific	S121	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
subgroups	subgroup	S126	NNS	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
multiple	multiple	M431	JJ	B-ADJP	O
,	,	0000	,	O	O
geographically	geographically	G261	RB	B-ADVP	O
and	and	A530	CC	I-ADVP	O
ethnically	ethnically	E352	RB	I-ADVP	O
distinct	distinct	D235	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
for	for	F600	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
European	European	E615	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
factor	factor	F236	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
serological	serological	S642	JJ	I-NP	O
family	family	F540	NN	I-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
connective	connective	C523	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
diseases	disease	D200	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
factor	factor	F236	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
C2	C2	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
developed	develop	D141	VBD	B-VP	O
cutaneous	cutaneous	C352	JJ	B-NP	B-Disease
vasculitis	vasculitis	V243	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
sicca	sicca	S200	NN	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
each	each	E200	DT	B-NP	O
member	member	M516	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
A25	A25	A000	NN	B-NP	O
,	,	0000	,	O	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
DR2	DR2	D600	NN	B-NP	O
(	(	0000	(	O	O
w15	w15	W000	NN	B-NP	O
)	)	0000	)	O	O
haplotype	haplotype	H143	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
had	have	H300	VBD	B-VP	O
seropositive	seropositive	S612	JJ	B-NP	B-Disease
rheumatoid	rheumatoid	R530	JJ	I-NP	I-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
cryoglobulins	cryoglobulin	C624	NNS	B-NP	O
,	,	0000	,	O	O
antibodies	antibody	A531	NNS	B-NP	O
against	against	A252	IN	B-PP	O
endothelial	endothelial	E534	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
anticardiolipin	anticardiolipin	A532	NN	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

New	New	N000	JJ	B-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
-	-	0000	HYPH	I-VP	O
greater	great	G636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
G	G	G000	NN	B-NP	O
transversion	transversion	T652	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
mother	mother	M360	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
sibship	sibship	S121	NN	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
merzbacher	merzbacher	M621	NN	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
transversion	transversion	T652	NN	I-NP	O
should	should	S430	MD	B-VP	O
not	not	N300	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
does	do	D200	VBZ	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
HaeIII	HaeIII	H000	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
concordant	concordant	C526	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
hundred	hundred	H536	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
ten	ten	T500	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
negative	negative	N231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
this	this	T200	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	I-NP	O
PMD	PMD	P530	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
intriguing	intrigue	I536	VBG	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
can	can	C500	MD	B-VP	O
serve	serve	S610	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
for	for	F600	IN	B-PP	O
following	follow	F452	VBG	B-VP	O
segregation	segregation	S262	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Uncoupling	Uncoupling	U521	NN	B-NP	O
of	of	O100	IN	B-PP	O
hypomyelination	hypomyelination	H154	NN	B-NP	B-Disease
and	and	A530	CC	O	O
glial	glial	G400	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
death	death	D300	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Proteolipid	Proteolipid	P634	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
;	;	0000	:	O	O
M	M	M000	NN	B-NP	O
(	(	0000	(	O	O
r	r	R000	NN	B-NP	O
)	)	0000	)	O	O
30	30	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
major	major	M260	JJ	I-NP	O
polytopic	polytopic	P431	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
myelin	myelin	M450	NN	B-NP	O
but	but	B300	CC	O	O
its	its	I320	PRP$	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
function	function	F523	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
obscure	obscure	O126	JJ	B-ADJP	O
.	.	0000	.	O	O

Neurological	Neurological	N642	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
can	can	C500	MD	B-VP	O
often	often	O135	RB	I-VP	O
provide	provide	P613	VB	I-VP	O
model	model	M340	NN	B-NP	O
systems	system	S235	NNS	I-NP	O
for	for	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
lethal	lethal	L340	JJ	B-ADJP	O
,	,	0000	,	O	O
identified	identify	I353	VBN	B-VP	O
first	first	F623	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
jimpy	jimpy	J510	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	O	O
subsequently	subsequently	S125	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
unexplained	unexplained	U521	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
includes	include	I524	VBZ	B-VP	O
degeneration	degeneration	D256	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
premature	premature	P653	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
death	death	D300	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
oligodendrocytes	oligodendrocyte	O423	NNS	B-NP	I-Disease
with	with	W300	IN	B-PP	O
associated	associate	A230	VBN	B-NP	O
hypomyelination	hypomyelination	H154	NN	I-NP	B-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
rumpshaker	rumpshaker	R512	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
defined	define	D153	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
Ile	Ile	I400	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
Thr	Thr	T600	NN	I-NP	O
at	at	A300	IN	B-PP	O
residue	residue	R230	NN	B-NP	O
186	186	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
membrane	membrane	M516	NN	I-NP	O
-	-	0000	HYPH	O	O
embedded	embed	E513	VBN	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
rumpshaker	rumpshaker	R512	NN	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
myelin	myelin	M450	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
deficient	deficient	D125	JJ	B-ADJP	I-Disease
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
normal	normal	N654	JJ	B-NP	O
longevity	longevity	L521	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
morphologically	morphologically	M614	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
oligodendrocytes	oligodendrocyte	O423	NNS	I-NP	O
.	.	0000	.	O	O

Hypomyelination	Hypomyelination	H154	NN	B-NP	B-Disease
can	can	C500	MD	B-VP	O
thus	thus	T200	RB	I-VP	O
be	be	B000	VB	I-VP	O
genetically	genetically	G532	RB	I-VP	O
separated	separate	S163	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
oligodendrocyte	oligodendrocyte	O423	NN	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PLP	PLP	P410	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
vital	vital	V340	JJ	I-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
glial	glial	G400	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
development	development	D141	NN	I-NP	O
,	,	0000	,	O	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
later	later	L360	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
myelin	myelin	M450	NN	B-NP	O
assembly	assembly	A251	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
dichotomy	dichotomy	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
action	action	A235	NN	B-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
pseudodeficiency	pseudodeficiency	P231	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
carriers	carrier	C620	NNS	I-NP	O
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
beta	beta	B300	SYM	B-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
hexosaminidase	hexosaminidase	H253	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
(	(	0000	(	O	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
typically	typically	T124	RB	B-ADVP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
healthy	healthy	H430	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
deficient	deficient	D125	JJ	B-ADJP	B-Disease
in	in	I500	IN	B-PP	I-Disease
Hex	Hex	H200	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
activity	activity	A231	NN	I-NP	O
(	(	0000	(	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	I-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
pseudodeficient	pseudodeficient	P231	JJ	B-ADJP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
tests	test	T232	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
pseudodeficient	pseudodeficient	P231	JJ	I-NP	O
subject	subject	S123	NN	I-NP	O
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
both	both	B300	CC	O	O
a	a	A000	DT	B-NP	O
C739	C739	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
that	that	T300	WDT	B-NP	O
changes	change	C520	VBZ	B-VP	O
Arg247	Arg247	A620	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
Trp	Trp	T610	NN	B-NP	O
on	on	O500	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
pseudodeficient	pseudodeficient	P231	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
C739	C739	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
32	32	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
62	62	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	O	O
defined	define	D153	VBN	B-VP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
carriers	carrier	C620	NNS	I-NP	O
but	but	B300	CC	B-PP	O
for	for	F600	IN	B-PP	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
36	36	0000	CD	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
defined	define	D153	VBN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
who	who	W000	WP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
known	know	K500	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
group	group	G610	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C739	C739	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
"	"	0000	``	I-NP	O
true	true	T600	JJ	I-NP	O
"	"	0000	''	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
causes	cause	C200	VBZ	B-VP	O
Hex	Hex	H200	NNP	B-NP	O
A	A	A000	NNP	I-NP	O
pseudodeficiency	pseudodeficiency	P231	NN	I-NP	O
.	.	0000	.	O	O

Given	Give	G150	VBN	B-VP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
standard	standard	S353	JJ	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
differentiate	differentiate	D165	VB	I-VP	O
between	between	B350	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C739	C739	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
DNA	DNA	D500	NN	B-NP	O
testing	testing	T235	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
risk	risk	R200	NN	I-NP	O
couples	couple	C142	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
.	.	0000	.	O	O

Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
Thr181	Thr181	T600	CD	B-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
Pro	Pro	P600	NN	I-NP	O
and	and	A530	CC	I-NP	O
Leu223	Leu223	L000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
Pro	Pro	P600	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-VP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
presented	present	P625	VBN	B-VP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
,	,	0000	,	O	O
requesting	request	R235	VBG	B-VP	O
carrier	carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

RFLP	RFLP	R141	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
probe	probe	P610	NN	I-NP	O
was	be	W200	VBD	B-VP	O
uninformative	uninformative	U516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
chorionic	chorionic	C652	JJ	I-NP	O
villus	villus	V420	NN	I-NP	O
sample	sample	S514	NN	I-NP	O
(	(	0000	(	O	O
CVS	CVS	C120	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
using	use	U252	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
was	be	W200	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
unaffected	unaffected	U512	JJ	B-ADJP	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
CVS	CVS	C120	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
-	-	0000	HYPH	I-NP	O
carrier	carrier	C600	NN	I-NP	O
mother	mother	M360	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
carrier	carrier	C600	NN	I-NP	O
grandmother	grandmother	G653	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
541	541	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
women	woman	W500	NNS	I-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
change	change	C520	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Thr	Thr	T600	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
Pro	Pro	P600	NN	I-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
181	181	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
concluded	conclude	C524	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
5	5	0000	CD	I-NP	O
variant	variant	V653	JJ	I-NP	O
band	band	B530	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
on	on	O500	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
by	by	B000	IN	B-PP	O
sequencing	sequence	S252	VBG	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
668	668	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Leu	Leu	L000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
Pro	Pro	P600	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
mother	mother	M360	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
two	two	T000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
sons	son	S520	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
illustrate	illustrate	I423	VB	B-VP	O
the	the	T000	DT	B-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
in	in	I500	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
B	B	B000	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
selectively	selectively	S423	RB	B-ADVP	O
abolishes	abolish	A142	VBZ	B-VP	O
ristocetin	ristocetin	R232	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	I-VP	O
platelet	platelet	P434	VB	I-VP	O
glycoprotein	glycoprotein	G421	NN	B-NP	O
Ib	Ib	I100	NN	I-NP	O
.	.	0000	.	O	O

von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
vWF	vWF	V100	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
multimeric	multimeric	M435	JJ	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
that	that	T300	WDT	B-NP	O
mediates	mediate	M320	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
adhesion	adhesion	A325	NN	I-NP	O
of	of	O100	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
subendothelium	subendothelium	S153	NN	I-NP	O
by	by	B000	IN	B-PP	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	I-VP	O
platelet	platelet	P434	VB	I-VP	O
glycoprotein	glycoprotein	G421	NN	B-NP	O
Ib	Ib	I100	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
vWF	vWF	V100	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
interaction	interaction	I536	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
induced	induce	I532	VBN	I-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
antibiotic	antibiotic	A531	JJ	I-NP	O
ristocetin	ristocetin	R232	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
snake	snake	S520	NN	I-NP	O
venom	venom	V500	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
botrocetin	botrocetin	B362	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
Gly	Gly	G400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
561	561	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
Ser	Ser	S600	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
proposed	propose	P612	VBN	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
Ib	Ib	I100	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
with	with	W300	IN	B-PP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
B	B	B000	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
no	no	N000	DT	B-NP	O
ristocetin	ristocetin	R232	NN	I-NP	O
-	-	0000	HYPH	O	O
induced	induce	I532	VBN	B-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
normal	normal	N654	JJ	B-NP	O
botrocetin	botrocetin	B362	NN	I-NP	O
-	-	0000	HYPH	O	O
induced	induce	I532	VBN	B-VP	O
,	,	0000	,	O	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
glycoprotein	glycoprotein	G421	NN	B-NP	O
Ib	Ib	I100	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
rvWF	rvWF	R100	NN	B-NP	O
(	(	0000	(	O	O
G561S	G561S	G200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
formed	form	F653	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
multimers	multimer	M435	NNS	I-NP	O
and	and	A530	CC	O	O
exhibited	exhibit	E213	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
functional	functional	F523	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
plasma	plasma	P425	NN	I-NP	O
vWF	vWF	V100	NN	I-NP	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
B	B	B000	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
botrocetin	botrocetin	B362	NN	B-NP	O
and	and	A530	CC	I-NP	O
ristocetin	ristocetin	R232	NN	I-NP	O
cofactor	cofactor	C123	NN	I-NP	O
activities	activity	A231	NNS	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
dissociated	dissociate	D230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
confirm	confirm	C516	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mediators	mediator	M362	NNS	I-NP	O
promote	promote	P653	VBP	B-VP	O
vWF	vWF	V100	NN	B-NP	O
binding	bind	B535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
by	by	B000	IN	B-PP	O
different	different	D165	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
botrocetin	botrocetin	B362	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
induced	induce	I532	VBN	B-NP	O
binding	binding	B535	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
ristocetin	ristocetin	R232	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
binding	binding	B535	NN	I-NP	O
of	of	O100	IN	B-PP	O
rvWF	rvWF	R100	NN	B-NP	O
(	(	0000	(	O	O
G561S	G561S	G200	NN	B-NP	O
)	)	0000	)	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
B	B	B000	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
allosteric	allosteric	A423	JJ	I-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
Ib	Ib	I100	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Typical	Typical	T124	JJ	B-NP	O
and	and	A530	CC	I-NP	O
partial	partial	P634	JJ	I-NP	O
cat	cat	C300	NN	I-NP	B-Disease
eye	eye	E000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
by	by	B000	IN	B-PP	O
FISH	FISH	F200	NN	B-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
children	child	C436	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
cat	cat	C300	NN	I-NP	B-Disease
eye	eye	E000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
CES	CES	C200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
more	more	M600	JJR	I-NP	O
children	child	C436	NNS	I-NP	O
with	with	W300	IN	B-PP	O
partial	partial	P634	JJ	B-NP	O
CES	CES	C200	NNS	I-NP	B-Disease
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
coloboma	coloboma	C415	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
supernumerary	supernumerary	S165	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
FISH	FISH	F200	NN	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
library	library	L160	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
centromeric	centromeric	C536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
particularly	particularly	P632	RB	I-NP	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
of	of	O100	IN	B-PP	O
22q11	22q11	Q000	CD	B-NP	O
,	,	0000	,	O	O
partial	partial	P634	JJ	B-NP	O
tetrasomy	tetrasomy	T362	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

[	[	0000	(	O	O
Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Shekii	Shekii	S200	NNP	I-NP	O
district	district	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
Azerbaijan	Azerbaijan	A261	NNP	B-NP	O
]	]	0000	)	O	O

Examination	Examination	E253	NN	B-NP	O
on	on	O500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
349	349	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Shekii	Shekii	S200	NNP	B-NP	O
district	district	D236	NN	I-NP	O
hospital	hospital	H213	NN	I-NP	O
(	(	0000	(	O	O
Azerbaijan	Azerbaijan	A261	NN	B-NP	O
)	)	0000	)	O	O
revealed	reveal	R143	VBD	B-VP	O
16	16	0000	CD	B-NP	O
hemi	hemi	H500	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
homo	homo	H500	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
and	and	A530	CC	O	O
9	9	0000	CD	B-NP	O
heterozygotic	heterozygotic	H362	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

Gd	Gd	G300	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
frequency	frequency	F625	NN	I-NP	O
,	,	0000	,	O	O
calculated	calculate	C424	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
compared	compare	C516	VBN	I-VP	O
to	to	T000	TO	B-PP	O
neighbouring	neighbour	N216	VBG	B-VP	O
regions	region	R252	NNS	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
(	(	0000	(	O	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Carriers	Carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
residents	resident	R235	NNS	B-NP	O
of	of	O100	IN	B-PP	O
11	11	0000	CD	B-NP	O
villages	village	V420	NNS	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Alasani	Alasani	A425	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
Aphtalan	Aphtalan	A134	NNP	I-NP	O
valley	valley	V400	NN	I-NP	O
,	,	0000	,	O	O
highly	highly	H240	RB	B-ADJP	O
endemic	endemic	E535	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
past	past	P230	NN	I-NP	O
;	;	0000	:	O	O
nearly	nearly	N640	RB	B-NP	O
all	all	A400	DT	I-NP	O
marriages	marriage	M620	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
endogamic	endogamic	E532	JJ	B-ADJP	O
.	.	0000	.	O	O

Physico	Physico	P200	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
chemical	chemical	C524	JJ	I-NP	O
and	and	A530	CC	I-NP	O
kinetic	kinetic	K532	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
,	,	0000	,	O	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
WHO	WHO	W000	WP	B-NP	O
program	program	P626	NN	I-NP	O
,	,	0000	,	O	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
II	II	I000	CD	I-NP	O
class	class	C420	NN	I-NP	O
(	(	0000	(	O	O
Shekii	Shekii	S200	NNP	B-NP	O
,	,	0000	,	O	O
Bideiz	Bideiz	B320	NNP	B-NP	O
,	,	0000	,	O	O
Shirin	Shirin	S650	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Bulakh	Bulakh	B420	NNP	I-NP	O
,	,	0000	,	O	O
Okhut	Okhut	O230	NNP	B-NP	O
I	I	I000	NNP	I-NP	O
and	and	A530	CC	O	O
Zakataly	Zakataly	Z234	NNP	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
III	III	I000	CD	I-NP	O
class	class	C420	NN	I-NP	O
(	(	0000	(	O	O
Okhut	Okhut	O230	NN	B-NP	O
II	II	I000	CD	I-NP	O
and	and	A530	CC	O	O
Martinique	Martinique	M635	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
like	like	L200	JJ	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Resemblance	Resemblance	R251	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
variants	variant	V653	NNS	B-NP	O
in	in	I500	IN	B-PP	O
electrophoretic	electrophoretic	E423	JJ	B-NP	O
mobility	mobility	M143	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
erythrocyte	erythrocyte	E636	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
permit	permit	P653	NN	I-NP	O
to	to	T000	TO	B-VP	O
suggest	suggest	S230	VB	I-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
parental	parental	P653	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
distributed	distribute	D236	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
area	area	A600	NN	I-NP	O
.	.	0000	.	O	O

Craniofrontonasal	Craniofrontonasal	C651	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
craniofrontonasal	craniofrontonasal	C651	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
(	(	0000	(	O	O
CFND	CFND	C153	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
classical	classical	C424	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
facial	facial	F240	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
suggestive	suggestive	S231	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
frontonasal	frontonasal	F653	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
and	and	A530	CC	O	O
coronal	coronal	C654	JJ	B-NP	B-Disease
craniosynostosis	craniosynostosis	C652	NN	I-NP	I-Disease
.	.	0000	.	O	O

Extracranial	Extracranial	E236	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
brittle	brittle	B634	JJ	B-NP	B-Disease
nails	nail	N420	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	I-Disease
prominent	prominent	P653	JJ	B-NP	I-Disease
longitudinal	longitudinal	L523	JJ	I-NP	I-Disease
grooves	groove	G612	NNS	I-NP	I-Disease
or	or	O600	CC	O	O
syndactyly	syndactyly	S532	RB	B-ADVP	B-Disease
of	of	O100	IN	B-PP	I-Disease
fingers	finger	F526	NNS	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
toes	toe	T200	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
abnormalities	abnormality	A156	NNS	B-NP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
to	to	T000	TO	B-PP	O
13	13	0000	CD	B-NP	O
-	-	0000	HYPH	B-NP	O
year	year	Y600	NN	I-NP	O
follow	follow	F400	VB	B-VP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
on	on	O500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Hypotonia	Hypotonia	H135	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
laxity	laxity	L230	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
joints	joint	J532	NNS	B-NP	I-Disease
are	be	A600	VBP	B-VP	O
common	common	C500	JJ	B-ADJP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
necessitate	necessitate	N230	VB	I-VP	O
supportive	supportive	S163	JJ	B-NP	O
measures	measure	M262	NNS	I-NP	O
.	.	0000	.	O	O

Mild	Mild	M430	JJ	B-NP	O
developmental	developmental	D141	JJ	I-NP	B-Disease
delay	delay	D400	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
six	six	S200	CD	I-NP	O
classical	classical	C424	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
detail	detail	D340	NN	B-NP	O
.	.	0000	.	O	O

Unlike	Unlike	U542	IN	B-PP	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
other	other	O360	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
clinical	clinical	C452	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
CFND	CFND	C153	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
generally	generally	G564	RB	B-ADVP	O
much	much	M200	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
previous	previous	P612	JJ	B-NP	O
reports	report	R163	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
severely	severely	S164	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
cases	case	C200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
male	male	M400	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
French	French	F652	NNP	B-NP	O
Canada	Canada	C530	NNP	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
HEXA	HEXA	H200	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
which	which	W200	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
elevated	elevate	E413	VBN	I-VP	O
frequency	frequency	F625	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
and	and	A530	CC	O	O
French	French	F652	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
population	population	P143	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
+	+	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
abolishes	abolish	A142	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Cultured	Culture	C436	VBN	B-NP	O
human	human	H500	JJ	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
(	(	0000	(	O	O
and	and	A530	CC	O	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
)	)	0000	)	O	O
produce	produce	P632	VBP	B-VP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
HEXA	HEXA	H200	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
base	base	B200	NN	I-NP	O
adjacent	adjacent	A325	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
G805A	G805A	G000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
a	a	A000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
EcoRII	EcoRII	E260	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
abolished	abolish	A142	VBN	I-VP	O
.	.	0000	.	O	O

Unambiguous	Unambiguous	U512	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
requires	require	R262	VBZ	B-VP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
between	between	B350	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Obligate	Obligate	O142	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
7	7	0000	CD	I-NP	O
+	+	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
born	bear	B650	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Saguenay	Saguenay	S250	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
Lac	Lac	L200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
St	St	S300	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
Jean	Jean	J500	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Quebec	Quebec	Q120	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
recent	recent	R253	JJ	I-NP	O
ancestors	ancestor	A523	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
obligate	obligate	O142	VB	I-VP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Charlevoix	Charlevoix	C641	NNP	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
province	province	P615	NN	I-NP	O
of	of	O100	IN	B-PP	O
Quebec	Quebec	Q120	NNP	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
thus	thus	T200	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
geographic	geographic	G261	JJ	I-NP	O
centre	centre	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
diffusion	diffusion	D125	NN	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADJP	O
less	less	L200	RBR	I-ADJP	O
common	common	C500	JJ	I-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
1	1	0000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
French	French	F652	JJ	B-NP	O
Canadians	Canadian	C535	NNS	I-NP	O
.	.	0000	.	O	O

Neither	Neither	N360	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
France	France	F652	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
homeland	homeland	H545	NN	I-NP	O
of	of	O100	IN	B-PP	O
French	French	F652	NNP	B-NP	O
Canada	Canada	C530	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Assignment	Assignment	A253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
aspartylglucosaminidase	aspartylglucosaminidase	A216	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
4q33	4q33	Q000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
q35	q35	Q000	NN	B-NP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
46	46	0000	CD	I-NP	O
,	,	0000	,	O	O
XX	XX	X200	NN	B-NP	O
,	,	0000	,	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q33	q33	Q000	NN	B-NP	O
)	)	0000	)	O	O
karyotype	karyotype	K631	NN	B-NP	O
.	.	0000	.	O	O

Aspartylglucosaminuria	Aspartylglucosaminuria	A216	NN	B-NP	B-Disease
(	(	0000	(	O	O
AGU	AGU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
autosomally	autosomally	A325	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	B-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
aspartylglucosaminidase	aspartylglucosaminidase	A216	NN	I-NP	I-Disease
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
human	human	H500	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
4q21	4q21	Q000	CD	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
qter	qter	Q360	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	B-NP	O
AGA	AGA	A200	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
46	46	0000	CD	I-NP	O
,	,	0000	,	O	O
XX	XX	X200	NN	B-NP	O
,	,	0000	,	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q33	q33	Q000	NN	B-NP	O
)	)	0000	)	O	O
karyotype	karyotype	K631	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
girl	girl	G640	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hemizygote	hemizygote	H523	NN	I-NP	O
for	for	F600	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
,	,	0000	,	O	O
permitting	permit	P653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
AGA	AGA	A200	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
4q33	4q33	Q000	CD	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
qter	qter	Q360	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Resolution	Resolution	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
,	,	0000	,	I-NP	O
AN1	AN1	A500	NN	I-NP	O
and	and	A530	CC	I-NP	O
AN2	AN2	A500	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11p13	11p13	P000	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
loci	locus	L200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
for	for	F600	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
;	;	0000	:	O	O
AN1	AN1	A500	NN	B-NP	O
for	for	F600	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
2p	2p	P000	NN	I-NP	O
and	and	A530	CC	I-NP	O
AN2	AN2	A500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAGR	WAGR	W260	NN	I-NP	B-Disease
contiguous	contiguous	C532	JJ	I-NP	I-Disease
gene	gene	G500	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11p13	11p13	P000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
suggested	suggest	S230	VBD	B-VP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
acid	acid	A230	NN	B-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
ACP1	ACP1	A210	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AN1	AN1	A500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
2p	2p	P000	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
updated	update	U130	VBN	I-VP	O
and	and	A530	CC	I-VP	O
expanded	expand	E215	VBN	I-VP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
ACP1	ACP1	A210	NN	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
support	support	S163	VB	I-VP	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
results	result	R243	NNS	I-NP	O
,	,	0000	,	O	O
excluding	exclude	E243	VBG	B-PP	O
linkage	linkage	L520	NN	B-NP	O
up	up	U100	IN	B-PP	O
to	to	T000	TO	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

17	17	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

Tests	Test	T232	NNS	B-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
2p	2p	P000	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

APOB	APOB	A100	NN	B-NP	O
,	,	0000	,	O	O
D2S71	D2S71	D200	NN	B-NP	O
,	,	0000	,	O	O
D2S5	D2S5	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D2S1	D2S1	D200	NN	B-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-ADVP	O
excluded	exclude	E243	VBD	B-VP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O

Markers	Marker	M626	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11p13	11p13	P000	NN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
then	then	T500	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
D11S323	D11S323	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
give	give	G100	VBP	B-VP	O
significant	significant	S251	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PvuII	PvuII	P100	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
probe	probe	P610	NN	B-NP	O
p5S1	p5S1	P200	NN	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
detects	detect	D323	NNS	I-NP	O
no	no	N000	DT	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

97	97	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
00	00	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
HaeIII	HaeIII	H000	NNP	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
p5BE1	p5BE1	P100	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
gives	give	G120	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

57	57	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
00	00	0000	CD	I-NP	O
.	.	0000	.	O	O

Locus	Locus	L200	NN	B-NP	O
D11S325	D11S325	D200	NN	I-NP	O
gives	give	G120	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
Z	Z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

53	53	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
00	00	0000	CD	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
(	(	0000	(	O	O
AN1	AN1	A500	NN	B-NP	O
)	)	0000	)	O	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
2p	2p	P000	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
misassigned	misassigne	M253	VBN	I-VP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
segregating	segregate	S262	VBG	I-VP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
markers	marker	M626	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
11p13	11p13	P000	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Fatal	Fatal	F340	JJ	B-NP	O
pyoderma	pyoderma	P365	NN	I-NP	B-Disease
gangrenosum	gangrenosum	G526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
pyoderma	pyoderma	P365	NN	B-NP	B-Disease
gangrenosum	gangrenosum	G526	NN	I-NP	I-Disease
(	(	0000	(	O	O
PG	PG	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
systemic	systemic	S235	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
an	an	A500	DT	B-NP	O
aggressive	aggressive	A262	JJ	I-NP	O
and	and	A530	CC	I-NP	O
ultimately	ultimately	U435	RB	I-NP	O
fatal	fatal	F340	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PG	PG	P200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
congenital	congenital	C525	JJ	I-NP	O
C7	C7	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Deficiencies	Deficiency	D125	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C7	C7	C000	NN	B-NP	I-Disease
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
neutrophil	neutrophil	N361	NN	I-NP	O
chemotaxis	chemotaxis	C532	NN	I-NP	O
,	,	0000	,	O	O
phagocytosis	phagocytosis	P232	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
opsonization	opsonization	O125	NN	B-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
immunologic	immunologic	I542	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
described	describe	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PG	PG	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
patients	patient	P353	NNS	I-NP	O
decreased	decrease	D262	VBD	B-VP	O
complement	complement	C514	NN	B-NP	O
level	level	L140	NN	I-NP	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
not	not	N300	RB	O	O
directly	directly	D623	RB	B-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
PG	PG	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
contributed	contribute	C536	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
aggressive	aggressive	A262	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Diverse	Diverse	D162	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
polymorphism	polymorphism	P456	NN	B-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
PHOSPHATE	PHOSPHATE	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
;	;	0000	:	O	I-Disease
EC	EC	E200	NNP	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
1	1	0000	CD	B-NP	I-Disease
.	.	0000	.	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
49	49	0000	CD	O	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
enzymopathy	enzymopathy	E525	NN	I-NP	B-Disease
,	,	0000	,	O	O
affecting	affect	A123	VBG	B-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
200	200	0000	CD	I-NP	O
million	million	M450	CD	I-NP	O
people	people	P140	NNS	I-NP	O
worldwide	worldwide	W643	RB	B-ADVP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
greater	great	G636	JJR	B-NP	O
than	than	T500	IN	I-NP	O
400	400	0000	CD	I-NP	O
variants	variant	V653	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
criteria	criterion	C636	NNS	I-NP	O
,	,	0000	,	O	O
little	little	L340	JJ	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
human	human	H500	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
enables	enable	E514	VBZ	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
directly	directly	D623	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

During	During	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
past	past	P230	JJ	I-NP	O
10	10	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
21	21	0000	CD	B-NP	O
,	,	0000	,	O	O
271	271	0000	CD	B-NP	O
newborn	newborn	N165	JJ	I-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
infants	infant	I515	NNS	I-NP	O
(	(	0000	(	O	O
11	11	0000	CD	B-NP	O
,	,	0000	,	O	O
400	400	0000	CD	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
9	9	0000	CD	B-NP	O
,	,	0000	,	O	O
871	871	0000	CD	B-NP	O
females	female	F542	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
314	314	0000	CD	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
males	male	M420	NNS	B-NP	O
and	and	A530	CC	O	O
246	246	0000	CD	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
females	female	F542	NNS	B-NP	O
having	have	H152	VBG	B-VP	O
low	low	L000	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
10	10	0000	CD	B-NP	O
randomly	randomly	R535	RB	I-NP	O
selected	select	S423	VBN	I-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
relatives	relative	R431	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
amplified	amplify	A514	VBN	B-VP	O
,	,	0000	,	O	O
subcloned	subclone	S124	VBN	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
(	(	0000	(	O	O
487	487	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
487	487	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	O	O
163	163	0000	CD	O	O
)	)	0000	)	O	O
Gly	Gly	G400	NN	B-NP	O
to	to	T000	TO	B-PP	O
Ser	Ser	S600	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
(	(	0000	(	O	O
493	493	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
other	other	O360	JJ	I-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
group	group	G610	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBD	B-VP	O
Chinese	Chinese	C520	NNP	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
to	to	T000	TO	B-PP	O
G	G	G000	NN	B-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
493	493	0000	CD	I-NP	O
,	,	0000	,	O	O
producing	produce	P632	VBG	B-VP	O
an	an	A500	DT	B-NP	O
(	(	0000	(	I-NP	O
165	165	0000	CD	I-NP	O
)	)	0000	)	I-NP	O
Asn	Asn	A250	NN	I-NP	O
to	to	T000	TO	B-PP	O
Asp	Asp	A210	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
487	487	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
493	493	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
G	G	G000	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
create	create	C630	VBP	B-VP	O
Alu	Alu	A400	NN	B-NP	O
I	I	I000	CD	I-NP	O
and	and	A530	CC	O	O
Ava	Ava	A100	NNP	B-NP	O
II	II	I000	CD	I-NP	O
recognition	recognition	R253	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
rapidly	rapidly	R134	RB	I-VP	O
detect	detect	D323	VB	I-VP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
/	/	0000	SYM	O	O
restriction	restriction	R236	NN	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
(	(	0000	(	O	O
RE	RE	R000	NN	B-NP	O
)	)	0000	)	O	O
digestion	digestion	D235	NN	B-NP	O
method	method	M300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
1376	1376	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
affected	affect	A123	VBD	B-VP	O
Chinese	Chinese	C520	NNP	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
1376	1376	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
(	(	0000	(	O	O
459	459	0000	CD	O	O
)	)	0000	)	O	O
Arg	Arg	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
Leu	Leu	L000	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
1376	1376	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBD	B-VP	O
Chinese	Chinese	C520	NNP	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
1388	1388	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1388	1388	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
produces	produce	P632	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
(	(	0000	(	O	O
463	463	0000	CD	O	O
)	)	0000	)	O	O
Arg	Arg	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
His	His	H200	PRP$	B-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
studies	study	S320	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
the	the	T000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
proof	proof	P610	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Taiwan	Taiwan	T500	NNP	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
/	/	0000	SYM	B-NP	O
RE	RE	R000	NN	I-NP	O
digestion	digestion	D235	NN	I-NP	O
method	method	M300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
suitable	suitable	S314	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
simultaneous	simultaneous	S543	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
487	487	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
493	493	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
G	G	G000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
error	error	E600	NN	I-NP	O
in	in	I500	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
processing	processing	P625	NN	I-NP	O
in	in	I500	IN	B-PP	O
golden	golden	G435	JJ	B-NP	B-Disease
retriever	retriever	R361	NN	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Golden	Golden	G435	JJ	B-NP	B-Disease
retriever	retriever	R361	NN	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
GRMD	GRMD	G653	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
spontaneous	spontaneous	S153	JJ	I-NP	O
,	,	0000	,	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
linked	link	L523	VBN	B-VP	O
,	,	0000	,	O	O
progressively	progressively	P626	RB	B-NP	O
fatal	fatal	F340	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
of	of	O100	IN	B-PP	O
dogs	dog	D200	NNS	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
thirds	third	T632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
carry	carry	C600	VBP	B-VP	O
detectable	detectable	D323	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
third	third	T630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
undetermined	undetermined	U536	JJ	B-ADJP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
canine	canine	C500	JJ	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
GRMD	GRMD	G653	NN	I-NP	B-Disease
dogs	dog	D200	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
failed	fail	F430	VBN	I-VP	O
to	to	T000	TO	I-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
any	any	A500	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
a	a	A000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
processing	processing	P625	NN	I-NP	O
error	error	E600	NN	I-NP	O
in	in	I500	IN	B-PP	O
GRMD	GRMD	G653	NN	B-NP	B-Disease
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
consensus	consensus	C525	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seventh	seventh	S153	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
then	then	T500	RB	I-VP	O
skipped	skip	S213	VBN	I-VP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
predicts	predict	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
termination	termination	T653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
within	within	W350	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
skipping	skipping	S215	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
during	during	D652	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
splicing	splicing	S142	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
(	(	0000	(	O	O
C2D	C2D	C300	NN	B-NP	O
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
C2	C2	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
translation	translation	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	O
I	I	I000	CD	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
type	type	T100	NN	B-NP	O
II	II	I000	CD	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
block	block	B420	NN	I-NP	O
in	in	I500	IN	B-PP	O
C2	C2	C000	NN	B-NP	O
secretion	secretion	S263	NN	I-NP	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
C2	C2	C000	NN	I-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
C2Q0	C2Q0	C200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
/	/	0000	SYM	B-VP	O
complotype	complotype	C514	NN	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
A25	A25	A000	NN	I-NP	O
,	,	0000	,	O	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
C2Q0	C2Q0	C200	NN	B-NP	O
,	,	0000	,	O	O
BfS	BfS	B120	NN	B-NP	O
,	,	0000	,	O	O
C4A4	C4A4	C000	NN	B-NP	O
,	,	0000	,	O	O
C4B2	C4B2	C100	NN	B-NP	O
,	,	0000	,	O	O
Drw2	Drw2	D600	NN	B-NP	O
;	;	0000	:	O	O
this	this	T200	DT	B-NP	O
extended	extend	E235	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
over	over	O160	IN	B-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
(	(	0000	(	O	O
common	common	C500	JJ	B-NP	O
complotype	complotype	C514	NN	I-NP	O
/	/	0000	SYM	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
C2	C2	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
type	type	T100	NN	I-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
associated	associate	A230	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
/	/	0000	SYM	B-NP	O
complotype	complotype	C514	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
I	I	I000	CD	I-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
beginning	begin	B252	VBG	B-VP	O
9	9	0000	CD	B-NP	O
base	base	B200	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
generates	generate	G563	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
C2	C2	C000	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
(	(	0000	(	O	O
134	134	0000	CD	B-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
studies	study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
kindred	kindred	K536	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
type	type	T100	NN	I-NP	O
I	I	I000	CD	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
complotype	complotype	C514	NN	I-NP	O
/	/	0000	SYM	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
;	;	0000	:	O	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C2	C2	C000	NN	I-NP	O
nor	nor	N600	CC	B-PP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
1	1	0000	LS	B-LST	O
)	)	0000	)	O	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
skipping	skipping	S215	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
during	during	D652	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
splicing	splicing	S142	NN	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
generation	generation	G563	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
2	2	0000	LS	B-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
I	I	I000	CD	I-NP	O
C2Q0	C2Q0	C200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
strongly	strongly	S365	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
/	/	0000	SYM	B-NP	O
complotype	complotype	C514	NN	I-NP	O
A25	A25	A000	NN	I-NP	O
,	,	0000	,	O	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
C2Q0	C2Q0	C200	NN	B-NP	O
,	,	0000	,	O	O
BfS	BfS	B120	NN	B-NP	O
,	,	0000	,	O	O
C4A4	C4A4	C000	NN	B-NP	O
,	,	0000	,	O	O
C4B2	C4B2	C100	NN	B-NP	O
,	,	0000	,	O	O
Drw2	Drw2	D600	NN	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
deficient	deficient	D125	JJ	B-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
/	/	0000	SYM	B-NP	O
complotype	complotype	C514	NN	I-NP	O
will	will	W400	MD	B-VP	O
harbor	harbor	H616	VB	I-VP	O
the	the	T000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
C2	C2	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3	3	0000	LS	B-LST	O
)	)	0000	)	O	O
type	type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
yet	yet	Y300	RB	B-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
,	,	0000	,	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
structure	structure	S362	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
L74P	L74P	L100	NN	B-NP	O
and	and	A530	CC	I-NP	O
F171S	F171S	F200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
S135L	S135L	S400	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
reconstructed	reconstruct	R252	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	O	O
overexpressed	overexpresse	O162	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
near	near	N600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
affect	affect	A123	VBP	B-VP	O
evolutionarily	evolutionarily	E143	RB	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
residues	residue	R232	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
functionally	functionally	F523	RB	B-ADJP	O
important	important	I516	JJ	I-ADJP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonconserved	nonconserved	N525	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
presumably	presumably	P625	RB	B-ADVP	O
not	not	N300	RB	O	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
enzymatic	enzymatic	E525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
F171S	F171S	F200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
close	close	C420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
active	active	A231	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
nucleophile	nucleophile	N241	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
further	further	F636	RB	B-ADVP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
GALT	GALT	G430	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
useful	useful	U214	JJ	B-NP	O
tools	tool	T420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
highlighting	highlight	H242	VBG	B-VP	O
different	different	D165	JJ	B-NP	O
functional	functional	F523	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
GALT	GALT	G430	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
HLA	HLA	H400	NN	B-NP	O
and	and	A530	CC	I-NP	O
glyoxalase	glyoxalase	G424	NN	I-NP	O
I	I	I000	CD	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

Immunogenetic	Immunogenetic	I525	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
C2	C2	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individual	individual	I531	NN	I-NP	O
and	and	A530	CC	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A25	A25	A000	NN	I-NP	O
,	,	0000	,	I-NP	O
B18	B18	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C2o	C2o	C000	NN	I-NP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
D	D	D000	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
5	5	0000	CD	B-NP	O
members	member	M516	NNS	I-NP	O
typed	type	T130	VBN	B-VP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
Dw2	Dw2	D000	NN	I-NP	O
typing	typing	T152	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
with	with	W300	IN	I-PP	O
Dw2	Dw2	D000	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
2	2	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C2	C2	C000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
C2	C2	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
propositus	propositus	P612	NN	I-NP	O
and	and	A530	CC	I-NP	O
brother	brother	B636	NN	I-NP	O
were	be	W600	VBD	B-VP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
B	B	B000	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
but	but	B300	CC	I-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
glyoxalase	glyoxalase	G424	NN	I-NP	O
I	I	I000	CD	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
C2o	C2o	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
linked	link	L523	VBN	I-VP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
A25	A25	A000	NN	I-NP	O
,	,	0000	,	O	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
Dw2	Dw2	D000	NN	B-NP	O
,	,	0000	,	O	O
GLO1	GLO1	G400	NN	B-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
A25	A25	A000	NN	I-NP	O
,	,	0000	,	O	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
D	D	D000	NN	B-NP	O
unknown	unknown	U525	JJ	I-NP	O
,	,	0000	,	I-NP	O
GL02	GL02	G400	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
event	event	E153	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2o	C2o	C000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
C2o	C2o	C000	NN	B-NP	O
segregated	segregate	S262	VBD	B-VP	O
with	with	W300	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
B	B	B000	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
would	would	W430	MD	B-VP	O
suggest	suggest	S230	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2o	C2o	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
maps	map	M120	VBZ	B-VP	O
between	between	B350	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
B	B	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sixth	sixth	S230	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
urogenital	urogenital	U625	JJ	I-NP	O
development	development	D141	NN	I-NP	O
in	in	I500	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Denys	Denys	D520	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
condition	condition	C535	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
severe	severe	S160	JJ	B-NP	O
urogenital	urogenital	U625	JJ	I-NP	B-Disease
aberrations	aberration	A163	NNS	I-NP	I-Disease
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
,	,	0000	,	O	O
pseudohermaphroditism	pseudohermaphroditism	P236	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
(	(	0000	(	O	O
nephroblastoma	nephroblastoma	N161	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
possible	possible	P214	JJ	I-NP	O
role	role	R400	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilms	Wilms	W452	NNP	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WT1	WT1	W300	NN	B-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
ten	ten	T500	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
copy	copy	C100	NN	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
within	within	W350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
(	(	0000	(	O	O
zinc	zinc	Z520	NN	B-NP	O
finger	finger	F526	NN	I-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
(	(	0000	(	O	O
zinc	zinc	Z520	NN	B-NP	O
finger	finger	F526	NN	I-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
directly	directly	D623	RB	B-VP	O
affect	affect	A123	VBP	I-VP	O
DNA	DNA	D500	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
recognition	recognition	R253	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
arise	arise	A620	VB	I-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
.	.	0000	.	O	O

Wilms	Wilm	W452	NNS	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
from	from	F650	IN	B-PP	O
three	three	T600	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
juvenile	juvenile	J154	JJ	I-NP	O
granulosa	granulosa	G654	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
demonstrate	demonstrate	D523	VBP	B-VP	O
reduction	reduction	R323	NN	B-NP	O
to	to	T000	TO	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
WT1	WT1	W300	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
in	in	I500	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
thus	thus	T200	RB	B-NP	O
urogenital	urogenital	U625	JJ	I-NP	O
system	system	S235	NN	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
application	application	A142	NN	I-NP	O
in	in	I500	IN	B-PP	O
post	post	P230	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
performed	perform	P616	VBN	I-VP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
DXS52	DXS52	D200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
clotting	clotting	C435	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
VIII	VIII	V000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
F8C	F8C	F200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
large	large	L620	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
tight	tight	T230	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
DXS52	DXS52	D200	NN	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
extended	extend	E235	VBN	I-VP	O
giving	give	G152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
maximal	maximal	M254	JJ	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
22	22	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
1	1	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
.	.	0000	.	O	O

F8C	F8C	F200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
tightly	tightly	T234	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximal	maximal	M254	JJ	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
without	without	W300	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
.	.	0000	.	O	O

Multipoint	Multipoint	M431	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
DXS304	DXS304	D200	NN	I-NP	O
,	,	0000	,	O	O
DXS52	DXS52	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
F8C	F8C	F200	NN	B-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
F8C	F8C	F200	NN	B-NP	O
are	be	A600	VBP	B-VP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS52	DXS52	D200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Xqter	Xqter	X236	NN	I-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-ADJP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
blindness	blindness	B453	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	I-Disease
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
use	use	U200	NN	B-NP	O
in	in	I500	IN	B-PP	O
determination	determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
females	female	F542	NNS	B-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
determination	determination	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
for	for	F600	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
BamHI	BamHI	B500	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	B-Disease
phenylketonuria	phenylketonuria	P542	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
abolition	abolition	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
invariant	invariant	I516	JJ	I-NP	O
BamHI	BamHI	B500	NN	I-NP	O
site	site	S300	NN	I-NP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
)	)	0000	)	O	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
recognition	recognition	R253	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
272	272	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
273	273	0000	CD	I-NP	O
(	(	0000	(	O	O
272gly	272gly	G400	RB	O	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
stop	stop	S310	NN	B-NP	O
and	and	A530	CC	O	O
273ser	273ser	S600	SYM	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
phe	phe	P000	NN	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
north	north	N630	JJ	B-NP	O
eastern	eastern	E236	JJ	I-NP	O
France	France	F652	NNP	I-NP	O
or	or	O600	CC	I-NP	O
Belgium	Belgium	B425	NNP	I-NP	O
and	and	A530	CC	O	O
occurred	occur	O263	VBD	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
background	background	B265	NN	I-NP	O
of	of	O100	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
7	7	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
view	view	V000	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
4	4	0000	CD	I-NP	O
provides	provide	P613	VBZ	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
and	and	A530	CC	I-NP	O
position	position	P235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
.	.	0000	.	O	O

Utilizing	Utilize	U342	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CEPH	CEPH	C100	NN	I-NP	O
reference	reference	R165	NN	I-NP	O
panel	panel	P540	NN	I-NP	O
and	and	A530	CC	O	O
genotypic	genotypic	G531	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
for	for	F600	IN	B-PP	O
53	53	0000	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
constructed	construct	C523	VBN	I-VP	O
a	a	A000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
locus	locus	L200	NN	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

New	New	N000	JJ	B-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
for	for	F600	IN	B-PP	O
four	four	F600	CD	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
integrates	integrate	I532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
4p16	4p16	P000	CD	B-NP	O
into	into	I530	IN	B-PP	O
a	a	A000	DT	B-NP	O
continuous	continuous	C535	JJ	I-NP	O
map	map	M100	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
to	to	T000	TO	B-PP	O
4q31	4q31	Q000	CD	B-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
unlinked	unlinked	U545	JJ	I-NP	O
cluster	cluster	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
loci	locus	L200	NNS	I-NP	O
at	at	A300	IN	B-PP	O
4q35	4q35	Q000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
20	20	0000	CD	I-NP	O
linked	link	L523	VBN	I-NP	O
markers	marker	M626	NNS	I-NP	O
form	form	F650	VBP	B-VP	O
a	a	A000	DT	B-NP	O
continuous	continuous	C535	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
152	152	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
and	and	A530	CC	O	O
202	202	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
.	.	0000	.	O	O

Likely	Likely	L240	RB	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
locations	location	L235	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
provided	provide	P613	VBN	I-VP	O
for	for	F600	IN	B-PP	O
25	25	0000	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
and	and	A530	CC	O	O
28	28	0000	CD	B-NP	O
gene	gene	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
employing	employ	E514	VBG	I-VP	O
the	the	T000	DT	B-NP	O
LINKAGE	LINKAGE	L520	NN	I-NP	O
and	and	A530	CC	I-NP	O
CRIMAP	CRIMAP	C651	NN	I-NP	O
computational	computational	C513	JJ	I-NP	O
methodologies	methodology	M342	NNS	I-NP	O
to	to	T000	TO	B-VP	O
build	build	B430	VB	I-VP	O
the	the	T000	DT	B-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
map	map	M100	NN	I-NP	O
via	via	V000	IN	B-PP	O
a	a	A000	DT	B-NP	O
stepwise	stepwise	S312	JJ	I-NP	O
algorithm	algorithm	A426	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
10	10	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
4p16	4p16	P000	CD	I-NP	O
region	region	R250	NN	I-NP	O
constructed	construct	C523	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
CEPH	CEPH	C100	NN	I-NP	O
panel	panel	P540	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
maps	map	M120	NNS	I-NP	O
constructed	construct	C523	VBN	B-VP	O
from	from	F650	IN	B-PP	O
families	family	F542	NNS	B-NP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
additionally	additionally	A354	RB	B-ADVP	O
provides	provide	P613	VBZ	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
position	position	P235	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
telomeric	telomeric	T456	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
4p	4p	P000	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Carrier	Carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
anonymous	anonymous	A520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
carrier	carrier	C600	NN	B-NP	O
identification	identification	I353	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
using	use	U252	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Pelizaeus	Pelizaeus	P420	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
affected	affect	A123	VBN	I-NP	O
male	male	M400	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
traced	trace	T623	VBN	I-VP	O
back	back	B200	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
his	his	H200	PRP$	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
grandfather	grandfather	G653	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
family	family	F540	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
fetus	fetus	F320	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
female	female	F540	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
we	we	W000	PRP	B-NP	O
predict	predict	P632	VBP	B-VP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
noncarrier	noncarrier	N526	NN	I-NP	O
of	of	O100	IN	B-PP	O
PMD	PMD	P530	NN	B-NP	B-Disease
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
genotype	genotype	G531	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Small	Small	S540	JJ	B-ADJP	O
(	(	0000	(	O	O
100	100	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
260	260	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
nested	nest	N230	VBN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
candidate	candidate	C530	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
MCC	MCC	M200	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
located	locate	L230	VBN	I-VP	O
outside	outside	O323	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
contained	contain	C535	VBD	B-VP	O
sequence	sequence	S252	NN	B-NP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
SRP19	SRP19	S610	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
19	19	0000	CD	I-NP	O
kd	kd	K300	NN	I-NP	O
component	component	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ribosomal	ribosomal	R125	JJ	I-NP	O
signal	signal	S254	NN	I-NP	O
recognition	recognition	R253	NN	I-NP	O
particle	particle	P632	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
,	,	0000	,	O	O
provisionally	provisionally	P612	RB	B-NP	O
designated	designate	D253	VBN	I-NP	O
DP1	DP1	D100	NN	I-NP	O
(	(	0000	(	O	O
deleted	delete	D430	VBN	B-VP	O
in	in	I500	IN	B-PP	O
polyposis	polyposis	P412	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
orientation	orientation	O653	NN	I-NP	O
as	as	A200	IN	B-PP	O
MCC	MCC	M200	NN	B-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
,	,	0000	,	O	O
DP2	DP2	D100	NN	B-NP	O
and	and	A530	CC	I-NP	O
DP3	DP3	D100	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
overlap	overlap	O164	VB	I-VP	O
,	,	0000	,	O	O
forming	form	F652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
DP2	DP2	D100	NN	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
orientation	orientation	O653	NN	I-NP	O
as	as	A200	IN	B-PP	O
SRP19	SRP19	S610	NN	B-NP	O
.	.	0000	.	O	O

Exclusion	Exclusion	E242	NN	B-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
between	between	B350	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
amyloid	amyloid	A543	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
SAA	SAA	S000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
cluster	cluster	C423	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
amyloid	amyloid	A543	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
SAA	SAA	S000	NN	B-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
by	by	B000	IN	B-PP	O
comparing	compare	C516	VBG	B-VP	O
alleles	allele	A420	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
conventional	conventional	C515	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
RFLP	RFLP	R141	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
SAA	SAA	S000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
in	in	I500	IN	B-PP	O
Israeli	Israeli	I264	JJ	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
a	a	A000	DT	B-NP	O
minimum	minimum	M500	JJ	I-NP	O
crossover	crossover	C621	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
22	22	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
SAA	SAA	S000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
and	and	A530	CC	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
conventional	conventional	C515	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
this	this	T200	DT	B-NP	O
eliminates	eliminate	E453	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
minimum	minimum	M500	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
including	include	I524	VBG	B-PP	O
and	and	A530	CC	O	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
SAA	SAA	S000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FMF	FMF	F510	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
although	although	A432	IN	B-SBAR	O
SAA	SAA	S000	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
prominent	prominent	P653	JJ	B-NP	O
physiologic	physiologic	P242	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
acute	acute	A230	JJ	I-NP	O
attacks	attack	A320	NNS	I-NP	O
.	.	0000	.	O	O

PRAD1	PRAD1	P630	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
BCL1	BCL1	B240	NN	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
:	:	0000	:	O	O
mapping	mapping	M152	NN	B-NP	O
and	and	A530	CC	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
centrocytic	centrocytic	C536	JJ	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
.	.	0000	.	O	O

Rearrangement	Rearrangement	R652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BCL1	BCL1	B240	NN	I-NP	O
(	(	0000	(	O	O
B	B	B000	NN	B-NP	O
-	-	0000	HYPH	O	O
cell	cell	C400	NN	B-NP	O
lymphoma	lymphoma	L515	NN	I-NP	O
1	1	0000	CD	O	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11q13	11q13	Q000	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
highly	highly	H240	RB	B-ADJP	O
characteristic	characteristic	C623	JJ	I-ADJP	O
of	of	O100	IN	B-PP	O
centrocytic	centrocytic	C536	JJ	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
infrequently	infrequently	I516	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
B	B	B000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Rearrangement	Rearrangement	R652	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
deregulate	deregulate	D624	VB	I-VP	O
a	a	A000	DT	B-NP	O
nearby	nearby	N610	JJ	I-NP	O
protooncogene	protooncogene	P635	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
transcribed	transcribe	T652	VBN	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
immediate	immediate	I530	JJ	I-NP	O
vicinity	vicinity	V253	NN	I-NP	O
of	of	O100	IN	B-PP	O
BCL1	BCL1	B240	NN	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

PRAD1	PRAD1	P630	NN	B-NP	O
,	,	0000	,	O	O
previously	previously	P612	RB	B-NP	O
designated	designate	D253	VBN	I-NP	O
D11S287E	D11S287E	D200	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
on	on	O500	IN	B-PP	O
11q13	11q13	Q000	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
region	region	R250	NN	I-NP	O
rearranged	rearrange	R652	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
parathyroid	parathyroid	P636	JJ	I-NP	O
hormone	hormone	H650	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
parathyroid	parathyroid	P636	JJ	B-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
;	;	0000	:	O	O
this	this	T200	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
putative	putative	P310	JJ	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
cyclin	cyclin	C245	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BCL1	BCL1	B240	NN	B-NP	O
and	and	A530	CC	O	O
implicated	implicate	I514	VBN	B-VP	O
also	also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
subsets	subset	S123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
squamous	squamous	S252	JJ	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
11q13	11q13	Q000	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
pulsed	pulse	P423	VBN	I-VP	O
-	-	0000	HYPH	B-NP	O
field	field	F430	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
showing	show	S520	VBG	B-VP	O
BCL1	BCL1	B240	NN	B-NP	O
and	and	A530	CC	I-NP	O
PRAD1	PRAD1	P630	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
no	no	N000	RB	B-NP	O
more	more	M600	JJR	I-NP	O
than	than	T500	IN	I-NP	O
130	130	0000	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
apart	apart	A163	RB	B-ADVP	O
.	.	0000	.	O	O

PRAD1	PRAD1	P630	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
abundantly	abundantly	A153	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
centrocytic	centrocytic	C536	JJ	I-NP	B-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
(	(	0000	(	O	O
Kiel	Kiel	K400	NN	B-NP	O
classification	classification	C421	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
13	13	0000	CD	B-NP	O
closely	closely	C424	RB	I-NP	O
related	related	R430	JJ	I-NP	O
but	but	B300	CC	I-NP	O
noncentrocytic	noncentrocytic	N525	JJ	I-NP	B-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
centrocytic	centrocytic	C536	JJ	I-NP	B-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
detectable	detectable	D323	JJ	B-NP	O
BCL1	BCL1	B240	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
.	.	0000	.	O	O

Also	Also	A420	RB	B-ADVP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
CLL	CLL	C400	NN	B-NP	O
with	with	W300	IN	B-PP	O
BCL1	BCL1	B240	NN	B-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
overexpressed	overexpresse	O162	VBD	B-VP	O
PRAD1	PRAD1	P630	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
five	five	F100	CD	B-NP	O
CLL	CLL	C400	NN	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
PRAD1	PRAD1	P630	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
excellent	excellent	E245	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
"	"	0000	``	O	O
BCL1	BCL1	B240	NN	B-NP	O
oncogene	oncogene	O525	NN	I-NP	O
.	.	0000	.	O	O

"	"	0000	''	O	O
Its	Its	I320	PRP$	B-NP	O
overexpression	overexpression	O162	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
rearrangement	rearrangement	R652	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BCL1	BCL1	B240	NN	I-NP	O
vicinity	vicinity	V253	NN	I-NP	O
in	in	I500	IN	B-PP	O
B	B	B000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
unifying	unifying	U515	JJ	I-NP	O
pathogenetic	pathogenetic	P325	JJ	I-NP	O
feature	feature	F360	NN	I-NP	O
in	in	I500	IN	B-PP	O
centrocytic	centrocytic	C536	JJ	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
juvenile	juvenile	J154	JJ	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
patient	patient	P353	NN	B-NP	O
.	.	0000	.	O	O

Fragments	Fragment	F625	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
juvenile	juvenile	J154	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
and	and	A530	CC	O	O
ligated	ligate	L230	VBN	B-VP	O
into	into	I530	IN	B-PP	O
MP13	MP13	M100	NN	B-NP	O
cloning	cloning	C452	NN	I-NP	O
vectors	vector	V236	NNS	I-NP	O
.	.	0000	.	O	O

Clones	Clone	C452	NNS	B-NP	O
hybridizing	hybridize	H163	VBG	B-VP	O
with	with	W300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
for	for	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
were	be	W600	VBD	B-VP	O
selected	select	S423	VBN	I-VP	O
,	,	0000	,	O	O
examined	examine	E253	VBN	B-VP	O
for	for	F600	IN	B-PP	O
appropriate	appropriate	A161	JJ	B-NP	O
size	size	S200	NN	I-NP	O
inserts	insert	I526	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
used	use	U230	VBN	B-VP	O
to	to	T000	TO	B-VP	O
prepare	prepare	P616	VB	I-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
stranded	stranded	S365	JJ	I-NP	O
phage	phage	P200	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

Examination	Examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	coding	C352	NN	I-NP	O
and	and	A530	CC	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
two	two	T000	CD	B-NP	O
putative	putative	P310	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
isoleucine	isoleucine	I242	NN	B-NP	O
by	by	B000	IN	B-PP	O
serine	serine	S650	NN	B-NP	O
.	.	0000	.	O	O

Introduction	Introduction	I536	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
alteration	alteration	A436	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
decrease	decrease	D262	NN	I-NP	O
in	in	I500	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
on	on	O500	IN	B-PP	O
transient	transient	T652	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
baby	baby	B100	NN	I-NP	O
hamster	hamster	H523	NN	I-NP	O
kidney	kidney	K350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

About	About	A130	RB	B-NP	O
5	5	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
control	control	C536	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
residual	residual	R234	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
,	,	0000	,	O	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
recognition	recognition	R253	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
between	between	B350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
following	following	F452	JJ	I-NP	O
intron	intron	I536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Apparently	Apparently	A165	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
were	be	W600	VBD	B-VP	O
generated	generate	G563	VBN	I-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
or	or	O600	CC	O	O
immuno	immuno	I500	AFX	O	O
-	-	0000	HYPH	B-NP	O
cross	cross	C620	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
reactive	reactive	R231	JJ	I-NP	O
material	material	M364	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
collection	collection	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
known	know	K500	VBN	B-NP	O
or	or	O600	CC	I-NP	O
suspected	suspect	S212	VBN	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
nearly	nearly	N640	RB	I-NP	O
100	100	0000	CD	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
segregation	segregation	S262	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
family	family	F540	NN	I-NP	O
was	be	W200	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
available	available	A141	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
either	either	E360	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
combinations	combination	C515	NNS	B-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
does	do	D200	VBZ	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
late	late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
following	follow	F452	VBG	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
produces	produce	P632	VBZ	B-VP	O
late	late	L300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
when	when	W500	WRB	B-ADVP	O
combined	combine	C515	VBN	B-VP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
null	null	N400	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
implying	imply	I514	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
completely	completely	C514	RB	B-ADJP	O
silent	silent	S453	JJ	I-ADJP	O
enzymatically	enzymatically	E525	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
and	and	A530	CC	O	O
presumptive	presumptive	P625	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
hematopoietic	hematopoietic	H531	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lineages	lineage	L520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
thrombocytopenic	thrombocytopenic	T651	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
female	female	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
thrombocytopenic	thrombocytopenic	T651	JJ	I-NP	B-Disease
female	female	F540	NN	I-NP	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
RFLP	RFLP	R141	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
with	with	W300	IN	B-PP	O
probe	probe	P610	NN	B-NP	O
M27	M27	M000	NN	I-NP	O
beta	beta	B300	NN	I-NP	O
,	,	0000	,	O	O
closely	closely	C424	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
she	she	S000	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
small	small	S540	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sized	sized	S230	JJ	I-NP	O
and	and	A530	CC	I-NP	O
normal	normal	N654	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
sized	size	S230	VBN	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
unlike	unlike	U542	IN	B-PP	O
the	the	T000	DT	B-NP	O
vast	vast	V230	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
she	she	S000	PRP	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
manifest	manifest	M512	VB	I-VP	O
nonrandom	nonrandom	N565	JJ	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
thrombopoietic	thrombopoietic	T651	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
lineage	lineage	L520	NN	I-NP	O
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
and	and	A530	CC	I-NP	O
methylation	methylation	M343	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
nonrandom	nonrandom	N565	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
T	T	T000	NN	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
random	random	R535	VBP	B-VP	O
in	in	I500	IN	B-PP	O
granulocytes	granulocyte	G654	NNS	B-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
complete	complete	C514	JJ	I-NP	O
report	report	R163	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
female	female	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
atypical	atypical	A312	JJ	B-NP	O
lyonization	lyonization	L523	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
extends	extend	E235	VBZ	B-VP	O
up	up	U100	RP	B-PRT	O
to	to	T000	TO	B-PP	O
)	)	0000	)	O	O
a	a	A000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
multipotent	multipotent	M431	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
hematopoietic	hematopoietic	H531	JJ	I-NP	O
differentiation	differentiation	D165	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
German	German	G650	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
German	German	G650	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
HphI	HphI	H100	NN	I-NP	O
site	site	S300	NN	I-NP	O
and	and	A530	CC	I-NP	O
changes	change	C520	NNS	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
155	155	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
threonine	threonine	T650	NN	B-NP	O
to	to	T000	TO	B-PP	O
isoleucine	isoleucine	I242	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
108	108	0000	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
5	5	0000	CD	B-NP	O
concordances	concordance	C526	NNS	I-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
discrepancy	discrepancy	D261	NN	I-NP	O
between	between	B350	IN	B-PP	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
and	and	A530	CC	O	O
those	those	T200	DT	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
by	by	B000	IN	B-PP	O
magnetic	magnetic	M253	JJ	B-NP	O
resonance	resonance	R252	NN	I-NP	O
imaging	imaging	I525	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
kinetic	kinetic	K532	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
a	a	A000	DT	B-NP	I-Disease
hepatic	hepatic	H132	JJ	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
phenylalanine	phenylalanine	P545	NN	B-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
while	while	W400	IN	B-SBAR	O
persistence	persistence	P623	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
gives	give	G120	VBZ	B-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
variant	variant	V653	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
delta	delta	D430	SYM	B-NP	O
194	194	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
markedly	markedly	M623	RB	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
affinity	affinity	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
for	for	F600	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
(	(	0000	(	O	O
Km	Km	K500	NN	B-NP	O
=	=	0000	SYM	B-VP	O
160	160	0000	CD	B-NP	O
nM	nM	N500	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
functional	functional	F523	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
responsibility	responsibility	R215	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
presents	present	P625	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
homology	homology	H542	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
hydroxylases	hydroxylas	H362	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
specificity	specificity	S121	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
for	for	F600	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
98	98	0000	CD	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
this	this	T200	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
study	study	S300	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
event	event	E153	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
occurred	occur	O263	VBD	B-VP	O
recently	recently	R253	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
background	background	B265	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
2	2	0000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Portugal	Portugal	P632	NNP	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
(	(	0000	(	O	O
mast	mast	M230	NN	B-NP	O
/	/	0000	SYM	O	O
stem	stem	S350	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
)	)	0000	)	O	O
protooncogene	protooncogene	P635	NN	B-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
piebaldism	piebaldism	P143	NN	I-NP	B-Disease
.	.	0000	.	O	O

Piebaldism	Piebaldism	P143	NNP	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cogenital	cogenital	C253	JJ	B-NP	O
patches	patch	P320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
skin	skin	S250	NN	B-NP	O
and	and	A530	CC	I-NP	O
hair	hair	H600	NN	I-NP	O
from	from	F650	IN	B-PP	O
which	which	W200	WDT	B-NP	O
melanocytes	melanocyte	M452	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
completely	completely	C514	RB	B-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
dominant	dominant	D530	JJ	B-NP	O
white	white	W300	JJ	I-NP	O
spotting	spotting	S135	NN	I-NP	O
(	(	0000	(	O	O
W	W	W000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
c	c	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Kit	Kit	K300	NN	I-NP	O
protooncogene	protooncogene	P635	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
and	and	A530	CC	O	O
receptor	receptor	R213	NN	B-NP	O
for	for	F600	IN	B-PP	O
mast	mast	M230	NN	B-NP	O
/	/	0000	SYM	I-NP	O
stem	stem	S350	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
piebaldism	piebaldism	P143	NN	I-NP	B-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Gly	Gly	G400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
Arg	Arg	A620	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
664	664	0000	CD	I-NP	O
,	,	0000	,	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
completely	completely	C514	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
piebald	piebald	P143	JJ	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Piebaldism	Piebaldism	P143	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
thus	thus	T200	RB	B-ADVP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
to	to	T000	TO	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
white	white	W300	JJ	I-NP	O
spotting	spotting	S135	NN	I-NP	O
(	(	0000	(	O	O
W	W	W000	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
normotriglyceridemic	normotriglyceridemic	N653	JJ	B-NP	B-Disease
abetalipoproteinemia	abetalipoproteinemia	A134	NN	I-NP	I-Disease
indicates	indicate	I532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
B	B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Normotriglyceridemic	Normotriglyceridemic	N653	JJ	B-NP	B-Disease
abetalipoproteinemia	abetalipoproteinemia	A134	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
apoB	apoB	A100	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
100	100	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
apoB	apoB	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
48	48	0000	CD	B-NP	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
100	100	0000	CD	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoB	apoB	A100	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
using	use	U252	VBG	B-VP	O
three	three	T600	CD	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
and	and	A530	CC	O	O
her	her	H600	PRP$	B-NP	O
affected	affect	A123	VBN	I-NP	O
brother	brother	B636	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
completely	completely	C514	RB	B-NP	O
different	different	D165	JJ	I-NP	O
apoB	apoB	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
itself	itself	I324	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
related	related	R430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
American	American	A562	JJ	I-NP	O
case	case	C200	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
generating	generate	G563	VBG	B-VP	O
an	an	A500	DT	B-ADVP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
defect	defect	D123	NN	B-NP	O
(	(	0000	(	O	O
s	s	S000	NNS	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	O	O
an	an	A500	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Localisation	Localisation	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
between	between	B350	IN	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS426	DXS426	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
Xp	Xp	X100	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
informative	informative	I516	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
DXS426	DXS426	D200	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
interval	interval	I536	JJ	I-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
Xp11	Xp11	X100	NN	I-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	O	O

23	23	0000	CD	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
refine	refine	R150	VB	I-VP	O
further	further	F636	RBR	B-ADVP	O
the	the	T000	DT	B-NP	O
localisation	localisation	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
NDP	NDP	N310	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
multiply	multiply	M431	JJ	I-NP	O
informative	informative	I516	JJ	I-NP	O
crossover	crossover	C621	NN	I-NP	O
localize	localize	L242	VBP	B-VP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
conjunction	conjunction	C525	NN	B-NP	O
with	with	W300	IN	B-PP	O
information	information	I516	NN	B-NP	O
from	from	F650	IN	B-PP	O
2	2	0000	CD	B-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
for	for	F600	IN	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
for	for	F600	IN	I-PP	O
DSX426	DSX426	D200	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
between	between	B350	IN	B-PP	O
DXS7	DXS7	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS426	DXS426	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
proximal	proximal	P625	JJ	B-NP	O
Xp	Xp	X100	NN	I-NP	O
.	.	0000	.	O	O

Aberrant	Aberrant	A165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
:	:	0000	:	O	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
for	for	F600	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
parts	part	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
aberrant	aberrant	A165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
tight	tight	T230	JJ	B-NP	O
association	association	A235	NN	I-NP	O
with	with	W300	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
6	6	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
36	36	0000	CD	B-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Bulgaria	Bulgaria	B426	NNP	B-NP	O
,	,	0000	,	O	O
Italy	Italy	I340	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Turkey	Turkey	T620	NNP	B-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
classical	classical	C424	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
546	546	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
10	10	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
11	11	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
10	10	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
boundary	boundary	B536	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
activates	activate	A231	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
and	and	A530	CC	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
between	between	B350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
10	10	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
processed	process	P623	VBN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

Normal	Normal	N654	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
PAH	PAH	P000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
conformational	conformational	C516	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
amino	amino	A500	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
Gly	Gly	G400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
Leu	Leu	L000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
Gln	Gln	G450	NN	I-NP	O
)	)	0000	)	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
10	10	0000	CD	I-NP	O
and	and	A530	CC	O	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Gardner	Gardner	G635	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
interstitial	interstitial	I536	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
described	describe	D261	VBD	B-VP	O
a	a	A000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
Gardner	Gardner	G635	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
GS	GS	G200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
craniofacial	craniofacial	C651	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

High	High	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
banding	banding	B535	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
q22	q22	Q000	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
q31	q31	Q000	NN	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
q31	q31	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
case	case	C200	NN	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
5q	5q	Q000	NN	I-NP	O
-	-	0000	SYM	O	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
GS	GS	G200	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
familial	familial	F540	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
FPC	FPC	F120	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5q22	5q22	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
childhood	childhood	C430	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	JJ	I-NP	O
Tourette	Tourette	T630	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
man	man	M500	NN	I-NP	O
with	with	W300	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
Tourette	Tourette	T630	NN	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
TS	TS	T200	NN	B-NP	B-Disease
)	)	0000	)	O	O
developed	develop	D141	VBD	B-VP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
believe	believe	B410	VBP	B-VP	O
this	this	T200	DT	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
reported	report	R163	VBN	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
TS	TS	T200	NN	I-NP	B-Disease
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
.	.	0000	.	O	O

Discovery	Discovery	D216	NNP	B-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
both	both	B300	DT	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
clues	clue	C420	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
pathophysiology	pathophysiology	P312	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
conditions	condition	C535	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
causing	cause	C252	VBG	B-VP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
requires	require	R262	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
capacity	capacity	C123	NN	I-NP	O
to	to	T000	TO	B-VP	O
readily	readily	R340	RB	I-VP	O
screen	screen	S265	VB	I-VP	O
the	the	T000	DT	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
most	most	M230	RBS	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
portions	portion	P635	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
introns	intron	I536	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
14	14	0000	CD	I-NP	O
HEXA	HEXA	H200	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
specify	specify	S121	VB	I-VP	O
oligonucleotide	oligonucleotide	O425	NN	B-NP	O
primers	primer	P656	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
and	and	A530	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
junction	junction	J523	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
electrophoresis	electrophoresis	E423	NN	B-NP	O
in	in	I500	IN	B-PP	O
nondenaturing	nondenaturing	N535	JJ	B-NP	O
polyacrylamide	polyacrylamide	P426	NN	I-NP	O
gels	gel	G420	NNS	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	DT	B-NP	O
heteroduplexes	heteroduplex	H363	NNS	I-NP	O
,	,	0000	,	O	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
annealing	annealing	A545	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
strands	strand	S365	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
renaturation	renaturation	R536	NN	I-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
stranded	stranded	S365	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
TCTCC	TCTCC	T232	NN	B-NP	O
in	in	I500	IN	B-PP	O
IVS	IVS	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
9	9	0000	CD	I-NP	O
;	;	0000	:	O	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
TG	TG	T200	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
;	;	0000	:	O	O
G78	G78	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
,	,	0000	,	O	O
giving	give	G152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
;	;	0000	:	O	O
G533	G533	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
producing	produce	P632	VBG	B-VP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
at	at	A300	IN	B-PP	O
this	this	T200	DT	B-NP	O
site	site	S300	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
C	C	C000	NN	B-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
IVS	IVS	I120	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	O	O
expected	expect	E212	VBN	B-VP	O
to	to	T000	TO	I-VP	O
produce	produce	P632	VB	I-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	O	O
G1496	G1496	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
:	:	0000	:	O	O
correlation	correlation	C643	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
with	with	W300	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
conserved	conserved	C526	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
galactose	galactose	G423	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyl	uridyl	U634	NN	I-NP	O
transferase	transferase	T652	NN	I-NP	O
.	.	0000	.	O	O

Galactosemia	Galactosemia	G423	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
human	human	H500	JJ	B-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
uridyl	uridyl	U634	NN	I-NP	I-Disease
transferase	transferase	T652	NN	I-NP	I-Disease
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
present	present	P625	JJ	B-ADJP	O
not	not	N300	RB	O	O
well	well	W400	RB	B-VP	O
understood	understand	U536	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
low	low	L000	JJ	B-NP	O
or	or	O600	CC	I-NP	O
undetectable	undetectable	U532	JJ	I-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

First	First	F623	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
591	591	0000	CD	I-NP	O
a	a	A000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
which	which	W200	WDT	B-NP	O
substitutes	substitute	S123	VBZ	B-VP	O
glutamine	glutamine	G435	NN	B-NP	O
188	188	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
glutamine	glutamine	G435	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	B-VP	O
only	only	O540	RB	I-VP	O
highly	highly	H240	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
evolution	evolution	E143	NN	B-NP	O
(	(	0000	(	O	O
conserved	conserve	C526	VBN	B-VP	O
also	also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
Escherichia	Escherichia	E262	NNP	B-NP	O
coli	coli	C400	NNP	I-NP	O
and	and	A530	CC	O	O
Saccharomyces	Saccharomyces	S265	NNP	B-NP	O
cerevisiae	cerevisiae	C612	NNP	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
two	two	T000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
residues	residue	R232	NNS	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
active	active	A231	JJ	I-NP	O
site	site	S300	NN	I-NP	O
histidine	histidine	H235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
proline	proline	P645	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
histidine	histidine	H235	NN	I-NP	O
triad	triad	T630	NN	I-NP	O
and	and	A530	CC	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
about	about	A130	RB	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
188	188	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
fourth	fourth	F630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

Second	Second	S253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
333	333	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
tryptophan	tryptophan	T613	NN	B-NP	O
,	,	0000	,	O	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1025	1025	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
area	area	A600	NN	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
this	this	T200	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
domain	domain	D500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
from	from	F650	IN	B-PP	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
coli	coli	C400	NN	B-NP	O
,	,	0000	,	O	O
yeast	yeast	Y230	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
undetectable	undetectable	U532	JJ	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
rare	rare	R600	JJ	B-ADJP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
only	only	O540	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
we	we	W000	PRP	B-NP	O
sequenced	sequence	S252	VBD	B-VP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
level	level	L140	NN	I-NP	O
,	,	0000	,	O	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
which	which	W200	WDT	B-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
related	related	R430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hypoxanthine	Hypoxanthine	H125	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
guanine	guanine	G500	NN	I-NP	I-Disease
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
and	and	A530	CC	I-NP	O
allele	allele	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
chromosome	chromosome	C652	NN	I-NP	I-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
virtual	virtual	V634	JJ	I-NP	O
absence	absence	A125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hypoxanthine	hypoxanthine	H125	NN	B-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
guanine	guanine	G500	NN	B-NP	I-Disease
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
HPRT	HPRT	H163	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
activity	activity	A231	NN	B-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
can	can	C500	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
gouty	gouty	G300	NN	B-NP	B-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
reduction	reduction	R323	NN	B-NP	O
or	or	O600	CC	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
HPRTPerth	HPRTPerth	H163	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
with	with	W300	IN	B-PP	O
partial	partial	P634	JJ	B-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
HPRT	HPRT	H163	NN	B-NP	I-Disease
activity	activity	A231	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
designated	designate	D253	VBN	I-VP	O
HPRTUrangan	HPRTUrangan	H163	NNP	B-NP	O
,	,	0000	,	O	O
HPRTSwan	HPRTSwan	H163	NNP	B-NP	O
and	and	A530	CC	O	O
HPRTToowong	HPRTToowong	H163	NNP	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
2	2	0000	CD	B-NP	O
or	or	O600	CC	I-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
case	case	C200	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
translated	translate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
base	base	B200	NN	I-NP	O
change	change	C520	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
interesting	interesting	I536	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
note	note	N300	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
found	find	F530	VBN	B-VP	O
for	for	F600	IN	B-PP	O
HPRTPerth	HPRTPerth	H163	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
reported	report	R163	VBN	B-VP	O
for	for	F600	IN	B-PP	O
HPRTFlint	HPRTFlint	H163	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
events	event	E153	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
and	and	A530	CC	I-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
normotriglyceridemic	normotriglyceridemic	N653	JJ	I-NP	B-Disease
abetalipoproteinemia	abetalipoproteinemia	A134	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
,	,	0000	,	O	O
normotriglyceridemic	normotriglyceridemic	N653	JJ	B-NP	B-Disease
abetalipoproteinemia	abetalipoproteinemia	A134	NN	I-NP	I-Disease
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
virtual	virtual	V634	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
low	low	L000	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
and	and	A530	CC	O	O
complete	complete	C514	JJ	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoB	apoB	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
100	100	0000	CD	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
with	with	W300	IN	B-PP	O
apparently	apparently	A165	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
secretion	secretion	S263	NN	I-NP	O
of	of	O100	IN	B-PP	O
triglyceride	triglyceride	T624	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
apoB	apoB	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
48	48	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
plasma	plasma	P425	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
on	on	O500	IN	B-PP	O
polyacrylamide	polyacrylamide	P426	NN	B-NP	O
gels	gel	G420	NNS	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
antibody	antibody	A531	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
truncated	truncate	T652	VBN	I-NP	O
apoB	apoB	A100	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
apoB	apoB	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
50	50	0000	CD	I-NP	O
,	,	0000	,	O	O
circulating	circulate	C624	VBG	B-VP	O
along	along	A452	IN	B-ADVP	O
with	with	W300	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
apoB	apoB	A100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
48	48	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
this	this	T200	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
apoB	apoB	A100	NN	B-NP	O
codon	codon	C350	NN	I-NP	O
2252	2252	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	B-Disease
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	I-Disease
.	.	0000	.	O	O

Electron	Electron	E423	NN	B-NP	O
photomicrographs	photomicrograph	P352	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
diameters	diameter	D536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
particles	particle	P632	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
d	d	D000	NN	I-NP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

006	006	0000	CD	B-NP	O
g	g	G000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
the	the	T000	DT	I-NP	O
postprandial	postprandial	P231	JJ	I-NP	O
and	and	A530	CC	I-NP	O
postabsorptive	postabsorptive	P231	JJ	I-NP	O
state	state	S300	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
bimodally	bimodally	B534	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molar	molar	M460	JJ	I-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoE	apoE	A100	NN	B-NP	O
to	to	T000	TO	B-PP	O
apoB	apoB	A100	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
particles	particle	P632	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
VLDL	VLDL	V434	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
LDL	LDL	L340	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
both	both	B300	CC	O	O
spherical	spherical	S162	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cuboidal	cuboidal	C134	JJ	I-NP	O
particles	particle	P632	NNS	I-NP	O
.	.	0000	.	O	O

Autologous	Autologous	A342	JJ	B-NP	O
reinfusion	reinfusion	R512	NN	I-NP	O
of	of	O100	IN	B-PP	O
labeled	label	L143	VBN	B-NP	O
d	d	D000	NN	I-NP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

006	006	0000	CD	B-NP	O
g	g	G000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
exponential	exponential	E215	JJ	B-NP	O
disappearance	disappearance	D216	NN	I-NP	O
from	from	F650	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
removal	removal	R514	NN	I-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
min	min	M500	NN	I-NP	O
,	,	0000	,	O	O
somewhat	somewhat	S530	RB	B-ADJP	O
slower	slow	S460	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
chylomicrons	chylomicron	C452	NNS	I-NP	O
but	but	B300	CC	B-PP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
for	for	F600	IN	B-PP	O
VLDL	VLDL	V434	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
calculated	calculate	C424	VBN	I-NP	O
production	production	P632	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
for	for	F600	IN	B-PP	O
apoB	apoB	A100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Yemenite	Yemenite	Y530	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
recessive	recessive	R210	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
varies	vary	V620	VBZ	B-VP	O
widely	widely	W340	RB	B-ADVP	O
across	across	A262	IN	B-PP	O
different	different	D165	JJ	B-NP	O
geographic	geographic	G261	JJ	I-NP	O
areas	area	A620	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
highest	high	H230	JJS	B-ADJP	O
(	(	0000	(	O	O
about	about	A130	RB	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
5	5	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
live	live	L100	JJ	I-NP	O
births	birth	B632	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Ireland	Ireland	I645	NNP	B-NP	O
and	and	A530	CC	O	O
western	western	W236	JJ	B-NP	O
Scotland	Scotland	S234	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
among	among	A520	IN	B-PP	O
Yemenite	Yemenite	Y530	NNP	B-NP	O
Jews	Jew	J200	NNPS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
limited	limited	L530	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
European	European	E615	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	:	O	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
Yemenite	Yemenite	Y530	NNP	I-NP	O
Jews	Jew	J200	NNPS	I-NP	O
.	.	0000	.	O	O

Examination	Examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
random	random	R535	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
Yemenite	Yemenite	Y530	NN	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
probe	probe	P610	NN	I-NP	O
that	that	T300	WDT	B-NP	O
detects	detect	D323	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
defective	defective	D123	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
community	community	C530	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
traced	trace	T623	VBN	I-VP	O
to	to	T000	TO	B-PP	O
25	25	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
locations	location	L235	NNS	I-NP	O
throughout	throughout	T623	IN	B-PP	O
Yemen	Yemen	Y500	NN	B-NP	O
,	,	0000	,	O	O
family	family	F540	NN	B-NP	O
histories	history	H236	NNS	I-NP	O
and	and	A530	CC	O	O
official	official	O124	JJ	B-NP	O
documents	document	D253	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Yemenite	Yemenite	Y530	NN	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
community	community	C530	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
lived	live	L130	VBD	B-VP	O
in	in	I500	IN	B-PP	O
Sana	Sana	S500	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
capital	capital	C134	NN	I-NP	O
of	of	O100	IN	B-PP	O
Yemen	Yeman	Y500	NNS	B-NP	O
,	,	0000	,	O	O
before	before	B160	IN	B-PP	O
the	the	T000	DT	B-NP	O
eighteenth	eighteenth	E235	JJ	I-NP	O
century	century	C536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
aspartylglucosaminuria	aspartylglucosaminuria	A216	NN	B-NP	B-Disease
(	(	0000	(	O	O
AGU	AGU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
marker	marker	M626	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

Aspartylglucosaminuria	Aspartylglucosaminuria	A216	NN	B-NP	B-Disease
(	(	0000	(	O	O
AGU	AGU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
aspartylglucosaminidase	aspartylglucosaminidase	A216	NN	I-NP	O
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
4q21	4q21	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
qter	qter	Q360	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
the	the	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AGU	AGU	A200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
relation	relation	R435	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
marker	marker	M626	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4	4	0000	CD	I-NP	O
using	use	U252	VBG	B-VP	O
linkage	linkage	L520	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
ADH2	ADH2	A300	NN	I-NP	O
,	,	0000	,	O	O
ADH3	ADH3	A300	NN	B-NP	O
,	,	0000	,	O	O
EGF	EGF	E210	NN	B-NP	O
,	,	0000	,	O	O
FG	FG	F200	NN	B-NP	O
alpha	alpha	A410	NN	I-NP	O
and	and	A530	CC	O	O
FG	FG	F200	NN	B-NP	O
beta	beta	B300	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
and	and	A530	CC	O	O
blood	blood	B430	NN	B-NP	O
group	group	G610	NN	I-NP	O
antigens	antigen	A532	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
MNS	MNS	M520	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
AGU	AGU	A200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
AGA	AGA	A200	NN	B-NP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
both	both	B300	CC	O	O
pairwise	pairwise	P620	JJ	B-NP	O
and	and	A530	CC	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

Loose	Loose	L200	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AGU	AGU	A200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
FG	FG	F200	NN	I-NP	O
and	and	A530	CC	I-NP	O
MNS	MNS	M520	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
(	(	0000	(	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
16	16	0000	CD	B-NP	O
,	,	0000	,	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Multipoint	Multipoint	M431	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
fixed	fix	F230	VBN	I-NP	O
map	map	M100	NN	I-NP	O
[	[	0000	(	O	O
ADH	ADH	A300	NN	B-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
EGF	EGF	E210	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
35	35	0000	CD	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
FG	FG	F200	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
(	(	0000	(	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
11	11	0000	CD	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
MNS	MNS	M520	NN	I-NP	O
]	]	0000	)	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AGU	AGU	A200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

30	30	0000	CD	B-NP	O
recombination	recombination	R251	NN	I-NP	O
units	unit	U532	NNS	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
MNS	MNS	M520	NN	B-NP	O
(	(	0000	(	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
cen	cen	C500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ADH	ADH	A300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
EGF	EGF	E210	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FG	FG	F200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
MNS	MNS	M520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AGU	AGU	A200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
35	35	0000	CD	B-NP	O
times	time	T520	NNS	I-NP	O
more	more	M600	RBR	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
next	next	N230	JJ	I-NP	O
best	good	B230	JJS	I-NP	O
order	order	O636	NN	I-NP	O
cen	cen	C500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ADH	ADH	A300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
EGF	EGF	E210	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AGU	AGU	A200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FG	FG	F200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
MNS	MNS	M520	NN	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
relationships	relationship	R435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
C1	C1	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
cytochrome	cytochrome	C326	NN	I-NP	O
P450	P450	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP2A	CYP2A	C100	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
C1	C1	C000	NN	I-NP	O
(	(	0000	(	O	O
APOC1	APOC1	A120	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
cytochrome	cytochrome	C326	NN	I-NP	O
P450	P450	P000	NN	I-NP	O
(	(	0000	(	O	O
CYP2A	CYP2A	C100	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
relation	relation	R435	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
peak	peak	P200	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O

29	29	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
2	2	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
for	for	F600	IN	B-PP	O
APOC1	APOC1	A120	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
DM	DM	D500	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
.	.	0000	.	O	O

55	55	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
4	4	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
for	for	F600	IN	B-PP	O
CYP2A	CYP2A	C100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
DM	DM	D500	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
close	close	C420	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
each	each	E200	DT	B-NP	O
other	other	O360	JJ	I-NP	O
(	(	0000	(	O	O
theta	theta	T300	SYM	O	O
max	max	M200	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
,	,	0000	,	O	O
Zmax	Zmax	Z520	NN	B-NP	O
=	=	0000	SYM	B-VP	O
9	9	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
09	09	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
examination	examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
CYP2A	CYP2A	C100	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
map	map	M100	VB	I-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DM	DM	D500	NN	B-NP	O
because	because	B200	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
individual	individual	I531	JJ	I-NP	O
CYP2A	CYP2A	C100	NN	I-NP	O
,	,	0000	,	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
and	and	A530	CC	I-NP	O
CKMM	CKMM	C250	NN	I-NP	O
had	have	H300	VBD	B-VP	O
all	all	A400	DT	O	O
recombined	recombine	R251	VBN	B-VP	O
with	with	W300	IN	B-PP	O
DM	DM	D500	NN	B-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
from	from	F650	IN	B-PP	O
another	another	A536	DT	B-NP	O
CYP2A	CYP2A	C100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DM	DM	D500	NN	I-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
individual	individual	I531	JJ	I-NP	O
places	place	P420	NNS	I-NP	O
CYP2A	CYP2A	C100	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
and	and	A530	CC	I-NP	O
CKMM	CKMM	C250	NN	I-NP	O
.	.	0000	.	O	O

Localisation	Localisation	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
CYP2A	CYP2A	C100	NN	B-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DM	DM	D500	NN	B-NP	O
and	and	A530	CC	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
/	/	0000	SYM	B-NP	O
C1	C1	C000	NN	I-NP	O
/	/	0000	SYM	I-NP	O
E	E	E000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
close	close	C420	RB	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	O
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5q	5q	Q000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
hundred	hundred	H536	CD	I-NP	O
fifty	fifty	F130	CD	I-NP	O
-	-	0000	HYPH	O	O
five	five	F100	CD	B-NP	O
typed	type	T130	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
kindred	kindred	K536	NN	I-NP	O
provided	provide	P613	VBD	B-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
90	90	0000	CD	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
crucial	crucial	C624	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
events	event	E153	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
informative	informative	I516	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
three	three	T600	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
loci	locus	L200	NNS	I-NP	O
,	,	0000	,	O	O
allowing	allow	A452	VBG	B-VP	O
confident	confident	C513	JJ	B-NP	O
ordering	ordering	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
parts	part	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
all	all	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
showing	show	S520	VBG	B-VP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	B-NP	O
marker	marker	M626	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Recombination	Recombination	R251	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
support	support	S163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
centromere	centromere	C536	NN	B-NP	O
-	-	0000	HYPH	O	O
pi	pi	P000	SYM	B-NP	O
227	227	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C11P11	C11P11	C100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ECB27	ECB27	E210	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
L5	L5	L000	NN	I-NP	O
.	.	0000	.	O	O

62	62	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
APC	APC	A120	NN	I-NP	O
-	-	0000	HYPH	O	O
EF5	EF5	E100	NN	B-NP	O
62	62	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
APC	APC	A120	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
EF5	EF5	E100	NN	I-NP	O
.	.	0000	.	O	O

44	44	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
YN5	YN5	Y500	NN	B-NP	O
44	44	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
YN5	YN5	Y500	NN	I-NP	O
.	.	0000	.	O	O

48	48	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
telomer	telomer	T456	NN	I-NP	O
e	e	E000	NN	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
EF5	EF5	E100	NN	B-NP	O
.	.	0000	.	O	O

44	44	0000	CD	B-NP	O
could	could	C430	MD	B-VP	O
lie	lie	L000	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
interval	interval	I536	JJ	I-NP	O
L5	L5	L000	NN	I-NP	O
.	.	0000	.	O	O

62	62	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
APC	APC	A120	NN	I-NP	O
or	or	O600	CC	I-NP	O
ECB27	ECB27	E210	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
L5	L5	L000	NN	I-NP	O
.	.	0000	.	O	O

62	62	0000	CD	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
between	between	B350	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
and	and	A530	CC	O	O
either	either	E360	DT	B-NP	O
EF5	EF5	E100	NN	I-NP	O
.	.	0000	.	O	O

44	44	0000	CD	B-NP	O
or	or	O600	CC	O	O
YN5	YN5	Y500	NN	B-NP	O
.	.	0000	.	O	O

48	48	0000	CD	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
published	publish	P142	VBN	B-NP	O
deletion	deletion	D435	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
YN5	YN5	Y500	NN	B-NP	O
.	.	0000	.	O	O

48	48	0000	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
3	3	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
from	from	F650	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
YN5	YN5	Y500	NN	B-NP	O
.	.	0000	.	O	O

48	48	0000	CD	B-NP	O
and	and	A530	CC	O	O
L5	L5	L000	NN	B-NP	O
.	.	0000	.	O	O

62	62	0000	CD	B-NP	O
delineate	delineate	D453	VBP	B-VP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
within	within	W350	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
EF5	EF5	E100	NN	I-NP	O
.	.	0000	.	O	O

44	44	0000	CD	B-NP	O
locus	locus	L200	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
very	very	V600	RB	B-ADJP	O
close	close	C420	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	B-VP	O
allow	allow	A400	VB	I-VP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
flanking	flanking	F452	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
for	for	F600	IN	B-PP	O
presymptomatic	presymptomatic	P625	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
for	for	F600	IN	B-PP	O
isolation	isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
itself	itself	I324	PRP	B-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
further	further	F636	JJ	B-NP	O
assessment	assessment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
biology	biology	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Serum	Serum	S650	NN	B-NP	O
amyloid	amyloid	A543	NN	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
P	P	P000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
recent	recent	R253	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
amyloid	amyloid	A543	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
SAA	SAA	S000	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
P	P	P000	NN	B-NP	O
(	(	0000	(	O	O
APCS	APCS	A120	NN	B-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
MEF	MEF	M100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
SAA	SAA	S000	NN	B-NP	O
and	and	A530	CC	I-NP	O
APCS	APCS	A120	NN	I-NP	O
in	in	I500	IN	B-PP	O
MEF	MEF	M100	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
amyloidosis	amyloidosis	A543	NN	B-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
17	17	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
Armenians	Armenian	A652	NNPS	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jews	Jew	J200	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
8	8	0000	CD	B-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
amyloidosis	amyloidosis	A543	NN	B-NP	B-Disease
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
approach	approach	A162	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
any	any	A500	DT	B-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
41	41	0000	CD	I-NP	O
Armenian	Armenian	A650	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
family	family	F540	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
allowed	allow	A430	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
rule	rule	R400	VB	I-VP	O
out	out	O300	RP	B-PRT	O
tight	tight	T230	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
SAA	SAA	S000	NN	B-NP	O
and	and	A530	CC	O	O
MEF	MEF	M100	NN	B-NP	B-Disease
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
score	score	S260	NN	I-NP	O
=	=	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
16	16	0000	CD	I-NP	O
,	,	0000	,	O	O
theta	theta	T300	DT	O	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
or	or	O600	CC	O	O
equal	equal	E240	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
06	06	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
APCS	APCS	A120	NN	B-NP	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
amyloidosis	amyloidosis	A543	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
18	18	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
MEF	MEF	M100	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
without	without	W300	IN	B-PP	O
amyloidosis	amyloidosis	A543	NN	B-NP	B-Disease
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
33	33	0000	CD	I-NP	O
healthy	healthy	H430	JJ	I-NP	O
parents	parent	P653	NNS	I-NP	O
.	.	0000	.	O	O

Some	Some	S500	DT	B-NP	O
Mexican	Mexican	M250	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
revisited	revisit	R123	VBN	B-VP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
fairly	fairly	F640	RB	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
Mexico	Mexico	M200	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
electrophoretically	electrophoretically	E423	RB	I-NP	O
fast	fast	F230	RB	I-NP	O
Mexican	Mexican	M250	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
-	-	0000	HYPH	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
Distrito	Distrito	D236	NNP	I-NP	O
Federal	Federal	F364	NNP	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Tepic	Tepic	T120	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Castilla	Castilla	C234	NNP	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
believed	believe	B413	VBN	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
and	and	A530	CC	I-NP	O
population	population	P143	NN	I-NP	O
origin	origin	O625	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
unique	unique	U520	JJ	B-ADJP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
202	202	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
G	G	G000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
376	376	0000	CD	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
that	that	T300	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
recognize	recognize	R252	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
Mexican	Mexican	M250	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
five	five	F100	CD	I-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	I-NP	O
NlaIII	NlaIII	N400	NN	I-NP	O
/	/	0000	SYM	I-NP	O
FokI	FokI	F200	NN	I-NP	O
/	/	0000	SYM	I-NP	O
PvuII	PvuII	P100	NN	I-NP	O
/	/	0000	SYM	B-NP	O
PstI	PstI	P230	NN	I-NP	O
)	)	0000	)	O	O
haplotype	haplotype	H143	NN	B-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
in	in	I500	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PvuII	PvuII	P100	NN	I-NP	O
+	+	0000	SYM	B-NP	O
genotype	genotype	G531	NN	I-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
rare	rare	R600	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
genes	gene	G520	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
their	their	T600	PRP$	B-NP	O
ancient	ancient	A525	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Mexican	Mexican	M250	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
202A	202A	A000	NN	I-NP	O
/	/	0000	SYM	I-NP	O
376G	376G	G000	NN	I-NP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
imported	import	I516	VBN	I-VP	O
more	more	M600	RBR	B-ADVP	O
recently	recently	R253	RB	I-ADVP	O
from	from	F650	IN	B-PP	O
Spain	Spain	S150	NNP	B-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
this	this	T200	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
formerly	formerly	F656	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
G6PD	G6PD	G130	NNP	B-NP	O
Betica	Betica	B320	NNP	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
prevalent	prevalent	P614	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
discoid	discoid	D230	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
29	29	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
discoid	discoid	D230	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-NP	O
classic	classic	C420	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
complement	complement	C514	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Hypocomplementemia	Hypocomplementemia	H125	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
selective	selective	S423	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
children	child	C436	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
deficient	deficient	D125	JJ	B-ADJP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
documented	document	D253	VBN	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
discoid	discoid	D230	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
and	and	A530	CC	O	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Founder	Founder	F536	NN	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Oriental	Oriental	O653	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
[	[	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
;	;	0000	:	O	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
monooxygenase	monooxygenase	M525	NN	I-NP	O
;	;	0000	:	O	O
L	L	L000	NN	B-NP	O
-	-	0000	HYPH	O	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
,	,	0000	,	O	O
tetrahydrobiopterin	tetrahydrobiopterin	T363	NN	B-NP	O
oxygen	oxygen	O250	NN	I-NP	O
oxidoreductase	oxidoreductase	O236	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
hydroxylating	hydroxylate	H362	VBG	B-VP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
EC	EC	E200	NNP	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
]	]	0000	)	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
base	base	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
413	413	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pro413	Pro413	P600	NN	B-NP	O
for	for	F600	IN	B-PP	O
Arg413	Arg413	A620	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
R413P	R413P	R100	NN	B-NP	O
)	)	0000	)	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
negligible	negligible	N242	JJ	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
heterologous	heterologous	H364	JJ	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
classic	classic	C420	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Population	Population	P143	NN	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
reveal	reveal	R140	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
tightly	tightly	T234	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
restriction	restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
predominant	predominant	P635	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Oriental	Oriental	O653	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
13	13	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
and	and	A530	CC	I-NP	O
27	27	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
unambiguously	unambiguously	U512	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
after	after	A136	IN	B-PP	O
racial	racial	R240	JJ	B-NP	O
divergence	divergence	D162	NN	I-NP	O
of	of	O100	IN	B-PP	O
Orientals	Oriental	O653	NNPS	B-NP	O
and	and	A530	CC	I-NP	O
Caucasians	Caucasian	C252	NNPS	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
spread	spread	S163	VBN	I-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
Orient	Orient	O653	NNP	I-NP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
eastern	eastern	E236	JJ	B-NP	O
Asia	Asia	A200	NNP	I-NP	O
have	have	H100	VBP	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
"	"	0000	``	O	O
northern	northern	N636	JJ	B-NP	O
Mongoloids	Mongoloid	M524	NNS	I-NP	O
"	"	0000	''	O	O
represented	represent	R162	VBD	B-VP	O
a	a	A000	DT	B-NP	O
founding	founding	F535	JJ	I-NP	O
population	population	P143	NN	I-NP	O
in	in	I500	IN	B-PP	O
Asia	Asia	A200	NNP	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
in	in	I500	IN	B-PP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
might	might	M230	MD	B-VP	O
have	have	H100	VB	I-VP	O
occurred	occur	O263	VBD	I-VP	O
in	in	I500	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
Mongoloids	Mongoloid	M524	NNS	I-NP	O
and	and	A530	CC	O	O
subsequently	subsequently	S125	RB	B-VP	O
spread	spread	S163	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
/	/	0000	SYM	I-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
/	/	0000	SYM	O	I-Disease
galactose	galactose	G423	NN	B-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
(	(	0000	(	O	O
GGM	GGM	G250	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
manifesting	manifest	M512	VBG	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
weeks	week	W200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
life	life	L100	NN	B-NP	O
and	and	A530	CC	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
failure	failure	F460	NN	I-NP	O
to	to	T000	TO	B-VP	O
absorb	absorb	A126	VB	I-VP	O
dietary	dietary	D360	JJ	B-NP	O
glucose	glucose	G420	NN	I-NP	O
and	and	A530	CC	I-NP	O
galactose	galactose	G423	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
intestine	intestine	I532	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
consequent	consequent	C525	JJ	I-NP	O
severe	severe	S160	JJ	I-NP	O
diarrhoea	diarrhoea	D600	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
dehydration	dehydration	D363	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
usually	usually	U240	RB	B-ADVP	O
fatal	fatal	F340	JJ	B-ADJP	O
unless	unless	U542	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
sugars	sugar	S262	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
eliminated	eliminate	E453	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
diet	diet	D300	NN	I-NP	O
.	.	0000	.	O	O

Intestinal	Intestinal	I532	JJ	B-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
GGM	GGM	G250	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
Na	Na	N000	NN	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
absorption	absorption	A126	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brush	brush	B620	JJ	I-NP	O
border	border	B636	NN	I-NP	O
.	.	0000	.	O	O

Normal	Normal	N654	JJ	B-NP	O
glucose	glucose	G420	NN	I-NP	O
absorption	absorption	A126	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mediated	mediate	M300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brush	brush	B620	JJ	I-NP	O
border	border	B636	NN	I-NP	O
membrane	membrane	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
epithelium	epithelium	E134	NN	I-NP	O
.	.	0000	.	O	O

Cellular	Cellular	C460	JJ	B-NP	O
influx	influx	I514	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
driven	drive	D615	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	B-VP	O
electrochemical	electrochemical	E423	JJ	B-NP	O
potential	potential	P353	JJ	I-NP	O
gradient	gradient	G635	NN	I-NP	O
;	;	0000	:	O	O
thereafter	thereafter	T613	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
sugar	sugar	S260	NN	I-NP	O
moves	move	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
blood	blood	B430	NN	I-NP	O
across	across	A262	IN	B-PP	O
the	the	T000	DT	B-NP	O
basolateral	basolateral	B243	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
via	via	V000	IN	B-PP	O
the	the	T000	DT	B-NP	O
facilitated	facilitate	F243	VBN	I-NP	O
glucose	glucose	G420	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
a	a	A000	DT	B-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
from	from	F650	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
ileum	ileum	I450	NN	I-NP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
SGLT1	SGLT1	S243	NN	B-NP	O
,	,	0000	,	O	O
resides	reside	R232	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
q	q	Q000	NN	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22	22	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
amplified	amplify	A514	VBN	I-VP	O
SGLT1	SGLT1	S243	NN	B-NP	O
complementary	complementary	C514	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
GGM	GGM	G250	NN	B-NP	B-Disease
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
SGLT1	SGLT1	S243	NN	B-NP	O
which	which	W200	WDT	B-NP	O
cosegregates	cosegregate	C262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
GGM	GGM	G250	NNP	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Na	Na	N000	NN	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
Xenopus	Xenopus	X512	NNP	B-NP	O
oocytes	oocyte	O232	NNS	I-NP	O
injected	inject	I523	VBN	B-VP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
complementary	complementary	C514	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
unbalanced	unbalanced	U514	JJ	I-NP	O
reciprocal	reciprocal	R216	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
as	as	A200	IN	B-PP	O
paternal	paternal	P365	NN	B-NP	O
in	in	I500	IN	B-PP	O
origin	origin	O625	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Interstitial	Interstitial	I536	JJ	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
paternally	paternally	P365	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
unbalanced	unbalanced	U514	JJ	I-NP	O
karyotype	karyotype	K631	NN	I-NP	O
-	-	0000	HYPH	O	O
45	45	0000	CD	B-NP	O
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
,	,	0000	,	O	O
-	-	0000	HYPH	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
-	-	0000	HYPH	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
+	+	0000	CC	O	O
der	der	D600	NN	B-NP	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
)	)	0000	)	O	O
t	t	T000	NN	B-NP	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
;	;	0000	:	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q34	q34	Q000	NN	B-NP	O
;	;	0000	:	O	O
q13	q13	Q000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
pML34	pML34	P540	NN	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
single	single	S524	JJ	I-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
PWCR	PWCR	P260	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q12	q12	Q000	NN	I-NP	O
)	)	0000	)	O	O
copy	copy	C100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O

Hybridisation	Hybridisation	H163	NN	B-NP	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
and	and	A530	CC	O	O
parental	parental	P653	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
multi	multi	M430	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
probe	probe	P610	NN	I-NP	O
CMW1	CMW1	C500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
pter	pter	P360	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
15q13	15q13	Q000	CD	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
paternal	paternal	P365	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
origin	origin	O625	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
paternally	paternally	P365	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
derived	derive	D613	VBN	I-NP	O
PWCR	PWCR	P260	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
unbalanced	unbalanced	U514	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
arisen	arise	A625	VBN	I-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
.	.	0000	.	O	O

Localisation	Localisation	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
to	to	T000	TO	B-PP	O
19q13	19q13	Q000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
-	-	0000	:	O	O
19q13	19q13	Q000	CD	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
relationship	relationship	R435	NN	I-NP	O
to	to	T000	TO	B-VP	O
twelve	twelve	T410	VB	I-VP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
on	on	O500	IN	B-PP	O
19q	19q	Q000	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
fourteen	fourteen	F635	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
localised	localise	L242	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
19	19	0000	CD	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
established	establish	E231	VBN	I-VP	O
by	by	B000	IN	B-PP	O
multipoint	multipoint	M431	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
40	40	0000	CD	B-NP	O
CEPH	CEPH	C100	NN	I-NP	O
(	(	0000	(	O	O
Centre	Centre	C536	NNP	B-NP	O
dEtude	dEtude	D300	NNP	I-NP	O
de	de	D000	IN	I-NP	O
Polymorphisme	Polymorphisme	P456	NNP	I-NP	O
Humain	Humain	H500	NNP	I-NP	O
,	,	0000	,	O	O
Paris	Paris	P620	NNP	B-NP	O
)	)	0000	)	O	O
reference	reference	R165	NN	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
to	to	T000	TO	B-VP	O
twelve	twelve	T410	VB	I-VP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
studied	study	S300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
45	45	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
map	map	M100	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
supported	support	S163	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
localisation	localisation	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
.	.	0000	.	O	O

Ten	Ten	T500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
twelve	twelve	T410	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
,	,	0000	,	O	O
PRKCG	PRKCG	P620	NN	B-NP	O
and	and	A530	CC	I-NP	O
D19S22	D19S22	D200	NN	I-NP	O
,	,	0000	,	O	O
distal	distal	D234	JJ	B-ADJP	O
but	but	B300	CC	B-PP	O
at	at	A300	IN	B-PP	O
distances	distance	D235	NNS	B-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
25	25	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
closest	close	C423	JJS	I-NP	O
proximal	proximal	P625	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
APOC2	APOC2	A120	NN	B-NP	O
(	(	0000	(	O	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
CKM	CKM	C250	NN	B-NP	O
(	(	0000	(	O	O
creatine	creatine	C635	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
,	,	0000	,	O	O
muscle	muscle	M240	NN	B-NP	O
)	)	0000	)	O	O
approximately	approximately	A162	RB	B-NP	O
3	3	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
cM	cM	C500	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CKM	CKM	C250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DM	DM	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
distance	distance	D235	NN	I-NP	O
between	between	B350	IN	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
,	,	0000	,	I-NP	O
CKM	CKM	C250	NN	I-NP	O
and	and	A530	CC	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
(	(	0000	(	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
million	million	M450	CD	I-NP	O
base	base	B200	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
known	know	K500	VBN	I-NP	O
orientation	orientation	O653	NN	I-NP	O
should	should	S430	MD	B-VP	O
permit	permit	P653	VB	I-VP	O
directional	directional	D623	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
walking	walking	W425	NN	I-NP	O
and	and	A530	CC	I-NP	O
jumping	jumping	J515	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
should	should	S430	MD	B-VP	O
enable	enable	E514	VB	I-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
or	or	O600	CC	O	O
not	not	N300	RB	O	O
new	new	N000	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
/	/	0000	SYM	B-NP	O
CKM	CKM	C250	NN	I-NP	O
and	and	A530	CC	O	O
thus	thus	T200	RB	B-VP	O
potentially	potentially	P353	RB	I-VP	O
flank	flank	F452	VB	I-VP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Localization	Localization	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
histidase	histidase	H232	NN	B-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
12q22	12q22	Q000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
q24	q24	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	O	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
10C2	10C2	C000	CD	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
D1	D1	D000	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
histidase	histidase	H232	NN	B-NP	O
(	(	0000	(	O	O
histidine	histidine	H235	NN	B-NP	O
ammonia	ammonia	A500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
lyase	lyase	L200	NN	I-NP	O
;	;	0000	:	O	O
HAL	HAL	H400	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
histidinemia	histidinemia	H235	NN	B-NP	B-Disease
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
X	X	X000	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
sublocalized	sublocalize	S142	VBN	I-VP	O
to	to	T000	TO	B-PP	O
region	region	R250	NN	B-NP	O
12q22	12q22	Q000	CD	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
q24	q24	Q000	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
histidase	histidase	H232	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
(	(	0000	(	O	O
Hal	Hal	H400	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
region	region	R250	NN	B-NP	O
10C2	10C2	C000	CD	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
D1	D1	D000	NN	B-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

10	10	0000	CD	B-NP	O
Robertsonian	Robertsonian	R163	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
assignments	assignment	A253	NNS	I-NP	O
extend	extend	E235	VBP	B-VP	O
the	the	T000	DT	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
syntenic	syntenic	S535	JJ	I-NP	O
region	region	R250	NN	I-NP	O
between	between	B350	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
and	and	A530	CC	O	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10	10	0000	CD	B-NP	O
that	that	T300	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
,	,	0000	,	O	O
gamma	gamma	G500	NN	B-NP	O
interferon	interferon	I536	NN	I-NP	O
,	,	0000	,	O	O
peptidase	peptidase	P132	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
citrate	citrate	C363	NN	B-NP	O
synthase	synthase	S532	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
histidase	histidase	H232	NN	B-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10	10	0000	CD	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
histidase	histidase	H232	NN	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
Hsd	Hsd	H230	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
histidinemia	histidinemia	H235	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
his	his	H200	PRP$	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
both	both	B300	DT	O	O
known	know	K500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
alleles	allele	A420	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
histidase	histidase	H232	NN	I-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Determination	Determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

Hypoxanthine	Hypoxanthine	H125	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
guanine	guanine	G500	NN	B-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
purine	purine	P650	NN	I-NP	O
salvage	salvage	S412	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
that	that	T300	WDT	B-NP	O
catalyzes	catalyze	C342	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
conversion	conversion	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	O
to	to	T000	TO	B-PP	O
inosine	inosine	I525	NN	B-NP	O
monophosphate	monophosphate	M512	NN	I-NP	O
and	and	A530	CC	O	O
guanine	guanine	G500	NN	B-NP	O
to	to	T000	TO	B-PP	O
guanosine	guanosine	G525	NN	B-NP	O
monophosphate	monophosphate	M512	NN	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
level	level	L140	NN	I-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
investigation	investigation	I512	NN	I-NP	O
further	further	F636	RBR	B-ADVP	O
verifies	verify	V612	VBZ	B-VP	O
this	this	T200	DT	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
and	and	A530	CC	O	O
identifies	identify	I353	VBZ	B-VP	O
insertions	insertion	I526	NNS	B-NP	O
,	,	0000	,	O	O
deletions	deletion	D435	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
reverse	reverse	R162	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
transcribed	transcribe	T652	VBN	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
enabled	enable	E514	VBD	B-VP	O
the	the	T000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
17	17	0000	CD	B-NP	O
previously	previously	P612	RB	I-NP	O
uncharacterized	uncharacterized	U526	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
at	at	A300	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
to	to	T000	TO	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	I-NP	B-Disease
present	present	P625	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
that	that	T300	WDT	B-NP	O
contained	contain	C535	VBD	B-VP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
either	either	E360	CC	O	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
or	or	O600	CC	O	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
clearly	clearly	C464	RB	B-ADVP	O
supported	support	S163	VBD	B-VP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
mode	mode	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
nonneonatal	nonneonatal	N534	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
with	with	W300	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
at	at	A300	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
suggested	suggest	S230	VBD	B-VP	O
segregation	segregation	S262	NN	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
nonneonatal	nonneonatal	N534	JJ	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
showed	show	S300	VBD	B-VP	O
,	,	0000	,	O	O
furthermore	furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
phenotypic	phenotypic	P531	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
between	between	B350	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
necessarily	necessarily	N264	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
allelic	allelic	A420	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
different	different	D165	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
maximal	maximal	M254	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
multiallelic	multiallelic	M434	JJ	I-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
at	at	A300	IN	B-PP	O
DXS52	DXS52	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
made	make	M300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
or	or	O600	CC	I-NP	O
presymptomatic	presymptomatic	P625	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
and	and	A530	CC	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
reliable	reliable	R414	JJ	B-ADJP	O
.	.	0000	.	O	O

Skewed	Skew	S230	VBN	B-NP	O
X	X	X000	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
MZ	MZ	M200	NN	I-NP	O
twin	twin	T500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
MZ	MZ	M200	NN	I-NP	O
twins	twin	T520	NNS	I-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Physical	Physical	P240	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
,	,	0000	,	O	O
creatine	creatine	C635	NN	B-NP	O
phosphokinase	phosphokinase	P212	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
muscle	muscle	M240	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
were	be	W600	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
her	her	H600	PRP$	B-NP	O
sex	sex	S200	NN	I-NP	O
she	she	S000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
limb	limb	L510	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
girdle	girdle	G634	NN	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
probes	probe	P612	NNS	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
twins	twin	T520	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
mutation	mutation	M350	NN	I-NP	O
which	which	W200	WDT	B-NP	O
arose	arise	A620	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
by	by	B000	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
junction	junction	J523	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
generated	generate	G563	VBN	B-VP	O
by	by	B000	IN	B-PP	O
HindIII	HindIII	H530	NN	B-NP	O
,	,	0000	,	O	O
PstI	PstI	P230	NN	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
TaqI	TaqI	T200	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
probed	probe	P613	VBN	B-VP	O
with	with	W300	IN	B-PP	O
cDNA8	cDNA8	C350	NN	B-NP	O
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
given	give	G150	VBN	I-VP	O
by	by	B000	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
SfiI	SfiI	S100	NN	I-NP	O
junction	junction	J523	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
probes	probe	P612	NNS	B-NP	O
p20	p20	P000	NN	I-NP	O
,	,	0000	,	O	O
J	J	J000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
Bir	Bir	B600	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
J	J	J000	NN	B-NP	O
-	-	0000	HYPH	O	O
66	66	0000	CD	B-NP	O
on	on	O500	IN	B-PP	O
pulsed	pulsed	P423	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
field	field	F430	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
PFGE	PFGE	P120	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Immunoblot	Immunoblot	I514	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
twin	twin	T500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
dystrophin	dystrophin	D236	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
size	size	S200	NN	I-NP	O
but	but	B300	CC	B-PP	O
of	of	O100	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
amount	amount	A530	NN	I-NP	O
.	.	0000	.	O	O

Immunofluorescent	Immunofluorescent	I514	JJ	B-NP	O
visualization	visualization	V242	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
foci	focus	F200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
fibers	fiber	F162	NNS	I-NP	O
adjacent	adjacent	A325	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
foci	focus	F200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
negative	negative	N231	JJ	I-NP	O
fibers	fiber	F162	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
twin	twin	T500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
manifesting	manifest	M512	VBG	I-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
her	her	H600	PRP$	B-NP	O
myopathy	myopathy	M130	NN	I-NP	B-Disease
being	be	B520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
underexpression	underexpression	U536	NN	B-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
.	.	0000	.	O	O

Cytogenetic	Cytogenetic	C325	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
karyotypes	karyotype	K631	NNS	I-NP	O
,	,	0000	,	O	O
eliminating	eliminate	E453	VBG	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
affecting	affect	A123	VBG	B-VP	O
DMD	DMD	D530	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
fingerprint	fingerprint	F526	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
each	each	E200	DT	B-NP	O
twin	twin	T500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
eliminating	eliminate	E453	VBG	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
uniparental	uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
methylation	methylation	M343	NN	B-NP	O
differences	difference	D165	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
and	and	A530	CC	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
MZ	MZ	M200	NN	I-NP	O
twins	twin	T520	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
uneven	uneven	U515	JJ	B-NP	O
lyonization	lyonization	L523	NN	I-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
female	female	F540	JJ	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	I-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
partial	partial	P634	JJ	B-NP	O
adrenal	adrenal	A365	JJ	I-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
over	over	O160	IN	B-PP	O
three	three	T600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
demonstrating	demonstrate	D523	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
AMN	AMN	A500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

Pituitary	Pituitary	P360	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
adrenal	adrenal	A365	JJ	I-NP	O
function	function	F523	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
females	female	F542	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
as	as	A200	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
pituitary	pituitary	P360	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
adrenal	adrenal	A365	JJ	I-NP	I-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
basal	basal	B240	JJ	B-NP	O
morning	morning	M652	NN	I-NP	O
plasma	plasma	P425	NN	I-NP	O
adrenocorticotropic	adrenocorticotropic	A365	JJ	I-NP	O
hormone	hormone	H650	NN	I-NP	O
(	(	0000	(	O	O
ACTH	ACTH	A230	NN	B-NP	O
)	)	0000	)	O	O
levels	level	L142	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
markedly	markedly	M623	RB	B-ADJP	O
elevated	elevated	E413	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
males	male	M420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
,	,	0000	,	O	O
despite	despite	D213	IN	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
morning	morning	M652	NN	B-NP	O
plasma	plasma	P425	NN	I-NP	O
cortisol	cortisol	C632	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
maximal	maximal	M254	JJ	B-NP	O
exogenous	exogenous	E252	JJ	I-NP	O
ACTH	ACTH	A230	NN	I-NP	O
stimulation	stimulation	S354	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
integrated	integrate	I532	VBN	I-NP	O
24	24	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hour	hour	H600	NN	I-NP	O
response	response	R215	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
administration	administration	A352	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
subnormal	subnormal	S156	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
people	people	P140	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
subclinical	subclinical	S124	JJ	B-NP	O
partial	partial	P634	JJ	I-NP	O
adrenocrotical	adrenocrotical	A365	JJ	I-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
endocrinologic	endocrinologic	E532	JJ	I-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Regional	Regional	R254	JJ	B-NP	O
localisation	localisation	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Friedreich	Friedreich	F636	NNP	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
9q13	9q13	Q000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
assigned	assign	A253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
Friedreich	Friedreich	F636	NNP	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
9	9	0000	CD	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
maximal	maximal	M254	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
between	between	B350	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	O
and	and	A530	CC	O	O
MCT112	MCT112	M230	NN	B-NP	O
(	(	0000	(	O	O
D9S15	D9S15	D200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
greater	great	G636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
50	50	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
MCT112	MCT112	M230	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
hence	hence	H520	RB	B-ADVP	O
FRDA	FRDA	F630	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
determined	determine	D365	VBN	I-VP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
MCT112	MCT112	M230	NN	B-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
9	9	0000	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
inferred	infer	I516	VBD	B-VP	O
a	a	A000	DT	B-NP	O
location	location	L235	NN	I-NP	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
centromere	centromere	C536	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridisation	hybridisation	H163	NN	I-NP	O
with	with	W300	IN	B-PP	O
MCT112	MCT112	M230	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
corresponding	corresponding	C621	JJ	I-NP	O
cosmid	cosmid	C253	NN	I-NP	O
MJ1	MJ1	M200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
DR47	DR47	D600	NN	B-NP	O
(	(	0000	(	O	O
D9S5	D9S5	D200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
mapping	map	M152	VBG	B-VP	O
studies	study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
hybrid	hybrid	H163	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
panels	panel	P542	NNS	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
more	more	M600	RBR	B-ADVP	O
precisely	precisely	P624	RB	I-ADVP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
in	in	I500	FW	I-NP	O
situ	situ	S300	FW	I-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
probes	probe	P612	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
9q13	9q13	Q000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
q21	q21	Q000	NN	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
heterochromatin	heterochromatin	H362	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Physical	Physical	P240	JJ	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
FRDA	FRDA	F630	NN	B-NP	O
will	will	W400	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
hybrid	hybrid	H163	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
AND	AND	A530	CC	I-NP	O
METHODS	METHODS	M320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
CETP	CETP	C310	NN	B-NP	O
)	)	0000	)	O	O
catalyzes	catalyze	C342	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
transfer	transfer	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholesteryl	cholesteryl	C423	NN	B-NP	O
esters	ester	E236	NNS	I-NP	O
from	from	F650	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
HDL	HDL	H340	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
and	and	A530	CC	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
11	11	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
HDL	HDL	H340	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
radioimmunoassay	radioimmunoassay	R352	NN	I-NP	O
for	for	F600	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	O
and	and	A530	CC	I-NP	O
DNA	DNA	D500	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
fragment	fragment	F625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
CETP	CETP	C310	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
.	.	0000	.	O	O

Family	Family	F540	RB	B-NP	O
members	member	M516	NNS	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
moderate	moderate	M363	JJ	B-NP	O
hypercholesterolemia	hypercholesterolemia	H162	NN	I-NP	B-Disease
(	(	0000	(	O	O
mean	mean	M500	JJ	B-NP	O
total	total	T340	JJ	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
level	level	L140	NN	I-NP	O
[	[	0000	(	O	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
SD	SD	S300	NN	I-NP	O
]	]	0000	)	O	O
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O
01	01	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
83	83	0000	CD	I-NP	O
mmol	mmol	M540	NN	I-NP	O
per	per	P600	IN	B-PP	O
liter	liter	L360	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
markedly	markedly	M623	RB	B-NP	O
increased	increase	I526	VBN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	O	O
24	24	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
mmol	mmol	M540	NN	I-NP	O
per	per	P600	IN	B-PP	O
liter	liter	L360	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
I	I	I000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
decreased	decrease	D262	VBD	B-VP	O
levels	level	L142	NNS	B-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
99	99	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
80	80	0000	CD	I-NP	O
mmol	mmol	M540	NN	I-NP	O
per	per	P600	IN	B-PP	O
liter	liter	L360	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
B	B	B000	NN	I-NP	O
.	.	0000	.	O	O

Members	Member	M516	NNS	B-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whose	whose	W200	WP$	B-NP	O
CETP	CETP	C310	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
moderately	moderately	M363	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
levels	level	L142	NNS	B-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
and	and	A530	CC	O	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
I	I	I000	NN	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
subclass	subclass	S124	NN	I-NP	O
2	2	0000	CD	I-NP	O
to	to	T000	TO	I-NP	O
HDL	HDL	H340	NN	I-NP	O
subclass	subclass	S124	NN	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
unaffected	unaffected	U512	JJ	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
5	5	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
8	8	0000	CD	I-NP	O
vs	v	V200	NNS	I-NP	O
.	.	0000	.	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
7	7	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
4	4	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
elevated	elevate	E413	VBN	B-NP	O
HDL	HDL	H340	NN	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
from	from	F650	IN	B-PP	O
different	different	D165	JJ	B-NP	O
parts	part	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	State	S320	NNPS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
.	.	0000	.	O	O

CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
HDL	HDL	H340	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
that	that	T300	IN	B-NP	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
in	in	I500	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
CETP	CETP	C310	NN	B-NP	O
normally	normally	N654	RB	B-ADVP	O
plays	play	P420	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
part	part	P630	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
levels	level	L142	NNS	B-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
subclass	subclass	S124	NN	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
premature	premature	P653	JJ	B-NP	B-Disease
atherosclerosis	atherosclerosis	A362	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
fact	fact	F230	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
profile	profile	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
persons	person	P625	NNS	B-NP	O
with	with	W300	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
potentially	potentially	P353	RB	B-ADJP	O
antiatherogenic	antiatherogenic	A536	JJ	I-ADJP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
life	life	L100	NN	I-NP	O
span	span	S150	NN	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11q23	11q23	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
mapped	map	M130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
group	group	G610	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ATA	ATA	A300	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11q22	11q22	Q000	NN	I-NP	O
-	-	0000	HYPH	O	O
23	23	0000	CD	B-NP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
THY1	THY1	T000	NN	I-NP	O
and	and	A530	CC	I-NP	O
pYNB3	pYNB3	P510	NN	I-NP	O
.	.	0000	.	O	O

12	12	0000	CD	B-NP	O
(	(	0000	(	O	O
D11S144	D11S144	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
likely	likely	L240	JJ	I-NP	O
order	order	O636	NN	I-NP	O
was	be	W200	VBD	B-VP	O
cent	cent	C530	JJ	B-ADJP	O
-	-	0000	HYPH	B-NP	O
AT	AT	A300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
S144	S144	S000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
THY1	THY1	T000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
paper	paper	P160	NN	I-NP	O
describes	describe	D261	VBZ	B-VP	O
further	far	F636	JJR	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AT	AT	A300	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
span	span	S150	VBP	B-VP	O
approximately	approximately	A162	RB	B-NP	O
60	60	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
11q22	11q22	Q000	NN	I-NP	O
-	-	0000	HYPH	O	O
23	23	0000	CD	B-NP	O
region	region	R250	NN	I-NP	O
centered	centered	C536	JJ	B-ADJP	O
around	around	A653	IN	B-PP	O
S144	S144	S000	NN	B-NP	O
and	and	A530	CC	I-NP	O
THY1	THY1	T000	NN	I-NP	O
.	.	0000	.	O	O

Location	Location	L235	NN	B-NP	O
scores	score	S262	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
three	three	T600	CD	B-NP	O
contiguous	contiguous	C532	JJ	I-NP	O
subsegments	subsegment	S125	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
[	[	0000	(	I-NP	O
S144	S144	S000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
THY1	THY1	T000	NN	I-NP	O
]	]	0000	)	I-NP	O
segment	segment	S253	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
three	three	T600	CD	B-NP	O
contiguous	contiguous	C532	JJ	I-NP	O
segments	segment	S253	NNS	I-NP	O
telomeric	telomeric	T456	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
THY1	THY1	T000	NN	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
each	each	E200	DT	O	O
unlikely	unlikely	U542	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
contain	contain	C535	VB	I-VP	O
the	the	T000	DT	B-NP	O
AT	AT	A300	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
centromeric	centromeric	C536	JJ	I-NP	O
[	[	0000	(	I-NP	O
STMY	STMY	S350	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
S144	S144	S000	NN	I-NP	O
]	]	0000	)	I-NP	O
segment	segment	S253	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
most	most	M230	RBS	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
contain	contain	C535	VB	I-VP	O
the	the	T000	DT	B-NP	O
AT	AT	A300	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
recent	recent	R253	JJ	B-NP	O
refinements	refinement	R153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
and	and	A530	CC	O	O
physical	physical	P240	JJ	B-NP	O
maps	map	M120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
11q22	11q22	Q000	NN	B-NP	O
-	-	0000	HYPH	O	O
23	23	0000	CD	B-NP	O
,	,	0000	,	O	O
place	place	P420	VBP	B-VP	O
the	the	T000	DT	B-NP	O
AT	AT	A300	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
at	at	A300	IN	B-PP	O
11q23	11q23	Q000	NN	B-NP	O
.	.	0000	.	O	O

Recurrent	Recurrent	R265	JJ	B-NP	O
meningitis	meningitis	M523	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
C9	C9	C000	NN	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
.	.	0000	.	O	O

First	First	F623	JJ	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Europe	Europe	E610	NNP	B-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Swiss	Swiss	S200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
members	member	M516	NNS	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
with	with	W300	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
half	half	H410	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
C9	C9	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
experienced	experienced	E216	JJ	I-NP	O
bacterial	bacterial	B236	JJ	I-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
index	index	I532	NN	I-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
56	56	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
old	old	O430	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
man	man	M500	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
purulent	purulent	P645	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
23	23	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
acute	acute	A230	JJ	I-NP	B-Disease
meningococcal	meningococcal	M524	JJ	I-NP	I-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
impairment	impairment	I516	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
cellular	cellular	C460	JJ	B-NP	I-Disease
immunity	immunity	I530	NN	I-NP	I-Disease
or	or	O600	CC	O	O
immunoglobulin	immunoglobulin	I524	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	O
assays	assay	A200	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
C9	C9	C000	NN	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
individual	individual	I531	JJ	I-NP	O
component	component	C515	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
(	(	0000	(	O	O
measured	measure	M263	VBN	B-VP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CH50	CH50	C000	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
only	only	O540	RB	I-VP	O
slightly	slightly	S423	RB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
study	study	S300	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
complete	complete	C514	JJ	B-NP	B-Disease
C9	C9	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
healthy	healthy	H430	JJ	B-NP	O
brother	brother	B636	NN	I-NP	O
and	and	A530	CC	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
C9	C9	C000	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
in	in	I500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
sister	sister	S236	NN	I-NP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
son	son	S500	NN	I-NP	O
(	(	0000	(	O	O
who	who	W000	WP	B-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
experienced	experience	E216	VBN	I-VP	O
an	an	A500	DT	B-NP	O
episode	episode	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
bacterial	bacterial	B236	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
niece	niece	N200	NN	I-NP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
first	first	F623	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
white	white	W300	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
complete	complete	C514	JJ	B-NP	B-Disease
C9	C9	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
complement	complement	C514	NN	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
bacterial	bacterial	B236	JJ	B-NP	B-Disease
,	,	0000	,	O	I-Disease
especially	especially	E212	RB	B-ADJP	I-Disease
neisserial	neisserial	N264	JJ	I-ADJP	I-Disease
,	,	0000	,	O	I-Disease
infections	infection	I512	NNS	B-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
98	98	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
oligonucleotide	oligonucleotide	O425	NN	B-NP	O
primer	primer	P656	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
amplify	amplify	A514	VB	I-VP	O
eight	eight	E230	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
plus	plus	P420	CC	O	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
promoter	promoter	P653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
multiplex	multiplex	M431	JJ	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
used	use	U230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
conjunction	conjunction	C525	NN	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
existing	exist	E235	VBG	I-NP	O
primer	primer	P656	NN	I-NP	O
set	set	S300	NN	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
multiplex	multiplex	M431	JJ	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
detect	detect	D323	VBP	B-VP	O
about	about	A130	IN	B-NP	O
98	98	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
,	,	0000	,	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
primers	primer	P656	NNS	I-NP	O
amplify	amplify	A514	VBP	B-VP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
prone	prone	P650	NN	I-NP	O
"	"	0000	``	B-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
"	"	0000	''	I-NP	O
region	region	R250	NN	I-NP	O
around	around	A653	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
44	44	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
53	53	0000	CD	B-NP	O
,	,	0000	,	O	O
allowing	allow	A452	VBG	B-VP	O
determination	determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
endpoints	endpoint	E531	NNS	I-NP	O
and	and	A530	CC	O	O
prediction	prediction	P632	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutational	mutational	M354	JJ	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
translational	translational	T652	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
assays	assay	A200	NNS	I-NP	O
will	will	W400	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
deletion	deletion	D435	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
BMD	BMD	B530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Italy	Italy	I340	NNP	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
study	study	S300	NN	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Matera	Matera	M360	NNP	I-NP	O
district	district	D236	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
gel	gel	G400	NN	B-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
and	and	A530	CC	B-PP	O
by	by	B000	IN	B-PP	O
quantitative	quantitative	Q531	JJ	B-NP	O
assay	assay	A200	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
unselected	unselected	U524	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
1524	1524	0000	CD	B-NP	O
schoolboys	schoolboy	S241	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
province	province	P615	NN	I-NP	O
of	of	O100	IN	B-PP	O
Matera	Matera	M360	NNP	B-NP	O
(	(	0000	(	O	O
Lucania	Lucania	L250	NNP	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Italy	Italy	I340	NNP	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
43	43	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
,	,	0000	,	O	O
31	31	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
severe	severe	S160	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
nine	nine	N500	CD	B-NP	O
had	have	H300	VBD	B-VP	O
mild	mild	M430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
moderate	moderate	M363	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ionian	Ionian	I500	NNP	I-NP	O
Coast	Coast	C230	NNP	I-NP	O
to	to	T000	TO	B-PP	O
zero	zero	Z600	CD	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
eastern	eastern	E236	JJ	I-NP	O
side	side	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lucanian	Lucanian	L250	JJ	I-NP	O
Apennines	Apennine	A152	NNS	I-NP	O
,	,	0000	,	O	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
inversely	inversely	I516	RB	I-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
distance	distance	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
town	town	T500	NN	I-NP	O
examined	examine	E253	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ionian	Ionian	I500	NNP	I-NP	O
Coast	Coast	C230	NNP	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
geographic	geographic	G261	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
may	may	M000	MD	B-VP	O
reflect	reflect	R142	VB	I-VP	O
,	,	0000	,	O	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
in	in	I500	IN	B-PP	O
part	part	P630	NN	B-NP	O
,	,	0000	,	O	O
gene	gene	G500	NN	B-NP	O
flow	flow	F400	NN	I-NP	O
from	from	F650	IN	B-PP	O
Greek	Greek	G620	JJ	B-NP	O
settlers	settler	S346	NNS	I-NP	O
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
several	several	S164	JJ	B-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
known	know	K500	VBN	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
Cagliari	Cagliari	C246	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-ADJP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Metaponto	Metaponto	M315	NN	I-NP	O
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Montalbano	Montalbano	M534	NNP	I-NP	O
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Pisticci	Pisticci	P232	NNS	I-NP	O
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
IV	IV	I100	CD	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Tursi	Tursi	T620	NN	I-NP	O
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Ferrandina	Ferrandina	F653	NNP	I-NP	O
(	(	0000	(	O	O
class	class	C420	NN	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
marked	marked	M623	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
narrow	narrow	N600	JJ	I-NP	O
geographic	geographic	G261	JJ	I-NP	O
area	area	A600	NN	I-NP	O
and	and	A530	CC	O	O
they	they	T000	PRP	B-NP	O
prove	prove	P610	VBP	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Italian	Italian	I345	JJ	I-NP	O
peninsula	peninsula	P524	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
GdA	GdA	G300	NN	B-NP	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
regarded	regard	R263	VBN	B-VP	O
as	as	A200	IN	B-PP	O
characteristically	characteristically	C623	RB	B-ADJP	O
African	African	A162	JJ	I-ADJP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
murine	murine	M650	JJ	I-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
exon	exon	E250	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
ascertain	ascertain	A263	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
murine	murine	M650	JJ	B-NP	O
C5	C5	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
genomic	genomic	G520	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
libraries	library	L162	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
from	from	F650	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
liver	liver	L160	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
mRNA	mRNA	M650	NN	B-NP	O
employing	employ	E514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
congenic	congenic	C525	JJ	I-NP	O
strains	strain	S365	NNS	I-NP	O
B10	B10	B000	NN	I-NP	O
.	.	0000	.	O	O

D2	D2	D000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
nSnJ	nSnJ	N252	NN	I-NP	O
and	and	A530	CC	I-NP	O
B10	B10	B000	NN	I-NP	O
.	.	0000	.	O	O

D2	D2	D000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
oSnJ	oSnJ	O252	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
deficient	deficient	D125	JJ	I-ADJP	B-Disease
for	for	F600	IN	B-PP	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
fragments	fragment	F625	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
which	which	W200	WDT	B-NP	O
correspond	correspond	C621	VBP	B-VP	O
to	to	T000	TO	B-PP	O
PvuII	PvuII	P100	NN	B-NP	O
and	and	A530	CC	I-NP	O
HindIII	HindIII	H530	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
from	from	F650	IN	B-PP	O
single	single	S524	JJ	B-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
neither	neither	N360	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
would	would	W430	MD	B-VP	O
probably	probably	P614	RB	I-VP	O
cause	cause	C200	VB	I-VP	O
or	or	O600	CC	I-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
sufficient	sufficient	S125	JJ	I-NP	O
and	and	A530	CC	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
2	2	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
"	"	0000	``	I-NP	O
TA	TA	T000	NN	I-NP	O
"	"	0000	''	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
shifts	shift	S132	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
so	so	S000	IN	B-SBAR	O
that	that	T300	IN	I-SBAR	O
the	the	T000	DT	B-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
UGA	UGA	U200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-NP	O
4	4	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
corresponding	correspond	C621	VBG	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
area	area	A600	NN	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
C5	C5	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
strains	strain	S365	NNS	I-NP	O
,	,	0000	,	O	O
A	A	A000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
HeJ	HeJ	H200	NN	I-NP	O
,	,	0000	,	O	O
AKR	AKR	A260	NN	B-NP	O
/	/	0000	SYM	I-NP	O
J	J	J000	NN	I-NP	O
,	,	0000	,	O	O
DBA	DBA	D100	NN	B-NP	O
/	/	0000	SYM	I-NP	O
2J	2J	J000	NN	I-NP	O
,	,	0000	,	O	O
NZB	NZB	N210	NN	B-NP	O
/	/	0000	SYM	I-NP	O
B1NJ	B1NJ	B520	NN	I-NP	O
,	,	0000	,	O	O
SWR	SWR	S600	NN	B-NP	O
/	/	0000	SYM	I-NP	O
J	J	J000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
B10	B10	B000	NN	B-NP	O
.	.	0000	.	O	O

D2	D2	D000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
oSnJ	oSnJ	O252	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
C5	C5	C000	NN	I-NP	O
-	-	0000	HYPH	O	O
sufficient	sufficient	S125	JJ	B-NP	O
strains	strain	S365	NNS	I-NP	O
,	,	0000	,	O	O
Balb	Balb	B410	NN	B-NP	O
/	/	0000	SYM	I-NP	O
CJ	CJ	C200	NN	I-NP	O
,	,	0000	,	O	O
C57Bl	C57Bl	C140	NN	B-NP	O
/	/	0000	SYM	I-NP	O
6J	6J	J000	NN	I-NP	O
,	,	0000	,	O	O
DBA	DBA	D100	NN	B-NP	O
/	/	0000	SYM	I-NP	O
1J	1J	J000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
B10	B10	B000	NN	B-NP	O
.	.	0000	.	O	O

D2	D2	D000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
nSnJ	nSnJ	N252	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
deleted	delete	D430	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
tested	test	T230	VBN	B-VP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	I-PP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
sufficient	sufficient	S125	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
1	1	0000	LS	B-LST	O
)	)	0000	)	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
different	different	D165	JJ	I-NP	O
C5	C5	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mouse	mouse	M200	NN	I-NP	O
strains	strain	S365	NNS	I-NP	O
;	;	0000	:	O	O
2	2	0000	LS	B-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
transcribed	transcribe	T652	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5D	C5D	C300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
retains	retain	R352	VBZ	B-VP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
3	3	0000	LS	B-LST	O
)	)	0000	)	O	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
should	should	S430	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
protein	protein	P635	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
eastern	eastern	E236	JJ	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
secondary	secondary	S253	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
and	and	A530	CC	O	O
specific	specific	S121	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	B-Disease
lesion	lesion	L250	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Hungarian	Hungarian	H526	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	O	O
amplified	amplify	A514	VBN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
Arg243	Arg243	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	I-NP	O
nine	nine	N500	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
4	4	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
among	among	A520	IN	B-PP	O
Eastern	Eastern	E236	NNP	B-NP	O
Europeans	European	E615	NNPS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
present	present	P625	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
Western	Western	W236	JJ	B-NP	O
Europeans	European	E615	NNPS	I-NP	O
and	and	A530	CC	I-NP	O
Asians	Asian	A252	NNPS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rarity	rarity	R630	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
restricted	restricted	R236	JJ	I-NP	O
geographic	geographic	G261	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
event	event	E153	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
recently	recently	R253	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
4	4	0000	CD	I-NP	O
background	background	B265	NN	I-NP	O
in	in	I500	IN	B-PP	O
Eastern	Eastern	E236	NNP	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
green	green	G650	JJ	I-NP	O
visual	visual	V240	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
recent	recent	R253	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
established	establish	E231	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
synthetase	synthetase	S532	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
unidentified	unidentified	U535	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
,	,	0000	,	O	O
like	like	L200	IN	B-PP	O
the	the	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
and	and	A530	CC	I-NP	O
green	green	G650	JJ	I-NP	O
color	color	C460	NN	I-NP	O
pigment	pigment	P253	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	B-Disease
color	color	C460	NN	I-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
rearrangements	rearrangement	R652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
color	color	C460	NN	I-NP	O
vision	vision	V250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
led	lead	L300	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
propose	propose	P612	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
could	could	C430	MD	B-VP	O
underlie	underlie	U536	VB	I-VP	O
both	both	B300	CC	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
and	and	A530	CC	O	O
abnormal	abnormal	A156	JJ	B-NP	B-Disease
color	color	C460	NN	I-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
34	34	0000	CD	B-NP	O
French	French	F652	JJ	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
reveal	reveal	R140	VB	I-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
than	than	T500	IN	B-PP	O
expected	expect	E212	VBN	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
green	green	G650	JJ	B-NP	O
/	/	0000	SYM	I-NP	O
red	red	R300	JJ	I-NP	O
visual	visual	V240	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
3	3	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
/	/	0000	SYM	I-NP	O
green	green	G650	JJ	I-NP	O
color	color	C460	NN	I-NP	O
vision	vision	V250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
such	such	S200	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
small	small	S540	JJ	B-NP	O
numbers	number	N516	NNS	I-NP	O
and	and	A530	CC	O	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
knowledge	knowledge	K543	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
"	"	0000	``	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
"	"	0000	''	I-NP	O
color	color	C460	NN	I-NP	O
vision	vision	V250	NN	I-NP	O
arrays	array	A620	NNS	I-NP	O
on	on	O500	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
twice	twice	T200	RB	B-ADJP	O
as	as	A200	RB	I-ADJP	O
high	high	H200	JJ	I-ADJP	O
as	as	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	B-Disease
color	color	C460	NN	I-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
/	/	0000	SYM	I-NP	O
green	green	G650	JJ	I-NP	O
color	color	C460	NN	I-NP	O
pigment	pigment	P253	NN	I-NP	O
(	(	0000	(	O	O
R	R	R000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
GCP	GCP	G210	NN	I-NP	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
pulsed	pulsed	P423	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
field	field	F430	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
in	in	I500	IN	B-PP	O
14	14	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
find	find	F530	VB	I-VP	O
any	any	A500	DT	B-NP	O
fragment	fragment	F625	NN	I-NP	O
size	size	S200	NN	I-NP	O
difference	difference	D165	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
pigment	pigment	P253	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
R	R	R000	NN	I-NP	O
/	/	0000	SYM	B-VP	O
GCP	GCP	G210	NN	B-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
in	in	I500	IN	B-PP	O
29	29	0000	CD	B-NP	O
French	French	F652	NNP	I-NP	O
and	and	A530	CC	O	O
seven	seven	S150	CD	B-NP	O
North	North	N630	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
six	six	S200	CD	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
,	,	0000	,	O	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
walk	walk	W420	NN	I-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
flank	flank	F452	VBP	B-VP	O
the	the	T000	DT	B-NP	O
color	color	C460	NN	I-NP	O
vision	vision	V250	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
with	with	W300	IN	B-PP	O
probes	probe	P612	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
lie	lie	L000	VBP	B-VP	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
green	green	G650	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
blue	blue	B400	JJ	B-NP	O
cone	cone	C500	NN	I-NP	O
monochromacy	monochromacy	M526	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
45	45	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
color	color	C460	NN	I-NP	O
vision	vision	V250	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
AMN	AMN	A500	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
suggest	suggest	S230	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
lies	lie	L200	NNS	I-NP	O
5	5	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
red	red	R300	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
color	color	C460	NN	I-NP	B-Disease
vision	vision	V250	NN	I-NP	I-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
owe	owe	O000	VBP	B-VP	O
their	their	T600	PRP$	B-NP	O
origin	origin	O625	NN	I-NP	O
to	to	T000	TO	B-PP	O
deleted	delete	D430	VBN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
regulatory	regulatory	R243	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
color	color	C460	NN	B-NP	O
vision	vision	V250	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
phenotypic	phenotypic	P531	JJ	B-NP	O
color	color	C460	NN	I-NP	B-Disease
vision	vision	V250	NN	I-NP	I-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
AMN	AMN	A500	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
phenocopies	phenocopy	P521	NNS	B-NP	O
secondary	secondary	S253	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
retinal	retinal	R354	JJ	B-NP	O
or	or	O600	CC	I-NP	O
neural	neural	N640	JJ	I-NP	O
involvement	involvement	I514	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
blue	blue	B400	JJ	B-NP	O
cone	cone	C500	NN	I-NP	O
monochromacy	monochromacy	M526	NN	I-NP	O
may	may	M000	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
fortuitous	fortuitous	F632	JJ	I-NP	O
coincidence	coincidence	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
diseases	disease	D200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Paroxysmal	Paroxysmal	P625	JJ	B-NP	B-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
haemoglobinuria	haemoglobinuria	H524	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
coexisting	coexist	C235	VBG	B-VP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
ninth	ninth	N530	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
:	:	0000	:	O	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
massive	massive	M210	JJ	B-NP	O
haemolytic	haemolytic	H543	JJ	I-NP	B-Disease
attack	attack	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
paroxysmal	paroxysmal	P625	JJ	B-NP	B-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
haemoglobinuria	haemoglobinuria	H524	NN	I-NP	I-Disease
(	(	0000	(	O	O
PNH	PNH	P500	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
ninth	ninth	N530	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
(	(	0000	(	O	O
C9	C9	C000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
complement	complement	C514	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
lysis	lysis	L200	NN	I-NP	O
tests	test	T232	NNS	I-NP	O
,	,	0000	,	O	O
80	80	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
erythrocytes	erythrocyte	E636	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
markedly	markedly	M623	RB	B-NP	O
complement	complement	C514	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
(	(	0000	(	O	O
PNH	PNH	P500	NN	B-NP	O
-	-	0000	HYPH	O	O
III	III	I000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Laser	Laser	L260	NN	B-NP	O
cytofluorimetry	cytofluorimetry	C314	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibody	antibody	A531	NN	I-NP	O
against	against	A252	IN	B-PP	O
decay	decay	D200	NN	B-NP	O
-	-	0000	HYPH	O	O
accelerating	accelerate	A246	VBG	B-VP	O
factor	factor	F236	NN	B-NP	O
(	(	0000	(	O	O
DAF	DAF	D100	NN	B-NP	O
)	)	0000	)	O	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
erythrocytes	erythrocyte	E636	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
DAF	DAF	D100	NN	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
negative	negative	N231	JJ	B-ADJP	O
.	.	0000	.	O	O

Surprisingly	Surprisingly	S616	RB	B-ADVP	O
,	,	0000	,	O	O
she	she	S000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
suffered	suffer	S163	VBN	I-VP	O
only	only	O540	RB	B-NP	O
mild	mild	M430	JJ	I-NP	O
haemolysis	haemolysis	H542	NN	I-NP	B-Disease
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
never	never	N160	RB	I-VP	O
experienced	experience	E216	VBN	I-VP	O
massive	massive	M210	JJ	B-NP	O
spontaneous	spontaneous	S153	JJ	I-NP	O
haemolysis	haemolysis	H542	NN	I-NP	B-Disease
.	.	0000	.	O	O

Gross	Gross	G620	NN	B-NP	O
haemoglobinuria	haemoglobinuria	H524	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
jaundice	jaundice	J532	NN	I-NP	B-Disease
occurred	occur	O263	VBD	B-VP	O
only	only	O540	RB	B-ADVP	O
after	after	A136	IN	B-PP	O
receiving	receive	R215	VBG	B-VP	O
postoperative	postoperative	P231	JJ	B-NP	O
transfusion	transfusion	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
whole	whole	W400	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
C9	C9	C000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
detectable	detectable	D323	JJ	B-ADJP	O
either	either	E360	CC	O	O
by	by	B000	IN	B-PP	O
immunological	immunological	I542	JJ	B-ADJP	O
or	or	O600	CC	O	O
by	by	B000	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
assays	assay	A200	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
the	the	T000	DT	B-NP	O
Ham	Ham	H500	NNP	I-NP	O
test	test	T230	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
sugar	sugar	S260	NN	I-NP	O
water	water	W360	NN	I-NP	O
test	test	T230	NN	I-NP	O
using	use	U252	VBG	B-VP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
or	or	O600	CC	I-NP	O
plasma	plasma	P425	NN	I-NP	O
yielded	yield	Y430	VBD	B-VP	O
marked	marked	M623	JJ	B-NP	O
haemolysis	haemolysis	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
erythrocytes	erythrocyte	E636	NNS	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
or	or	O600	CC	I-NP	O
plasma	plasma	P425	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
trace	trace	T620	NN	I-NP	O
of	of	O100	IN	B-PP	O
lysis	lysis	L200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Addition	Addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
human	human	H500	JJ	I-NP	O
C9	C9	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
her	her	H600	PRP$	B-NP	O
plasma	plasma	P425	NN	I-NP	O
fully	fully	F400	RB	B-VP	O
restored	restore	R236	VBD	I-VP	O
haemolysis	haemolysis	H542	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
C9	C9	C000	NN	B-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
haemolytic	haemolytic	H543	JJ	B-NP	B-Disease
attacks	attack	A320	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PNH	PNH	P500	NN	B-NP	B-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
characteristic	characteristic	C623	JJ	B-NP	O
haemolysis	haemolysis	H542	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
PNH	PNH	P500	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
tempered	temper	T516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
coexisting	coexist	C235	VBG	B-VP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Duplicational	Duplicational	D142	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
:	:	0000	:	O	O
its	its	I320	PRP$	B-NP	O
frequency	frequency	F625	NN	I-NP	O
,	,	0000	,	O	O
distribution	distribution	D236	NN	B-NP	O
,	,	0000	,	O	O
origin	origin	O625	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
phenotypegenotype	phenotypegenotype	P531	NN	B-NP	O
correlation	correlation	C643	NN	I-NP	O
.	.	0000	.	O	O

Partial	Partial	P634	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Becker	Becker	B260	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Partial	Partial	P634	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
duplication	duplication	D142	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
a	a	A000	DT	B-NP	O
survey	survey	S610	NN	I-NP	O
for	for	F600	IN	B-PP	O
duplication	duplication	D142	NN	B-NP	O
in	in	I500	IN	B-PP	O
72	72	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
nondeletion	nondeletion	N534	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
analyzed	analyze	A542	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
with	with	W300	IN	B-PP	O
clones	clone	C452	NNS	B-NP	O
representing	represent	R162	VBG	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
careful	careful	C614	JJ	B-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
hybridization	hybridization	H163	NN	B-NP	O
band	band	B530	NN	I-NP	O
intensity	intensity	I535	NN	I-NP	O
,	,	0000	,	O	O
10	10	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
a	a	A000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
nondeletion	nondeletion	N534	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
(	(	0000	(	O	O
10	10	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
72	72	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
(	(	0000	(	O	O
10	10	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
181	181	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
duplications	duplication	D142	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
published	publish	P142	VBN	I-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
HindIII	HindIII	H530	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
map	map	M100	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
10	10	0000	CD	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
that	that	T300	WDT	B-NP	O
spanned	span	S153	VBD	B-VP	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
junction	junction	J523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
translational	translational	T652	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
predicted	predict	P632	VBN	I-VP	O
for	for	F600	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
duplications	duplication	D142	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
shift	shift	S130	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
remained	remain	R530	VBD	B-VP	O
uninterrupted	uninterrupted	U536	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

RFLP	RFLP	R141	NN	B-NP	O
and	and	A530	CC	I-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
Southern	Southern	S365	JJ	I-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
grandpaternal	grandpaternal	G653	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
duplication	duplication	D142	NN	B-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
grandmaternal	grandmaternal	G653	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
five	five	F100	CD	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
originate	originate	O625	VB	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Unequal	Unequal	U524	JJ	B-NP	O
sister	sister	S236	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
chromatid	chromatid	C653	NN	I-NP	O
exchange	exchange	E252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
proposed	propose	P612	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
duplications	duplication	D142	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
:	:	0000	:	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
Alexandra	Alexandra	A425	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
jaundice	jaundice	J532	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
)	)	0000	)	O	O
Camperdown	Camperdown	C516	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
young	young	Y520	JJ	I-NP	O
man	man	M500	NN	I-NP	O
with	with	W300	IN	B-PP	O
lamellar	lamellar	L546	JJ	B-NP	B-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
male	male	M400	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
unusual	unusual	U524	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
presentations	presentation	P625	NNS	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
hitherto	hitherto	H363	RB	B-NP	O
undescribed	undescribed	U532	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
Italian	Italian	I345	JJ	B-NP	O
extraction	extraction	E236	NN	I-NP	O
,	,	0000	,	O	O
suffered	suffer	S163	VBN	B-VP	O
from	from	F650	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
neonatal	neonatal	N534	JJ	I-NP	B-Disease
jaundice	jaundice	J532	NN	I-NP	I-Disease
following	follow	F452	VBG	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
ingestion	ingestion	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
fresh	fresh	F620	JJ	B-NP	O
broad	broad	B630	JJ	I-NP	O
beans	bean	B520	NNS	I-NP	O
(	(	0000	(	O	O
Vicia	Vicia	V200	NNP	B-NP	O
fava	fava	F100	NNP	I-NP	O
)	)	0000	)	O	O
both	both	B300	CC	O	O
prenatally	prenatally	P653	RB	B-ADVP	O
and	and	A530	CC	I-ADVP	O
postnatally	postnatally	P235	RB	I-ADVP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
much	much	M200	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
neonatal	neonatal	N534	JJ	I-NP	O
period	period	P630	NN	I-NP	O
than	than	T500	IN	B-PP	O
on	on	O500	IN	B-PP	O
retesting	reteste	R323	VBG	B-VP	O
in	in	I500	IN	B-PP	O
adolescence	adolescence	A342	NN	B-NP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
biochemical	biochemical	B252	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
unique	unique	U520	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
justify	justify	J231	VBP	B-VP	O
designation	designation	D253	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
variant	variant	V653	JJ	I-NP	O
Gd	Gd	G300	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	O	O
)	)	0000	)	O	O
Alexandra	Alexandra	A425	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Maltese	Maltese	M432	JJ	B-NP	O
extraction	extraction	E236	NN	I-NP	O
who	who	W000	WP	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
bilateral	bilateral	B436	JJ	B-NP	B-Disease
lamellar	lamellar	L546	JJ	I-NP	I-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
4	4	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficient	deficient	D125	JJ	B-ADJP	I-Disease
only	only	O540	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
survey	survey	S610	NN	I-NP	O
of	of	O100	IN	B-PP	O
children	child	C436	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Mediterranean	Mediterranean	M365	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
with	with	W300	IN	B-PP	O
unexplained	unexplained	U521	JJ	B-NP	O
cataract	cataract	C362	NN	I-NP	B-Disease
formation	formation	F653	NN	I-NP	O
;	;	0000	:	O	O
he	he	H000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
approximately	approximately	A162	RB	B-NP	O
15	15	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
another	another	A536	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
led	lead	L300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
its	its	I320	PRP$	B-NP	O
designation	designation	D253	NN	I-NP	O
as	as	A200	IN	B-PP	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Camperdown	Camperdown	C516	NNP	B-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
association	association	A235	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
coincidental	coincidental	C523	JJ	B-ADJP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
prompts	prompt	P651	VBZ	B-VP	O
further	further	F636	JJ	B-NP	O
attention	attention	A353	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
under	under	U536	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
circumstances	circumstance	C625	NNS	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
favor	favor	F160	VB	I-VP	O
cataract	cataract	C362	NN	B-NP	B-Disease
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
illustrate	illustrate	I423	VBP	B-VP	O
the	the	T000	DT	B-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
characterization	characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
whenever	whenever	W516	WRB	B-ADVP	O
unexpected	unexpected	U521	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
or	or	O600	CC	I-NP	O
laboratory	laboratory	L163	JJ	I-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Statistical	Statistical	S323	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
stage	stage	S320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
model	model	M340	NN	I-NP	O
in	in	I500	IN	B-PP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
and	and	A530	CC	O	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
incidence	incidence	I523	NN	I-NP	O
curves	curve	C612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
unilateral	unilateral	U543	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
bilateral	bilateral	B436	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
led	lead	L300	VBD	B-VP	O
Knudson	Knudson	K532	NNP	B-NP	O
to	to	T000	TO	B-VP	O
propose	propose	P612	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
may	may	M000	MD	B-VP	O
arise	arise	A620	VB	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
event	event	E153	NN	I-NP	O
and	and	A530	CC	O	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
two	two	T000	CD	I-NP	O
stage	stage	S320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
suggested	suggest	S230	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
arise	arise	A620	VB	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
two	two	T000	CD	I-NP	O
stage	stage	S320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analysed	analyse	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
incidence	incidence	I523	NN	I-NP	O
curves	curve	C612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
symptomatic	symptomatic	S513	JJ	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
26	26	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
68	68	0000	CD	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
109	109	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
compared	compare	C516	VBD	B-VP	O
them	them	T500	PRP	B-NP	O
to	to	T000	TO	B-PP	O
104	104	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
43	43	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
incidence	incidence	I523	NN	I-NP	O
curves	curve	C612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
model	model	M340	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
incidence	incidence	I523	NN	I-NP	O
curves	curve	C612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
suggested	suggest	S230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
two	two	T000	CD	I-NP	O
stage	stage	S320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
functioning	function	F523	VBG	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Sporadic	Sporadic	S163	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
haemangioblastoma	haemangioblastoma	H521	NN	I-NP	I-Disease
and	and	A530	CC	O	O
some	some	S500	DT	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
arise	arise	A620	VB	I-VP	O
from	from	F650	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
inactivating	inactivate	I523	VBG	B-VP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Screening	Screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
among	among	A520	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
based	base	B230	VBN	B-VP	O
and	and	A530	CC	O	O
enzyme	enzyme	E525	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
based	base	B230	VBN	I-NP	O
tests	test	T232	NNS	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
AND	AND	A530	CC	I-NP	O
METHODS	METHODS	M320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
prevention	prevention	P615	NN	I-NP	O
of	of	O100	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
GM2	GM2	G500	NN	B-NP	B-Disease
gangliosidosis	gangliosidosis	G524	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
type	type	T100	NN	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
)	)	0000	)	O	O
depends	depend	D153	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	B-NP	O
test	test	T230	NN	I-NP	O
widely	widely	W340	RB	B-VP	O
used	use	U230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
test	test	T230	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
developed	develop	D141	VBD	B-VP	O
methods	method	M320	NNS	B-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
occur	occur	O260	VBP	B-VP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
among	among	A520	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
cause	cause	C200	VBP	B-VP	O
infantile	infantile	I515	JJ	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
segments	segment	S253	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
these	these	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
and	and	A530	CC	O	O
analyzed	analyze	A542	VBN	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
62	62	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
obligate	obligate	O142	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
specific	specific	S121	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
(	(	0000	(	O	O
98	98	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
216	216	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
177	177	0000	CD	B-NP	O
(	(	0000	(	O	O
82	82	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
identified	identify	I353	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
177	177	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
79	79	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
insertion	insertion	I526	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
18	18	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
12	12	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
junction	junction	J523	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3	3	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
7	7	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
tests	test	T232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
39	39	0000	CD	I-NP	O
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
18	18	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
)	)	0000	)	O	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
defined	define	D153	VBN	I-VP	O
as	as	A200	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
but	but	B300	CC	B-PP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
identify	identify	I353	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
were	be	W600	VBD	B-VP	O
probably	probably	P614	RB	B-ADVP	O
false	false	F420	JJ	B-NP	O
positive	positive	P231	JJ	I-NP	O
(	(	0000	(	O	O
although	although	A432	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
remains	remain	R520	VBZ	B-VP	O
some	some	S500	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
unidentified	unidentified	U535	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
152	152	0000	CD	B-NP	O
persons	person	P625	NNS	I-NP	O
defined	define	D153	VBN	B-VP	O
as	as	A200	IN	B-PP	O
noncarriers	noncarrier	N526	NNS	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	B-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
(	(	0000	(	O	O
i	i	I000	JJ	O	O
.	.	0000	.	O	O
e	e	E000	NNP	B-NP	O
e	e	E000	NNP	I-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
false	false	F420	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
test	test	T230	NN	I-NP	O
result	result	R243	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
specificity	specificity	S121	NN	I-NP	O
and	and	A530	CC	I-NP	O
predictive	predictive	P632	JJ	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	B-NP	O
test	test	T230	NN	I-NP	O
make	make	M200	VBP	B-VP	O
it	it	I300	PRP	B-NP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
adjunct	adjunct	A325	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
tests	test	T232	NNS	I-NP	O
currently	currently	C653	RB	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Total	Total	T340	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
plasma	plasma	P425	NN	B-NP	I-Disease
cholesteryl	cholesteryl	C423	NN	I-NP	I-Disease
ester	ester	E236	NN	I-NP	I-Disease
transfer	transfer	T652	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
splicing	splicing	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholesteryl	cholesteryl	C423	NN	B-NP	B-Disease
ester	ester	E236	NN	I-NP	I-Disease
transfer	transfer	T652	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
CETP	CETP	C310	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
4	4	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
CETP	CETP	C310	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
exceeded	exceed	E230	VBD	B-VP	O
150	150	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
totally	totally	T340	RB	B-ADJP	O
deficient	deficient	D125	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	I-NP	O
mass	mass	M200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
two	two	T000	CD	B-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
primers	primer	P656	NNS	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
12	12	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
14	14	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
directly	directly	D623	RB	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
change	change	C520	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
change	change	C520	NN	I-NP	O
would	would	W430	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
impaired	impaired	I516	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
pre	pre	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
two	two	T000	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
totally	totally	T340	RB	B-VP	O
lacked	lack	L230	VBD	I-VP	O
CETP	CETP	C310	NN	B-NP	O
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
other	other	O360	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
or	or	O600	CC	O	O
metabolic	metabolic	M314	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
influencing	influence	I514	VBG	B-VP	O
CETP	CETP	C310	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
are	be	A600	VBP	B-VP	O
implicated	implicate	I514	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
plasma	plasma	P425	NN	I-NP	O
CETP	CETP	C310	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
who	who	W000	WP	B-NP	O
totally	totally	T340	RB	B-VP	O
lack	lack	L200	VBP	I-VP	O
plasma	plasma	P425	NN	B-NP	O
CETP	CETP	C310	NN	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
lipoprotein	lipoprotein	L163	NN	B-NP	O
profiles	profile	P614	NNS	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
homozygotes	homozygote	H523	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
Mediterranean	Mediterranean	M365	JJ	B-NP	O
variant	variant	V653	NN	I-NP	O
and	and	A530	CC	I-NP	O
description	description	D261	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Andalus1361A	Andalus1361A	A534	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
;	;	0000	:	O	I-Disease
E	E	E000	NN	B-NP	I-Disease
.	.	0000	.	O	I-Disease
C	C	C000	NN	B-NP	I-Disease
.	.	0000	.	O	I-Disease
1	1	0000	CD	B-NP	I-Disease
.	.	0000	.	O	I-Disease
1	1	0000	CD	B-NP	I-Disease
.	.	0000	.	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
49	49	0000	CD	O	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
enzymopathy	enzymopathy	E525	NN	I-NP	B-Disease
;	;	0000	:	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
300	300	0000	CD	I-NP	O
different	different	D165	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
parts	part	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
the	the	T000	DT	B-NP	O
Mediterranean	Mediterranean	M365	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
prevalent	prevalent	P614	JJ	B-ADJP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	B-NP	O
has	have	H200	VBZ	B-VP	O
come	come	C500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
generic	generic	G562	JJ	I-NP	O
term	term	T650	NN	I-NP	O
applied	apply	A143	VBN	B-VP	O
to	to	T000	TO	B-PP	O
similar	similar	S546	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
thought	think	T230	VBD	B-VP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
represent	represent	R162	VB	I-VP	O
a	a	A000	DT	B-NP	O
somewhat	somewhat	S530	RB	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
group	group	G610	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
563	563	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Vulliamy	Vulliamy	V450	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
De	De	D000	NNP	B-NP	O
Vita	Vita	V300	NNP	I-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Sassari	Sassari	S260	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Cagliari	Cagliari	C246	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1311	1311	0000	NN	I-NP	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
produce	produce	P632	VB	I-VP	O
a	a	A000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
change	change	C520	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
Spanish	Spanish	S152	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
having	have	H152	VBG	B-VP	O
enzymatically	enzymatically	E525	RB	I-VP	O
documented	document	D253	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
had	have	H300	VBD	B-VP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
563	563	0000	CD	I-NP	O
and	and	A530	CC	O	O
that	that	T300	DT	B-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1311	1311	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
sixth	sixth	S230	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
,	,	0000	,	O	O
resembling	resemble	R251	VBG	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
kinetically	kinetically	K532	RB	B-ADVP	O
but	but	B300	CC	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
slightly	slightly	S423	RB	I-NP	O
rapid	rapid	R130	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
designated	designate	D253	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Andalus	Andalus	A534	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1361	1361	0000	CD	I-NP	O
,	,	0000	,	O	O
producing	produce	P632	VBG	B-VP	O
an	an	A500	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
histidine	histidine	H235	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	B-NP	O
is	be	I200	VBZ	B-VP	O
,	,	0000	,	O	O
after	after	A136	IN	B-PP	O
all	all	A400	DT	B-NP	O
,	,	0000	,	O	O
relatively	relatively	R431	RB	B-ADJP	O
homogeneous	homogeneous	H525	JJ	I-ADJP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
exon	exon	E250	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
with	with	W300	IN	B-PP	O
identical	identical	I353	JJ	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
single	single	S524	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
middle	middle	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
;	;	0000	:	O	O
one	one	O500	CD	B-NP	O
brother	brother	B636	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
Becker	Becker	B260	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
diagnosed	diagnose	D252	VBN	B-VP	O
at	at	A300	IN	B-PP	O
11	11	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
older	old	O436	JJR	I-NP	O
brother	brother	B636	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
18	18	0000	CD	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counselling	counselling	C524	NN	I-NP	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Becker	Becker	B260	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
diseased	diseased	D230	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
myogenic	myogenic	M252	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
cultures	culture	C436	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
muscle	muscle	M240	NN	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
from	from	F650	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
fetal	fetal	F340	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
adult	adult	A343	JJ	B-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
and	and	A530	CC	I-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cultured	culture	C436	VBN	B-NP	O
muscle	muscle	M240	NN	I-NP	O
after	after	A136	IN	B-PP	O
myoblast	myoblast	M142	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
revealed	reveal	R143	VBN	I-VP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
RNA	RNA	R500	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
regenerating	regenerate	R256	VBG	B-VP	O
muscle	muscle	M240	NN	B-NP	O
fibers	fiber	F162	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
and	and	A530	CC	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Eighty	Eighty	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
or	or	O600	CC	B-NP	O
Becker	Becker	B260	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
includes	include	I524	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
five	five	F100	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cDNA5b	cDNA5b	C351	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cDNA8	cDNA8	C350	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
two	two	T000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cDNA9	cDNA9	C350	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
80	80	0000	CD	I-NP	O
individuals	individual	I531	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
75	75	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
109	109	0000	CD	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
detected	detect	D323	VBN	B-VP	O
among	among	A520	IN	B-PP	O
181	181	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

Endpoints	Endpoint	E531	NNS	B-NP	O
for	for	F600	IN	B-PP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
further	further	F636	RBR	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
two	two	T000	CD	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
probes	probe	P612	NNS	I-NP	O
,	,	0000	,	O	O
p20	p20	P000	NN	B-NP	O
(	(	0000	(	O	O
DXS269	DXS269	D200	NN	B-NP	O
;	;	0000	:	O	O
Wapenaar	Wapenaar	W156	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
GMGX11	GMGX11	G520	NN	B-NP	O
(	(	0000	(	O	O
DXS239	DXS239	D200	NN	B-NP	O
;	;	0000	:	O	O
present	present	P625	JJ	B-NP	O
paper	paper	P160	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
presented	present	P625	VBN	I-VP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
80	80	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
allowing	allow	A452	VBG	B-VP	O
a	a	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
severity	severity	S163	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
.	.	0000	.	O	O

Thirty	Thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
eight	eight	E230	CD	I-NP	O
independent	independent	I531	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
old	old	O430	JJ	B-ADJP	O
enough	enough	E520	RB	I-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
,	,	0000	,	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
intermediate	intermediate	I536	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
with	with	W300	IN	B-PP	O
sequenced	sequence	S252	VBN	B-NP	O
intron	intron	I536	NN	I-NP	O
/	/	0000	SYM	B-NP	O
exon	exon	E250	NN	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
,	,	0000	,	O	O
eight	eight	E230	CD	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
had	have	H300	VBD	B-VP	O
gene	gene	G500	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	I-VP	O
leave	leave	L100	VB	I-VP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
intact	intact	I532	JJ	B-ADJP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
21	21	0000	CD	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
had	have	H300	VBD	B-VP	O
gene	gene	G500	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	B-VP	O
disrupt	disrupt	D261	VB	I-VP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
exceptions	exception	E213	NNS	I-NP	O
,	,	0000	,	O	O
frameshift	frameshift	F652	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
more	more	M600	RBR	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
than	than	T500	IN	B-SBAR	O
did	do	D300	VBD	B-VP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
agreement	agreement	A265	NN	B-NP	O
with	with	W300	IN	B-PP	O
recent	recent	R253	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
by	by	B000	IN	B-PP	O
Baumbach	Baumbach	B512	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
and	and	A530	CC	O	O
Koenig	Koenig	K520	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
findings	finding	F535	NNS	B-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
Malhotra	Malhotra	M436	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
of	of	O100	IN	B-PP	O
breakpoints	breakpoint	B621	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
translocation	translocation	T652	NN	I-NP	O
identifies	identify	I353	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Chromosome	Chromosome	C652	NN	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
involving	involve	I514	VBG	B-VP	O
11p13	11p13	P000	NN	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
highlighting	highlight	H242	VBG	B-VP	O
the	the	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAGR	WAGR	W260	NN	I-NP	B-Disease
complex	complex	C514	NN	I-NP	O
(	(	0000	(	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
,	,	0000	,	O	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
genitourinary	genitourinary	G536	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
kindred	kindred	K536	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
probes	probe	P612	NNS	B-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
and	and	A530	CC	I-VP	O
clone	clone	C450	VB	I-VP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
phage	phage	P200	NN	B-NP	O
restriction	restriction	R236	NN	I-NP	O
maps	map	M120	NNS	I-NP	O
exclude	exclude	E243	VBP	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
sizable	sizable	S214	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

Sequences	Sequence	S252	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
are	be	A600	VBP	B-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
species	specie	S120	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
falls	fall	F420	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
C2	C2	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
19	19	0000	CD	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
C2	C2	C000	NN	I-NP	O
(	(	0000	(	O	O
APOC2	APOC2	A120	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
situated	situate	S300	VBN	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19	19	0000	CD	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
APOC2	APOC2	A120	NN	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
(	(	0000	(	O	O
TaqI	TaqI	T200	NNP	B-NP	O
,	,	0000	,	O	O
BglI	BglI	B240	NNP	B-NP	O
,	,	0000	,	O	O
BanI	BanI	B500	NNP	B-NP	O
,	,	0000	,	O	O
BamHI	BamHI	B500	NNP	B-NP	O
,	,	0000	,	O	O
NcoI	NcoI	N200	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
AvaII	AvaII	A100	NN	B-NP	O
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
to	to	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
utilizing	utilize	U342	VBG	B-VP	O
all	all	A400	DT	B-NP	O
six	six	S200	CD	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
and	and	A530	CC	O	O
involving	involve	I514	VBG	B-VP	O
50	50	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
372	372	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
informative	informative	I516	JJ	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
descending	descend	D253	VBG	B-VP	O
order	order	O636	NN	B-NP	O
,	,	0000	,	O	O
NcoI	NcoI	N200	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
64	64	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
BglI	BglI	B240	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
AvaII	AvaII	A100	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
02	02	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
BanI	BanI	B500	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
76	76	0000	CD	I-NP	O
,	,	0000	,	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
TaqI	TaqI	T200	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
4	4	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
29	29	0000	CD	I-NP	O
,	,	0000	,	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
06	06	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
BamHI	BamHI	B500	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
75	75	0000	CD	I-NP	O
,	,	0000	,	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
over	over	O160	IN	B-PP	O
those	those	T200	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
individual	individual	I531	JJ	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
(	(	0000	(	O	O
composed	compose	C512	VBN	B-VP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
17	17	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
87	87	0000	CD	I-NP	O
,	,	0000	,	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
observed	observe	O126	VBN	I-VP	O
significant	significant	S251	JJ	B-NP	O
inter	inter	I536	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
RFLP	RFLP	R141	NN	I-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
most	most	M230	RBS	I-NP	O
informative	informative	I516	JJ	I-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
BanI	BanI	B500	NNP	B-NP	O
,	,	0000	,	O	O
TaqI	TaqI	T200	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
either	either	E360	DT	O	O
BglI	BglI	B240	NNP	B-NP	O
,	,	0000	,	O	O
AvaII	AvaII	A100	NNP	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
NcoI	NcoI	N200	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
between	between	B350	IN	B-PP	O
DM	DM	D500	NN	B-NP	O
and	and	A530	CC	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
French	French	F652	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
population	population	P143	NN	I-NP	O
(	(	0000	(	O	O
standardized	standardized	S353	JJ	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
constant	constant	C523	NN	I-NP	O
phi	phi	P000	NN	I-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
22	22	0000	CD	B-NP	O
,	,	0000	,	O	O
chi	chi	C000	NN	B-NP	O
2	2	0000	CD	I-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
df	df	D100	NN	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-VP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
04	04	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
between	between	B350	IN	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Phenylalanine	Phenylalanine	P545	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Polynesians	Polynesian	P452	NNPS	B-NP	O
:	:	0000	:	O	O
evolutionary	evolutionary	E143	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
and	and	A530	CC	O	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
alleles	allele	A420	NNS	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
630	630	0000	CD	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
locus	locus	L200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
groups	group	G612	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Polynesians	Polynesian	P452	NNPS	B-NP	O
comprising	comprise	C516	VBG	B-VP	O
Samoans	Samoans	S520	NNP	B-NP	O
,	,	0000	,	O	O
Tongans	Tongans	T525	NNP	B-NP	O
,	,	0000	,	O	O
Cook	Cook	C200	NNP	B-NP	O
Islanders	Islanders	I245	NNP	I-NP	O
,	,	0000	,	O	O
Maori	Maori	M600	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Niueans	Niuean	N520	NNS	B-NP	O
.	.	0000	.	O	O

Considerable	Considerable	C523	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
continuity	continuity	C535	NN	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
between	between	B350	IN	B-PP	O
these	these	T200	DT	B-NP	O
widely	widely	W340	RB	I-NP	O
dispersed	dispersed	D216	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
three	three	T600	CD	B-NP	O
common	common	C500	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
7	7	0000	CD	B-NP	O
)	)	0000	)	O	O
constituted	constitute	C523	VBN	B-VP	O
over	over	O160	IN	B-PP	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
alleles	allele	A420	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
control	control	C536	NN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
from	from	F650	IN	B-PP	O
Southeast	Southeast	S323	NNP	B-NP	O
Asia	Asia	A200	NNP	I-NP	O
shared	share	S630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
major	major	M260	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
7	7	0000	CD	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
Polynesians	Polynesian	P452	NNPS	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
support	support	S163	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
theories	theory	T620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
homogeneity	homogeneity	H525	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
Asian	Asian	A250	JJ	B-NP	O
affinities	affinity	A153	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Polynesian	Polynesian	P452	JJ	I-NP	O
precursor	precursor	P626	NN	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
Polynesians	Polynesian	P452	NNPS	B-NP	O
and	and	A530	CC	O	O
Southeast	Southeast	S323	NNP	B-NP	O
Asians	Asian	A252	NNPS	I-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
mutants	mutant	M353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
arisen	arise	A625	VBN	I-VP	O
among	among	A520	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Preferential	Preferential	P616	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
event	event	E153	NN	I-NP	O
triggering	trigger	T626	VBG	B-VP	O
malignant	malignant	M425	JJ	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
in	in	I500	IN	B-PP	O
70	70	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
for	for	F600	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
13q14	13q14	Q000	NN	I-NP	O
,	,	0000	,	O	O
whereby	whereby	W610	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
allele	allele	A400	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
lost	lose	L230	VBN	I-VP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
already	already	A463	RB	I-NP	O
mutated	mutate	M300	VBN	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
suffers	suffer	S162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
event	event	E153	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
deletion	deletion	D435	NN	B-NP	O
,	,	0000	,	O	O
duplication	duplication	D142	NN	B-NP	O
or	or	O600	CC	O	O
point	point	P530	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
manuscript	manuscript	M526	NN	B-NP	O
in	in	I500	IN	B-PP	O
preparation	preparation	P616	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-ADJP	O
either	either	E360	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
(	(	0000	(	O	O
all	all	A400	DT	B-NP	O
bilateral	bilateral	B436	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
retinal	retinal	R354	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
(	(	0000	(	O	O
most	most	M230	RBS	B-NP	O
unilateral	unilateral	U543	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
bilateral	bilateral	B436	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
no	no	N000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
presumed	presume	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
new	new	N000	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
arose	arise	A620	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
egg	egg	E200	NN	I-NP	O
,	,	0000	,	O	O
sperm	sperm	S165	NN	B-NP	O
or	or	O600	CC	O	O
early	early	E640	JJ	B-NP	O
embryo	embryo	E516	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
parental	parental	P653	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retained	retain	R353	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
from	from	F650	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
RB1	RB1	R100	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
retained	retain	R353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
retained	retain	R353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
unilateral	unilateral	U543	JJ	I-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
retained	retain	R353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
retained	retain	R353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
suggested	suggest	S230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
case	case	C200	NN	I-NP	O
in	in	I500	IN	B-PP	O
osteosarcoma	osteosarcoma	O232	NN	B-NP	B-Disease
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
tumours	tumour	T562	NNS	B-NP	B-Disease
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
five	five	F100	CD	I-NP	O
bilateral	bilateral	B436	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
retained	retain	R353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
either	either	E360	CC	O	O
that	that	T300	IN	B-SBAR	O
new	new	N000	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
RB1	RB1	R100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
arise	arise	A620	VBP	B-VP	O
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
during	during	D652	IN	B-PP	O
spermatogenesis	spermatogenesis	S165	NN	B-NP	O
than	than	T500	IN	B-PP	O
during	during	D652	IN	B-PP	O
oogenesis	oogenesis	O252	NN	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
that	that	T300	IN	B-SBAR	O
imprinting	imprinting	I516	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
embryo	embryo	E516	NN	I-NP	O
affects	affect	A123	VBZ	B-VP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
mutation	mutation	M350	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Turkish	Turkish	T620	JJ	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
the	the	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
and	and	A530	CC	I-NP	O
normal	normal	N654	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
alleles	allele	A420	NNS	B-NP	O
for	for	F600	IN	B-PP	O
17	17	0000	CD	B-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
families	family	F542	VBZ	B-VP	O
20	20	0000	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
27	27	0000	CD	I-NP	O
mutated	mutate	M300	VBN	I-NP	O
PAH	PAH	P000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
6	6	0000	CD	I-NP	O
(	(	0000	(	O	O
29	29	0000	CD	B-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
(	(	0000	(	O	O
18	18	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
36	36	0000	CD	B-NP	O
(	(	0000	(	O	O
11	11	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
19	19	0000	CD	I-NP	O
different	different	D165	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
differed	differ	D163	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Northern	Northern	N636	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
sites	site	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
analysed	analyse	A542	VBN	B-VP	O
.	.	0000	.	O	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
locus	locus	L200	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
63	63	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
between	between	B350	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
and	and	A530	CC	O	O
G8	G8	G000	NN	B-NP	O
(	(	0000	(	O	O
D4S10	D4S10	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
included	include	I524	VBD	B-VP	O
57	57	0000	CD	B-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
,	,	0000	,	I-NP	O
four	four	F600	CD	I-NP	O
Black	Black	B420	NNP	I-NP	O
American	American	A562	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
Japanese	Japanese	J152	NNPS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
combined	combined	C515	JJ	I-NP	O
maximum	maximum	M250	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
was	be	W200	VBD	B-VP	O
87	87	0000	CD	B-NP	O
.	.	0000	.	O	O

69	69	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

04	04	0000	CD	B-NP	O
(	(	0000	(	O	O
99	99	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
018	018	0000	CD	I-NP	O
-	-	0000	:	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
071	071	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
maximum	maximum	M250	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
was	be	W200	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

03	03	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
and	and	A530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
.	.	0000	.	O	O

Fifty	Fifty	F130	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
seven	seven	S150	CD	I-NP	O
families	family	F542	NNS	I-NP	O
gave	give	G100	VBD	B-VP	O
positive	positive	P231	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
;	;	0000	:	O	O
five	five	F100	CD	B-NP	O
small	small	S540	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
gave	give	G100	VBD	B-VP	O
mildly	mildly	M434	RB	B-NP	O
negative	negative	N231	JJ	I-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
maximum	maximum	M250	JJ	I-NP	O
likelihood	likelihood	L243	NN	I-NP	O
estimate	estimate	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
alpha	alpha	A410	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
linked	link	L523	VBN	B-NP	O
loci	locus	L200	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
99	99	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

88	88	0000	CD	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
rare	rare	R600	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
ruled	rule	R430	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
and	and	A530	CC	I-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
Finnish	Finnish	F520	JJ	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Multipoint	Multipoint	M431	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
(	(	0000	(	O	O
TCD	TCD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
seven	seven	S150	CD	B-NP	O
X	X	X000	NN	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
RFLPs	RFLP	R141	NNS	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
in	in	I500	IN	B-PP	O
18	18	0000	CD	B-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
place	place	P420	NN	I-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
PGK	PGK	P200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXS72	DXS72	D200	NN	I-NP	O
,	,	0000	,	O	O
very	very	V600	RB	B-ADVP	O
close	close	C420	RB	I-ADVP	O
to	to	T000	TO	B-PP	O
DXYS1	DXYS1	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXYS5	DXYS5	D200	NN	I-NP	O
(	(	0000	(	O	O
Zmax	Zmax	Z520	NN	B-NP	O
=	=	0000	SYM	B-VP	O
24	24	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DXYS4	DXYS4	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXYS12	DXYS12	D200	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
agrees	agree	A262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
other	other	O360	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
physical	physical	P240	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
carrier	carrier	C600	NN	B-NP	O
females	female	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
DXYS1	DXYS1	D200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
coupling	couple	C145	VBG	B-VP	O
with	with	W300	IN	B-PP	O
TCD	TCD	T230	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Northeastern	Northeastern	N632	NNP	B-NP	O
Finland	Finland	F545	NNP	I-NP	O
,	,	0000	,	O	O
66	66	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
69	69	0000	CD	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
TCD	TCD	T230	NN	B-NP	B-Disease
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
loci	locus	L200	NNS	B-NP	O
DXS72	DXS72	D200	NN	I-NP	O
,	,	0000	,	O	O
DXYS1	DXYS1	D200	NN	B-NP	O
,	,	0000	,	O	O
DXYS4	DXYS4	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
DXYS12	DXYS12	D200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
15	15	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
not	not	N300	RB	B-VP	O
carrying	carry	C652	VBG	I-VP	O
TCD	TCD	T230	NN	B-NP	B-Disease
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
71	71	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
104	104	0000	CD	I-NP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
TCD	TCD	T230	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
six	six	S200	CD	B-NP	O
marker	marker	M626	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
76	76	0000	CD	I-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Northern	Northern	N636	JJ	I-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
comprising	comprise	C516	VBG	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-NP	O
80	80	0000	CD	I-NP	O
living	living	L152	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
representing	represent	R162	VBG	B-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	B-PP	O
a	a	A000	DT	B-NP	O
fifth	fifth	F130	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
described	describe	D261	VBN	B-VP	O
worldwide	worldwide	W643	RB	B-ADVP	O
,	,	0000	,	O	O
carry	carry	C600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
and	and	A530	CC	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
improved	improved	I516	JJ	B-NP	O
opportunities	opportunity	O163	NNS	I-NP	O
for	for	F600	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11p13	11p13	P000	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
catalase	catalase	C342	NN	I-NP	O
and	and	A530	CC	I-NP	O
D11S151	D11S151	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
close	close	C420	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
AN2	AN2	A500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
catalase	catalase	C342	NN	I-NP	O
(	(	0000	(	O	O
CAT	CAT	C300	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
zeta	zeta	Z300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
7	7	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
27	27	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
D11S151	D11S151	D200	NN	B-NP	O
(	(	0000	(	O	O
zeta	zeta	Z300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
86	86	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
10	10	0000	CD	B-NP	O
)	)	0000	)	O	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
.	.	0000	.	O	O

Positive	Positive	P231	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
obtained	obtain	O135	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
11p13	11p13	P000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
11p14	11p14	P000	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
D11S16	D11S16	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
FSHB	FSHB	F210	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
group	group	G610	NN	I-NP	O
CAT	CAT	C300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
AN2	AN2	A500	NN	I-NP	O
/	/	0000	SYM	B-NP	O
D11S151	D11S151	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
AN2	AN2	A500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
excluded	exclude	E243	VBN	I-VP	O
linkage	linkage	L520	NN	B-NP	O
(	(	0000	(	O	O
zeta	zeta	Z300	NN	B-NP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
-	-	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
18	18	0000	CD	I-NP	O
)	)	0000	)	O	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
2p25	2p25	P000	CD	I-NP	O
marker	marker	M626	NN	I-NP	O
D2S1	D2S1	D200	NN	I-NP	O
(	(	0000	(	O	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
ACP1	ACP1	A210	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Recombination	Recombination	R251	NN	B-NP	O
events	event	E153	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
locate	locate	L230	VBP	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
on	on	O500	IN	B-PP	O
19q	19q	Q000	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
previously	previously	P612	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
placed	place	P423	VBD	B-VP	O
the	the	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
D19S19	D19S19	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
APOC2	APOC2	A120	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
side	side	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Haplotyping	Haplotyping	H143	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
more	more	M600	RBR	B-ADVP	O
recently	recently	R253	RB	I-ADVP	O
characterized	characterize	C623	VBN	B-NP	O
probes	probe	P612	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
either	either	E360	RB	B-VP	O
tightly	tightly	T234	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
or	or	O600	CC	O	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
group	group	G610	NN	I-NP	O
at	at	A300	IN	B-PP	O
q13	q13	Q000	NN	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
other	other	O360	JJ	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
where	where	W600	WRB	B-ADVP	O
DM	DM	D500	NN	B-NP	B-Disease
segregates	segregate	S262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
distal	distal	D234	JJ	B-NP	O
probes	probe	P612	NNS	I-NP	O
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
marker	marker	M626	NN	I-NP	O
to	to	T000	TO	B-PP	O
marker	marker	M626	NN	B-NP	O
recombinations	recombination	R251	NNS	I-NP	O
in	in	I500	IN	B-PP	O
unaffected	unaffected	U512	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
and	and	A530	CC	I-NP	O
orientation	orientation	O653	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
linkage	linkage	L520	NN	I-NP	O
group	group	G610	NN	I-NP	O
as	as	A200	IN	B-PP	O
pter	pter	P360	NN	B-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
INSR	INSR	I526	NN	B-NP	O
,	,	0000	,	O	O
LDLR	LDLR	L346	NN	B-NP	O
,	,	0000	,	O	O
S9	S9	S000	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
S19	S19	S000	NN	B-NP	O
,	,	0000	,	O	O
BCL3	BCL3	B240	NN	B-NP	O
,	,	0000	,	O	O
APOC2	APOC2	A120	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
CKMM	CKMM	C250	NN	B-NP	O
,	,	0000	,	O	O
DM	DM	D500	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
S22	S22	S000	NN	B-NP	O
,	,	0000	,	O	O
+	+	0000	SYM	B-NP	O
+	+	0000	SYM	B-VP	O
+	+	0000	SYM	B-NP	O
PRKCG	PRKCG	P620	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
qter	qter	Q360	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
cannot	cannot	C530	MD	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
or	or	O600	CC	I-ADJP	O
distal	distal	D234	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
CKMM	CKMM	C250	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
consequences	consequence	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
order	order	O636	NN	I-NP	O
for	for	F600	IN	B-PP	O
antenatal	antenatal	A535	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
and	and	A530	CC	O	O
future	future	F360	JJ	B-NP	O
research	research	R262	NN	I-NP	O
aiming	aim	A520	VBG	B-VP	O
to	to	T000	TO	I-VP	O
isolate	isolate	I243	VB	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
affected	affect	A123	VBN	I-VP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
discussed	discuss	D230	VBN	I-VP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
.	.	0000	.	O	O

Inactivation	Inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
during	during	D652	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
retinal	retinal	R354	JJ	I-NP	O
development	development	D141	NN	I-NP	O
initiates	initiate	I532	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
(	(	0000	(	O	I-Disease
RB	RB	R100	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
tumor	tumor	T560	NN	B-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
inactivate	inactivate	I523	VBP	B-VP	O
RB1	RB1	R100	NN	B-NP	O
,	,	0000	,	O	O
21	21	0000	CD	B-NP	O
RB	RB	R100	NN	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
19	19	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
or	or	O600	CC	O	O
an	an	A500	DT	B-NP	O
RNase	RNase	R520	NN	I-NP	O
protection	protection	P632	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
or	or	O600	CC	O	O
both	both	B300	DT	B-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
21	21	0000	CD	B-NP	O
RB	RB	R100	NN	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
precise	precise	P620	JJ	I-NP	O
errors	error	E620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
involved	involve	I514	VBD	B-VP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
or	or	O600	CC	I-NP	O
duplication	duplication	D142	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
three	three	T600	CD	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
splice	splice	S142	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
and	and	A530	CC	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
unable	unable	U514	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphoblasts	lymphoblast	L514	NNS	B-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
bilaterally	bilaterally	B436	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
transcripts	transcript	T652	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
obvious	obvious	O120	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB	RB	R100	NN	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
variations	variation	V635	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
deregulation	deregulation	D624	NN	B-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
transcription	transcription	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Partial	Partial	P634	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
8q	8q	Q000	NN	I-NP	O
without	without	W300	IN	B-PP	O
Langer	Langer	L526	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
recognisable	recognisable	R252	JJ	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
two	two	T000	CD	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
pter	pter	P360	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
q24	q24	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
breakpoints	breakpoint	B621	NNS	B-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
band	band	B530	NN	B-NP	O
8q24	8q24	Q000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
stigmata	stigmata	S325	NN	I-NP	O
of	of	O100	IN	B-PP	O
Langer	Langer	L526	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
LGS	LGS	L200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
three	three	T600	CD	B-NP	O
other	other	O360	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
reported	report	R163	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
8	8	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
the	the	T000	DT	I-NP	O
same	same	S500	JJ	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
without	without	W300	IN	B-PP	O
LGS	LGS	L200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
some	some	S500	DT	B-NP	O
similarities	similarity	S546	NNS	I-NP	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
two	two	T000	CD	I-NP	O
with	with	W300	IN	B-PP	O
LGS	LGS	L200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
would	would	W430	MD	B-VP	O
support	support	S163	VB	I-VP	O
the	the	T000	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
LGS	LGS	L200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
or	or	O600	CC	O	O
involves	involve	I514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
8q24	8q24	Q000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
review	review	R100	NN	I-NP	O
of	of	O100	IN	B-PP	O
published	publish	P142	VBN	B-NP	O
reports	report	R163	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
aetiology	aetiology	A342	NN	I-NP	O
of	of	O100	IN	B-PP	O
LGS	LGS	L200	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
complex	complex	C514	JJ	I-NP	O
issue	issue	I200	NN	I-NP	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
creatine	creatine	C635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
CKMM	CKMM	C250	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
genetic	genetic	G532	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
creatine	creatine	C635	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
muscle	muscle	M240	NN	I-NP	O
type	type	T100	NN	I-NP	O
(	(	0000	(	O	O
CKMM	CKMM	C250	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
65	65	0000	CD	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Canada	Canada	C530	NNP	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Netherlands	Netherlands	N364	NNP	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
(	(	0000	(	O	O
Zmax	Zmax	Z520	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
22	22	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

03	03	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
.	.	0000	.	O	O

Tight	Tight	T230	NN	B-NP	O
linkage	linkage	L520	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
for	for	F600	IN	B-PP	O
CKMM	CKMM	C250	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
C2	C2	C000	NN	I-NP	O
(	(	0000	(	O	O
ApoC2	ApoC2	A120	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
establishes	establish	E231	VBZ	B-VP	O
CKMM	CKMM	C250	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
for	for	F600	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease

Color	Color	C460	NN	B-NP	B-Disease
vision	vision	V250	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	B-Disease
color	color	C460	NN	I-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
and	and	A530	CC	O	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
27	27	0000	CD	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
31	31	0000	CD	B-NP	O
age	age	A200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
matched	match	M323	VBN	I-NP	O
controls	control	C536	NNS	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Farnsworth	Farnsworth	F652	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
Munsell	Munsell	M524	NNP	I-NP	O
100	100	0000	CD	I-NP	O
Hue	Hue	H000	NNP	I-NP	O
test	test	T230	NN	I-NP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
(	(	0000	(	O	O
44	44	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
test	test	T230	NN	B-NP	O
scores	score	S262	NNS	I-NP	O
significantly	significantly	S251	RB	B-ADVP	O
above	above	A100	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
axes	ax	A200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
bipolarity	bipolarity	B146	NN	B-NP	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
testing	testing	T235	NN	I-NP	O
differed	differ	D163	VBD	B-VP	O
widely	widely	W340	RB	B-ADVP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
scores	score	S262	NNS	I-NP	O
,	,	0000	,	O	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
different	different	D165	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
visual	visual	V240	JJ	B-NP	O
pigment	pigment	P253	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
confirm	confirm	C516	VBP	B-VP	O
our	our	O600	PRP$	B-NP	O
earlier	early	E646	JJR	I-NP	O
impression	impression	I516	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	B-Disease
color	color	C460	NN	I-NP	I-Disease
vision	vision	V250	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
increased	increase	I526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
supports	support	S163	VBZ	B-VP	O
our	our	O600	PRP$	B-NP	O
contentions	contention	C535	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
(	(	0000	(	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
companion	companion	C515	NN	I-NP	O
,	,	0000	,	I-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
very	very	V600	RB	I-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
visual	visual	V240	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
at	at	A300	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
this	this	T200	DT	B-NP	O
proximity	proximity	P625	NN	I-NP	O
might	might	M230	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
the	the	T000	DT	B-NP	O
opportunity	opportunity	O163	NN	I-NP	O
to	to	T000	TO	B-VP	O
observe	observe	O126	VB	I-VP	O
contiguous	contiguous	C532	JJ	B-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-VP	O
recessive	recessive	R210	JJ	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	B-Disease
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	I-Disease
[	[	0000	(	O	I-Disease
HPRT	HPRT	H163	NN	B-NP	I-Disease
]	]	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Cytogenetic	Cytogenetic	C325	JJ	B-NP	O
and	and	A530	CC	I-NP	O
carrier	carrier	C600	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
structurally	structurally	S362	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
her	her	H600	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
gametic	gametic	G532	JJ	I-NP	O
event	event	E153	NN	I-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
DNA	DNA	D500	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
microdeletion	microdeletion	M263	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
gamete	gamete	G530	NN	I-NP	O
and	and	A530	CC	O	O
involved	involve	I514	VBD	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
partially	partially	P634	RB	B-ADJP	O
responsible	responsible	R215	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
,	,	0000	,	O	O
generated	generate	G563	VBN	B-VP	O
to	to	T000	TO	I-VP	O
separate	separate	S163	VB	I-VP	O
maternal	maternal	M365	JJ	B-NP	O
and	and	A530	CC	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
,	,	0000	,	O	O
phosphoglycerate	phosphoglycerate	P212	JJ	B-NP	O
kinase	kinase	K520	NN	I-NP	O
and	and	A530	CC	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
contained	contain	C535	VBD	B-VP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
functionally	functionally	F523	RB	I-NP	O
inactive	inactive	I523	JJ	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
comparison	comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
methylation	methylation	M343	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
known	know	K500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
regulation	regulation	R243	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
differences	difference	D165	NNS	B-NP	O
between	between	B350	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
keeping	keep	K152	VBG	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
active	active	A231	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
inactive	inactive	I523	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
nonrandom	nonrandom	N565	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytogenetically	cytogenetically	C325	RB	I-NP	O
normal	normal	N654	JJ	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
microdeletion	microdeletion	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
an	an	A500	DT	B-NP	O
active	active	A231	JJ	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
were	be	W600	VBD	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
neurologic	neurologic	N642	JJ	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
myelin	myelin	M450	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
proteolipid	proteolipid	P634	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nosology	nosology	N242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
errors	error	E620	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
myelin	myelin	M450	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
stymied	stymie	S353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Historically	Historically	H236	RB	B-ADVP	O
,	,	0000	,	O	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
encompassed	encompass	E525	VBN	I-VP	O
a	a	A000	DT	B-NP	O
host	host	H230	NN	I-NP	O
of	of	O100	IN	B-PP	O
neurologic	neurologic	N642	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
present	present	P625	VBP	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficit	deficit	D123	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
myelin	myelin	M450	NN	B-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
membrane	membrane	M516	NN	I-NP	O
elaborated	elaborate	E416	VBN	B-VP	O
by	by	B000	IN	B-PP	O
glial	glial	G400	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
encircles	encircle	E526	VBZ	B-VP	O
and	and	A530	CC	O	O
successively	successively	S214	RB	B-VP	O
enwraps	enwrap	E561	VBZ	I-VP	O
axons	axon	A252	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
Pelizaeus	Pelizaeus	P420	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
pedigree	pedigree	P326	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
type	type	T100	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
progression	progression	P626	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
pathologic	pathologic	P342	JJ	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
myelinating	myelinating	M453	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
myelin	myelin	M450	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
discriminate	discriminate	D265	VB	I-VP	O
variants	variant	V653	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
oligonucleotide	oligonucleotide	O425	NN	B-NP	O
primers	primer	P656	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chain	chain	C500	NN	I-NP	O
-	-	0000	HYPH	O	O
reaction	reaction	R235	NN	B-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
amplify	amplify	A514	VB	B-VP	O
and	and	A530	CC	I-VP	O
sequence	sequence	S252	VB	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
proteolipid	proteolipid	P634	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
comprises	comprise	C516	VBZ	B-VP	O
half	half	H410	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myelin	myelin	M450	NN	I-NP	O
sheath	sheath	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
mother	mother	M360	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
more	more	M600	JJR	I-NP	O
than	than	T500	IN	I-NP	O
2	2	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
sequenced	sequence	S252	VBN	B-VP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
would	would	W430	MD	B-VP	O
create	create	C630	VB	I-VP	O
a	a	A000	DT	B-NP	O
serine	serine	S650	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
for	for	F600	IN	B-PP	O
proline	proline	P645	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
delineate	delineate	D453	VBP	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
define	define	D150	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
pathology	pathology	P342	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
dysmyelinating	dysmyelinate	D254	VBG	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
address	address	A362	VBP	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
classification	classification	C421	NN	I-NP	O
of	of	O100	IN	B-PP	O
inborn	inborn	I516	JJ	B-NP	B-Disease
errors	error	E620	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
myelin	myelin	M450	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
form	form	F650	NN	I-NP	O
(	(	0000	(	O	O
type	type	T100	NN	B-NP	O
I	I	I000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	O	O
more	more	M600	RBR	B-ADVP	O
severely	severely	S164	RB	B-VP	O
affected	affect	A123	VBN	I-VP	O
,	,	0000	,	O	O
connatal	connatal	C534	JJ	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
type	type	T100	NN	B-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
)	)	0000	)	O	I-Disease
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
display	display	D214	VB	I-VP	O
mutation	mutation	M350	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
(	(	0000	(	O	O
types	type	T120	NNS	B-NP	O
III	III	I000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
VI	VI	V000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
sometimes	sometimes	S535	RB	I-VP	O
been	be	B500	VBN	I-VP	O
categorized	categorize	C326	VBN	I-VP	O
as	as	A200	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
represent	represent	R162	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
encoding	encode	E523	VBG	B-VP	O
other	other	O360	JJ	B-NP	O
structural	structural	S362	JJ	I-NP	O
myelin	myelin	M450	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
or	or	O600	CC	I-NP	O
proteins	protein	P635	NNS	I-NP	O
critical	critical	C632	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
myelination	myelination	M453	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
platelet	platelet	P434	NN	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
vWD	vWD	V300	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
bleeding	bleed	B435	VBG	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
can	can	C500	MD	B-VP	O
result	result	R243	VB	I-VP	O
from	from	F650	IN	B-PP	O
either	either	E360	CC	O	O
a	a	A000	DT	B-NP	O
quantitative	quantitative	Q531	JJ	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
qualitative	qualitative	Q431	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
adhesive	adhesive	A321	JJ	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
,	,	0000	,	O	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
vWF	vWF	V100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
vWD	vWD	V300	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
limited	limit	L530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	I-NP	O
difficulty	difficulty	D124	NN	I-NP	O
in	in	I500	IN	B-PP	O
obtaining	obtain	O135	VBG	B-VP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
adaptation	adaptation	A313	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
,	,	0000	,	O	O
vWF	vWF	V100	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
silent	silent	S453	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
cis	cis	C200	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
or	or	O600	CC	I-NP	O
processing	processing	P625	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
type	type	T100	NN	I-NP	B-Disease
IIA	IIA	I000	NN	I-NP	I-Disease
vWD	vWD	V300	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
but	but	B300	CC	I-NP	O
adjacent	adjacent	A325	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
identify	identify	I353	VB	I-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
functional	functional	F523	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
in	in	I500	IN	B-PP	O
heterologous	heterologous	H364	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
recombinant	recombinant	R251	JJ	B-NP	O
vWF	vWF	V100	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
reproduced	reproduce	R163	VBD	B-VP	O
the	the	T000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
IIA	IIA	I000	NN	I-NP	I-Disease
vWD	vWD	V300	NN	I-NP	I-Disease
plasma	plasma	P425	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
an	an	A500	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
girl	girl	G640	NN	I-NP	O
suffering	suffer	S165	VBG	B-VP	O
from	from	F650	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
absence	absence	A125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C7	C7	C000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Diagnosis	Diagnosis	D252	NN	B-NP	O
was	be	W200	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
by	by	B000	IN	B-PP	O
haemolytic	haemolytic	H543	JJ	B-NP	O
titration	titration	T363	NN	I-NP	O
and	and	A530	CC	O	O
western	western	W236	JJ	B-NP	O
blotting	blotting	B435	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
lacked	lack	L230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
85	85	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
C7	C7	C000	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
.	.	0000	.	O	O

Haemolytic	Haemolytic	H543	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
was	be	W200	VBD	B-VP	O
reconstituted	reconstitute	R252	VBN	I-VP	O
with	with	W300	IN	B-PP	O
either	either	E360	CC	O	O
pooled	pool	P430	VBN	B-VP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
or	or	O600	CC	B-PP	O
with	with	W300	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C7	C7	C000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relatives	relative	R431	NNS	I-NP	O
(	(	0000	(	O	O
parents	parent	P653	NNS	B-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
sister	sister	S236	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
half	half	H410	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
immunochemically	immunochemically	I525	RB	B-ADVP	O
and	and	A530	CC	O	O
functionally	functionally	F523	RB	B-NP	O
determined	determine	D365	VBN	I-NP	O
C7	C7	C000	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
state	state	S300	NN	I-NP	O
for	for	F600	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Translocation	Translocation	T652	NN	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
;	;	0000	:	O	O
11	11	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q13	q13	Q000	NN	B-NP	O
.	.	0000	.	B-NP	O
1	1	0000	CD	I-NP	O
;	;	0000	:	O	O
p13	p13	P000	NN	B-NP	O
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
isolated	isolate	I243	VBN	I-NP	B-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	I-NP	O
daughter	daughter	D236	NN	I-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
aniridia	aniridia	A563	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
an	an	A500	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
balanced	balanced	B452	JJ	I-NP	O
,	,	0000	,	I-NP	O
reciprocal	reciprocal	R216	JJ	I-NP	O
translocation	translocation	T652	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
chromosomes	chromosome	C652	NNS	B-NP	O
5	5	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
11	11	0000	CD	I-NP	O
[	[	0000	(	O	O
t	t	T000	NN	B-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
;	;	0000	:	O	O
11	11	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q13	q13	Q000	NN	B-NP	O
.	.	0000	.	B-NP	O
1	1	0000	CD	I-NP	O
;	;	0000	:	O	O
p13	p13	P000	NN	B-NP	O
)	)	0000	)	O	O
]	]	0000	)	O	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
often	often	O135	RB	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
3	3	0000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
instances	instance	I523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
breaks	break	B620	NNS	I-NP	O
at	at	A300	IN	B-PP	O
11p13	11p13	P000	NN	B-NP	O
and	and	A530	CC	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
,	,	0000	,	O	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
AN2	AN2	A500	NN	B-NP	O
to	to	T000	TO	B-PP	O
11p13	11p13	P000	NN	B-NP	O
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	B-Disease
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
abetalipoproproteinemia	abetalipoproproteinemia	A134	NN	B-NP	B-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

apoB	apoB	A100	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
,	,	0000	,	O	O
RNA	RNA	R500	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
protein	protein	P635	NN	B-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	B-Disease
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	I-Disease
(	(	0000	(	O	O
HBL	HBL	H140	NN	B-NP	B-Disease
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
and	and	A530	CC	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
10	10	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
without	without	W300	IN	B-PP	O
major	major	M260	JJ	B-NP	O
insertions	insertion	I526	NNS	I-NP	O
,	,	0000	,	O	O
deletions	deletion	D435	NNS	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
rearrangements	rearrangement	R652	NNS	B-NP	O
.	.	0000	.	O	O

Northern	Northern	N636	NN	B-NP	O
and	and	A530	CC	I-NP	O
slot	slot	S430	NN	I-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
liver	liver	L160	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
from	from	F650	IN	B-PP	O
HBL	HBL	H140	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
documented	document	D253	VBD	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
size	size	S200	NN	I-NP	O
apoB	apoB	A100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
greatly	greatly	G634	RB	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
quantities	quantity	Q532	NNS	I-NP	O
.	.	0000	.	O	O

ApoB	ApoB	A100	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
within	within	W350	IN	B-PP	O
HBL	HBL	H140	NN	B-NP	B-Disease
hepatocytes	hepatocyte	H132	NNS	I-NP	O
utilizing	utilize	U342	VBG	B-VP	O
immunohistochemical	immunohistochemical	I523	JJ	B-NP	O
techniques	technique	T252	NNS	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
markedly	markedly	M623	RB	I-VP	O
reduced	reduce	R323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
quantity	quantity	Q530	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
control	control	C536	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detectable	detectable	D323	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
of	of	O100	IN	B-PP	O
HBL	HBL	H140	NN	B-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
ELISA	ELISA	E420	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
most	most	M230	RBS	B-ADJP	O
consistent	consistent	C523	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
apoB	apoB	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
HBL	HBL	H140	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
apoB	apoB	A100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
apoB	apoB	A100	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
previously	previously	P612	RB	B-VP	O
noted	note	N300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
abetalipoproteinemia	abetalipoproteinemia	A134	NN	B-NP	B-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	O
apoB	apoB	A100	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	I-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
apoB	apoB	A100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Spontaneous	Spontaneous	S153	JJ	B-NP	O
reversion	reversion	R162	NN	I-NP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
by	by	B000	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
duplication	duplication	D142	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
cloning	cloning	C452	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
which	which	W200	WDT	B-NP	O
shows	show	S200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
precise	precise	P620	JJ	I-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
2	2	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
internal	internal	I536	JJ	I-NP	O
duplication	duplication	D142	NN	I-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
duplication	duplication	D142	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
generated	generate	G563	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
unequal	unequal	U524	JJ	I-NP	O
crossing	cross	C625	VBG	I-NP	O
-	-	0000	HYPH	B-VP	O
over	over	O160	RP	B-PRT	O
event	event	E153	NN	B-NP	O
between	between	B350	IN	B-PP	O
two	two	T000	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Growth	Growth	G630	NN	B-NP	O
of	of	O100	IN	B-PP	O
Epstein	Epstein	E123	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Barr	Barr	B600	NNP	I-NP	I-Disease
virus	virus	V620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
transformed	transform	T652	VBN	I-NP	O
lymphoblasts	lymphoblast	L514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
in	in	I500	IN	B-PP	O
selective	selective	S423	JJ	B-NP	O
medium	medium	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
permitted	permit	P653	VBN	I-VP	O
isolation	isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
spontaneous	spontaneous	S153	JJ	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
+	+	0000	SYM	B-NP	O
revertants	revertant	R163	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
reversion	reversion	R162	NN	I-NP	O
event	event	E153	NN	I-NP	O
involves	involve	I514	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
major	major	M260	JJ	I-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
most	most	M230	JJS	B-NP	O
or	or	O600	CC	O	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
duplicated	duplicated	D142	JJ	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
therefore	therefore	T616	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	NN	I-NP	O
for	for	F600	IN	B-PP	O
spontaneous	spontaneous	S153	JJ	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
reversion	reversion	R162	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
mild	mild	M430	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
exhibited	exhibit	E213	VBN	B-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Complex	Complex	C514	NN	B-NP	B-Disease
glycerol	glycerol	G426	NN	I-NP	I-Disease
kinase	kinase	K520	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
molecular	molecular	M424	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
,	,	0000	,	I-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
male	male	M400	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
complex	complex	C514	JJ	B-NP	B-Disease
glycerol	glycerol	G426	NN	I-NP	I-Disease
kinase	kinase	K520	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
CGKD	CGKD	C230	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
relatives	relative	R431	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
clinically	clinically	C452	RB	B-ADVP	O
,	,	0000	,	O	O
cytogenetically	cytogenetically	C325	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-ADJP	O
-	-	0000	HYPH	O	O
genetically	genetically	G532	RB	B-ADVP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
muscle	muscle	M240	NN	I-NP	B-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
adrenal	adrenal	A365	JJ	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
glycerol	glycerol	G426	NN	B-NP	B-Disease
kinase	kinase	K520	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

High	High	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
GTG	GTG	G320	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
banded	band	B530	VBN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
microdeletion	microdeletion	M263	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Xp21	Xp21	X100	NN	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
five	five	F100	CD	I-NP	O
mothers	mother	M362	NNS	I-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	JJ	B-NP	O
hybridizations	hybridization	H163	NNS	I-NP	O
,	,	0000	,	O	O
after	after	A136	IN	B-PP	O
digestions	digestion	D235	NNS	B-NP	O
by	by	B000	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
endonucleases	endonuclease	E535	VBZ	B-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
various	various	V620	JJ	B-NP	O
cloned	clone	C453	VBN	I-NP	O
DNAs	DNA	D520	NNS	I-NP	O
(	(	0000	(	O	O
D2	D2	D000	NN	B-NP	O
,	,	0000	,	O	O
99	99	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
B24	B24	B000	NN	B-NP	O
,	,	0000	,	O	O
C7	C7	C000	NN	B-NP	O
,	,	0000	,	O	O
L1	L1	L000	NN	B-NP	O
-	-	0000	HYPH	O	O
4	4	0000	CD	B-NP	O
,	,	0000	,	O	O
cDMD13	cDMD13	C353	NN	B-NP	O
-	-	0000	HYPH	O	O
14	14	0000	CD	B-NP	O
,	,	0000	,	O	O
J66	J66	J000	NN	B-NP	O
-	-	0000	HYPH	O	O
HI	HI	H000	NN	B-NP	O
,	,	0000	,	O	O
P20	P20	P000	NN	B-NP	O
,	,	0000	,	O	O
J	J	J000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
Bir	Bir	B600	NN	I-NP	O
,	,	0000	,	O	O
ERT87	ERT87	E630	NN	B-NP	O
-	-	0000	HYPH	O	O
30	30	0000	CD	B-NP	O
,	,	0000	,	O	O
ERT87	ERT87	E630	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
ERT87	ERT87	E630	NN	B-NP	O
-	-	0000	HYPH	O	O
8	8	0000	CD	B-NP	O
,	,	0000	,	O	O
ERT87	ERT87	E630	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
XJ	XJ	X200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
754	754	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
cx5	cx5	C200	CD	I-NP	O
.	.	0000	.	I-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
OTC	OTC	O320	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
around	around	A653	IN	B-PP	O
Xp21	Xp21	X100	NN	B-NP	O
also	also	A420	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	I-NP	O
mothers	mother	M362	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
differed	differ	D163	VBD	B-VP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
segment	segment	S253	NN	I-NP	O
commonly	commonly	C540	RB	B-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
was	be	W200	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
L1	L1	L000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
cDMD13	cDMD13	C353	NN	I-NP	O
-	-	0000	:	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
glycerol	glycerol	G426	NN	B-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
GK	GK	G200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
segment	segment	S253	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
five	five	F100	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
reported	report	R163	VBD	B-VP	O
CGKD	CGKD	C230	NN	B-NP	B-Disease
or	or	O600	CC	O	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
deletion	deletion	D435	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
certain	certain	C635	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
gonadotropin	gonadotropin	G536	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
GTD	GTD	G300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
and	and	A530	CC	O	O
results	result	R243	NNS	B-NP	O
of	of	O100	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
genes	gene	G520	NNS	B-NP	O
for	for	F600	IN	B-PP	O
ornithine	ornithine	O653	NN	B-NP	O
transcarbamylase	transcarbamylase	T652	NN	I-NP	O
(	(	0000	(	O	O
OTC	OTC	O320	NNP	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
GK	GK	G200	NN	B-NP	O
and	and	A530	CC	O	O
putative	putative	P310	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
adrenal	adrenal	A365	JJ	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
(	(	0000	(	O	O
AHC	AHC	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
GTD	GTD	G300	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
arranged	arrange	A652	VBN	I-VP	O
from	from	F650	IN	B-PP	O
telomere	telomere	T456	NN	B-NP	O
to	to	T000	TO	B-VP	O
centromere	centromere	C536	VB	I-VP	O
as	as	A200	IN	B-PP	O
pter	pter	P360	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
GTD	GTD	G300	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
AHC	AHC	A200	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
GK	GK	G200	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	B-NP	O
DMD	DMD	D530	NN	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
OTC	OTC	O320	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
cen	cen	C500	NN	B-NP	O

Genetically	Genetically	G532	RB	B-NP	O
determined	determine	D365	VBN	I-NP	O
low	low	L000	JJ	I-NP	O
C4	C4	C000	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
predisposing	predispose	P632	VBG	I-NP	O
factor	factor	F236	NN	I-NP	O
to	to	T000	TO	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	B-Disease
chronic	chronic	C652	JJ	I-NP	I-Disease
active	active	A231	JJ	I-NP	I-Disease
hepatitis	hepatitis	H132	NN	I-NP	I-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
26	26	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	B-Disease
chronic	chronic	C652	JJ	I-NP	I-Disease
active	active	A231	JJ	I-NP	I-Disease
hepatitis	hepatitis	H132	NN	I-NP	I-Disease
(	(	0000	(	O	O
CAH	CAH	C000	NN	B-NP	B-Disease
)	)	0000	)	O	O
starting	start	S363	VBG	B-VP	O
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
18	18	0000	CD	I-NP	O
(	(	0000	(	O	O
69	69	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
low	low	L000	JJ	B-NP	O
C4	C4	C000	NN	I-NP	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
(	(	0000	(	O	O
19	19	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
low	low	L000	JJ	B-NP	O
C3	C3	C000	NN	I-NP	O
serum	serum	S650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Impaired	Impaired	I516	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
and	and	A530	CC	O	O
immune	immune	I500	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
consumption	consumption	C525	NN	I-NP	O
were	be	W600	VBD	B-VP	O
unlikely	unlikely	U542	JJ	B-ADJP	O
since	since	S520	IN	B-SBAR	O
transferrin	transferrin	T652	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
albumin	albumin	A415	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
persistently	persistently	P623	RB	B-ADJP	O
low	low	L000	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
only	only	O540	RB	B-NP	O
3	3	0000	CD	I-NP	O
had	have	H300	VBD	B-VP	O
raised	raise	R230	VBN	I-VP	O
levels	level	L142	NNS	B-NP	O
of	of	O100	IN	B-PP	O
activation	activation	A231	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
C3d	C3d	C300	NN	I-NP	O
.	.	0000	.	O	O

C4d	C4d	C300	NN	B-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
with	with	W300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
C4	C4	C000	NN	I-NP	O
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
parents	parent	P653	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
low	low	L000	JJ	B-NP	O
C4	C4	C000	NN	I-NP	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
levels	level	L142	NNS	B-NP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
limit	limit	L530	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
from	from	F650	IN	B-PP	O
5	5	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
low	low	L000	JJ	B-NP	O
C4	C4	C000	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
low	low	L000	JJ	B-NP	O
C4	C4	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
CAH	CAH	C000	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
genetically	genetically	G532	RB	I-VP	O
determined	determine	D365	VBN	I-VP	O
.	.	0000	.	O	O

C4	C4	C000	NN	B-NP	O
phenotyping	phenotyping	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
26	26	0000	CD	B-NP	O
parents	parent	P653	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
81	81	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
null	null	N400	JJ	B-NP	O
allotypes	allotype	A431	NNS	I-NP	O
at	at	A300	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
C4A	C4A	C000	NN	I-NP	O
or	or	O600	CC	I-NP	O
C4B	C4B	C100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
59	59	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
defective	defective	D123	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
structural	structural	S362	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
C4	C4	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
with	with	W300	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
,	,	0000	,	O	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
monooxygenase	monooxygenase	M525	NN	I-NP	O
,	,	0000	,	O	O
EC	EC	E200	NNP	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

PKU	PKU	P200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
error	error	E600	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
amino	amino	A500	JJ	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
acid	acid	A230	NN	I-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
caucasian	caucasian	C250	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
and	and	A530	CC	O	O
approximately	approximately	A162	RB	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
50	50	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
twelve	twelve	T410	CD	B-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
RFLP	RFLP	R141	NN	B-NP	O
)	)	0000	)	O	O
haplotypes	haplotype	H143	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
northern	northern	N636	JJ	I-NP	O
European	European	E615	JJ	I-NP	O
population	population	P143	NN	I-NP	O
and	and	A530	CC	O	O
observed	observe	O126	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
are	be	A600	VBP	B-VP	O
confined	confine	C515	VBN	I-VP	O
to	to	T000	TO	B-PP	O
four	four	F600	CD	B-NP	O
common	common	C500	JJ	I-NP	O
RFLP	RFLP	R141	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
recently	recently	R253	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
a	a	A000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
3	3	0000	CD	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
about	about	A130	RB	B-NP	O
40	40	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	B-Disease
lesion	lesion	L250	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
RFLP	RFLP	R141	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
2	2	0000	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
(	(	0000	(	O	O
Arg	Arg	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
Trp	Trp	T610	NN	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
residue	residue	R230	NN	B-NP	O
408	408	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
hybridization	hybridization	H163	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
with	with	W300	IN	B-PP	O
RFLP	RFLP	R141	NN	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
2	2	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
make	make	M200	VBP	B-VP	O
up	up	U100	RP	B-PRT	O
about	about	A130	IN	B-NP	O
20	20	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O

Choroideremia	Choroideremia	C636	NN	B-NP	B-Disease
:	:	0000	:	O	O
close	close	C420	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
DXYS1	DXYS1	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
DXYS12	DXYS12	D200	NN	I-NP	O
demonstrated	demonstrate	D523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
historical	historical	H236	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
genealogical	genealogical	G542	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
restriction	restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
disorder	disorder	D263	NN	B-NP	I-Disease
,	,	0000	,	O	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
TCD	TCD	T230	NN	B-NP	B-Disease
for	for	F600	IN	B-PP	O
Progressive	Progressive	P626	JJ	B-NP	B-Disease
Tapeto	Tapeto	T130	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Choroidal	Choroidal	C634	NNP	I-NP	I-Disease
Dystrophy	Dystrophy	D236	NNP	I-NP	I-Disease
.	.	0000	.	O	O

Previously	Previously	P612	RB	B-NP	O
demonstrated	demonstrate	D523	VBN	I-NP	O
close	close	C420	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
with	with	W300	IN	B-PP	O
locus	locus	L200	NN	B-NP	O
DXYS1	DXYS1	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O
44	44	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
0	0	0000	CD	B-NP	O
recombination	recombination	R251	NN	I-NP	O
distance	distance	D235	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
locus	locus	L200	NN	B-NP	O
DXYS12	DXYS12	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
with	with	W300	IN	B-PP	O
TCD	TCD	T230	NN	B-NP	B-Disease
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O
31	31	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
0	0	0000	CD	B-NP	O
recombination	recombination	R251	NN	I-NP	O
distance	distance	D235	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
mainly	mainly	M540	RB	B-ADVP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
large	large	L620	JJ	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
remote	remote	R530	JJ	B-NP	O
Northern	Northern	N636	NNP	I-NP	O
Finland	Finland	F545	NNP	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
formal	formal	F654	JJ	B-NP	O
genealogical	genealogical	G542	JJ	I-NP	O
proof	proof	P610	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
lacking	lack	L252	VBG	I-VP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
presently	presently	P625	RB	I-NP	O
living	live	L152	VBG	I-NP	O
(	(	0000	(	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
80	80	0000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
120	120	0000	CD	B-NP	O
carrier	carrier	C600	NN	I-NP	O
females	female	F542	NNS	I-NP	O
)	)	0000	)	O	O
probably	probably	P614	RB	B-ADVP	O
originate	originate	O625	VBP	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
couple	couple	C140	NN	I-NP	O
born	bear	B650	VBN	B-VP	O
in	in	I500	IN	B-PP	O
1644	1644	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
1646	1646	0000	CD	I-NP	O
,	,	0000	,	O	O
twelve	twelve	T410	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
36	36	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
48	48	0000	CD	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
(	(	0000	(	O	O
TCD	TCD	T230	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
DXYS1	DXYS1	D200	NN	B-NP	O
,	,	0000	,	O	O
11kb	11kb	K100	NN	B-NP	O
/	/	0000	SYM	I-NP	O
DXYS12	DXYS12	D200	NN	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
6kb	6kb	K100	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Given	Give	G150	VBN	B-VP	O
that	that	T300	IN	B-SBAR	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
105	105	0000	CD	I-NP	O
female	female	F540	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
transmitting	transmit	T652	VBG	B-VP	O
TCD	TCD	T230	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
occurred	occur	O263	VBN	I-VP	O
since	since	S520	IN	B-PP	O
1650	1650	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
extremely	extremely	E236	RB	B-NP	O
close	close	C420	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
TCD	TCD	T230	NN	B-NP	B-Disease
,	,	0000	,	I-NP	O
DXYS1	DXYS1	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
DXYS12	DXYS12	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
above	above	A100	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
useful	useful	U214	JJ	I-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
TCD	TCD	T230	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
our	our	O600	PRP$	B-NP	O
historical	historical	H236	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
genealogical	genealogical	G542	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
to	to	T000	TO	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
possible	possible	P214	JJ	B-ADJP	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
populations	population	P143	NNS	I-NP	O

Von	Von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3	3	0000	CD	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

Von	Von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
VHL	VHL	V400	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
various	various	V620	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
hemangioblastomas	hemangioblastoma	H521	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
phaeochromocytomas	phaeochromocytoma	P265	NNS	B-NP	B-Disease
,	,	0000	,	O	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
malignancies	malignancy	M425	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Renal	Renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
constitute	constitute	C523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
particularly	particularly	P632	RB	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
death	death	D300	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
,	,	0000	,	O	O
occurring	occur	O265	VBG	B-VP	O
as	as	A200	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
multifocal	multifocal	M431	JJ	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
presenting	present	P625	VBG	B-VP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
earlier	early	E646	JJR	I-NP	O
age	age	A200	NN	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
,	,	0000	,	O	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
familial	familial	F540	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
homologoue	homologoue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RAF1	RAF1	R100	NN	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3p25	3p25	P000	CD	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Crossovers	Crossover	C621	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RAF1	RAF1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
itself	itself	I324	PRP	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
or	or	O600	CC	I-NP	O
prior	prior	P600	JJ	I-NP	O
event	event	E153	NN	I-NP	O
to	to	T000	TO	B-PP	O
oncogene	oncogene	O525	NN	B-NP	O
activation	activation	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
tumour	tumour	T560	NN	B-NP	B-Disease
formation	formation	F653	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
forms	form	F652	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Sporadic	Sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
regions	region	R252	NNS	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3p	3p	P000	NN	I-NP	O
(	(	0000	(	O	O
refs	ref	R120	NNS	B-NP	O
5	5	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
6	6	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Consequently	Consequently	C525	RB	B-ADVP	O
,	,	0000	,	O	O
sporadic	sporadic	S163	JJ	B-NP	O
and	and	A530	CC	I-NP	O
VHL	VHL	V400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
might	might	M230	MD	B-VP	O
both	both	B300	DT	O	O
result	result	R243	VB	B-VP	O
from	from	F650	IN	B-PP	O
alterations	alteration	A436	NNS	B-NP	O
causing	cause	C252	VBG	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Tightly	Tightly	T234	RB	B-NP	O
linked	link	L523	VBN	I-NP	O
flanking	flanking	F452	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lowe	Lowe	L000	JJ	I-NP	B-Disease
oculocerebrorenal	oculocerebrorenal	O242	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
application	application	A142	NN	B-NP	O
to	to	T000	TO	B-PP	O
carrier	carrier	C600	NN	B-NP	O
assessment	assessment	A253	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Lowe	Lowe	L000	JJ	I-NP	B-Disease
oculocerebrorenal	oculocerebrorenal	O242	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	O
cataract	cataract	C362	NN	I-NP	B-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
defective	defective	D123	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
tubular	tubular	T146	JJ	I-NP	I-Disease
function	function	F523	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
map	map	M100	NN	I-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	O
Xq24	Xq24	X200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
q26	q26	Q000	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
made	make	M300	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
DXS42	DXS42	D200	NN	B-NP	O
at	at	A300	IN	B-PP	O
Xq24	Xq24	X200	NN	B-NP	O
-	-	0000	HYPH	O	O
q26	q26	Q000	NN	B-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
,	,	0000	,	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O
09	09	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
with	with	W300	IN	B-PP	O
DXS10	DXS10	D200	NN	B-NP	O
at	at	A300	IN	B-PP	O
Xq26	Xq26	X200	NN	B-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
,	,	0000	,	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
45	45	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
at	at	A300	IN	B-PP	O
DXS42	DXS42	D200	NN	B-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
35	35	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
detecting	detect	D323	VBG	B-VP	O
the	the	T000	DT	B-NP	O
original	original	O625	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
at	at	A300	IN	B-PP	O
DXS42	DXS42	D200	NN	B-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
OCRL	OCRL	O264	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
made	make	M300	VBD	B-VP	O
informative	informative	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
DXS42	DXS42	D200	NN	B-NP	O
,	,	0000	,	O	O
theta	theta	T300	NN	B-NP	O
remained	remain	R530	VBD	B-VP	O
0	0	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

63	63	0000	CD	B-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
for	for	F600	IN	B-PP	O
DXS10	DXS10	D200	NN	B-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

03	03	0000	CD	B-NP	O
and	and	A530	CC	O	O
z	z	Z000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

07	07	0000	CD	B-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
placing	place	P425	VBG	B-VP	O
OCRL	OCRL	O264	NN	B-NP	O
at	at	A300	IN	B-PP	O
Xq25	Xq25	X200	NN	B-NP	O
also	also	A420	RB	B-ADVP	O
comes	come	C520	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	O
;	;	0000	:	O	O
3	3	0000	CD	B-NP	O
translocation	translocation	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
Xq25	Xq25	X200	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
linked	link	L523	VBN	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
away	away	A000	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
normal	normal	N654	JJ	I-NP	O
counterpart	counterpart	C536	NN	I-NP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
.	.	0000	.	O	O

DXS42	DXS42	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
X	X	X000	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
Xpterq25	Xpterq25	X136	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
DXS10	DXS10	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
3	3	0000	CD	I-NP	O
containing	contain	C535	VBG	I-NP	O
Xq25	Xq25	X200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
qter	qter	Q360	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
DXS10	DXS10	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
DXS42	DXS42	D200	NN	I-NP	O
therefore	therefore	T616	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
tight	tight	T230	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
with	with	W300	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
flank	flank	F452	VB	B-VP	O
the	the	T000	DT	B-NP	O
Xq25	Xq25	X200	NN	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	O
;	;	0000	:	O	O
3	3	0000	CD	B-NP	O
translocation	translocation	T652	NN	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
flanking	flanking	F452	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
OCRL	OCRL	O264	NN	B-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
in	in	I500	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
determination	determination	D365	NN	I-NP	O
by	by	B000	IN	B-PP	O
ophthalmologic	ophthalmologic	O134	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
,	,	0000	,	O	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
slit	slit	S430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
lamp	lamp	L510	NN	I-NP	O
exam	exam	E250	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
and	and	A530	CC	I-NP	O
specific	specific	S121	JJ	I-NP	O
method	method	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
determination	determination	D365	NN	I-NP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypoxanthine	hypoxanthine	H125	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
guanine	guanine	G500	NN	I-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HPRTYale	HPRTYale	H163	NN	B-NP	O
)	)	0000	)	O	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Complete	Complete	C514	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hypoxanthine	hypoxanthine	H125	NN	B-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
guanine	guanine	G500	NN	B-NP	I-Disease
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	I-Disease
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
,	,	0000	,	O	O
HPRTYale	HPRTYale	H163	NNP	B-NP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
revealed	reveal	R143	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cathodal	cathodal	C340	JJ	B-NP	O
migration	migration	M263	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
PAGE	PAGE	P200	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
HPRTYale	HPRTYale	H163	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
HPRTYale	HPRTYale	H163	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
C	C	C000	NN	B-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
211	211	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
transversion	transversion	T652	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
for	for	F600	IN	B-PP	O
glycine	glycine	G425	NN	B-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
71	71	0000	CD	I-NP	O
,	,	0000	,	O	O
explaining	explain	E214	VBG	B-VP	O
the	the	T000	DT	B-NP	O
cathodal	cathodal	C340	JJ	I-NP	O
migration	migration	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRTYale	HPRTYale	H163	NN	B-NP	O
.	.	0000	.	O	O

Chou	Chou	C000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
Fasman	Fasman	F250	NN	I-NP	O
secondary	secondary	S253	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
change	change	C520	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
turn	turn	T650	NN	I-NP	O
formation	formation	F653	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Inclusion	Inclusion	I524	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
bulky	bulky	B420	JJ	I-NP	O
arginine	arginine	A625	NN	I-NP	O
side	side	S300	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
in	in	I500	IN	B-PP	O
place	place	P420	NN	B-NP	O
of	of	O100	IN	B-PP	O
glycine	glycine	G425	NN	B-NP	O
probably	probably	P614	RB	B-ADVP	O
disrupts	disrupt	D261	VBZ	B-VP	O
protein	protein	P635	NN	B-NP	O
folding	folding	F435	NN	I-NP	O
as	as	A200	RB	B-ADVP	O
well	well	W400	RB	I-ADVP	O
.	.	0000	.	O	O

Cloning	Clone	C452	VBG	B-VP	O
mutant	mutant	M353	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
allows	allow	A420	VBZ	B-VP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
provides	provide	P613	VBZ	B-VP	O
insight	insight	I523	NN	B-NP	O
into	into	I530	IN	B-PP	O
mutational	mutational	M354	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
facilitates	facilitate	F243	VBZ	B-VP	O
structure	structure	S362	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	I-VP	O
gene	gene	G500	NN	B-NP	O
encoding	encode	E523	VBG	B-VP	O
glucose	glucose	G420	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	B-ADJP	O
polymorphic	polymorphic	P456	JJ	I-ADJP	O
;	;	0000	:	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
300	300	0000	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
geographical	geographical	G261	JJ	I-NP	O
areas	area	A620	NNS	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
arisen	arise	A625	VBN	I-VP	O
through	through	T620	IN	B-PP	O
independent	independent	I531	JJ	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
population	population	P143	NN	I-NP	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
example	example	E251	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
island	island	I245	NN	I-NP	O
of	of	O100	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
careful	careful	C614	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
four	four	F600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
cloned	clone	C453	VBD	B-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBD	B-VP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
only	only	O540	RB	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
area	area	A600	NN	I-NP	O
one	one	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
Seattle	Seattle	S340	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
like	like	L200	JJ	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
all	all	A400	DT	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
severe	severe	S160	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Chronic	Chronic	C652	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
(	(	0000	(	O	O
CNSHA	CNSHA	C520	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
glucose	glucose	G420	NN	B-NP	B-Disease
6	6	0000	CD	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
amyloidotic	amyloidotic	A543	JJ	I-NP	I-Disease
polyneuropathy	polyneuropathy	P456	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
Clinic	Clinic	C452	NN	I-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
markedly	markedly	M623	RB	B-NP	O
acidic	acidic	A232	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
optimum	optimum	O135	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
variant	variant	V653	NN	B-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
erythrocytic	erythrocytic	E636	JJ	I-NP	B-Disease
G6PD	G6PD	G130	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
optimum	optimum	O135	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
young	young	Y520	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
(	(	0000	(	O	O
CNSHA	CNSHA	C520	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
familial	familial	F540	JJ	B-NP	B-Disease
amyloidotic	amyloidotic	A543	JJ	I-NP	I-Disease
polyneuropathy	polyneuropathy	P456	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Chronic	Chronic	C652	JJ	B-NP	B-Disease
hemolysis	hemolysis	H542	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
infections	infection	I512	NNS	B-NP	O
,	,	0000	,	O	O
oxidant	oxidant	O235	JJ	B-NP	O
drugs	drug	D620	NNS	I-NP	O
or	or	O600	CC	O	O
ingestion	ingestion	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
faba	faba	F100	NN	B-NP	O
beans	bean	B520	NNS	I-NP	O
.	.	0000	.	O	O

Residual	Residual	R234	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
about	about	A130	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	I-NP	O
63	63	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	I-NP	O
leucocytes	leucocyte	L232	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
study	study	S300	NN	I-NP	O
using	use	U252	VBG	B-VP	O
standard	standard	S353	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
normal	normal	N654	JJ	B-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
(	(	0000	(	O	O
at	at	A300	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O
0	0	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
0	0	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
affinity	affinity	A153	NN	I-NP	O
for	for	F600	IN	B-PP	O
substrates	substrate	S123	NNS	B-NP	O
(	(	0000	(	O	O
Km	Km	K500	NN	B-NP	O
,	,	0000	,	O	O
G6P	G6P	G100	NN	B-NP	O
and	and	A530	CC	O	O
NADP	NADP	N310	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
slightly	slightly	S423	RB	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
utilization	utilization	U342	NN	I-NP	O
of	of	O100	IN	B-PP	O
substrate	substrate	S123	NN	B-NP	O
analogues	analogue	A542	NNS	I-NP	O
(	(	0000	(	O	O
decreased	decrease	D262	VBN	B-VP	O
deamino	deamino	D500	AFX	O	O
-	-	0000	HYPH	O	O
NADP	NADP	N310	NN	B-NP	O
and	and	A530	CC	O	O
increased	increase	I526	VBD	B-VP	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
deoxyglucose	deoxyglucose	D242	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
utilization	utilization	U342	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Heat	Heat	H300	NN	B-NP	O
stability	stability	S314	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
residual	residual	R234	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
after	after	A136	IN	B-PP	O
20	20	0000	CD	B-NP	O
min	min	M500	NN	I-NP	O
of	of	O100	IN	B-PP	O
incubation	incubation	I521	NN	B-NP	O
at	at	A300	IN	B-PP	O
46	46	0000	CD	B-NP	O
degrees	degree	D262	NNS	I-NP	O
C	C	C000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
characteristic	characteristic	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
biphasic	biphasic	B120	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
curve	curve	C610	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
greatly	greatly	G634	RB	I-NP	O
increased	increase	I526	VBN	I-NP	O
activity	activity	A231	NN	I-NP	O
at	at	A300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
pH	pH	P000	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
molecular	molecular	M424	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
closely	closely	C424	RB	B-ADVP	O
resemble	resemble	R251	VBP	B-VP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Bangkok	Bangkok	B520	NN	I-NP	O
and	and	A530	CC	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
distinguished	distinguish	D235	VBN	I-VP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
and	and	A530	CC	I-NP	O
all	all	A400	DT	I-NP	O
other	other	O360	JJ	I-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
variants	variant	V653	NNS	I-NP	O
by	by	B000	IN	B-PP	O
virtue	virtue	V630	NN	B-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
curve	curve	C610	NN	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
designated	designate	D253	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Clinic	Clinic	C452	NN	I-NP	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
it	it	I300	PRP	B-NP	O
from	from	F650	IN	B-PP	O
other	other	O360	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O

Molecular	Molecular	M424	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
disrupt	disrupt	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
with	with	W300	IN	B-PP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
properties	property	P616	NNS	I-NP	O
predicted	predict	P632	VBN	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
(	(	0000	(	O	O
S	S	S000	NNP	B-NP	O
.	.	0000	.	I-NP	O
H	H	H000	NNP	I-NP	O
.	.	0000	VBD	B-VP	O
Friend	Friend	F653	NNP	B-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Bernards	Bernards	B656	NNP	I-NP	O
,	,	0000	,	O	O
S	S	S000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Rogelj	Rogelj	R242	NNP	I-NP	O
,	,	0000	,	O	O
R	R	R000	NNP	B-NP	O
.	.	0000	.	I-NP	O
A	A	A000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Weinberg	Weinberg	W516	NNP	I-NP	O
,	,	0000	,	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
M	M	M000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Rapaport	Rapaport	R163	NNP	I-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	I-NP	O
M	M	M000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Albert	Albert	A416	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
T	T	T000	NN	B-NP	O
.	.	0000	VBD	B-VP	O
P	P	P000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Dryja	Dryja	D620	NNP	I-NP	O
,	,	0000	,	O	O
Nature	Nature	N360	NNP	B-NP	O
[	[	0000	(	O	O
London	London	L535	NNP	B-NP	O
]	]	0000	)	O	O
323	323	0000	CD	B-NP	O
643	643	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
645	645	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1986	1986	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ca	ca	C000	NN	B-NP	O
.	.	0000	.	O	O
200	200	0000	CD	B-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
[	[	0000	(	O	O
kb	kb	K100	NN	B-NP	O
]	]	0000	)	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
multiple	multiple	M431	JJ	I-NP	O
dispersed	dispersed	D216	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
(	(	0000	(	O	O
Wiggs	Wiggs	W200	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
N	N	N000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Engl	Engl	E524	NNP	I-NP	O
.	.	0000	.	I-NP	O
J	J	J000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Med	Med	M300	NNP	I-NP	O
.	.	0000	.	O	O
318	318	0000	CD	B-NP	O
151	151	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
157	157	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
1988	1988	0000	CD	I-NP	O
)	)	0000	)	O	O
complicate	complicate	C514	VBP	B-VP	O
molecular	molecular	M424	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
strategies	strategy	S363	NNS	I-NP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
and	and	A530	CC	I-NP	O
presymptomatic	presymptomatic	P625	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
field	field	F430	NN	B-NP	O
inversion	inversion	I516	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
FIGE	FIGE	F200	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-VP	O
construct	construct	C523	VB	I-VP	O
a	a	A000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
probes	probe	P612	NNS	I-NP	O
from	from	F650	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
a	a	A000	DT	B-NP	O
250	250	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
EagI	EagI	E200	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
unaffected	unaffected	U512	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
probes	probe	P612	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
hybridizing	hybridize	H163	VBG	I-NP	O
fragment	fragment	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
each	each	E200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
permitting	permit	P653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
mapped	map	M130	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
cloned	clone	C453	VBN	I-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
translocation	translocation	T652	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
allowed	allow	A430	VBD	B-VP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
oriented	orient	O653	VBN	I-VP	O
with	with	W300	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
toward	toward	T630	IN	B-PP	O
the	the	T000	DT	B-NP	O
centromere	centromere	C536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
clustering	clustering	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
sites	site	S320	NNS	B-NP	O
for	for	F600	IN	B-PP	O
several	several	S164	JJ	B-NP	O
infrequently	infrequently	I516	RB	I-NP	O
cleaving	cleave	C415	VBG	I-NP	O
restriction	restriction	R236	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
HpaII	HpaII	H100	NN	I-NP	O
tiny	tiny	T500	JJ	I-NP	O
fragment	fragment	F625	NN	I-NP	O
island	island	I245	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
and	and	A530	CC	I-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
to	to	T000	TO	B-PP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
substantiated	substantiate	S123	VBD	B-VP	O
the	the	T000	DT	B-NP	O
authenticity	authenticity	A353	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
utility	utility	U343	NN	I-NP	O
of	of	O100	IN	B-PP	O
FIGE	FIGE	F200	NN	B-NP	O
in	in	I500	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
affecting	affect	A123	VBG	B-VP	O
this	this	T200	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
C3	C3	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
infections	infection	I512	NNS	I-NP	O
and	and	A530	CC	I-NP	O
glomerulonephritis	glomerulonephritis	G456	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
Laotian	Laotian	L350	JJ	I-NP	O
boy	boy	B000	NN	I-NP	O
had	have	H300	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
third	third	T630	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
and	and	A530	CC	O	O
recurrent	recurrent	R265	JJ	B-NP	O
bacterial	bacterial	B236	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
beginning	begin	B252	VBG	B-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
5	5	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
.	.	0000	.	O	O

Cellular	Cellular	C460	JJ	B-NP	O
and	and	A530	CC	I-NP	O
humoral	humoral	H564	JJ	I-NP	O
immunity	immunity	I530	NN	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
were	be	W600	VBD	B-VP	O
polymorphonuclear	polymorphonuclear	P456	JJ	B-NP	O
leukocyte	leukocyte	L230	NN	I-NP	O
chemotaxis	chemotaxis	C532	NN	I-NP	O
and	and	A530	CC	O	O
bactericidal	bactericidal	B236	JJ	B-NP	O
activities	activity	A231	NNS	I-NP	O
.	.	0000	.	O	O

Serum	Serum	S650	NN	B-NP	O
complement	complement	C514	NN	I-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-VP	O
hemolytic	hemolytic	H543	JJ	B-ADJP	O
,	,	0000	,	O	O
chemotactic	chemotactic	C532	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
opsonic	opsonic	O125	JJ	B-NP	O
activities	activity	A231	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
addition	addition	A350	NN	I-NP	O
of	of	O100	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C3	C3	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
patient	patient	P353	NN	B-NP	O
serum	serum	S650	NN	I-NP	O
restored	restore	R236	VBD	B-VP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
plasma	plasma	P425	NN	B-NP	O
infusion	infusion	I512	NN	I-NP	O
during	during	D652	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
episodes	episode	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
pneumonia	pneumonia	P500	NN	B-NP	B-Disease
significantly	significantly	S251	RB	B-ADVP	O
enhanced	enhance	E523	VBD	B-VP	O
serum	serum	S650	NN	B-NP	O
opsonic	opsonic	O125	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
for	for	F600	IN	B-PP	O
as	as	A200	RB	B-ADVP	O
long	long	L520	JJ	I-ADVP	O
as	as	A200	IN	B-PP	O
36	36	0000	CD	B-NP	O
hours	hour	H620	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
renal	renal	R540	JJ	I-NP	O
biopsy	biopsy	B120	NN	I-NP	O
specimen	specimen	S125	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
mesangiopathic	mesangiopathic	M252	JJ	B-NP	B-Disease
glomerulonephritis	glomerulonephritis	G456	NN	I-NP	I-Disease
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
significant	significant	S251	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
circulating	circulate	C624	VBG	B-VP	O
IgG	IgG	I200	NN	B-NP	O
immune	immune	I500	JJ	I-NP	O
complexes	complex	C514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
further	further	F636	RB	B-ADVP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
immune	immune	I500	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
complex	complex	C514	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
plasma	plasma	P425	NN	B-NP	O
infusion	infusion	I512	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
adjunct	adjunct	A325	NN	I-NP	O
to	to	T000	TO	B-PP	O
antibiotic	antibiotic	A531	JJ	B-NP	O
therapy	therapy	T610	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
management	management	M525	NN	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
pyogenic	pyogenic	P252	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
restriction	restriction	R236	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
alpha	alpha	A410	SYM	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
antitrypsin	antitrypsin	A536	NN	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
for	for	F600	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	O
allele	allele	A400	NN	I-NP	O
PI	PI	P000	NN	I-NP	O
Z	Z	Z000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
protease	protease	P632	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
alpha	alpha	A410	SYM	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
antitrypsin	antitrypsin	A536	JJ	I-ADJP	O
(	(	0000	(	O	O
AAT	AAT	A300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
plasma	plasma	P425	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
of	of	O100	IN	B-PP	O
leukocyte	leukocyte	L230	NN	B-NP	O
elastase	elastase	E423	NN	I-NP	O
and	and	A530	CC	O	O
bacterial	bacterial	B236	JJ	B-NP	O
proteases	protease	P632	NNS	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
encoded	encode	E523	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PI	PI	P000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14	14	0000	CD	I-NP	O
(	(	0000	(	O	O
14q24	14q24	Q000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q32	q32	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
AAT	AAT	A300	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
PI	PI	P000	NN	I-NP	O
Z	Z	Z000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
about	about	A130	RB	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
caucasians	caucasian	C252	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
adult	adult	A343	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
emphysema	emphysema	E512	NN	I-NP	B-Disease
and	and	A530	CC	O	O
liver	liver	L160	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
used	use	U230	VBN	I-VP	O
DNA	DNA	D500	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
AAT	AAT	A300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PI	PI	P000	NN	I-NP	O
Z	Z	Z000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
two	two	T000	CD	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
probes	probe	P612	NNS	I-NP	O
extending	extend	E235	VBG	B-VP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
flanking	flanking	F452	NN	I-NP	O
regions	region	R252	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
eight	eight	E230	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

Extensive	Extensive	E235	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
probed	probed	P613	JJ	I-NP	O
region	region	R250	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PI	PI	P000	NN	I-NP	O
Z	Z	Z000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-PP	O
with	with	W300	IN	I-PP	O
normal	normal	N654	JJ	B-NP	O
PI	PI	P000	NN	I-NP	O
M	M	M000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Z	Z	Z000	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
one	one	O500	CD	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
,	,	0000	,	I-NP	O
relatively	relatively	R431	RB	I-NP	O
recent	recent	R253	JJ	I-NP	O
,	,	0000	,	I-NP	O
origin	origin	O625	NN	I-NP	O
in	in	I500	IN	B-PP	O
caucasians	caucasian	C252	NNS	B-NP	O

Segregation	Segregation	S262	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
localised	localised	L242	JJ	I-NP	O
Xp21	Xp21	X100	NN	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
Xp21	Xp21	X100	NN	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
C7	C7	C000	NN	I-NP	O
,	,	0000	,	O	O
localised	localised	L242	JJ	B-NP	O
Xp21	Xp21	X100	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
Xp21	Xp21	X100	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
kindreds	kindred	K536	NNS	B-NP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Becker	Becker	B260	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
four	four	F600	CD	B-NP	O
crossovers	crossover	C621	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
38	38	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
between	between	B350	IN	B-PP	O
C7	C7	C000	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
z	z	Z000	NN	B-NP	O
max	max	M200	NN	I-NP	O
=	=	0000	SYM	B-VP	O
+	+	0000	SYM	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
72	72	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
BMD	BMD	B530	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
no	no	N000	DT	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
16	16	0000	CD	I-NP	O
informative	informative	I516	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
localisation	localisation	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
being	be	B520	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Xp21	Xp21	X100	NN	B-NP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
also	also	A420	RB	B-ADVP	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
754	754	0000	CD	I-NP	O
support	support	S163	NN	I-NP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
physical	physical	P240	JJ	I-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
as	as	A200	IN	B-PP	O
X	X	X000	NN	B-NP	O
centromere	centromere	C536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
754	754	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
DMD	DMD	D530	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
BMD	BMD	B530	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
C7	C7	C000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
X	X	X000	NN	I-NP	O
telomere	telomere	T456	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

11	11	0000	CD	B-NP	O
(	(	0000	(	O	O
z	z	Z000	NN	B-NP	O
max	max	M200	NN	I-NP	O
=	=	0000	SYM	B-VP	O
+	+	0000	SYM	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
58	58	0000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	O
-	-	0000	HYPH	O	O
754	754	0000	CD	B-NP	O
by	by	B000	IN	B-PP	O
combining	combine	C515	VBG	B-VP	O
our	our	O600	PRP$	B-NP	O
previously	previously	P612	RB	I-NP	O
published	publish	P142	VBN	I-NP	O
data	datum	D300	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
.	.	0000	.	O	O

C7	C7	C000	NN	B-NP	O
and	and	A530	CC	O	O
754	754	0000	CD	B-NP	O
thus	thus	T200	RB	B-ADVP	O
provide	provide	P613	VBP	B-VP	O
good	good	G300	JJ	B-NP	O
bridging	bridging	B632	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease

Isolation	Isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
probes	probe	P612	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15	15	0000	CD	I-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Flow	Flow	F400	NN	B-NP	O
cytometry	cytometry	C353	NN	I-NP	O
and	and	A530	CC	O	O
recombinant	recombinant	R251	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
techniques	technique	T252	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
obtain	obtain	O135	VB	I-VP	O
reagents	reagent	R253	NNS	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

HindIII	HindIII	H530	LS	B-NP	O
total	total	T340	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
digest	digest	D230	NN	I-NP	O
libraries	library	L162	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
prepared	prepare	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
lambda	lambda	L513	NN	B-NP	O
phage	phage	P200	NN	I-NP	O
Charon	Charon	C650	NNP	I-NP	O
21A	21A	A000	NN	I-NP	O
from	from	F650	IN	B-PP	O
flow	flow	F400	NN	B-NP	O
-	-	0000	HYPH	O	O
sorted	sort	S630	VBN	B-VP	O
inverted	invert	I516	VBN	I-VP	O
duplicated	duplicate	D142	VBN	B-VP	O
no	no	N000	DT	B-NP	O
.	.	0000	.	I-NP	O
15	15	0000	CD	I-NP	O
human	human	H500	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
and	and	A530	CC	O	O
propagated	propagate	P612	VBN	B-VP	O
on	on	O500	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
-	-	0000	HYPH	O	O
proficient	proficient	P612	JJ	O	O
(	(	0000	(	O	O
LE392	LE392	L000	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
recBC	recBC	R212	NN	B-NP	O
-	-	0000	HYPH	B-ADJP	O
,	,	0000	,	O	O
sbcB	sbcB	S121	NN	B-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DB1257	DB1257	D100	NN	B-NP	O
)	)	0000	)	O	O
bacteria	bacteria	B236	NNS	B-NP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15	15	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
probes	probe	P612	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
localized	localize	L242	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
13	13	0000	CD	B-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
sublocalized	sublocalize	S142	VBD	B-VP	O
to	to	T000	TO	B-PP	O
band	band	B530	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
.	.	0000	.	O	O

Heteroduplex	Heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
clones	clone	C452	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
grew	grow	G600	VBD	B-VP	O
on	on	O500	IN	B-PP	O
DB1257	DB1257	D100	NN	B-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
on	on	O500	IN	I-PP	O
LE392	LE392	L000	NN	B-NP	O
,	,	0000	,	O	O
revealed	reveal	R143	VBD	B-VP	O
stem	stem	S350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
loop	loop	L100	NN	I-NP	O
structures	structure	S362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
inserts	insert	I526	NNS	I-NP	O
,	,	0000	,	O	O
indicative	indicative	I532	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
inverted	invert	I516	VBN	B-VP	O
,	,	0000	,	O	O
repeated	repeat	R130	VBN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
elements	element	E453	NNS	I-NP	O
.	.	0000	.	O	O

Such	Such	S200	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
might	might	M230	MD	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cloning	cloning	C452	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
segments	segment	S253	NNS	I-NP	O
from	from	F650	IN	B-PP	O
proximal	proximal	P625	JJ	B-NP	O
15q	15q	Q000	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
physical	physical	P240	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeated	repeat	R130	VBN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
band	band	B530	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	LS	B-NP	O
may	may	M000	MD	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
diseases	disease	D200	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15	15	0000	CD	I-NP	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Becker	Becker	B260	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Duchenne	Duchenne	D250	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
as	as	A200	RB	B-PP	O
yet	yet	Y300	RB	B-ADJP	O
unknown	unknown	U525	JJ	I-ADJP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
cloned	clone	C453	VBN	I-NP	O
segments	segment	S253	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
which	which	W200	WDT	B-NP	O
detect	detect	D323	VBP	B-VP	O
structural	structural	S362	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
within	within	W350	IN	B-PP	O
or	or	O600	CC	I-PP	O
near	near	N600	IN	I-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cloned	clone	C453	VBN	I-NP	O
segments	segment	S253	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
as	as	A200	IN	B-PP	O
tightly	tightly	T234	RB	B-ADVP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
boys	boy	B200	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
attempt	attempt	A351	NN	I-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
more	more	M600	RBR	B-ADVP	O
precisely	precisely	P624	RB	I-ADVP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
accuracy	accuracy	A262	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
segments	segment	S253	NNS	I-NP	O
,	,	0000	,	O	O
DXS164	DXS164	D200	NN	B-NP	O
(	(	0000	(	O	O
pERT87	pERT87	P630	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
determining	determine	D365	VBG	B-VP	O
the	the	T000	DT	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
subclones	subclone	S124	NNS	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
15	15	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
made	make	M300	VBN	I-VP	O
available	available	A141	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
many	many	M500	JJ	B-NP	O
investigators	investigator	I512	NNS	I-NP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
combined	combine	C515	VBN	I-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
20	20	0000	CD	I-NP	O
research	research	R262	NN	I-NP	O
laboratories	laboratory	L163	NNS	I-NP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DXS164	DXS164	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	O	O
Becker	Becker	B260	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DXS164	DXS164	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
apparently	apparently	A165	RB	B-ADVP	O
recombines	recombine	R251	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADVP	O
located	located	L230	JJ	B-ADJP	O
between	between	B350	IN	B-PP	O
independent	independent	I531	JJ	B-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
which	which	W200	WDT	B-NP	O
yield	yield	Y430	VBP	B-VP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
some	some	S500	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
delineated	delineate	D453	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DXS164	DXS164	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
evident	evident	E135	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
frequent	frequent	F625	JJ	B-ADJP	O
and	and	A530	CC	O	O
extremely	extremely	E236	RB	B-ADJP	O
large	large	L620	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
through	through	T620	IN	B-PP	O
introduction	introduction	I536	NN	B-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
into	into	I530	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
neurological	neurological	N642	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
behavioural	behavioural	B164	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
affecting	affect	A123	VBG	B-VP	O
only	only	O540	JJ	B-NP	O
males	male	M420	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
activity	activity	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
purine	purine	P650	NN	I-NP	O
salvage	salvage	S412	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
hypoxanthine	hypoxanthine	H125	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
guanosine	guanosine	G525	NN	I-NP	O
phosphoribosyl	phosphoribosyl	P216	NN	I-NP	O
transferase	transferase	T652	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

How	How	H000	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
purine	purine	P650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
not	not	N300	RB	O	O
understood	understand	U536	VBN	B-VP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Hprt	Hprt	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
activity	activity	A231	NN	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
laboratory	laboratory	L163	NN	B-NP	O
animals	animal	A542	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
derive	derive	D610	VB	I-VP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
cultured	culture	C436	VBN	B-NP	O
mouse	mouse	M200	NN	I-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
mutagenized	mutagenize	M325	VBN	B-VP	O
by	by	B000	IN	B-PP	O
retroviral	retroviral	R361	JJ	B-NP	O
insertion	insertion	I526	NN	I-NP	O
and	and	A530	CC	O	O
selected	select	S423	VBN	B-VP	O
for	for	F600	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
construct	construct	C523	VB	I-VP	O
chimaeric	chimaeric	C562	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
clonal	clonal	C454	JJ	I-NP	O
lines	line	L520	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
different	different	D165	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
Hprt	Hprt	H163	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
given	give	G150	VBN	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
germ	germ	G650	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
chimaeras	chimaera	C562	NNS	B-NP	O
,	,	0000	,	O	O
allowing	allow	A452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
derivation	derivation	D613	NN	I-NP	O
of	of	O100	IN	B-PP	O
strains	strain	S365	NNS	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
having	have	H152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
as	as	A200	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Male	Male	M400	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
viable	viable	V140	JJ	B-ADJP	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
cells	cell	C420	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	JJ	I-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Re	Re	R000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sublocalization	sublocalization	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
esterase	esterase	E236	NN	B-NP	O
D	D	D000	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
relation	relation	R435	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
esterase	esterase	E236	NN	I-NP	O
D	D	D000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ESD	ESD	E230	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
hybridized	hybridize	H163	VBD	B-VP	O
most	most	M230	RBS	B-ADVP	O
strongly	strongly	S365	RB	I-ADVP	O
to	to	T000	TO	B-PP	O
13q14	13q14	Q000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
13q14	13q14	Q000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	LS	B-LST	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
raises	raise	R200	VBZ	B-VP	O
doubts	doubt	D132	NNS	B-NP	O
concerning	concern	C526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
recently	recently	R253	RB	I-NP	O
published	publish	P142	VBN	I-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
ESD	ESD	E230	NN	B-NP	O
to	to	T000	TO	B-PP	O
13q14	13q14	Q000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	LS	B-LST	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
to	to	T000	TO	I-VP	O
separate	separate	S163	VB	I-VP	O
the	the	T000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
ESD	ESD	E230	NN	I-NP	O
and	and	A530	CC	I-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
(	(	0000	(	O	O
RB1	RB1	R100	NN	B-NP	O
)	)	0000	)	O	O
loci	locus	L200	NNS	B-NP	O
,	,	0000	,	O	O
placing	place	P425	VBG	B-VP	O
ESD	ESD	E230	NN	B-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
RB1	RB1	R100	NN	B-NP	O
.	.	0000	.	O	O

Quantitative	Quantitative	Q531	JJ	B-NP	O
in	in	I500	FW	I-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
confirm	confirm	C516	VB	I-VP	O
this	this	T200	DT	B-NP	O
interpretation	interpretation	I536	NN	I-NP	O
.	.	0000	.	O	O

Rather	Rather	R360	RB	B-ADVP	O
,	,	0000	,	O	O
they	they	T000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
ESD	ESD	E230	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
missing	miss	M252	VBG	B-ADJP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
deleted	delete	D430	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
13	13	0000	CD	I-NP	O
and	and	A530	CC	O	O
duplicated	duplicate	D142	VBN	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
orientation	orientation	O653	NN	I-NP	O
nor	nor	N600	CC	O	O
the	the	T000	DT	B-NP	O
sublocalization	sublocalization	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
ESD	ESD	E230	NN	B-NP	O
and	and	A530	CC	I-NP	O
RB1	RB1	R100	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
13q14	13q14	Q000	CD	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
common	common	C500	JJ	B-NP	O
variable	variable	V614	JJ	I-NP	O
immunodeficiency	immunodeficiency	I531	NN	I-NP	B-Disease
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
19	19	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
boy	boy	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
variable	variable	V614	JJ	B-NP	O
immunodeficiency	immunodeficiency	I531	NN	I-NP	B-Disease
manifested	manifest	M512	VBN	B-VP	O
by	by	B000	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
hypoimmunoglobulinemia	hypoimmunoglobulinemia	H152	NN	I-NP	B-Disease
and	and	A530	CC	O	O
impaired	impaired	I516	JJ	B-NP	O
antibody	antibody	A531	NN	I-NP	O
responses	response	R215	NNS	I-NP	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
circulating	circulate	C624	VBG	I-NP	O
B	B	B000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
subnormal	subnormal	S156	JJ	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
functions	function	F523	NNS	I-NP	O
.	.	0000	.	O	O

Neither	Neither	N360	DT	B-NP	O
antilymphocytic	antilymphocytic	A534	JJ	I-NP	O
autoantibodies	autoantibody	A353	NNS	I-NP	O
nor	nor	N600	CC	O	O
chromosomal	chromosomal	C652	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Serum	Serum	S650	NN	B-NP	O
immunoglobulin	immunoglobulin	I524	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
within	within	W350	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
limits	limit	L532	NNS	I-NP	O
in	in	I500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	I-NP	O
brother	brother	B636	NN	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
but	but	B300	CC	O	O
expressed	express	E216	VBD	B-VP	O
an	an	A500	DT	B-NP	O
antigen	antigen	A532	NN	I-NP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
DW2	DW2	D000	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mild	Mild	M430	JJ	B-NP	O
and	and	A530	CC	I-NP	O
severe	severe	S160	JJ	I-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Xp21	Xp21	X100	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
over	over	O160	IN	B-PP	O
300	300	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
suffering	suffer	S165	VBG	B-VP	O
from	from	F650	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
or	or	O600	CC	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Deletions	Deletion	D435	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterised	characterise	C623	VBN	I-VP	O
which	which	W200	WDT	B-NP	O
encompass	encompass	E525	VBP	B-VP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
pERT87	pERT87	P630	NN	I-NP	O
(	(	0000	(	O	O
DXS164	DXS164	D200	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
only	only	O540	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
XJ1	XJ1	X200	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
(	(	0000	(	O	O
DXS206	DXS206	D200	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
HIP25	HIP25	H100	NN	B-NP	O
loci	locus	L200	NNS	I-NP	O
only	only	O540	RB	B-ADVP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lie	lie	L000	VB	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
covering	cover	C165	VBG	B-VP	O
several	several	S164	JJ	B-NP	O
hundred	hundred	H536	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
(	(	0000	(	O	O
kb	kb	K100	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
mildly	mildly	M434	RB	B-VP	O
affected	affect	A123	VBD	I-VP	O
BMD	BMD	B530	NN	B-NP	B-Disease
patient	patient	P353	NN	I-NP	O
possesses	possess	P200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
110	110	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
including	include	I524	VBG	B-PP	O
exons	exon	E252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
exon	exon	E250	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
smaller	small	S546	JJR	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
show	show	S000	VBP	B-VP	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
typical	typical	T124	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
explained	explain	E214	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
discuss	discuss	D200	VBP	B-VP	O
this	this	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
context	context	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
candidate	candidate	C530	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Patterns	Pattern	P365	NNS	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
screened	screen	S265	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
Cf56a	Cf56a	C100	NN	I-NP	O
and	and	A530	CC	I-NP	O
Cf23a	Cf23a	C100	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
detect	detect	D323	VBP	B-VP	O
exons	exon	E252	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
exons	exon	E252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
and	and	A530	CC	O	O
prove	prove	P610	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
and	and	A530	CC	I-NP	O
extent	extent	E235	NN	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

Deletions	Deletion	D435	NNS	B-NP	O
specific	specific	S121	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
BMD	BMD	B530	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

Half	Half	H410	NN	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
particular	particular	P632	JJ	I-NP	O
small	small	S540	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
;	;	0000	:	O	O
smaller	small	S546	JJR	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
same	same	S500	JJ	I-NP	O
group	group	G610	NN	I-NP	O
produce	produce	P632	VBP	B-VP	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
third	third	T630	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	B-Disease
rash	rash	R200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
arthralgias	arthralgia	A636	NNS	B-NP	B-Disease
:	:	0000	:	O	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
transfusion	transfusion	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
whole	whole	W400	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
well	well	W400	RB	I-NP	O
34	34	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
month	month	M530	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
male	male	M400	NN	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	B-Disease
rash	rash	R200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
arthralgias	arthralgia	A636	NNS	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lack	lack	L200	VB	I-VP	O
C3	C3	C000	NN	B-NP	O
by	by	B000	IN	B-PP	O
immunochemical	immunochemical	I525	JJ	O	O
(	(	0000	(	O	O
undetectable	undetectable	U532	JJ	B-ADJP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
hemolytic	hemolytic	H543	JJ	B-ADJP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
normal	normal	N654	JJ	B-ADJP	O
)	)	0000	)	O	O
assays	assay	A200	NNS	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
infectious	infectious	I512	JJ	I-NP	O
agent	agent	A253	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
.	.	0000	.	O	O

Protein	Protein	P635	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Clq	Clq	C420	NN	B-NP	O
.	.	0000	.	O	O

C4	C4	C000	NN	B-NP	O
,	,	0000	,	O	O
C5	C5	C000	NN	B-NP	O
,	,	0000	,	O	O
properdin	properdin	P616	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
C3b	C3b	C100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
INA	INA	I500	NN	I-NP	O
and	and	A530	CC	O	O
hemolytic	hemolytic	H543	JJ	B-NP	O
activities	activity	A231	NNS	I-NP	O
of	of	O100	IN	B-PP	O
complement	complement	C514	NN	B-NP	O
components	component	C515	NNS	I-NP	O
C1	C1	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
C9	C9	C000	NN	B-NP	O
except	except	E213	IN	B-PP	O
C3	C3	C000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
or	or	O600	CC	I-ADJP	O
elevated	elevated	E413	JJ	I-ADJP	O
;	;	0000	:	O	O
total	total	T340	JJ	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
reconstituted	reconstitute	R252	VBN	I-VP	O
by	by	B000	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C3	C3	C000	NN	I-NP	O
.	.	0000	.	O	O

Properdin	Properdin	P616	NN	B-NP	O
factor	factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
702	702	0000	CD	B-NP	O
(	(	0000	(	O	O
normal	normal	N654	JJ	B-ADJP	O
175	175	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
275	275	0000	CD	B-NP	O
)	)	0000	)	O	O
mug	mug	M200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
cleaver	cleaver	C416	VB	I-VP	O
upon	upon	U150	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
zymosan	zymosan	Z525	NN	B-NP	O
or	or	O600	CC	I-NP	O
cobra	cobra	C160	NN	I-NP	O
venom	venom	V500	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
immune	immune	I500	JJ	I-NP	O
adherence	adherence	A365	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
was	be	W200	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
ability	ability	A143	NN	B-NP	O
to	to	T000	TO	B-VP	O
opsonize	opsonize	O125	VB	I-VP	O
Candida	Candida	C530	NNP	B-NP	O
albicans	albican	A412	NNS	I-NP	O
for	for	F600	IN	B-PP	O
uptake	uptake	U132	NN	B-NP	O
and	and	A530	CC	O	O
Escherichia	Escherichia	E262	FW	B-NP	O
coli	coli	C400	FW	I-NP	O
for	for	F600	IN	B-PP	O
killing	killing	K452	NN	B-NP	O
by	by	B000	IN	B-PP	O
neurophils	neurophil	N614	NNS	B-NP	O
,	,	0000	,	O	O
generate	generate	G563	JJ	B-NP	O
neutrophil	neutrophil	N361	NN	I-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
and	and	A530	CC	O	O
inhibit	inhibit	I513	VBP	B-VP	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
coli	coli	C400	NN	B-NP	O
;	;	0000	:	O	O
these	these	T200	DT	B-NP	O
activities	activity	A231	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
restored	restore	R236	VBN	I-VP	O
by	by	B000	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C3	C3	C000	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
transfusion	transfusion	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
320	320	0000	CD	B-NP	O
ml	ml	M400	NN	I-NP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
hour	hour	H600	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
old	old	O430	JJ	I-NP	O
normal	normal	N654	JJ	I-NP	O
whole	whole	W400	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fifty	fifty	F130	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
second	second	S253	JJ	I-NP	O
day	day	D000	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
transitory	transitory	T652	JJ	B-NP	O
elevation	elevation	E413	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C3	C3	C000	NN	I-NP	O
level	level	L140	NN	I-NP	O
to	to	T000	TO	B-PP	O
25	25	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
fall	fall	F400	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
off	off	O100	RP	B-PRT	O
(	(	0000	(	O	O
approximately	approximately	A162	RB	B-NP	O
2	2	0000	CD	I-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	B-NP	O
2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
per	per	P600	IN	B-PP	O
hour	hour	H600	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
undetectable	undetectable	U532	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
by	by	B000	IN	B-PP	O
69	69	0000	CD	B-NP	O
hours	hour	H620	NNS	I-NP	O
;	;	0000	:	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
followed	follow	F430	VBN	I-VP	O
by	by	B000	IN	B-PP	O
disappearance	disappearance	D216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
skin	skin	S250	NN	I-NP	B-Disease
rash	rash	R200	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
arthralgias	arthralgia	A636	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
return	return	R365	VB	B-VP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
elevated	elevate	E413	VBN	I-NP	O
temperature	temperature	T516	NN	I-NP	O
and	and	A530	CC	I-NP	O
CRP	CRP	C610	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

C3	C3	C000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
seven	seven	S150	CD	B-NP	O
of	of	O100	IN	I-NP	O
24	24	0000	CD	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
normal	normal	N654	JJ	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
C3	C3	C000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
C3b	C3b	C100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
INA	INA	I500	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
catabolism	catabolism	C314	NN	B-NP	O
of	of	O100	IN	B-PP	O
transfused	transfuse	T652	VBN	B-NP	O
C3	C3	C000	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
was	be	W200	VBD	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
codominance	codominance	C352	NN	I-NP	O
and	and	A530	CC	O	O
involved	involve	I514	VBN	B-VP	O
decreased	decrease	D262	VBD	B-VP	B-Disease
synthesis	synthesis	S532	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
C3	C3	C000	NN	B-NP	I-Disease
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
child	child	C430	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
C3	C3	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
repeated	repeated	R130	JJ	B-NP	O
infections	infection	I512	NNS	I-NP	O
,	,	0000	,	O	O
whose	whose	W200	WP$	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
of	of	O100	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	B-Disease
rash	rash	R200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
arthralgia	arthralgia	A636	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
abated	abate	A130	VBN	I-VP	O
by	by	B000	IN	B-PP	O
whole	whole	W400	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
transfusion	transfusion	T652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Guangdong	Guangdong	G523	NNP	B-NP	O
,	,	0000	,	O	O
China	China	C500	NNP	B-NP	O
.	.	0000	.	O	O

Erythrocyte	Erythrocyte	E636	NN	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
97	97	0000	CD	B-NP	O
randomly	randomly	R535	RB	I-NP	O
selected	select	S423	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Guangdong	Guangdong	G523	NNP	B-NP	O
Province	Province	P615	NNP	I-NP	O
,	,	0000	,	O	O
China	China	C500	NNP	B-NP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
(	(	0000	(	O	O
Gd	Gd	G300	NNP	B-NP	O
Kaiping	Kaiping	K152	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Boluo	Boluo	B400	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Huiyang	Huiyang	H520	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Gaomin	Gaomin	G500	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Qing	Qing	Q520	NNP	I-NP	O
-	-	0000	HYPH	O	O
Baijiang	Baijiang	B252	NNP	B-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Gaozhou	Gaozhou	G200	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Huazhou	Huazhou	H200	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Nanhai	Nanhai	N500	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Gd	Gd	G300	NNP	B-NP	O
Guangzhou	Guangzhou	G520	NNP	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
31	31	0000	CD	I-NP	O
variants	variant	V653	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
province	province	P615	NN	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Kaiping	Kaiping	K152	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Taiwan	Taiwan	T500	NNP	I-NP	O
-	-	0000	HYPH	O	O
Hakka	Hakka	H200	NNP	B-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Haad	Haad	H300	NNP	I-NP	O
Yai	Yai	Y000	NNP	I-NP	O
,	,	0000	,	O	O
Gd	Gd	G300	NNP	B-NP	O
Haad	Haad	H300	NNP	I-NP	O
Yai	Yai	Y000	NNP	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Gd	Gd	G300	NNP	I-NP	O
Huiyang	Huiyang	H520	NNP	I-NP	O
occurred	occur	O263	VBD	B-VP	O
most	most	M230	RBS	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
high	high	H200	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
area	area	A600	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	O
and	and	A530	CC	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
and	and	A530	CC	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	B-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Severe	Severe	S160	JJ	B-NP	B-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
undetectable	undetectable	U532	JJ	B-NP	O
or	or	O600	CC	I-NP	O
trace	trace	T620	NN	I-NP	O
quantities	quantity	Q532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
and	and	A530	CC	I-NP	O
tissue	tissue	T200	NN	I-NP	O
stores	store	S362	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
six	six	S200	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
using	use	U252	VBG	B-VP	O
probes	probe	P612	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
ends	end	E532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	JJ	B-NP	O
blots	blot	B432	NNS	I-NP	O
of	of	O100	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
digests	digest	D232	NNS	I-NP	O
and	and	A530	CC	O	O
gene	gene	G500	NN	B-NP	O
dosage	dosage	D200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
measurements	measurement	M265	NNS	I-NP	O
carried	carry	C630	VBN	B-VP	O
out	out	O300	RP	B-PRT	O
with	with	W300	IN	B-PP	O
quantitative	quantitative	Q531	JJ	B-NP	O
slot	slot	S430	NN	I-NP	O
blots	blot	B432	NNS	I-NP	O
of	of	O100	IN	B-PP	O
undigested	undigested	U532	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
separated	separate	S163	VBD	B-VP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
into	into	I530	IN	B-PP	O
three	three	T600	CD	B-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
group	group	G610	NN	I-NP	O
consisted	consist	C523	VBD	B-VP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
dosage	dosage	D200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
was	be	W200	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
group	group	G610	NN	I-NP	O
was	be	W200	VBD	B-VP	O
comprised	comprise	C516	VBN	I-VP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
doubly	doubly	D140	RB	B-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
interacting	interact	I536	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
vWF	vWF	V100	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
group	group	G610	NN	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Alloantibodies	Alloantibody	A453	NNS	B-NP	O
developed	develop	D141	VBD	B-VP	O
only	only	O540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
techniques	technique	T252	NNS	I-NP	O
should	should	S430	MD	B-VP	O
prove	prove	P610	VB	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
identifying	identify	I353	VBG	B-VP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	B-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
defining	define	D152	VBG	B-VP	O
patients	patient	P353	NNS	B-NP	O
predictably	predictably	P632	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
alloantibodies	alloantibody	A453	NNS	B-NP	O
to	to	T000	TO	B-PP	O
vWF	vWF	V100	NN	B-NP	O
.	.	0000	.	O	O

Sjogren	Sjogren	S265	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Larsson	Larsson	L625	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Impaired	Impaired	I516	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
alcohol	alcohol	A424	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
alcohol	alcohol	A424	NN	I-NP	O
:	:	0000	:	O	O
nicotinamide	nicotinamide	N235	NN	B-NP	O
adenine	adenine	A350	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
oxidoreductase	oxidoreductase	O236	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Lipid	Lipid	L130	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
Sjogren	Sjogren	S265	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Larsson	Larsson	L625	NN	B-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
SLS	SLS	S420	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Intact	Intact	I532	JJ	B-NP	O
SLS	SLS	S420	NN	I-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
incubated	incubate	I521	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
[	[	0000	(	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
14C	14C	C000	NN	I-NP	O
]	]	0000	)	I-NP	O
palmitate	palmitate	P453	NN	I-NP	O
accumulated	accumulate	A254	VBD	B-VP	O
more	more	M600	RBR	B-NP	O
radioactive	radioactive	R323	JJ	I-NP	O
hexadecanol	hexadecanol	H232	NN	I-NP	O
than	than	T500	IN	B-SBAR	O
did	do	D300	VBD	O	O
normal	normal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
incorporation	incorporation	I526	NN	B-NP	O
of	of	O100	IN	B-PP	O
radioactivity	radioactivity	R323	NN	B-NP	O
into	into	I530	IN	B-PP	O
other	other	O360	JJ	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
lipids	lipid	L132	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
unaltered	unaltered	U543	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hexadecanol	hexadecanol	H232	NN	I-NP	O
content	content	C535	NN	I-NP	O
of	of	O100	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
abnormally	abnormally	A156	RB	B-ADJP	O
elevated	elevated	E413	JJ	I-ADJP	O
.	.	0000	.	O	O

Hexadecanol	Hexadecanol	H232	NN	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
increased	increase	I526	VBN	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
alcohol	alcohol	A424	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
nor	nor	N600	CC	O	O
its	its	I320	PRP$	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
utilization	utilization	U342	NN	I-NP	O
for	for	F600	IN	B-PP	O
glycerol	glycerol	G426	NN	B-NP	O
ether	ether	E360	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
life	life	L100	NN	I-NP	O
of	of	O100	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
hexadecanol	hexadecanol	H232	NN	I-NP	O
loaded	load	L300	VBN	B-VP	O
into	into	I530	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
(	(	0000	(	O	O
70	70	0000	CD	B-NP	O
min	min	M500	NN	I-NP	O
)	)	0000	)	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
min	min	M500	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
intact	intact	I532	JJ	B-NP	O
SLS	SLS	S420	NN	I-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
impaired	impaired	I516	JJ	B-NP	O
oxidation	oxidation	O235	NN	I-NP	O
of	of	O100	IN	B-PP	O
[	[	0000	(	O	O
14C	14C	C000	NN	B-NP	O
]	]	0000	)	O	O
-	-	0000	HYPH	B-NP	O
hexadecanol	hexadecanol	H232	NN	I-NP	O
to	to	T000	TO	B-PP	O
fatty	fatty	F300	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
.	.	0000	.	O	O

Fatty	Fatty	F300	JJ	B-NP	O
alcohol	alcohol	A424	NN	I-NP	O
NAD	NAD	N300	NN	I-NP	O
+	+	0000	SYM	B-NP	O
oxidoreductase	oxidoreductase	O236	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
catalyzing	catalyze	C342	VBG	B-VP	O
this	this	T200	DT	B-NP	O
reaction	reaction	R235	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

Mean	Mean	M500	JJ	B-NP	O
total	total	T340	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
fibroblasts	fibroblast	F161	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
13	13	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
palmitoyl	palmitoyl	P453	NN	B-NP	O
CoA	CoA	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
inhibitable	inhibitable	I513	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
.	.	0000	.	O	O

Fibroblasts	Fibroblast	F161	NNS	B-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
SLS	SLS	S420	NN	I-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
enzyme	enzyme	E525	NN	B-NP	O
activities	activity	A231	NNS	I-NP	O
intermediate	intermediate	I536	VBP	B-VP	O
between	between	B350	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
and	and	A530	CC	I-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
SLS	SLS	S420	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
fatty	fatty	F300	JJ	B-NP	I-Disease
alcohol	alcohol	A424	NN	I-NP	I-Disease
NAD	NAD	N300	NN	I-NP	I-Disease
+	+	0000	SYM	B-NP	I-Disease
oxidoreductase	oxidoreductase	O236	NN	I-NP	I-Disease
.	.	0000	.	O	O

SLS	SLS	S420	NN	B-NP	B-Disease
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
abnormality	abnormality	A156	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
fatty	fatty	F300	JJ	B-NP	I-Disease
alcohol	alcohol	A424	NN	I-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Germinal	Germinal	G654	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
pedigree	pedigree	P326	VBP	B-VP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
segregation	segregation	S262	NN	I-NP	O
products	product	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
female	female	F540	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
using	use	U252	VBG	B-VP	O
marker	marker	M626	NN	B-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
RFLPs	RFLP	R141	NNS	B-NP	O
)	)	0000	)	O	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
probes	probe	P612	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
lie	lie	L000	VBP	B-VP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
female	female	F540	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
three	three	T600	CD	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
to	to	T000	TO	B-PP	O
her	her	H600	PRP$	B-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
postulating	postulate	P234	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
postzygotic	postzygotic	P232	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
was	be	W200	VBD	B-VP	O
consequently	consequently	C525	RB	B-ADJP	O
germinally	germinally	G654	RB	I-ADJP	O
mosaic	mosaic	M200	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Nebulin	Nebulin	N145	NN	B-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
males	male	M420	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
nebulin	nebulin	N145	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
specimen	specimen	S125	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
precludes	preclude	P624	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Expression	Expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
and	and	A530	CC	I-NP	O
brain	brain	B650	NN	I-NP	O
.	.	0000	.	O	O

Complementary	Complementary	C514	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
represent	represent	R162	VBP	B-VP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
Dmd	Dmd	D530	NN	B-NP	O
)	)	0000	)	O	O
messenger	messenger	M252	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
(	(	0000	(	O	O
mRNA	mRNA	M650	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Mouse	Mouse	M200	NN	B-NP	O
Dmd	Dmd	D530	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detectable	detectable	D323	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
and	and	A530	CC	B-PP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
level	level	L140	NN	I-NP	O
approximately	approximately	A162	RB	B-NP	O
90	90	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
lower	low	L600	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
.	.	0000	.	O	O

Dmd	Dmd	D530	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
at	at	A300	IN	B-PP	O
much	much	M200	RB	B-ADJP	O
lower	low	L600	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
the	the	T000	DT	I-NP	O
muscle	muscle	M240	NN	I-NP	O
and	and	A530	CC	I-NP	O
brain	brain	B650	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
strains	strain	S365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dystrophic	dystrophic	D236	JJ	B-NP	B-Disease
mdx	mdx	M320	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dmd	Dmd	D530	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
raises	raise	R200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
relation	relation	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
human	human	H500	JJ	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
males	male	M420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
Dmd	Dmd	D530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
hematologic	hematologic	H534	JJ	B-NP	B-Disease
malignancy	malignancy	M425	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
and	and	A530	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
481	481	0000	CD	B-NP	O
Sardinian	Sardinian	S635	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hematological	hematological	H534	JJ	B-NP	B-Disease
malignancies	malignancy	M425	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
219	219	0000	CD	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
conclusion	conclusion	C524	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GdB	GdB	G310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
23	23	0000	CD	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
women	woman	W500	NNS	I-NP	O
having	have	H152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
clonal	clonal	C454	JJ	I-NP	O
hematologic	hematologic	H534	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
control	control	C536	NN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
37	37	0000	CD	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
present	present	P625	JJ	B-ADJP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protective	protective	P632	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
against	against	A252	IN	B-PP	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
hematologic	hematologic	H534	JJ	B-NP	B-Disease
neoplasms	neoplasm	N142	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Hepatoblastoma	Hepatoblastoma	H131	NN	B-NP	B-Disease
,	,	0000	,	O	O
pigmented	pigment	P253	VBD	B-VP	B-Disease
ocular	ocular	O246	JJ	B-NP	I-Disease
fundus	fundus	F532	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
jaw	jaw	J000	NN	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Gardner	Gardner	G635	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Hepatoblastoma	Hepatoblastoma	H131	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
neoplasm	neoplasm	N142	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	O
infants	infant	I515	NNS	B-NP	O
and	and	A530	CC	I-NP	O
children	child	C436	NNS	I-NP	O
only	only	O540	RB	B-VP	O
recently	recently	R253	RB	I-VP	O
documented	document	D253	VBN	I-VP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
colon	colon	C450	NN	I-NP	I-Disease
[	[	0000	(	O	O
Kingston	Kingston	K523	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1983	1983	0000	CD	B-NP	O
]	]	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
four	four	F600	CD	B-NP	O
children	child	C436	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hepatoblastoma	hepatoblastoma	H131	NN	B-NP	B-Disease
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Gardner	Gardner	G635	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
GS	GS	G200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
child	child	C430	NN	I-NP	O
,	,	0000	,	O	O
now	now	N000	RB	B-NP	O
19	19	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
old	old	O430	JJ	B-ADJP	O
,	,	0000	,	O	O
survived	survive	S613	VBD	B-VP	O
after	after	A136	IN	B-PP	O
a	a	A000	DT	B-NP	O
resection	resection	R235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
hepatoblastoma	hepatoblastoma	H131	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
infancy	infancy	I515	NN	B-NP	O
and	and	A530	CC	O	O
recently	recently	R253	RB	B-ADVP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
GS	GS	G200	NN	B-NP	B-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
associated	associate	A230	VBN	I-NP	O
odontoma	odontoma	O353	NN	I-NP	B-Disease
and	and	A530	CC	O	O
pigmented	pigment	P253	VBD	B-VP	B-Disease
ocular	ocular	O246	JJ	B-NP	I-Disease
fundus	fundus	F532	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
clinical	clinical	C452	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
of	of	O100	IN	B-PP	O
GS	GS	G200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
four	four	F600	CD	I-NP	O
GS	GS	G200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	CC	O	O
affected	affect	A123	VBN	B-VP	O
and	and	A530	CC	O	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
osteomatous	osteomatous	O235	JJ	B-NP	B-Disease
jaw	jaw	J000	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
pigmented	pigment	P253	VBN	B-VP	B-Disease
ocular	ocular	O246	JJ	B-NP	I-Disease
fundus	fundus	F532	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
search	search	S620	NN	I-NP	O
for	for	F600	IN	B-PP	O
colonic	colonic	C452	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
made	make	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
of	of	O100	IN	B-PP	O
infants	infant	I515	NNS	B-NP	O
and	and	A530	CC	I-NP	O
children	child	C436	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hepatoblastoma	hepatoblastoma	H131	NN	B-NP	B-Disease
.	.	0000	.	O	O

If	If	I100	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
child	child	C430	NN	I-NP	O
survives	survive	S612	VBZ	B-VP	O
,	,	0000	,	O	O
he	he	H000	PRP	B-NP	O
or	or	O600	CC	I-NP	O
she	she	S000	PRP	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
monitored	monitor	M536	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
appearance	appearance	A165	NN	I-NP	O
of	of	O100	IN	B-PP	O
colonic	colonic	C452	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
jaw	jaw	J000	NN	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
pigmented	pigment	P253	VBN	B-VP	B-Disease
ocular	ocular	O246	JJ	B-NP	I-Disease
fundus	fundus	F532	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
are	be	A600	VBP	B-VP	O
indications	indication	I532	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GS	GS	G200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	O	O
acetylhexosaminidase	acetylhexosaminidase	A234	NN	B-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
27	27	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
lethal	lethal	L340	JJ	I-NP	O
,	,	0000	,	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
yet	yet	Y300	RB	B-ADJP	O
evident	evident	E135	JJ	I-ADJP	O
whether	whether	W360	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
has	have	H200	VBZ	B-VP	O
resulted	result	R243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
and	and	A530	CC	O	O
random	random	R535	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
drift	drift	D613	NN	I-NP	O
or	or	O600	CC	B-PP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cloned	clone	C453	VBN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
change	change	C520	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
for	for	F600	IN	B-PP	O
G	G	G000	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
12	12	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
expected	expect	E212	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
amplification	amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
rection	rection	R235	NN	I-NP	O
and	and	A530	CC	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
DdeI	DdeI	D300	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
generated	generate	G563	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
case	case	C200	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
,	,	0000	,	O	O
infantile	infantile	I515	JJ	B-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
warrants	warrant	W653	VBZ	B-VP	O
further	far	F636	JJR	B-NP	O
examination	examination	E253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-PP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Mus	Mus	M200	NNP	B-NP	O
musculus	musculus	M242	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
recovered	recover	R216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
offspring	offspring	O121	NN	B-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
ethyl	ethyl	E340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
nitrosourea	nitrosourea	N362	NN	I-NP	O
-	-	0000	HYPH	O	O
treated	treat	T630	VBN	B-NP	O
male	male	M400	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
alteration	alteration	A436	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
but	but	B300	CC	O	O
can	can	C500	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
extracts	extract	E236	NNS	I-NP	O
.	.	0000	.	O	O

Hemizygous	Hemizygous	H520	JJ	B-NP	O
,	,	0000	,	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
homozygous	homozygous	H520	JJ	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
about	about	A130	RB	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
60	60	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
remaining	remain	R520	VBG	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
blood	blood	B430	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
compared	compare	C516	VBN	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

Erythrocyte	Erythrocyte	E636	NN	B-NP	O
indices	index	I532	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
show	show	S000	VB	I-VP	O
differences	difference	D165	NNS	B-NP	O
between	between	B350	IN	B-PP	O
mutants	mutant	M353	NNS	B-NP	O
and	and	A530	CC	O	O
wild	wild	W430	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
the	the	T000	DT	B-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
migration	migration	M263	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
isoelectric	isoelectric	I242	JJ	I-NP	O
point	point	P530	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
thermal	thermal	T654	JJ	I-NP	O
stability	stability	S314	NN	I-NP	O
.	.	0000	.	O	O

Kinetic	Kinetic	K532	JJ	B-NP	O
properties	property	P616	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
Km	Km	K500	NN	I-NP	O
for	for	F600	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
or	or	O600	CC	B-PP	O
for	for	F600	IN	B-PP	O
NADP	NADP	N310	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
utilization	utilization	U342	NN	I-NP	O
of	of	O100	IN	B-PP	O
substrate	substrate	S123	NN	B-NP	O
analogues	analogue	A542	NNS	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
differences	difference	D165	NNS	I-NP	O
between	between	B350	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
and	and	A530	CC	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
exception	exception	E213	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
utilization	utilization	U342	NN	I-NP	O
of	of	O100	IN	B-PP	O
deamino	deamino	D500	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
NADP	NADP	N310	NN	I-NP	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
lower	low	L600	JJR	I-ADJP	O
in	in	I500	IN	B-PP	O
mutants	mutant	M353	NNS	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
presently	presently	P625	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
G6PD	G6PD	G130	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Diverse	Diverse	D162	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	O
or	or	O600	CC	I-NP	O
severe	severe	S160	JJ	I-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	B-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
;	;	0000	:	O	I-Disease
EC	EC	E200	NNP	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
1	1	0000	CD	B-NP	I-Disease
.	.	0000	.	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
49	49	0000	CD	O	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
400	400	0000	CD	I-NP	O
million	million	M450	CD	I-NP	O
people	people	P140	NNS	I-NP	O
worldwide	worldwide	W643	RB	B-ADVP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
many	many	M500	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
exhibiting	exhibit	E213	VBG	B-VP	O
a	a	A000	DT	B-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypes	phenotype	P531	NNS	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
well	well	W400	RB	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
hematological	hematological	H534	JJ	I-NP	O
point	point	P530	NN	I-NP	O
of	of	O100	IN	B-PP	O
view	view	V000	NN	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
until	until	U534	IN	B-PP	O
now	now	N000	RB	B-ADVP	O
,	,	0000	,	O	O
their	their	T600	PRP$	B-NP	O
precise	precise	P620	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
remained	remain	R530	VBN	I-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
seven	seven	S150	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nondeficient	nondeficient	N531	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
variant	variant	V653	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
A	A	A000	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
six	six	S200	CD	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
investigated	investigate	I512	VBN	B-VP	O
were	be	W600	VBD	B-VP	O
all	all	A400	DT	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
commonest	commonest	C523	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
favism	favism	F125	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
other	other	O360	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
replacement	replacement	R142	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
(	(	0000	(	O	O
serine	serine	S650	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
)	)	0000	)	O	O
it	it	I300	PRP	B-NP	O
must	must	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
stability	stability	S314	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

Single	Single	S524	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Metaponto	Metaponto	M315	NNP	I-NP	O
(	(	0000	(	O	O
Southern	Southern	S365	NNP	B-NP	O
Italy	Italy	I340	NNP	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Ilesha	Ilesha	I420	NN	I-NP	O
(	(	0000	(	O	O
Nigeria	Nigeria	N260	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
asymptomatic	asymptomatic	A251	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NNP	B-NP	O
Chatham	Chatham	C350	NNP	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
Indian	Indian	I535	JJ	I-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
jaundice	jaundice	J532	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
"	"	0000	``	O	O
Matera	Matera	M360	NNP	B-NP	O
,	,	0000	,	O	O
"	"	0000	''	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
now	now	N000	RB	I-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
as	as	A200	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
separate	separate	S163	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
G6PD	G6PD	G130	NNP	B-NP	O
Santiago	Santiago	S532	NNP	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
glycine	glycine	G425	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
arginine	arginine	A625	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
chronic	chronic	C652	JJ	I-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	B-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
show	show	S000	VBP	B-VP	O
a	a	A000	DT	B-NP	O
striking	striking	S362	JJ	I-NP	O
predominance	predominance	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
C	C	C000	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
transitions	transition	T652	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
CG	CG	C200	NN	B-NP	O
doublets	doublet	D143	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
diverse	diverse	D162	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
account	account	A253	VB	I-VP	O
largely	largely	L624	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Tight	Tight	T230	NN	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
E	E	E000	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
with	with	W300	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotides	oligonucleotide	O425	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotides	oligonucleotide	O425	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
employed	employ	E514	VBN	I-VP	O
to	to	T000	TO	I-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
E	E	E000	NN	I-NP	O
(	(	0000	(	O	O
APOE	APOE	A100	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
and	and	A530	CC	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
.	.	0000	.	O	O

Synthetic	Synthetic	S532	JJ	B-NP	O
oligonucleotides	oligonucleotide	O425	NNS	I-NP	O
,	,	0000	,	O	O
designed	design	D253	VBN	B-VP	O
to	to	T000	TO	I-VP	O
discriminate	discriminate	D265	VB	I-VP	O
between	between	B350	IN	B-PP	O
APOE	APOE	A100	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
epsilon	epsilon	E124	NN	B-NP	O
3	3	0000	CD	I-NP	O
and	and	A530	CC	O	O
epsilon	epsilon	E124	NN	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	O	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
hybridization	hybridization	H163	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
relevant	relevant	R415	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APOE	APOE	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
enzymatically	enzymatically	E525	RB	I-VP	O
amplified	amplify	A514	VBN	I-VP	O
to	to	T000	TO	I-VP	O
increase	increase	I526	VB	I-VP	O
the	the	T000	DT	B-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
method	method	M300	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
DM	DM	D500	NN	B-NP	O
and	and	A530	CC	I-NP	O
APOE	APOE	A100	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
(	(	0000	(	O	O
zmax	zmax	Z520	NN	B-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

47	47	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
theta	theta	T300	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

047	047	0000	CD	B-NP	O
(	(	0000	(	O	O
male	male	M400	JJ	B-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	JJ	I-NP	O
female	female	F540	JJ	I-NP	O
theta	theta	T300	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
(	(	0000	(	O	O
maximum	maximum	M250	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O
61	61	0000	CD	B-NP	O
at	at	A300	IN	B-PP	O
theta	theta	T300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
APOE	APOE	A100	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
CII	CII	C000	NN	I-NP	O
(	(	0000	(	O	O
APOC2	APOC2	A120	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
APOC2	APOC2	A120	NN	B-NP	O
,	,	0000	,	O	O
APOE	APOE	A100	NNP	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
for	for	F600	IN	B-PP	O
presymptomatic	presymptomatic	P625	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
diagnosis	diagnosis	D252	NN	I-NP	O
.	.	0000	.	O	O

Regional	Regional	R254	JJ	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
using	use	U252	VBG	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
males	male	M420	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
who	who	W000	WP	B-NP	O
suffer	suffer	S160	VBP	B-VP	O
from	from	F650	IN	B-PP	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
time	time	T500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
resolution	resolution	R243	NN	I-NP	O
banding	banding	B535	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
as	as	A200	IN	B-PP	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q21	q21	Q000	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
q21	q21	Q000	NN	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	O	O
33	33	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q21	q21	Q000	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	O	O
-	-	0000	HYPH	O	O
q21	q21	Q000	NN	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	O	O
31	31	0000	CD	B-NP	O
)	)	0000	)	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
ten	ten	T500	CD	B-NP	O
different	different	D165	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
TCD	TCD	T230	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
probe	probe	P610	NN	I-NP	O
,	,	0000	,	O	O
p31	p31	P000	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cover	cover	C160	VB	I-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
smallest	small	S542	JJS	I-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
following	follow	F452	VBG	I-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
cen	cen	C500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS106	DXS106	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS72	DXS72	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
TCD	TCD	T230	NN	I-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DXYS1	DXYS1	D200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
DXYS23	DXYS23	D200	NN	I-NP	O
/	/	0000	SYM	I-NP	O
DXYS5	DXYS5	D200	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
DXYS2	DXYS2	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DXYS12	DXYS12	D200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
DXS3	DXS3	D200	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DXS17	DXS17	D200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
DXS101	DXS101	D200	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
Xqter	Xqter	X236	NN	I-NP	O
.	.	0000	.	O	O

Retroviral	Retroviral	R361	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
mediated	mediate	M300	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
into	into	I530	IN	B-PP	O
NIH	NIH	N000	NN	B-NP	O
3T3	3T3	T000	NN	I-NP	O
and	and	A530	CC	O	O
hepatoma	hepatoma	H135	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
hepatic	hepatic	H132	JJ	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
human	human	H500	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
inserted	insert	I526	VBN	I-VP	O
into	into	I530	IN	B-PP	O
pzip	pzip	P210	NN	B-NP	O
-	-	0000	HYPH	O	O
neoSV	neoSV	N210	NN	B-NP	O
(	(	0000	(	O	O
X	X	X000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
retroviral	retroviral	R361	JJ	I-NP	O
vector	vector	V236	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
bacterial	bacterial	B236	JJ	I-NP	O
neo	neo	N000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recombinant	recombinant	R251	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
transfected	transfecte	T652	VBN	I-VP	O
into	into	I530	IN	B-PP	O
psi	psi	P200	NN	B-NP	O
2	2	0000	CD	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
provide	provide	P613	VBP	B-VP	O
synthesis	synthesis	S532	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retroviral	retroviral	R361	JJ	I-NP	O
capsid	capsid	C123	NN	I-NP	O
.	.	0000	.	O	O

Recombinant	Recombinant	R251	JJ	B-NP	O
virus	virus	V620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
culture	culture	C436	NN	I-NP	O
medium	medium	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transfected	transfecte	T652	VBN	I-NP	O
psi	psi	P200	NN	I-NP	O
2	2	0000	CD	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
transmitting	transmit	T652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
into	into	I530	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
NIH	NIH	N000	NN	I-NP	O
3T3	3T3	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
by	by	B000	IN	B-PP	O
infection	infection	I512	NN	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
stable	stable	S314	JJ	B-NP	O
incorporation	incorporation	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
provirus	provirus	P616	NN	I-NP	O
.	.	0000	.	O	O

Infected	Infected	I512	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
express	express	E216	VBP	B-VP	O
PAH	PAH	P000	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
,	,	0000	,	O	O
immunoreactive	immunoreactive	I562	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
exhibit	exhibit	E213	VBP	B-VP	O
pterin	pterin	P365	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
virus	virus	V620	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
infecting	infect	I512	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
hepatoma	hepatoma	H135	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
normally	normally	N654	RB	I-VP	O
synthesize	synthesize	S532	VB	I-VP	O
PAH	PAH	P000	NN	B-NP	O
.	.	0000	.	O	O

PAH	PAH	P000	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
extracts	extract	E236	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
hydroxylation	hydroxylation	H362	NN	I-NP	O
system	system	S235	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
reconstituted	reconstitute	R252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hepatoma	hepatoma	H135	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
infected	infect	I512	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
viruses	virus	V620	NNS	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
recombinant	recombinant	R251	JJ	B-NP	O
viruses	virus	V620	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
human	human	H500	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
means	means	M520	NN	I-NP	O
for	for	F600	IN	B-PP	O
introducing	introduce	I536	VBG	B-VP	O
functional	functional	F523	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
into	into	I530	IN	B-PP	O
mammalian	mammalian	M545	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	O	O
can	can	C500	MD	B-VP	O
potentially	potentially	P353	RB	I-VP	O
be	be	B000	VB	I-VP	O
introduced	introduce	I536	VBN	I-VP	O
into	into	I530	IN	B-PP	O
whole	whole	W400	JJ	B-NP	O
animals	animal	A542	NNS	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
for	for	F600	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Estimation	Estimation	E235	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
to	to	T000	TO	B-PP	O
female	female	F540	JJ	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
rates	rate	R320	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
segregation	segregation	S262	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
procedure	procedure	P623	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
presented	present	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
estimate	estimate	E235	VB	I-VP	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	O
to	to	T000	TO	B-PP	O
female	female	F540	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
establish	establish	E231	VB	I-VP	O
DNA	DNA	D500	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
generation	generation	G563	NN	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
their	their	T600	PRP$	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
grandfathers	grandfather	G653	NNS	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
rates	rate	R320	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
calculated	calculate	C424	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
classical	classical	C424	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proposed	propose	P612	VBN	I-NP	O
procedure	procedure	P623	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
restricted	restricted	R236	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
or	or	O600	CC	I-NP	O
familiar	familiar	F546	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
nor	nor	N600	CC	O	O
is	be	I200	VBZ	B-VP	O
any	any	A500	DT	B-NP	O
information	information	I516	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
relatives	relative	R431	NNS	I-NP	O
required	require	R263	VBN	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Deletions	Deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
retinoblastomas	retinoblastoma	R351	NNS	B-NP	B-Disease
and	and	A530	CC	O	O
mesenchymal	mesenchymal	M252	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
:	:	0000	:	O	O
organization	organization	O625	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
encoded	encode	E523	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Retinoblastoma	Retinoblastoma	R351	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
childhood	childhood	C430	NN	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
can	can	C500	MD	B-VP	O
arise	arise	A620	VB	I-VP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
mutant	mutant	M353	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
acquired	acquire	A263	VBN	B-VP	O
as	as	A200	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
or	or	O600	CC	I-NP	O
germinal	germinal	G654	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
carried	carry	C630	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
creating	create	C635	VBG	B-VP	O
these	these	T200	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
act	act	A230	VBP	B-VP	O
by	by	B000	IN	B-PP	O
inactivating	inactivate	I523	VBG	B-VP	O
copies	copy	C120	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
band	band	B530	NN	B-NP	O
q14	q14	Q000	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
13	13	0000	CD	I-NP	O
and	and	A530	CC	O	O
termed	term	T653	VBN	B-VP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
isolation	isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
that	that	T300	WDT	B-NP	O
recognizes	recognize	R252	VBZ	B-VP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
possessing	possess	P252	VBG	B-VP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
attributes	attribute	A361	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
segment	segment	S253	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
additionally	additionally	A354	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
target	target	T623	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mesenchymal	mesenchymal	M252	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
having	have	H152	VBG	B-VP	O
no	no	N000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
provide	provide	P613	VBP	B-VP	O
additional	additional	A354	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
cloned	clone	C453	VBN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
representative	representative	R162	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
target	target	T623	NN	I-NP	O
of	of	O100	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
during	during	D652	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
little	little	L340	JJ	B-NP	O
insight	insight	I523	NN	I-NP	O
into	into	I530	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
normal	normal	N654	JJ	I-NP	O
functional	functional	F523	JJ	I-NP	O
role	role	R400	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Treatment	Treatment	T635	NN	B-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
hormone	hormone	H650	NN	I-NP	O
inhibitors	inhibitor	I513	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
controlled	controlled	C536	JJ	I-NP	O
,	,	0000	,	I-NP	O
double	double	D140	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
blind	blind	B453	JJ	I-NP	O
therapeutic	therapeutic	T613	JJ	I-NP	O
trial	trial	T640	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
drug	drug	D620	NN	I-NP	O
mazindol	mazindol	M253	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
hormone	hormone	H650	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pair	pair	P600	NN	I-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
2	2	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
monozygotic	monozygotic	M523	JJ	I-NP	O
twins	twin	T520	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
rationale	rationale	R354	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
trial	trial	T640	NN	I-NP	O
was	be	W200	VBD	B-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
reported	report	R163	VBN	B-VP	O
previously	previously	P612	RB	B-ADVP	O
)	)	0000	)	O	O
affected	affect	A123	VBN	B-VP	O
simultaneously	simultaneously	S543	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
growth	growth	G630	NN	I-NP	B-Disease
hormone	hormone	H650	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
GH	GH	G000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
is	be	I200	VBZ	B-VP	O
showing	show	S520	VBG	I-VP	O
a	a	A000	DT	B-NP	O
benign	benign	B525	JJ	I-NP	O
course	course	C620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophic	dystrophic	D236	JJ	I-NP	B-Disease
process	process	P620	NN	I-NP	I-Disease
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	I-VP	O
walking	walk	W425	VBG	I-VP	O
at	at	A300	IN	B-PP	O
18	18	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
twins	twin	T520	NNS	I-NP	O
received	receive	R213	VBD	B-VP	O
2	2	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mazindol	mazindol	M253	NN	B-NP	O
daily	daily	D400	RB	B-ADVP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
received	receive	R213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
placebo	placebo	P421	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
assessment	assessment	A253	NN	I-NP	O
,	,	0000	,	O	O
repeated	repeat	R130	VBD	B-VP	O
every	every	E160	DT	B-NP	O
2	2	0000	CD	I-NP	O
months	month	M532	NNS	I-NP	O
,	,	0000	,	O	O
included	include	I524	VBD	B-VP	O
weight	weight	W230	NN	B-NP	O
and	and	A530	CC	I-NP	O
height	height	H230	NN	I-NP	O
measurements	measurement	M265	NNS	I-NP	O
,	,	0000	,	O	O
functional	functional	F523	JJ	B-NP	O
and	and	A530	CC	I-NP	O
motor	motor	M360	NN	I-NP	O
ability	ability	A143	NN	I-NP	O
tests	test	T232	NNS	I-NP	O
,	,	0000	,	O	O
ergometry	ergometry	E625	NN	B-NP	O
and	and	A530	CC	I-NP	O
determinations	determination	D365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
and	and	A530	CC	O	O
GH	GH	G000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
one	one	O500	CD	B-NP	O
year	year	Y600	NN	I-NP	O
of	of	O100	IN	B-PP	O
trial	trial	T640	NN	B-NP	O
the	the	T000	DT	B-NP	O
code	code	C300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
broken	break	B625	VBN	I-VP	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
twin	twin	T500	NN	I-NP	O
under	under	U536	IN	B-PP	O
placebo	placebo	P421	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
strikingly	strikingly	S362	RB	B-ADJP	O
worse	worse	W620	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
brother	brother	B636	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
progression	progression	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
whose	whose	W200	WP$	B-NP	O
condition	condition	C535	NN	I-NP	O
was	be	W200	VBD	B-VP	O
practically	practically	P623	RB	I-VP	O
arrested	arrest	A623	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
strongly	strongly	S365	RB	B-VP	O
suggest	suggest	S230	VBP	I-VP	O
that	that	T300	IN	B-SBAR	O
treatment	treatment	T635	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
GH	GH	G000	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
beneficial	beneficial	B512	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
by	by	B000	IN	B-PP	O
ribonuclease	ribonuclease	R152	NN	B-NP	O
A	A	A000	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
.	.	0000	.	O	O

Many	Many	M500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
single	single	S524	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
has	have	H200	VBZ	B-VP	O
prompted	prompt	P651	VBN	I-VP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
assays	assay	A200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
ribonuclease	ribonuclease	R152	NN	I-NP	O
A	A	A000	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
procedure	procedure	P623	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
polyuridylic	polyuridylic	P463	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
paper	paper	P160	NN	I-NP	O
affinity	affinity	A153	NN	I-NP	O
chromatography	chromatography	C653	NN	I-NP	O
step	step	S310	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
identify	identify	I353	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
lesions	lesion	L252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypoxanthine	hypoxanthine	H125	NN	I-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
)	)	0000	)	O	O
messenger	messenger	M252	NN	B-NP	O
RNAs	RNA	R520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Distinctive	Distinctive	D235	JJ	B-NP	O
ribonuclease	ribonuclease	R152	NN	I-NP	O
A	A	A000	NN	I-NP	O
cleavage	cleavage	C412	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
messenger	messenger	M252	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
from	from	F650	IN	B-PP	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
chosen	choose	C250	VBN	I-VP	O
because	because	B200	IN	B-SBAR	O
no	no	N000	DT	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
Southern	Southern	S365	JJ	I-NP	O
or	or	O600	CC	I-NP	O
Northern	Northern	N636	JJ	I-NP	O
blotting	blotting	B435	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
now	now	N000	RB	B-ADVP	O
allows	allow	A420	VBZ	B-VP	O
HPRT	HPRT	H163	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
50	50	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
polyuridylic	polyuridylic	P463	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
paper	paper	P160	NN	I-NP	O
affinity	affinity	A153	NN	I-NP	O
procedure	procedure	P623	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
abundance	abundance	A153	NN	I-NP	O
messenger	messenger	M252	NN	I-NP	O
RNAs	RNA	R520	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
non	non	N500	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
spherocytic	spherocytic	S162	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
:	:	0000	:	O	O
G6PD	G6PD	G130	NN	B-NP	O
Wayne	Wayne	W500	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Huron	Huron	H650	NNP	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
causing	cause	C252	VBG	B-VP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
(	(	0000	(	O	O
HNSHA	HNSHA	H520	NN	B-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
unique	unique	U520	JJ	B-ADJP	O
and	and	A530	CC	O	O
they	they	T000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
named	name	N530	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Wayne	Wayne	W500	NNP	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Huron	Huron	H650	NNP	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Wayne	Wayne	W500	NNP	I-NP	O
underwent	undergo	U536	VBD	B-VP	O
splenectomy	splenectomy	S145	NN	B-NP	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
objective	objective	O123	JJ	I-NP	O
improvement	improvement	I516	NN	I-NP	O
was	be	W200	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Huron	Huron	H650	NNP	B-NP	O
were	be	W600	VBD	B-VP	O
under	under	U536	IN	B-PP	O
medical	medical	M324	JJ	B-NP	O
observation	observation	O126	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
period	period	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
time	time	T500	NN	B-NP	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
being	be	B520	VBG	B-VP	O
entertained	entertain	E536	VBN	I-VP	O
because	because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
was	be	W200	VBD	B-VP	O
of	of	O100	IN	B-PP	O
Northern	Northern	N636	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
sporadic	sporadic	S163	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
causing	cause	C252	VBG	B-VP	O
HNSHA	HNSHA	H520	NN	B-NP	B-Disease
show	show	S000	VBP	B-VP	O
no	no	N000	DT	B-NP	O
special	special	S124	JJ	I-NP	O
racial	racial	R240	JJ	I-NP	O
predilection	predilection	P634	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
should	should	S430	MD	B-VP	O
always	always	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
considered	consider	C523	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Sialophorin	Sialophorin	S416	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
surface	surface	S612	NN	I-NP	O
sialoglycoprotein	sialoglycoprotein	S424	NN	I-NP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
T	T	T000	NN	I-NP	O
lymphocyte	lymphocyte	L512	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mAb	mAb	M100	NN	I-NP	O
L10	L10	L000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
sialophorin	sialophorin	S416	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
heavily	heavily	H140	RB	I-NP	O
glycosylated	glycosylate	G424	VBN	I-NP	O
surface	surface	S612	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
/	/	0000	SYM	O	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
immunodeficiency	immunodeficiency	I531	NN	I-NP	I-Disease
Wiskott	Wiskott	W230	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Dual	Dual	D400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
parameter	parameter	P653	NN	I-NP	O
FACS	FACS	F200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
sialophorin	sialophorin	S416	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
on	on	O500	IN	B-PP	O
CD4	CD4	C300	NN	B-NP	O
+	+	0000	SYM	B-NP	O
and	and	A530	CC	O	O
CD8	CD8	C300	NN	B-NP	O
+	+	0000	SYM	O	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subpopulation	subpopulation	S143	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
B	B	B000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
all	all	A400	DT	B-NP	O
thymocytes	thymocyte	T523	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subpopulation	subpopulation	S143	NN	I-NP	O
of	of	O100	IN	B-PP	O
bone	bone	B500	NN	B-NP	O
marrow	marrow	M600	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Functional	Functional	F523	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
L10	L10	L000	NN	B-NP	O
mAb	mAb	M100	NN	I-NP	O
stimulates	stimulate	S354	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
measured	measure	M263	VBN	B-VP	O
by	by	B000	IN	B-PP	O
stimulation	stimulation	S354	NN	B-NP	O
of	of	O100	IN	B-PP	O
[	[	0000	(	B-NP	O
3H	3H	H000	NN	I-NP	O
]	]	0000	)	I-NP	O
thymidine	thymidine	T535	NN	I-NP	O
incorporation	incorporation	I526	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
course	course	C620	NN	I-NP	O
and	and	A530	CC	I-NP	O
magnitude	magnitude	M253	NN	I-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
[	[	0000	(	I-NP	O
3H	3H	H000	NN	I-NP	O
]	]	0000	)	I-NP	O
thymidine	thymidine	T535	NN	I-NP	O
incorporation	incorporation	I526	NN	I-NP	O
by	by	B000	IN	B-PP	O
T	T	T000	NN	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
response	response	R215	NN	B-NP	O
to	to	T000	TO	B-PP	O
L10	L10	L000	NN	B-NP	O
mAb	mAb	M100	NN	I-NP	O
paralleled	parallel	P643	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
induced	induce	I532	VBN	B-VP	O
by	by	B000	IN	B-PP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
CD3	CD3	C300	NN	I-NP	O
mAb	mAb	M100	NN	I-NP	O
.	.	0000	.	O	O

Effective	Effective	E123	JJ	B-NP	O
stimulation	stimulation	S354	NN	I-NP	O
was	be	W200	VBD	B-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
monocytes	monocyte	M523	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Fc	Fc	F200	NN	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
L10	L10	L000	NN	B-NP	O
mAb	mAb	M100	NN	I-NP	O
.	.	0000	.	O	O

Stimulation	Stimulation	S354	NN	B-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
by	by	B000	IN	B-PP	O
L10	L10	L000	NN	B-NP	O
,	,	0000	,	O	O
like	like	L200	IN	B-PP	O
stimulation	stimulation	S354	NN	B-NP	O
by	by	B000	IN	B-PP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
CD3	CD3	C300	NN	I-NP	O
mAb	mAb	M100	NN	I-NP	O
,	,	0000	,	O	O
involves	involve	I514	VBZ	B-VP	O
increased	increase	I526	VBN	I-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
4F2	4F2	F000	NN	B-NP	O
,	,	0000	,	O	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
DR	DR	D600	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
IL	IL	I400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
R	R	R000	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
sialophorin	sialophorin	S416	NN	B-NP	O
functions	function	F523	NNS	I-NP	O
in	in	I500	IN	B-PP	O
T	T	T000	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
activation	activation	A231	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hypopigmentation	Hypopigmentation	H125	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Cutaneous	Cutaneous	C352	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ocular	ocular	O246	JJ	I-NP	I-Disease
pigmentation	pigmentation	P253	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
in	in	I500	IN	B-PP	O
29	29	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Criteria	Criterion	C636	NNS	B-NP	O
for	for	F600	IN	B-PP	O
hypopigmentation	hypopigmentation	H125	NN	B-NP	B-Disease
included	include	I524	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
type	type	T100	NN	B-NP	O
I	I	I000	CD	I-NP	O
or	or	O600	CC	I-NP	O
II	II	I000	CD	I-NP	O
skin	skin	S250	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
lightest	light	L232	JJS	I-NP	O
skin	skin	S250	NN	I-NP	O
type	type	T100	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
by	by	B000	IN	B-PP	O
history	history	H236	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
iris	iris	I620	NN	B-NP	O
translucency	translucency	T652	NN	I-NP	O
on	on	O500	IN	B-PP	O
globe	globe	G410	NN	B-NP	O
transillumination	transillumination	T652	NN	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
criteria	criterion	C636	NNS	I-NP	O
,	,	0000	,	O	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
hypopigmented	hypopigmente	H125	VBN	I-VP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypopigmentation	hypopigmentation	H125	NN	B-NP	B-Disease
correlated	correlate	C643	VBD	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	O	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
meet	meet	M300	VB	I-VP	O
the	the	T000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
criteria	criterion	C636	NNS	I-NP	O
for	for	F600	IN	B-PP	O
hypopigmentation	hypopigmentation	H125	NN	B-NP	B-Disease
.	.	0000	.	O	O

Hairbulb	Hairbulb	H614	NN	B-NP	O
tyrosinase	tyrosinase	T625	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
glutathione	glutathione	G435	NN	B-NP	O
content	content	C535	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
urine	urine	U650	NN	B-NP	O
cysteinyldopa	cysteinyldopa	C235	NN	I-NP	O
excretion	excretion	E263	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
low	low	L000	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
and	and	A530	CC	I-PP	O
without	without	W300	IN	I-PP	O
hypopigmentation	hypopigmentation	H125	NN	B-NP	B-Disease
and	and	A530	CC	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
separate	separate	S163	VB	I-VP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
hypopigmentation	hypopigmentation	H125	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
hypopigmentation	hypopigmentation	H125	NN	I-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypopigmentation	hypopigmentation	H125	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Phenotype	Phenotype	P531	NN	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
among	among	A520	IN	B-PP	O
hemizygotes	hemizygote	H523	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
biochemically	biochemically	B252	RB	B-ADVP	O
screened	screen	S265	VBD	B-VP	O
for	for	F600	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
two	two	T000	CD	B-NP	O
clinically	clinically	C452	RB	I-NP	O
,	,	0000	,	O	O
neurologically	neurologically	N642	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
relatives	relative	R431	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
;	;	0000	:	O	O
they	they	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
repeatedly	repeatedly	R134	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
hemizygote	hemizygote	H523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
assay	assay	A200	NN	I-NP	O
consisted	consist	C523	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
determination	determination	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
lyophilized	lyophilize	L142	VBN	B-NP	O
and	and	A530	CC	I-NP	O
reconstituted	reconstitute	R252	VBN	I-NP	O
plasma	plasma	P425	NN	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
neurologic	neurologic	N642	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
leukodystrophy	leukodystrophy	L232	NN	B-NP	B-Disease
or	or	O600	CC	O	O
myeloneuropathy	myeloneuropathy	M456	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
hemizygotes	hemizygote	H523	NNS	I-NP	O
,	,	0000	,	O	O
adrenocortical	adrenocortical	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
provoking	provoke	P612	VBG	B-VP	O
compensatory	compensatory	C515	JJ	B-NP	O
high	high	H200	JJ	I-NP	O
ACTH	ACTH	A230	NN	I-NP	O
release	release	R420	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
taken	take	T250	VBN	I-VP	O
into	into	I530	IN	B-PP	O
consideration	consideration	C523	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
counseling	counsel	C524	VBG	B-VP	O
families	family	F542	NNS	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
cases	case	C200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
clinically	clinically	C452	RB	B-NP	O
expressed	express	E216	VBN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
represented	represent	R162	VBN	I-VP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
Duchenne	Duchenne	D250	NNP	B-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
sequences	sequence	S252	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
has	have	H200	VBZ	B-VP	O
opened	open	O153	VBN	I-VP	O
up	up	U100	RP	B-PRT	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
related	related	R430	JJ	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
species	specie	S120	NNS	I-NP	O
.	.	0000	.	O	O

Until	Until	U534	IN	B-PP	O
relatively	relatively	R431	RB	B-ADVP	O
recently	recently	R253	RB	I-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
therapeutic	therapeutic	T613	JJ	B-NP	O
strategies	strategy	S363	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
mutant	mutant	M353	NN	I-NP	O
showing	show	S520	VBG	B-VP	O
muscular	muscular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
mdx	mdx	M320	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
provided	provide	P613	VBN	I-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
mild	mild	M430	JJ	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mdx	mdx	M320	NN	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
it	it	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
more	more	M600	RBR	B-NP	O
in	in	I500	IN	B-PP	O
common	common	C500	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Becker	Becker	B260	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
.	.	0000	.	O	O

But	But	B300	CC	O	O
the	the	T000	DT	B-NP	O
close	close	C420	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
mdx	mdx	M320	NN	B-NP	O
to	to	T000	TO	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
and	and	A530	CC	I-NP	O
Hprt	Hprt	H163	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
comparatively	comparatively	C516	RB	I-NP	O
mild	mild	M430	JJ	I-NP	O
pathology	pathology	P342	NN	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
instead	instead	I523	RB	I-VP	O
correspond	correspond	C621	VB	I-VP	O
to	to	T000	TO	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
itself	itself	I324	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
DNA	DNA	D500	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
at	at	A300	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
qter	qter	Q360	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
interspecific	interspecific	I536	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
domesticus	domesticus	D523	NN	I-NP	O
/	/	0000	SYM	B-NP	O
spretus	spretus	S163	NN	I-NP	O
cross	cross	C620	RB	B-ADVP	O
,	,	0000	,	O	O
segregating	segregate	S262	VBG	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
positioned	position	P235	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
cDNA	cDNA	C350	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
provocatively	provocatively	P612	RB	B-ADVP	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
unexpectedly	unexpectedly	U521	RB	B-ADJP	O
distant	distant	D235	JJ	I-ADJP	O
from	from	F650	IN	B-PP	O
sparse	sparse	S162	JJ	B-NP	O
fur	fur	F600	NN	I-NP	O
,	,	0000	,	O	O
spf	spf	S100	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
OTC	OTC	O320	NNP	B-NP	O
(	(	0000	(	O	O
ornithine	ornithine	O653	NN	B-NP	O
transcarbamylase	transcarbamylase	T652	NN	I-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Localization	Localization	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
progress	progress	P626	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
resulted	result	R243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
the	the	T000	DT	B-NP	I-Disease
milder	mild	M436	JJR	I-NP	I-Disease
Becker	Becker	B260	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophies	dystrophy	D236	NNS	I-NP	I-Disease
being	be	B520	VBG	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
itself	itself	I324	PRP	B-NP	O
extends	extend	E235	VBZ	B-VP	O
over	over	O160	IN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
to	to	T000	TO	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
(	(	0000	(	O	O
kb	kb	K100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
how	how	H000	WRB	B-ADVP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
affect	affect	A123	NN	I-NP	O
muscle	muscle	M240	NN	I-NP	O
development	development	D141	NN	I-NP	O
and	and	A530	CC	O	O
integrity	integrity	I532	NN	B-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
interest	interest	I536	NN	B-NP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
available	available	A141	JJ	B-ADJP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
mdx	mdx	M320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
affects	affect	A123	VBZ	B-VP	O
muscle	muscle	M240	NN	B-NP	O
and	and	A530	CC	O	O
confers	confer	C516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
dystrophic	dystrophic	D236	JJ	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
clear	clear	C460	JJ	B-ADJP	O
whether	whether	W360	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
equivalent	equivalent	E214	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
Duchenne	Duchenne	D250	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
Becker	Becker	B260	NN	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
cross	cross	C620	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
hybridize	hybridize	H163	NN	I-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
to	to	T000	TO	B-VP	O
localize	localize	L242	VB	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
centimorgan	centimorgan	C535	NN	I-NP	O
lying	lie	L520	VBG	B-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
Tabby	Tabby	T100	NNP	I-NP	O
(	(	0000	(	O	O
Ta	Ta	T000	NNP	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
St14	St14	S300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
DxPas8	DxPas8	D212	NN	B-NP	O
)	)	0000	)	O	O
loci	locus	L200	NNS	B-NP	O
,	,	0000	,	O	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
phosphorylase	phosphorylase	P216	NN	I-NP	O
b	b	B000	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
Phk	Phk	P200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
analogy	analogy	A542	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	O	O
chromosome	chromosome	C652	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6pd	G6pd	G130	NN	I-NP	O
and	and	A530	CC	I-NP	O
St14	St14	S300	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
may	may	M000	MD	B-VP	O
contain	contain	C535	VB	I-VP	O
two	two	T000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
distinct	distinct	D235	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
myopathies	myopathy	M132	NNS	I-NP	B-Disease
Emery	Emery	E560	NNP	I-NP	B-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
St14	St14	S300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
homologue	homologue	H542	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

GT	GT	G300	NN	B-NP	O
to	to	T000	TO	B-PP	O
AT	AT	A300	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
skipping	skipping	S215	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
preceding	precede	P623	VBG	I-NP	O
exon	exon	E250	NN	I-NP	O
in	in	I500	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	B-Disease
Phenylketonuria	Phenylketonuria	P542	NN	I-NP	I-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
genetic	genetic	G532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
isolated	isolate	I243	VBD	B-VP	O
several	several	S164	JJ	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
individual	individual	I531	NN	I-NP	O
and	and	A530	CC	O	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
contained	contain	C535	VBD	B-VP	O
an	an	A500	DT	B-NP	O
internal	internal	I536	JJ	I-NP	O
116	116	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
corresponding	correspond	C621	VBG	B-VP	O
precisely	precisely	P624	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
lacking	lack	L252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
52	52	0000	CD	I-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
transfer	transfer	T652	NN	I-NP	O
and	and	A530	CC	O	O
expression	expression	E216	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
abolishes	abolish	A142	VBZ	B-VP	O
PAH	PAH	P000	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
individual	individual	I531	JJ	I-NP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
contain	contain	C535	VB	I-VP	O
a	a	A000	DT	B-NP	O
GT	GT	G300	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
greater	great	G636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
AT	AT	A300	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
liver	liver	L160	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
skipping	skipping	S215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
preceding	precede	P623	VBG	I-NP	O
exon	exon	E250	NN	I-NP	O
during	during	D652	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
splicing	splicing	S142	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Conservation	Conservation	C526	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
and	and	A530	CC	I-NP	O
humans	human	H520	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
transcript	transcript	T652	NN	I-NP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
fetal	fetal	F340	JJ	I-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
and	and	A530	CC	O	O
mouse	mouse	M200	NN	B-NP	O
adult	adult	A343	JJ	I-NP	O
heart	heart	H630	NN	I-NP	O
was	be	W200	VBD	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
,	,	0000	,	O	O
representing	represent	R162	VBG	B-VP	O
approximately	approximately	A162	RB	B-NP	O
25	25	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
total	total	T340	NN	I-NP	O
,	,	0000	,	O	O
14	14	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
transcript	transcript	T652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nucleic	nucleic	N242	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
and	and	A530	CC	O	O
predicted	predict	P632	VBD	B-VP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
species	specie	S120	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
nearly	nearly	N640	RB	B-NP	O
90	90	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
product	product	P632	NN	I-NP	O
might	might	M230	MD	B-VP	O
serve	serve	S610	VB	I-VP	O
a	a	A000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
abundance	abundance	A153	NN	I-NP	O
and	and	A530	CC	I-NP	O
tissue	tissue	T200	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
nebulin	nebulin	N145	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	O
Prader	Prader	P636	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
apparently	apparently	A165	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
4	4	0000	CD	B-NP	O
sibs	sib	S120	NNS	I-NP	O
(	(	0000	(	O	O
2F	2F	F000	NN	B-NP	O
,	,	0000	,	O	O
2M	2M	M000	NN	B-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Diagnosis	Diagnosis	D252	NN	B-NP	O
was	be	W200	VBD	B-VP	O
made	make	M300	VBN	I-VP	O
clinically	clinically	C452	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
history	history	H236	NN	B-NP	O
,	,	0000	,	O	O
behavior	behavior	B160	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
physical	physical	P240	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sibs	sib	S120	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
child	child	C430	NN	I-NP	O
had	have	H300	VBD	B-VP	O
died	die	D300	VBN	I-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
10	10	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
typical	typical	T124	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
first	first	F623	JJ	B-NP	O
phase	phase	P200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
surviving	survive	S615	VBG	B-NP	O
sibs	sib	S120	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
implications	implication	I514	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
familial	familial	F540	JJ	I-NP	O
occurrence	occurrence	O265	NN	I-NP	O
for	for	F600	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
discussed	discuss	D230	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Nebulin	Nebulin	N145	NN	B-NP	O
and	and	A530	CC	I-NP	O
titin	titin	T350	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
appears	appear	A162	VBZ	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

Monoclonal	Monoclonal	M524	JJ	B-NP	O
antibodies	antibody	A531	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
recognize	recognize	R252	VBP	B-VP	O
different	different	D165	JJ	B-NP	O
epitopes	epitope	E131	NNS	I-NP	O
on	on	O500	IN	B-PP	O
either	either	E360	CC	O	O
titin	titin	T350	NN	B-NP	O
or	or	O600	CC	I-NP	O
nebulin	nebulin	N145	NN	I-NP	O
show	show	S000	VBP	B-VP	O
normal	normal	N654	JJ	B-NP	O
staining	stain	S352	VBG	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
on	on	O500	IN	B-PP	O
frozen	freeze	F625	VBN	B-NP	O
sections	section	S235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
muscle	muscle	M240	NN	I-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Gel	Gel	G400	NN	B-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
and	and	A530	CC	I-NP	O
immunoblotting	immunoblotting	I514	NN	I-NP	O
performed	perform	P616	VBN	B-VP	O
on	on	O500	IN	B-PP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
titin	titin	T350	NN	B-NP	O
and	and	A530	CC	I-NP	O
nebulin	nebulin	N145	NN	I-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
argue	argue	A620	VBP	B-VP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
proposal	proposal	P612	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
nebulin	nebulin	N145	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mutated	mutate	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	B-Disease
C2	C2	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
angioedema	angioedema	A523	NN	B-NP	B-Disease
,	,	0000	,	O	O
myasthenia	myasthenia	M235	NN	B-NP	B-Disease
gravis	gravis	G612	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
systemic	systemic	S235	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
myasthenia	myasthenia	M235	NN	B-NP	B-Disease
gravis	gravis	G612	NN	I-NP	I-Disease
,	,	0000	,	O	O
systemic	systemic	S235	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
angioedema	angioedema	A523	NN	B-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
complement	complement	C514	NN	I-NP	B-Disease
factor	factor	F236	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
(	(	0000	(	O	I-Disease
C2	C2	C000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
association	association	A235	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
controversial	controversial	C536	JJ	B-ADJP	O
,	,	0000	,	O	O
though	though	T200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
antigens	antigen	A532	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
possible	possible	P214	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
to	to	T000	TO	B-PP	O
immune	immune	I500	JJ	B-NP	O
response	response	R215	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
autoimmune	autoimmune	A350	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
discuss	discuss	D200	VBP	B-VP	O
the	the	T000	DT	B-NP	O
aetiological	aetiological	A342	JJ	I-NP	O
implications	implication	I514	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
third	third	T630	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
Brittany	Brittany	B635	NNP	B-NP	O
spaniel	spaniel	S154	NN	I-NP	O
dogs	dog	D200	NNS	I-NP	O
.	.	0000	.	O	O

Genetically	Genetically	G532	RB	B-NP	O
determined	determine	D365	VBN	I-NP	O
C3	C3	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Brittany	Brittany	B635	NNP	B-NP	O
spaniel	spaniel	S154	NN	I-NP	O
dogs	dog	D200	VBZ	B-VP	O
shares	share	S620	NNS	B-NP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
and	and	A530	CC	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
allelic	allelic	A420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
C3	C3	C000	NN	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
study	study	S300	NN	I-NP	O
used	use	U230	VBD	B-VP	O
allotype	allotype	A431	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
canine	canine	C500	JJ	B-NP	O
C3	C3	C000	NN	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
dogs	dog	D200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
allelic	allelic	A420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
C3	C3	C000	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
preliminary	preliminary	P645	JJ	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
canine	canine	C500	JJ	B-NP	O
C3	C3	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
apparently	apparently	A165	RB	B-ADVP	O
not	not	N300	RB	O	O
closely	closely	C424	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dog	dog	D200	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Brittany	Brittany	B635	NNP	B-NP	O
spaniel	spaniel	S154	NN	I-NP	O
dogs	dog	D200	VBZ	B-VP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
shares	share	S620	VBZ	B-VP	O
biochemical	biochemical	B252	JJ	B-NP	O
and	and	A530	CC	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
with	with	W300	IN	B-PP	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
also	also	A420	RB	B-VP	O
shares	share	S620	VBZ	I-VP	O
some	some	S500	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
transfer	transfer	T652	NN	I-NP	O
and	and	A530	CC	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
complementary	complementary	C514	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
inserted	insert	I526	VBN	I-VP	O
into	into	I530	IN	B-PP	O
a	a	A000	DT	B-NP	O
eukaryotic	eukaryotic	E263	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
vector	vector	V236	NN	I-NP	O
and	and	A530	CC	O	O
transferred	transfer	T652	VBN	B-VP	O
into	into	I530	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
NIH3T3	NIH3T3	N300	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
normally	normally	N654	RB	I-VP	O
express	express	E216	VB	I-VP	O
PAH	PAH	P000	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
transformed	transform	T652	VBN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
expressed	express	E216	VBD	B-VP	O
PAH	PAH	P000	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
,	,	0000	,	O	O
immunoreactive	immunoreactive	I562	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
enzymatic	enzymatic	E525	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
liver	liver	L160	NN	I-NP	O
products	product	P632	NNS	I-NP	O
,	,	0000	,	O	O
demonstrating	demonstrate	D523	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
necessary	necessary	N260	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
information	information	I516	NN	I-NP	O
to	to	T000	TO	B-VP	O
code	code	C300	VB	I-VP	O
for	for	F600	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
in	in	I500	IN	B-PP	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
and	and	A530	CC	I-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
provide	provide	P613	VB	I-VP	O
new	new	N000	JJ	B-NP	O
opportunities	opportunity	O163	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
investigation	investigation	I512	NN	I-NP	O
of	of	O100	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
therapies	therapy	T612	NNS	I-NP	O
for	for	F600	IN	B-PP	O
PKU	PKU	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Regional	Regional	R254	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
phenylketonuria	phenylketonuria	P542	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
metabolism	metabolism	M314	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
hepatic	hepatic	H132	JJ	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
phenylalanine	phenylalanine	P545	NN	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
;	;	0000	:	O	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
monooxygenase	monooxygenase	M525	NN	I-NP	O
,	,	0000	,	O	O
EC	EC	E200	NNP	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
for	for	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
PAH	PAH	P000	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
assign	assign	A250	VB	I-VP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
regional	regional	R254	JJ	I-NP	O
map	map	M100	NN	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
DNA	DNA	D500	NN	B-NP	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
hamster	hamster	H523	NN	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
with	with	W300	IN	B-PP	O
various	various	V620	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
PAH	PAH	P000	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
hybridization	hybridization	H163	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
detailed	detailed	D343	JJ	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hybrid	hybrid	H163	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
12	12	0000	CD	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
defined	define	D153	VBN	I-VP	O
as	as	A200	IN	B-PP	O
12q14	12q14	Q000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
qter	qter	Q360	SYM	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
qter	qter	Q360	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
map	map	M100	NN	I-NP	O
position	position	P235	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
12	12	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
further	further	F636	RB	I-VP	O
localized	localize	L242	VBN	I-VP	O
by	by	B000	IN	B-PP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
of	of	O100	IN	B-PP	O
125I	125I	I000	NN	B-NP	O
-	-	0000	HYPH	O	O
labeled	label	L143	VBN	B-NP	O
human	human	H500	JJ	I-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
prepared	prepare	P616	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
lymphoblastoid	lymphoblastoid	L514	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
12	12	0000	CD	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
PKU	PKU	P200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
12q22	12q22	Q000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
12q24	12q24	Q000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	LS	B-LST	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
not	not	N300	RB	B-VP	O
only	only	O540	RB	I-VP	O
provide	provide	P613	VB	I-VP	O
a	a	A000	DT	B-NP	O
regionalized	regionalized	R254	JJ	I-NP	O
map	map	M100	NN	I-NP	O
position	position	P235	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
can	can	C500	MD	B-VP	O
serve	serve	S610	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
reference	reference	R165	NN	I-NP	O
point	point	P530	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
12	12	0000	CD	I-NP	O

Heterogeneity	Heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
subgroup	subgroup	S126	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
von	von	V500	NN	I-NP	I-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
vWD	vWD	V300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
equally	equally	E240	RB	B-NP	O
low	low	L000	JJ	I-NP	O
plasma	plasma	P425	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
antigen	antigen	A532	NN	I-NP	O
(	(	0000	(	O	O
vWF	vWF	V100	NN	B-NP	O
Ag	Ag	A200	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
ristocetin	ristocetin	R232	NN	B-NP	O
cofactor	cofactor	C123	NN	I-NP	O
(	(	0000	(	O	O
RiCof	RiCof	R210	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
vWF	vWF	V100	NN	I-NP	O
multimers	multimer	M435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sodium	sodium	S350	NN	B-NP	O
dodecyl	dodecyl	D324	NN	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
(	(	0000	(	O	O
SDS	SDS	S320	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
agarose	agarose	A262	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
17	17	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
13	13	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
)	)	0000	)	O	O
diagnosed	diagnose	D252	VBN	B-VP	O
with	with	W300	IN	B-PP	O
these	these	T200	DT	B-NP	O
criteria	criterion	C636	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
the	the	T000	DT	B-NP	O
platelet	platelet	P434	NN	I-NP	O
contents	content	C535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
Ag	Ag	A200	NN	I-NP	O
and	and	A530	CC	I-NP	O
RiCof	RiCof	R210	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
changes	change	C520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
after	after	A136	IN	B-PP	O
DDAVP	DDAVP	D310	NN	B-NP	O
infusion	infusion	I512	NN	I-NP	O
.	.	0000	.	O	O

Platelet	Platelet	P434	NN	B-NP	O
vWF	vWF	V100	NN	I-NP	O
Ag	Ag	A200	NN	I-NP	O
and	and	A530	CC	I-NP	O
RiCof	RiCof	R210	NN	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
(	(	0000	(	O	O
called	call	C430	VBN	B-VP	O
"	"	0000	``	O	O
platelet	platelet	P434	NN	B-NP	O
normal	normal	N654	JJ	I-NP	O
"	"	0000	``	I-NP	O
subgroup	subgroup	S126	NN	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
following	follow	F452	VBG	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
deamino	deamino	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
8	8	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
D	D	D000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
arginine	arginine	A625	NN	I-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
;	;	0000	:	O	O
plasma	plasma	P425	NN	B-NP	O
vWF	vWF	V100	NN	I-NP	O
Ag	Ag	A200	NN	I-NP	O
,	,	0000	,	O	O
RiCof	RiCof	R210	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
bleeding	bleeding	B435	NN	I-NP	O
time	time	T500	NN	I-NP	O
(	(	0000	(	O	O
BT	BT	B300	NN	B-NP	O
)	)	0000	)	O	O
became	become	B250	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
platelet	platelet	P434	NN	B-NP	O
vWF	vWF	V100	NN	I-NP	O
Ag	Ag	A200	NN	I-NP	O
and	and	A530	CC	I-NP	O
RiCof	RiCof	R210	NN	I-NP	O
were	be	W600	VBD	B-VP	O
equally	equally	E240	RB	B-ADJP	O
low	low	L000	JJ	I-ADJP	O
(	(	0000	(	O	O
platelet	platelet	P434	NN	B-NP	O
low	low	L000	NN	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
after	after	A136	IN	B-PP	O
DDAVP	DDAVP	D310	NN	B-NP	O
,	,	0000	,	O	O
plasma	plasma	P425	NN	B-NP	O
vWF	vWF	V100	NN	I-NP	O
Ag	Ag	A200	NN	I-NP	O
and	and	A530	CC	I-NP	O
RiCof	RiCof	R210	NN	I-NP	O
remained	remain	R530	VBD	B-VP	O
low	low	L000	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
BT	BT	B300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
prolonged	prolong	P645	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
platelets	platelet	P434	NNS	B-NP	O
contained	contain	C535	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
Ag	Ag	A200	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
RiCof	RiCof	R210	NNP	B-NP	O
was	be	W200	VBD	B-VP	O
very	very	V600	RB	B-ADJP	O
low	low	L000	JJ	I-ADJP	O
(	(	0000	(	O	O
platelet	platelet	P434	NN	B-NP	O
discordant	discordant	D263	NN	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
even	even	E150	RB	B-SBAR	O
though	though	T200	IN	I-SBAR	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
multimers	multimer	M435	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
and	and	A530	CC	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
small	small	S540	JJ	I-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
large	large	L620	JJ	B-NP	O
multimers	multimer	M435	NNS	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
DDAVP	DDAVP	D310	NN	B-NP	O
,	,	0000	,	O	O
plasma	plasma	P425	NN	B-NP	O
vWF	vWF	V100	NN	I-NP	O
Ag	Ag	A200	NN	I-NP	O
became	become	B250	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
RiCof	RiCof	R210	NNP	B-NP	O
remained	remain	R530	VBD	B-VP	O
low	low	L000	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
BT	BT	B300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
very	very	V600	RB	B-ADJP	O
prolonged	prolonged	P645	JJ	I-ADJP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
(	(	0000	(	O	O
RiCof	RiCof	R210	NN	B-NP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
Ag	Ag	A200	NN	I-NP	O
)	)	0000	)	O	O
even	even	E150	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
vWD	vWD	V300	NN	I-NP	I-Disease
,	,	0000	,	O	O
coexisting	coexist	C235	VBG	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
multimers	multimer	M435	NNS	I-NP	O
(	(	0000	(	O	O
platelet	platelet	P434	NN	B-NP	O
discordant	discordant	D263	NN	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
shown	show	S500	VBN	I-VP	O
more	more	M600	RBR	B-ADVP	O
clearly	clearly	C464	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
or	or	O600	CC	B-NP	O
else	else	E420	RB	I-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
after	after	A136	IN	B-PP	O
DDAVP	DDAVP	D310	NN	B-NP	O
infusion	infusion	I512	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
DDAVP	DDAVP	D310	NN	B-NP	O
normalizes	normalize	N654	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
BT	BT	B300	NN	I-NP	O
only	only	O540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
those	those	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
platelet	platelet	P434	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
vWF	vWF	V100	NN	B-NP	O
Ag	Ag	A200	NN	I-NP	O
and	and	A530	CC	O	O
RiCof	RiCof	R210	NN	B-NP	O
(	(	0000	(	O	O
platelet	platelet	P434	NN	B-NP	O
normal	normal	N654	JJ	B-ADJP	O
)	)	0000	)	O	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
van	van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
brought	bring	B623	VBN	I-VP	O
together	together	T236	RB	B-NP	O
information	information	I516	NN	I-NP	O
on	on	O500	IN	B-PP	O
864	864	0000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
164	164	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
including	include	I524	VBG	B-PP	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
)	)	0000	)	O	O
reported	report	R163	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
137	137	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
period	period	P630	NN	I-NP	O
since	since	S520	IN	B-PP	O
1845	1845	0000	CD	B-NP	O
when	when	W500	WRB	B-ADVP	O
Demarquay	Demarquay	D562	NNP	B-NP	O
first	first	F623	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
what	what	W300	WP	B-NP	O
was	be	W200	VBD	B-VP	O
later	later	L360	RB	I-VP	O
called	call	C430	VBN	I-VP	O
van	van	V500	NNP	B-NP	B-Disease
der	der	D600	NNP	I-NP	I-Disease
Woude	Woude	W300	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
VWS	VWS	V200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
oral	oral	O640	JJ	B-NP	B-Disease
cleft	cleft	C413	NN	I-NP	I-Disease
,	,	0000	,	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
(	(	0000	(	O	O
CP	CP	C100	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
lip	lip	L100	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
or	or	O600	CC	B-PP	O
without	without	W300	IN	B-PP	O
CP	CP	C100	NN	B-NP	B-Disease
(	(	0000	(	O	O
CLP	CLP	C410	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
segregate	segregate	S262	VBP	B-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
lower	low	L600	JJR	B-NP	O
lip	lip	L100	NN	I-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
or	or	O600	CC	I-NP	O
fistulae	fistula	F234	NNS	I-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
mode	mode	M300	NN	I-NP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
estimated	estimate	E235	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
K	K	K000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O

89	89	0000	CD	B-NP	O
and	and	A530	CC	O	O
.	.	0000	.	O	O

99	99	0000	CD	B-NP	O
by	by	B000	IN	B-PP	O
different	different	D165	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
.	.	0000	.	O	O

Cleft	Cleft	C413	NN	B-NP	O
types	type	T120	NNS	I-NP	O
(	(	0000	(	O	O
CLP	CLP	C410	NN	B-NP	B-Disease
and	and	A530	CC	O	O
CP	CP	C100	NN	B-NP	B-Disease
)	)	0000	)	O	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
proportions	proportion	P616	NNS	I-NP	O
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
VWS	VWS	V200	NN	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
ie	ie	I000	FW	B-NP	O
,	,	0000	,	O	O
about	about	A130	RB	B-NP	O
twice	twice	T200	RB	I-NP	O
as	as	A200	IN	I-NP	O
many	many	M500	JJ	I-NP	O
cleft	cleft	C413	NN	I-NP	O
-	-	0000	HYPH	O	O
bearing	bear	B652	VBG	B-VP	O
individuals	individual	I531	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
CLP	CLP	C410	NN	B-NP	B-Disease
as	as	A200	IN	B-SBAR	O
have	have	H100	VBP	B-VP	O
CP	CP	C100	NN	B-NP	B-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
hand	hand	H530	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
find	find	F530	VB	I-VP	O
the	the	T000	DT	B-NP	O
usually	usually	U240	RB	I-NP	O
observed	observe	O126	VBN	I-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
females	female	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
CP	CP	C100	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
males	male	M420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
CLP	CLP	C410	NN	B-NP	B-Disease
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
the	the	T000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
ratios	ratio	R320	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
more	more	M600	RBR	B-ADJP	O
nearly	nearly	N640	RB	I-ADJP	O
equal	equal	E240	JJ	I-ADJP	O
.	.	0000	.	O	O

Lip	Lip	L100	NN	B-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
also	also	A420	RB	B-ADVP	O
are	be	A600	VBP	B-VP	O
equally	equally	E240	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
sexes	sex	S200	NNS	I-NP	O
.	.	0000	.	O	O

Affected	Affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	I-NP	O
females	female	F542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
equally	equally	E240	RB	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
transmit	transmit	T652	VB	I-VP	O
VWS	VWS	V200	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
less	less	L200	RBR	B-VP	O
severely	severely	S164	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
individuals	individual	I531	NNS	B-NP	O
among	among	A520	IN	B-PP	O
transmitters	transmitter	T652	NNS	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
of	of	O100	IN	B-PP	O
more	more	M600	RBR	B-VP	O
severely	severely	S164	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
,	,	0000	,	O	O
brought	bring	B623	VBN	B-VP	O
about	about	A130	RP	B-PRT	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
bias	bias	B200	NN	I-NP	O
and	and	A530	CC	O	O
differential	differential	D165	JJ	B-NP	O
fecundity	fecundity	F253	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
significantly	significantly	S251	RB	I-VP	O
modified	modify	M313	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
background	background	B265	NN	I-NP	O
More	More	M600	JJR	B-NP	O
extreme	extreme	E236	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
parents	parent	P653	NNS	B-NP	O
tend	tend	T530	VBP	B-VP	O
to	to	T000	TO	I-VP	O
produce	produce	P632	VB	I-VP	O
more	more	M600	RBR	B-NP	O
extreme	extreme	E236	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
children	child	C436	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
transmitting	transmit	T652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
cleft	cleft	C413	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
26	26	0000	CD	B-NP	O
.	.	0000	.	O	O

45	45	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
transmitting	transmit	T652	VBG	B-VP	O
lower	low	L600	JJR	B-NP	O
lip	lip	L100	NN	I-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
23	23	0000	CD	B-NP	O
.	.	0000	.	O	O

55	55	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
of	of	O100	IN	B-PP	O
lip	lip	L100	NN	B-NP	B-Disease
pits	pit	P320	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
show	show	S000	VBP	B-VP	O
no	no	N000	DT	B-NP	O
clefts	cleft	C413	NNS	I-NP	O
among	among	A520	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Control	Control	C536	NN	B-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
VWS	VWS	V200	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
target	target	T623	NN	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
independent	independent	I531	JJ	B-ADJP	O
and	and	A530	CC	O	O
separately	separately	S163	RB	B-ADJP	O
designated	designate	D253	VBN	I-ADJP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VWS	VWS	V200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
X	X	X000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Diagnosis	Diagnosis	D252	NN	B-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
44	44	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
yr	yr	Y600	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
old	old	O430	JJ	I-NP	O
woman	woman	W500	NN	I-NP	O
of	of	O100	IN	B-PP	O
French	French	F652	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
descent	descent	D253	NN	I-NP	O
having	have	H152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
B	B	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
27	27	0000	CD	I-NP	O
positive	positive	P231	JJ	I-NP	O
ankylosing	ankylose	A524	VBG	I-NP	B-Disease
spondylitis	spondylitis	S153	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C7	C7	C000	NN	B-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-SBAR	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
and	and	A530	CC	I-NP	O
immunochemical	immunochemical	I525	JJ	I-NP	O
methods	method	M320	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
against	against	A252	IN	B-PP	O
C7	C7	C000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
other	other	O360	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
components	component	C515	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
opsonic	opsonic	O125	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
basic	basic	B200	JJ	B-NP	O
coagulation	coagulation	C243	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
investigation	investigation	I512	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
sisters	sister	S236	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
but	but	B300	CC	O	O
were	be	W600	VBD	B-VP	O
otherwise	otherwise	O362	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
good	good	G300	JJ	B-NP	O
health	health	H430	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
other	other	O360	JJ	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
aunt	aunt	A530	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
C7	C7	C000	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
generation	generation	G563	NN	I-NP	O
,	,	0000	,	O	O
six	six	S200	CD	B-NP	O
children	child	C436	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
sisters	sister	S236	NNS	I-NP	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
children	child	C436	NNS	I-NP	O
of	of	O100	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
available	available	A141	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
testing	testing	T235	NN	B-NP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
antigens	antigen	A532	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
22	22	0000	CD	I-NP	O
subjects	subject	S123	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
spouses	spouse	S120	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
no	no	N000	DT	B-NP	O
close	close	C420	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
CM	CM	C500	NN	I-NP	B-Disease
deficienty	deficienty	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
simultaneous	simultaneous	S543	JJ	I-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
complement	complement	C514	NN	I-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
(	(	0000	(	O	I-Disease
C2	C2	C000	NN	B-NP	I-Disease
and	and	A530	CC	O	I-Disease
C7	C7	C000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
was	be	W200	VBD	B-VP	O
discovered	discover	D216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
remarkable	remarkable	R562	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
defect	defect	D123	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
secretion	secretion	S263	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
C5	C5	C000	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
(	(	0000	(	O	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
component	component	C515	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement1	complement1	C514	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
3	3	0000	CD	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
weight	weight	W230	NN	I-NP	O
(	(	0000	(	O	O
MW	MW	M000	NN	B-NP	O
)	)	0000	)	O	O
220	220	0000	CD	B-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
39	39	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
inbred	inbred	I516	JJ	B-NP	O
strains	strain	S365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mice3	mice3	M200	NN	B-NP	O
.	.	0000	.	O	O

Sera	Sera	S600	NN	B-NP	O
of	of	O100	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
lack	lack	L200	VBP	B-VP	O
detectable	detectable	D323	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein2	protein2	P635	NN	I-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
produce	produce	P632	VBP	B-VP	O
antibody	antibody	A531	NN	B-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
C5	C5	C000	NN	I-NP	O
when	when	W500	WRB	B-ADVP	O
injected	inject	I523	VBN	B-VP	O
with	with	W300	IN	B-PP	O
sera	sera	S600	NN	B-NP	O
from	from	F650	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
sufficient	sufficient	S125	JJ	B-ADVP	O
(	(	0000	(	O	O
normal	normal	N654	JJ	B-ADJP	O
)	)	0000	)	O	O
strains	strain	S365	NNS	B-NP	O
.	.	0000	.	O	O

Levy	Levy	L100	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
between	between	B350	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
deficient	deficient	D125	JJ	B-ADJP	O
(	(	0000	(	O	O
B10	B10	B000	NN	B-NP	O
.	.	0000	SYM	I-NP	O
D2	D2	D000	NN	I-NP	O
/	/	0000	SYM	B-VP	O
old	old	O430	JJ	B-NP	O
line	line	L500	NN	I-NP	O
)	)	0000	)	O	O
macrophages	macrophage	M261	NNS	B-NP	O
and	and	A530	CC	O	O
either	either	E360	CC	O	O
C5	C5	C000	NN	B-NP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
(	(	0000	(	O	O
B10	B10	B000	NN	B-NP	O
.	.	0000	SYM	I-NP	O
D2	D2	D000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
new	new	N000	JJ	I-NP	O
line	line	L500	NN	I-NP	O
)	)	0000	)	O	O
mouse	mouse	M200	NN	B-NP	O
kidney	kidney	K350	NN	I-NP	O
or	or	O600	CC	I-NP	O
chicken	chicken	C250	NN	I-NP	O
erythroblasts	erythroblast	E636	NNS	I-NP	O
secreted	secrete	S263	VBN	B-VP	O
haemolytically	haemolytically	H543	RB	B-NP	O
active	active	A231	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
C5	C5	C000	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
possible	possible	P214	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
to	to	T000	TO	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
insufficient	insufficient	I521	JJ	B-NP	O
direct	direct	D623	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
available	available	A141	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
choose	choose	C200	VB	I-VP	O
among	among	A520	IN	B-PP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
mouse	mouse	M200	NN	B-NP	O
(	(	0000	(	O	O
CD	CD	C300	NNP	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
strain	strain	S365	NN	I-NP	O
)	)	0000	)	O	O
peritoneal	peritoneal	P635	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
synthesise	synthesise	S532	NN	I-NP	O
and	and	A530	CC	O	O
secrete	secrete	S263	VB	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
precursor	precursor	P626	NN	I-NP	O
,	,	0000	,	O	O
pro	pro	P600	AFX	O	O
-	-	0000	HYPH	O	O
C5	C5	C000	NN	B-NP	O
(	(	0000	(	O	O
MW	MW	M000	NN	B-NP	O
approximately	approximately	A162	RB	B-NP	O
210	210	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
(	(	0000	(	O	O
alpha	alpha	A410	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
,	,	0000	,	O	O
125	125	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
and	and	A530	CC	O	O
beta	beta	B300	SYM	B-NP	O
chain	chain	C500	NN	B-NP	O
83	83	0000	CD	I-NP	O
,	,	0000	,	O	O
000	000	0000	CD	B-NP	O
MW	MW	M000	NN	I-NP	O
)	)	0000	)	O	O
C5	C5	C000	NN	B-NP	O
protein6	protein6	P635	NN	I-NP	O
.	.	0000	.	O	O

Radiolabelled	Radiolabelle	R341	VBN	B-NP	O
precursor	precursor	P626	NN	I-NP	O
C5	C5	C000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
contained	contain	C535	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
secreted	secrete	S263	VBN	I-VP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
tissue	tissue	T200	NN	I-NP	O
culture	culture	C436	NN	I-NP	O
media	medium	M300	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
similar	similar	S546	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
find	find	F530	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mouse	mouse	M200	NN	I-NP	O
strains	strain	S365	NNS	I-NP	O
(	(	0000	(	O	O
AKR	AKR	A260	NN	B-NP	O
,	,	0000	,	O	O
SWR	SWR	S600	NN	B-NP	O
,	,	0000	,	O	O
DBA	DBA	D100	NN	B-NP	O
/	/	0000	SYM	I-NP	O
2J8	2J8	J000	NN	I-NP	O
A	A	A000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
HeJ	HeJ	H200	NN	I-NP	O
and	and	A530	CC	I-NP	O
B10	B10	B000	NN	I-NP	O
.	.	0000	.	I-NP	O
D2	D2	D000	NN	I-NP	O
/	/	0000	SYM	B-VP	O
old	old	O430	JJ	B-NP	O
line	line	L500	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
in	in	I500	IN	B-PP	O
secretion	secretion	S263	NN	B-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
not	not	N300	RB	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
in	in	I500	IN	B-PP	O
biosynthesis	biosynthesis	B253	NN	B-NP	O
of	of	O100	IN	B-PP	O
pro	pro	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
C5	C5	C000	NN	I-NP	O

Recurrent	Recurrent	R265	JJ	B-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
absence	absence	A125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
sixth	sixth	S230	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
underlying	underlie	U536	VBG	B-VP	O
immunologic	immunologic	I542	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
51	51	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
old	old	O430	JJ	I-NP	O
black	black	B420	JJ	I-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
absence	absence	A125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
sixth	sixth	S230	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C6	C6	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
explore	explore	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
neisserial	neisserial	N264	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
C6	C6	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
immune	immune	I500	JJ	I-NP	O
competence	competence	C513	NN	I-NP	O
was	be	W200	VBD	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
.	.	0000	.	O	O

Her	Her	H600	PRP$	B-NP	O
serum	serum	S650	NN	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
,	,	0000	,	I-NP	O
opsonic	opsonic	O125	JJ	I-NP	O
,	,	0000	,	I-NP	O
alternative	alternative	A436	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
specific	specific	S121	JJ	B-NP	O
antibody	antibody	A531	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
lacked	lack	L230	VBD	B-VP	O
complement	complement	C514	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
bacteriolytic	bacteriolytic	B236	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
her	her	H600	PRP$	B-NP	O
C6	C6	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
serum	serum	S650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
indistinguishable	indistinguishable	I532	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
serum	serum	S650	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
complement	complement	C514	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
assay	assay	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
phagocyte	phagocyte	P230	NN	B-NP	O
bactericidal	bactericidal	B236	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Absent	Absent	A125	JJ	B-NP	O
bacteriolysis	bacteriolysis	B236	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	RB	I-NP	O
consistent	consistent	C523	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
neisserial	neisserial	N264	JJ	I-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acting	act	A235	VBG	I-NP	O
complement	complement	C514	NN	I-NP	O
components	component	C515	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
,	,	0000	,	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
immunologic	immunologic	I542	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
discovery	discovery	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
heritable	heritable	H631	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C5	C5	C000	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
permitted	permit	P653	VBN	I-VP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
,	,	0000	,	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
immunologic	immunologic	I542	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
concerning	concern	C526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
has	have	H200	VBZ	B-VP	O
had	have	H300	VBD	I-VP	O
nine	nine	N500	CD	B-NP	O
episodes	episode	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
disseminated	disseminate	D253	VBN	B-NP	O
gonococcal	gonococcal	G524	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
C5	C5	C000	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
C5	C5	C000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detectable	detectable	D323	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
low	low	L000	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
bactericidal	bactericidal	B236	JJ	I-NP	O
assay	assay	A200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
twin	twin	T500	VBP	B-VP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
another	another	A536	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
extremely	extremely	E236	RB	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
(	(	0000	(	O	O
approximately	approximately	A162	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
5	5	0000	CD	I-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
normal	normal	N654	JJ	B-ADJP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
both	both	B300	PDT	O	O
these	these	T200	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
healthy	healthy	H430	JJ	B-ADJP	O
.	.	0000	.	O	O

Hemolytic	Hemolytic	H543	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
and	and	A530	CC	O	O
bacteriolytic	bacteriolytic	B236	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
restored	restore	R236	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
addition	addition	A350	NN	I-NP	O
of	of	O100	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C5	C5	C000	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
for	for	F600	IN	B-PP	O
polymorphonuclear	polymorphonuclear	P456	JJ	B-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
generated	generate	G563	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C5	C5	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
serums	serum	S652	NNS	I-NP	O
upon	upon	U150	IN	B-PP	O
activation	activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
classic	classic	C420	JJ	I-NP	O
or	or	O600	CC	I-NP	O
alternative	alternative	A436	JJ	I-NP	O
pathways	pathway	P320	NNS	I-NP	O
,	,	0000	,	O	O
again	again	A250	RB	B-ADVP	O
demonstrating	demonstrate	D523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
importance	importance	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
production	production	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
chemotactic	chemotactic	C532	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
responsiveness	responsiveness	R215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
polymorphonuclear	polymorphonuclear	P456	JJ	B-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
and	and	A530	CC	I-NP	O
monocytes	monocyte	M523	NNS	I-NP	O
to	to	T000	TO	B-PP	O
preformed	preformed	P616	JJ	B-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
depressed	depress	D162	VBN	I-VP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
two	two	T000	CD	I-NP	O
of	of	O100	IN	B-PP	O
32	32	0000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
from	from	F650	IN	B-PP	O
three	three	T600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
depressed	depress	D162	VBN	I-VP	O
whole	whole	W400	JJ	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
19	19	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
levels	level	L142	NNS	B-NP	O
of	of	O100	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
ranged	range	R523	VBD	B-VP	O
from	from	F650	IN	B-PP	O
13	13	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
64	64	0000	CD	B-NP	O
per	per	P600	IN	B-PP	O
cent	cent	C530	NN	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
for	for	F600	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
or	or	O600	CC	I-NP	O
B	B	B000	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
codominant	codominant	C353	JJ	I-NP	O
mode	mode	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheritance	inheritance	I563	NN	B-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C5	C5	C000	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
good	good	G300	JJ	B-NP	O
health	health	H430	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
repeated	repeat	R130	VBN	B-NP	O
disseminated	disseminate	D253	VBN	I-NP	O
gonococcal	gonococcal	G524	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease

Incidence	Incidence	I523	NN	B-NP	O
and	and	A530	CC	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
3000	3000	0000	CD	B-NP	O
men	man	M500	NNS	I-NP	O
living	live	L152	VBG	B-VP	O
in	in	I500	IN	B-PP	O
Yamaguchi	Yamaguchi	Y520	NNP	B-NP	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
using	use	U252	VBG	B-VP	O
Beutlers	Beutler	B346	NNS	B-NP	O
spot	spot	S130	NN	I-NP	O
test	test	T230	NN	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
starch	starch	S362	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
used	use	U230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
phosphate	phosphate	P213	NN	I-NP	O
buffer	buffer	B160	NN	I-NP	O
system	system	S235	NN	I-NP	O
at	at	A300	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
TRIS	TRIS	T620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
EDTA	EDTA	E300	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
borate	borate	B630	JJ	I-NP	O
buffer	buffer	B160	NN	I-NP	O
system	system	S235	NN	I-NP	O
at	at	A300	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
TRIS	TRIS	T620	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
hydrochloride	hydrochloride	H362	NN	I-NP	O
buffer	buffer	B160	NN	I-NP	O
system	system	S235	NN	I-NP	O
at	at	A300	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Fifteen	Fifteen	F135	CD	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
classified	classify	C421	VBN	B-VP	O
into	into	I530	IN	B-PP	O
four	four	F600	CD	B-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
new	new	N000	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Konan	Konan	K500	NNP	I-NP	O
,	,	0000	,	O	O
Kamiube	Kamiube	K510	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Kiwa	Kiwa	K000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
variants	variant	V653	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
to	to	T000	TO	I-NP	O
moderate	moderate	M363	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
Konan	Konan	K500	NNP	I-NP	O
had	have	H300	VBD	B-VP	O
fast	fast	F230	JJ	B-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
as	as	A200	IN	B-PP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Kiwa	Kiwa	K000	NNP	B-NP	O
had	have	H300	VBD	B-VP	O
slightly	slightly	S423	RB	B-NP	O
elevated	elevated	E413	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Kamiube	Kamiube	K510	NNP	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
variants	variant	V653	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Km	Km	K500	NN	B-NP	O
G6P	G6P	G100	NN	I-NP	O
,	,	0000	,	O	O
Km	Km	K500	NN	B-NP	O
NADP	NADP	N310	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Ki	Ki	K000	NN	B-NP	O
NADPH	NADPH	N310	NN	I-NP	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
utilizations	utilization	U342	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	B-NP	O
2	2	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
deoxy	deoxy	D200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
G6P	G6P	G100	NN	I-NP	O
and	and	A530	CC	I-NP	O
deamino	deamino	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
NAPD	NAPD	N130	NN	I-NP	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
heat	heat	H300	NN	I-NP	O
stability	stability	S314	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
curve	curve	C610	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Ube	Ube	U100	NNP	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Yamaguchi	Yamaguchi	Y520	NNP	B-NP	O
(	(	0000	(	O	O
Nakashima	Nakashima	N250	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1977	1977	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Ube	Ube	U100	NNP	I-NP	O
was	be	W200	VBD	B-VP	O
Korean	Korean	K650	JJ	B-ADJP	O

Utilization	Utilization	U342	NN	B-NP	O
of	of	O100	IN	B-PP	O
purines	purine	P652	NNS	B-NP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
intelligent	intelligent	I534	JJ	I-NP	O
,	,	0000	,	I-NP	O
nonmutilative	nonmutilative	N534	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
features	feature	F362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
H	H	H000	NN	B-NP	O
.	.	0000	.	O	O

Chr	Chr	C600	NN	B-NP	O
.	.	0000	.	O	O

B	B	B000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
reported	report	R163	VBN	B-VP	O
with	with	W300	IN	B-PP	O
hyperuricemia	hyperuricemia	H162	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
central	central	C536	JJ	I-NP	B-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
symptoms	symptom	S513	NNS	I-NP	I-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	O
guanine	guanine	G500	NN	I-NP	O
phosphoribosyl	phosphoribosyl	P216	NN	I-NP	O
transferase	transferase	T652	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
;	;	0000	:	O	O
E	E	E000	NN	B-NP	O
.	.	0000	.	O	O
C	C	C000	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
had	have	H300	VBD	B-VP	O
chroeoathetosis	chroeoathetosis	C632	NN	B-NP	B-Disease
,	,	0000	,	O	O
spasticity	spasticity	S123	NN	B-NP	B-Disease
,	,	0000	,	O	O
dysarthric	dysarthric	D263	JJ	B-NP	B-Disease
speech	speech	S120	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hyperuricemia	hyperuricemia	H162	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
intelligence	intelligence	I534	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
and	and	A530	CC	O	O
he	he	H000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
self	self	S410	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mutilation	mutilation	M343	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lysates	lysate	L232	NNS	I-NP	O
of	of	O100	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	O	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
analyzed	analyze	A542	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
usual	usual	U240	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
developed	develop	D141	VBN	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
purine	purine	P650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
in	in	I500	IN	B-PP	O
intact	intact	I532	JJ	B-NP	O
cultured	culture	C436	VBN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
metabolize	metabolize	M314	VB	I-VP	O
some	some	S500	DT	B-NP	O
9	9	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
14C	14C	C000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
hypoxanthine	hypoxanthine	H125	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
isotope	isotope	I231	NN	I-NP	O
utilized	utilize	U342	VBN	B-VP	O
was	be	W200	VBD	B-VP	O
converted	convert	C516	VBN	I-VP	O
to	to	T000	TO	B-PP	O
adenine	adenine	A350	NN	B-NP	O
and	and	A530	CC	I-NP	O
guanine	guanine	G500	NN	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
cells	cell	C420	NNS	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
virtually	virtually	V634	RB	B-ADJP	O
completely	completely	C514	RB	I-ADJP	O
unable	unable	U514	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
convert	convert	C516	VB	I-VP	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	O
to	to	T000	TO	B-PP	O
nucleotides	nucleotide	N243	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
even	even	E150	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
efficient	efficient	E125	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
14C	14C	C000	NN	I-NP	O
-	-	0000	HYPH	O	O
guanine	guanine	G500	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
utilized	utilize	U342	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
over	over	O160	IN	B-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
converted	convert	C516	VBN	I-VP	O
to	to	T000	TO	B-PP	O
guanine	guanine	G500	NN	B-NP	O
and	and	A530	CC	I-NP	O
adenine	adenine	A350	NN	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cultured	culture	C436	VBN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
intermediate	intermediate	I536	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
media	medium	M300	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
hypoxanthine	hypoxanthine	H125	NN	B-NP	O
aminopterin	aminopterin	A513	NN	I-NP	O
thymidine	thymidine	T535	NN	I-NP	O
(	(	0000	(	O	O
HAT	HAT	H300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
Lesch	Lesch	L200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
inhibited	inhibit	I513	VBN	I-VP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
grew	grow	G600	VBD	B-VP	O
normally	normally	N654	RB	B-ADVP	O
.	.	0000	.	O	O

Similarly	Similarly	S546	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azaguanine	azaguanine	A250	NN	I-NP	O
,	,	0000	,	O	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
thioguanine	thioguanine	T250	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
azahypoxanthine	azahypoxanthine	A212	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
cells	cell	C420	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
intermediate	intermediate	I536	JJ	B-ADJP	O
between	between	B350	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Lesch	Lesch	L200	JJ	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
disorders	disorder	D263	NNS	B-NP	O
in	in	I500	IN	B-PP	O
purine	purine	P650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
the	the	T000	DT	B-NP	O
HPRT	HPRT	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
document	document	D253	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
famous	famous	F520	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
Lesch	Lesch	L200	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease

Localisation	Localisation	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Becker	Becker	B260	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
cloned	clone	C453	VBN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
Becker	Becker	B260	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
BMD	BMD	B530	NN	B-NP	B-Disease
)	)	0000	)	O	O
kindreds	kindred	K536	NNS	B-NP	O
using	use	U252	VBG	B-VP	O
three	three	T600	CD	B-NP	O
cloned	clone	C453	VBN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
which	which	W200	WDT	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
restriction	restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
RFLPs	RFLP	R141	NNS	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
BMD	BMD	B530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
p21	p21	P000	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Becker	Becker	B260	NNP	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
Duchenne	Duchenne	D250	NNP	I-NP	I-Disease
dystrophies	dystrophy	D236	NNS	I-NP	I-Disease
must	must	M230	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
be	be	B000	VB	I-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
,	,	0000	,	O	O
if	if	I100	IN	B-CONJP	O
not	not	N300	RB	I-CONJP	O
allelic	allelic	A420	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
any	any	A500	DT	B-NP	O
future	future	F360	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
probes	probe	P612	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
practical	practical	P623	JJ	B-NP	O
use	use	U200	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
disorder	disorder	D263	NN	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
equally	equally	E240	RB	B-ADJP	O
applicable	applicable	A142	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
provides	provide	P613	VBZ	B-VP	O
data	data	D300	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
across	across	A262	IN	B-PP	O
the	the	T000	DT	B-NP	O
centromeric	centromeric	C536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hprt	hprt	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Hypoxanthine	Hypoxanthine	H125	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
guanine	guanine	G500	NN	I-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
(	(	0000	(	O	O
HPRT	HPRT	H163	NN	B-NP	O
;	;	0000	:	O	O
EC2	EC2	E200	NN	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
functions	function	F523	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
salvage	salvage	S412	NN	I-NP	O
of	of	O100	IN	B-PP	O
purines	purine	P652	NNS	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
encoded	encode	E523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

Partial	Partial	P634	JJ	B-NP	O
HPRT	HPRT	H163	NN	I-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
gouty	gouty	G300	NN	B-NP	B-Disease
arthritis	arthritis	A636	NN	I-NP	I-Disease
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
activity	activity	A231	NN	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
L	L	L000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
N	N	N000	NN	B-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

L	L	L000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
N	N	N000	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
fail	fail	F400	VBP	B-VP	O
to	to	T000	TO	I-VP	O
reproduce	reproduce	R163	VB	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
state	state	S300	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
confer	confer	C516	VB	I-VP	O
no	no	N000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
Haldanes	Haldanes	H435	NNP	B-NP	O
principle	principle	P652	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hprt	hprt	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
must	must	M230	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
frequently	frequently	F625	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
order	order	O636	NN	B-NP	O
for	for	F600	IN	B-PP	O
L	L	L000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
N	N	N000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
maintained	maintain	M535	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
constant	constant	C523	JJ	I-NP	O
introduction	introduction	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
expected	expect	E212	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
collection	collection	C423	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
novel	novel	N140	JJ	B-ADJP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hprt	hprt	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
L	L	L000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
N	N	N000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
selected	select	S423	VBN	B-VP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
survey	survey	S610	NN	I-NP	O
of	of	O100	IN	B-PP	O
28	28	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
distinctly	distinctly	D235	RB	B-ADJP	O
different	different	D165	JJ	I-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
predicted	predict	P632	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
four	four	F600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
of	of	O100	IN	B-PP	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hprt	hprt	H163	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
should	should	S430	MD	B-VP	O
aid	aid	A300	VB	I-VP	O
in	in	I500	IN	B-PP	O
resolving	resolve	R241	VBG	B-VP	O
the	the	T000	DT	B-NP	O
issue	issue	I200	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
hprt	hprt	H163	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
and	and	A530	CC	I-NP	O
females	female	F542	NNS	I-NP	O

Allelic	Allelic	A420	JJ	B-NP	O
exclusion	exclusion	E242	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
in	in	I500	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
and	and	A530	CC	O	O
T	T	T000	NN	B-NP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
obligate	obligate	O142	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
who	who	W000	WP	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
B	B	B000	NN	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
her	her	H600	PRP	B-NP	O
it	it	I300	PRP	B-NP	O
became	become	B250	VBD	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
allelic	allelic	A420	JJ	B-NP	O
exclusion	exclusion	E242	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	O	O
types	type	T120	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O

If	If	I100	IN	B-SBAR	O
so	so	S000	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	B-NP	O
would	would	W430	MD	B-VP	O
express	express	E216	VB	I-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
normal	normal	N654	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
and	and	A530	CC	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
isoenzyme	isoenzyme	I252	NN	I-NP	O
would	would	W430	MD	B-VP	O
be	be	B000	VB	I-VP	O
demonstrable	demonstrable	D523	JJ	B-ADJP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
had	have	H300	VBD	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
B	B	B000	NN	I-NP	O
isoenzyme	isoenzyme	I252	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
in	in	I500	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
and	and	A530	CC	I-NP	O
thymus	thymus	T520	NN	I-NP	O
-	-	0000	HYPH	O	O
derived	derive	D613	VBN	B-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
isoenzymes	isoenzyme	I252	NNS	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
B	B	B000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	I-NP	O
neutrophils	neutrophil	N361	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
selection	selection	S423	NN	B-NP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
and	and	A530	CC	I-NP	O
thymus	thymus	T520	NN	I-NP	O
-	-	0000	HYPH	O	O
derived	derive	D613	VBN	B-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
defects	defect	D123	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	O	O
types	type	T120	NNS	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genesis	genesis	G520	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
nephritis	nephritis	N163	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
report	report	R163	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
three	three	T600	CD	B-NP	O
children	child	C436	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C3	C3	C000	NN	B-NP	I-Disease
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
both	both	B300	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
children	child	C436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C3	C3	C000	NN	I-NP	O
null	null	N400	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C3	C3	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
membranoproliferative	membranoproliferative	M516	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	G456	NN	I-NP	B-Disease
;	;	0000	:	O	O
proteinuria	proteinuria	P635	NN	B-NP	B-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
microscopical	microscopical	M262	JJ	B-NP	O
haematuria	haematuria	H536	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
C3	C3	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
children	child	C436	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
children	child	C436	NNS	I-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
or	or	O600	CC	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
C3	C3	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
varying	vary	V652	VBG	I-NP	O
degree	degree	D260	NN	I-NP	O
,	,	0000	,	O	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
infection	infection	I512	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
child	child	C430	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
infection	infection	I512	NN	B-NP	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
study	study	S300	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
further	further	F636	JJ	B-NP	O
support	support	S163	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
proposal	proposal	P612	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
C3	C3	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
predisposes	predispose	P632	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
nephritis	nephritis	N163	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterogeneity	Heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Algeria	Algeria	A426	NNP	B-NP	O
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
in	in	I500	IN	B-PP	O
Northern	Northern	N636	JJ	B-NP	O
Algeria	Algeria	A426	NNP	I-NP	O
with	with	W300	IN	B-PP	O
description	description	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
population	population	P143	NN	I-NP	O
living	live	L152	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
urban	urban	U615	JJ	I-NP	O
area	area	A600	NN	I-NP	O
of	of	O100	IN	B-PP	O
Algiers	Algier	A426	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
originated	originate	O625	VBN	B-VP	O
from	from	F650	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
geographic	geographic	G261	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Northern	Northern	N636	NNP	B-NP	O
Algeria	Algeria	A426	NNP	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
prevalence	prevalence	P614	NN	B-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Berber	Berber	B616	NNP	B-NP	O
-	-	0000	HYPH	I-NP	O
Kabyle	Kabyle	K140	NNP	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

Red	Red	R300	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
partially	partially	P634	RB	I-VP	O
purified	purify	P613	VBN	I-VP	O
and	and	A530	CC	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
males	male	M420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
17	17	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
six	six	S200	CD	B-NP	O
different	different	D165	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
them	them	T500	PRP	B-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Gd	Gd	G300	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Kabyle	Kabyle	K140	NNP	B-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
five	five	F100	CD	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
new	new	N000	JJ	B-NP	O
Gd	Gd	G300	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Laghouat	Laghouat	L230	NN	B-NP	O
(	(	0000	(	O	O
four	four	F600	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Blida	Blida	B430	NNP	B-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Thenia	Thenia	T500	NN	B-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Titteri	Titteri	T360	NNP	B-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
case	case	C200	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Gd	Gd	G300	NN	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
)	)	0000	)	O	O
Alger	Alger	A426	NNP	B-NP	O
(	(	0000	(	O	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Strikingly	Strikingly	S362	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
Algeria	Algeria	A426	NNP	I-NP	O
where	where	W600	WRB	B-ADVP	O
autochtonous	autochtonous	A323	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
seem	seem	S500	VBP	B-VP	O
to	to	T000	TO	I-VP	O
prevail	prevail	P614	VB	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Kabyle	Kabyle	K140	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
country	country	C536	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
inhibits	inhibit	I513	VBZ	B-VP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
Plasmodium	Plasmodium	P425	NNP	B-NP	O
falciparum	falciparum	F421	NNP	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
;	;	0000	:	O	I-Disease
EC	EC	E200	NNP	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	I-Disease
1	1	0000	CD	B-NP	I-Disease
.	.	0000	.	I-NP	I-Disease
49	49	0000	CD	I-NP	I-Disease
)	)	0000	)	O	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
red	red	R300	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
male	male	M400	JJ	B-NP	O
hemizygotes	hemizygote	H523	NNS	I-NP	O
and	and	A530	CC	O	O
female	female	F540	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
island	island	I245	NN	I-NP	O
of	of	O100	IN	B-PP	O
Sardinia	Sardinia	S635	NNP	B-NP	O
were	be	W600	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
support	support	S163	VB	I-VP	O
growth	growth	G630	NN	B-NP	O
in	in	I500	FW	B-PP	O
vitro	vitro	V360	FW	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
malaria	malaria	M460	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	O
causing	cause	C252	VBG	B-NP	O
organism	organism	O625	NN	I-NP	O
Plasmodium	Plasmodium	P425	NNP	I-NP	O
falciparum	falciparum	F421	NNP	I-NP	O
.	.	0000	.	O	O

Parasite	Parasite	P623	NN	B-NP	O
growth	growth	G630	NN	I-NP	O
was	be	W200	VBD	B-VP	O
approximately	approximately	A162	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
third	third	T630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
hemi	hemi	H500	AFX	O	O
-	-	0000	HYPH	O	O
and	and	A530	CC	O	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Sardinians	Sardinian	S635	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
0	0	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
thalassemia	thalassemia	T425	NN	I-NP	O
trait	trait	T630	NN	I-NP	O
,	,	0000	,	O	O
parasite	parasite	P623	NN	B-NP	O
growth	growth	G630	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
except	except	E213	IN	B-PP	O
when	when	W500	WRB	B-ADVP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
occurred	occur	O263	VBD	B-VP	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
thalassemia	thalassemia	T425	NN	I-NP	B-Disease
trait	trait	T630	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
confer	confer	C516	VB	I-VP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
malarious	malarious	M462	JJ	I-NP	B-Disease
area	area	A600	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
because	because	B200	IN	B-SBAR	O
resistance	resistance	R235	NN	B-NP	O
to	to	T000	TO	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
equals	equal	E242	NNS	I-NP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	O
hemizygotes	hemizygote	H523	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
fatal	fatal	F340	JJ	B-NP	B-Disease
hemolysis	hemolysis	H542	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
less	less	L200	JJR	B-ADJP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
more	more	M600	RBR	B-NP	O
female	female	F540	JJ	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
must	must	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
studied	study	S300	VBN	I-VP	O
to	to	T000	TO	B-VP	O
confirm	confirm	C516	VB	I-VP	O
this	this	T200	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
protective	protective	P632	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
0	0	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
thalassemia	thalassemia	T425	NN	I-NP	O
trait	trait	T630	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

Bone	Bone	B500	NN	B-NP	O
marrow	marrow	M600	NN	I-NP	O
transplant	transplant	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
allogeneic	allogeneic	A425	JJ	I-NP	O
bone	bone	B500	NN	I-NP	O
marrow	marrow	M600	NN	I-NP	O
transplant	transplant	T652	NN	I-NP	O
(	(	0000	(	O	O
BMT	BMT	B530	NN	B-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
HLA	HLA	H400	NN	I-NP	O
identical	identical	I353	JJ	I-NP	O
sibling	sibling	S145	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
13	13	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
rapidly	rapidly	R134	RB	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Engraftment	Engraftment	E526	NN	B-NP	O
and	and	A530	CC	I-NP	O
complete	complete	C514	JJ	I-NP	O
hematologic	hematologic	H534	JJ	I-NP	O
recovery	recovery	R216	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
within	within	W350	IN	B-PP	O
4	4	0000	CD	B-NP	O
weeks	week	W200	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
neurologic	neurologic	N642	JJ	B-NP	B-Disease
deterioration	deterioration	D363	NN	I-NP	I-Disease
continued	continue	C535	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
died	die	D300	VBD	B-VP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
adenovirus	adenovirus	A351	NN	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
141	141	0000	CD	B-NP	O
days	day	D200	NNS	I-NP	O
after	after	A136	IN	B-PP	O
BMT	BMT	B530	NN	B-NP	O
.	.	0000	.	O	O

ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
abnormally	abnormally	A156	RB	B-NP	O
high	high	H200	JJ	I-NP	O
plasma	plasma	P425	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
VLCFA	VLCFA	V421	NN	B-NP	O
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
impaired	impaired	I516	JJ	B-NP	O
capacity	capacity	C123	NN	I-NP	O
to	to	T000	TO	B-VP	O
degrade	degrade	D263	VB	I-VP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

Ten	Ten	T500	CD	B-NP	O
days	day	D200	NNS	I-NP	O
after	after	A136	IN	B-PP	O
BMT	BMT	B530	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
white	white	W300	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
VLCFA	VLCFA	V421	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
became	become	B250	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
;	;	0000	:	O	O
after	after	A136	IN	B-PP	O
3	3	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
progressive	progressive	P626	JJ	B-NP	O
reduction	reduction	R323	NN	I-NP	O
of	of	O100	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
VLCFA	VLCFA	V421	NN	I-NP	O
to	to	T000	TO	B-PP	O
levels	level	L142	NNS	B-NP	O
only	only	O540	RB	B-ADVP	O
slightly	slightly	S423	RB	I-ADVP	O
above	above	A100	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

[	[	0000	(	O	O
Gd	Gd	G300	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
allele	allele	A400	NN	I-NP	O
distribution	distribution	D236	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Azerbaijan	Azerbaijan	A261	NNP	B-NP	O
.	.	0000	.	I-NP	O
III	III	I000	CD	I-NP	O
.	.	0000	.	O	O
The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
]	]	0000	)	O	O

In	In	I500	IN	B-PP	O
28	28	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
living	live	L152	VBG	B-VP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
settlements	settlement	S345	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Shekii	Shekii	S200	NNP	B-NP	O
district	district	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
Azerbaijan	Azerbaijan	A261	NN	B-NP	O
11	11	0000	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
II	II	I000	CD	B-NP	O
and	and	A530	CC	I-NP	O
III	III	I000	CD	I-NP	O
classes	class	C420	NNS	I-NP	O
differing	differ	D165	VBG	B-VP	O
by	by	B000	IN	B-PP	O
kinetic	kinetic	K532	JJ	B-NP	O
properties	property	P616	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
according	accord	A263	VBG	B-PP	O
WHO	WHO	W000	WP	B-NP	O
program	program	P626	NN	I-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
spectra	spectrum	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
subpopulations	subpopulation	S143	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mixed	mix	M230	VBN	I-NP	O
group	group	G610	NN	I-NP	O
permits	permit	P653	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
make	make	M200	VB	I-VP	O
a	a	A000	DT	B-NP	O
conclusion	conclusion	C524	NN	I-NP	O
about	about	A130	IN	B-PP	O
existence	existence	E235	NN	B-NP	O
of	of	O100	IN	B-PP	O
common	common	C500	JJ	B-NP	O
and	and	A530	CC	I-NP	O
rare	rare	R600	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
examined	examine	E253	VBN	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
distribute	distribute	D236	VBP	B-VP	O
by	by	B000	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
drift	drift	D613	NN	I-NP	O
supported	support	S163	VBN	B-VP	O
by	by	B000	IN	B-PP	O
natural	natural	N364	JJ	B-NP	O
selection	selection	S423	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
7	7	0000	CD	B-NP	O
samples	sample	S514	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
and	and	A530	CC	O	O
increased	increase	I526	VBN	B-NP	O
activity	activity	A231	NN	I-NP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
IV	IV	I100	CD	B-NP	O
class	class	C420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	I-NP	O
Nukha	Nukha	N200	NN	I-NP	O
and	and	A530	CC	I-NP	O
Bash	Bash	B200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Kungut	Kungut	K523	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	SYM	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
:	:	0000	:	O	O
survey	survey	S610	NN	B-NP	O
of	of	O100	IN	B-PP	O
303	303	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
:	:	0000	:	O	O
biochemistry	biochemistry	B252	NN	B-NP	O
,	,	0000	,	O	O
diagnosis	diagnosis	D252	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
therapy	therapy	T610	NN	B-NP	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
genetically	genetically	G532	RB	I-NP	O
determined	determine	D365	VBN	I-NP	O
disorder	disorder	D263	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	B-Disease
central	central	C536	JJ	I-NP	I-Disease
demyelination	demyelination	D545	NN	I-NP	I-Disease
and	and	A530	CC	O	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
cortical	cortical	C632	JJ	I-NP	I-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
affected	affected	A123	JJ	I-NP	O
persons	person	P625	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
increased	increase	I526	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
saturated	saturate	S363	VBN	B-NP	O
unbranched	unbranched	U516	JJ	I-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
hexacosanoate	hexacosanoate	H253	NN	B-NP	O
(	(	0000	(	O	O
C26	C26	C000	NN	B-NP	O
0	0	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
impaired	impaired	I516	JJ	B-NP	O
capacity	capacity	C123	NN	I-NP	O
to	to	T000	TO	B-VP	O
degrade	degrade	D263	VB	I-VP	O
these	these	T200	DT	B-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
degradation	degradation	D263	NN	I-NP	O
normally	normally	N654	RB	B-ADVP	O
takes	take	T200	VBZ	B-VP	O
place	place	P420	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
organelle	organelle	O625	NN	I-NP	O
called	call	C430	VBN	B-VP	O
the	the	T000	DT	B-NP	O
peroxisome	peroxisome	P625	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
Zellwegers	Zellwegers	Z426	NNP	B-NP	B-Disease
cerebrohepatorenal	cerebrohepatorenal	C616	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
now	now	N000	RB	I-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
belong	belong	B452	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
formed	form	F653	VBN	I-NP	O
category	category	C326	NN	I-NP	O
of	of	O100	IN	B-PP	O
peroxisomal	peroxisomal	P625	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
assays	assay	A200	NNS	I-NP	O
permit	permit	P653	VBP	B-VP	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
most	most	M230	JJS	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
303	303	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
217	217	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variation	variation	V635	NN	I-NP	O
.	.	0000	.	O	O

Sixty	Sixty	S230	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
had	have	H300	VBD	B-VP	O
childhood	childhood	C430	NN	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
and	and	A530	CC	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	I-NP	B-Disease
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
mapped	map	M130	VBN	B-VP	O
to	to	T000	TO	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
.	.	0000	.	O	O

Neonatal	Neonatal	N534	JJ	B-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
and	and	A530	CC	I-NP	O
points	point	P532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
resemblance	resemblance	R251	NN	B-NP	O
to	to	T000	TO	B-PP	O
Zellwegers	Zellwegers	Z426	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
excess	excess	E200	JJ	B-NP	O
C26	C26	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
partially	partially	P634	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
dietary	dietary	D360	JJ	B-NP	O
C26	C26	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
restriction	restriction	R236	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
produce	produce	P632	VB	I-VP	O
clear	clear	C460	JJ	B-NP	O
benefit	benefit	B513	NN	I-NP	O
.	.	0000	.	O	O

Bone	Bone	B500	NN	B-NP	O
marrow	marrow	M600	NN	I-NP	O
transplant	transplant	T652	NN	I-NP	O
lowered	lower	L630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
C26	C26	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
level	level	L140	NN	I-NP	O
but	but	B300	CC	O	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
arrest	arrest	A623	VB	I-VP	O
neurological	neurological	N642	JJ	B-NP	O
progression	progression	P626	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Bulgarian	Bulgarian	B426	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Considerable	Considerable	C523	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Bulgarian	Bulgarian	B426	JJ	I-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
14	14	0000	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
from	from	F650	IN	B-PP	O
117	117	0000	CD	B-NP	O
hemizygous	hemizygous	H520	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
type	type	T100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
and	and	A530	CC	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
Corinth	Corinth	C653	NNP	B-NP	O
occurred	occur	O263	VBD	B-VP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
-	-	0000	HYPH	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
Rudosem	Rudosem	R325	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Nedelino	Nedelino	N345	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
selected	select	S423	VBN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
78	78	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
established	establish	E231	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranian	Mediterranian	M365	NNP	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NNP	B-NP	O
Corinth	Corinth	C653	NNP	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Seattle	Seattle	S340	NN	I-NP	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Ohut	Ohut	O300	NN	I-NP	O
II	II	I000	CD	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Seventy	Seventy	S153	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
known	know	K500	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Institute	Institute	I523	NNP	I-NP	O
of	of	O100	IN	B-PP	O
Child	Child	C430	NNP	B-NP	O
Health	Health	H430	NNP	I-NP	O
fall	fall	F400	VBP	B-VP	O
into	into	I530	IN	B-PP	O
three	three	T600	CD	B-NP	O
categories	category	C326	NNS	I-NP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
potential	potential	P353	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
RC8	RC8	R200	NN	I-NP	O
and	and	A530	CC	I-NP	O
L1	L1	L000	NN	I-NP	O
.	.	0000	.	O	O

28	28	0000	CD	B-NP	O
that	that	T300	WDT	B-NP	O
bridge	bridge	B632	VBP	B-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Families	Family	F542	NNS	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
obligatory	obligatory	O142	JJ	I-NP	O
female	female	F540	JJ	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
13	13	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-NP	O
prediction	prediction	P632	NN	I-NP	O
and	and	A530	CC	I-NP	O
exclusion	exclusion	E242	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
transmission	transmission	T652	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
possible	possible	P214	JJ	B-ADJP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
accuracy	accuracy	A262	NN	I-NP	O
being	be	B520	VBG	B-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
closeness	closeness	C425	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
;	;	0000	:	O	O
an	an	A500	DT	B-NP	O
illustrative	illustrative	I423	JJ	I-NP	O
case	case	C200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

Families	Family	F542	NNS	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
affected	affect	A123	VBN	I-NP	O
boy	boy	B000	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
also	also	A420	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
healthy	healthy	H430	JJ	I-NP	O
brothers	brother	B636	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
26	26	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Given	Give	G150	VBN	B-PP	O
an	an	A500	DT	B-NP	O
informative	informative	I516	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
RFLP	RFLP	R141	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
reassessed	reassess	R230	VBN	I-VP	O
;	;	0000	:	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
possible	possible	P214	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
exclude	exclude	E243	VB	I-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
.	.	0000	.	O	O

Families	Family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
affected	affect	A123	VBN	I-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
brother	brother	B636	NN	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
30	30	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-NP	O
exclusion	exclusion	E242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
possible	possible	P214	JJ	B-ADJP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
was	be	W200	VBD	B-VP	O
there	there	T600	RB	B-ADVP	O
no	no	N000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
of	of	O100	IN	B-PP	O
useful	useful	U214	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
required	require	R263	VBN	B-VP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
need	need	N300	NN	I-NP	O
to	to	T000	TO	B-VP	O
check	check	C200	VB	I-VP	O
DMD	DMD	D530	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
informative	informative	I516	JJ	B-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
stressed	stress	S362	VBN	I-VP	O
.	.	0000	.	O	O

Family	Family	F540	RB	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Bechterew	Bechterew	B236	NNP	B-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
s	s	S000	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
)	)	0000	)	O	O
III	III	I000	CD	B-NP	O
.	.	0000	.	O	O

Genetics	Genetic	G532	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
75	75	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
had	have	H300	VBD	B-VP	O
ankylosing	ankylose	A524	VBG	I-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
presented	present	P625	VBN	I-VP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
278	278	0000	CD	I-NP	O
adult	adult	A343	NN	I-NP	O
,	,	0000	,	O	O
living	live	L152	VBG	B-VP	O
first	first	F623	JJ	B-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
,	,	0000	,	O	O
approximately	approximately	A162	RB	B-NP	O
85	85	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
cooperated	cooperate	C163	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
radiographical	radiographical	R326	JJ	I-NP	O
examinations	examination	E253	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
and	and	A530	CC	O	O
HLA	HLA	H400	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
was	be	W200	VBD	B-VP	O
conducted	conduct	C532	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
in	in	I500	IN	B-PP	O
agreement	agreement	A265	NN	B-NP	O
with	with	W300	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
different	different	D165	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
interact	interact	I536	VBP	B-VP	O
.	.	0000	.	O	O

Such	Such	S200	JJ	B-NP	O
known	know	K500	VBN	I-NP	O
factors	factor	F236	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
HLA	HLA	H400	NN	B-NP	O
B27	B27	B000	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
disease	disease	D200	NN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
,	,	0000	,	O	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
psoriatic	psoriatic	P263	JJ	B-NP	B-Disease
arthropathy	arthropathy	A636	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
entero	entero	E536	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
arthropathy	arthropathy	A636	NN	I-NP	I-Disease
.	.	0000	.	O	O

Radiographical	Radiographical	R326	JJ	B-NP	O
sacro	sacro	S260	AFX	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
iliitis	iliitis	I432	NN	B-NP	I-Disease
was	be	W200	VBD	B-VP	O
restricted	restricted	R236	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
HLA	HLA	H400	NN	B-NP	O
B27	B27	B000	NN	I-NP	O
positive	positive	P231	JJ	I-NP	O
relatives	relative	R431	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
more	more	M600	RBR	I-VP	O
frequently	frequently	F625	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
to	to	T000	TO	B-PP	O
probands	proband	P615	NNS	B-NP	O
with	with	W300	IN	B-PP	O
psoriasis	psoriasis	P262	NN	B-NP	B-Disease
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
to	to	T000	TO	B-PP	O
probands	proband	P615	NNS	B-NP	O
without	without	W300	IN	B-PP	O
psoriasis	psoriasis	P262	NN	B-NP	B-Disease
.	.	0000	.	O	O

Environmental	Environmental	E516	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
(	(	0000	(	O	O
intestinal	intestinal	I532	JJ	B-NP	O
bacteria	bacteria	B236	NNS	I-NP	O
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
trigger	trigger	T626	VB	I-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
persons	person	P625	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
postulated	postulate	P234	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	DT	B-NP	O
or	or	O600	CC	I-NP	O
most	most	M230	JJS	I-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
disease	disease	D200	NN	B-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
multifactorial	multifactorial	M431	JJ	I-NP	O
etiology	etiology	E342	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expressions	expression	E216	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
predispositions	predisposition	P632	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
,	,	0000	,	O	O
include	include	I524	VBP	B-VP	O
sacro	sacro	S260	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
iliitis	iliitis	I432	NN	B-NP	I-Disease
,	,	0000	,	O	O
psoriasis	psoriasis	P262	NN	B-NP	B-Disease
,	,	0000	,	O	O
acute	acute	A230	JJ	B-NP	B-Disease
anterior	anterior	A536	JJ	I-NP	I-Disease
uveitis	uveitis	U132	NN	I-NP	I-Disease
,	,	0000	,	O	O
peripheral	peripheral	P616	JJ	B-NP	O
arthropathy	arthropathy	A636	NN	I-NP	B-Disease
and	and	A530	CC	O	O
inflammatory	inflammatory	I514	JJ	B-NP	B-Disease
bowel	bowel	B400	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
descriptive	descriptive	D261	JJ	I-NP	O
name	name	N500	NN	I-NP	O
HEREDITARY	HEREDITARY	H636	NN	I-NP	B-Disease
MULTIFOCAL	MULTIFOCAL	M431	NN	I-NP	I-Disease
RELAPSING	RELAPSING	R412	NN	I-NP	I-Disease
INFLAMMATION	INFLAMMATION	I514	NN	I-NP	I-Disease
(	(	0000	(	O	O
HEMRI	HEMRI	H560	NN	B-NP	B-Disease
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O

Ankylosing	Ankylose	A524	VBG	B-NP	B-Disease
spondylitis	spondylitis	S153	NN	I-NP	I-Disease
,	,	0000	,	O	O
psoriatic	psoriatic	P263	JJ	B-NP	B-Disease
arthropathy	arthropathy	A636	NN	I-NP	I-Disease
and	and	A530	CC	O	O
entero	entero	E536	AFX	O	B-Disease
-	-	0000	HYPH	O	I-Disease
arthropathy	arthropathy	A636	NN	B-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
sub	sub	S100	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
discussion	discussion	D250	NN	I-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	B-Disease
15	15	0000	CD	I-NP	I-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
17	17	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
were	be	W600	VBD	B-VP	O
clinically	clinically	C452	RB	I-VP	O
suspected	suspect	S212	VBN	I-VP	O
of	of	O100	IN	B-PP	O
having	have	H152	VBG	B-VP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
were	be	W600	VBD	B-VP	O
very	very	V600	RB	B-ADJP	O
similar	similar	S546	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
originally	originally	O625	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
hand	hand	H530	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
karyotype	karyotype	K631	NN	I-NP	O
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
features	feature	F362	NNS	I-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
strictly	strictly	S362	RB	I-VP	O
correspond	correspond	C621	VBP	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
definition	definition	D153	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
PWS	PWS	P200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
can	can	C500	MD	B-VP	O
neither	neither	N360	CC	I-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
balanced	balanced	B452	JJ	I-NP	O
translocations	translocation	T652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
nor	nor	N600	CC	O	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
supernumerary	supernumerary	S165	JJ	I-NP	O
metacentric	metacentric	M325	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
isochromosome	isochromosome	I265	NN	I-NP	O
15	15	0000	CD	I-NP	O
for	for	F600	IN	B-PP	O
band	band	B530	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
North	North	N630	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
:	:	0000	:	O	O
geographic	geographic	G261	JJ	B-NP	O
variations	variation	V635	NNS	I-NP	O
and	and	A530	CC	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
data	datum	D300	NNS	B-NP	O
collected	collect	C423	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
North	North	N630	NNP	I-NP	O
American	American	A562	NNP	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
heterozygote	heterozygote	H362	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
program	program	P626	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
among	among	A520	IN	B-PP	O
46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
304	304	0000	CD	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
.	.	0000	.	O	O

0324	0324	0000	CD	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
31	31	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
earlier	early	E646	JJR	B-NP	O
estimates	estimate	E235	NNS	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
incidence	incidence	I523	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
.	.	0000	.	O	O

TSD	TSD	T230	NN	B-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
then	then	T500	RB	I-VP	O
examined	examine	E253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
country	country	C536	NN	I-NP	O
and	and	A530	CC	O	O
single	single	S524	JJ	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
origin	origin	O625	NN	B-NP	O
in	in	I500	IN	B-PP	O
28	28	0000	CD	B-NP	O
,	,	0000	,	O	O
029	029	0000	CD	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
for	for	F600	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
such	such	S200	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
available	available	A141	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
.	.	0000	.	O	O

Jews	Jew	J200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Polish	Polish	P420	JJ	O	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
Russian	Russian	R250	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
constituted	constitute	C523	VBD	B-VP	O
88	88	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
.	.	0000	.	O	O

0327	0327	0000	CD	B-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
166	166	0000	CD	I-NP	O
Jews	Jew	J200	NNPS	I-NP	O
of	of	O100	IN	B-PP	O
Near	Near	N600	NNP	B-NP	O
Eastern	Eastern	E236	NNP	I-NP	O
origins	origin	O625	NNS	I-NP	O
.	.	0000	.	O	O

Relative	Relative	R431	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
Jews	Jew	J200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Polish	Polish	P420	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Russian	Russian	R250	JJ	I-NP	O
origins	origin	O625	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
a	a	A000	DT	B-NP	O
twofold	twofold	T143	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Jews	Jews	J200	NNP	B-NP	O
of	of	O100	IN	B-PP	O
Austrian	Austrian	A236	NNP	B-NP	O
,	,	0000	,	O	O
Hungarian	Hungarian	H526	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Czechoslovakian	Czechoslovakian	C241	JJ	B-NP	O
origins	origin	O625	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
less	less	L200	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
.	.	0000	.	B-NP	O
005	005	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
proliferated	proliferate	P641	VBD	B-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
antecedents	antecedent	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
modern	modern	M365	JJ	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewry	Jewry	J600	NNP	I-NP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
Second	Second	S253	NNP	I-NP	O
Diaspora	Diaspora	D216	NNP	I-NP	O
(	(	0000	(	O	O
70	70	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	I-NP	O
D	D	D000	NNP	I-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
before	before	B160	IN	B-SBAR	O
their	their	T600	PRP$	B-NP	O
major	major	M260	JJ	I-NP	O
migrations	migration	M263	NNS	I-NP	O
to	to	T000	TO	B-PP	O
regions	region	R252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Poland	Poland	P453	NNP	B-NP	O
and	and	A530	CC	I-NP	O
Russia	Russia	R200	NNP	I-NP	O
(	(	0000	(	O	O
before	before	B160	IN	O	O
1100	1100	0000	CD	B-NP	O
A	A	A000	NNP	I-NP	O
.	.	0000	.	I-NP	O
D	D	D000	NNP	I-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
sixth	sixth	S230	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
haemostasis	haemostasis	H523	NN	I-NP	B-Disease
abnormality	abnormality	A156	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
complete	complete	C514	JJ	I-NP	O
C6	C6	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
31	31	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
male	male	M400	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
occasion	occasion	O250	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
episode	episode	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
.	.	0000	.	O	O

Serum	Serum	S650	NN	B-NP	O
complement	complement	C514	NN	I-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
and	and	A530	CC	I-NP	O
bactericidal	bactericidal	B236	JJ	I-NP	O
activities	activity	A231	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
lacking	lack	L252	VBG	I-VP	O
and	and	A530	CC	O	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
restored	restore	R236	VBN	I-VP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
appropriate	appropriate	A161	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
purified	purify	P613	VBN	B-NP	O
C6	C6	C000	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
hemostatic	hemostatic	H523	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Absence	Absence	A125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
meningococcemia	meningococcemia	M525	NN	I-NP	I-Disease
presenting	present	P625	VBG	B-VP	O
as	as	A200	IN	B-PP	O
vasculitis	vasculitis	V243	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
healthy	healthy	H430	JJ	I-NP	O
40	40	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
man	man	M500	NN	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
fever	fever	F160	NN	B-NP	B-Disease
,	,	0000	,	O	O
arthritis	arthritis	A636	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
cutaneous	cutaneous	C352	JJ	B-NP	B-Disease
vasculitis	vasculitis	V243	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
meningococcemia	meningococcemia	M525	NN	I-NP	I-Disease
.	.	0000	.	O	O

Evaluation	Evaluation	E143	NN	B-NP	O
of	of	O100	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
complement	complement	C514	NN	I-NP	O
system	system	S235	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
and	and	A530	CC	I-NP	O
antigenic	antigenic	A532	JJ	I-NP	O
C7	C7	C000	NN	I-NP	O
,	,	0000	,	O	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
.	.	0000	.	O	O

Study	Study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
family	family	F540	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
four	four	F600	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
C7	C7	C000	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
members	member	M516	NNS	I-NP	O
.	.	0000	.	O	O

Chronic	Chronic	C652	JJ	B-NP	B-Disease
neisserial	neisserial	N264	JJ	I-NP	I-Disease
infection	infection	I512	NN	I-NP	I-Disease
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
must	must	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
distinguished	distinguish	D235	VBN	I-VP	O
from	from	F650	IN	B-PP	O
other	other	O360	JJ	B-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cutaneous	cutaneous	C352	JJ	B-NP	B-Disease
vasculitis	vasculitis	V243	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
discoid	discoid	D230	JJ	I-NP	I-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
heterozygote	heterozygote	H362	NN	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
with	with	W300	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
discoid	discoid	D230	JJ	I-NP	I-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
with	with	W300	IN	B-PP	O
histocompatibility	histocompatibility	H232	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
B18	B18	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Dw2	Dw2	D000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
slow	slow	S400	JJ	I-NP	O
allotype	allotype	A431	NN	I-NP	O
of	of	O100	IN	B-PP	O
factor	factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
a	a	A000	DT	B-NP	O
close	close	C420	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
genes	gene	G520	NNS	B-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
B18	B18	B000	NN	B-NP	O
,	,	0000	,	O	O
Dw2	Dw2	D000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
BfS	BfS	B120	NN	B-NP	O
antigens	antigen	A532	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ACB	ACB	A210	NN	I-NP	O
/	/	0000	SYM	B-NP	O
DBf	DBf	D100	NN	I-NP	O
recombinant	recombinant	R251	JJ	B-ADJP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
showing	show	S520	VBG	B-VP	O
closer	close	C426	JJR	B-NP	O
linkage	linkage	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
and	and	A530	CC	I-NP	O
Bf	Bf	B100	NN	I-NP	O
than	than	T500	IN	B-PP	O
between	between	B350	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B	B	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
Bf	Bf	B100	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Severe	Severe	S160	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	B-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
,	,	0000	,	O	O
granulocyte	granulocyte	G654	NN	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
increased	increase	I526	VBD	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
infections	infection	I512	NNS	B-NP	O
:	:	0000	:	O	O
description	description	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
Barcelona	Barcelona	B624	NNP	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
,	,	0000	,	I-NP	O
kinetic	kinetic	K532	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
functional	functional	F523	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
on	on	O500	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
(	(	0000	(	O	O
CNSHA	CNSHA	C520	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
increased	increase	I526	VBD	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
infections	infection	I512	NNS	B-NP	O
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
red	red	R300	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
about	about	A130	RB	B-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
in	in	I500	IN	B-PP	O
leukocytes	leukocyte	L232	NNS	B-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
standard	standard	S353	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
(	(	0000	(	O	O
WHO	WHO	W000	NN	B-NP	O
,	,	0000	,	O	O
1967	1967	0000	CD	B-NP	O
)	)	0000	)	O	O
showed	show	S300	VBD	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
slightly	slightly	S423	RB	I-NP	O
fast	fast	F230	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
at	at	A300	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
otherwise	otherwise	O362	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
(	(	0000	(	O	O
heat	heat	H300	NN	B-NP	O
stability	stability	S314	NN	I-NP	O
at	at	A300	IN	B-PP	O
46	46	0000	CD	B-NP	O
degrees	degree	D262	NNS	I-NP	O
C	C	C000	JJ	B-NP	O
,	,	0000	,	I-NP	O
apparent	apparent	A165	JJ	I-NP	O
affinity	affinity	A153	NN	I-NP	O
for	for	F600	IN	B-PP	O
substrates	substrate	S123	NNS	B-NP	O
,	,	0000	,	O	O
optimum	optimum	O135	JJ	B-NP	O
pH	pH	P000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
utilization	utilization	U342	NN	B-NP	O
of	of	O100	IN	B-PP	O
substrate	substrate	S123	NN	B-NP	O
analogues	analogue	A542	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
tests	test	T232	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
granulocytes	granulocyte	G654	NNS	I-NP	O
to	to	T000	TO	B-VP	O
engulf	engulf	E524	VB	I-VP	O
latex	latex	L320	JJ	B-NP	O
particles	particle	P632	NNS	I-NP	O
normally	normally	N654	RB	B-ADVP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
to	to	T000	TO	B-VP	O
have	have	H100	VB	I-VP	O
impaired	impair	I516	VBN	I-VP	O
reduction	reduction	R323	NN	B-NP	O
of	of	O100	IN	B-PP	O
nitroblue	nitroblue	N361	JJ	B-NP	O
tetrazolium	tetrazolium	T362	NN	I-NP	O
and	and	A530	CC	I-NP	O
ferricytochrome	ferricytochrome	F623	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
c	c	C000	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
reduced	reduce	R323	VBN	B-NP	O
iodination	iodination	I353	NN	I-NP	O
.	.	0000	.	O	O

Chemotaxis	Chemotaxis	C532	NNP	B-NP	O
and	and	A530	CC	O	O
random	random	R535	JJ	B-NP	O
migration	migration	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
granulocytes	granulocyte	G654	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
as	as	A200	IN	B-SBAR	O
were	be	W600	VBD	B-VP	O
myeloperoxidase	myeloperoxidase	M416	NN	B-NP	O
,	,	0000	,	O	O
leukocyte	leukocyte	L230	NN	B-NP	O
alkaline	alkaline	A424	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
(	(	0000	(	O	O
LAP	LAP	L100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
ultrastructural	ultrastructural	U436	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
differed	differ	D163	VBD	B-VP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
variants	variant	V653	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
CNSHA	CNSHA	C520	NN	B-NP	B-Disease
,	,	0000	,	O	O
so	so	S000	IN	O	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
provisionally	provisionally	P612	RB	I-VP	O
called	call	C430	VBN	I-VP	O
G6PD	G6PD	G130	NNP	B-NP	O
Barcelona	Barcelona	B624	NNP	I-NP	O
to	to	T000	TO	B-VP	O
distinguish	distinguish	D235	VB	I-VP	O
it	it	I300	PRP	B-NP	O
from	from	F650	IN	B-PP	O
other	other	O360	JJ	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

Possible	Possible	P214	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
and	and	A530	CC	I-NP	O
granulocytes	granulocyte	G654	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
by	by	B000	IN	B-PP	O
studies	study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
immunologic	immunologic	I542	JJ	I-NP	O
specific	specific	S121	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
description	description	D261	NN	I-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
362	362	0000	CD	B-NP	O
males	male	M420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
red	red	R300	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
six	six	S200	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
purified	purify	P613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
13	13	0000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
several	several	S164	JJ	B-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
previously	previously	P612	RB	B-NP	O
described	describe	D261	VBN	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
illustrates	illustrate	I423	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
extreme	extreme	E236	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
people	people	P140	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Heterogeneity	Heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
"	"	0000	``	O	O
Mediterranean	Mediterranean	M365	JJ	B-NP	O
type	type	T100	NN	I-NP	O
"	"	0000	``	O	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
Spain	Spain	S150	NNP	B-NP	O
and	and	A530	CC	O	O
description	description	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
favism	favism	F125	NN	B-NP	B-Disease
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
EC	EC	E200	NN	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	LS	B-LST	O
.	.	0000	.	O	O

1	1	0000	LS	B-LST	O
.	.	0000	.	O	O

49	49	0000	CD	B-NP	O
from	from	F650	IN	B-PP	O
thirty	thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
six	six	S200	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
partially	partially	P634	RB	I-VP	O
purified	purify	P613	VBN	I-VP	O
from	from	F650	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
biochemically	biochemically	B252	RB	B-VP	O
and	and	A530	CC	I-VP	O
electrophoretically	electrophoretically	E423	RB	I-VP	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
methods	method	M320	NNS	I-NP	O
recommended	recommend	R253	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
Health	Health	H430	NNP	I-NP	O
Organization	Organization	O625	NNP	I-NP	O
.	.	0000	.	O	O

Subjects	Subject	S123	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
from	from	F650	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
geographic	geographic	G261	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
within	within	W350	IN	B-PP	O
Spain	Spain	S150	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
suffered	suffer	S163	VBD	B-VP	O
from	from	F650	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	B-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
,	,	0000	,	O	O
either	either	E360	CC	O	O
acute	acute	A230	JJ	O	O
(	(	0000	(	O	O
34	34	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
chronic	chronic	C652	JJ	B-NP	O
nonspherocytic	nonspherocytic	N521	JJ	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Almost	Almost	A452	RB	B-NP	O
all	all	A400	PDT	I-NP	O
the	the	T000	DT	I-NP	O
variants	variant	V653	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
presented	present	P625	VBD	B-VP	O
residual	residual	R234	JJ	B-NP	O
erythrocyte	erythrocyte	E636	NN	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
0	0	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
others	other	O362	NNS	B-NP	O
previously	previously	P612	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NN	I-NP	O
(	(	0000	(	O	O
11	11	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Athens	Athens	A352	NNP	I-NP	O
-	-	0000	HYPH	O	O
like	like	L200	JJ	O	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Union	Union	U500	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
numerous	numerous	N562	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
already	already	A463	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
considered	consider	C523	VBN	I-VP	O
as	as	A200	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
.	.	0000	.	O	O

Provisionally	Provisionally	P612	RB	B-ADVP	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
called	call	C430	VBN	I-VP	O
G6PD	G6PD	G130	NNP	B-NP	O
Betica	Betica	B320	NNP	I-NP	O
(	(	0000	(	O	O
19	19	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
G6PD	G6PD	G130	NN	B-NP	O
Menorca	Menorca	M562	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
case	case	C200	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
constitutes	constitute	C523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
attempt	attempt	A351	NN	I-NP	O
to	to	T000	TO	B-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
deficient	deficient	D125	JJ	I-NP	B-Disease
G6PD	G6PD	G130	NN	I-NP	I-Disease
variants	variant	V653	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Spain	Spain	S150	NNP	B-NP	O
and	and	A530	CC	O	O
supplies	supply	S142	VBZ	B-VP	O
new	new	N000	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
important	important	I516	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
summarized	summarize	S562	VBN	I-VP	O
as	as	A200	IN	B-SBAR	O
follows	follow	F420	VBZ	B-VP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
The	The	T000	DT	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
Although	Although	A432	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
is	be	I200	VBZ	B-VP	O
very	very	V600	RB	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
presents	present	P625	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
polymorphism	polymorphism	P456	NN	B-NP	O
.	.	0000	.	O	O

(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
Favism	Favism	F125	NNP	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
all	all	A400	DT	B-NP	O
kinds	kind	K532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
variants	variant	V653	NNS	B-NP	O
described	describe	D261	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
.	.	0000	.	O	O

(	(	0000	(	B-LST	O
4	4	0000	LS	I-LST	O
)	)	0000	)	O	O
G6PD	G6PD	G130	NN	B-NP	O
Betica	Betica	B320	NNP	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
favism	favism	F125	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
except	except	E213	IN	B-PP	O
one	one	O500	CD	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
Nagano	Nagano	N250	NNP	I-NP	O
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
variant	variant	V653	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
chronic	chronic	C652	JJ	B-NP	B-Disease
nonspherocytic	nonspherocytic	N521	JJ	I-NP	I-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
male	male	M400	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
noticed	notice	N323	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
hemolytic	hemolytic	H543	JJ	B-NP	B-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
soon	soon	S500	RB	B-ADVP	O
after	after	A136	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
made	make	M300	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
episodes	episode	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	B-Disease
crisis	crisis	C620	NN	I-NP	I-Disease
several	several	S164	JJ	B-NP	O
times	time	T520	NNS	I-NP	O
after	after	A136	IN	B-PP	O
upper	upper	U160	JJ	B-NP	B-Disease
respiratory	respiratory	R216	JJ	I-NP	I-Disease
infection	infection	I512	NN	I-NP	I-Disease
.	.	0000	.	O	O

G6PD	G6PD	G130	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
when	when	W500	WRB	B-ADVP	O
he	he	H000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
5	5	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
old	old	O430	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
faster	faster	F236	RBR	B-ADVP	O
-	-	0000	HYPH	B-NP	O
than	than	T500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
normal	normal	N654	JJ	I-NP	O
electrophoretic	electrophoretic	E423	JJ	I-NP	O
mobility	mobility	M143	NN	I-NP	O
,	,	0000	,	O	O
low	low	L000	JJ	B-NP	O
Km	Km	K500	NN	I-NP	O
G6P	G6P	G100	NN	I-NP	O
,	,	0000	,	O	O
high	high	H200	JJ	B-NP	O
Km	Km	K500	NN	I-NP	O
NADP	NADP	N310	NN	I-NP	O
,	,	0000	,	O	O
low	low	L000	JJ	B-NP	O
Ki	Ki	K000	NN	I-NP	O
NADPH	NADPH	N310	NN	I-NP	O
,	,	0000	,	O	O
normal	normal	N654	JJ	B-NP	O
utilization	utilization	U342	NN	I-NP	O
of	of	O100	IN	B-PP	O
substrate	substrate	S123	NN	B-NP	O
analogues	analogue	A542	NNS	I-NP	O
,	,	0000	,	O	O
heat	heat	H300	NN	B-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
optimum	optimum	O135	JJ	I-NP	O
curve	curve	C610	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
considered	consider	C523	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
designated	designate	D253	VBN	I-VP	O
G6PD	G6PD	G130	NN	B-NP	O
Nagano	Nagano	N250	NNP	I-NP	O
.	.	0000	.	O	O

Infection	Infection	I512	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
hemolysis	hemolysis	H542	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
chronic	chronic	C652	JJ	I-NP	B-Disease
hemolytic	hemolytic	H543	JJ	I-NP	I-Disease
anemia	anemia	A500	NN	I-NP	I-Disease
seem	seem	S500	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
markedly	markedly	M623	RB	B-NP	O
impaired	impaired	I516	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
thermal	thermal	T654	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
myasthenia	myasthenia	M235	NN	I-NP	B-Disease
gravis	gravis	G612	NN	I-NP	I-Disease
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
states	state	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
myasthenia	myasthenia	M235	NN	B-NP	B-Disease
gravis	gravis	G612	NN	I-NP	I-Disease
(	(	0000	(	O	O
MG	MG	M200	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
19	19	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
woman	woman	W500	NN	I-NP	O
with	with	W300	IN	B-PP	O
typical	typical	T124	JJ	B-NP	O
MG	MG	M200	NN	I-NP	B-Disease
and	and	A530	CC	O	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
along	along	A452	IN	B-PP	O
with	with	W300	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	O	O
her	her	H600	PRP$	B-NP	O
immediate	immediate	I530	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
:	:	0000	:	O	O
increased	increase	I526	VBN	B-NP	O
plasma	plasma	P425	NN	I-NP	O
content	content	C535	NN	I-NP	O
of	of	O100	IN	B-PP	O
saturated	saturate	S363	VBN	B-NP	O
very	very	V600	RB	I-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
method	method	M300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
measured	measure	M263	VBD	B-VP	O
the	the	T000	DT	B-NP	O
saturated	saturate	S363	VBN	I-NP	O
very	very	V600	RB	I-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
of	of	O100	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
hemizygotes	hemizygote	H523	NNS	B-NP	O
,	,	0000	,	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
controls	control	C536	NNS	B-NP	O
.	.	0000	.	O	O

ALD	ALD	A430	NN	B-NP	B-Disease
hemizygotes	hemizygote	H523	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
increased	increase	I526	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hexacosanoate	hexacosanoate	H253	NN	B-NP	O
(	(	0000	(	O	O
C26	C26	C000	NN	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
represented	represent	R162	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

081	081	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

0066	0066	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
SEM	SEM	S500	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

015	015	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

0032	0032	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

C25	C25	C000	NN	B-NP	O
,	,	0000	,	O	O
C24	C24	C000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
C23	C23	C000	NN	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
C22	C22	C000	NN	I-NP	O
and	and	A530	CC	I-NP	O
C20	C20	C000	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

C26	C26	C000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mean	mean	M500	JJ	I-NP	O
level	level	L140	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

057	057	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

0063	0063	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
technique	technique	T252	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
and	and	A530	CC	I-NP	O
carrier	carrier	C600	NN	I-NP	O
identification	identification	I353	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
therapy	therapy	T610	NN	B-NP	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
profiles	profile	P614	NNS	I-NP	O
and	and	A530	CC	O	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
cerebrotendinous	cerebrotendinous	C616	JJ	I-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Abnormalities	Abnormality	A156	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
HDL	HDL	H340	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
their	their	T600	PRP$	B-NP	O
increased	increase	I526	VBN	I-NP	O
atherogenesis	atherogenesis	A362	NN	I-NP	O
and	and	A530	CC	O	O
excessive	excessive	E210	JJ	B-NP	O
deposits	deposit	D123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
tissue	tissue	T200	NN	B-NP	O
sterols	sterol	S364	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
or	or	O600	CC	I-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
normal	normal	N654	JJ	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
(	(	0000	(	O	O
165	165	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
25	25	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
low	low	L000	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
(	(	0000	(	O	O
LDL	LDL	L340	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mean	mean	M500	JJ	I-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
concentration	concentration	C525	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTX	CTX	C320	NN	I-NP	B-Disease
plasmas	plasmas	P425	NN	I-NP	O
was	be	W200	VBD	B-VP	O
14	14	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
,	,	0000	,	O	O
about	about	A130	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
third	third	T630	JJ	I-NP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
value	value	V400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	O	O
cholesterol	cholesterol	C423	NN	B-NP	O
reflects	reflect	R142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
concentration	concentration	C525	NN	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
lipid	lipid	L130	NN	I-NP	O
composition	composition	C512	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
HDL	HDL	H340	NN	I-NP	O
.	.	0000	.	O	O

Relative	Relative	R431	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
HDL	HDL	H340	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
esters	ester	E236	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
low	low	L000	JJ	B-NP	O
,	,	0000	,	I-NP	O
free	free	F600	JJ	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
and	and	A530	CC	I-NP	O
phospholipids	phospholipid	P214	NNS	I-NP	O
essentially	essentially	E253	RB	B-ADJP	O
normal	normal	N654	JJ	I-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
triglycerides	triglyceride	T624	NNS	B-NP	O
increased	increase	I526	VBD	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoprotein	apoprotein	A163	NN	B-NP	O
(	(	0000	(	O	O
apo	apo	A100	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
total	total	T340	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HDL	HDL	H340	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
two	two	T000	CD	B-NP	O
to	to	T000	TO	I-NP	O
three	three	T600	CD	I-NP	O
times	time	T520	NNS	I-NP	O
greater	great	G636	JJR	I-NP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTX	CTX	C320	NN	I-NP	B-Disease
HDL	HDL	H340	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoAI	apoAI	A100	NN	B-NP	O
to	to	T000	TO	B-PP	O
apoAII	apoAII	A100	NN	B-NP	O
was	be	W200	VBD	B-VP	O
high	high	H200	JJ	B-ADJP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoC	apoC	A120	NN	B-NP	O
low	low	L000	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
normally	normally	N654	RB	I-NP	O
minor	minor	M560	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoAI	apoAI	A100	NN	B-NP	O
increased	increase	I526	VBD	B-VP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
forms	form	F652	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
HDL	HDL	H340	NN	I-NP	O
in	in	I500	IN	B-PP	O
electron	electron	E423	NN	B-NP	O
micrographs	micrograph	M262	NNS	I-NP	O
appeared	appear	A163	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
morphologically	morphologically	M614	RB	B-ADVP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
particle	particle	P632	NN	B-NP	O
size	size	S200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
in	in	I500	IN	B-PP	O
lipoprotein	lipoprotein	L163	NN	B-NP	O
distribution	distribution	D236	NN	I-NP	O
profile	profile	P614	NN	I-NP	O
and	and	A530	CC	I-NP	O
composition	composition	C512	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
plasma	plasma	P425	NN	I-NP	O
HDL	HDL	H340	NN	I-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
metabolic	metabolic	M314	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
understood	understand	U536	VBN	I-VP	O
but	but	B300	CC	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
bile	bile	B400	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
in	in	I500	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
probable	probable	P614	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
functions	function	F523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HDL	HDL	H340	NN	I-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-ADVP	O
including	include	I524	VBG	B-PP	O
modulation	modulation	M343	NN	B-NP	O
of	of	O100	IN	B-PP	O
LDL	LDL	L340	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
uptake	uptake	U132	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
removal	removal	R514	NN	I-NP	O
of	of	O100	IN	B-PP	O
excess	excess	E200	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
perturbed	perturb	P636	VBN	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Genetics	Genetic	G532	NNS	B-NP	O
of	of	O100	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
with	with	W300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Sephardim	Sephardim	S163	NN	B-NP	O
of	of	O100	IN	B-PP	O
Moroccan	Moroccan	M625	NNP	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
described	describe	D261	VBD	B-VP	O
6	6	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
from	from	F650	IN	B-PP	O
3	3	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
)	)	0000	)	O	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
are	be	A600	VBP	B-VP	O
Sephardic	Sephardic	S163	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Moroccan	Moroccan	M625	NN	B-NP	O
extraction	extraction	E236	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
view	view	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
diagnosed	diagnose	D252	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
(	(	0000	(	O	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
including	include	I524	VBG	B-PP	O
our	our	O600	PRP$	B-NP	O
6	6	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
probably	probably	P614	RB	I-VP	O
dealing	deal	D452	VBG	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
subgroup	subgroup	S126	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
CTX	CTX	C320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
108	108	0000	CD	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
recommend	recommend	R253	VBP	B-VP	O
cholestanol	cholestanol	C423	NN	B-NP	O
study	study	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
undiagnosed	undiagnosed	U532	JJ	B-NP	O
cataract	cataract	C362	NN	I-NP	B-Disease
or	or	O600	CC	O	O
tendinous	tendinous	T535	JJ	B-NP	B-Disease
xanthomas	xanthoma	X535	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
or	or	O600	CC	O	O
early	early	E640	JJ	B-NP	O
adolescence	adolescence	A342	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
in	in	I500	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-CONJP	O
also	also	A420	RB	I-CONJP	O
in	in	I500	IN	B-PP	O
veiw	veiw	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

New	New	N000	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Italy	Italy	I340	NNP	B-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
erythrocyte	erythrocyte	E636	NN	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Italian	Italian	I345	JJ	B-NP	O
males	male	M420	NNS	I-NP	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
only	only	O540	RB	B-NP	O
two	two	T000	CD	I-NP	O
with	with	W300	IN	B-PP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
haemolysis	haemolysis	H542	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
variants	variant	V653	NNS	I-NP	O
reported	report	R163	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
must	must	M230	MD	B-VP	O
thus	thus	T200	RB	I-VP	O
far	far	F600	RB	I-VP	O
be	be	B000	VB	I-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-ADJP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
map	map	M100	VB	I-VP	O
in	in	I500	IN	B-PP	O
parts	part	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Italy	Italy	I340	NNP	B-NP	O
where	where	W600	WRB	B-ADVP	O
common	common	C500	JJ	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
also	also	A420	RB	B-ADVP	O
prevalent	prevalent	P614	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Variants	Variant	V653	NNS	B-NP	O
of	of	O100	IN	B-PP	O
erythrocyte	erythrocyte	E636	NN	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Bulgarian	Bulgarian	B426	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Ten	Ten	T500	CD	B-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
erythrocyte	erythrocyte	E636	NN	B-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
22	22	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
three	three	T600	CD	B-NP	O
districts	district	D236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Bulgaria	Bulgaria	B426	NNP	B-NP	O
.	.	0000	.	O	O

Corinth	Corinth	C653	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Fayoum	Fayoum	F500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
;	;	0000	:	O	O
Mediterranean	Mediterranean	M365	NNP	B-NP	O
,	,	0000	,	O	O
Ohut	Ohut	O300	NNP	B-NP	O
II	II	I000	NNP	I-NP	O
,	,	0000	,	O	O
Kilgore	Kilgore	K426	NNP	B-NP	O
,	,	0000	,	O	O
Boston	Boston	B235	NNP	B-NP	O
,	,	0000	,	O	O
Poznan	Poznan	P250	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Panay	Panay	P500	NNP	B-NP	O
variants	variant	V653	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
Petrich	Petrich	P362	NNP	B-NP	O
and	and	A530	CC	O	O
Gotze	Gotze	G320	NNP	B-NP	O
Delchev	Delchev	D421	NNP	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
each	each	E200	DT	B-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
two	two	T000	CD	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
was	be	W200	VBD	B-VP	O
revealed	reveal	R143	VBN	I-VP	O
between	between	B350	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Nephropathy	Nephropathy	N161	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Nephropathy	Nephropathy	N161	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
32	32	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
participating	participate	P632	VBG	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
transfer	transfer	T652	NN	B-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
TF	TF	T100	NN	B-NP	O
)	)	0000	)	O	O
therapy	therapy	T610	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
nephropathy	nephropathy	N161	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
before	before	B160	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
and	and	A530	CC	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
changed	change	C523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
subsequently	subsequently	S125	RB	B-ADVP	O
developed	develop	D141	VBD	B-VP	O
progressive	progressive	P626	JJ	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
requiring	require	R265	VBG	I-NP	O
dialysis	dialysis	D420	NN	I-NP	O
beginning	begin	B252	VBG	B-VP	O
5	5	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
/	/	0000	SYM	B-NP	O
2	2	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
after	after	A136	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
decreased	decrease	D262	VBD	B-VP	O
renal	renal	R540	JJ	B-NP	O
function	function	F523	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
very	very	V600	RB	B-ADVP	O
soon	soon	S500	RB	I-ADVP	O
after	after	A136	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
administration	administration	A352	NN	I-NP	O
of	of	O100	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
gradually	gradually	G634	RB	I-VP	O
decreasing	decrease	D262	VBG	I-VP	O
renal	renal	R540	JJ	B-NP	O
function	function	F523	NN	I-NP	O
beginning	begin	B252	VBG	B-VP	O
after	after	A136	IN	B-PP	O
two	two	T000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
who	who	W000	WP	B-NP	O
died	die	D300	VBD	B-VP	O
with	with	W300	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
having	have	H152	VBG	B-VP	O
received	receive	R213	VBN	B-NP	O
TF	TF	T100	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
renal	renal	R540	JJ	B-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
than	than	T500	IN	B-SBAR	O
generally	generally	G564	RB	B-ADVP	O
recognized	recognize	R252	VBN	B-VP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
administration	administration	A352	NN	B-NP	O
of	of	O100	IN	B-PP	O
TF	TF	T100	NN	B-NP	O
may	may	M000	MD	B-VP	O
precipitate	precipitate	P621	VB	I-VP	O
or	or	O600	CC	I-VP	O
accelerate	accelerate	A246	VB	I-VP	O
the	the	T000	DT	B-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
cellular	cellular	C460	JJ	B-NP	O
impairments	impairment	I516	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
implication	implication	I514	NN	I-NP	O
for	for	F600	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
male	male	M400	JJ	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
affected	affect	A123	VBN	I-VP	O
with	with	W300	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
G	G	G000	NN	B-NP	O
-	-	0000	HYPH	O	O
6	6	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
PD	PD	P300	NN	I-NP	O
isoenzymes	isoenzyme	I252	NNS	I-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
marker	marker	M626	NN	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
.	.	0000	.	O	O

Isolated	Isolate	I243	VBN	B-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
types	type	T120	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
doubly	doubly	D140	RB	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
males	male	M420	NNS	I-NP	O
seemingly	seemingly	S524	RB	B-ADVP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
express	express	E216	VB	I-VP	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
PD	PD	P300	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
cis	cis	C200	NN	B-NP	O
position	position	P235	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
while	while	W400	IN	B-SBAR	O
her	her	H600	PRP$	B-NP	O
cultured	culture	C436	VBN	I-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
expressed	express	E216	VBD	B-VP	O
both	both	B300	CC	O	O
G	G	G000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
PD	PD	P300	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
histogram	histogram	H232	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
platelet	platelet	P434	NN	B-NP	O
size	size	S200	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
abnormally	abnormally	A156	RB	B-NP	O
small	small	S540	JJ	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
propositus	propositus	P612	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
appreciable	appreciable	A162	JJ	I-NP	O
small	small	S540	JJ	I-NP	O
platelet	platelet	P434	NN	I-NP	O
subpopulation	subpopulation	S143	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
culture	culture	C436	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemopoietic	hemopoietic	H513	JJ	B-NP	O
progenitor	progenitor	P625	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
progenitor	progenitor	P625	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
express	express	E216	VB	I-VP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
PD	PD	P300	NN	I-NP	O
type	type	T100	NN	I-NP	O
linked	link	L523	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
progenitors	progenitor	P625	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
among	among	A520	IN	B-PP	O
more	more	M600	JJR	B-NP	O
primitive	primitive	P653	JJ	I-NP	O
progenitors	progenitor	P625	NNS	I-NP	O
(	(	0000	(	O	O
those	those	T200	DT	B-NP	O
giving	give	G152	VBG	I-NP	O
rise	rise	R200	NN	I-NP	O
to	to	T000	TO	B-PP	O
later	later	L360	RB	B-VP	O
appearing	appear	A165	VBG	I-VP	O
colonies	colony	C452	NNS	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
selection	selection	S423	NN	B-NP	O
against	against	A252	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
takes	take	T200	VBZ	B-VP	O
place	place	P420	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemopoietic	hemopoietic	H513	JJ	I-NP	O
system	system	S235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
female	female	F540	NN	I-NP	O
and	and	A530	CC	O	O
offers	offer	O162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
means	mean	M520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
carrier	carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
women	woman	W500	NNS	I-NP	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
one	one	O500	CD	B-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
probable	probable	P614	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
PD	PD	P300	NN	I-NP	O
among	among	A520	IN	B-PP	O
three	three	T600	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
loci	locus	L200	NNS	I-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
closely	closely	C424	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
CT	CT	C300	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
in	in	I500	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
CT	CT	C300	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
call	call	C400	VBP	B-VP	O
Type	Type	T100	NN	B-NP	O
II	II	I000	CD	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
posterior	posterior	P236	JJ	B-NP	O
periventricular	periventricular	P615	JJ	I-NP	O
areas	area	A620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
attenuation	attenuation	A353	NN	I-NP	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
trigone	trigone	T625	NN	I-NP	O
on	on	O500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
contrast	contrast	C536	NN	I-NP	O
scans	scan	S252	NNS	I-NP	O
after	after	A136	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
infusion	infusion	I512	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
striking	striking	S362	JJ	B-NP	O
enhancement	enhancement	E525	NN	I-NP	O
of	of	O100	IN	B-PP	O
various	various	V620	JJ	B-NP	O
white	white	W300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
matter	matter	M360	NN	I-NP	O
structures	structure	S362	NNS	I-NP	O
(	(	0000	(	O	O
tracts	tract	T623	NNS	B-NP	O
or	or	O600	CC	O	O
fiber	fiber	F160	NN	B-NP	O
systems	system	S235	NNS	I-NP	O
)	)	0000	)	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
internal	internal	I536	JJ	I-NP	O
capsules	capsule	C124	NNS	I-NP	O
,	,	0000	,	O	O
corpus	corpus	C612	NN	B-NP	O
callosum	callosum	C425	NN	I-NP	O
,	,	0000	,	O	O
corona	corona	C650	NN	B-NP	O
radiata	radiata	R300	NN	I-NP	O
,	,	0000	,	O	O
forceps	forcep	F621	VBZ	B-VP	O
major	major	M260	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cerebral	cerebral	C616	JJ	B-NP	O
peduncles	peduncle	P352	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
numerous	numerous	N562	JJ	B-NP	O
previous	previous	P612	JJ	I-NP	O
descriptions	description	D261	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CT	CT	C300	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
in	in	I500	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

Type	Type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
other	other	O360	JJ	I-NP	O
leukoencephalopathy	leukoencephalopathy	L252	NN	I-NP	B-Disease
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADVP	O
specific	specific	S121	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
or	or	O600	CC	O	O
an	an	A500	DT	B-NP	O
evolving	evolve	E141	VBG	I-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
from	from	F650	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
Markham	Markham	M625	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
characterized	characterize	C623	VBN	I-NP	O
Salata	Salata	S430	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
widely	widely	W340	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Papua	Papua	P100	NNP	B-NP	O
New	New	N000	NNP	I-NP	O
Guinea	Guinea	G500	NNP	I-NP	O
.	.	0000	.	O	O

Th	Th	T000	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
previously	previously	P612	RB	B-NP	O
published	publish	P142	VBN	I-NP	O
studies	study	S320	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
much	much	M200	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
common	common	C500	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
cataracts	cataract	C362	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
deficient	deficient	D125	JJ	B-ADJP	B-Disease
in	in	I500	IN	B-PP	I-Disease
glucose	glucose	G420	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
RBCs	RBC	R120	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
more	more	M600	RBR	I-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
210	210	0000	CD	B-NP	O
male	male	M400	JJ	I-NP	O
cataractous	cataractous	C362	JJ	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
672	672	0000	CD	B-NP	O
control	control	C536	NN	I-NP	O
subjects	subject	S123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Sardinian	Sardinian	S635	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
was	be	W200	VBD	B-VP	O
increasingly	increasingly	I526	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
in	in	I500	IN	B-PP	O
presenile	presenile	P625	JJ	B-NP	O
cataracts	cataract	C362	NNS	I-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
group	group	G610	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
cortical	cortical	C632	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
total	total	T340	JJ	I-NP	I-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
decrease	decrease	D262	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
lens	lens	L520	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
accompanies	accompany	A251	VBZ	B-VP	O
its	its	I320	PRP$	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
erythrocyte	erythrocyte	E636	NN	I-NP	O
,	,	0000	,	O	O
might	might	M230	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cataracto	cataracto	C362	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
genesis	genesis	G520	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
added	add	A300	VBN	I-VP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
conditions	condition	C535	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
the	the	T000	DT	B-NP	O
galactosemic	galactosemic	G423	JJ	I-NP	B-Disease
states	state	S320	NNS	I-NP	O
and	and	A530	CC	O	O
riboflavin	riboflavin	R141	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
cataracts	cataract	C362	NNS	B-NP	B-Disease
represent	represent	R162	VBP	B-VP	O
a	a	A000	DT	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
indicator	indicator	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
metabolic	metabolic	M314	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RBC	RBC	R120	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
very	very	V600	RB	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
CoA	CoA	C000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
causing	cause	C252	VBG	B-VP	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
and	and	A530	CC	O	O
sudden	sudden	S350	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

beta	beta	B300	SYM	B-NP	O
-	-	0000	:	O	O
Oxidation	Oxidation	O235	NN	B-NP	O
of	of	O100	IN	B-PP	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
source	source	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
energy	energy	E562	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heart	heart	H630	NN	I-NP	O
.	.	0000	.	O	O

Defects	Defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
enzymes	enzyme	E525	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
pathway	pathway	P300	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
sudden	sudden	S350	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
unexplained	unexplained	U521	JJ	I-NP	I-Disease
death	death	D300	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
,	,	0000	,	O	O
acute	acute	A230	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	B-Disease
encephalopathy	encephalopathy	E521	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
liver	liver	L160	NN	I-NP	B-Disease
failure	failure	F460	NN	I-NP	I-Disease
,	,	0000	,	O	O
skeletal	skeletal	S243	JJ	B-NP	B-Disease
myopathy	myopathy	M130	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
.	.	0000	.	O	O

Very	Very	V600	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
[	[	0000	(	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
;	;	0000	:	O	O
very	very	V600	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
(	(	0000	(	O	O
acceptor	acceptor	A213	NN	B-NP	O
)	)	0000	)	O	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
oxidoreductase	oxidoreductase	O236	NN	I-NP	O
,	,	0000	,	O	O
EC	EC	E200	NNP	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O
99	99	0000	CD	B-NP	O
99	99	0000	CD	I-NP	O
.	.	0000	.	B-NP	O
13	13	0000	CD	I-NP	O
]	]	0000	)	O	O
catalyzes	catalyze	C342	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
oxidation	oxidation	O235	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	O	O
gene	gene	G500	NN	B-NP	O
and	and	A530	CC	O	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Polymerase	Polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
exons	exon	E252	NNS	I-NP	O
defined	define	D153	VBD	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
unexplained	unexplained	U521	JJ	B-NP	O
cardiac	cardiac	C632	JJ	I-NP	B-Disease
arrest	arrest	A623	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
consensus	consensus	C525	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
(	(	0000	(	O	O
g	g	G000	NN	B-NP	O
+	+	0000	SYM	O	O
1	1	0000	CD	O	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
a	a	A000	DT	O	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
universal	universal	U516	JJ	B-NP	O
skipping	skipping	S215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
prior	prior	P600	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
C1837	C1837	C000	NN	B-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	B-VP	O
T	T	T000	NN	B-NP	O
,	,	0000	,	O	O
changing	change	C525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
at	at	A300	IN	B-PP	O
residue	residue	R230	NN	B-NP	O
613	613	0000	CD	I-NP	O
to	to	T000	TO	B-VP	O
tryptophan	tryptophan	T613	VB	I-VP	O
on	on	O500	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
-	-	0000	HYPH	O	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
boundary	boundary	B536	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
delineation	delineation	D453	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
reduces	reduce	R320	VBZ	B-VP	O
myocardial	myocardial	M263	JJ	B-NP	O
fatty	fatty	F300	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
and	and	A530	CC	I-NP	O
energy	energy	E562	NN	I-NP	O
production	production	P632	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
and	and	A530	CC	O	O
sudden	sudden	S350	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

Aberrant	Aberrant	A165	JJ	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
220	220	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kilodalton	kilodalton	K434	NN	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
phosphoprotein	phosphoprotein	P216	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
breast	breast	B623	NN	B-NP	O
ductal	ductal	D234	JJ	I-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
18	18	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
and	and	A530	CC	I-NP	O
ovary	ovary	O160	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
17	17	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
lines	line	L520	NNS	I-NP	O
and	and	A530	CC	O	O
17	17	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
17	17	0000	CD	B-NP	O
samples	sample	S514	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
malignant	malignant	M425	JJ	B-NP	O
effusions	effusion	E125	NNS	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
localized	localize	L242	VBD	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
cytoplasm	cytoplasm	C314	NN	B-NP	O
.	.	0000	.	O	O

Absence	Absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	O	O
aberrant	aberrant	A165	JJ	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
location	location	L235	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
extent	extent	E235	NN	I-NP	O
in	in	I500	IN	B-PP	O
histological	histological	H234	JJ	B-NP	O
sections	section	S235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
many	many	M500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
biopsies	biopsy	B120	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
many	many	M500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
sporadic	sporadic	S163	JJ	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
familial	familial	F540	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mapping	Mapping	M152	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilson	Wilson	W425	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

ATP7B	ATP7B	A310	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
altered	alter	A436	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
WD	WD	W300	JJ	O	B-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
lies	lie	L200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
block	block	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
homology	homology	H542	NN	B-NP	O
shared	share	S630	VBN	B-VP	O
between	between	B350	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
13q14	13q14	Q000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATP7B	ATP7B	A310	NN	B-NP	O
(	(	0000	(	O	O
Atp7b	Atp7b	A310	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
80	80	0000	CD	B-NP	O
interspecific	interspecific	I536	JJ	I-NP	O
backcross	backcross	B262	NN	I-NP	O
offspring	offspring	O121	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-PP	O
position	position	P235	NN	B-NP	O
Atp7b	Atp7b	A310	NN	I-NP	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
D8Mit3	D8Mit3	D530	NN	B-NP	O
and	and	A530	CC	O	O
another	another	A536	DT	B-NP	O
ATPase	ATPase	A312	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
Atp4b	Atp4b	A310	NN	B-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

ATP4B	ATP4B	A310	NN	B-NP	O
lies	lie	L200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
13q34	13q34	Q000	CD	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
separated	separate	S163	VBN	I-VP	O
from	from	F650	IN	B-PP	O
ATP7B	ATP7B	A310	NN	B-NP	O
by	by	B000	IN	B-PP	O
several	several	S164	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
whose	whose	W200	WP$	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologues	homologue	H542	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
14	14	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
Atp7b	Atp7b	A310	NN	B-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
identifies	identify	I353	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
unrecognized	unrecognized	U562	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
homology	homology	H542	NN	B-NP	O
between	between	B350	IN	B-PP	O
this	this	T200	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	O	O
chromosome	chromosome	C652	NN	B-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
assignment	assignment	A253	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
location	location	L235	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
toxic	toxic	T200	JJ	I-NP	O
milk	milk	M420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
WD	WD	W300	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlation	correlation	C643	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
discovered	discover	D216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
80	80	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
lifetime	lifetime	L135	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
60	60	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
two	two	T000	CD	I-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
32	32	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
53	53	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
14	14	0000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
previously	previously	P612	RB	B-ADJP	O
unreported	unreported	U561	JJ	I-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ratio	ratio	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
incidence	incidence	I523	NN	I-NP	O
within	within	W350	IN	B-PP	O
each	each	E200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
such	such	S200	JJ	B-NP	O
that	that	T300	IN	I-NP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
third	third	T630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
previous	previous	P612	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
suggest	suggest	S230	VBP	B-VP	O
some	some	S500	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
common	common	C500	JJ	B-NP	O
ancestors	ancestor	A523	NNS	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
two	two	T000	CD	I-NP	O
examples	example	E251	NNS	I-NP	O
where	where	W600	WRB	B-ADVP	O
recurrent	recurrent	R265	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
arisen	arise	A625	VBN	I-VP	O
independently	independently	I531	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
and	and	A530	CC	O	O
recurrent	recurrent	R265	JJ	B-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
:	:	0000	:	O	O
investigations	investigation	I512	NNS	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
haemolytic	haemolytic	H543	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
for	for	F600	IN	B-PP	O
complement	complement	C514	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
C7	C7	C000	NN	B-NP	O
M	M	M000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
N	N	N000	NN	I-NP	O
allotyping	allotyping	A431	NN	I-NP	O
.	.	0000	.	O	O

Terminal	Terminal	T654	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
predisposes	predispose	P632	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
co	co	C000	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
2	2	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
recurrent	recurrent	R265	JJ	B-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
for	for	F600	IN	B-PP	O
terminal	terminal	T654	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
brothers	brother	B636	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
completely	completely	C514	RB	B-ADJP	B-Disease
deficient	deficient	D125	JJ	I-ADJP	I-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
seventh	seventh	S153	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C7	C7	C000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Enzyme	Enzyme	E525	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
linked	link	L523	VBN	B-NP	O
immunosorbent	immunosorbent	I526	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
for	for	F600	IN	B-PP	O
C7	C7	C000	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
lower	low	L600	JJR	B-ADVP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
brother	brother	B636	NN	I-NP	O
and	and	A530	CC	I-NP	O
parents	parent	P653	NNS	I-NP	O
.	.	0000	.	O	O

C7	C7	C000	NN	B-NP	O
M	M	M000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
N	N	N000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
allotyping	allotyping	A431	NN	I-NP	O
,	,	0000	,	O	O
used	use	U230	VBN	B-VP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
segregation	segregation	S262	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C7	C7	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
complement	complement	C514	JJ	I-NP	O
sufficient	sufficient	S125	JJ	I-NP	O
brother	brother	B636	NN	I-NP	O
was	be	W200	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
C7	C7	C000	NN	I-NP	B-Disease
deficient	deficient	D125	JJ	B-ADJP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
individual	individual	I531	JJ	I-NP	O
suffering	suffer	S165	VBG	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
infection	infection	I512	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
uncommon	uncommon	U525	JJ	I-NP	O
meningococcal	meningococcal	M524	JJ	I-NP	B-Disease
serogroup	serogroup	S626	NN	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
complement	complement	C514	NN	B-NP	B-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
allows	allow	A420	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
implementation	implementation	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
strategies	strategy	S363	NNS	B-NP	O
to	to	T000	TO	B-VP	O
prevent	prevent	P615	VB	I-VP	O
recurrent	recurrent	R265	JJ	B-NP	O
infection	infection	I512	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
subtotal	subtotal	S134	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
C6	C6	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	O	O
carboxy	carboxy	C612	AFX	O	O
-	-	0000	HYPH	B-VP	O
terminally	terminally	T654	RB	I-VP	O
truncated	truncate	T652	VBN	I-VP	O
but	but	B300	CC	O	O
functionally	functionally	F523	RB	B-NP	O
active	active	A231	JJ	I-NP	O
C6	C6	C000	NN	I-NP	O
.	.	0000	.	O	O

Individuals	Individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
subtotal	subtotal	S134	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
C6	C6	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
possess	possess	P200	VBP	B-VP	O
a	a	A000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
shorter	short	S636	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
and	and	A530	CC	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
low	low	L000	JJ	B-NP	O
but	but	B300	CC	I-NP	O
detectable	detectable	D323	JJ	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
mean	mean	M500	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
dysmorphic	dysmorphic	D256	JJ	I-NP	O
C6	C6	C000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
bactericidally	bactericidally	B236	RB	B-ADJP	O
active	active	A231	JJ	I-ADJP	O
and	and	A530	CC	O	O
lacks	lack	L200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
epitope	epitope	E131	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
carboxy	carboxy	C612	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
C6	C6	C000	NN	B-NP	O
using	use	U252	VBG	B-VP	O
C6	C6	C000	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
expressed	express	E216	VBN	B-VP	O
as	as	A200	IN	B-PP	O
fusion	fusion	F250	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pUEX	pUEX	P200	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
thus	thus	T200	RB	B-ADVP	O
predicted	predict	P632	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
C6	C6	C000	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
carboxy	carboxy	C612	AFX	O	O
-	-	0000	HYPH	O	O
terminally	terminally	T654	RB	B-VP	O
truncated	truncate	T652	VBN	I-VP	O
and	and	A530	CC	O	O
sought	seek	S230	VBN	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
area	area	A600	NN	I-NP	O
approximately	approximately	A162	RB	B-NP	O
14	14	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
sequencing	sequence	S252	VBG	B-VP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
might	might	M230	MD	B-VP	O
plausibly	plausibly	P421	RB	I-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
would	would	W430	MD	B-VP	O
probably	probably	P614	RB	I-VP	O
prevent	prevent	P615	VB	I-VP	O
splicing	splicing	S142	NN	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
17	17	0000	CD	B-NP	O
codons	codon	C352	NNS	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
boundary	boundary	B536	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
would	would	W430	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
smaller	small	S546	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
result	result	R243	NN	I-NP	O
was	be	W200	VBD	B-VP	O
unexpected	unexpected	U521	JJ	B-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
earlier	early	E646	JJR	B-NP	O
studies	study	S320	NNS	I-NP	O
mapped	map	M130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
C5b	C5b	C100	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
enzymatic	enzymatic	E525	JJ	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
C6	C6	C000	NN	B-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
three	three	T600	CD	I-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
probably	probably	P614	RB	B-ADVP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	B-NP	O
subtotal	subtotal	S134	JJ	I-NP	B-Disease
C6	C6	C000	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
complete	complete	C514	JJ	B-NP	I-Disease
C6	C6	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
:	:	0000	:	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
by	by	B000	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
variable	variable	V614	JJ	I-NP	O
and	and	A530	CC	I-NP	O
multisystemic	multisystemic	M432	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
understood	understand	U536	VBN	I-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
particularly	particularly	P632	RB	B-ADJP	O
difficult	difficult	D124	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
rationalize	rationalize	R354	VB	I-VP	O
the	the	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
outside	outside	O323	IN	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	O	O
encoding	encode	E523	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
elements	element	E453	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
translated	translate	T652	VBN	I-VP	O
into	into	I530	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
use	use	U200	VBP	B-VP	O
muscle	muscle	M240	NN	B-NP	O
biopsies	biopsy	B120	NNS	I-NP	O
from	from	F650	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
adult	adult	A343	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcripts	transcript	T652	NNS	B-NP	O
from	from	F650	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
expanded	expand	E215	VBN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
compare	compare	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
myopathic	myopathic	M132	JJ	I-NP	B-Disease
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
relatively	relatively	R431	RB	B-NP	O
small	small	S540	JJ	I-NP	O
decreases	decrease	D262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
total	total	T340	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
pool	pool	P400	NN	I-NP	O
from	from	F650	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
reductions	reduction	R323	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	O	O
disease	disease	D200	NN	B-NP	O
specific	specific	S121	JJ	B-ADJP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
poly	poly	P400	NN	B-NP	O
(	(	0000	(	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	I-NP	O
+	+	0000	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
dramatic	dramatic	D653	JJ	B-NP	O
decreases	decrease	D262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
and	and	A530	CC	I-NP	O
normal	normal	N654	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
RNAs	RNA	R520	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
these	these	T200	DT	B-NP	O
changes	change	C520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
disease	disease	D200	NN	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
specific	specific	S121	JJ	B-ADJP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
pathogenetic	pathogenetic	P325	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
expanded	expand	E215	VBN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
transcribed	transcribe	T652	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
RNA	RNA	R500	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
by	by	B000	IN	B-PP	O
preventing	prevent	P615	VBG	B-VP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
poly	poly	P400	NN	B-NP	O
(	(	0000	(	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	I-NP	O
+	+	0000	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
to	to	T000	TO	B-VP	O
alter	alter	A436	VB	I-VP	O
accumulation	accumulation	A254	NN	B-NP	O
of	of	O100	IN	B-PP	O
poly	poly	P400	NN	B-NP	O
(	(	0000	(	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	I-NP	O
+	+	0000	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
trans	tran	T652	NNS	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
manifested	manifest	M512	VBN	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
17q	17q	Q000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
influences	influence	I514	VBZ	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
positional	positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
methods	method	M320	NNS	I-NP	O
.	.	0000	.	O	O

Probable	Probable	P614	JJ	B-NP	O
predisposing	predispose	P632	VBG	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
of	of	O100	IN	I-NP	O
eight	eight	E230	CD	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
presumed	presume	P625	VBN	B-VP	O
to	to	T000	TO	B-VP	O
segregate	segregate	S262	VB	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
include	include	I524	VBP	B-VP	O
an	an	A500	DT	B-NP	O
11	11	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
substitution	substitution	S123	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
inferred	inferred	I516	JJ	I-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
numerous	numerous	N562	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
breast	breast	B623	NN	B-NP	O
and	and	A530	CC	I-NP	O
ovary	ovary	O160	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
1863	1863	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
otherwise	otherwise	O362	RB	B-ADJP	O
unrelated	unrelated	U564	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
previously	previously	P612	RB	B-NP	O
described	describe	D261	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
should	should	S430	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
early	early	E640	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
better	good	B360	JJR	I-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
biology	biology	B420	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
(	(	0000	(	O	O
type	type	T100	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	NNPS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
two	two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
N314D	N314D	N300	NN	B-NP	O
and	and	A530	CC	I-NP	O
R333W	R333W	R000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
previously	previously	P612	RB	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNS	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
an	an	A500	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
by	by	B000	IN	B-PP	O
histidine	histidine	H235	NN	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
231	231	0000	CD	I-NP	O
(	(	0000	(	O	O
R231H	R231H	R000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
R231H	R231H	R000	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
construct	construct	C523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
to	to	T000	TO	B-PP	O
15	15	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
COS	COS	C200	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
G	G	G000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
38th	38th	T000	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
(	(	0000	(	O	O
318A	318A	A000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
38	38	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
by	by	B000	IN	B-PP	O
activating	activate	A231	VBG	B-VP	O
a	a	A000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
alleles	allele	A420	NNS	I-NP	O
for	for	F600	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
form	form	F650	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
for	for	F600	IN	B-PP	O
Duarte	Duarte	D630	JJ	B-NP	O
variant	variant	V653	NN	I-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
R231H	R231H	R000	NN	I-NP	O
and	and	A530	CC	I-NP	O
318A	318A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
N314D	N314D	N300	NN	I-NP	O
and	and	A530	CC	I-NP	O
R333W	R333W	R000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
on	on	O500	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
each	each	E200	DT	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Q188R	Q188R	Q600	NN	I-NP	O
was	be	W200	VBD	B-VP	O
prevalent	prevalent	P614	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	State	S320	NNPS	I-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
N314D	N314D	N300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
persons	person	P625	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
United	United	U530	NNP	I-NP	O
States	State	S320	NNPS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
speculate	speculate	S124	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
classic	classic	C420	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
differ	differ	D160	VB	I-VP	O
between	between	B350	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
limited	limited	L530	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
set	set	S300	VBN	B-VP	O
on	on	O500	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
suggests	suggest	S232	NNS	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
N314D	N314D	N300	NN	I-NP	O
GALT	GALT	G430	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Duarte	Duarte	D630	NNP	I-NP	O
variant	variant	V653	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
before	before	B160	RB	B-NP	O
Asian	Asian	A250	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
people	people	P140	NNS	I-NP	O
diverged	diverge	D162	VBD	B-VP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
classic	classic	C420	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
mutations	mutation	M352	NNS	I-NP	O
arose	arise	A620	VBD	B-VP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
accumulated	accumulate	A254	VBN	B-VP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
divergence	divergence	D162	NN	I-NP	O
of	of	O100	IN	B-PP	O
Asian	Asian	A250	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Aniridia	Aniridia	A563	NNP	B-NP	B-Disease
(	(	0000	(	O	O
iris	iris	I620	NN	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
congenital	congenital	C525	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
(	(	0000	(	O	O
PAX6	PAX6	P200	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
various	various	V620	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
reported	report	R163	VBD	B-VP	O
here	here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
was	be	W200	VBD	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
C	C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
240	240	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
were	be	W600	VBD	B-VP	O
novel	novel	N140	JJ	B-ADJP	O
two	two	T000	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proline	proline	P645	NN	I-NP	O
/	/	0000	SYM	B-NP	O
serine	serine	S650	NN	I-NP	O
/	/	0000	SYM	B-NP	O
threonine	threonine	T650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
(	(	0000	(	O	O
PST	PST	P230	NN	B-NP	O
)	)	0000	)	O	O
region	region	R250	NN	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PST	PST	P230	NN	I-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
cataracts	cataract	C362	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PST	PST	P230	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
anosmia	anosmia	A525	NN	B-NP	B-Disease
(	(	0000	(	O	O
inability	inability	I514	NN	B-NP	O
to	to	T000	TO	B-VP	O
smell	smell	S540	VB	I-VP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
new	new	N000	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
reported	report	R163	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
incomplete	incomplete	I525	JJ	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
theory	theory	T600	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
human	human	H500	JJ	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
haploinsufficiency	haploinsufficiency	H145	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
PAX6	PAX6	P200	NN	B-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
approximately	approximately	A162	RB	B-NP	O
1	1	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
major	major	M260	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
,	,	0000	,	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
50	50	0000	CD	I-NP	O
unique	unique	U520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
risk	risk	R200	NN	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
female	female	F540	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
80	80	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
90	90	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
lifetime	lifetime	L135	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
stats	stat	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
unselected	unselected	U524	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
determined	determine	D365	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
known	know	K500	VBN	I-VP	O
whether	whether	W360	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
such	such	S200	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
confer	confer	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
as	as	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
risk	risk	R200	NN	I-NP	O
families	family	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
.	.	0000	.	O	O

Following	Follow	F452	VBG	B-PP	O
the	the	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
breast	breast	B623	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ovarian	ovarian	O165	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
858	858	0000	CD	B-NP	O
Ashkenazim	Ashkenazim	A252	NN	I-NP	O
seeking	seek	S252	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
for	for	F600	IN	B-PP	O
conditions	condition	C535	NNS	B-NP	O
unrelated	unrelated	U564	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
815	815	0000	CD	B-NP	O
reference	reference	R165	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
not	not	N300	RB	B-VP	O
selected	select	S423	VBN	I-VP	O
for	for	F600	IN	B-PP	O
ethnic	ethnic	E352	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
the	the	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazim	Ashkenazim	A252	NN	B-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
limit	limit	L530	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
reference	reference	R165	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
one	one	O500	CD	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
hundred	hundred	H536	CD	I-NP	O
women	woman	W500	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
descent	descent	D253	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
at	at	A300	IN	B-PP	O
especially	especially	E212	RB	B-NP	O
high	high	H200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
huntingtin	huntingtin	H535	NN	B-NP	O
in	in	I500	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
lymphoblastoid	lymphoblastoid	L514	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
with	with	W300	IN	B-PP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
antibodies	antibody	A531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
phenotype	phenotype	P531	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
IT15	IT15	I300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
348	348	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
named	name	N530	VBN	B-VP	O
huntington	huntington	H535	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
polyclonal	polyclonal	P424	JJ	B-NP	O
and	and	A530	CC	I-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
anti	anti	A530	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
antibodies	antibody	A531	NNS	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
native	native	N310	JJ	B-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
in	in	I500	IN	B-PP	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
monkey	monkey	M520	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-ADJP	O
.	.	0000	.	O	O

Western	Western	W236	JJ	B-NP	O
blots	blot	B432	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
expected	expect	E212	VBN	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
soluble	soluble	S414	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
rat	rat	R300	NN	B-NP	O
and	and	A530	CC	I-NP	O
monkey	monkey	M520	NN	I-NP	O
brain	brain	B650	NN	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
and	and	A530	CC	O	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
control	control	C536	NN	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
lymphoblastoid	lymphoblastoid	L514	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
from	from	F650	IN	B-PP	O
juvenile	juvenile	J154	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
huntingtin	huntingtin	H535	NN	I-NP	O
are	be	A600	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
increasing	increase	I526	VBG	B-VP	O
repeat	repeat	R130	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
lower	low	L600	JJR	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Immunocytochemistry	Immunocytochemistry	I523	NN	B-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
huntingtin	huntingtin	H535	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
neurons	neuron	N652	NNS	B-NP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
levels	level	L142	NNS	I-NP	O
evident	evident	E135	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
larger	large	L626	JJR	B-NP	O
neurons	neuron	N652	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
striatum	striatum	S363	NN	I-NP	O
,	,	0000	,	O	O
huntingtin	huntingtin	H535	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
enriched	enrich	E562	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patch	patch	P320	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
,	,	0000	,	O	O
potentially	potentially	P353	RB	B-VP	O
corresponding	correspond	C621	VBG	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
areas	area	A620	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

Subcellular	Subcellular	S124	JJ	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
huntingtin	huntingtin	H535	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
cytosolic	cytosolic	C324	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
primarily	primarily	P656	RB	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
somatodendritic	somatodendritic	S535	JJ	B-NP	O
regions	region	R252	NNS	I-NP	O
.	.	0000	.	O	O

Huntingtin	Huntingtin	H535	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
particularly	particularly	P632	RB	I-VP	O
associate	associate	A230	VB	I-VP	O
with	with	W300	IN	B-PP	O
microtubules	microtubule	M263	NNS	B-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
synaptic	synaptic	S513	JJ	B-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
huntingtin	huntingtin	H535	NN	B-NP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
microtubules	microtubule	M263	NNS	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
speculate	speculate	S124	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
impairs	impair	I516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cytoskeletal	cytoskeletal	C324	JJ	I-NP	O
anchoring	anchoring	A526	NN	I-NP	O
or	or	O600	CC	I-NP	O
transport	transport	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
mitochondria	mitochondrion	M325	NNS	B-NP	O
,	,	0000	,	O	O
vesicles	vesicle	V242	NNS	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
organelles	organelle	O625	NNS	I-NP	O
or	or	O600	CC	I-NP	O
molecules	molecule	M424	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Marked	Mark	M623	VBN	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
spinocerebellar	spinocerebellar	S152	JJ	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
3	3	0000	CD	I-NP	I-Disease
/	/	0000	SYM	I-NP	I-Disease
Machado	Machado	M230	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
spinocerebellar	spinocerebellar	S152	JJ	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
3	3	0000	CD	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
for	for	F600	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
autosomal	autosomal	A325	JJ	I-NP	I-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
ADCA	ADCA	A320	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
and	and	A530	CC	O	O
genetically	genetically	G532	RB	B-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
neurodegenerative	neurodegenerative	N632	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14q32	14q32	Q000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

ADCA	ADCA	A320	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
families	family	F542	NNS	B-NP	O
segregating	segregate	S262	VBG	B-VP	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
share	share	S600	NN	I-NP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
common	common	C500	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
those	those	T200	DT	B-NP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
French	French	F652	JJ	I-NP	O
ADCA	ADCA	A320	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
kindreds	kindred	K536	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
neuropathological	neuropathological	N613	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
ataxochoreic	ataxochoreic	A326	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
dentatorubropallidoluysian	dentatorubropallidoluysian	D536	JJ	B-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
carries	carry	C620	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
located	located	L230	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
as	as	A200	IN	B-PP	O
that	that	T300	DT	B-NP	O
for	for	F600	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
size	size	S200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Instability	Instability	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
triplet	triplet	T614	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
sex	sex	S200	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
transmitting	transmit	T652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
for	for	F600	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
gonadal	gonadal	G534	JJ	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
for	for	F600	IN	B-PP	O
alleles	allele	A420	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
expanded	expand	E215	VBN	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

Overexpression	Overexpression	O162	NN	B-NP	O
of	of	O100	IN	B-PP	O
DM20	DM20	D500	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
sex	sex	S200	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-ADJP	I-Disease
,	,	0000	,	O	I-Disease
dysmyelinating	dysmyelinate	D254	VBG	B-VP	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
central	central	C536	JJ	I-NP	I-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
myelin	myelin	M450	NN	I-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
25	25	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
studied	study	S300	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
exonic	exonic	E252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
underlying	underlying	U536	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
major	major	M260	JJ	I-NP	O
alternatively	alternatively	A436	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
called	call	C430	VBN	B-VP	O
PLP	PLP	P410	NN	B-NP	O
and	and	A530	CC	I-NP	O
DM20	DM20	D500	NN	I-NP	O
.	.	0000	.	O	O

PLP	PLP	P410	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
specifically	specifically	S121	RB	I-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
central	central	C536	JJ	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
tissue	tissue	T200	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
DM20	DM20	D500	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
central	central	C536	JJ	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
cardiac	cardiac	C632	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
cultured	culture	C436	VBN	I-VP	O
skin	skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
2	2	0000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
exonic	exonic	E252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PLP	PLP	P410	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Examination	Examination	E253	NN	B-NP	O
of	of	O100	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
from	from	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM20	DM20	D500	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
elevated	elevate	E413	VBN	I-VP	O
sixfold	sixfold	S214	RB	B-ADVP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
male	male	M400	JJ	B-NP	O
control	control	C536	NN	I-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
female	female	F540	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
exonic	exonic	E252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
threefold	threefold	T614	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM20	DM20	D500	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
overexpression	overexpression	O162	NN	B-NP	O
of	of	O100	IN	B-PP	O
PLP	PLP	P410	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
a	a	A000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
increase	increase	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM20	DM20	D500	NN	B-NP	O
messenger	messenger	M252	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
in	in	I500	IN	B-PP	O
females	female	F542	NNS	B-NP	O
,	,	0000	,	O	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O
,	,	0000	,	O	O
can	can	C500	MD	B-VP	O
identify	identify	I353	VB	I-VP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
congenital	congenital	C525	JJ	I-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
,	,	0000	,	O	O
small	small	S540	JJ	B-NP	O
platelets	platelet	P434	NNS	I-NP	O
,	,	0000	,	O	O
eczema	eczema	E250	NN	B-NP	B-Disease
,	,	0000	,	O	O
recurrent	recurrent	R265	JJ	B-NP	O
infections	infection	I512	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
immunodeficiency	immunodeficiency	I531	NN	B-NP	B-Disease
.	.	0000	.	O	O

Besides	Besides	B232	IN	B-PP	O
the	the	T000	DT	B-NP	O
classic	classic	C420	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
X	X	X000	NN	I-NP	I-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	I-Disease
(	(	0000	(	O	O
XLT	XLT	X430	NN	B-NP	B-Disease
)	)	0000	)	O	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
small	small	S540	JJ	B-NP	O
platelets	platelet	P434	NNS	I-NP	O
but	but	B300	CC	O	O
only	only	O540	RB	B-NP	O
transient	transient	T652	JJ	I-NP	O
eczema	eczema	E250	NN	I-NP	B-Disease
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
any	any	A500	DT	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
minimal	minimal	M540	JJ	B-NP	O
immune	immune	I500	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
correlate	correlate	C643	VB	I-VP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NNP	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
fingerprinting	fingerprinting	F526	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
technique	technique	T252	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	B-NP	O
approximate	approximate	A162	JJ	I-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
13	13	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
severe	severe	S160	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
derived	derive	D613	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
12	12	0000	CD	B-NP	O
unique	unique	U520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
distributed	distribute	D236	VBN	B-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
insertions	insertion	I526	NNS	B-NP	O
,	,	0000	,	O	O
deletions	deletion	D435	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
termination	termination	T653	NN	B-NP	O
,	,	0000	,	O	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
splicing	splicing	S142	NN	B-NP	O
defects	defect	D123	NNS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
4	4	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLT	XLT	X430	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
affecting	affect	A123	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
1	1	0000	CD	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
affecting	affect	A123	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
had	have	H300	VBD	B-VP	O
more	more	M600	RBR	B-NP	O
complex	complex	C514	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
termination	termination	T653	NN	B-NP	O
codons	codon	C352	NNS	I-NP	O
,	,	0000	,	O	O
frameshift	frameshift	F652	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
early	early	E640	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
direct	direct	D623	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
XLT	XLT	X430	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
severe	severe	S160	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
complex	complex	C514	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Myotonia	Myotonia	M350	NN	B-NP	B-Disease
levior	levior	L160	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
chloride	chloride	C463	NN	I-NP	B-Disease
channel	channel	C540	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	B-Disease
non	non	N500	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
dystrophic	dystrophic	D236	JJ	I-NP	I-Disease
myotonias	myotonia	M352	NNS	I-NP	I-Disease
,	,	0000	,	O	O
comprising	comprise	C516	VBG	B-VP	O
disorders	disorder	D263	NNS	B-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
clinically	clinically	C452	RB	B-NP	O
similar	similar	S546	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
myogenic	myogenic	M252	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
stiffness	stiffness	S315	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
inhomogeneous	inhomogeneous	I525	JJ	I-ADJP	O
.	.	0000	.	O	O

Dominant	Dominant	D530	JJ	B-NP	B-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
congenita	congenita	C525	NN	I-NP	I-Disease
(	(	0000	(	O	O
Thomsens	Thomsens	T525	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
CLCN1	CLCN1	C425	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
chloride	chloride	C463	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
,	,	0000	,	O	O
localized	localize	L242	VBN	B-VP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
7q35	7q35	Q000	CD	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
dominant	dominant	D530	JJ	B-NP	B-Disease
myotonias	myotonia	M352	NNS	I-NP	I-Disease
sensitive	sensitive	S523	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
potassium	potassium	P325	NN	B-NP	O
are	be	A600	VBP	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
SCN4A	SCN4A	S250	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q	17q	Q000	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
sodium	sodium	S350	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
or	or	O600	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
as	as	A200	IN	B-SBAR	O
yet	yet	Y300	RB	B-ADJP	O
available	available	A141	JJ	I-ADJP	O
on	on	O500	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
levior	levior	L160	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
milder	mild	M436	JJR	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
and	and	A530	CC	O	O
later	later	L360	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
Thomsens	Thomsens	T525	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	B-Disease
hypertrophy	hypertrophy	H163	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
CLCN1	CLCN1	C425	NN	I-NP	O
Gln	Gln	G450	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
552	552	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
Arg	Arg	A620	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
levior	levior	L160	NN	I-NP	I-Disease
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
Thomsens	Thomsens	T525	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
low	low	L000	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expressivity	expressivity	E216	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
Ile	Ile	I400	NNP	I-NP	O
-	-	0000	HYPH	B-NP	O
290	290	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
Met	Met	M300	NN	I-NP	O
CLCN1	CLCN1	C425	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
Thomsen	Thomsen	T525	NNP	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
family	family	F540	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
Thomsens	Thomsens	T525	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
unexpectedly	unexpectedly	U521	RB	B-ADVP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
CLCN1	CLCN1	C425	NN	I-NP	O
14	14	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
known	know	K500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
recessive	recessive	R210	JJ	B-NP	B-Disease
myotonia	myotonia	M350	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
Trp	Trp	T610	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
118	118	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
Gly	Gly	G400	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Southern	Southern	S365	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypoxanthine	hypoxanthine	H125	NN	I-NP	O
phosphoribosyltransferase	phosphoribosyltransferase	P216	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Whole	Whole	W400	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
hprt	hprt	H163	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
the	the	T000	DT	B-NP	O
integrity	integrity	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hprt	hprt	H163	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
that	that	T300	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
HPRT	HPRT	H163	NN	B-NP	B-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
causal	causal	C240	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
Lesch	Lesch	L200	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Nyhan	Nyhan	N500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
endpoints	endpoint	E531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
and	and	A530	CC	I-NP	O
third	third	T630	JJ	I-NP	O
introns	intron	I536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
probes	probe	P612	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
aided	aid	A300	VBN	B-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
RFLP	RFLP	R141	NN	I-NP	O
carried	carry	C630	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
mothers	mother	M362	NNS	I-NP	O
normal	normal	N654	JJ	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Characterisation	Characterisation	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
amelogenesis	amelogenesis	A542	NN	I-NP	I-Disease
imperfecta	imperfecta	I516	NN	I-NP	I-Disease
(	(	0000	(	O	O
AIH1	AIH1	A000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Amelogenins	Amelogenin	A542	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
an	an	A500	DT	B-NP	O
heterogenous	heterogenous	H362	JJ	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
produced	produce	P632	VBN	B-VP	O
by	by	B000	IN	B-PP	O
ameloblasts	ameloblast	A541	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enamel	enamel	E540	NN	I-NP	O
organ	organ	O625	NN	I-NP	O
during	during	D652	IN	B-PP	O
tooth	tooth	T300	DT	B-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Disturbances	Disturbance	D236	NNS	B-NP	O
of	of	O100	IN	B-PP	O
enamel	enamel	E540	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
occur	occur	O260	VBP	B-VP	O
in	in	I500	IN	B-PP	O
amelogenesis	amelogenesis	A542	NN	B-NP	B-Disease
imperfecta	imperfecta	I516	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
heterogenous	heterogenous	H362	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
characterised	characterise	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
enamel	enamel	E540	NN	I-NP	O
biomineralisation	biomineralisation	B564	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
amelogenin	amelogenin	A542	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
AMGX	AMGX	A520	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
(	(	0000	(	O	O
Xp22	Xp22	X100	NN	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
p22	p22	P000	NN	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
pathology	pathology	P342	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
amelogenesis	amelogenesis	A542	NN	I-NP	I-Disease
imperfecta	imperfecta	I516	NN	I-NP	I-Disease
(	(	0000	(	O	O
AIH1	AIH1	A000	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
exhibiting	exhibit	E213	VBG	B-VP	O
AIH1	AIH1	A000	NN	B-NP	B-Disease
and	and	A530	CC	O	O
screened	screen	S265	VBD	B-VP	O
the	the	T000	DT	B-NP	O
AMGX	AMGX	A520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
using	use	U252	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
and	and	A530	CC	O	O
single	single	S524	JJ	B-NP	O
cytosine	cytosine	C325	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
family	family	F540	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
enable	enable	E514	VB	I-VP	O
early	early	E640	JJ	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
correlation	correlation	C643	NN	B-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
an	an	A500	DT	B-NP	O
objective	objective	O123	JJ	I-NP	O
system	system	S235	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
classification	classification	C421	NN	I-NP	O
.	.	0000	.	O	O

Frequency	Frequency	F625	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
442D	442D	D000	NN	B-NP	O
:	:	0000	:	O	O
G	G	G000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
cholesteryl	cholesteryl	C423	NN	B-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
hyperalphalipoproteinemic	hyperalphalipoproteinemic	H164	JJ	B-NP	B-Disease
Japanese	Japanese	J152	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

Cholesteryl	Cholesteryl	C423	NN	B-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
CETP	CETP	C310	NN	B-NP	O
)	)	0000	)	O	O
transfers	transfer	T652	VBZ	B-VP	O
cholesteryl	cholesteryl	C423	NN	B-NP	O
ester	ester	E236	NN	I-NP	O
from	from	F650	IN	B-PP	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-VP	O
apo	apo	A100	VB	I-VP	O
B	B	B000	NN	B-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
lipoproteins	lipoprotein	L163	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hyperalphalipoproteinemia	hyperalphalipoproteinemia	H164	NN	I-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
fairly	fairly	F640	RB	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

0049	0049	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
442D	442D	D000	NN	B-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	I-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
hyperalphalipoproteinemic	hyperalphalipoproteinemic	H164	JJ	I-NP	B-Disease
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
>	>	0000	SYM	B-VP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
100	100	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
)	)	0000	)	O	O
subjects	subject	S123	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
and	and	A530	CC	I-NP	O
easy	easy	E200	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
developed	develop	D141	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
site	site	S300	NN	I-NP	O
-	-	0000	HYPH	O	O
directed	direct	D623	VBN	B-NP	O
mutagenesis	mutagenesis	M325	NN	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
117	117	0000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
hyperalphalipoproteinemic	hyperalphalipoproteinemic	H164	JJ	I-NP	B-Disease
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	O	O
cholesterol	cholesterol	C423	NN	B-NP	O
;	;	0000	:	O	O
116	116	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
7	7	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
5	5	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-VP	O
dl	dl	D400	NN	B-NP	O
,	,	0000	,	O	O
mean	mean	M500	NN	B-NP	O
+	+	0000	SYM	B-VP	O
/	/	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
S	S	S000	NN	I-NP	O
.	.	0000	.	I-NP	O
D	D	D000	NN	I-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
34	34	0000	CD	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
(	(	0000	(	O	O
29	29	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
442D	442D	D000	NN	I-NP	O
G	G	G000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

17	17	0000	CD	B-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
442D	442D	D000	NN	I-NP	O
G	G	G000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
by	by	B000	IN	B-PP	O
us	us	U200	PRP	B-NP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
hyperalphalipoproteinemia	hyperalphalipoproteinemia	H164	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
corneal	corneal	C654	JJ	B-NP	B-Disease
opacity	opacity	O123	NN	I-NP	I-Disease
and	and	A530	CC	O	O
coronary	coronary	C656	JJ	B-NP	B-Disease
heart	heart	H630	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
reported	report	R163	VBN	I-NP	O
subject	subject	S123	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
also	also	A420	RB	B-ADVP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
atherosclerotic	atherosclerotic	A362	JJ	B-NP	B-Disease
symptoms	symptom	S513	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
,	,	0000	,	O	O
CETP	CETP	C310	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
ranged	range	R523	VBD	B-VP	O
from	from	F650	IN	B-PP	O
37	37	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
to	to	T000	TO	B-PP	O
62	62	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
value	value	V400	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
transient	transient	T652	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
experiment	experiment	E216	NN	I-NP	O
previously	previously	P612	RB	B-ADVP	O
reported	report	R163	VBN	B-VP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
as	as	A200	RB	B-ADJP	O
low	low	L000	JJ	I-ADJP	O
as	as	A200	IN	B-SBAR	O
expected	expect	E212	VBN	B-VP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
ABSTRACT	ABSTRACT	A123	NN	B-NP	O
TRUNCATED	TRUNCATED	T652	VBN	B-VP	O
AT	AT	A300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	W632	NNS	I-NP	O
)	)	0000	)	O	O

Mucopolysaccharidosis	Mucopolysaccharidosis	M214	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
:	:	0000	:	O	O
common	common	C500	JJ	B-NP	O
double	double	D140	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
GALNS	GALNS	G452	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Mucopolysaccharidosis	Mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
(	(	0000	(	O	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
N	N	N000	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
sulfatase	sulfatase	S413	NN	I-NP	I-Disease
(	(	0000	(	O	O
GALNS	GALNS	G452	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
two	two	T000	CD	B-NP	O
separate	separate	S163	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nearly	nearly	N640	RB	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
some	some	S500	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
Alu	Alu	A400	NNP	B-NP	O
repetitive	repetitive	R131	JJ	I-NP	O
elements	element	E453	NNS	I-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
8	8	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
Alu	Alu	A400	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
Alu	Alu	A400	NN	I-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
involved	involve	I514	VBD	B-VP	O
illegitimate	illegitimate	I423	JJ	B-NP	O
recombinational	recombinational	R251	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
between	between	B350	IN	B-PP	O
incomplete	incomplete	I525	JJ	B-NP	O
short	short	S630	JJ	I-NP	O
direct	direct	D623	JJ	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
at	at	A300	IN	B-PP	O
deletion	deletion	D435	NN	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
rearrangement	rearrangement	R652	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
heteroallelic	heteroallelic	H364	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
documentation	documentation	D253	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
double	double	D140	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
1	1	0000	CD	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
epidemiological	epidemiological	E135	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
one	one	O500	CD	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
cloning	cloning	C452	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
allows	allow	A420	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
feasibility	feasibility	F214	NN	I-NP	O
of	of	O100	IN	B-PP	O
presymptomatic	presymptomatic	P625	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
one	one	O500	CD	B-NP	O
affected	affect	A123	VBN	B-VP	O
individual	individual	I531	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
24	24	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
SSCP	SSCP	S210	NN	B-NP	O
assays	assay	A200	NNS	I-NP	O
.	.	0000	.	O	O

Variant	Variant	V653	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
bands	band	B532	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
subcloned	subclone	S124	VBN	I-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
verify	verify	V610	VB	I-VP	O
sequence	sequence	S252	NN	B-NP	O
changes	change	C520	NNS	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
control	control	C536	NN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
proband	proband	P615	NN	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
prostate	prostate	P623	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
who	who	W000	WP	B-NP	O
developed	develop	D141	VBD	B-VP	O
intra	intra	I536	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
abdominal	abdominal	A135	JJ	I-NP	I-Disease
carcinomatosis	carcinomatosis	C625	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
after	after	A136	IN	B-PP	O
prophylactic	prophylactic	P614	JJ	B-NP	O
oophorectomy	oophorectomy	O162	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
can	can	C500	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
array	array	A600	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
development	development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
test	test	T230	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
technically	technically	T252	RB	B-ADJP	O
challenging	challenging	C452	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
not	not	N300	RB	O	O
previously	previously	P612	RB	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-ADVP	O
illustrates	illustrate	I423	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
difficulties	difficulty	D124	NNS	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
for	for	F600	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
known	know	K500	VBN	B-VP	O
to	to	T000	TO	B-VP	O
carry	carry	C600	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Natural	Natural	N364	JJ	B-NP	O
selection	selection	S423	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemi	hemi	H500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	O	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
by	by	B000	IN	B-PP	O
resistance	resistance	R235	NN	B-NP	O
to	to	T000	TO	B-PP	O
severe	severe	S160	JJ	B-NP	O
malaria	malaria	M460	NN	I-NP	B-Disease
.	.	0000	.	O	O

Glucose	Glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
enzymopathy	enzymopathy	E525	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
affects	affect	A123	VBZ	B-VP	O
over	over	O160	IN	B-NP	O
400	400	0000	CD	I-NP	O
million	million	M450	CD	I-NP	O
people	people	P140	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
geographical	geographical	G261	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
distribution	distribution	D236	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
historical	historical	H236	JJ	I-NP	O
endemicity	endemicity	E535	NN	I-NP	O
of	of	O100	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
risen	rise	R250	VBN	I-VP	O
in	in	I500	IN	B-PP	O
frequency	frequency	F625	NN	B-NP	O
through	through	T620	IN	B-PP	O
natural	natural	N364	JJ	B-NP	O
selection	selection	S423	NN	I-NP	O
by	by	B000	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
attempts	attempt	A351	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
confirm	confirm	C516	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
protective	protective	P632	JJ	B-ADJP	O
in	in	I500	IN	B-SBAR	O
case	case	C200	NN	O	O
-	-	0000	HYPH	O	O
control	control	C536	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
yielded	yield	Y430	VBN	I-VP	O
conflicting	conflict	C514	VBG	I-VP	O
results	result	R243	NNS	B-NP	O
.	.	0000	.	O	O

Hence	Hence	H520	RB	B-ADVP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
disorder	disorder	D263	NN	B-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
whether	whether	W360	IN	B-SBAR	O
both	both	B300	CC	O	O
male	male	M400	JJ	B-NP	O
hemizygotes	hemizygote	H523	NNS	I-NP	O
and	and	A530	CC	O	O
female	female	F540	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
protected	protect	P632	VBN	I-VP	O
or	or	O600	CC	O	O
,	,	0000	,	O	O
as	as	A200	RB	O	O
frequently	frequently	F625	RB	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
females	female	F542	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
how	how	H000	WRB	B-ADVP	O
much	much	M200	JJ	O	O
protection	protection	P632	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
afforded	afford	A163	VBN	I-VP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
large	large	L620	JJ	I-NP	O
case	case	C200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
control	control	C536	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
African	African	A162	JJ	I-NP	O
children	child	C436	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
-	-	0000	SYM	B-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
46	46	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
58	58	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
malaria	malaria	M460	NN	I-NP	B-Disease
for	for	F600	IN	B-PP	O
both	both	B300	DT	B-NP	O
female	female	F540	JJ	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
and	and	A530	CC	O	O
male	male	M400	JJ	B-NP	O
hemizygotes	hemizygote	H523	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mathematical	mathematical	M353	JJ	I-NP	O
model	model	M340	NN	I-NP	O
incorporating	incorporate	I526	VBG	B-VP	O
the	the	T000	DT	B-NP	O
measured	measure	M263	VBN	I-NP	O
selective	selective	S423	JJ	I-NP	O
advantage	advantage	A315	NN	I-NP	O
against	against	A252	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
counterbalancing	counterbalance	C536	VBG	I-NP	O
selective	selective	S423	JJ	I-NP	O
disadvantage	disadvantage	D231	NN	I-NP	O
,	,	0000	,	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
retarded	retard	R363	VBN	I-VP	O
its	its	I320	PRP$	B-NP	O
rise	rise	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
frequency	frequency	F625	NN	B-NP	O
in	in	I500	IN	B-PP	O
malaria	malaria	M460	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	O
endemic	endemic	E535	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
now	now	N000	RB	I-VP	O
regarded	regard	R263	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
generally	generally	G564	RB	I-NP	O
benign	benign	B525	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
earlier	early	E646	JJR	B-NP	O
environmental	environmental	E516	JJ	I-NP	O
conditions	condition	C535	NNS	I-NP	O
it	it	I300	PRP	B-NP	O
could	could	C430	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
significantly	significantly	S251	RB	B-ADJP	O
disadvantageous	disadvantageous	D231	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
alveolar	alveolar	A414	JJ	I-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
PAX3	PAX3	P200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activator	activator	A231	NN	I-NP	O
.	.	0000	.	O	O

Chimeric	Chimeric	C562	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
factors	factor	F236	NNS	I-NP	O
,	,	0000	,	O	O
created	create	C630	VBN	B-VP	O
by	by	B000	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
fusions	fusion	F252	NNS	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
translocations	translocation	T652	NNS	I-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
pathologically	pathologically	P342	RB	I-NP	O
disparate	disparate	D216	JJ	I-NP	O
solid	solid	S430	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
/	/	0000	SYM	B-VP	O
FKHR	FKHR	F260	NN	B-NP	O
fusion	fusion	F250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
formed	form	F653	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
;	;	0000	:	O	O
13	13	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q35	q35	Q000	NN	B-NP	O
;	;	0000	:	O	O
q14	q14	Q000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
alveolar	alveolar	A414	JJ	B-NP	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	R135	NN	I-NP	I-Disease
,	,	0000	,	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hybrid	hybrid	H163	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
both	both	B300	CC	O	O
PAX3	PAX3	P200	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
box	box	B200	NN	I-NP	O
and	and	A530	CC	I-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
,	,	0000	,	O	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
bisected	bisect	B230	VBN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
FKHR	FKHR	F260	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
forkhead	forkhead	F623	NN	I-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
factors	factor	F236	NNS	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
PAX3	PAX3	P200	NN	B-NP	O
and	and	A530	CC	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
/	/	0000	SYM	O	O
FKHR	FKHR	F260	NN	B-NP	O
display	display	D214	NN	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
identical	identical	I353	JJ	B-NP	O
transactivation	transactivation	T652	NN	I-NP	O
activities	activity	A231	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
tested	test	T230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
model	model	M340	NN	B-NP	O
Pax	Pax	P200	NN	I-NP	O
recognition	recognition	R253	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
role	role	R400	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
ascribed	ascribe	A261	VBN	I-VP	O
solely	solely	S400	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
FKHR	FKHR	F260	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
FKHR	FKHR	F260	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
contribute	contribute	C536	VB	I-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
carboxyl	carboxyl	C612	NN	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
activation	activation	A231	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
replacing	replace	R142	VBG	B-VP	O
the	the	T000	DT	B-NP	O
one	one	O500	CD	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unrearranged	unrearranged	U565	JJ	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
native	native	N310	JJ	I-NP	O
PAX3	PAX3	P200	NN	I-NP	O
/	/	0000	SYM	B-VP	O
FKHR	FKHR	F260	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
translocation	translocation	T652	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
in	in	I500	FW	I-NP	O
vitro	vitro	V360	FW	I-NP	O
expressed	express	E216	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX3	PAX3	P200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
FKHR	FKHR	F260	NN	I-NP	O
hybrid	hybrid	H163	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
to	to	T000	TO	B-VP	O
bind	bind	B530	VB	I-VP	O
DNA	DNA	D500	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
specific	specific	S121	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
transactivate	transactivate	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
artificial	artificial	A631	JJ	B-NP	O
reporter	reporter	R163	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
its	its	I320	PRP$	B-NP	O
aberrant	aberrant	A165	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
could	could	C430	MD	B-VP	O
subvert	subvert	S163	VB	I-VP	O
the	the	T000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
programs	program	P626	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
normally	normally	N654	RB	B-ADVP	O
control	control	C536	VBP	B-VP	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
,	,	0000	,	O	O
differentiation	differentiation	D165	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
survival	survival	S614	NN	B-NP	O
of	of	O100	IN	B-PP	O
primitive	primitive	P653	JJ	B-NP	O
myogenic	myogenic	M252	JJ	I-NP	O
precursors	precursor	P626	NNS	I-NP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
p16INK4a	p16INK4a	P520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
insensitive	insensitive	I525	JJ	I-NP	O
CDK4	CDK4	C320	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
targeted	target	T623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
cytolytic	cytolytic	C343	JJ	B-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
cyclin	cyclin	C245	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
kinase	kinase	K520	NN	I-NP	O
4	4	0000	CD	I-NP	O
(	(	0000	(	O	O
CDK4	CDK4	C320	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
antigen	antigen	A532	NN	I-NP	O
recognized	recognize	R252	VBN	B-VP	O
by	by	B000	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A2	A2	A000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
restricted	restricted	R236	JJ	I-NP	O
autologous	autologous	A342	JJ	I-NP	O
cytolytic	cytolytic	C343	JJ	I-NP	O
T	T	T000	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
(	(	0000	(	O	O
CTLs	CTL	C342	NNS	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
CDK4	CDK4	C320	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
autologous	autologous	A342	JJ	B-NP	O
cultured	culture	C436	VBN	I-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	O	O
metastasis	metastasis	M323	NN	B-NP	O
tissue	tissue	T200	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
cysteine	cysteine	C235	NN	I-NP	O
exchange	exchange	E252	NN	I-NP	O
at	at	A300	IN	B-PP	O
residue	residue	R230	NN	B-NP	O
24	24	0000	CD	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CDK4	CDK4	C320	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
recognized	recognize	R252	VBN	B-VP	O
by	by	B000	IN	B-PP	O
CTLs	CTL	C342	NNS	B-NP	O
and	and	A530	CC	O	O
prevented	prevent	P615	VBD	B-VP	O
binding	binding	B535	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CDK4	CDK4	C320	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
p16INK4a	p16INK4a	P520	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-PP	O
of	of	O100	IN	I-PP	O
p21	p21	P000	NN	B-NP	O
or	or	O600	CC	B-PP	O
of	of	O100	IN	B-PP	O
p27KIP1	p27KIP1	P210	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
among	among	A520	IN	B-PP	O
28	28	0000	CD	B-NP	O
melanomas	melanoma	M452	NNS	I-NP	B-Disease
analyzed	analyze	A542	VBN	B-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
CDK4	CDK4	C320	NN	B-NP	O
can	can	C500	MD	B-VP	O
create	create	C630	VB	I-VP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
antigen	antigen	A532	NN	I-NP	O
and	and	A530	CC	O	O
can	can	C500	MD	B-VP	O
disrupt	disrupt	D261	VB	I-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
regulation	regulation	R243	NN	I-NP	O
exerted	exert	E263	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
p16INK4a	p16INK4a	P520	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Rapid	Rapid	R130	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
.	.	0000	.	O	O

More	More	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
75	75	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
truncated	truncate	T652	VBN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
(	(	0000	(	O	O
PTT	PTT	P300	NN	B-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
61	61	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
45	45	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
six	six	S200	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
two	two	T000	CD	B-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
insertions	insertion	I526	NNS	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
small	small	S540	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
identified	identify	I353	VBD	B-VP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
amplify	amplify	A514	VB	I-VP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
by	by	B000	IN	B-PP	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	O	O
PCR	PCR	P260	NN	B-NP	O
using	use	U252	VBG	B-VP	O
lymphocyte	lymphocyte	L512	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-VP	O
with	with	W300	IN	B-PP	O
PTT	PTT	P300	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
aberrantly	aberrantly	A165	RB	B-NP	O
spliced	splice	S142	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
affecting	affect	A123	VBG	B-VP	O
exons	exon	E252	NNS	B-NP	O
5	5	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
6	6	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
families	family	F542	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
promises	promise	P652	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
become	become	B250	VB	I-VP	O
a	a	A000	DT	B-NP	O
valuable	valuable	V414	JJ	I-NP	O
technique	technique	T252	NN	I-NP	O
in	in	I500	IN	B-PP	O
detecting	detect	D323	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
overlapping	overlap	O164	VBG	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
991	991	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
and	and	A530	CC	O	O
736	736	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
precursor	precursor	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
mitochondrial	mitochondrial	M325	JJ	I-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
sequenced	sequence	S252	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
inserts	insert	I526	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
clones	clone	C452	NNS	I-NP	O
together	together	T236	RB	B-ADVP	O
encompass	encompass	E525	VBP	B-VP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
177	177	0000	CD	B-NP	O
bases	base	B200	NNS	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
655	655	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
leader	leader	L360	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
615	615	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
mature	mature	M360	JJ	I-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
.	.	0000	.	O	O

PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-PP	O
amplified	amplify	A514	VBN	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
105	105	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
bases	base	B200	NNS	B-NP	O
1078	1078	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1182	1182	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
seems	seem	S520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
exon	exon	E250	NN	B-NP	O
skipping	skipping	S215	NN	I-NP	O
during	during	D652	IN	B-PP	O
processing	processing	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
pre	pre	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mRNA	mRNA	M650	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
demonstration	demonstration	D523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Quantitative	Quantitative	Q531	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
vaccinia	vaccinia	V250	NN	B-NP	O
viral	viral	V640	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
normal	normal	N654	JJ	I-NP	I-Disease
VLCAD	VLCAD	V423	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
causes	cause	C200	VBZ	B-VP	O
impaired	impaired	I516	JJ	B-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
oxidation	oxidation	O235	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
raising	raise	R252	VBG	B-VP	O
VLCAD	VLCAD	V423	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
to	to	T000	TO	B-PP	O
approximately	approximately	A162	RB	B-NP	O
20	20	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
control	control	C536	NN	I-NP	O
fibroblast	fibroblast	F161	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
raised	raise	R230	VBD	B-VP	O
palmitic	palmitic	P453	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
oxidation	oxidation	O235	NN	I-NP	O
flux	flux	F420	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
control	control	C536	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
offer	offer	O160	VB	I-VP	O
important	important	I516	JJ	B-NP	O
information	information	I516	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
rational	rational	R354	JJ	I-NP	O
design	design	D250	NN	I-NP	O
of	of	O100	IN	B-PP	O
future	future	F360	JJ	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
for	for	F600	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Brain	Brain	B650	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19	19	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Expansion	Expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
severity	severity	S163	NN	B-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
extensive	extensive	E235	JJ	B-NP	O
cognitive	cognitive	C253	JJ	I-NP	O
testing	testing	T235	NN	I-NP	O
,	,	0000	,	O	O
cerebral	cerebral	C616	JJ	B-NP	O
magnetic	magnetic	M253	JJ	I-NP	O
resonance	resonance	R252	NN	I-NP	O
imaging	imaging	I525	NN	I-NP	O
(	(	0000	(	O	O
MRI	MRI	M600	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
28	28	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
and	and	A530	CC	I-NP	O
brain	brain	B650	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Performance	Performance	P616	NN	B-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cognitive	cognitive	C253	JJ	I-NP	O
tests	test	T232	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
pathological	pathological	P342	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Fourteen	Fourteen	F635	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
subcortical	subcortical	S126	JJ	B-NP	O
white	white	W300	JJ	I-NP	B-Disease
matter	matter	M360	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
on	on	O500	IN	B-PP	O
MRI	MRI	M600	NN	B-NP	O
,	,	0000	,	O	O
14	14	0000	CD	B-NP	O
had	have	H300	VBD	B-VP	O
cerebral	cerebral	C616	JJ	B-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
.	.	0000	.	O	O

Amplification	Amplification	A514	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
with	with	W300	IN	B-PP	O
cognitive	cognitive	C253	JJ	B-NP	O
test	test	T230	NN	I-NP	O
deficits	deficit	D123	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
exceeding	exceed	E235	VBG	B-VP	O
a	a	A000	DT	B-NP	O
length	length	L523	NN	I-NP	O
of	of	O100	IN	B-PP	O
over	over	O160	IN	B-NP	O
1000	1000	0000	CD	I-NP	O
trinucleotides	trinucleotide	T652	NNS	I-NP	O
.	.	0000	.	O	O

MRI	MRI	M600	NN	B-NP	O
lesions	lesion	L252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
impaired	impaired	I516	JJ	B-NP	O
psychometric	psychometric	P253	JJ	I-NP	O
performance	performance	P616	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
MRI	MRI	M600	NN	B-NP	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
only	only	O540	RB	B-ADVP	O
weakly	weakly	W240	RB	B-ADJP	O
related	relate	R430	VBN	I-ADJP	O
.	.	0000	.	O	O

Disease	Disease	D200	NN	B-NP	O
duration	duration	D635	NN	I-NP	O
influenced	influence	I514	VBD	B-VP	O
the	the	T000	DT	B-NP	O
appearance	appearance	A165	NN	I-NP	O
and	and	A530	CC	I-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
white	white	W300	JJ	B-NP	B-Disease
matter	matter	M360	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
on	on	O500	IN	B-PP	O
MRI	MRI	M600	NN	B-NP	O
.	.	0000	.	O	O

Quantification	Quantification	Q531	NN	B-NP	O
of	of	O100	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
size	size	S200	NN	I-NP	O
may	may	M000	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
estimate	estimate	E235	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
brain	brain	B650	NN	B-NP	O
involvement	involvement	I514	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
;	;	0000	:	O	O
cognitive	cognitive	C253	JJ	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
white	white	W300	JJ	B-NP	B-Disease
matter	matter	M360	NN	I-NP	I-Disease
lesions	lesion	L252	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
cerebral	cerebral	C616	JJ	B-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
later	later	L360	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
course	course	C620	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	O	O
coding	cod	C352	VBG	B-VP	O
sequence	sequence	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
by	by	B000	IN	B-PP	O
reverse	reverse	R162	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
transcription	transcription	T652	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
,	,	0000	,	O	O
SSCP	SSCP	S210	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
female	female	F540	JJ	I-NP	O
relatives	relative	R431	NNS	I-NP	O
;	;	0000	:	O	O
these	these	T200	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expressions	expression	E216	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
cerebral	cerebral	C616	JJ	B-NP	O
childhood	childhood	C430	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
,	,	0000	,	O	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
"	"	0000	``	O	O
Addison	Addison	A325	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
only	only	O540	RB	B-ADVP	I-Disease
"	"	0000	''	O	O
(	(	0000	(	O	O
ADO	ADO	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
phenotype	phenotype	P531	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
exhibiting	exhibit	E213	VBG	B-VP	O
the	the	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
picture	picture	P236	NN	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
childhood	childhood	C430	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
a	a	A000	DT	B-NP	O
38	38	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
that	that	T300	WDT	B-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATP	ATP	A310	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
AMN	AMN	A500	NN	B-NP	B-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
212	212	0000	CD	I-NP	O
,	,	0000	,	O	O
along	along	A452	IN	B-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
178	178	0000	CD	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
ADO	ADO	A300	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
position	position	P235	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALDP	ALDP	A431	NN	I-NP	O
/	/	0000	SYM	B-NP	O
PMP70	PMP70	P510	NN	I-NP	O
comparison	comparison	C516	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disruptive	disruptive	D261	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	O	O
e	e	E000	NN	B-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
biochemically	biochemically	B252	RB	B-NP	O
proved	prove	P613	VBN	I-NP	O
childhood	childhood	C430	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
further	further	F636	RB	B-ADVP	O
strongly	strongly	S365	RB	B-VP	O
supports	support	S163	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
play	play	P400	VBP	B-VP	O
a	a	A000	DT	B-NP	O
crucial	crucial	C624	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
current	current	C653	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
techniques	technique	T252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
carrier	carrier	C600	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
families	family	F542	NNS	I-NP	O
lack	lack	L200	VBP	B-VP	O
sufficient	sufficient	S125	JJ	B-NP	O
reliability	reliability	R414	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
procedure	procedure	P623	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
for	for	F600	IN	B-PP	O
systematic	systematic	S235	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
scanning	scanning	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
improving	improve	I516	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
and	and	A530	CC	O	O
prenatal	prenatal	P653	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O

Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	O	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
an	an	A500	DT	B-NP	O
intrafamilial	intrafamilial	I536	JJ	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
responsible	responsible	R215	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
mildly	mildly	M434	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
mother	mother	M360	NN	I-NP	O
(	(	0000	(	O	O
160	160	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
;	;	0000	:	O	O
normal	normal	N654	JJ	B-NP	O
27	27	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
her	her	H600	PRP	B-NP	O
more	more	M600	RBR	B-VP	O
severely	severely	S164	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
son	son	S500	NN	B-NP	O
(	(	0000	(	O	O
650	650	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
his	his	H200	PRP$	B-NP	O
sister	sister	S236	NN	I-NP	O
(	(	0000	(	O	O
650	650	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
propositus	propositus	P612	NN	I-NP	O
was	be	W200	VBD	B-VP	O
an	an	A500	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
still	still	S340	RB	B-ADVP	O
ambulatory	ambulatory	A514	JJ	B-ADJP	O
post	post	P230	IN	B-PP	O
age	age	A200	NN	B-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
could	could	C430	MD	B-VP	O
interfere	interfere	I536	VB	I-VP	O
to	to	T000	TO	B-PP	O
some	some	S500	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
progression	progression	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
other	other	O360	JJ	B-NP	O
interpretations	interpretation	I536	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
revertant	revertant	R163	NN	I-NP	O
fibers	fiber	F162	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
observed	observe	O126	VBN	B-VP	O
by	by	B000	IN	B-PP	O
immunohistochemistry	immunohistochemistry	I523	NN	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
ameliorate	ameliorate	A546	VB	I-VP	O
typical	typical	T124	JJ	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
clinical	clinical	C452	JJ	I-NP	O
severity	severity	S163	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
may	may	M000	MD	B-VP	O
present	present	P625	VB	I-VP	O
a	a	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mosaic	mosaic	M200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pathophysiological	pathophysiological	P312	JJ	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
unlinked	unlinked	U545	JJ	I-NP	O
disorders	disorder	D263	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
discussed	discuss	D230	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
histopathological	histopathological	H231	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Age	Age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
indicator	indicator	I532	NN	I-NP	O
of	of	O100	IN	B-PP	O
eligibility	eligibility	E421	NN	B-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
testing	testing	T235	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
searched	search	S623	VBD	B-VP	O
for	for	F600	IN	B-PP	O
criteria	criterion	C636	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
could	could	C430	MD	B-VP	O
indicate	indicate	I532	VB	I-VP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prior	prior	P600	JJ	I-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
being	be	B520	VBG	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17	17	0000	CD	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
end	end	E530	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
study	study	S300	NN	I-NP	O
with	with	W300	IN	B-PP	O
59	59	0000	CD	B-NP	O
consecutively	consecutively	C523	RB	I-NP	O
collected	collect	C423	VBN	I-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
16	16	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
an	an	A500	DT	B-NP	O
intake	intake	I532	NN	I-NP	O
cut	cut	C300	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
off	off	O100	RP	B-PRT	O
of	of	O100	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
any	any	A500	DT	B-NP	O
age	age	A200	NN	I-NP	O
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
13	13	0000	CD	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
mean	mean	M500	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
of	of	O100	IN	B-PP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
45	45	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
unexpectedly	unexpectedly	U521	RB	I-NP	O
low	low	L000	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Given	Give	G150	VBN	B-PP	O
the	the	T000	DT	B-NP	O
expected	expect	E212	VBN	I-NP	O
logistical	logistical	L232	JJ	I-NP	O
problems	problem	P614	NNS	I-NP	O
in	in	I500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
management	management	M525	NN	I-NP	O
now	now	N000	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
an	an	A500	DT	B-NP	O
interim	interim	I536	JJ	I-NP	O
period	period	P630	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
only	only	O540	RB	B-ADVP	O
families	family	F542	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
positive	positive	P231	JJ	I-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
for	for	F600	IN	B-PP	O
early	early	E640	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
offered	offer	O163	VBN	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
testing	testing	T235	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
26	26	0000	CD	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
26	26	0000	CD	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
markers	marker	M626	NNS	B-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
15	15	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contain	contain	C535	VBP	B-VP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
94	94	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
recombinant	recombinant	R251	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
placement	placement	P425	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
telomeric	telomeric	T456	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
D17S776	D17S776	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
helps	help	H412	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
assignment	assignment	A253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	O
interest	interest	I536	NN	B-NP	O
that	that	T300	WDT	B-NP	O
appeared	appear	A163	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
families	family	F542	NNS	I-NP	O
included	include	I524	VBD	B-VP	O
primary	primary	P656	JJ	B-NP	B-Disease
peritoneal	peritoneal	P635	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
cancer	cancer	C526	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fallopian	fallopian	F415	JJ	I-NP	I-Disease
tube	tube	T100	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Structural	Structural	S362	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
conservation	conservation	C526	NN	B-NP	O
of	of	O100	IN	B-PP	O
putative	putative	P310	JJ	B-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
di	di	D000	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
previously	previously	P612	RB	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
characterized	characterize	C623	VBN	B-VP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
conserved	conserve	C526	VBN	B-NP	O
synteny	synteny	S535	NN	I-NP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
4p16	4p16	P000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
promoter	promoter	P653	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	NN	I-NP	O
(	(	0000	(	O	O
Hdh	Hdh	H300	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
genes	gene	G520	NNS	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
five	five	F100	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
share	share	S600	VBP	B-VP	O
identical	identical	I353	JJ	B-NP	O
exon	exon	E250	NN	I-NP	O
boundaries	boundary	B536	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
have	have	H100	VBP	B-VP	O
different	different	D165	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
size	size	S200	NN	I-NP	O
introns	intron	I536	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
(	(	0000	(	O	O
CT	CT	C300	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
intronic	intronic	I536	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
Hdh	Hdh	H300	NN	B-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
CA	CA	C000	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
940	940	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
5	5	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
translation	translation	T652	NN	I-NP	O
start	start	S363	NN	I-NP	O
site	site	S300	NN	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
78	78	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
)	)	0000	)	O	O
between	between	B350	IN	B-PP	O
Hdh	Hdh	H300	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
-	-	0000	HYPH	B-ADVP	O
56	56	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
-	-	0000	SYM	B-NP	O
206	206	0000	CD	I-NP	O
(	(	0000	(	O	O
of	of	O100	IN	B-PP	O
Hdh	Hdh	H300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Neither	Neither	N360	CC	O	O
Hdh	Hdh	H300	NN	B-NP	O
nor	nor	N600	CC	O	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
typical	typical	T124	JJ	B-NP	O
TATA	TATA	T300	NN	I-NP	O
or	or	O600	CC	I-NP	O
CCAAT	CCAAT	C230	NN	I-NP	O
elements	element	E453	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
both	both	B300	DT	B-NP	O
show	show	S000	VBP	B-VP	O
one	one	O500	CD	B-NP	O
putative	putative	P310	JJ	I-NP	O
AP2	AP2	A100	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
site	site	S300	NN	I-NP	O
and	and	A530	CC	O	O
numerous	numerous	N562	JJ	B-NP	O
potential	potential	P353	JJ	I-NP	O
Sp1	Sp1	S100	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
between	between	B350	IN	B-PP	O
Hdh	Hdh	H300	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
200	200	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
5	5	0000	CD	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
translation	translation	T652	NN	I-NP	O
start	start	S363	NN	I-NP	O
site	site	S300	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
regulating	regulate	R243	VBG	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bisphosphate	bisphosphate	B212	NN	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
.	.	0000	.	O	O

Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
also	also	A420	RB	B-VP	O
known	know	K500	VBN	I-VP	O
as	as	A200	IN	B-PP	O
oculocerebrorenal	oculocerebrorenal	O242	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
encoded	encode	E523	VBN	B-NP	O
OCRL	OCRL	O264	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
OCRL	OCRL	O264	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
51	51	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
inositol	inositol	I523	NN	B-NP	O
polyphosphate	polyphosphate	P412	NN	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
II	II	I000	CD	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
platelets	platelet	P434	NNS	I-NP	O
over	over	O160	IN	B-PP	O
a	a	A000	DT	B-NP	O
span	span	S150	NN	I-NP	O
of	of	O100	IN	B-PP	O
744	744	0000	CD	B-NP	O
aa	aa	A000	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
OCRL	OCRL	O264	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
engineered	engineer	E525	VBD	B-VP	O
a	a	A000	DT	B-NP	O
construct	construct	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
OCRL	OCRL	O264	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
amino	amino	A500	JJ	B-NP	O
acids	acid	A232	NNS	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
platelet	platelet	P434	NN	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
for	for	F600	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
in	in	I500	IN	B-PP	O
baculovirus	baculovirus	B241	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
infected	infect	I512	VBN	I-NP	O
Sf9	Sf9	S100	NN	I-NP	O
insect	insect	I523	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
aa	aa	A000	SYM	B-NP	O
264	264	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
968	968	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
OCRL	OCRL	O264	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
catalyze	catalyze	C342	VB	I-VP	O
the	the	T000	DT	B-NP	O
reactions	reaction	R235	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
carried	carry	C630	VBD	B-VP	O
out	out	O300	RP	B-PRT	O
by	by	B000	IN	B-PP	O
platelet	platelet	P434	NN	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	B-NP	O
II	II	I000	CD	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-NP	O
OCRL	OCRL	O264	NN	I-NP	O
converts	convert	C516	VBZ	B-VP	O
inositol	inositol	I523	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
trisphosphate	trisphosphate	T621	NN	I-NP	O
to	to	T000	TO	B-PP	O
inositol	inositol	I523	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bisphosphate	bisphosphate	B212	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
it	it	I300	PRP	B-NP	O
converts	convert	C516	VBZ	B-VP	O
inositol	inositol	I523	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
tetrakisphosphate	tetrakisphosphate	T362	NN	I-NP	O
to	to	T000	TO	B-PP	O
inositol	inositol	I523	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
trisphosphate	trisphosphate	T621	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-ADJP	O
important	important	I516	JJ	I-ADJP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
converts	convert	C516	VBZ	B-VP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bisphosphate	bisphosphate	B212	NN	I-NP	O
to	to	T000	TO	B-PP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	O
to	to	T000	TO	B-VP	O
catalyze	catalyze	C342	VB	I-VP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
II	II	I000	CD	I-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
isoenzyme	isoenzyme	I252	NN	I-NP	O
from	from	F650	IN	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
,	,	0000	,	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
phosphatase	phosphatase	P213	NN	B-NP	O
I	I	I000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
OCRL	OCRL	O264	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
hydrolyzes	hydrolyze	H364	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
phospholipid	phospholipid	P214	NN	I-NP	O
substrate	substrate	S123	NN	I-NP	O
10	10	0000	CD	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
30	30	0000	CD	B-NP	O
-	-	0000	HYPH	B-ADJP	O
fold	fold	F430	RB	I-ADJP	O
better	good	B360	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
II	II	I000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
I	I	I000	CD	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
cleave	cleave	C410	VB	I-VP	O
the	the	T000	DT	B-NP	O
lipid	lipid	L130	NN	I-NP	O
at	at	A300	IN	B-ADVP	O
all	all	A400	DT	I-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
OCRL	OCRL	O264	NN	B-NP	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
phosphatidylinositol	phosphatidylinositol	P213	NN	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bisphosphate	bisphosphate	B212	NN	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
in	in	I500	IN	B-PP	O
OCRL	OCRL	O264	NN	B-NP	O
-	-	0000	HYPH	O	O
expressing	express	E216	VBG	B-VP	O
Sf9	Sf9	S100	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
OCRL	OCRL	O264	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
mainly	mainly	M540	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
lipid	lipid	L130	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
control	control	C536	VB	I-VP	O
cellular	cellular	C460	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
metabolite	metabolite	M314	NN	I-NP	O
,	,	0000	,	O	O
phosphatidylinositol	phosphatidylinositol	P213	NN	B-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bisphosphate	bisphosphate	B212	NN	I-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
apparently	apparently	A165	RB	B-ADVP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
protean	protean	P635	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Lowe	Lowe	L000	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

New	New	N000	JJ	B-NP	O
founder	founder	F536	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
southern	southern	S365	JJ	B-NP	O
Africa	Africa	A162	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
nearby	nearby	N610	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonin	myotonin	M350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Alu	Alu	A400	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
/	/	0000	SYM	B-VP	O
deletion	deletion	D435	NN	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DMK	DMK	D520	NN	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
G	G	G000	NN	B-NP	O
/	/	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
)	)	0000	)	O	O
intron	intron	I536	NN	B-NP	O
9	9	0000	CD	I-NP	O
/	/	0000	SYM	I-NP	O
HinfI	HinfI	H510	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
in	in	I500	IN	B-PP	O
South	South	S300	JJ	B-NP	O
African	African	A162	JJ	I-NP	O
Negroids	Negroid	N263	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

South	South	S300	JJ	B-NP	O
African	African	A162	JJ	I-NP	O
Negroids	Negroid	N263	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
distribution	distribution	D236	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
different	different	D165	JJ	I-ADJP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
Caucasoids	Caucasoid	C232	NNS	B-NP	O
and	and	A530	CC	O	O
Japanese	Japanese	J152	VB	B-VP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
>	>	0000	SYM	B-NP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
19	19	0000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
very	very	V600	RB	B-ADJP	O
rare	rare	R600	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
striking	striking	S362	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
between	between	B350	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Alu	Alu	A400	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
Alu	Alu	A400	NN	B-NP	O
(	(	0000	(	O	O
ins	in	I520	NNS	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Alu	Alu	A400	NN	B-NP	O
(	(	0000	(	O	O
del	del	D400	NN	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
HinfI	HinfI	H510	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
HinfI	HinfI	H510	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
HinfI	HinfI	H510	NN	I-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Caucasoid	Caucasoid	C230	NNP	B-NP	O
(	(	0000	(	O	O
Europeans	European	E615	NNPS	B-NP	O
and	and	A530	CC	I-NP	O
Canadians	Canadian	C535	NNPS	I-NP	O
)	)	0000	)	O	O
populations	population	P143	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
South	South	S300	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
Negroid	Negroid	N263	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Numerous	Numerous	N562	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
not	not	N300	RB	B-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Europeans	European	E615	NNPS	B-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
thus	thus	T200	RB	B-ADVP	O
seems	seem	S520	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
only	only	O540	RB	B-NP	O
a	a	A000	DT	I-NP	O
small	small	S540	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
"	"	0000	``	I-NP	O
African	African	A162	JJ	I-NP	O
"	"	0000	''	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
progenitors	progenitor	P625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
African	African	A162	JJ	I-NP	O
peoples	people	P142	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
support	support	S163	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
"	"	0000	''	O	O
out	out	O300	IN	B-PP	O
of	of	O100	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
"	"	0000	``	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
modern	modern	M365	JJ	B-NP	O
humans	human	H520	NNS	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
event	event	E153	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
occurred	occur	O263	VBD	I-VP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
migration	migration	M263	NN	I-NP	O
from	from	F650	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
,	,	0000	,	O	O
hence	hence	H520	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
sub	sub	S100	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Saharan	Saharan	S650	NNP	I-NP	O
Negroid	Negroid	N263	NNP	I-NP	O
peoples	people	P142	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Discordant	Discordant	D263	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
relatives	relative	R431	NNS	I-NP	O
showing	show	S520	VBG	B-VP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
>	>	0000	SYM	O	O
700	700	0000	CD	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
family	family	F540	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
discordant	discordant	D263	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
children	child	C436	NNS	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
sisters	sister	S236	NNS	I-NP	O
with	with	W300	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
CTG	CTG	C320	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
and	and	A530	CC	O	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
congenital	congenital	C525	JJ	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
early	early	E640	JJ	B-NP	O
severe	severe	S160	JJ	I-NP	O
childhood	childhood	C430	NN	I-NP	O
and	and	A530	CC	O	O
later	later	L360	JJ	B-NP	O
childhood	childhood	C430	NN	I-NP	O
onset	onset	O523	NN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
coexist	coexist	C230	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
strengthens	strengthen	S365	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
limited	limit	L530	VBN	I-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
number	number	N516	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
predicting	predict	P632	VBG	B-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Purification	Purification	P612	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
and	and	A530	CC	O	O
characterization	characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Mitochondrial	Mitochondrial	M325	JJ	B-NP	O
very	very	V600	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
(	(	0000	(	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
purified	purify	P613	VBN	I-VP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
liver	liver	L160	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
masses	mass	M200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
native	native	N310	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
subunit	subunit	S153	NN	I-NP	O
were	be	W600	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
154	154	0000	CD	B-NP	O
and	and	A530	CC	O	O
70	70	0000	CD	B-NP	O
kD	kD	K300	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
catalyze	catalyze	C342	VB	I-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
palmitoylcoenzyme	palmitoylcoenzyme	P453	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenation	dehydrogenation	D362	NN	I-NP	O
in	in	I500	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
,	,	0000	,	O	O
heart	heart	H630	NN	B-NP	O
,	,	0000	,	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
skin	skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
(	(	0000	(	O	O
89	89	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
97	97	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
86	86	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
99	99	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
96	96	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
99	99	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
78	78	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
87	87	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Skin	Skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
26	26	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
suspected	suspect	S212	VBN	B-VP	O
of	of	O100	IN	B-PP	O
having	have	H152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
using	use	U252	VBG	B-VP	O
immunoblotting	immunoblotting	I514	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
contained	contain	C535	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-NP	O
or	or	O600	CC	I-NP	O
trace	trace	T620	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
fibroblast	fibroblast	F161	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
measuring	measure	M265	VBG	B-VP	O
acyl	acyl	A240	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
A	A	A000	NN	I-NP	O
dehydrogenation	dehydrogenation	D362	NN	I-NP	O
activities	activity	A231	NNS	I-NP	O
,	,	0000	,	O	O
overall	overall	O164	JJ	B-NP	O
palmitic	palmitic	P453	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
protein	protein	P635	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
using	use	U252	VBG	B-VP	O
pulse	pulse	P420	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
chase	chase	C200	NN	I-NP	O
,	,	0000	,	O	O
further	further	F636	RB	B-ADVP	O
confirming	confirm	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
heterogenous	heterogenous	H362	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Clinically	Clinically	C452	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
exhibited	exhibit	E213	VBD	B-VP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

At	At	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
hypertrophic	hypertrophic	H163	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
>	>	0000	SYM	B-NP	O
57	57	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
much	much	M200	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
accompanied	accompany	A251	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
infants	infant	I515	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

II	II	I000	CD	B-NP	O
.	.	0000	.	O	O

Biological	Biological	B424	JJ	B-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
human	human	H500	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
known	know	K500	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C5	C5	C000	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
documented	document	D253	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
accompanying	accompany	A251	VBG	I-NP	O
report	report	R163	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
examines	examine	E252	VBZ	B-VP	O
several	several	S164	JJ	B-NP	O
biological	biological	B424	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
(	(	0000	(	O	O
C5D	C5D	C300	NN	B-NP	B-Disease
)	)	0000	)	I-NP	O
human	human	H500	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
sera	serum	S600	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
C5D	C5D	C300	NN	I-NP	B-Disease
homozygotes	homozygote	H523	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
has	have	H200	VBZ	B-VP	O
inactive	inactive	I523	JJ	B-NP	O
systemic	systemic	S235	JJ	I-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
completely	completely	C514	RB	I-VP	O
lacking	lack	L252	VBG	I-VP	O
C5	C5	C000	NN	B-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
her	her	H600	PRP$	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
sister	sister	S236	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
sera	serum	S600	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
severely	severely	S164	RB	B-ADJP	O
impaired	impaired	I516	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
chemotactic	chemotactic	C532	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
neutrophils	neutrophil	N361	NNS	I-NP	O
upon	upon	U150	IN	B-PP	O
incubation	incubation	I521	NN	B-NP	O
with	with	W300	IN	B-PP	O
aggregated	aggregate	A262	VBN	B-NP	O
human	human	H500	JJ	I-NP	O
gamma	gamma	G500	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
globulin	globulin	G414	NN	B-NP	O
or	or	O600	CC	O	O
Escherichia	Escherichia	E262	FW	B-NP	O
coli	coli	C400	FW	I-NP	O
endotoxin	endotoxin	E532	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
function	function	F523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
fully	fully	F400	RB	I-VP	O
restored	restore	R236	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
substantially	substantially	S123	RB	B-VP	O
improved	improve	I516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
purified	purify	P613	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
C5	C5	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
serum	serum	S650	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
.	.	0000	.	O	O

Sera	Sera	S600	NN	B-NP	O
from	from	F650	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
apparently	apparently	A165	RB	B-ADJP	O
heterozygous	heterozygous	H362	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
gave	give	G100	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
chemotactic	chemotactic	C532	JJ	I-NP	O
scores	score	S262	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
C5D	C5D	C300	NN	B-NP	B-Disease
serum	serum	S650	NN	I-NP	O
to	to	T000	TO	B-VP	O
opsonize	opsonize	O125	VB	I-VP	O
Saccharomyces	Saccharomyces	S265	NNP	B-NP	O
cerevisiae	cerevisiae	C612	NNS	I-NP	O
(	(	0000	(	O	O
bakers	baker	B262	NNS	B-NP	O
yeast	yeast	Y230	NN	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
Candida	Candida	C530	NN	B-NP	O
albicans	albican	A412	NNS	I-NP	O
for	for	F600	IN	B-PP	O
ingestion	ingestion	I523	NN	B-NP	O
by	by	B000	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
neutrophils	neutrophil	N361	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
completely	completely	C514	RB	B-ADJP	O
normal	normal	N654	JJ	I-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
C5D	C5D	C300	NN	B-NP	B-Disease
serum	serum	S650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
capable	capable	C140	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
promoting	promote	P653	VBG	B-VP	O
normal	normal	N654	JJ	B-NP	O
phagocytosis	phagocytosis	P232	NN	I-NP	O
and	and	A530	CC	O	O
intracellular	intracellular	I536	JJ	B-NP	O
killing	killing	K452	NN	I-NP	O
of	of	O100	IN	B-PP	O
Staphylococcus	Staphylococcus	S314	FW	B-NP	O
aureus	aureus	A620	FW	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
was	be	W200	VBD	B-VP	O
incapable	incapable	I521	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
mediating	mediate	M352	VBG	B-VP	O
lysis	lysis	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
paroxysmal	paroxysmal	P625	JJ	B-NP	B-Disease
nocturnal	nocturnal	N236	JJ	I-NP	I-Disease
hemoglobinuria	hemoglobinuria	H524	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
sucrose	sucrose	S262	NN	I-NP	O
hemolysia	hemolysia	H542	NN	I-NP	O
and	and	A530	CC	O	O
acid	acid	A230	NN	B-NP	O
hemolysis	hemolysis	H542	NN	I-NP	O
tests	test	T232	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
also	also	A420	RB	B-ADVP	O
lacked	lack	L230	VBD	B-VP	O
bactericidal	bactericidal	B236	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
against	against	A252	IN	B-PP	O
sensitized	sensitize	S523	VBN	B-NP	O
or	or	O600	CC	I-NP	O
unsensitized	unsensitized	U525	JJ	I-NP	O
Salmonella	Salmonella	S454	NNP	I-NP	O
typhi	typhi	T100	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
containing	contain	C535	VBG	B-VP	O
only	only	O540	RB	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
,	,	0000	,	O	O
effectively	effectively	E123	RB	B-NP	O
lysed	lyse	L230	VBN	I-NP	O
S	S	S000	NN	I-NP	O
.	.	0000	.	I-NP	O
typhi	typhi	T100	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
only	only	O540	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
eightfold	eightfold	E231	RB	B-NP	O
lower	low	L600	JJR	I-NP	O
serum	serum	S650	NN	I-NP	O
dilutions	dilution	D435	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
normals	normal	N654	NNS	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
underscore	underscore	U536	VBP	B-VP	O
the	the	T000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
generation	generation	G563	NN	I-NP	O
of	of	O100	IN	B-PP	O
chemotactic	chemotactic	C532	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
cytolytic	cytolytic	C343	JJ	B-NP	O
reactions	reaction	R235	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
opposed	oppose	O123	VBN	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
nonobligatory	nonobligatory	N514	JJ	I-NP	O
or	or	O600	CC	I-NP	O
minimal	minimal	M540	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
opsonization	opsonization	O125	NN	B-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
organisms	organism	O625	NNS	I-NP	O
under	under	U536	IN	B-PP	O
study	study	S300	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
targeting	targeting	T623	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
receptor	receptor	R213	NN	I-NP	O
restores	restore	R236	VBZ	B-VP	O
peroxisomal	peroxisomal	P625	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
import	import	I516	NN	I-NP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
fatal	fatal	F340	JJ	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
targeting	targeting	T623	NN	I-NP	O
signals	signal	S254	NNS	I-NP	O
,	,	0000	,	O	O
PTS1	PTS1	P320	NN	B-NP	O
and	and	A530	CC	I-NP	O
PTS2	PTS2	P320	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
import	import	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
peroxisome	peroxisome	P625	NN	I-NP	O
matrix	matrix	M362	NN	I-NP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
fatal	fatal	F340	JJ	B-NP	O
generalized	generalize	G564	VBN	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
fall	fall	F400	VBP	B-VP	O
into	into	I530	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
nine	nine	N500	CD	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
complementation	complementation	C514	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

Cells	Cell	C420	NNS	B-NP	O
from	from	F650	IN	B-PP	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
import	import	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
PTS1	PTS1	P320	NN	B-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
proteins	protein	P635	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
import	import	I516	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
(	(	0000	(	O	O
PTS1R	PTS1R	P326	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Pichia	Pichia	P200	NNP	I-NP	O
pastoris	pastoris	P236	NN	I-NP	O
PAS8	PAS8	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
PTS1	PTS1	P320	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
McCollum	McCollum	M245	NNP	B-NP	O
,	,	0000	,	O	O
D	D	D000	NNP	B-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
E	E	E000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Monosov	Monosov	M521	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
S	S	S000	NNP	B-NP	O
.	.	0000	.	I-NP	O
Subramani	Subramani	S165	NNP	I-NP	O
.	.	0000	.	I-NP	O
1993	1993	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
J	J	J000	NNP	I-NP	O
.	.	0000	.	I-NP	O
Cell	Cell	C400	NNP	I-NP	O
Biol	Biol	B400	NNP	I-NP	O
.	.	0000	.	O	O
121	121	0000	CD	B-NP	O
761	761	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
774	774	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
human	human	H500	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
.	.	0000	.	O	O

Antibodies	Antibody	A531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
recognize	recognize	R252	VBP	B-VP	O
this	this	T200	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
,	,	0000	,	I-NP	O
monkey	monkey	M520	NN	I-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
hamster	hamster	H523	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
localized	localize	L242	VBN	I-VP	O
mainly	mainly	M540	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cytosol	cytosol	C324	NN	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
peroxisomes	peroxisome	P625	NNS	B-NP	O
.	.	0000	.	O	O

Part	Part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
tightly	tightly	T234	RB	B-ADJP	O
bound	bind	B530	VBN	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
.	.	0000	.	O	O

Antibodies	Antibody	A531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
PTS1R	PTS1R	P326	NN	B-NP	O
inhibit	inhibit	I513	VBP	B-VP	O
peroxisomal	peroxisomal	P625	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
import	import	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
PTS1	PTS1	P320	NN	B-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
proteins	protein	P635	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
permeabilized	permeabilized	P651	JJ	I-NP	O
CHO	CHO	C000	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
system	system	S235	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
-	-	0000	HYPH	B-NP	O
translated	translate	T652	VBN	I-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
specifically	specifically	S121	RB	B-ADVP	O
binds	bind	B532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
serine	serine	S650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
lysine	lysine	L250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
leucine	leucine	L250	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
peptide	peptide	P130	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
PAS8	PAS8	P200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
fusion	fusion	F250	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
complements	complement	C514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
P	P	P000	NN	I-NP	O
.	.	0000	.	O	O
pastoris	pastoris	P236	NN	B-NP	O
pas8	pas8	P200	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
complements	complement	C514	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
PTS1	PTS1	P320	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
import	import	I516	NN	I-NP	I-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
skin	skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
-	-	0000	HYPH	B-ADJP	O
-	-	0000	HYPH	O	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
complementation	complementation	C514	NN	B-NP	O
group	group	G610	NN	I-NP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	HYPH	B-NP	O
diagnosed	diagnose	D252	VBN	B-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
neonatal	neonatal	N534	JJ	B-NP	B-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
Zellweger	Zellweger	Z426	NN	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PTS1R	PTS1R	P326	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
location	location	L235	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
no	no	N000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
genes	gene	G520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
map	map	M100	VB	I-VP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
case	case	C200	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
import	import	I516	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
understood	understand	U536	VBN	I-VP	O
.	.	0000	.	O	O

Spectrum	Spectrum	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
232	232	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
non	non	N500	JJ	I-NP	I-Disease
hereditary	hereditary	H636	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
confer	confer	C516	VBP	B-VP	O
hereditary	hereditary	H636	JJ	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
performed	perform	P616	VBN	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
survey	survey	S610	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
232	232	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
non	non	N500	JJ	I-NP	I-Disease
hereditary	hereditary	H636	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
systematically	systematically	S235	RB	B-ADVP	O
explored	explore	E214	VBD	B-VP	O
all	all	A400	DT	B-NP	O
27	27	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	O	O
flanking	flank	F452	VBG	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
promotor	promotor	P653	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
represented	represent	R162	VBN	I-VP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
unequally	unequally	U524	RB	I-VP	O
distributed	distribute	D236	VBN	I-VP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
,	,	0000	,	O	O
exons	exon	E252	NNS	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
18	18	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
19	19	0000	CD	I-NP	O
are	be	A600	VBP	B-VP	O
preferentially	preferentially	P616	RB	I-VP	O
altered	alter	A436	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
frequency	frequency	F625	NN	B-NP	O
of	of	O100	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
about	about	A130	RB	B-NP	O
20	20	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
other	other	O360	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
RB1	RB1	R100	NN	B-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
should	should	S430	MD	B-VP	O
help	help	H410	VB	I-VP	O
to	to	T000	TO	I-VP	O
improve	improve	I516	VB	I-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
management	management	M525	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Aniridia	Aniridia	A563	NN	B-NP	B-Disease
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-VP	O
cytogenetic	cytogenetic	C325	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
position	position	P235	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
may	may	M000	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Current	Current	C653	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
(	(	0000	(	O	O
absence	absence	A125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
iris	iris	I620	NN	B-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
11p13	11p13	P000	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
the	the	T000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
characterisation	characterisation	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
segregates	segregate	S262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
involve	involve	I514	VBP	B-VP	O
11p13	11p13	P000	NN	B-NP	O
but	but	B300	CC	O	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
disrupt	disrupt	D261	VB	I-VP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
three	three	T600	CD	B-NP	O
human	human	H500	JJ	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
encompass	encompass	E525	VBP	B-VP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
these	these	T200	DT	B-NP	O
to	to	T000	TO	B-VP	O
show	show	S000	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
the	the	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
85	85	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
open	open	O150	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
apparently	apparently	A165	RB	B-ADJP	O
free	free	F600	JJ	I-ADJP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
rearranged	rearrange	R652	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
inappropriate	inappropriate	I516	JJ	I-NP	O
chromatin	chromatin	C653	NN	I-NP	O
environment	environment	E516	NN	I-NP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
position	position	P235	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q21	17q21	Q000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
tumours	tumour	T562	NNS	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analysed	analyse	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumour	tumour	T560	NN	B-NP	B-Disease
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
fractions	fraction	F623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
47	47	0000	CD	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
using	use	U252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
technique	technique	T252	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
now	now	N000	RB	B-ADVP	O
describe	describe	D261	VBP	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
which	which	W200	WDT	B-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
(	(	0000	(	O	O
LOH	LOH	L000	NN	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
;	;	0000	:	O	O
somatic	somatic	S532	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	I-NP	O
LOH	LOH	L000	NN	I-NP	O
may	may	M000	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Decreased	Decrease	D262	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
accelerates	accelerate	A246	VBZ	B-VP	O
growth	growth	G630	NN	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
during	during	D652	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
progression	progression	P626	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	O	B-Disease
-	-	0000	HYPH	O	I-Disease
hereditary	hereditary	H636	JJ	O	I-Disease
(	(	0000	(	O	I-Disease
sporadic	sporadic	S163	JJ	B-ADJP	I-Disease
)	)	0000	)	O	I-Disease
breast	breast	B623	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
analyzed	analyze	A542	VBD	B-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
antisense	antisense	A532	JJ	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proliferative	proliferative	P641	JJ	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
mammary	mammary	M560	JJ	B-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
during	during	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
from	from	F650	IN	B-PP	O
carcinoma	carcinoma	C625	NN	B-NP	B-Disease
in	in	I500	FW	B-ADVP	I-Disease
situ	situ	S300	FW	I-ADVP	I-Disease
to	to	T000	TO	B-PP	O
invasive	invasive	I512	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Experimental	Experimental	E216	JJ	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
with	with	W300	IN	B-PP	O
antisense	antisense	A532	JJ	B-NP	O
oligonucleotides	oligonucleotide	O425	NNS	I-NP	O
produced	produce	P632	VBD	B-VP	O
accelerated	accelerate	A246	VBN	B-NP	O
growth	growth	G630	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
and	and	A530	CC	I-NP	O
malignant	malignant	M425	JJ	I-NP	O
mammary	mammary	M560	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mammary	mammary	M560	JJ	I-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
may	may	M000	MD	B-VP	O
normally	normally	N654	RB	I-VP	O
serve	serve	S610	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
regulator	regulator	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
mammary	mammary	M560	JJ	B-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
function	function	F523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
compromised	compromise	C516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
either	either	E360	CC	B-PP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
or	or	O600	CC	O	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
monozygotic	monozygotic	M523	JJ	I-NP	O
twins	twin	T520	NNS	I-NP	O
discordant	discordant	D263	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
opposite	opposite	O123	JJ	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
pair	pair	P600	NN	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
monozygotic	monozygotic	M523	JJ	I-NP	O
(	(	0000	(	O	O
MZ	MZ	M200	JJ	B-ADJP	O
)	)	0000	)	O	O
twins	twin	T520	NNS	B-NP	O
,	,	0000	,	O	O
heterozygous	heterozygous	H362	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	I-NP	O
discordant	discordant	D263	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
methylation	methylation	M343	NN	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
to	to	T000	TO	B-VP	O
search	search	S620	VB	I-VP	O
for	for	F600	IN	B-PP	O
opposite	opposite	O123	JJ	B-NP	O
X	X	X000	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
explanation	explanation	E214	NN	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
discordance	discordance	D263	NN	I-NP	O
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
and	and	A530	CC	O	O
skin	skin	S250	NN	B-NP	O
fibroblast	fibroblast	F161	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
mirror	mirror	M600	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
preferentially	preferentially	P616	RB	B-ADJP	O
active	active	A231	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
twin	twin	T500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
deleted	delete	D430	VBN	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
preferentially	preferentially	P616	RB	B-ADJP	O
active	active	A231	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
twin	twin	T500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
review	review	R100	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
MZ	MZ	M200	JJ	B-NP	O
female	female	F540	JJ	I-NP	O
twins	twin	T520	NNS	I-NP	O
discordant	discordant	D263	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
linked	link	L523	VBN	I-NP	I-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
uncommon	uncommon	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Twinning	Twinning	T520	NN	B-NP	O
and	and	A530	CC	I-NP	O
X	X	X000	NN	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
interrelated	interrelate	I536	VBN	I-VP	O
and	and	A530	CC	O	O
could	could	C430	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
twins	twin	T520	NNS	I-NP	O
discordant	discordant	D263	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
linked	link	L523	VBN	I-NP	O
traits	trait	T632	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
5	5	0000	CD	B-NP	O
different	different	D165	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Fragments	Fragment	F625	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
cDNA	cDNA	C350	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
adolescent	adolescent	A342	JJ	B-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
amplified	amplify	A514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
and	and	A530	CC	O	O
subcloned	subclone	S124	VBN	B-VP	O
.	.	0000	.	O	O

Bidirectional	Bidirectional	B362	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
disclosed	disclose	D242	VBD	B-VP	O
a	a	A000	DT	B-NP	O
cytosine	cytosine	C325	NN	I-NP	O
to	to	T000	TO	B-PP	O
guanine	guanine	G500	NN	B-NP	O
transversion	transversion	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
1451	1451	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
five	five	F100	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
proline	proline	P645	NN	B-NP	O
484	484	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
comprising	comprise	C516	VBG	B-VP	O
two	two	T000	CD	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	I-NP	B-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
Addison	Addison	A325	NN	I-NP	B-Disease
only	only	O540	RB	O	I-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
symptomatic	symptomatic	S513	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
(	(	0000	(	O	O
all	all	A400	DT	B-NP	O
accumulating	accumulate	A254	VBG	B-VP	O
very	very	V600	RB	B-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
)	)	0000	)	O	O
carried	carry	C630	VBD	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
persons	person	P625	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
twenty	twenty	T530	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
generated	generate	G563	VBD	B-VP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
per	per	P600	FW	B-ADVP	O
se	se	S000	FW	I-ADVP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
must	must	M230	MD	B-VP	O
have	have	H100	VB	I-VP	O
originated	originate	O625	VBN	I-VP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
pathogenetic	pathogenetic	P325	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
ND	ND	N300	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
males	male	M420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
unrelated	unrelated	U564	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
;	;	0000	:	O	O
they	they	T000	PRP	B-NP	O
showed	show	S300	VBD	B-VP	O
typical	typical	T124	JJ	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ND	ND	N300	NN	B-NP	B-Disease
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
mental	mental	M534	JJ	I-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
hearing	hearing	H652	NN	I-NP	B-Disease
impairment	impairment	I516	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ATG	ATG	A320	NN	B-NP	O
to	to	T000	TO	B-PP	O
GTG	GTG	G320	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
otherwise	otherwise	O362	RB	B-NP	O
normal	normal	N654	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
mothers	mother	M362	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
expected	expect	E212	VBN	I-VP	O
for	for	F600	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
would	would	W430	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
the	the	T000	DT	B-NP	O
failure	failure	F460	NN	I-NP	O
of	of	O100	IN	B-PP	O
ND	ND	N300	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
translation	translation	T652	NN	B-NP	O
thereby	thereby	T610	RB	B-VP	O
truncating	truncate	T652	VBG	I-VP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
terminus	terminus	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
ND	ND	N300	NN	B-NP	B-Disease
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
view	view	V000	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rarity	rarity	R630	NN	I-NP	O
and	and	A530	CC	I-NP	O
marked	marked	M623	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
apparently	apparently	A165	RB	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
lived	live	L130	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
area	area	A600	NN	I-NP	O
for	for	F600	IN	B-PP	O
over	over	O160	IN	B-NP	O
two	two	T000	CD	I-NP	O
centuries	century	C536	NNS	I-NP	O
presumably	presumably	P625	RB	B-ADVP	O
share	share	S600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Anticipation	Anticipation	A532	NN	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
elimination	elimination	E453	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
follow	follow	F400	NN	I-NP	O
up	up	U100	RP	B-PRT	O
study	study	S300	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
extended	extend	E235	VBN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
re	re	R000	AFX	B-PP	O
-	-	0000	HYPH	B-NP	O
examined	examine	E253	VBN	B-VP	O
an	an	A500	DT	B-NP	O
extended	extended	E235	JJ	I-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
family	family	F540	NN	B-NP	O
,	,	0000	,	O	O
previously	previously	P612	RB	B-VP	O
described	describe	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
1955	1955	0000	CD	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
term	term	T650	NN	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
anticipation	anticipation	A532	NN	B-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-ADJP	O
the	the	T000	DT	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
families	family	F542	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
follow	follow	F400	NN	I-NP	O
up	up	U100	RP	B-PRT	O
study	study	S300	NN	B-NP	O
provides	provide	P613	VBZ	B-VP	O
data	datum	D300	NNS	B-NP	O
on	on	O500	IN	B-PP	O
35	35	0000	CD	B-NP	O
gene	gene	G500	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
and	and	A530	CC	O	O
46	46	0000	CD	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
anticipation	anticipation	A532	NN	I-NP	O
,	,	0000	,	O	O
defined	define	D153	VBN	B-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
cascade	cascade	C230	NN	I-NP	O
of	of	O100	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
,	,	0000	,	I-NP	O
adult	adult	A343	JJ	I-NP	O
,	,	0000	,	I-NP	O
childhood	childhood	C430	NN	I-NP	O
,	,	0000	,	I-NP	O
or	or	O600	CC	I-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
subsequent	subsequent	S125	JJ	B-NP	O
generations	generation	G563	NNS	I-NP	O
,	,	0000	,	O	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
relentless	relentless	R453	JJ	I-NP	O
process	process	P620	NN	I-NP	O
,	,	0000	,	O	O
occurring	occur	O265	VBG	B-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
branches	branch	B652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cascade	cascade	C230	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
proceed	proceed	P623	VB	I-VP	O
asynchronously	asynchronously	A252	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
branches	branch	B652	NNS	I-NP	O
,	,	0000	,	O	O
mainly	mainly	M540	RB	B-ADVP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
an	an	A500	DT	B-NP	O
unequal	unequal	U524	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
generations	generation	G563	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
mild	mild	M430	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
type	type	T100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
transmission	transmission	T652	NN	B-NP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

Stable	Stable	S314	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
/	/	0000	SYM	I-NP	O
mild	mild	M430	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
bias	bias	B200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
further	further	F636	RB	B-ADVP	O
examined	examine	E253	VBD	B-VP	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
and	and	A530	CC	I-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
gene	gene	G500	NN	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
.	.	0000	.	O	O

Gene	Gene	G500	NN	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
group	group	G610	NN	I-NP	O
was	be	W200	VBD	B-VP	O
complete	complete	C514	JJ	B-ADJP	O
,	,	0000	,	O	O
owing	owe	O520	VBG	B-VP	O
to	to	T000	TO	B-PP	O
infertility	infertility	I516	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
disease	disease	D200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
mentally	mentally	M534	RB	B-NP	B-Disease
retarded	retarded	R363	JJ	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
procreate	procreate	P626	VB	I-VP	O
.	.	0000	.	O	O

Out	Out	O300	IN	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
46	46	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
subjects	subject	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
youngest	young	Y523	JJS	I-NP	O
generations	generation	G563	NNS	I-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
subject	subject	S123	NN	I-NP	O
who	who	W000	WP	B-NP	O
may	may	M000	MD	B-VP	O
transmit	transmit	T652	VB	I-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
sixth	sixth	S230	JJ	I-NP	O
generation	generation	G563	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
protomutation	protomutation	P635	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
and	and	A530	CC	I-NP	O
fifth	fifth	F130	JJ	I-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	B-ADJP	O
probable	probable	P614	JJ	I-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
eliminated	eliminate	E453	VBN	I-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
within	within	W350	IN	B-PP	O
one	one	O500	CD	B-NP	O
generation	generation	G563	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
population	population	P143	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
can	can	C500	MD	B-VP	O
at	at	A300	IN	B-PP	O
present	present	P625	JJ	B-ADJP	O
not	not	N300	RB	O	O
be	be	B000	VB	B-VP	O
explained	explain	E214	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
contribution	contribution	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
asymptomatic	asymptomatic	A251	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
younger	young	Y526	JJR	I-NP	O
generations	generation	G563	NNS	I-NP	O
of	of	O100	IN	B-PP	O
known	known	K500	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
events	event	E153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
spinal	spinal	S154	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
3	3	0000	CD	I-NP	O
(	(	0000	(	O	O
SCA3	SCA3	S200	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
3	3	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14q24	14q24	Q000	CD	I-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q32	q32	Q000	NN	I-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

SCA3	SCA3	S200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
spinal	spinal	S154	JJ	B-NP	B-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
recently	recently	R253	RB	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
between	between	B350	IN	B-PP	O
D14S67	D14S67	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D14S81	D14S81	D200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14q	14q	Q000	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
French	French	F652	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
candidate	candidate	C530	NN	I-NP	O
region	region	R250	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
refined	refine	R153	VBN	I-VP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
four	four	F600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
(	(	0000	(	O	O
D14S256	D14S256	D200	NN	B-NP	O
,	,	0000	,	O	O
D14S291	D14S291	D200	NN	B-NP	O
,	,	0000	,	O	O
D14S280	D14S280	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
AFM343vf1	AFM343vf1	A151	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
two	two	T000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
19	19	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
genotyped	genotype	G531	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
French	French	F652	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-VP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
point	point	P530	NN	I-NP	O
linkage	linkage	L520	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
,	,	0000	,	O	O
D14S280	D14S280	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
AFM343vf1	AFM343vf1	A151	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
tightly	tightly	T234	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
maximal	maximal	M254	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
fraction	fraction	F623	NN	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	O	O
theta	theta	T300	SYM	O	O
)	)	0000	)	O	O
=	=	0000	SYM	B-NP	O
.	.	0000	.	O	O

00	00	0000	CD	B-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O

05	05	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O

70	70	0000	CD	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-NP	O
multipoint	multipoint	M431	JJ	I-NP	O
and	and	A530	CC	I-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
localize	localize	L242	VBP	B-VP	O
the	the	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
flanked	flank	F452	VBN	B-VP	O
by	by	B000	IN	B-PP	O
D14S291	D14S291	D200	NN	B-NP	O
and	and	A530	CC	I-NP	O
D14S81	D14S81	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
for	for	F600	IN	B-PP	O
D14S280	D14S280	D200	NN	B-NP	O
segregates	segregate	S262	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
frequent	frequent	F625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
clearly	clearly	C464	RB	I-VP	O
established	establish	E231	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
SCA3	SCA3	S200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
29	29	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
14q24	14q24	Q000	NN	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q32	q32	Q000	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Machado	Machado	M230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
clinically	clinically	C452	RB	I-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
SCA3	SCA3	S200	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
cannot	cannot	C530	MD	B-VP	O
yet	yet	Y300	RB	I-VP	O
be	be	B000	VB	I-VP	O
concluded	conclude	C524	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
diseases	disease	D200	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
alterations	alteration	A436	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O

An	An	A500	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
145	145	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Breast	Breast	B623	NNP	B-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Linkage	Linkage	L520	NNP	I-NP	O
Consortium	Consortium	C526	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
ovary	ovary	O160	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
family	family	F540	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
ovaries	ovary	O162	NNS	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
region	region	R250	NN	I-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q21	q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-NP	O
all	all	A400	DT	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovary	ovary	O160	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
145	145	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
contain	contain	C535	VBP	B-VP	O
either	either	E360	CC	O	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
(	(	0000	(	O	O
before	before	B160	IN	B-PP	O
age	age	A200	NN	B-NP	O
60	60	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
or	or	O600	CC	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
families	family	F542	NNS	I-NP	O
contained	contain	C535	VBD	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
76	76	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
145	145	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
13	13	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
linked	link	L523	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
92	92	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
76	76	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
100	100	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
male	male	M400	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
family	family	F540	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
heterogeneous	heterogeneous	H362	JJ	I-ADJP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
essential	essential	E253	JJ	B-NP	B-Disease
fructosuria	fructosuria	F623	NN	I-NP	I-Disease
:	:	0000	:	O	O
molecular	molecular	M424	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
and	and	A530	CC	O	O
mutational	mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ketohexokinase	ketohexokinase	K325	NN	I-NP	O
(	(	0000	(	O	O
fructokinase	fructokinase	F623	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Essential	Essential	E253	JJ	B-NP	B-Disease
fructosuria	fructosuria	F623	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
oldest	old	O432	JJS	I-NP	O
known	know	K500	VBN	I-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
errors	error	E620	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
metabolism	metabolism	M314	NN	B-NP	I-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
benign	benign	B525	JJ	I-NP	O
condition	condition	C535	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
believed	believe	B413	VBN	I-VP	O
to	to	T000	TO	I-VP	O
result	result	R243	VB	I-VP	O
from	from	F650	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hepatic	hepatic	H132	JJ	B-NP	I-Disease
fructokinase	fructokinase	F623	NN	I-NP	I-Disease
(	(	0000	(	O	O
ketohexokinase	ketohexokinase	K325	NN	B-NP	O
,	,	0000	,	O	O
KHK	KHK	K200	NN	B-NP	O
,	,	0000	,	O	O
E	E	E000	NN	B-NP	O
.	.	0000	.	I-NP	O
C	C	C000	NN	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
catalyses	catalyse	C342	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
step	step	S310	NN	I-NP	O
of	of	O100	IN	B-PP	O
metabolism	metabolism	M314	NN	B-NP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
fructose	fructose	F623	NN	I-NP	O
,	,	0000	,	O	O
conversion	conversion	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
fructose	fructose	F623	NN	B-NP	O
to	to	T000	TO	B-PP	O
fructose	fructose	F623	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
.	.	0000	.	O	O

Despite	Despite	D213	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
recognition	recognition	R253	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
KHK	KHK	K200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
essential	essential	E253	JJ	B-NP	B-Disease
fructosuria	fructosuria	F623	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	B-ADJP	O
defined	define	D153	VBN	I-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
and	and	A530	CC	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
human	human	H500	JJ	B-NP	O
ketohexokinase	ketohexokinase	K325	NN	I-NP	O
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

Alternative	Alternative	A436	JJ	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
species	specie	S120	NNS	I-NP	O
and	and	A530	CC	O	O
alternative	alternative	A436	JJ	B-NP	O
KHK	KHK	K200	NN	I-NP	O
isozymes	isozyme	I252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
produced	produce	P632	VBN	I-VP	O
by	by	B000	IN	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
polyadenylation	polyadenylation	P435	NN	I-NP	O
and	and	A530	CC	I-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KHK	KHK	K200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
KHK	KHK	K200	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
conservation	conservation	C526	NN	I-NP	O
relative	relative	R431	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
rat	rat	R300	NN	B-NP	O
KHK	KHK	K200	NN	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KHK	KHK	K200	NN	I-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
essential	essential	E253	JJ	B-NP	B-Disease
fructosuria	fructosuria	F623	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
obtained	obtain	O135	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
well	well	W400	RB	I-NP	O
-	-	0000	HYPH	I-NP	O
characterized	characterize	C623	VBN	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	I-NP	O
eight	eight	E230	CD	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
fructosuria	fructosuria	F623	NN	B-NP	B-Disease
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
Gly40Arg	Gly40Arg	G462	NN	I-NP	O
and	and	A530	CC	I-NP	O
Ala43Thr	Ala43Thr	A436	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
G	G	G000	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transitions	transition	T652	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
each	each	E200	DT	B-NP	O
alters	alter	A436	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KHK	KHK	K200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

Neither	Neither	N360	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
52	52	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
control	control	C536	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
conservative	conservative	C526	JJ	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
change	change	C520	NN	I-NP	O
(	(	0000	(	O	O
Val49IIe	Val49IIe	V400	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
KHK	KHK	K200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
bearing	bear	B652	VBG	B-VP	O
Ala43Thr	Ala43Thr	A436	NN	B-NP	O

Homozygous	Homozygous	H520	JJ	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
crossover	crossover	C621	NN	I-NP	O
(	(	0000	(	O	O
fusion	fusion	F250	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
)	)	0000	)	O	O
mutation	mutation	M350	NN	B-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
type	type	T100	NN	I-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
Gaucher	Gaucher	G260	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
fetus	fetus	F320	NN	I-NP	O
:	:	0000	:	O	O
is	be	I200	VBZ	B-VP	O
this	this	T200	DT	B-NP	O
analogous	analogous	A542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Gaucher	Gaucher	G260	NNP	I-NP	O
knock	knock	K520	VB	B-VP	O
-	-	0000	HYPH	O	O
out	out	O300	RP	B-PRT	O
mouse	mouse	M200	NN	B-NP	O
model	model	M340	NN	I-NP	O
?	?	0000	.	O	O

Gaucher	Gaucher	G260	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
GD	GD	G300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
beta	beta	B300	SYM	O	I-Disease
-	-	0000	HYPH	O	I-Disease
glucocerebrosidase	glucocerebrosidase	G426	NN	B-NP	I-Disease
(	(	0000	(	O	O
EC	EC	E200	NNP	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
45	45	0000	CD	I-NP	O
,	,	0000	,	O	O
gene	gene	G500	NN	B-NP	O
symbol	symbol	S514	NN	I-NP	O
GBA	GBA	G100	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
GD	GD	G300	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
CNS	CNS	C520	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
involved	involve	I514	VBN	I-VP	O
(	(	0000	(	O	O
nonneuronopathic	nonneuronopathic	N565	JJ	B-ADVP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
GD	GD	G300	NN	I-NP	I-Disease
(	(	0000	(	O	O
acute	acute	A230	JJ	B-NP	O
neuronopathic	neuronopathic	N651	JJ	I-NP	O
)	)	0000	)	I-NP	O
CNS	CNS	C520	NN	I-NP	O
involvement	involvement	I514	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
early	early	E640	JJ	B-ADJP	O
and	and	A530	CC	O	O
rapidly	rapidly	R134	RB	B-ADJP	O
progressive	progressive	P626	JJ	I-ADJP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
III	III	I000	CD	I-NP	I-Disease
GD	GD	G300	NN	I-NP	I-Disease
(	(	0000	(	O	O
subacute	subacute	S123	JJ	B-NP	O
neuronopathic	neuronopathic	N651	JJ	I-NP	O
)	)	0000	)	I-NP	O
CNS	CNS	C520	NN	I-NP	O
involvement	involvement	I514	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
later	later	L360	RB	B-ADVP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
slowly	slowly	S400	RB	B-ADJP	O
progressive	progressive	P626	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
T6433C	T6433C	T200	NN	I-NP	O
(	(	0000	(	O	O
L444P	L444P	L100	NN	B-NP	O
)	)	0000	)	O	O
substitution	substitution	S123	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
prevalent	prevalent	P614	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
type	type	T100	NN	B-NP	B-Disease
GD	GD	G300	NN	I-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
may	may	M000	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
alone	alone	A450	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
pair	pair	P600	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
but	but	B300	CC	O	O
often	often	O135	RB	B-ADVP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
as	as	A200	IN	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
additional	additional	A354	JJ	B-NP	O
GBA	GBA	G100	NN	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
G6468C	G6468C	G200	NN	B-NP	O
(	(	0000	(	O	O
A456P	A456P	A100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
G6482C	G6482C	G200	NN	B-NP	O
(	(	0000	(	O	O
V460V	V460V	V100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
(	(	0000	(	O	O
recNciI	recNciI	R252	NN	B-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
with	with	W300	IN	B-PP	O
(	(	0000	(	O	O
recTL	recTL	R234	NN	B-NP	O
)	)	0000	)	O	O
G5957C	G5957C	G200	NN	B-NP	O
(	(	0000	(	O	O
D409H	D409H	D000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
presumed	presume	P625	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
formed	form	F653	VBN	I-VP	O
by	by	B000	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
(	(	0000	(	O	O
crossover	crossover	C621	NN	B-NP	O
,	,	0000	,	O	O
fusion	fusion	F250	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
structural	structural	S362	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
pseudogene	pseudogene	P232	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
complex	complex	C514	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
never	never	N160	RB	I-VP	O
been	be	B500	VBN	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
to	to	T000	TO	B-VP	O
coexist	coexist	C230	VB	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
devised	devise	D123	VBD	B-VP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
method	method	M300	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
fusion	fusion	F250	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
procedure	procedure	P623	NN	I-NP	O
we	we	W000	PRP	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
fusion	fusion	F250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
form	form	F650	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
time	time	T500	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Macedonian	Macedonian	M235	JJ	I-NP	O
/	/	0000	SYM	I-NP	O
Ashkenazi	Ashkenazi	A252	JJ	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
GD	GD	G300	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
fetus	fetus	F320	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
conceptus	conceptus	C521	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
was	be	W200	VBD	B-VP	O
stillborn	stillborn	S341	VBN	I-VP	B-Disease
at	at	A300	IN	B-PP	O
36	36	0000	CD	B-NP	O
weeks	week	W200	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
features	feature	F362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
type	type	T100	NN	I-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
GD	GD	G300	NN	I-NP	I-Disease
.	.	0000	.	O	O

Neonates	Neonate	N532	NNS	B-NP	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
analogous	analogous	A542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
neonatal	neonatal	N534	JJ	I-NP	O
lethal	lethal	L340	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
occurring	occur	O265	VBG	B-VP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
produced	produce	P632	VBN	B-VP	O
by	by	B000	IN	B-PP	O
targeted	target	T623	VBN	B-NP	O
disruption	disruption	D261	NN	I-NP	O
of	of	O100	IN	B-PP	O
GBA	GBA	G100	NN	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
.	.	0000	.	O	O

(	(	0000	(	O	O
ABSTRACT	ABSTRACT	A123	NN	B-NP	O
TRUNCATED	TRUNCATED	T652	VBN	B-VP	O
AT	AT	A300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	W632	NNS	I-NP	O
)	)	0000	)	O	O

Late	Late	L300	JJ	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Israel	Israel	I264	NNP	B-NP	O
.	.	0000	.	O	O

Metachromatic	Metachromatic	M326	JJ	B-NP	B-Disease
Leukodystrophy	Leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
neurodegenerative	neurodegenerative	N632	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
Aryl	Aryl	A640	NN	B-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
deficient	deficient	D125	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
frequency	frequency	F625	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
40	40	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
live	live	L100	JJ	I-NP	O
births	birth	B632	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
up	up	U100	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
now	now	N000	RB	B-ADVP	O
eight	eight	E230	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
MLD	MLD	M430	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
PD	PD	P300	NN	B-NP	O
,	,	0000	,	O	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
(	(	0000	(	O	O
pseudodeficiency	pseudodeficiency	P231	NN	B-NP	O
)	)	0000	)	O	O
without	without	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
known	known	K500	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PD	PD	P300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
frequent	frequent	F625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
Israel	Israel	I264	NNP	B-NP	O
,	,	0000	,	O	O
late	late	L300	JJ	B-NP	O
infantile	infantile	I515	JJ	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
very	very	V600	RB	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
isolate	isolate	I243	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Habbanite	Habbanite	H153	NNP	I-NP	O
Jews	Jew	J200	NNPS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	O	O
75	75	0000	CD	B-NP	O
live	live	L100	JJ	I-NP	O
births	birth	B632	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Habbanite	Habbanite	H153	NNP	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
on	on	O500	IN	B-PP	O
an	an	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PD	PD	P300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
C	C	C000	NN	I-NP	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
change	change	C520	NN	I-NP	O
of	of	O100	IN	B-PP	O
proline	proline	P645	NN	B-NP	O
to	to	T000	TO	B-PP	O
leucine	leucine	L250	NN	B-NP	O
.	.	0000	.	O	O

MLD	MLD	M430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
frequent	frequent	F625	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
Moslem	Moslem	M245	NNP	B-NP	O
Arabs	Arabs	A612	NNP	I-NP	O
in	in	I500	IN	B-PP	O
Jerusalem	Jerusalem	J624	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transition	transition	T652	NN	I-NP	O
G	G	G000	NN	I-NP	O
>	>	0000	SYM	B-NP	O
A	A	A000	NN	I-NP	O
destroying	destroy	D236	VBG	B-VP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
from	from	F650	IN	B-PP	O
different	different	D165	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Christian	Christian	C623	NNP	I-NP	O
Arabs	Arab	A612	NNPS	I-NP	O
in	in	I500	IN	B-PP	O
Israel	Israel	I264	NNP	B-NP	O
also	also	A420	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	O	O
10	10	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
live	live	L100	JJ	I-NP	O
births	birth	B632	NNS	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

Knowledge	Knowledge	K543	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
MLD	MLD	M430	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
defined	define	D153	VBN	I-NP	O
populations	population	P143	NNS	I-NP	O
will	will	W400	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
screening	screening	S265	NN	I-NP	O
program	program	P626	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
and	and	A530	CC	O	O
prevent	prevent	P615	VB	B-VP	O
the	the	T000	DT	B-NP	O
birth	birth	B630	NN	I-NP	O
of	of	O100	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
affected	affect	A123	VBN	I-NP	O
children	child	C436	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
(	(	0000	(	O	O
G103D	G103D	G300	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
triple	triple	T614	JJ	I-NP	O
helix	helix	H420	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
moderately	moderately	M363	RB	I-NP	O
severe	severe	S160	JJ	I-NP	O
chondrodysplasia	chondrodysplasia	C536	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
type	type	T100	NN	B-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
,	,	0000	,	O	O
COL2A1	COL2A1	C400	NN	B-NP	O
.	.	0000	.	O	O

Characteristics	Characteristic	C623	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
include	include	I524	VBP	B-VP	O
a	a	A000	DT	B-NP	O
short	short	S630	JJ	I-NP	B-Disease
trunk	trunk	T652	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
extremities	extremity	E236	NNS	I-NP	I-Disease
,	,	0000	,	O	O
mid	mid	M300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
face	face	F200	NN	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
cleft	cleft	C413	NN	B-NP	B-Disease
palate	palate	P430	NN	I-NP	I-Disease
,	,	0000	,	O	O
myopia	myopia	M100	NN	B-NP	B-Disease
,	,	0000	,	O	O
retinal	retinal	R354	JJ	B-NP	B-Disease
detachment	detachment	D325	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hearing	hearing	H652	NN	B-NP	B-Disease
loss	loss	L200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
deletions	deletion	D435	NNS	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
or	or	O600	CC	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
may	may	M000	MD	B-VP	O
primarily	primarily	P656	RB	I-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Kniest	Kni	K523	JJS	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
SSCP	SSCP	S210	NN	B-NP	O
to	to	T000	TO	B-VP	O
analyze	analyze	A542	VB	I-VP	O
an	an	A500	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
abnormality	abnormality	A156	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
that	that	T300	WDT	B-NP	O
implied	imply	I514	VBD	B-VP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
glycine103	glycine103	G425	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
triple	triple	T614	JJ	I-NP	O
helical	helical	H424	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
by	by	B000	IN	B-PP	O
aspartate	aspartate	A216	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
either	either	E360	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
parents	parent	P653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O

Protein	Protein	P635	NN	B-NP	O
microsequencing	microsequencing	M262	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
cartilage	cartilage	C634	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
single	single	S524	JJ	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
can	can	C500	MD	B-VP	O
produce	produce	P632	VB	I-VP	O
Kniest	Kni	K523	JJS	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
and	and	A530	CC	O	O
further	further	F636	RB	B-VP	O
support	support	S163	VBP	I-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
alteration	alteration	A436	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
II	II	I000	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

CAG	CAG	C200	NN	B-NP	O
expansions	expansion	E215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14q32	14q32	Q000	NN	I-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
CAG	CAG	C200	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
and	and	A530	CC	O	O
mapped	map	M130	VBD	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
14q32	14q32	Q000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
contains	contain	C535	VBZ	B-VP	O
between	between	B350	IN	B-NP	O
13	13	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
36	36	0000	CD	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
diagnosed	diagnose	D252	VBN	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
show	show	S000	VBP	B-VP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
number	number	N516	NN	I-NP	O
(	(	0000	(	O	O
from	from	F650	IN	B-PP	O
68	68	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
79	79	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
related	related	R430	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
raise	raise	R200	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
similar	similar	S546	JJ	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
in	in	I500	IN	B-PP	O
related	related	R430	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
may	may	M000	MD	B-VP	O
give	give	G100	VB	I-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
diseases	disease	D200	NNS	B-NP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analysed	analyse	A542	VBD	B-VP	O
50	50	0000	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
on	on	O500	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	O	O
amplified	amplify	A514	VBN	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
putative	putative	P310	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
causing	cause	C252	VBG	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
frameshifts	frameshift	F652	NNS	B-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
nonsense	nonsense	N525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
two	two	T000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
changes	change	C520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
final	final	F540	JJ	I-NP	O
cysteine	cysteine	C235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
to	to	T000	TO	B-PP	O
glycine	glycine	G425	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
model	model	M340	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
fact	fact	F230	NN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
clinical	clinical	C452	JJ	B-NP	O
application	application	A142	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
testing	testing	T235	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
technically	technically	T252	RB	B-ADJP	O
challenging	challenging	C452	JJ	I-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Confirmation	Confirmation	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
ten	ten	T500	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
provide	provide	P613	VBP	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
supporting	support	S163	VBG	B-VP	O
the	the	T000	DT	B-NP	O
identity	identity	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
63	63	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
10	10	0000	CD	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ten	ten	T500	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q21	17q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
RNA	RNA	R500	NN	B-NP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
protein	protein	P635	NN	B-NP	O
truncations	truncation	T652	NNS	I-NP	O
at	at	A300	IN	B-PP	O
sites	site	S320	NNS	B-NP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
which	which	W200	WDT	B-NP	O
occurred	occur	O263	VBD	B-VP	O
independently	independently	I531	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
)	)	0000	)	O	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
cysteine	cysteine	C235	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
single	single	S524	JJ	I-NP	O
basepair	basepair	B216	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
destroys	destroy	D236	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
and	and	A530	CC	O	O
activates	activate	A231	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
,	,	0000	,	O	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
59	59	0000	CD	I-NP	O
basepair	basepair	B216	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
and	and	A530	CC	O	O
chain	chain	C500	NN	B-NP	O
termination	termination	T653	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
had	have	H300	VBD	B-VP	O
chain	chain	C500	NN	B-NP	O
termination	termination	T653	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

High	High	H200	JJ	B-NP	O
resolution	resolution	R243	NN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
predisposing	predispose	P632	VBG	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
amplification	amplification	A514	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
over	over	O160	IN	B-NP	O
99	99	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
global	global	G414	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
complete	complete	C514	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
Alu	Alu	A400	NN	I-NP	O
element	element	E453	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	I-NP	O
few	few	F000	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
utilizing	utilize	U342	VBG	B-VP	O
this	this	T200	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
flanking	flanking	F452	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
Fragile	Fragile	F624	VB	I-VP	B-Disease
X	X	X000	NN	B-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
DM	DM	D500	NN	B-NP	B-Disease
exhibited	exhibit	E213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
(	(	0000	(	O	O
Imbert	Imbert	I516	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1993	1993	0000	CD	B-NP	O
Nature	Nature	N360	NNP	I-NP	O
Genet	Genet	G530	NNP	I-NP	O
.	.	0000	.	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
72	72	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
76	76	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
reproductive	reproductive	R163	JJ	I-NP	O
fitness	fitness	F352	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
endpoint	endpoint	E531	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
anticipation	anticipation	A532	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
)	)	0000	)	O	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
resolution	resolution	R243	NN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
using	use	U252	VBG	B-VP	O
PCR	PCR	P260	NN	B-NP	O
based	based	B230	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
,	,	0000	,	O	O
spanning	span	S152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
distance	distance	D235	NN	I-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
,	,	0000	,	O	O
within	within	W350	IN	B-PP	O
and	and	A530	CC	O	O
immediately	immediately	I534	RB	B-VP	O
flanking	flank	F452	VBG	I-VP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
persistent	persistent	P623	JJ	I-NP	O
complete	complete	C514	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
with	with	W300	IN	B-PP	O
all	all	A400	PDT	B-NP	O
these	these	T200	DT	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
further	further	F636	JJ	B-NP	O
support	support	S163	NN	I-NP	O
to	to	T000	TO	B-PP	O
previous	previous	P612	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
more	more	M600	RBR	B-ADVP	O
strongly	strongly	S365	RB	I-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
background	background	B265	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
particular	particular	P632	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	I-NP	O
CTG	CTG	C320	NN	I-NP	O
)	)	0000	)	I-NP	O
n	n	N000	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
became	become	B250	VBD	B-VP	O
inherently	inherently	I565	RB	B-ADJP	O
unstable	unstable	U523	JJ	I-ADJP	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-ADVP	O
predisposed	predispose	P632	VBN	B-VP	O
to	to	T000	TO	B-PP	O
amplification	amplification	A514	NN	B-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
the	the	T000	DT	B-NP	O
stability	stability	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
microsatellites	microsatellite	M262	NNS	B-NP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
lines	line	L520	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
5	5	0000	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
10	10	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
unstable	unstable	U523	JJ	I-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
clones	clone	C452	NNS	B-NP	O
and	and	A530	CC	I-NP	O
subclones	subclone	S124	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
serially	serially	S640	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
(	(	0000	(	O	O
2774	2774	0000	CD	B-NP	O
;	;	0000	:	O	O
serous	serous	S620	JJ	B-NP	B-Disease
cystadenocarcinoma	cystadenocarcinoma	C235	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
high	high	H200	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
microsatellites	microsatellite	M262	NNS	B-NP	O
distributed	distribute	D236	VBN	B-VP	O
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
different	different	D165	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
change	change	C520	VB	B-VP	O
their	their	T600	PRP$	B-NP	O
size	size	S200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mercurial	mercurial	M626	JJ	I-NP	O
fashion	fashion	F250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
genomic	genomic	G520	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dynamic	dynamic	D520	JJ	I-NP	O
and	and	A530	CC	I-NP	O
ongoing	ongoing	O525	JJ	I-NP	O
process	process	P620	NN	I-NP	O
whose	whose	W200	WP$	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
underestimated	underestimate	U536	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
allelotyping	allelotyping	A431	NN	I-NP	O
of	of	O100	IN	B-PP	O
bulk	bulk	B420	NN	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
tissue	tissue	T200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
the	the	T000	DT	B-NP	O
source	source	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
R524P	R524P	R100	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
mismatch	mismatch	M253	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
repair	repair	R160	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
(	(	0000	(	O	O
Salmonella	Salmonella	S454	NN	B-NP	O
MutS	MutS	M320	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
nonpolyposis	nonpolyposis	N514	NN	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Patient	Patient	P353	NN	B-NP	O
2774	2774	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
38	38	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
her	her	H600	PRP$	B-NP	O
normal	normal	N654	JJ	I-NP	O
tissue	tissue	T200	NN	I-NP	O
carried	carry	C630	VBD	B-VP	O
both	both	B300	CC	O	O
mutant	mutant	M353	JJ	B-NP	O
and	and	A530	CC	I-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
lost	lose	L230	VBN	I-VP	O
at	at	A300	IN	B-PP	O
some	some	S500	DT	B-NP	O
point	point	P530	NN	I-NP	O
early	early	E640	RB	B-ADVP	O
during	during	D652	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
so	so	S000	IN	B-SBAR	O
that	that	T300	IN	I-SBAR	O
DNA	DNA	D500	NN	B-NP	O
isolated	isolate	I243	VBN	B-VP	O
either	either	E360	CC	O	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
or	or	O600	CC	B-PP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
2774	2774	0000	CD	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
carries	carry	C620	VBZ	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
MSH2	MSH2	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mismatch	mismatch	M253	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
repair	repair	R160	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
MSH2	MSH2	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
progression	progression	P626	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
primary	primary	P656	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Loss	Loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
data	datum	D300	NNS	I-NP	O
from	from	F650	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
confers	confer	C516	VBZ	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
early	early	E640	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
onset	onset	O523	NN	I-NP	I-Disease
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
subject	subject	S123	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
allelic	allelic	A420	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
indication	indication	I532	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
somatically	somatically	S532	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
coding	coding	C352	NN	I-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
primary	primary	P656	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
show	show	S000	VBP	B-VP	O
allele	allele	A400	NN	B-NP	O
loss	loss	L200	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
32	32	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
12	12	0000	CD	B-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
;	;	0000	:	O	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
germline	germline	G654	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
and	and	A530	CC	O	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutation	mutation	M350	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
may	may	M000	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
critical	critical	C632	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
arise	arise	A620	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
germline	germline	G654	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

PAX6	PAX6	P200	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
dosage	dosage	D200	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
,	,	0000	,	O	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
anophthalmia	anophthalmia	A513	NN	B-NP	B-Disease
and	and	A530	CC	O	O
central	central	C536	JJ	B-NP	B-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
eye	eye	E000	NN	I-NP	O
malformation	malformation	M416	NN	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
haploinsufficiency	haploinsufficiency	H145	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
PAX6	PAX6	P200	NN	B-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
box	box	B200	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
this	this	T200	DT	B-NP	O
dosage	dosage	D200	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
two	two	T000	CD	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
segregating	segregate	S262	VBG	B-VP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
late	late	L300	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
corneal	corneal	C654	NN	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
codons	codon	C352	NNS	B-NP	O
103	103	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
353	353	0000	CD	I-NP	O
,	,	0000	,	O	O
truncate	truncate	T652	NN	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
paired	pair	P630	VBN	I-NP	O
and	and	A530	CC	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
PST	PST	P230	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PST	PST	P230	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
activates	activate	A231	VBZ	B-VP	O
transcription	transcription	T652	NN	B-NP	O
autonomously	autonomously	A352	RB	B-ADVP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
form	form	F650	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
partial	partial	P634	JJ	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
had	have	H300	VBD	B-VP	O
severe	severe	S160	JJ	B-NP	O
craniofacial	craniofacial	C651	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
central	central	C536	JJ	I-NP	I-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
defects	defect	D123	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	B-Disease
eyes	eye	E200	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
malformations	malformation	M416	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
Sey	Sey	S000	NNP	I-NP	O
mice	mouse	M200	NNS	I-NP	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
critical	critical	C632	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
in	in	I500	IN	B-PP	O
controlling	control	C536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
migration	migration	M263	NN	I-NP	O
and	and	A530	CC	I-NP	O
differentiation	differentiation	D165	NN	I-NP	O
of	of	O100	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
neuronal	neuronal	N654	JJ	I-NP	O
progenitor	progenitor	P625	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
map	map	M100	NN	I-NP	O
and	and	A530	CC	I-NP	O
candidate	candidate	C530	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
constructed	construct	C523	VBN	I-VP	O
a	a	A000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
comprises	comprise	C516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
contig	contig	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
137	137	0000	CD	B-NP	O
overlapping	overlap	O164	VBG	I-NP	O
yeast	yeast	Y230	NN	I-NP	O
artificial	artificial	A631	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
and	and	A530	CC	O	O
P1	P1	P000	NN	B-NP	O
clones	clone	C452	NNS	I-NP	O
,	,	0000	,	O	O
onto	onto	O530	IN	B-PP	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
placed	place	P423	VBN	I-VP	O
112	112	0000	CD	B-NP	O
PCR	PCR	P260	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
localized	localize	L242	VBN	I-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
20	20	0000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
map	map	M100	NN	I-NP	O
,	,	0000	,	O	O
ten	ten	T500	CD	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
had	have	H300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
previously	previously	P612	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
30	30	0000	CD	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
representing	represent	R162	VBG	B-VP	O
partial	partial	P634	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
as	as	A200	RB	B-NP	O
yet	yet	Y300	RB	I-NP	O
unidentified	unidentified	U535	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
lie	lie	L000	VBP	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
narrow	narrow	N600	JJ	I-NP	O
region	region	R250	NN	I-NP	O
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
sequenced	sequence	S252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
without	without	W300	IN	B-PP	O
revealing	reveal	R145	VBG	B-VP	O
any	any	A500	DT	B-NP	O
deleterious	deleterious	D436	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
new	new	N000	JJ	I-NP	O
reagents	reagent	R253	NNS	I-NP	O
should	should	S430	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
LEC	LEC	L200	NNP	I-NP	O
rat	rat	R300	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
copper	copper	C160	NN	I-NP	O
transporting	transport	T652	VBG	B-VP	O
ATPase	ATPase	A312	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Wilson	Wilson	W425	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Long	Long	L520	NNP	I-NP	O
-	-	0000	HYPH	I-NP	O
Evans	Evans	E152	NNP	I-NP	O
Cinnamon	Cinnamon	C500	NNP	I-NP	O
(	(	0000	(	O	O
LEC	LEC	L200	NNP	O	O
)	)	0000	)	O	O
rat	rat	R300	NN	B-NP	O
shows	show	S200	VBZ	B-VP	O
similarity	similarity	S546	NN	B-NP	O
to	to	T000	TO	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
many	many	M500	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
cloned	clone	C453	VBN	I-VP	O
cDNAs	cDNA	C352	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
rat	rat	R300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Atp7b	Atp7b	A310	NN	B-NP	O
)	)	0000	)	O	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Wilson	Wilson	W425	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
ATP7B	ATP7B	A310	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
them	them	T500	PRP	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
a	a	A000	DT	B-NP	O
partial	partial	P634	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Atp7b	Atp7b	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
LEC	LEC	L200	NNP	I-NP	O
rat	rat	R300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
removes	remove	R512	VBZ	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
900	900	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
,	,	0000	,	O	O
includes	include	I524	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
crucial	crucial	C624	JJ	I-NP	O
ATP	ATP	A310	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
and	and	A530	CC	O	O
extends	extend	E235	VBZ	B-VP	O
downstream	downstream	D523	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
convincing	convince	C515	VBG	I-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
defining	define	D152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
LEC	LEC	L200	NNP	I-NP	O
rat	rat	R300	NN	I-NP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
model	model	M340	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
liver	liver	L160	NN	B-NP	O
pathophysiology	pathophysiology	P312	NN	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
therapy	therapy	T610	NN	B-NP	O
for	for	F600	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
the	the	T000	DT	B-NP	O
pathway	pathway	P300	NN	I-NP	O
of	of	O100	IN	B-PP	O
copper	copper	C160	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
possible	possible	P214	JJ	I-NP	O
interaction	interaction	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
heavy	heavy	H100	JJ	I-NP	O
metals	metal	M342	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
neurodegenerative	neurodegenerative	N632	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
impairment	impairment	I516	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
very	very	V600	RB	B-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
fatty	fatty	F300	JJ	I-NP	I-Disease
acids	acid	A232	NNS	I-NP	I-Disease
beta	beta	B300	SYM	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
oxidation	oxidation	O235	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
recently	recently	R253	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
positional	positional	P235	JJ	B-NP	O
cloning	clone	C452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
,	,	0000	,	O	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
"	"	0000	``	I-NP	O
ABC	ABC	A120	NNP	I-NP	O
"	"	0000	''	I-NP	O
superfamily	superfamily	S161	NN	I-NP	O
of	of	O100	IN	B-PP	O
membrane	membrane	M516	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
transporters	transporter	T652	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
shows	show	S200	VBZ	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
,	,	0000	,	I-NP	O
significant	significant	S251	JJ	I-NP	O
homology	homology	H542	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
PMP70	PMP70	P510	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
extends	extend	E235	VBZ	B-VP	O
over	over	O160	IN	B-NP	O
21	21	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
intronic	intronic	I536	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
the	the	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
immediate	immediate	I530	JJ	I-NP	O
5	5	0000	CD	I-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Sequences	Sequence	S252	NNS	B-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
distal	distal	D234	JJ	B-NP	O
exons	exon	E252	NNS	I-NP	O
cross	cross	C620	AFX	O	O
-	-	0000	HYPH	O	O
hybridize	hybridize	H163	VB	B-VP	O
strongly	strongly	S365	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
additional	additional	A354	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
positioned	position	P235	VBN	I-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pulsed	pulsed	P423	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
field	field	F430	NN	I-NP	O
map	map	M100	NN	I-NP	O
between	between	B350	IN	B-PP	O
DXS15	DXS15	D200	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
L1CAM	L1CAM	L250	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
about	about	A130	RB	B-NP	O
650	650	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
color	color	C460	NN	I-NP	O
pigment	pigment	P253	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
color	color	C460	NN	B-NP	O
vision	vision	V250	NN	I-NP	O
anomalies	anomaly	A542	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
thus	thus	T200	RB	B-ADVP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
represent	represent	R162	VB	I-VP	O
a	a	A000	DT	B-NP	O
contiguous	contiguous	C532	JJ	I-NP	B-Disease
gene	gene	G500	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
secondary	secondary	S253	JJ	I-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologues	homologue	H542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Hdh	Hdh	H300	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
adducin	adducin	A325	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Add1	Add1	A300	NN	B-NP	O
)	)	0000	)	O	O
map	map	M100	NN	B-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
conserved	conserve	C526	VBN	B-NP	O
synteny	synteny	S535	NN	I-NP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
4p16	4p16	P000	CD	I-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
neurodegenerative	neurodegenerative	N632	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
IT15	IT15	I300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
reported	report	R163	VBD	B-VP	O
the	the	T000	DT	B-NP	O
cloning	cloning	C452	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hdh	Hdh	H300	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
IT15	IT15	I300	NN	B-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
interspecific	interspecific	I536	JJ	I-NP	O
backcross	backcross	B262	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
both	both	B300	CC	O	O
Hdh	Hdh	H300	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	O	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
adducin	adducin	A325	NN	B-NP	O
(	(	0000	(	O	O
Add1	Add1	A300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
membrane	membrane	M516	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
associated	associate	A230	VBN	B-NP	O
cytoskeletal	cytoskeletal	C324	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
position	position	P235	NN	I-NP	O
on	on	O500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
5	5	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
ancestral	ancestral	A523	JJ	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
and	and	A530	CC	O	O
show	show	S000	VBP	B-VP	O
no	no	N000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
with	with	W300	IN	B-PP	O
D5H4S43	D5H4S43	D200	NN	B-NP	O
,	,	0000	,	O	O
D5H4S115	D5H4S115	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D5H4S62	D5H4S62	D200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homologues	homologue	H542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
D4S43	D4S43	D200	NN	B-NP	O
,	,	0000	,	O	O
D4S115	D4S115	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D4S62	D4S62	D200	NN	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
mice	mouse	M200	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
mammalian	mammalian	M545	JJ	I-NP	O
species	specie	S120	NNS	I-NP	O
should	should	S430	MD	B-VP	O
reveal	reveal	R140	VB	I-VP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
affecting	affect	A123	VBG	B-VP	O
this	this	T200	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
segment	segment	S253	NN	I-NP	O
during	during	D652	IN	B-PP	O
mammalian	mammalian	M545	JJ	B-NP	O
evolution	evolution	E143	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	B-Disease
ester	ester	E236	NN	I-NP	I-Disease
transfer	transfer	T652	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
determinant	determinant	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
determinants	determinant	D365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
)	)	0000	)	O	O
levels	level	L142	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
are	be	A600	VBP	B-VP	O
poorly	poorly	P640	RB	I-VP	O
understood	understand	U536	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
previously	previously	P612	RB	B-ADVP	O
described	describe	D261	VBD	B-VP	O
plasma	plasma	P425	NN	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	B-Disease
ester	ester	E236	NN	I-NP	I-Disease
transfer	transfer	T652	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
CETP	CETP	C310	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
Int14	Int14	I530	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
very	very	V600	RB	B-NP	O
high	high	H200	JJ	I-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
.	.	0000	.	O	O

Subjects	Subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
>	>	0000	SYM	B-VP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
100	100	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	B-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
130	130	0000	CD	B-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
single	single	S524	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
or	or	O600	CC	I-NP	O
primer	primer	P656	NN	I-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
restriction	restriction	R236	NN	I-NP	O
map	map	M100	NN	I-NP	O
modification	modification	M312	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
intron	intron	I536	NN	I-NP	O
14	14	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
+	+	0000	SYM	B-NP	O
3	3	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon14	exon14	E250	NN	I-NP	O
/	/	0000	SYM	B-VP	O
intron14	intron14	I536	NN	B-NP	O
boundary	boundary	B536	NN	I-NP	O
(	(	0000	(	O	O
Int14	Int14	I530	NN	B-NP	O
T	T	T000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
Asp442	Asp442	A210	NN	B-NP	O
to	to	T000	TO	B-PP	O
Gly	Gly	G400	NN	B-NP	O
)	)	0000	)	O	O
within	within	W350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
(	(	0000	(	O	O
D442G	D442G	D200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Int14	Int14	I530	NN	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
only	only	O540	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
D442G	D442G	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
Int14	Int14	I530	NN	I-NP	O
A	A	A000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
highly	highly	H240	RB	B-ADJP	O
prevalent	prevalent	P614	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
>	>	0000	SYM	B-VP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
60	60	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
combined	combine	C515	VBN	B-NP	O
allele	allele	A400	NN	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
12	12	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
21	21	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
43	43	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
for	for	F600	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	O	O
C	C	C000	NN	B-NP	O
60	60	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
79	79	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
80	80	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
99	99	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
100	100	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
119	119	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
>	>	0000	SYM	B-NP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
120	120	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	O	O
dl	dl	D400	NN	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
prevalences	prevalence	P614	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
D442G	D442G	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
Int14	Int14	I530	NN	I-NP	O
A	A	A000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
extremely	extremely	E236	RB	B-ADJP	O
high	high	H200	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
men	man	M500	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
236	236	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
heterozygote	heterozygote	H362	JJ	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
about	about	A130	IN	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
total	total	T340	JJ	I-NP	O
variance	variance	V652	NN	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
C	C	C000	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
(	(	0000	(	O	O
Int14	Int14	I530	NN	B-NP	O
T	T	T000	NN	I-NP	O
and	and	A530	CC	I-NP	O
Int14	Int14	I530	NN	I-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
Int14	Int14	I530	NN	B-NP	O
A	A	A000	NN	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
(	(	0000	(	O	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
CETP	CETP	C310	NN	I-NP	O
and	and	A530	CC	O	O
markedly	markedly	M623	RB	B-VP	O
increased	increase	I526	VBD	I-VP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Int14	Int14	I530	NN	I-NP	O
T	T	T000	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
D442G	D442G	D200	NN	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
,	,	0000	,	O	O
mean	mean	M500	JJ	B-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
(	(	0000	(	O	O
86	86	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
26	26	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
lower	low	L600	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
Int14	Int14	I530	NN	B-NP	O
A	A	A000	NN	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
(	(	0000	(	O	O
158	158	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
35	35	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
reflecting	reflect	R142	VBG	B-VP	O
residual	residual	R234	JJ	B-NP	O
CETP	CETP	C310	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
47	47	0000	CD	B-NP	O
D442G	D442G	D200	NN	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
,	,	0000	,	O	O
mean	mean	M500	JJ	B-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
91	91	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
23	23	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
D442G	D442G	D200	NN	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
significantly	significantly	S251	RB	B-ADJP	O
greater	great	G636	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
mean	mean	M500	JJ	B-NP	O
HDL	HDL	H340	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Int14	Int14	I530	NN	B-NP	O
A	A	A000	NN	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
(	(	0000	(	O	O
69	69	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
15	15	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
dl	dl	D400	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
D442G	D442G	D200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
acts	act	A232	VBZ	B-VP	O
differently	differently	D165	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
null	null	N400	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
with	with	W300	IN	B-PP	O
weaker	weak	W260	JJR	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
state	state	S300	NN	I-NP	O
and	and	A530	CC	O	O
stronger	strong	S365	JJR	B-NP	O
effects	effect	E123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
dominant	dominant	D530	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
partially	partially	P634	RB	I-NP	O
defective	defective	D123	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

CETP	CETP	C310	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
reflecting	reflect	R142	VBG	B-VP	O
two	two	T000	CD	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
(	(	0000	(	O	O
D442G	D442G	D200	NN	B-NP	O
and	and	A530	CC	O	O
Int14	Int14	I530	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
state	state	S300	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
sufficiently	sufficiently	S125	RB	B-ADJP	O
common	common	C500	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
variation	variation	V635	NN	I-NP	O
in	in	I500	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
C	C	C000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Treatment	Treatment	T635	NN	B-NP	O
of	of	O100	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
:	:	0000	:	O	O
effects	effect	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
chenodeoxycholic	chenodeoxycholic	C532	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
,	,	0000	,	O	O
pravastatin	pravastatin	P612	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
combined	combine	C515	VBN	B-NP	O
use	use	U200	NN	I-NP	O
.	.	0000	.	O	O

Treatments	Treatment	T635	NNS	B-NP	O
by	by	B000	IN	B-PP	O
oral	oral	O640	JJ	B-NP	O
administration	administration	A352	NN	I-NP	O
of	of	O100	IN	B-PP	O
chenodeoxycholic	chenodeoxycholic	C532	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
(	(	0000	(	O	O
CDCA	CDCA	C320	NN	B-NP	O
)	)	0000	)	O	O
alone	alone	A450	RB	B-ADVP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
hydroxy	hydroxy	H362	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
methylglutaryl	methylglutaryl	M342	NN	I-NP	O
(	(	0000	(	O	O
HMG	HMG	H520	NN	B-NP	O
)	)	0000	)	O	O
CoA	CoA	C000	NN	B-NP	O
reductase	reductase	R323	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
(	(	0000	(	O	O
pravastatin	pravastatin	P612	NN	B-NP	O
)	)	0000	)	O	O
alone	alone	A450	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
combination	combination	C515	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
drugs	drug	D620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
attempted	attempt	A351	VBN	I-VP	O
for	for	F600	IN	B-PP	O
7	7	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

CDCA	CDCA	C320	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
dose	dose	D200	NN	I-NP	O
of	of	O100	IN	B-PP	O
300	300	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
day	day	D000	NN	I-NP	O
reduced	reduce	R323	VBD	B-VP	O
serum	serum	S650	NN	B-NP	O
cholestanol	cholestanol	C423	NN	I-NP	O
(	(	0000	(	O	O
67	67	0000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
reduction	reduction	R323	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
lathosterol	lathosterol	L323	NN	B-NP	O
(	(	0000	(	O	O
50	50	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
campesterol	campesterol	C512	NN	B-NP	O
(	(	0000	(	O	O
61	61	0000	CD	B-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
sitosterol	sitosterol	S323	NN	B-NP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
.	.	0000	.	O	O
7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
sera	serum	S600	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
changed	change	C523	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
"	"	0000	``	B-ADJP	O
atherogenic	atherogenic	A362	JJ	I-ADJP	O
"	"	0000	''	O	O
;	;	0000	:	O	O
total	total	T340	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
,	,	0000	,	O	O
triglyceride	triglyceride	T624	NN	B-NP	O
and	and	A530	CC	O	O
low	low	L000	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
LDL	LDL	L340	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
were	be	W600	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

Contrarily	Contrarily	C536	RB	B-ADVP	O
,	,	0000	,	O	O
pravastatin	pravastatin	P612	NN	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
dose	dose	D200	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
day	day	D000	NN	I-NP	O
improved	improve	I516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
sera	serum	S600	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
markedly	markedly	M623	RB	B-ADVP	O
"	"	0000	``	O	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
atherogenic	atherogenic	A362	JJ	I-NP	O
"	"	0000	''	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
reductions	reduction	R323	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cholestanol	cholestanol	C423	NN	B-NP	O
(	(	0000	(	O	O
30	30	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
lathosterol	lathosterol	L323	NN	B-NP	O
(	(	0000	(	O	O
44	44	0000	CD	B-NP	O
.	.	0000	.	O	O
0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
campesterol	campesterol	C512	NN	B-NP	O
(	(	0000	(	O	O
22	22	0000	CD	B-NP	O
.	.	0000	.	O	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
sitosterol	sitosterol	S323	NN	B-NP	O
(	(	0000	(	O	O
9	9	0000	CD	B-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
inadequate	inadequate	I532	JJ	B-ADJP	O
.	.	0000	.	O	O

Combined	Combine	C515	VBN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
with	with	W300	IN	B-PP	O
CDCA	CDCA	C320	NN	B-NP	O
and	and	A530	CC	I-NP	O
pravastatin	pravastatin	P612	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
good	good	G300	JJ	B-NP	O
overlapping	overlapping	O164	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
each	each	E200	DT	B-NP	O
drug	drug	D620	NN	I-NP	O
alone	alone	A450	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
sera	serum	S600	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
apparently	apparently	A165	RB	B-ADJP	O
more	more	M600	JJR	I-ADJP	O
"	"	0000	``	O	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
atherogenic	atherogenic	A362	JJ	I-NP	O
"	"	0000	''	O	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
after	after	A136	IN	B-PP	O
CDCA	CDCA	C320	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
.	.	0000	.	O	O

Serum	Serum	S650	NN	B-NP	O
cholestanol	cholestanol	C423	NN	I-NP	O
concentration	concentration	C525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
still	still	S340	RB	B-ADVP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
times	time	T520	NNS	I-NP	O
higher	high	H260	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
lathosterol	lathosterol	L323	NN	I-NP	O
level	level	L140	NN	I-NP	O
was	be	W200	VBD	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
enhancement	enhancement	E525	NN	I-NP	O
of	of	O100	IN	B-PP	O
overall	overall	O164	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
sufficiently	sufficiently	S125	RB	B-ADJP	O
suppressed	suppress	S162	VBN	I-ADJP	O
.	.	0000	.	O	O

Plant	Plant	P453	JJ	B-NP	O
sterol	sterol	S364	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
CDCA	CDCA	C320	NN	B-NP	O
and	and	A530	CC	I-NP	O
pravastatin	pravastatin	P612	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
good	good	G300	JJ	I-NP	O
treatment	treatment	T635	NN	I-NP	O
for	for	F600	IN	B-PP	O
CTX	CTX	C320	NN	B-NP	B-Disease
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
improvement	improvement	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
metabolism	metabolism	M314	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
suppression	suppression	S162	NN	I-NP	O
of	of	O100	IN	B-PP	O
cholesterol	cholesterol	C423	NN	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
reductions	reduction	R323	NNS	B-NP	O
of	of	O100	IN	B-PP	O
cholestanol	cholestanol	C423	NN	B-NP	O
and	and	A530	CC	I-NP	O
plant	plant	P453	NN	I-NP	O
sterol	sterol	S364	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
progression	progression	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
arrested	arrest	A623	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
dramatic	dramatic	D653	JJ	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
,	,	0000	,	O	O
xanthoma	xanthoma	X535	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
electrophysiological	electrophysiological	E423	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
could	could	C430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
found	find	F530	VBN	I-VP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
drugs	drug	D620	NNS	I-NP	O

Mutation	Mutation	M350	NN	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
Danish	Danish	D520	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Swedish	Swedish	S320	JJ	I-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recent	recent	R253	JJ	I-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
open	open	O150	JJ	I-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
(	(	0000	(	O	O
CHM	CHM	C500	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
intron	intron	I536	NN	I-NP	O
boundaries	boundary	B536	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
paved	pave	P130	VBN	I-VP	O
the	the	T000	DT	B-NP	O
way	way	W000	NN	I-NP	O
to	to	T000	TO	B-PP	O
mutation	mutation	M350	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
performed	perform	P616	VBN	I-VP	O
mutation	mutation	M350	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
15	15	0000	CD	B-NP	O
Danish	Danish	D520	NN	I-NP	O
and	and	A530	CC	O	O
Swedish	Swedish	S320	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
)	)	0000	)	O	O
technique	technique	T252	NN	B-NP	O
.	.	0000	.	O	O

Causative	Causative	C231	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
12	12	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
different	different	D165	JJ	B-NP	O
sizes	size	S200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
exon	exon	E250	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
comprised	comprise	C516	VBD	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Mapping	Mapping	M152	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
endpoints	endpoint	E531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
11	11	0000	CD	I-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
sizeable	sizeable	S214	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
enabled	enable	E514	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
construct	construct	C523	VB	I-VP	O
a	a	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
detailed	detailed	D343	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
intervals	interval	I536	NNS	B-NP	O
2	2	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
Xq21	Xq21	X200	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
11	11	0000	CD	I-NP	O
Danish	Danish	D520	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Swedish	Swedish	S320	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
8	8	0000	CD	I-NP	O
causative	causative	C231	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
SSCP	SSCP	S210	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
CHM	CHM	C500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
detected	detect	D323	VBD	B-VP	O
thus	thus	T200	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
choroideremia	choroideremia	C636	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
give	give	G100	VBP	B-VP	O
rise	rise	R200	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
introduction	introduction	I536	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Predominance	Predominance	P635	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	JJ	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
The	The	T000	DT	B-NP	O
Netherlands	Netherlands	N364	NNP	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
survey	survey	S610	NN	I-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
peroxisomal	peroxisomal	P625	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
accumulation	accumulation	A254	NN	B-NP	O
of	of	O100	IN	B-PP	O
saturated	saturate	S363	VBN	B-NP	O
very	very	V600	RB	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
central	central	C536	JJ	B-NP	O
and	and	A530	CC	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
demyelination	demyelination	D545	NN	I-NP	B-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
impaired	impair	I516	VBN	B-NP	B-Disease
function	function	F523	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
adrenal	adrenal	A365	JJ	B-NP	I-Disease
cortex	cortex	C632	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
testes	testis	T232	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	B-ADJP	O
variable	variable	V614	JJ	I-ADJP	O
,	,	0000	,	O	O
childhood	childhood	C430	NN	B-NP	B-Disease
cerebral	cerebral	C616	JJ	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
(	(	0000	(	O	O
CCALD	CCALD	C243	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
being	be	B520	VBG	B-VP	O
the	the	T000	DT	B-NP	O
main	main	M500	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
explored	explore	E214	VBD	B-VP	O
the	the	T000	DT	B-NP	O
30	30	0000	CD	I-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
well	well	W400	RB	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
/	/	0000	SYM	I-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
Study	Study	S300	NN	I-NP	O
Group	Group	G610	NN	I-NP	O
and	and	A530	CC	O	O
phenotyped	phenotype	P531	VBD	B-VP	O
77	77	0000	CD	B-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
35	35	0000	CD	B-NP	O
(	(	0000	(	O	O
46	46	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
AMN	AMN	A500	NN	B-NP	B-Disease
and	and	A530	CC	O	O
24	24	0000	CD	B-NP	O
(	(	0000	(	O	O
31	31	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
CCALD	CCALD	C243	NN	B-NP	B-Disease
or	or	O600	CC	O	O
adolescent	adolescent	A342	JJ	B-NP	B-Disease
cerebral	cerebral	C616	JJ	I-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
(	(	0000	(	O	O
AdolCALD	AdolCALD	A342	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
percentages	percentage	P625	NNS	I-NP	O
differ	differ	D160	VBP	B-VP	O
significantly	significantly	S251	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
reports	report	R163	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
25	25	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
28	28	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
developed	develop	D141	VBD	B-VP	O
AMN	AMN	A500	NN	B-NP	B-Disease
and	and	A530	CC	O	O
53	53	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
57	57	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
CCALD	CCALD	C243	NN	I-NP	B-Disease
or	or	O600	CC	I-NP	O
AdolCALD	AdolCALD	A342	NN	I-NP	B-Disease
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Netherlands	Netherlands	N364	NNP	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
80	80	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
antibody	antibody	A531	NN	I-NP	O
against	against	A252	IN	B-PP	O
the	the	T000	DT	B-NP	O
synthetic	synthetic	S532	JJ	I-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
peptides	peptide	P132	NNS	I-NP	O
deduced	deduce	D323	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	I-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
produced	produce	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
antibody	antibody	A531	NN	I-NP	O
reacted	react	R230	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
80	80	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
band	band	B530	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
control	control	C536	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
no	no	N000	DT	B-NP	O
bands	band	B532	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
(	(	0000	(	O	O
#	#	0000	#	B-NP	O
163	163	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
mRNA	mRNA	M650	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
Northern	Northern	N636	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
293T	293T	T000	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
transfected	transfecte	T652	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
full	full	F400	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
coding	cod	C352	VBG	B-VP	O
cDNA	cDNA	C350	NN	B-NP	O
inserted	insert	I526	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
vector	vector	V236	NN	I-NP	O
produced	produce	P632	VBD	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
80	80	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
Western	Western	W236	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
immunocytological	immunocytological	I523	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
staining	staining	S352	NN	I-NP	O
was	be	W200	VBD	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
punctate	punctate	P523	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
punctate	punctate	P523	NN	I-NP	O
staining	staining	S352	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
#	#	0000	#	I-NP	O
163	163	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
thus	thus	T200	RB	B-ADVP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
80	80	0000	CD	I-NP	O
kDa	kDa	K300	NN	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Isolation	Isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
McLeod	McLeod	M243	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

McLeod	McLeod	M243	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
multisystem	multisystem	M432	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
abnormalities	abnormality	A156	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
neuromuscular	neuromuscular	N652	JJ	I-NP	O
and	and	A530	CC	I-NP	O
hematopoietic	hematopoietic	H531	JJ	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
assembled	assemble	A251	VBN	I-VP	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
contig	contig	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
360	360	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encompasses	encompass	E525	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
McLeod	McLeod	M243	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
50	50	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
radiolabeled	radiolabele	R341	VBN	B-NP	O
whole	whole	W400	JJ	I-NP	O
cosmids	cosmid	C253	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
transcription	transcription	T652	NN	I-NP	O
units	unit	U532	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
,	,	0000	,	O	O
designated	designate	D253	VBN	B-VP	O
as	as	A200	IN	B-PP	O
XK	XK	X200	NN	B-NP	O
,	,	0000	,	O	O
correlates	correlate	C643	VBZ	B-VP	O
closely	closely	C424	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
McLeod	McLeod	M243	NNP	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

XK	XK	X200	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
structural	structural	S362	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
prokaryotic	prokaryotic	P626	JJ	B-NP	O
and	and	A530	CC	I-NP	O
eukaryotic	eukaryotic	E263	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Nucleotide	Nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
XK	XK	X200	NN	B-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
McLeod	McLeod	M243	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
identified	identify	I353	VBN	I-VP	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
at	at	A300	IN	B-PP	O
conserved	conserve	C526	VBN	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
and	and	A530	CC	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
direct	direct	D623	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
XK	XK	X200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
McLeod	McLeod	M243	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
spastic	spastic	S123	JJ	B-NP	I-Disease
paraplegia	paraplegia	P614	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
spastic	spastic	S123	JJ	B-NP	I-Disease
paraplegia	paraplegia	P614	NN	I-NP	I-Disease
(	(	0000	(	O	O
SPG	SPG	S120	NN	B-NP	B-Disease
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
defined	define	D153	VBN	I-VP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
SPG	SPG	S120	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
Xq28	Xq28	X200	NN	B-NP	O
while	while	W400	IN	B-SBAR	O
two	two	T000	CD	B-NP	O
clinically	clinically	C452	RB	I-NP	O
distinct	distinct	D235	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
map	map	M100	VBP	B-VP	O
to	to	T000	TO	B-PP	O
Xq22	Xq22	X200	NN	B-NP	O
(	(	0000	(	O	O
SPG2	SPG2	S120	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
dysmyelinating	dysmyelinate	D254	VBG	B-VP	I-Disease
disorder	disorder	D263	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
Pelizaeus	Pelizaeus	P420	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Merzbacher	Merzbacher	M621	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
PMD	PMD	P530	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Xq21	Xq21	X200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
q22	q22	Q000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proteolipid	proteolipid	P634	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PLP	PLP	P410	NN	B-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
myelin	myelin	M450	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	O	O
PLP	PLP	P410	NN	B-NP	O
and	and	A530	CC	I-NP	O
DM20	DM20	D500	NN	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
narrowing	narrow	N652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
interval	interval	I536	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
SPG2	SPG2	S120	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
PLP	PLP	P410	NN	B-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
closest	close	C423	JJS	I-NP	O
marker	marker	M626	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
implicating	implicate	I514	VBG	B-VP	O
PLP	PLP	P410	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
His139Tyr	His139Tyr	H236	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3B	3B	B000	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
male	male	M400	NN	I-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
PLP	PLP	P410	NN	I-NP	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
DM20	DM20	D500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
segregates	segregate	S262	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
(	(	0000	(	O	O
Zmax	Zmax	Z520	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
63	63	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
theta	theta	T300	NN	I-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
00	00	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
appears	appear	A162	VBZ	B-VP	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
SPG2	SPG2	S120	NN	B-NP	O
and	and	A530	CC	I-NP	O
PMD	PMD	P530	NN	I-NP	B-Disease
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease

Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
mutations	mutation	M352	NNS	B-NP	O
among	among	A520	IN	B-PP	O
Jewish	Jewish	J200	JJ	O	O
and	and	A530	CC	O	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	B-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Canavan	Canavan	C515	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
aspartoacylase	aspartoacylase	A216	NN	B-NP	I-Disease
(	(	0000	(	O	O
ASPA	ASPA	A210	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Sixty	Sixty	S230	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
four	four	F600	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	HYPH	B-NP	O
693C	693C	C000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
A	A	A000	NN	B-NP	O
,	,	0000	,	I-NP	O
854A	854A	A000	NN	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
914C	914C	C000	NN	B-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
>	>	0000	SYM	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
693C	693C	C000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
914C	914C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
base	base	B200	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
nonsense	nonsense	N525	JJ	B-NP	O
tyr231	tyr231	T600	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	B-NP	O
ter	ter	T600	NN	B-NP	O
and	and	A530	CC	O	O
missense	missense	M252	JJ	B-NP	O
ala305	ala305	A400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
glu	glu	G400	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
complete	complete	C514	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ASPA	ASPA	A210	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
expression	expression	E216	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
854A	854A	A000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
converted	convert	C516	VBD	B-VP	O
glu	glu	G400	NN	B-NP	O
to	to	T000	TO	B-PP	O
ala	ala	A400	NN	B-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
285	285	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
glu285	glu285	G400	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
ala	ala	A400	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
ASPA	ASPA	A210	NNP	I-NP	O
has	have	H200	VBZ	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
expressed	express	E216	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
fourth	fourth	F630	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
433	433	0000	CD	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	O	O
2	2	0000	CD	B-NP	O
(	(	0000	(	O	O
A	A	A000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
G	G	G000	NN	O	O
)	)	0000	)	O	O
transition	transition	T652	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
would	would	W430	MD	B-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
skipping	skipping	S215	NN	B-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
accompanied	accompany	A251	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
thus	thus	T200	RB	O	O
would	would	W430	MD	B-VP	O
produce	produce	P632	VB	I-VP	O
aberrant	aberrant	A165	JJ	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
128	128	0000	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Canavan	Canavan	C515	NNP	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
,	,	0000	,	O	O
88	88	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
from	from	F650	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
descent	descent	D253	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
glu285	glu285	G400	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
ala	ala	A400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
predominant	predominant	P635	JJ	B-ADJP	O
(	(	0000	(	O	O
82	82	0000	CD	B-NP	O
.	.	0000	.	O	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
tyr231	tyr231	T600	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	O	O
>	>	0000	SYM	O	O
ter	ter	T600	NN	B-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
433	433	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	SYM	I-NP	O
2	2	0000	CD	I-NP	O
(	(	0000	(	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
98	98	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Canavan	Canavan	C515	NNP	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ala305	ala305	A400	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
glu	glu	G400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
probands	proband	P615	NNS	I-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
and	and	A530	CC	O	O
constituted	constitute	C523	VBD	B-VP	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
40	40	0000	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

Predominant	Predominant	P635	JJ	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
and	and	A530	CC	O	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
would	would	W430	MD	B-VP	O
suggest	suggest	S230	VB	I-VP	O
a	a	A000	DT	B-NP	O
founding	founding	F535	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
father	father	F360	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
in	in	I500	IN	B-PP	O
propagation	propagation	P612	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O

Intelligence	Intelligence	I534	NN	B-NP	O
quotient	quotient	Q353	NN	I-NP	O
profile	profile	P614	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
intergenerational	intergenerational	I536	JJ	B-NP	O
deficit	deficit	D123	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
correlation	correlation	C643	NN	B-NP	O
with	with	W300	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
amplification	amplification	A514	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
abbreviated	abbreviate	A161	VBN	I-NP	O
Wechsler	Wechsler	W246	NNP	I-NP	O
Adult	Adult	A343	NNP	I-NP	O
Intelligence	Intelligence	I534	NNP	I-NP	O
Scale	Scale	S240	NNP	I-NP	O
Revised	Revised	R123	NNP	I-NP	O
(	(	0000	(	O	O
WAIS	WAIS	W200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
R	R	R000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
verbal	verbal	V614	JJ	B-NP	O
and	and	A530	CC	I-NP	O
arithmetical	arithmetical	A635	JJ	I-NP	O
cognitive	cognitive	C253	JJ	I-NP	O
performance	performance	P616	NN	I-NP	O
in	in	I500	IN	B-PP	O
55	55	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
covering	cover	C165	VBG	B-VP	O
all	all	A400	DT	B-NP	O
grades	grade	G632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
31	31	0000	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
at	at	A300	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheriting	inherit	I563	VBG	B-VP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Scaled	Scaled	S243	JJ	B-NP	O
scores	score	S262	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
assessment	assessment	A253	NN	I-NP	O
were	be	W600	VBD	B-VP	O
converted	convert	C516	VBN	I-VP	O
into	into	I530	IN	B-PP	O
an	an	A500	DT	B-NP	O
intelligence	intelligence	I534	NN	I-NP	O
quotient	quotient	Q353	NN	I-NP	O
(	(	0000	(	O	O
IQ	IQ	I200	NN	B-NP	O
)	)	0000	)	O	O
estimation	estimation	E235	NN	B-NP	O
on	on	O500	IN	B-PP	O
each	each	E200	DT	B-NP	O
person	person	P625	NN	I-NP	O
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-NP	O
IQ	IQ	I200	NN	I-NP	O
differences	difference	D165	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
all	all	A400	DT	B-NP	O
55	55	0000	CD	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
mean	mean	M500	NN	B-NP	O
90	90	0000	CD	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
,	,	0000	,	O	O
SD	SD	S300	NNP	B-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
31	31	0000	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
(	(	0000	(	O	O
102	102	0000	CD	B-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
,	,	0000	,	O	O
SD	SD	S300	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	DT	B-NP	O
group	group	G610	NN	I-NP	O
;	;	0000	:	O	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
15	15	0000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
parents	parent	P653	NNS	I-NP	O
(	(	0000	(	O	O
99	99	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
SD	SD	S300	NNP	B-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
affected	affect	A123	VBN	I-NP	O
children	child	C436	NNS	I-NP	O
(	(	0000	(	O	O
88	88	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
SD	SD	S300	NNP	B-NP	O
17	17	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
significance	significance	S251	NN	B-NP	O
was	be	W200	VBD	B-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
parental	parental	P653	JJ	B-NP	O
sex	sex	S200	NN	I-NP	O
being	be	B520	VBG	B-VP	O
female	female	F540	JJ	B-ADJP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
15	15	0000	CD	B-NP	O
pairs	pair	P620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
sibs	sib	S120	NNS	I-NP	O
(	(	0000	(	O	O
89	89	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
6	6	0000	CD	I-NP	O
,	,	0000	,	O	O
SD	SD	S300	NNP	B-NP	O
13	13	0000	CD	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
normal	normal	N654	JJ	I-NP	O
sibs	sib	S120	NNS	I-NP	O
(	(	0000	(	O	O
100	100	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	O	O
SD	SD	S300	NNP	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O
6	6	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

IQ	IQ	I200	NN	B-NP	O
steadily	steadily	S340	RB	B-ADVP	O
declined	decline	D245	VBD	B-VP	O
as	as	A200	IN	B-SBAR	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
signs	sign	S252	NNS	B-NP	O
and	and	A530	CC	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
decreased	decrease	D262	VBD	B-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
size	size	S200	NN	I-NP	O
increased	increase	I526	VBD	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
more	more	M600	RBR	B-ADJP	O
linear	linear	L560	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
age	age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
IQ	IQ	I200	NN	B-NP	O
difference	difference	D165	NN	I-NP	O
and	and	A530	CC	O	O
CTG	CTG	C320	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
child	child	C430	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
sib	sib	S100	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
affected	affect	A123	VBN	B-NP	O
sib	sib	S100	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
poor	poor	P600	JJ	B-ADJP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
CTG	CTG	C320	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
reliable	reliable	R414	JJ	I-NP	O
predictor	predictor	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
IQ	IQ	I200	NN	B-NP	O
either	either	E360	CC	O	O
in	in	I500	IN	B-PP	O
individual	individual	I531	JJ	B-NP	O
persons	person	P625	NNS	I-NP	O
or	or	O600	CC	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
cognitive	cognitive	C253	JJ	B-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
to	to	T000	TO	I-VP	O
clarify	clarify	C461	VB	I-VP	O
specific	specific	S121	JJ	B-NP	O
deficits	deficit	D123	NNS	I-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
group	group	G610	NN	I-NP	O

Adenomatous	Adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
intrachromosomal	intrachromosomal	I536	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
laboratory	laboratory	L163	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
institutionalised	institutionalised	I523	JJ	I-NP	O
adult	adult	A343	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
originally	originally	O625	RB	B-ADVP	O
referred	refer	R163	VBD	B-VP	O
for	for	F600	IN	B-PP	O
autism	autism	A325	NN	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
when	when	W500	WRB	B-ADVP	O
an	an	A500	DT	B-NP	O
interstitial	interstitial	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
del	del	D400	NN	B-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q15q22	q15q22	Q200	NN	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
and	and	A530	CC	O	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MCC	MCC	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
genes	gene	G520	NNS	I-NP	O
confirmed	confirm	C516	VBN	B-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Adenomatous	Adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
carcinoma	carcinoma	C625	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
rectum	rectum	R235	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
subsequently	subsequently	S125	RB	I-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

She	She	S000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
profoundly	profoundly	P615	RB	B-ADVP	O
mentally	mentally	M534	RB	B-ADJP	B-Disease
retarded	retarded	R363	JJ	I-ADJP	I-Disease
,	,	0000	,	O	O
autistic	autistic	A323	JJ	B-ADJP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
minor	minor	M560	JJ	B-NP	O
dysmorphic	dysmorphic	D256	JJ	I-NP	B-Disease
features	feature	F362	NNS	I-NP	I-Disease
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
similar	similar	S546	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
loop	loop	L100	NN	I-NP	O
formed	form	F653	VBN	B-VP	O
at	at	A300	IN	B-PP	O
meiosis	meiosis	M200	NN	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
insertion	insertion	I526	NN	I-NP	O
(	(	0000	(	O	O
dir	dir	D600	NN	B-NP	O
ins	in	I520	NNS	I-NP	O
(	(	0000	(	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q22	q22	Q000	NN	B-NP	O
.	.	0000	.	O	O
3q14	3q14	Q000	CD	B-NP	O
.	.	0000	.	O	O
2q15	2q15	Q000	CD	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
further	further	F636	RBR	B-ADVP	O
confirms	confirm	C516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
MCC	MCC	M200	NN	B-NP	O
and	and	A530	CC	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
genes	gene	G520	NNS	I-NP	O
to	to	T000	TO	B-PP	O
5q22	5q22	Q000	NN	B-NP	O
and	and	A530	CC	I-NP	O
comparison	comparison	C516	NN	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
recent	recent	R253	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
genes	gene	G520	NNS	B-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
markers	marker	M626	NNS	I-NP	O
lie	lie	L000	VBP	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
5q22	5q22	Q000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
subband	subband	S153	NN	I-NP	O

Familial	Familial	F540	JJ	B-NP	B-Disease
male	male	M400	JJ	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q	17q	Q000	NN	I-NP	O
.	.	0000	.	O	O

Breast	Breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
men	man	M500	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
about	about	A130	IN	B-PP	O
a	a	A000	DT	B-NP	O
hundredfold	hundredfold	H536	RB	I-NP	O
less	less	L200	RBR	I-NP	O
common	common	C500	JJ	I-ADJP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
has	have	H200	VBZ	B-VP	O
hindered	hinder	H536	VBN	I-VP	O
research	research	R262	NN	B-NP	O
into	into	I530	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
22	22	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
one	one	O500	CD	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q	17q	Q000	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
strong	strong	S365	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
against	against	A252	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
(	(	0000	(	O	O
lod	lod	L300	NN	B-NP	O
score	score	S260	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
63	63	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
best	good	B230	JJS	I-NP	O
estimate	estimate	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
linked	link	L523	VBN	B-NP	O
families	family	F542	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
18	18	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
which	which	W200	WDT	B-NP	O
predisposes	predispose	P632	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
and	and	A530	CC	O	O
which	which	W200	WDT	B-NP	O
confers	confer	C516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
additional	additional	A354	JJ	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
include	include	I524	VBP	B-VP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
may	may	M000	MD	B-VP	O
therefore	therefore	T616	RB	I-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
mapping	mapping	M152	NN	I-NP	O
and	and	A530	CC	I-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Ewing	Ewing	E520	NNP	B-NP	B-Disease
family	family	F540	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
tumors	tumor	T562	NNS	B-NP	I-Disease
,	,	0000	,	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
soft	soft	S130	JJ	B-NP	I-Disease
parts	part	P632	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
desmoplastic	desmoplastic	D251	JJ	B-NP	B-Disease
small	small	S540	JJ	I-NP	I-Disease
round	round	R530	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
codes	cod	C320	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
band	band	B530	NN	B-NP	O
q12	q12	Q000	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
22	22	0000	CD	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
solid	solid	S430	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
including	include	I524	VBG	B-PP	O
Ewing	Ewing	E520	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
,	,	0000	,	O	O
related	relate	R430	VBN	B-VP	O
primitive	primitive	P653	JJ	B-NP	O
neuroectodermal	neuroectodermal	N623	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
soft	soft	S130	JJ	B-NP	I-Disease
parts	part	P632	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
desmoplastic	desmoplastic	D251	JJ	B-NP	B-Disease
small	small	S540	JJ	I-NP	I-Disease
round	round	R530	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
fused	fuse	F230	VBN	I-VP	O
to	to	T000	TO	B-PP	O
genes	gene	G520	NNS	B-NP	O
encoding	encode	E523	VBG	B-VP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
activators	activator	A231	NNS	I-NP	O
/	/	0000	SYM	B-NP	O
repressors	repressor	R162	NNS	I-NP	O
,	,	0000	,	O	O
like	like	L200	IN	B-PP	O
Fli	Fli	F400	NNP	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
or	or	O600	CC	O	O
erg	erg	E620	NN	B-NP	O
or	or	O600	CC	O	O
ATF	ATF	A310	NN	B-NP	O
1	1	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
wt1	wt1	W300	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
better	well	B360	RBR	I-VP	O
understand	understand	U536	VB	I-VP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
cloned	clone	C453	VBD	B-VP	O
the	the	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
differential	differential	D165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
two	two	T000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
encoding	encode	E523	VBG	B-VP	O
72	72	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
alternatively	alternatively	A436	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
,	,	0000	,	I-NP	O
EWS	EWS	E200	NN	I-NP	O
and	and	A530	CC	I-NP	O
EWS	EWS	E200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
b	b	B000	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
EWS	EWS	E200	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
contain	contain	C535	VBP	B-VP	O
putative	putative	P310	JJ	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
motifs	motif	M312	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
b	b	B000	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
binds	bind	B532	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
RNA	RNA	R500	NN	B-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
specifically	specifically	S121	RB	B-ADVP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
poly	poly	P400	NN	B-NP	O
G	G	G000	NN	I-NP	O
and	and	A530	CC	O	O
poly	poly	P400	NN	B-NP	O
U	U	U000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
was	be	W200	VBD	B-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
carboxy	carboxy	C612	NN	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
86	86	0000	CD	I-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
constitute	constitute	C523	VBP	B-VP	O
RGG	RGG	R200	NN	B-NP	O
box	box	B200	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
EWS	EWS	E200	NN	B-NP	O
(	(	0000	(	O	O
NTD	NTD	N300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
EWS	EWS	E200	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
translocation	translocation	T652	NN	I-NP	O
may	may	M000	MD	B-VP	O
regulate	regulate	R243	VB	I-VP	O
the	the	T000	DT	B-NP	O
specificity	specificity	S121	NN	I-NP	O
of	of	O100	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
EWS	EWS	E200	NN	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
erg	erg	E620	NN	I-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Ewings	Ewings	E520	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activator	activator	A231	NN	I-NP	O
.	.	0000	.	O	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
EWS	EWS	E200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
erg	erg	E620	NN	I-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
NTD	NTD	N300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
EWS	EWS	E200	NN	I-NP	O
functions	function	F523	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
activation	activation	A231	NN	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
EWS	EWS	E200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
erg	erg	E620	NN	I-NP	O
chimeric	chimeric	C562	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
genomic	genomic	G520	JJ	B-NP	O
organization	organization	O625	NN	I-NP	O
and	and	A530	CC	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
to	to	T000	TO	B-PP	O
17p13	17p13	P000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
ter	ter	T600	NN	I-NP	O
and	and	A530	CC	I-NP	O
conservation	conservation	C526	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
during	during	D652	IN	B-PP	O
evolution	evolution	E143	NN	B-NP	O
.	.	0000	.	O	O

Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
or	or	O600	CC	O	O
spongy	spongy	S152	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
brain	brain	B650	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
leukodystrophy	leukodystrophy	L232	NN	I-NP	B-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
aspartoacylase	aspartoacylase	A216	NN	B-NP	I-Disease
(	(	0000	(	O	O
ASPA	ASPA	A210	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
coding	coding	C352	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Canavan	Canavan	C515	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
ASPA	ASPA	A210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
span	span	S150	VB	I-VP	O
29	29	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
aspartoacylase	aspartoacylase	A216	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
coded	cod	C300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
six	six	S200	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
intervened	intervene	I536	VBN	B-VP	O
by	by	B000	IN	B-PP	O
five	five	F100	CD	B-NP	O
introns	intron	I536	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
vary	vary	V600	VBP	B-VP	O
from	from	F650	IN	B-PP	O
94	94	0000	CD	B-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
III	III	I000	CD	I-NP	O
)	)	0000	)	O	O
to	to	T000	TO	B-PP	O
514	514	0000	CD	B-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
VI	VI	V000	CD	I-NP	O
)	)	0000	)	O	O
bases	base	B200	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
/	/	0000	SYM	B-VP	O
intron	intron	I536	NN	B-NP	O
splice	splice	S142	NN	I-NP	O
junction	junction	J523	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
follow	follow	F400	VBP	B-VP	O
the	the	T000	DT	B-NP	O
gt	gt	G300	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ag	ag	A200	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
rule	rule	R400	NN	I-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
/	/	0000	SYM	I-NP	O
mouse	mouse	M200	NN	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
hybrid	hybrid	H163	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
localized	localize	L242	VBD	B-VP	O
ASPA	ASPA	A210	NN	B-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17	17	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
ASPA	ASPA	A210	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
further	further	F636	RBR	I-VP	O
mapped	map	M130	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
17p13	17p13	P000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
ter	ter	T600	NN	I-NP	O
region	region	R250	NN	I-NP	O
by	by	B000	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
bovine	bovine	B150	JJ	I-NP	O
aspa	aspa	A210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
exon	exon	E250	NN	I-NP	O
/	/	0000	SYM	I-NP	O
intron	intron	I536	NN	I-NP	O
organization	organization	O625	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
500	500	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
upstream	upstream	U123	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
initiator	initiator	I536	NN	I-NP	O
ATG	ATG	A320	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
bovine	bovine	B150	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
77	77	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
ASPA	ASPA	A210	NN	I-NP	O
coding	coding	C352	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
cross	cross	C620	AFX	O	O
-	-	0000	HYPH	O	O
hybridize	hybridize	H163	NN	B-NP	O
with	with	W300	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
yeast	yeast	Y230	NN	B-NP	O
,	,	0000	,	O	O
chicken	chicken	C250	NN	B-NP	O
,	,	0000	,	O	O
rabbit	rabbit	R130	NN	B-NP	O
,	,	0000	,	O	O
cow	cow	C000	NN	B-NP	O
,	,	0000	,	O	O
dog	dog	D200	NN	B-NP	O
,	,	0000	,	O	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
monkey	monkey	M520	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
specificity	specificity	S121	NN	I-NP	O
of	of	O100	IN	B-PP	O
cross	cross	C620	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
species	species	S120	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
of	of	O100	IN	B-PP	O
coding	cod	C352	VBG	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
aspartoacylase	aspartoacylase	A216	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
during	during	D652	IN	B-PP	O
evolution	evolution	E143	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
should	should	S430	MD	B-VP	O
now	now	N000	RB	I-VP	O
be	be	B000	VB	I-VP	O
possible	possible	P214	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
noncoding	noncoding	N523	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
Canavan	Canavan	C515	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
ASPA	ASPA	A210	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
:	:	0000	:	O	O
size	size	S200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
and	and	A530	CC	I-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
dependent	dependent	D153	JJ	I-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
neuromuscular	neuromuscular	N652	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
elongations	elongation	E452	NNS	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
unambiguously	unambiguously	U512	RB	I-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
solely	solely	S400	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
CTG	CTG	C320	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
exclusive	exclusive	E242	JJ	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
congenital	congenital	C525	JJ	I-NP	O
form	form	F650	NN	I-NP	O
remains	remain	R520	VBZ	B-VP	O
unexplained	unexplained	U521	JJ	B-ADJP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
observation	observation	O126	NN	I-NP	O
of	of	O100	IN	B-PP	O
differently	differently	D165	RB	B-NP	O
sized	size	S230	VBN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
tissues	tissue	T200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
individual	individual	I531	NN	I-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
why	why	W000	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
necessarily	necessarily	N264	RB	I-VP	O
correlate	correlate	C643	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
and	and	A530	CC	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
symptoms	symptom	S513	NNS	B-NP	O
.	.	0000	.	O	O

Through	Through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
and	and	A530	CC	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
142	142	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
418	418	0000	CD	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
the	the	T000	DT	B-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
positive	positive	P231	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
enlargement	enlargement	E546	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
similarly	similarly	S546	RB	B-ADVP	O
through	through	T620	IN	B-PP	O
male	male	M400	JJ	B-NP	O
and	and	A530	CC	I-NP	O
female	female	F540	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
<	<	0000	SYM	B-NP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
CTG	CTG	C320	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Beyond	Beyond	B530	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
variation	variation	V635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
important	important	I516	JJ	I-ADJP	O
through	through	T620	IN	B-PP	O
female	female	F540	JJ	B-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
a	a	A000	DT	B-NP	O
tendency	tendency	T535	NN	I-NP	O
to	to	T000	TO	B-PP	O
compression	compression	C516	NN	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
almost	almost	A452	RB	B-ADVP	O
exclusively	exclusively	E242	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
for	for	F600	IN	B-PP	O
>	>	0000	SYM	B-NP	O
or	or	O600	CC	O	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
implies	imply	I514	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
size	size	S200	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
segregation	segregation	S262	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
congenital	congenital	C525	JJ	I-NP	O
form	form	F650	NN	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
reveals	reveal	R142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
excess	excess	E200	NN	I-NP	O
of	of	O100	IN	B-PP	O
transmitting	transmit	T652	VBG	B-VP	O
grandfathers	grandfather	G653	NNS	B-NP	O
partially	partially	P634	RB	B-ADVP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
fertility	fertility	F634	NN	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
males	male	M420	NNS	I-NP	O

Illegitimate	Illegitimate	I423	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
for	for	F600	IN	B-PP	O
identification	identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O

Taking	Take	T252	VBG	B-VP	O
advantage	advantage	A315	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
illegitimate	illegitimate	I423	JJ	I-NP	O
transcription	transcription	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenylalanine	phenylalanine	P545	NN	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
analyse	analyse	A542	VB	I-VP	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
hyperphenylalaninemic	hyperphenylalaninemic	H161	JJ	B-NP	B-Disease
children	child	C436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
circulating	circulate	C624	VBG	B-VP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
3	3	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
from	from	F650	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
and	and	A530	CC	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
migration	migration	M263	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
skipping	skipping	S215	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
of	of	O100	IN	B-PP	O
RNA	RNA	R500	NN	B-NP	O
translation	translation	T652	NN	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
3	3	0000	CD	B-NP	O
IVS10	IVS10	I120	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
10	10	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
11	11	0000	CD	I-NP	O
(	(	0000	(	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
L333F	L333F	L100	NN	B-NP	O
and	and	A530	CC	O	O
E390G	E390G	E200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
view	view	V000	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
circulating	circulate	C624	VBG	B-VP	O
lymphocytes	lymphocyte	L512	NNS	B-NP	O
give	give	G100	VBP	B-VP	O
easy	easy	E200	JJ	B-NP	O
access	access	A200	NN	I-NP	O
to	to	T000	TO	B-PP	O
PAH	PAH	P000	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
whose	whose	W200	WP$	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
reported	report	R163	VBN	B-VP	O
in	in	I500	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
and	and	A530	CC	O	O
therefore	therefore	T616	RB	B-ADVP	O
represent	represent	R162	VBP	B-VP	O
a	a	A000	DT	B-NP	O
useful	useful	U214	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
phenylketonuria	phenylketonuria	P542	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

High	High	H200	JJ	B-NP	O
residual	residual	R234	JJ	I-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
late	late	L300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
metachromatic	metachromatic	M326	JJ	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
suffering	suffer	S165	VBG	B-VP	O
from	from	F650	IN	B-PP	O
late	late	L300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
metachromatic	metachromatic	M326	JJ	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
who	who	W000	WP	B-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
about	about	A130	IN	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

Fibroblasts	Fibroblast	F161	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
show	show	S000	VBP	B-VP	O
significant	significant	S251	JJ	B-NP	O
sulfatide	sulfatide	S413	NN	I-NP	O
degradation	degradation	D263	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
exceeding	exceed	E235	VBG	B-VP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	B-Disease
MLD	MLD	M430	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
deletion	deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
C	C	C000	NN	B-NP	O
447	447	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
and	and	A530	CC	B-PP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
105	105	0000	CD	I-NP	O
;	;	0000	:	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
causes	cause	C200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
Gly309	Gly309	G400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
Ser	Ser	S600	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

Transient	Transient	T652	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
Ser309	Ser309	S600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
13	13	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
that	that	T300	DT	B-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
normal	normal	N654	JJ	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
correctly	correctly	C623	RB	I-VP	O
targeted	target	T623	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
lysosomes	lysosome	L252	NNS	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
unstable	unstable	U523	JJ	B-ADJP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
in	in	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
to	to	T000	TO	B-PP	O
previous	previous	P612	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
showing	show	S520	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
late	late	L300	JJ	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
MLD	MLD	M430	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
always	always	A420	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
influenced	influence	I514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
oligodendrocytes	oligodendrocyte	O423	NNS	B-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
lower	low	L600	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
others	other	O362	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
)	)	0000	)	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
T274M	T274M	T500	NN	B-NP	O
)	)	0000	)	O	O
causing	cause	C252	VBG	B-VP	O
late	late	L300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
metachromatic	metachromatic	M326	JJ	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
.	.	0000	.	O	O

Metachromatic	Metachromatic	M326	JJ	B-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
lysosomal	lysosomal	L254	JJ	I-NP	I-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
arylsulfatase	arylsulfatase	A642	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
;	;	0000	:	O	O
EC	EC	E200	NNP	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
8	8	0000	CD	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
and	and	A530	CC	O	O
adjacent	adjacent	A325	JJ	B-NP	O
intron	intron	I536	NN	I-NP	O
boundaries	boundary	B536	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
late	late	L300	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
infantile	infantile	I515	JJ	I-NP	I-Disease
metachromatic	metachromatic	M326	JJ	I-NP	I-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
amplified	amplify	A514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
discrete	discrete	D263	JJ	I-NP	O
reactions	reaction	R235	NNS	I-NP	O
.	.	0000	.	O	O

Amplified	Amplify	A514	VBN	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
IV	IV	I100	CD	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
substitution	substitution	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
threonine	threonine	T650	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
274	274	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
methionine	methionine	M350	NN	I-NP	O
(	(	0000	(	O	O
T274M	T274M	T500	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
29	29	0000	CD	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
for	for	F600	IN	B-PP	O
T274M	T274M	T500	NN	B-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
6	6	0000	CD	I-NP	O
T274M	T274M	T500	NN	I-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
(	(	0000	(	O	O
representing	represent	R162	VBG	B-VP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
of	of	O100	IN	B-PP	O
Lebanese	Lebanese	L152	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
were	be	W600	VBD	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
consanguineous	consanguineous	C525	JJ	B-NP	O
marriages	marriage	M620	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
rigidly	rigidly	R234	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
among	among	A520	IN	B-PP	O
10	10	0000	CD	B-NP	O
sulfatases	sulfatas	S413	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Escherichia	Escherichia	E262	FW	B-NP	O
coli	coli	C400	FW	I-NP	O
to	to	T000	TO	B-PP	O
humans	human	H520	NNS	B-NP	O
;	;	0000	:	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
most	most	M230	RBS	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
resultant	resultant	R243	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
will	will	W400	MD	B-VP	O
have	have	H100	VB	I-VP	O
little	little	L340	JJ	B-NP	O
or	or	O600	CC	I-NP	O
no	no	N000	DT	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
very	very	V600	RB	I-NP	O
low	low	L000	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
measured	measure	M263	VBN	B-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
uniformly	uniformly	U516	JJ	I-NP	O
severe	severe	S160	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
presentation	presentation	P625	NN	I-NP	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
14	14	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
analysed	analyse	A542	VBN	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
by	by	B000	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
using	use	U252	VBG	B-VP	O
SSCP	SSCP	S210	NN	B-NP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
family	family	F540	NN	I-NP	O
band	band	B530	NN	I-NP	O
shifts	shift	S132	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
gels	gel	G420	NNS	I-NP	O
for	for	F600	IN	B-PP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
exon	exon	E250	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
involved	involve	I514	VBD	B-VP	O
C	C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transitions	transition	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
CGAarg	CGAarg	C262	NN	B-NP	O
codons	codon	C352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
9	9	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
converted	convert	C516	VBD	B-VP	O
a	a	A000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
glutamine	glutamine	G435	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
TAG	TAG	T200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
stop	stop	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

Small	Small	S540	JJ	B-NP	O
insertions	insertion	I526	NNS	I-NP	O
created	create	C630	VBD	B-VP	O
frameshifts	frameshift	F652	NNS	B-NP	O
which	which	W200	WDT	B-NP	O
produced	produce	P632	VBD	B-VP	O
downstream	downstream	D523	JJ	B-NP	O
stop	stop	S310	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
two	two	T000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
disrupted	disrupt	D261	VBD	B-VP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
complete	complete	C514	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
case	case	C200	NN	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
carried	carry	C630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
family	family	F540	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
strongly	strongly	S365	RB	B-VP	O
supports	support	S163	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
candidature	candidature	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	O
protein	protein	P635	NN	I-NP	B-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
inherited	inherit	I563	VBN	B-NP	O
type	type	T100	NN	I-NP	B-Disease
I	I	I000	CD	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PROS1	PROS1	P620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
an	an	A500	DT	B-NP	O
abnormality	abnormality	A156	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
but	but	B300	CC	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
three	three	T600	CD	I-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
shared	share	S630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
+	+	0000	SYM	O	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
10	10	0000	CD	I-NP	O
.	.	0000	.	O	O

Also	Also	A420	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
stopcodon	stopcodon	S312	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PROS1	PROS1	P620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
;	;	0000	:	O	O
this	this	T200	DT	B-NP	O
transversion	transversion	T652	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
extended	extend	E235	VBN	I-VP	O
by	by	B000	IN	B-PP	O
14	14	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fifth	fifth	F130	JJ	I-NP	O
subject	subject	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
possess	possess	P200	VB	I-VP	O
two	two	T000	CD	B-NP	O
sequence	sequence	S252	NN	I-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
junction	junction	J523	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
2	2	0000	CD	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
this	this	T200	DT	B-NP	O
abnormality	abnormality	A156	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADVP	O
neutral	neutral	N364	JJ	B-ADJP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
S	S	S000	NN	I-NP	O
antigen	antigen	A532	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
T	T	T000	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
25	25	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
platelet	platelet	P434	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
stopcodon	stopcodon	S312	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
amounts	amount	A532	NNS	B-NP	O
comparable	comparable	C516	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
wildtype	wildtype	W431	JJ	B-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

mRNA	mRNA	M650	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
either	either	E360	CC	O	O
undetectable	undetectable	U532	JJ	B-NP	O
or	or	O600	CC	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
greatly	greatly	G634	RB	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
amounts	amount	A532	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
latter	latter	L360	JJ	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
based	based	B230	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
feasible	feasible	F214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
protein	protein	P635	NN	B-NP	B-Disease
S	S	S000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Characteristics	Characteristic	C623	NNS	B-NP	O
of	of	O100	IN	B-PP	O
intergenerational	intergenerational	I536	JJ	B-NP	O
contractions	contraction	C536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
generally	generally	G564	RB	B-ADVP	O
increases	increase	I526	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
successive	successive	S210	JJ	B-NP	O
generations	generation	G563	NNS	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
anticipation	anticipation	A532	NN	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
cases	case	C200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
contraction	contraction	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
489	489	0000	CD	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	O	O
offspring	offspre	O121	VBG	B-VP	O
pairs	pair	P620	NNS	B-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
95	95	0000	CD	B-NP	O
(	(	0000	(	O	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
showed	show	S300	VBD	B-VP	O
such	such	S200	JJ	B-NP	O
contractions	contraction	C536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
(	(	0000	(	O	O
PBL	PBL	P140	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
56	56	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
95	95	0000	CD	I-NP	O
pairs	pair	P620	NNS	I-NP	O
,	,	0000	,	O	O
clinical	clinical	C452	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
allowed	allow	A430	VBD	B-VP	O
an	an	A500	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
anticipation	anticipation	A532	NN	I-NP	O
status	status	S320	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
surprising	surprising	S616	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
anticipation	anticipation	A532	NN	B-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
27	27	0000	CD	B-NP	O
(	(	0000	(	O	O
48	48	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
56	56	0000	CD	I-NP	O
pairs	pair	P620	NNS	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
none	none	N500	NN	B-NP	O
clearly	clearly	C464	RB	B-ADVP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
symptomatic	symptomatic	S513	JJ	I-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
contraction	contraction	C536	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
76	76	0000	CD	B-NP	O
(	(	0000	(	O	O
10	10	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
753	753	0000	CD	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
transmissions	transmission	T652	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
19	19	0000	CD	B-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
736	736	0000	CD	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
transmissions	transmission	T652	NNS	I-NP	O
.	.	0000	.	O	O

Anticipation	Anticipation	A532	NN	B-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
(	(	0000	(	O	O
85	85	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
(	(	0000	(	O	O
37	37	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
transmissions	transmission	T652	NNS	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
parental	parental	P653	JJ	I-NP	O
repeat	repeat	R130	NN	I-NP	O
size	size	S200	NN	I-NP	O
correlated	correlate	C643	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
intergenerational	intergenerational	I536	JJ	B-NP	O
contraction	contraction	C536	NN	I-NP	O
(	(	0000	(	O	O
r2	r2	R000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	O	O
50	50	0000	CD	B-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
slope	slope	S410	NN	I-NP	O
of	of	O100	IN	B-PP	O
linear	linear	L560	JJ	B-NP	O
regression	regression	R262	NN	I-NP	O
was	be	W200	VBD	B-VP	O
steeper	steep	S316	JJR	B-ADJP	O
in	in	I500	IN	B-PP	O
paternal	paternal	P365	JJ	B-ADJP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
62	62	0000	CD	I-NP	O
)	)	0000	)	O	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
.	.	0000	.	O	O
30	30	0000	CD	O	O
)	)	0000	)	O	O
transmissions	transmission	T652	NNS	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	O	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Sixteen	Sixteen	S235	CD	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
parents	parent	P653	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
offspring	offspring	O121	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
contractions	contraction	C536	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
was	be	W200	VBD	B-VP	O
higher	high	H260	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
expected	expect	E212	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
contractions	contraction	C536	NNS	I-NP	O
(	(	0000	(	O	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
sib	sib	S100	NN	I-NP	O
population	population	P143	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
54	54	0000	CD	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
offspring	offspring	O121	NN	I-NP	O
per	per	P600	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
parent	parent	P653	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
968	968	0000	CD	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
parents	parent	P653	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
intergenerational	intergenerational	I536	JJ	B-NP	O
contractions	contraction	C536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
leukocyte	leukocyte	L230	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
frequently	frequently	F625	RB	B-ADVP	O
accompanies	accompany	A251	VBZ	B-VP	O
apparent	apparent	A165	JJ	B-NP	O
anticipation	anticipation	A532	NN	I-NP	O
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
when	when	W500	WRB	B-ADVP	O
DM	DM	D500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
maternally	maternally	M365	RB	I-VP	O
transmitted	transmit	T652	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
contraction	contraction	C536	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sibling	sibling	S145	NN	I-NP	O
increase	increase	I526	VBP	B-VP	O
the	the	T000	DT	B-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
contraction	contraction	C536	NN	I-NP	O

Gonosomal	Gonosomal	G525	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
:	:	0000	:	O	O
involvement	involvement	I514	NN	B-NP	O
of	of	O100	IN	B-PP	O
mitotic	mitotic	M320	JJ	B-NP	O
events	event	E153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
variation	variation	V635	NN	I-NP	O
and	and	A530	CC	I-NP	O
selection	selection	S423	NN	I-NP	O
against	against	A252	IN	B-PP	O
extreme	extreme	E236	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
abnormal	abnormal	A156	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
the	the	T000	DT	O	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
broad	broad	B630	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
tissue	tissue	T200	NN	B-NP	O
DNAs	DNA	D520	NNS	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mild	mild	M430	JJ	B-NP	O
,	,	0000	,	I-NP	O
classical	classical	C424	JJ	I-NP	O
,	,	0000	,	I-NP	O
or	or	O600	CC	I-NP	O
congenital	congenital	C525	JJ	I-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O

Differences	Difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
from	from	F650	IN	B-PP	O
single	single	S524	JJ	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	I-NP	O
twins	twin	T520	NNS	I-NP	O
.	.	0000	.	O	O

Repeats	Repeat	R132	NNS	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
expand	expand	E215	VB	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
extent	extent	E235	NN	I-NP	O
in	in	I500	IN	B-PP	O
tissues	tissue	T200	NNS	B-NP	O
originating	originate	O625	VBG	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
embryonal	embryonal	E516	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
male	male	M400	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
intermediate	intermediate	I536	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
or	or	O600	CC	I-NP	O
small	small	S540	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
sized	size	S230	VBN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
covered	cover	C163	VBD	B-VP	O
a	a	A000	DT	B-NP	O
markedly	markedly	M623	RB	I-NP	O
wider	wide	W360	JJR	I-NP	O
range	range	R520	NN	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
male	male	M400	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
large	large	L620	JJ	B-NP	O
allele	allele	A400	NN	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
in	in	I500	IN	B-PP	O
blood	blood	B430	NN	B-NP	O
(	(	0000	(	O	O
>	>	0000	SYM	B-NP	O
700	700	0000	CD	B-NP	O
CTGs	CTG	C320	NNS	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
similar	similar	S546	JJ	B-NP	O
or	or	O600	CC	I-NP	O
smaller	small	S546	JJR	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sperm	sperm	S165	NN	B-NP	O
,	,	0000	,	O	O
when	when	W500	WRB	B-ADVP	O
detectable	detectable	D323	JJ	B-ADJP	O
.	.	0000	.	O	O

Sperm	Sperm	S165	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
>	>	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
CTGs	CTG	C320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
considered	consider	C523	VBN	I-VP	O
gonosomal	gonosomal	G525	JJ	B-NP	O
mosaics	mosaic	M200	NNS	I-NP	O
,	,	0000	,	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	O	O

e	e	E000	NN	B-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
combined	combine	C515	VBD	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
tissue	tissue	T200	NN	I-NP	O
mosaics	mosaic	M200	NNS	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-ADVP	O
remarkably	remarkably	R562	RB	I-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
length	length	L523	NN	I-NP	O
distributions	distribution	D236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
intermediate	intermediate	I536	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
or	or	O600	CC	I-NP	O
small	small	S540	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
sized	size	S230	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
fathers	father	F362	NNS	B-NP	O
sperm	sperm	S165	NN	I-NP	O
were	be	W600	VBD	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
different	different	D165	JJ	I-ADJP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
offsprings	offspring	O121	NNS	I-NP	O
blood	blood	B430	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
combined	combined	C515	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
intergenerational	intergenerational	I536	JJ	B-NP	O
length	length	L523	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
are	be	A600	VBP	B-VP	O
most	most	M230	RBS	B-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
occur	occur	O260	VB	I-VP	O
during	during	D652	IN	B-PP	O
early	early	E640	JJ	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
mitotic	mitotic	M320	JJ	I-NP	O
divisions	division	D125	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
tissue	tissue	T200	NN	I-NP	O
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
length	length	L523	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
divisions	division	D125	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
tissue	tissue	T200	NN	B-NP	O
formation	formation	F653	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
perhaps	perhaps	P612	RB	B-ADVP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
selection	selection	S423	NN	I-NP	O
process	process	P620	NN	I-NP	O
in	in	I500	IN	B-PP	O
spermatogenesis	spermatogenesis	S165	NN	B-NP	O
may	may	M000	MD	B-VP	O
influence	influence	I514	VB	I-VP	O
the	the	T000	DT	B-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
process	process	P620	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
model	model	M340	NN	I-NP	O
explaining	explain	E214	VBG	B-VP	O
mitotic	mitotic	M320	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
and	and	A530	CC	I-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
segregation	segregation	S262	NN	I-NP	O
phenomena	phenomenon	P500	NNS	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
manifestation	manifestation	M512	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
discussed	discuss	D230	VBN	I-VP	O

Regionally	Regionally	R254	RB	B-NP	O
clustered	cluster	C423	VBN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
and	and	A530	CC	O	O
occur	occur	O260	VBP	B-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
new	new	N000	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
at	at	A300	IN	B-PP	O
5q21	5q21	Q000	NN	B-NP	O
-	-	0000	HYPH	O	O
22	22	0000	CD	B-NP	O
results	result	R243	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
dominantly	dominantly	D534	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
adenomatous	adenomatous	A353	JJ	I-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
event	event	E153	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	O
tumourigenesis	tumourigenesis	T562	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
are	be	A600	VBP	B-VP	O
concentrated	concentrate	C525	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
single	single	S524	JJ	B-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
heteroduplex	heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
variants	variant	V653	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
45	45	0000	CD	B-NP	O
affected	affect	A123	VBN	B-VP	O
but	but	B300	CC	O	O
unrelated	unrelated	U564	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Eighteen	Eighteen	E235	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
;	;	0000	:	O	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
11	11	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
presentation	presentation	P625	NN	B-NP	O
or	or	O600	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
6	6	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
27	27	0000	CD	B-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1309	1309	0000	CD	I-NP	O
reported	report	R163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
unselected	unselected	U524	JJ	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
worldwide	worldwide	W643	RB	B-ADVP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
18	18	0000	CD	I-NP	O
new	new	N000	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
27	27	0000	CD	I-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
all	all	A400	DT	B-NP	O
nine	nine	N500	CD	I-NP	O
were	be	W600	VBD	B-VP	O
classed	class	C423	VBN	I-VP	O
as	as	A200	IN	B-PP	O
severe	severe	S160	JJ	B-ADJP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
3	3	0000	CD	I-NP	O
new	new	N000	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
familial	familial	F540	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
were	be	W600	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1309	1309	0000	CD	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
similarly	similarly	S546	RB	B-VP	O
being	be	B520	VBG	I-VP	O
classed	class	C423	VBN	I-VP	O
as	as	A200	IN	B-PP	O
phenotypically	phenotypically	P531	RB	B-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
average	average	A162	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
were	be	W600	VBD	B-VP	O
located	located	L230	JJ	B-ADJP	O
prior	prior	P600	RB	I-ADJP	O
to	to	T000	TO	B-PP	O
codon	codon	C350	NN	B-NP	O
1309	1309	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
fresh	fresh	F620	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
explain	explain	E214	VB	I-VP	O
the	the	T000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
conflict	conflict	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
(	(	0000	(	O	O
20	20	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
on	on	O500	IN	B-PP	O
average	average	A162	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
lethal	lethal	L340	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
post	post	P230	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
reproductive	reproductive	R163	JJ	I-NP	O
age	age	A200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
heterogeneous	heterogeneous	H362	JJ	B-NP	O
anterior	anterior	A536	JJ	I-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
malformations	malformation	M416	NNS	I-NP	I-Disease
including	include	I524	VBG	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
or	or	O600	CC	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
underlies	underlie	U536	VBZ	B-VP	O
many	many	M500	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
lines	line	L520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
evidence	evidence	E135	NN	B-NP	O
now	now	N000	RB	B-ADVP	O
converge	converge	C516	VBP	B-VP	O
to	to	T000	TO	I-VP	O
implicate	implicate	I514	VB	I-VP	O
PAX6	PAX6	P200	NN	B-NP	O
more	more	M600	RBR	B-ADVP	O
widely	widely	W340	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
anterior	anterior	A536	JJ	B-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
malformations	malformation	M416	NNS	I-NP	I-Disease
including	include	I524	VBG	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
.	.	0000	.	O	O

First	First	F623	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
is	be	I200	VBZ	B-VP	O
deleted	delete	D430	VBN	I-VP	O
for	for	F600	IN	B-PP	O
one	one	O500	CD	B-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
.	.	0000	.	O	O

Second	Second	S253	RB	B-ADVP	O
,	,	0000	,	O	O
affected	affect	A123	VBN	B-VP	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
dominantly	dominantly	D534	RB	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
anterior	anterior	A536	JJ	I-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
malformations	malformation	M416	NNS	I-NP	I-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
are	be	A600	VBP	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
R26G	R26G	R200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
paired	paired	P630	JJ	I-NP	O
box	box	B200	NN	I-NP	O
.	.	0000	.	O	O

Third	Third	T630	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
Sey	Sey	S000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
+	+	0000	SYM	B-VP	O
Smalleye	Smalleye	S540	NN	B-NP	O
mice	mouse	M200	NNS	I-NP	O
,	,	0000	,	O	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
murine	murine	M650	JJ	B-NP	O
Pax	Pax	P200	NN	I-NP	O
-	-	0000	HYPH	O	O
6	6	0000	CD	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
an	an	A500	DT	B-NP	O
ocular	ocular	O246	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
resembling	resemble	R251	VBG	B-VP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
anterior	anterior	A536	JJ	B-NP	B-Disease
segment	segment	S253	NN	I-NP	I-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
CAG	CAG	C200	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
:	:	0000	:	O	O
phenocopies	phenocopy	P521	NNS	B-NP	O
or	or	O600	CC	I-NP	O
errors	error	E620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
assignment	assignment	A253	NN	B-NP	O
?	?	0000	.	O	O

Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
4p16	4p16	P000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
(	(	0000	(	O	O
IT15	IT15	I300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
of	of	O100	IN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
022	022	0000	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
persons	person	P625	NNS	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
cohort	cohort	C630	NN	I-NP	O
)	)	0000	)	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
CAG	CAG	C200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
range	range	R520	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
reasons	reason	R252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
not	not	N300	RB	O	O
observing	observe	O126	VBG	B-VP	O
expansion	expansion	E215	NN	B-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
important	important	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
determining	determine	D365	VBG	B-VP	O
the	the	T000	DT	B-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
of	of	O100	IN	B-PP	O
using	use	U252	VBG	B-VP	O
repeat	repeat	R130	NN	B-NP	O
length	length	L523	NN	I-NP	O
both	both	B300	CC	B-PP	O
for	for	F600	IN	I-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
predictive	predictive	P632	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
programs	program	P626	NNS	I-NP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
biological	biological	B424	JJ	B-NP	O
relevance	relevance	R415	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
underlying	underlie	U536	VBG	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
(	(	0000	(	O	O
18	18	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
sized	sized	S230	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
misdiagnosis	misdiagnosis	M232	NN	B-NP	O
,	,	0000	,	O	O
sample	sample	S514	NN	B-NP	O
mix	mix	M200	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
up	up	U100	RP	B-PRT	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
clerical	clerical	C462	JJ	B-NP	O
error	error	E600	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
12	12	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
possible	possible	P214	JJ	B-NP	O
phenocopies	phenocopy	P521	NNS	I-NP	O
for	for	F600	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
family	family	F540	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
phenocopies	phenocopy	P521	NNS	I-NP	O
excluded	exclude	E243	VBD	B-VP	O
4p16	4p16	P000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
CAG	CAG	C200	NN	B-NP	O
expansion	expansion	E215	NN	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
excluded	exclude	E243	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
eight	eight	E230	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
as	as	A200	RB	B-NP	O
many	many	M500	JJ	I-NP	O
as	as	A200	IN	I-NP	O
seven	seven	S150	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
persons	person	P625	NNS	I-NP	O
,	,	0000	,	O	O
retrospective	retrospective	R362	JJ	B-NP	O
review	review	R100	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
characteristics	characteristic	C623	NNS	B-NP	O
not	not	N300	RB	B-ADJP	O
typical	typical	T124	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
on	on	O500	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
occasions	occasion	O252	NNS	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
-	-	0000	HYPH	B-ADVP	O
yet	yet	Y300	RB	B-ADVP	O
-	-	0000	HYPH	B-NP	O
undefined	undefined	U531	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
can	can	C500	MD	B-VP	O
present	present	P625	VB	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
very	very	V600	RB	B-ADJP	O
similar	similar	S546	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease

Frequent	Frequent	F625	JJ	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
877	877	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
androgen	androgen	A536	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Prostatic	Prostatic	P623	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
specimens	specimen	S125	NNS	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
transurethral	transurethral	T652	JJ	B-NP	O
resections	resection	R235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
metastatic	metastatic	M323	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hormone	hormone	H650	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
androgen	androgen	A536	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
AR	AR	A600	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
derived	derive	D613	VBN	I-NP	O
DNAs	DNA	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
6	6	0000	CD	B-NP	O
of	of	O100	IN	I-NP	O
24	24	0000	CD	I-NP	O
specimens	specimen	S125	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
877	877	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
ACT	ACT	A230	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
GCT	GCT	G230	NN	B-NP	O
,	,	0000	,	O	O
Thr	Thr	T600	NN	B-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	B-NP	O
Ala	Ala	A400	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hormone	hormone	H650	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AR	AR	A600	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
same	same	S500	JJ	I-NP	O
AR	AR	A600	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
metastatic	metastatic	M323	JJ	I-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
,	,	0000	,	O	O
LNCaP	LNCaP	L521	NN	B-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
confers	confer	C516	VBZ	B-VP	O
upon	upon	U150	IN	B-PP	O
the	the	T000	DT	B-NP	O
AR	AR	A600	NN	I-NP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
ligand	ligand	L253	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
specificity	specificity	S121	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
stimulated	stimulate	S354	VBN	I-VP	O
by	by	B000	IN	B-PP	O
estrogens	estrogen	E236	NNS	B-NP	O
,	,	0000	,	O	O
progestagens	progestagen	P623	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
antiandrogens	antiandrogen	A535	NNS	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
possible	possible	P214	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
analogous	analogous	A542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
activated	activate	A231	VBN	I-NP	O
/	/	0000	SYM	I-NP	O
altered	alter	A436	VBN	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
oncogene	oncogene	O525	NN	I-NP	O
,	,	0000	,	O	O
codon	codon	C350	NN	B-NP	O
877	877	0000	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
AR	AR	A600	NNS	I-NP	O
with	with	W300	IN	B-PP	O
altered	alter	A436	VBN	B-NP	O
ligand	ligand	L253	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
a	a	A000	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
advantage	advantage	A315	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genesis	genesis	G520	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
estrogens	estrogen	E236	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
infrequently	infrequently	I516	RB	B-ADVP	O
,	,	0000	,	O	O
antiandrogens	antiandrogen	A535	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
increasingly	increasingly	I526	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
hormonal	hormonal	H654	JJ	B-NP	O
therapy	therapy	T610	NN	I-NP	O
for	for	F600	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
advanced	advance	A315	VBN	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
stimulatory	stimulatory	S354	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
therapeutic	therapeutic	T613	JJ	I-NP	O
agents	agent	A253	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
877	877	0000	CD	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
AR	AR	A600	NNS	I-NP	O
further	further	F636	RBR	B-ADVP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
frequently	frequently	F625	RB	I-NP	O
observed	observe	O126	VBN	I-NP	O
AR	AR	A600	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
treatment	treatment	T635	NN	I-NP	O
refractory	refractory	R162	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3q	3q	Q000	NN	I-NP	O
.	.	0000	.	O	O

Alkaptonuria	Alkaptonuria	A421	NN	B-NP	B-Disease
(	(	0000	(	O	O
AKU	AKU	A200	NN	B-NP	B-Disease
;	;	0000	:	O	O
McKusick	McKusick	M200	NNP	B-NP	O
no	no	N000	DT	B-NP	O
.	.	0000	.	I-NP	O
203500	203500	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
homogentisic	homogentisic	H525	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
oxidase	oxidase	O232	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
excrete	excrete	E263	VBP	B-VP	O
large	large	L620	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
homogentisic	homogentisic	H525	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
urine	urine	U650	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
black	black	B420	JJ	I-NP	O
ochronotic	ochronotic	O265	JJ	I-NP	O
pigment	pigment	P253	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
deposited	deposit	D123	VBN	I-VP	O
in	in	I500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
cartilage	cartilage	C634	NN	I-NP	O
and	and	A530	CC	I-NP	O
collagenous	collagenous	C425	JJ	I-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

Ochronosis	Ochronosis	O265	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
predominant	predominant	P635	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
complication	complication	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
ochronotic	ochronotic	O265	JJ	B-NP	B-Disease
arthropathy	arthropathy	A636	NN	I-NP	I-Disease
,	,	0000	,	O	O
dark	dark	D620	JJ	B-NP	O
urine	urine	U650	NN	I-NP	O
,	,	0000	,	O	O
pigment	pigment	P253	NN	B-NP	O
changes	change	C520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
skin	skin	S250	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
alkaptonuria	alkaptonuria	A421	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	O	O

Considering	Consider	C523	VBG	B-VP	O
conserved	conserve	C526	VBN	B-NP	O
synteny	synteny	S535	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
able	able	A140	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
map	map	M100	VB	I-VP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
3q	3q	Q000	NN	I-NP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
alkaptonuria	alkaptonuria	A421	NN	I-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Slovak	Slovak	S412	NN	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Structure	Structure	S362	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
.	.	0000	.	O	O

Intestinal	Intestinal	I532	JJ	B-NP	O
uptake	uptake	U132	NN	I-NP	O
of	of	O100	IN	B-PP	O
dietary	dietary	D360	JJ	B-NP	O
glucose	glucose	G420	NN	I-NP	O
and	and	A530	CC	I-NP	O
galactose	galactose	G423	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mediated	mediate	M300	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
brush	brush	B620	JJ	I-NP	O
border	border	B636	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
underlies	underlie	U536	VBZ	B-VP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
,	,	0000	,	O	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
potentially	potentially	P353	RB	B-NP	O
fatal	fatal	F340	JJ	I-NP	O
diarrhea	diarrhea	D600	NN	I-NP	B-Disease
;	;	0000	:	O	O
conversely	conversely	C516	RB	B-ADVP	O
,	,	0000	,	O	O
oral	oral	O640	JJ	B-NP	O
rehydration	rehydration	R363	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
exploits	exploit	E214	VBZ	B-VP	O
normal	normal	N654	JJ	B-NP	O
transport	transport	T652	NN	I-NP	O
to	to	T000	TO	B-VP	O
alleviate	alleviate	A413	VB	I-VP	O
life	life	L100	NN	B-NP	O
-	-	0000	HYPH	O	O
threatening	threaten	T635	VBG	B-VP	O
diarrhea	diarrhea	D600	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	O
infectious	infectious	I512	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
mapped	map	M130	VBN	I-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
cosmid	cosmid	C253	NN	B-NP	O
and	and	A530	CC	I-NP	O
lambda	lambda	L513	NN	I-NP	O
phage	phage	P200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
representing	represent	R162	VBG	B-VP	O
a	a	A000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
112	112	0000	CD	B-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
.	.	0000	.	O	O

Transcription	Transcription	T652	NN	B-NP	O
initiation	initiation	I535	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
site	site	S300	NN	I-NP	O
27	27	0000	CD	I-NP	O
base	base	B200	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
3	3	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
TATAA	TATAA	T300	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
flanking	flank	F452	VBG	B-NP	O
regions	region	R252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
112	112	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kilobase	kilobase	K412	NN	I-NP	O
region	region	R250	NN	I-NP	O
mapped	map	M130	VBN	B-VP	O
with	with	W300	IN	B-PP	O
four	four	F600	CD	B-NP	O
restriction	restriction	R236	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
.	.	0000	.	O	O

SGLT1	SGLT1	S243	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
comprised	comprise	C516	VBN	I-VP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
(	(	0000	(	O	O
spanning	span	S152	VBG	B-VP	O
72	72	0000	CD	B-NP	O
kilobases	kilobas	K412	NNS	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
a	a	A000	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
evolutionary	evolutionary	E143	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
six	six	S200	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
membrane	membrane	M516	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
span	span	S150	NN	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
precursor	precursor	P626	NN	I-NP	O
via	via	V000	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
duplication	duplication	D142	NN	I-NP	O
event	event	E153	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
from	from	F650	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
against	against	A252	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
secondary	secondary	S253	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
considerations	consideration	C523	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
causing	cause	C252	VBG	I-NP	O
glucose	glucose	G420	NN	I-NP	B-Disease
/	/	0000	SYM	I-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
Na	Na	N000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
reported	report	R163	VBD	B-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
facilitate	facilitate	F243	VBP	B-VP	O
the	the	T000	DT	B-NP	O
search	search	S620	NN	I-NP	O
for	for	F600	IN	B-PP	O
new	new	N000	JJ	B-NP	O
glucose	glucose	G420	NN	I-NP	B-Disease
/	/	0000	SYM	B-VP	I-Disease
galactose	galactose	G423	NN	B-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
important	important	I516	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
future	future	F360	JJ	B-NP	O
evolutionary	evolutionary	E143	JJ	I-NP	O
comparisons	comparison	C516	NNS	I-NP	O
with	with	W300	IN	B-PP	O
other	other	O360	JJ	B-NP	O
Na	Na	N000	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
cotransporters	cotransporter	C365	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
PEPD	PEPD	P130	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
prolidase	prolidase	P643	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
PEPD	PEPD	P130	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
prolidase	prolidase	P643	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
McKusick	McKusick	M200	NNP	B-NP	O
170100	170100	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
iminodipeptiduria	iminodipeptiduria	I531	NN	B-NP	B-Disease
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	B-Disease
ulcers	ulcer	U426	NNS	I-NP	I-Disease
,	,	0000	,	O	O
mental	mental	M534	JJ	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
recurrent	recurrent	R265	JJ	B-NP	O
infections	infection	I512	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
PEPD	PEPD	P130	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
from	from	F650	IN	B-PP	O
five	five	F100	CD	B-NP	O
severely	severely	S164	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
reverse	reverse	R162	NN	B-NP	O
-	-	0000	HYPH	O	O
transcribed	transcribe	T652	VBN	B-VP	O
,	,	0000	,	O	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	O	O
amplified	amplify	A514	VBN	B-VP	O
(	(	0000	(	O	O
RT	RT	R300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PCR	PCR	P260	NN	I-NP	O
)	)	0000	)	O	O
cDNA	cDNA	C350	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
on	on	O500	IN	B-PP	O
four	four	F600	CD	B-NP	O
overlapping	overlap	O164	VBG	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
covering	cover	C165	VBG	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PEPD	PEPD	P130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
detected	detect	D323	VBD	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
bands	band	B532	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
fragment	fragment	F625	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
all	all	A400	DT	B-NP	O
or	or	O600	CC	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
13	13	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
1342	1342	0000	CD	B-NP	O
substitution	substitution	S123	NN	I-NP	O
(	(	0000	(	O	O
G448R	G448R	G600	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
delta	delta	D430	SYM	B-NP	O
E452	E452	E000	NN	B-NP	O
or	or	O600	CC	O	O
delta	delta	D430	SYM	B-NP	O
E453	E453	E000	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
two	two	T000	CD	I-NP	O
probands	proband	P615	NNS	I-NP	O
the	the	T000	DT	B-NP	O
amplified	amplify	A514	VBN	I-NP	O
products	product	P632	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
of	of	O100	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
size	size	S200	NN	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
.	.	0000	.	O	O

Intronic	Intronic	I536	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
flanking	flank	F452	VBG	B-VP	O
exons	exon	E252	NNS	B-NP	O
5	5	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
7	7	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
inverse	inverse	I516	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

Conventional	Conventional	C515	JJ	B-NP	O
PCR	PCR	P260	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
then	then	T500	RB	B-ADVP	O
established	establish	E231	VBD	B-VP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
borders	border	B636	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
revealing	reveal	R145	VBG	B-VP	O
two	two	T000	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
4	4	0000	CD	I-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
prolidase	prolidase	P643	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
PEPD	PEPD	P130	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
we	we	W000	PRP	B-NP	O
attempt	attempt	A351	VBP	B-VP	O
to	to	T000	TO	I-VP	O
begin	begin	B250	VB	I-VP	O
the	the	T000	DT	B-NP	O
process	process	P620	NN	I-NP	O
of	of	O100	IN	B-PP	O
describing	describe	D261	VBG	B-VP	O
these	these	T200	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
and	and	A530	CC	O	O
cataloging	catalog	C342	VBG	B-VP	O
their	their	T600	PRP$	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Recombinations	Recombination	R251	NNS	B-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
descent	descent	D253	JJ	B-NP	O
localize	localize	L242	VBP	B-VP	O
the	the	T000	DT	B-NP	O
Friedreich	Friedreich	F636	NNP	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
cloned	clone	C453	VBN	I-NP	O
450	450	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
for	for	F600	IN	B-PP	O
Friedreich	Friedreich	F636	NNP	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
(	(	0000	(	O	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
neurodegenerative	neurodegenerative	N632	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
tightly	tightly	T234	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
markers	marker	M626	NNS	B-NP	O
D9S5	D9S5	D200	NN	I-NP	O
and	and	A530	CC	I-NP	O
D9S15	D9S15	D200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
rare	rare	R600	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
events	event	E153	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
cen	cen	C500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
FRDA	FRDA	F630	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D9S5	D9S5	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
D9S15	D9S15	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
qter	qter	Q360	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
construction	construction	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
YAC	YAC	Y200	NN	I-NP	O
contig	contig	C532	NN	I-NP	O
extending	extend	E235	VBG	B-VP	O
800	800	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
centromeric	centromeric	C536	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
D9S5	D9S5	D200	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
new	new	N000	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
map	map	M100	VB	I-VP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
cM	cM	C500	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
sought	seek	S230	VBD	B-VP	O
to	to	T000	TO	I-VP	O
increase	increase	I526	VB	I-VP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
information	information	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
available	available	A141	JJ	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
by	by	B000	IN	B-PP	O
considering	consider	C523	VBG	B-VP	O
homozygosity	homozygosity	H523	NN	B-NP	O
by	by	B000	IN	B-PP	O
descent	descent	D253	JJ	B-NP	O
and	and	A530	CC	I-NP	O
association	association	A235	NN	I-NP	O
with	with	W300	IN	B-PP	O
founder	founder	F536	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
allowed	allow	A430	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
one	one	O500	CD	B-NP	O
phase	phase	P200	NN	I-NP	O
-	-	0000	HYPH	O	O
known	know	K500	VBN	B-NP	O
recombination	recombination	R251	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
probable	probable	P614	JJ	I-NP	O
historic	historic	H236	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
on	on	O500	IN	B-PP	O
haplotypes	haplotype	H143	NNS	B-NP	O
from	from	F650	IN	B-PP	O
Reunion	Reunion	R500	NNP	B-NP	O
Island	Island	I245	NNP	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
place	place	P420	VBP	B-VP	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
five	five	F100	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
FRDA	FRDA	F630	NN	B-NP	B-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
represents	represent	R162	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
close	close	C420	JJ	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
flanking	flanking	F452	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
centromeric	centromeric	C536	JJ	I-NP	O
side	side	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
other	other	O360	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
allowed	allow	A430	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
narrow	narrow	N600	VB	I-VP	O
the	the	T000	DT	B-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
distal	distal	D234	JJ	I-NP	O
recombination	recombination	R251	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
>	>	0000	JJR	B-NP	O
180	180	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
from	from	F650	IN	B-PP	O
D9S5	D9S5	D200	NN	B-NP	O
(	(	0000	(	O	O
26P	26P	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Taken	Take	T250	VBN	B-VP	O
together	together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
place	place	P420	VBP	B-VP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
450	450	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
small	small	S540	JJ	B-ADJP	O
enough	enough	E520	RB	I-ADJP	O
for	for	F600	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
search	search	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
candidate	candidate	C530	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
detailed	detailed	D343	JJ	I-NP	O
rare	rare	R600	JJ	I-NP	O
cutter	cutter	C360	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
map	map	M100	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
contig	contig	C532	NN	I-NP	O
covering	cover	C165	VBG	B-VP	O
this	this	T200	DT	B-NP	O
interval	interval	I536	NN	I-NP	O
were	be	W600	VBD	B-VP	O
constructed	construct	C523	VBN	I-VP	O
and	and	A530	CC	O	O
should	should	S430	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
search	search	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Investigation	Investigation	I512	NN	B-NP	O
of	of	O100	IN	B-PP	O
thermoregulatory	thermoregulatory	T656	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
survey	survey	S610	NN	I-NP	O
instrument	instrument	I523	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
temperature	temperature	T516	NN	B-NP	O
regulation	regulation	R243	NN	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
compared	compare	C516	VBN	B-VP	O
to	to	T000	TO	B-PP	O
3	3	0000	CD	B-NP	O
control	control	C536	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
sibs	sib	S120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
SIB	SIB	S100	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
neurodevelopmentally	neurodevelopmentally	N631	RB	B-NP	B-Disease
handicapped	handicap	H532	VBN	I-NP	I-Disease
children	child	C436	NNS	I-NP	O
(	(	0000	(	O	O
ND	ND	N300	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
age	age	A200	NN	B-NP	O
and	and	A530	CC	I-NP	O
gender	gender	G536	NN	I-NP	O
matched	match	M323	VBD	B-VP	O
well	well	W400	RB	B-ADVP	O
children	child	C436	NNS	B-NP	O
(	(	0000	(	O	O
WC	WC	W200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
between	between	B350	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
SIB	SIB	S100	NN	B-NP	O
controls	control	C536	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
WC	WC	W200	NN	B-NP	O
controls	control	C536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
febrile	febrile	F164	JJ	B-NP	O
convulsions	convulsion	C514	NNS	I-NP	O
,	,	0000	,	O	O
fever	fever	F160	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
temperature	temperature	T516	NN	B-NP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
94	94	0000	CD	I-NP	O
degrees	degree	D262	NNS	I-NP	O
F	F	F000	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
differences	difference	D165	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ND	ND	N300	NN	I-NP	O
controls	control	C536	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
abnormalities	abnormality	A156	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
can	can	C500	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
neurodevelopmentally	neurodevelopmentally	N631	RB	I-NP	B-Disease
handicapped	handicap	H532	VBN	I-NP	I-Disease
individual	individual	I531	JJ	I-NP	O
,	,	0000	,	O	O
further	further	F636	RB	B-ADVP	O
suggesting	suggest	S235	VBG	B-VP	O
these	these	T200	DT	B-NP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
necessarily	necessarily	N264	RB	I-VP	O
reflect	reflect	R142	VB	I-VP	O
syndrome	syndrome	S536	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
hypothalamic	hypothalamic	H134	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Phenotypic	Phenotypic	P531	JJ	B-NP	O
variation	variation	V635	NN	I-NP	O
including	include	I524	VBG	B-PP	O
retinitis	retinitis	R353	NN	B-NP	B-Disease
pigmentosa	pigmentosa	P253	NN	I-NP	I-Disease
,	,	0000	,	O	O
pattern	pattern	P365	NN	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
fundus	fundus	F532	NN	B-NP	B-Disease
flavimaculatus	flavimaculatus	F415	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
153	153	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
154	154	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripherin	peripherin	P616	NN	I-NP	O
/	/	0000	SYM	B-NP	O
RDS	RDS	R320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
AND	AND	A530	CC	O	O
OBJECTIVES	OBJECTIVES	O123	VBZ	B-VP	O
Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripherin	peripherin	P616	NN	I-NP	O
/	/	0000	SYM	B-NP	O
RDS	RDS	R320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
retinitis	retinitis	R353	NN	I-NP	I-Disease
pigmentosa	pigmentosa	P253	NN	I-NP	I-Disease
,	,	0000	,	O	O
pattern	pattern	P365	NN	B-NP	O
macular	macular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
retinitis	retinitis	R353	NN	B-NP	B-Disease
punctata	punctata	P523	NN	I-NP	I-Disease
albescens	albescens	A412	NNP	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
herein	herein	H650	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
separate	separate	S163	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
153	153	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
154	154	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripherin	peripherin	P616	NN	I-NP	O
/	/	0000	SYM	B-NP	O
RDS	RDS	R320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

DESIGN	DESIGN	D250	NN	B-NP	O
Case	Case	C200	NN	I-NP	O
reports	report	R163	NNS	I-NP	O
with	with	W300	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
,	,	0000	,	O	O
fluorescein	fluorescein	F462	NN	B-NP	O
angiography	angiography	A526	NN	I-NP	O
,	,	0000	,	O	O
kinetic	kinetic	K532	JJ	B-NP	O
perimetry	perimetry	P653	NN	I-NP	O
,	,	0000	,	O	O
electrophysiological	electrophysiological	E423	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
genetics	genetic	G532	NNS	I-NP	O
.	.	0000	.	O	O

SETTING	SETTING	S352	VBG	B-VP	O
University	University	U516	NNP	B-NP	O
medical	medical	M324	JJ	I-NP	O
centers	center	C536	NNS	I-NP	O
.	.	0000	.	O	O

PATIENTS	PATIENTS	P353	NNS	B-NP	O
A	A	A000	DT	B-NP	O
75	75	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
woman	woman	W500	NN	I-NP	O
,	,	0000	,	O	O
her	her	H600	PRP$	B-NP	O
two	two	T000	CD	I-NP	O
daughters	daughter	D236	NNS	I-NP	O
(	(	0000	(	O	O
aged	age	A230	VBN	B-VP	O
44	44	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
50	50	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
her	her	H600	PRP	B-NP	O
49	49	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
son	son	S500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
peripherin	peripherin	P616	NN	B-NP	O
/	/	0000	SYM	B-VP	O
RDS	RDS	R320	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
The	The	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
presented	present	P625	VBD	B-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
63	63	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
profoundly	profoundly	P615	RB	I-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
electroretinogram	electroretinogram	E423	NN	I-NP	O
(	(	0000	(	O	O
ERG	ERG	E620	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
retinitis	retinitis	R353	NN	I-NP	B-Disease
pigmentosa	pigmentosa	P253	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
progressed	progress	P626	VBD	B-VP	O
dramatically	dramatically	D653	RB	B-NP	O
over	over	O160	IN	I-NP	O
12	12	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
visual	visual	V240	JJ	I-NP	O
field	field	F430	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
daughter	daughter	D236	NN	I-NP	O
developed	develop	D141	VBD	B-VP	O
pattern	pattern	P365	NN	B-NP	B-Disease
macular	macular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
31	31	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

At	At	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
44	44	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
her	her	H600	PRP$	B-NP	O
ERG	ERG	E620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
moderately	moderately	M363	RB	B-ADJP	O
abnormal	abnormal	A156	JJ	I-ADJP	O
but	but	B300	CC	O	O
her	her	H600	PRP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
macula	macula	M240	NN	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
daughter	daughter	D236	NN	I-NP	O
presented	present	P625	VBD	B-VP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
42	42	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
with	with	W300	IN	B-PP	O
macular	macular	M246	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
and	and	A530	CC	O	O
over	over	O160	IN	B-PP	O
10	10	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
developed	develop	D141	VBD	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
picture	picture	P236	NN	I-NP	O
of	of	O100	IN	B-PP	O
fundus	fundus	F532	NN	B-NP	B-Disease
flavimaculatus	flavimaculatus	F415	NN	I-NP	I-Disease
.	.	0000	.	O	O

Her	Her	H600	PRP$	B-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
visual	visual	V240	JJ	I-NP	O
field	field	F430	NN	I-NP	O
was	be	W200	VBD	B-VP	O
preserved	preserve	P626	VBN	I-VP	O
but	but	B300	CC	O	O
her	her	H600	PRP$	B-NP	O
ERG	ERG	E620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
moderately	moderately	M363	RB	B-ADJP	O
abnormal	abnormal	A156	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
son	son	S500	NN	I-NP	O
had	have	H300	VBD	B-VP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
macular	macular	M246	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
44	44	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Pericentral	Pericentral	P625	JJ	B-NP	B-Disease
scotomas	scotoma	S235	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
ERG	ERG	E620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
markedly	markedly	M623	RB	B-ADJP	O
abnormal	abnormal	A156	JJ	I-ADJP	O
.	.	0000	.	O	O

Fluorescein	Fluorescein	F462	NN	B-NP	O
angiography	angiography	A526	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
punctate	punctate	P523	NN	B-NP	O
pigment	pigment	P253	NN	I-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
A	A	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
153	153	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
154	154	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
peripherin	peripherin	P616	NN	I-NP	O
/	/	0000	SYM	B-NP	O
RDS	RDS	R320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
can	can	C500	MD	B-VP	O
produce	produce	P632	VB	I-VP	O
clinically	clinically	C452	RB	B-NP	O
disparate	disparate	D216	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
even	even	E150	RB	B-ADVP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Assignment	Assignment	A253	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22q13	22q13	Q000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Na	Na	N000	NN	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
glucose	glucose	G420	NN	B-NP	O
cotransporter	cotransporter	C365	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
uptake	uptake	U132	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dietary	dietary	D360	JJ	I-NP	O
sugars	sugar	S262	NNS	I-NP	O
glucose	glucose	G420	NN	I-NP	O
and	and	A530	CC	I-NP	O
galactose	galactose	G423	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
lumen	lumen	L500	NN	I-NP	O
.	.	0000	.	O	O

SGLT1	SGLT1	S243	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
currently	currently	C653	RB	I-VP	O
exploited	exploit	E214	VBN	I-VP	O
in	in	I500	IN	B-PP	O
oral	oral	O640	JJ	B-NP	O
rehydration	rehydration	R363	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
75	75	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kDa	kDa	K300	NN	I-NP	O
glycoprotein	glycoprotein	G421	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
localized	localize	L242	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brush	brush	B620	JJ	I-NP	O
border	border	B636	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
epithelium	epithelium	E134	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
comprise	comprise	C516	VB	I-VP	O
12	12	0000	CD	B-NP	O
membrane	membrane	M516	NN	I-NP	O
spans	span	S152	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
glucose	glucose	G420	NN	I-NP	I-Disease
/	/	0000	SYM	B-NP	I-Disease
galactose	galactose	G423	NN	I-NP	I-Disease
malabsorption	malabsorption	M412	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
underlying	underlying	U536	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
SGLT1	SGLT1	S243	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
Asp28	Asp28	A210	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
Asn	Asn	A250	NN	I-NP	O
change	change	C520	NN	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
to	to	T000	TO	B-VP	O
eliminate	eliminate	E453	VB	I-VP	O
SGLT1	SGLT1	S243	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
reside	reside	R230	VB	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
q	q	Q000	NN	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22	22	0000	CD	I-NP	O
(	(	0000	(	O	O
11	11	0000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
-	-	0000	HYPH	B-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
qter	qter	Q360	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
for	for	F600	IN	B-PP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
refines	refine	R152	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
to	to	T000	TO	B-PP	O
22q13	22q13	Q000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
an	an	A500	DT	B-NP	O
example	example	E251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
utility	utility	U343	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SGLT1	SGLT1	S243	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
diagnostic	diagnostic	D252	NN	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
translocations	translocation	T652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
22	22	0000	CD	I-NP	O
.	.	0000	.	O	O

Restriction	Restriction	R236	NN	B-NP	O
of	of	O100	IN	B-PP	O
ocular	ocular	O246	JJ	B-NP	O
fundus	fundus	F532	NN	I-NP	O
lesions	lesion	L252	NNS	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
subgroup	subgroup	S126	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
,	,	0000	,	O	O
alteration	alteration	A436	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
APC	APC	A120	NN	B-NP	B-Disease
,	,	0000	,	O	O
causes	cause	C200	VBZ	B-VP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
condition	condition	C535	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
predisposition	predisposition	P632	NN	B-NP	O
to	to	T000	TO	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
inconsistently	inconsistently	I525	RB	B-ADVP	O
associates	associate	A232	VBZ	B-VP	O
characteristic	characteristic	C623	JJ	B-NP	O
patches	patch	P320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	H163	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
pigment	pigment	P253	NN	I-NP	I-Disease
epithelium	epithelium	E134	NN	I-NP	I-Disease
(	(	0000	(	O	O
CHRPE	CHRPE	C610	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Ocular	Ocular	O246	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
patients	patient	P353	NNS	B-NP	O
expressing	express	E216	VBG	B-VP	O
CHRPE	CHRPE	C610	NN	B-NP	B-Disease
tend	tend	T530	NN	I-NP	O
to	to	T000	TO	B-VP	O
cluster	cluster	C423	VB	I-VP	O
within	within	W350	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
exact	exact	E230	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
42	42	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
CHRPE	CHRPE	C610	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
dependent	dependent	D153	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

CHRPE	CHRPE	C610	NN	B-NP	B-Disease
lesions	lesion	L252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
almost	almost	A452	RB	B-ADJP	O
always	always	A420	RB	I-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
if	if	I100	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
before	before	B160	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
are	be	A600	VBP	B-VP	O
systematically	systematically	S235	RB	B-ADJP	O
present	present	P625	JJ	I-ADJP	O
if	if	I100	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
after	after	A136	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
observed	observe	O126	VBN	B-VP	O
among	among	A520	IN	B-PP	O
affected	affected	A123	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
may	may	M000	MD	B-VP	O
result	result	R243	VB	I-VP	O
in	in	I500	IN	B-PP	O
part	part	P630	NN	B-NP	O
from	from	F650	IN	B-PP	O
different	different	D165	JJ	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ERG	ERG	E620	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
and	and	A530	CC	I-NP	O
humans	human	H520	NNS	I-NP	O
.	.	0000	.	O	O

PURPOSE	PURPOSE	P612	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
earlier	early	E646	JJR	B-NP	O
findings	finding	F535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
electroretinogram	electroretinogram	E423	NN	I-NP	O
(	(	0000	(	O	O
ERG	ERG	E620	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
boy	boy	B000	NN	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
led	lead	L300	VBD	B-VP	O
them	them	T500	PRP	B-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
dystrophin	dystrophin	D236	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	I-NP	O
ERGs	ERG	E620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
boys	boy	B200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
wanted	want	W530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
determined	determined	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
similar	similar	S546	JJ	B-NP	O
ERG	ERG	E620	NN	I-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
.	.	0000	.	O	O

Ganzfeld	Ganzfeld	G521	JJ	B-NP	O
ERGs	ERG	E620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
recorded	record	R263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
boys	boy	B200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
after	after	A136	IN	B-PP	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
ophthalmic	ophthalmic	O134	JJ	I-NP	O
examination	examination	E253	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

ERGs	ERG	E620	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
recorded	record	R263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
anesthetized	anesthetize	A523	VBN	B-NP	O
mdx	mdx	M320	NN	I-NP	O
and	and	A530	CC	I-NP	O
control	control	C536	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
modified	modify	M313	VBN	I-NP	O
Grass	Grass	G620	NN	I-NP	O
photostimulator	photostimulator	P323	NN	I-NP	O
(	(	0000	(	O	O
Grass	Grass	G620	NNP	B-NP	O
Instrument	Instrument	I523	NNP	I-NP	O
Company	Company	C515	NNP	I-NP	O
,	,	0000	,	O	O
Quincy	Quincy	Q520	NNP	B-NP	O
,	,	0000	,	O	O
MA	MA	M000	JJ	B-ADJP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
.	.	0000	.	O	O

Ophthalmic	Ophthalmic	O134	JJ	B-NP	O
examinations	examination	E253	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
five	five	F100	CD	I-NP	O
boys	boy	B200	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
,	,	0000	,	O	O
yet	yet	Y300	RB	B-ADVP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
ERG	ERG	E620	NN	I-NP	O
was	be	W200	VBD	B-VP	O
recorded	record	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
each	each	E200	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
gene	gene	G500	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
variable	variable	V614	JJ	B-ADJP	O
,	,	0000	,	O	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
large	large	L620	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
to	to	T000	TO	B-PP	O
no	no	N000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ERGs	ERG	E620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
and	and	A530	CC	O	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
differ	differ	D160	VB	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
control	control	C536	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
believe	believe	B410	VBP	B-VP	O
the	the	T000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
ERG	ERG	E620	NN	I-NP	O
recorded	record	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
defects	defect	D123	NNS	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
and	and	A530	CC	O	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ERG	ERG	E620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mdx	mdx	M320	NN	I-NP	O
mouse	mouse	M200	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
spared	spar	S163	VBN	I-VP	O
for	for	F600	IN	B-PP	O
several	several	S164	JJ	B-NP	O
reasons	reason	R252	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
milder	mild	M436	JJR	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
,	,	0000	,	O	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
and	and	A530	CC	O	O
retinal	retinal	R354	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
species	species	S120	NN	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ERG	ERG	E620	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
promise	promise	P652	NN	B-NP	O
of	of	O100	IN	B-PP	O
becoming	become	B252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
noninvasive	noninvasive	N512	JJ	I-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
milder	mild	M436	JJR	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Association	Association	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
catenins	catenin	C352	NNS	B-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
initiate	initiate	I530	VB	I-VP	O
sporadic	sporadic	S163	JJ	B-NP	O
and	and	A530	CC	I-NP	O
inherited	inherited	I563	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
well	well	W400	RB	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
,	,	0000	,	O	O
little	little	L340	JJ	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
cellular	cellular	C460	JJ	I-NP	O
proteins	protein	P635	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
associate	associate	A230	VBP	B-VP	O
with	with	W300	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	I-NP	O
peptide	peptide	P130	NN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
E	E	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cadherin	cadherin	C365	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
and	and	A530	CC	O	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
catenin	catenin	C350	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
residue	residue	R230	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
sufficient	sufficient	S125	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
interaction	interaction	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
catenins	catenin	C352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
initiation	initiation	I535	NN	I-NP	O
and	and	A530	CC	I-NP	O
cell	cell	C400	NN	I-NP	O
adhesion	adhesion	A325	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Difference	Difference	D165	NN	B-NP	O
in	in	I500	IN	B-PP	O
methylation	methylation	M343	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
D15S9	D15S9	D200	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
first	first	F623	JJ	B-NP	O
cousins	cousin	C252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Angelman	Angelman	A524	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Abnormalities	Abnormality	A156	NNS	B-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
region	region	R250	NN	I-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
Angelman	Angelman	A524	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Differences	Difference	D165	NNS	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
methylation	methylation	M343	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
which	which	W200	WDT	B-NP	O
hybridizes	hybridize	H163	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
,	,	0000	,	O	O
DN34	DN34	D500	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
first	first	F623	JJ	B-NP	O
cousins	cousin	C252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	O
paracentric	paracentric	P625	JJ	I-NP	O
inversion	inversion	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
methylation	methylation	M343	NN	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
conditions	condition	C535	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
phenomenon	phenomenon	P500	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
,	,	0000	,	O	O
whereby	whereby	W610	WRB	B-ADVP	O
genetic	genetic	G532	JJ	B-NP	O
information	information	I516	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
differently	differently	D165	RB	B-ADJP	O
dependent	dependent	D153	JJ	I-ADJP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
of	of	O100	IN	B-PP	O
origin	origin	O625	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
51	51	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
DNA	DNA	D500	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
of	of	O100	IN	B-PP	O
dinucleotide	dinucleotide	D524	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
(	(	0000	(	O	O
CA	CA	C000	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
13q14	13q14	Q000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
these	these	T200	DT	B-NP	O
markers	marker	M626	NNS	I-NP	O
for	for	F600	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wilson	Wilson	W425	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WND	WND	W530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
marker	marker	M626	NN	I-NP	O
(	(	0000	(	O	O
D13S133	D13S133	D200	NN	B-NP	O
)	)	0000	)	O	O
described	describe	D261	VBN	B-VP	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
three	three	T600	CD	B-NP	O
new	new	N000	JJ	I-NP	O
highly	highly	H240	RB	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
(	(	0000	(	O	O
D13S314	D13S314	D200	NN	B-NP	O
,	,	0000	,	O	O
D13S315	D13S315	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D13S316	D13S316	D200	NN	B-NP	O
)	)	0000	)	O	O
close	close	C420	RB	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
WND	WND	W530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
marker	marker	M626	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
D13S314	D13S314	D200	NN	B-NP	O
,	,	0000	,	O	O
D13S133	D13S133	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
D13S316	D13S316	D200	NN	B-NP	O
each	each	E200	DT	B-NP	O
show	show	S000	VBP	B-VP	O
nonrandom	nonrandom	N565	JJ	B-NP	O
distribution	distribution	D236	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
WND	WND	W530	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
haplotypes	haplotype	H143	NNS	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
markers	marker	M626	NNS	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
highly	highly	H240	RB	B-NP	O
significant	significant	S251	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
between	between	B350	IN	B-PP	O
WND	WND	W530	NN	B-NP	B-Disease
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
important	important	I516	JJ	B-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
breast	breast	B623	NN	I-NP	O
/	/	0000	SYM	B-VP	O
ovarian	ovarian	O165	JJ	B-NP	O
family	family	F540	NN	I-NP	O
:	:	0000	:	O	O
refinement	refinement	R153	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
multi	multi	M430	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
affected	affect	A123	VBN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
pedigree	pedigree	P326	NN	I-NP	O
(	(	0000	(	O	O
BOV3	BOV3	B100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
consistent	consistent	C523	JJ	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q	17q	Q000	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
confirming	confirm	C516	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
17q	17q	Q000	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
event	event	E153	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
bilateral	bilateral	B436	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
case	case	C200	NN	I-NP	O
which	which	W200	WDT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
D17S857	D17S857	D200	NN	B-NP	O
;	;	0000	:	O	O
D17S857	D17S857	D200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
thus	thus	T200	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
proximal	proximal	P625	JJ	I-NP	O
boundary	boundary	B536	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Combining	Combine	C515	VBG	B-VP	O
this	this	T200	DT	B-NP	O
information	information	I516	NN	I-NP	O
with	with	W300	IN	B-PP	O
previously	previously	P612	RB	B-NP	O
published	publish	P142	VBN	I-NP	O
mapping	mapping	M152	NN	I-NP	O
information	information	I516	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
contained	contain	C535	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
estimated	estimate	E235	VBN	B-VP	O
at	at	A300	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
in	in	I500	IN	B-PP	O
length	length	L523	NN	B-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
tumour	tumour	T560	NN	I-NP	I-Disease
/	/	0000	SYM	B-VP	O
blood	blood	B430	NN	B-NP	O
pairs	pair	P620	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
show	show	S000	NN	I-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
allel	allel	A400	NN	I-NP	O
retained	retain	R353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
was	be	W200	VBD	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
bearing	bear	B652	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
implicating	implicate	I514	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
17	17	0000	CD	I-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oestradiol	oestradiol	O236	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
EDH17B1	EDH17B1	E310	NN	B-NP	O
and	and	A530	CC	O	O
EDH17B2	EDH17B2	E310	NN	B-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
suggested	suggest	S230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
candidate	candidate	C530	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
kinase	kinase	K520	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
component	component	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
neuromuscular	neuromuscular	N652	JJ	B-NP	O
junctions	junction	J523	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
correlated	correlate	C643	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
[	[	0000	(	I-NP	O
CTG	CTG	C320	NN	I-NP	O
]	]	0000	)	I-NP	O
n	n	N000	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
forms	form	F652	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
potentially	potentially	P353	RB	B-ADVP	O
encodes	encode	E523	VBZ	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
serine	serine	S650	NN	I-NP	O
/	/	0000	SYM	B-NP	O
threonine	threonine	T650	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
,	,	0000	,	O	O
DM	DM	D500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PK	PK	P200	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
antisera	antiserum	A532	NNS	B-NP	O
against	against	A252	IN	B-PP	O
synthetic	synthetic	S532	JJ	B-NP	O
DM	DM	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PK	PK	P200	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
antigens	antigen	A532	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
use	use	U200	NN	I-NP	O
in	in	I500	IN	B-PP	O
biochemical	biochemical	B252	JJ	B-NP	O
and	and	A530	CC	I-NP	O
histochemical	histochemical	H232	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

Immunoreactive	Immunoreactive	I562	JJ	B-NP	O
DM	DM	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
kinase	kinase	K520	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
53	53	0000	CD	B-NP	O
kD	kD	K300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
extracts	extract	E236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Immunohistochemical	Immunohistochemical	I523	JJ	B-NP	O
staining	staining	S352	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
DM	DM	D500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
PK	PK	P200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
localised	localise	L242	VBN	I-VP	O
prominently	prominently	P653	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
sites	site	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
neuromuscular	neuromuscular	N652	JJ	B-NP	O
and	and	A530	CC	I-NP	O
myotendinous	myotendinous	M353	JJ	I-NP	O
junctions	junction	J523	NNS	I-NP	O
(	(	0000	(	O	O
NMJs	NMJ	N520	NNS	B-NP	O
and	and	A530	CC	I-NP	O
MTJs	MTJ	M320	NNS	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
and	and	A530	CC	I-NP	O
rodent	rodent	R353	JJ	I-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscles	muscle	M242	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
very	very	V600	RB	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
immunoreactive	immunoreactive	I562	JJ	B-NP	O
DM	DM	D500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PK	PK	P200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
are	be	A600	VBP	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sarcoplasm	sarcoplasm	S621	NN	I-NP	O
of	of	O100	IN	B-PP	O
predominantly	predominantly	P635	RB	B-NP	O
type	type	T100	NN	I-NP	O
I	I	I000	CD	I-NP	O
fibres	fibre	F162	NNS	I-NP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
muscles	muscle	M242	NNS	I-NP	O
.	.	0000	.	O	O

Strikingly	Strikingly	S362	RB	B-ADVP	O
,	,	0000	,	O	O
presence	presence	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
can	can	C500	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
for	for	F600	IN	B-PP	O
NMJs	NMJ	N520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
muscular	muscular	M246	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
and	and	A530	CC	I-NP	O
congenital	congenital	C525	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
no	no	N000	DT	B-NP	O
gross	gross	G620	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
structural	structural	S362	JJ	B-NP	O
organisation	organisation	O625	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
further	further	F636	JJ	B-NP	O
characterisation	characterisation	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
kinase	kinase	K520	NN	I-NP	O
in	in	I500	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
assembly	assembly	A251	NN	I-NP	O
processes	process	P620	NNS	I-NP	O
or	or	O600	CC	O	O
signal	signal	S254	NN	B-NP	O
mediation	mediation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
synaptic	synaptic	S513	JJ	B-NP	O
sites	site	S320	NNS	I-NP	O
and	and	A530	CC	O	O
ultimately	ultimately	U435	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
complex	complex	C514	JJ	I-NP	O
pathophysiology	pathophysiology	P312	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Markedly	Markedly	M623	RB	B-NP	O
accelerated	accelerate	A246	VBN	I-NP	O
catabolism	catabolism	C314	NN	I-NP	O
of	of	O100	IN	B-PP	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
(	(	0000	(	O	O
ApoA	ApoA	A100	NN	B-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
ApoA	ApoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
in	in	I500	IN	B-PP	O
classic	classic	C420	JJ	B-NP	O
lecithin	lecithin	L235	NN	I-NP	O
:	:	0000	:	O	O
cholesterol	cholesterol	C423	NN	B-NP	B-Disease
acyltransferase	acyltransferase	A243	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
fish	fish	F200	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Classic	Classic	C420	JJ	O	B-Disease
(	(	0000	(	O	I-Disease
complete	complete	C514	JJ	B-ADJP	I-Disease
)	)	0000	)	O	I-Disease
lecithin	lecithin	L235	JJ	B-NP	I-Disease
cholesterol	cholesterol	C423	NN	I-NP	I-Disease
acyltransferase	acyltransferase	A243	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
LCAT	LCAT	L230	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
and	and	A530	CC	O	O
Fish	Fish	F200	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
partial	partial	P634	JJ	B-NP	B-Disease
LCAT	LCAT	L230	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
syndromes	syndrome	S536	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
markedly	markedly	M623	RB	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
plasma	plasma	P425	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
high	high	H200	JJ	B-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
HDL	HDL	H340	NN	B-NP	O
)	)	0000	)	O	O
cholesterol	cholesterol	C423	NN	B-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
atherosclerotic	atherosclerotic	A362	JJ	B-NP	B-Disease
cardiovascular	cardiovascular	C631	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
the	the	T000	DT	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HDL	HDL	H340	NN	I-NP	O
apolipoproteins	apolipoprotein	A141	NNS	I-NP	O
(	(	0000	(	O	O
apo	apo	A100	NN	B-NP	O
)	)	0000	)	O	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
and	and	A530	CC	I-NP	O
apoA	apoA	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
five	five	F100	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
LCAT	LCAT	L230	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	B-Disease
LCAT	LCAT	L230	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
four	four	F600	CD	B-NP	O
with	with	W300	IN	B-PP	O
Fish	Fish	F200	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Plasma	Plasma	P425	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
proportionately	proportionately	P616	RB	I-NP	O
greater	great	G636	JJR	I-NP	O
extent	extent	E235	NN	I-NP	O
(	(	0000	(	O	O
23	23	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
)	)	0000	)	O	O
than	than	T500	IN	B-SBAR	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
I	I	I000	CD	I-NP	O
(	(	0000	(	O	O
30	30	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
plasma	plasma	P425	NN	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
particles	particle	P632	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
both	both	B300	CC	O	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
and	and	A530	CC	I-NP	O
apoA	apoA	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
(	(	0000	(	O	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
I	I	I000	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
much	much	M200	RB	B-ADJP	O
lower	low	L600	JJR	I-ADJP	O
(	(	0000	(	O	O
18	18	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
)	)	0000	)	O	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
particles	particle	P632	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
only	only	O540	RB	B-NP	O
apoA	apoA	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
I	I	I000	NN	B-NP	O
(	(	0000	(	O	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
I	I	I000	NN	I-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
51	51	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
and	and	A530	CC	I-NP	O
LpA	LpA	L100	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
five	five	F100	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
both	both	B300	CC	O	O
exogenous	exogenous	E252	JJ	B-NP	O
radiotracer	radiotracer	R362	NN	I-NP	O
and	and	A530	CC	O	O
endogenous	endogenous	E532	JJ	B-NP	O
stable	stable	S314	JJ	I-NP	O
isotope	isotope	I231	NN	I-NP	O
labeling	labeling	L145	NN	I-NP	O
techniques	technique	T252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mean	mean	M500	JJ	I-NP	O
plasma	plasma	P425	NN	I-NP	O
residence	residence	R235	NN	I-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	O	O
I	I	I000	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
at	at	A300	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

08	08	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

27	27	0000	CD	B-NP	O
d	d	D000	NN	I-NP	O
(	(	0000	(	O	O
controls	control	C536	NNS	B-NP	O
4	4	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
74	74	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
65	65	0000	CD	I-NP	O
days	day	D200	NNS	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
residence	residence	R235	NN	I-NP	O
time	time	T500	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
even	even	E150	RB	B-ADJP	O
shorter	short	S636	JJR	I-ADJP	O
at	at	A300	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

66	66	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

24	24	0000	CD	B-NP	O
d	d	D000	NN	I-NP	O
(	(	0000	(	O	O
controls	control	C536	NNS	B-NP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
25	25	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
61	61	0000	CD	I-NP	O
d	d	D000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
catabolism	catabolism	C314	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
in	in	I500	IN	B-PP	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
substantially	substantially	S123	RB	B-ADJP	O
faster	faster	F236	RBR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
in	in	I500	IN	B-PP	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
summary	summary	S560	NN	B-NP	O
,	,	0000	,	O	O
genetic	genetic	G532	JJ	B-NP	O
syndromes	syndrome	S536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	B-NP	O
complete	complete	C514	JJ	I-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
partial	partial	P634	JJ	I-NP	I-Disease
LCAT	LCAT	L230	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
low	low	L000	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
through	through	T620	IN	B-PP	O
preferential	preferential	P616	JJ	B-NP	O
hypercatabolism	hypercatabolism	H162	NN	I-NP	O
of	of	O100	IN	B-PP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
and	and	A530	CC	O	O
HDL	HDL	H340	NN	B-NP	O
particles	particle	P632	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
apoA	apoA	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
II	II	I000	CD	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	O	O
I	I	I000	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
more	more	M600	RBR	B-ADJP	O
protective	protective	P632	JJ	I-ADJP	O
than	than	T500	IN	B-PP	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
against	against	A252	IN	B-PP	O
atherosclerosis	atherosclerosis	A362	NN	B-NP	B-Disease
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
selective	selective	S423	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
of	of	O100	IN	B-PP	O
LpA	LpA	L100	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
I	I	I000	NN	I-NP	O
A	A	A000	NN	I-NP	O
-	-	0000	HYPH	O	O
II	II	I000	CD	B-NP	O
may	may	M000	MD	B-VP	O
provide	provide	P613	VB	I-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
why	why	W000	WRB	B-ADVP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	B-Disease
LCAT	LCAT	L230	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Fish	Fish	F200	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
at	at	A300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
atherosclerosis	atherosclerosis	A362	NN	I-NP	B-Disease
despite	despite	D213	IN	B-PP	O
markedly	markedly	M623	RB	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
and	and	A530	CC	I-NP	O
apoA	apoA	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
I	I	I000	PRP	B-NP	O

X	X	X000	NN	B-NP	B-Disease
linked	link	L523	VBD	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
Saudi	Saudi	S300	NNP	I-NP	O
Arab	Arab	A610	NNP	I-NP	O
boy	boy	B000	NN	I-NP	O
presented	present	P625	VBN	B-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
childhood	childhood	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
,	,	0000	,	O	O
morphologically	morphologically	M614	RB	B-NP	O
large	large	L620	JJ	I-NP	O
and	and	A530	CC	I-NP	O
normal	normal	N654	JJ	I-NP	O
sized	sized	S230	JJ	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
,	,	0000	,	O	O
increased	increase	I526	VBN	B-NP	O
mean	mean	M500	JJ	I-NP	O
platelet	platelet	P434	NN	I-NP	O
volume	volume	V450	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
hypermegakaryocytic	hypermegakaryocytic	H165	JJ	I-NP	O
bone	bone	B500	NN	I-NP	O
marrow	marrow	M600	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
laboratory	laboratory	L163	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
immunological	immunological	I542	JJ	I-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Similar	Similar	S546	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
brothers	brother	B636	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
strongly	strongly	S365	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
all	all	A400	DT	O	O
suffering	suffer	S165	VBG	B-VP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
linked	link	L523	VBD	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
thrombocytopenic	thrombocytopenic	T651	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
probe	probe	P610	NN	I-NP	O
M27	M27	M000	NN	I-NP	O
beta	beta	B300	NN	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	O
linkage	linkage	L520	NN	I-NP	O
and	and	A530	CC	O	O
indicate	indicate	I532	VBP	B-VP	O
also	also	A420	RB	B-ADVP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
relevant	relevant	R415	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
lies	lie	L200	VBZ	B-VP	O
close	close	C420	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
or	or	O600	CC	O	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
various	various	V620	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
include	include	I524	VBP	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
large	large	L620	JJ	B-NP	O
and	and	A530	CC	I-NP	O
normal	normal	N654	JJ	I-NP	O
sized	sized	S230	JJ	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
(	(	0000	(	O	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
small	small	S540	JJ	B-NP	O
platelets	platelet	P434	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
freedom	freedom	F635	NN	B-NP	O
from	from	F650	IN	B-PP	O
significant	significant	S251	JJ	B-NP	O
immune	immune	I500	JJ	I-NP	B-Disease
deficiencies	deficiency	D125	NNS	I-NP	I-Disease
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
linked	link	L523	VBD	B-VP	I-Disease
recessive	recessive	R210	JJ	B-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	O
entity	entity	E530	NN	I-NP	O
quite	quite	Q300	RB	B-ADJP	O
distinct	distinct	D235	JJ	I-ADJP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
classical	classical	C424	JJ	I-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
modified	modify	M313	VBN	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
producing	produce	P632	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
excluded	exclude	E243	VBN	I-VP	O
entirely	entirely	E536	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Macular	Macular	M246	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
172	172	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
retinal	retinal	R354	JJ	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
slow	slow	S400	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinal	retinal	R354	JJ	I-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
slow	slow	S400	JJ	B-ADJP	O
(	(	0000	(	O	O
rds	rd	R320	NNS	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
which	which	W200	WDT	B-NP	O
codes	cod	C320	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
peripherin	peripherin	P616	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
rds	rd	R320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
retinitis	retinitis	R353	NN	I-NP	I-Disease
pigmentosa	pigmentosa	P253	NN	I-NP	I-Disease
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
rods	rod	R320	NNS	I-NP	O
and	and	A530	CC	I-NP	O
cones	cone	C520	NNS	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
rds	rd	R320	NNS	I-NP	O
gene	gene	G500	NN	I-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
expected	expect	E212	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
degeneration	degeneration	D256	NN	B-NP	O
affecting	affect	A123	VBG	B-VP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
scotopic	scotopic	S231	JJ	I-NP	O
or	or	O600	CC	I-NP	O
photopic	photopic	P312	JJ	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
172	172	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rds	rd	R320	NNS	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominantly	dominantly	D534	RB	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
,	,	0000	,	O	O
progressive	progressive	P626	JJ	B-NP	O
macular	macular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Affected	Affect	A123	VBD	B-VP	O
individuals	individual	I531	NNS	B-NP	O
underwent	undergo	U536	VBD	B-VP	O
ophthalmic	ophthalmic	O134	JJ	B-NP	O
examination	examination	E253	NN	I-NP	O
,	,	0000	,	O	O
scotopic	scotopic	S231	JJ	B-NP	O
perimetry	perimetry	P653	NN	I-NP	O
,	,	0000	,	O	O
dark	dark	D620	JJ	B-NP	O
adaptometry	adaptometry	A313	NN	I-NP	O
,	,	0000	,	O	O
measurement	measurement	M265	NN	B-NP	O
of	of	O100	IN	B-PP	O
color	color	C460	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
contrast	contrast	C536	NN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
electroretinography	electroretinography	E423	NN	B-NP	O
to	to	T000	TO	B-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
photoreceptor	photoreceptor	P362	NN	I-NP	O
dysfunction	dysfunction	D215	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
but	but	B300	IN	B-PP	O
one	one	O500	CD	B-NP	O
affected	affected	A123	JJ	I-NP	O
member	member	M516	NN	I-NP	O
,	,	0000	,	O	O
symptoms	symptom	S513	NNS	B-NP	O
of	of	O100	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
central	central	C536	JJ	I-NP	O
visual	visual	V240	JJ	I-NP	B-Disease
loss	loss	L200	NN	I-NP	I-Disease
developed	develop	D141	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
or	or	O600	CC	I-NP	O
fourth	fourth	F630	JJ	I-NP	O
decade	decade	D230	NN	I-NP	O
of	of	O100	IN	B-PP	O
life	life	L100	NN	B-NP	O
accompanied	accompany	A251	VBN	B-VP	O
by	by	B000	IN	B-PP	O
central	central	C536	JJ	B-NP	B-Disease
scotoma	scotoma	S235	NN	I-NP	I-Disease
and	and	A530	CC	O	O
well	well	W400	RB	B-ADVP	O
-	-	0000	HYPH	I-ADVP	O
demarcated	demarcate	D562	VBN	B-NP	O
atrophy	atrophy	A361	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
pigment	pigment	P253	NN	I-NP	I-Disease
epithelium	epithelium	E134	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
choriocapillaris	choriocapillaris	C621	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
macula	macula	M240	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
general	general	G564	JJ	B-NP	O
,	,	0000	,	I-NP	O
cone	cone	C500	NN	I-NP	O
and	and	A530	CC	I-NP	O
rod	rod	R300	NN	I-NP	O
thresholds	threshold	T624	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
elevated	elevate	E413	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
color	color	C460	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
contrast	contrast	C536	NN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
visual	visual	V240	JJ	I-NP	O
field	field	F430	NN	I-NP	O
.	.	0000	.	O	O

Peripherally	Peripherally	P616	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
scotopic	scotopic	S231	JJ	I-NP	O
sensitivities	sensitivity	S523	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
recovery	recovery	R216	NN	I-NP	O
from	from	F650	IN	B-PP	O
bleach	bleach	B420	NN	B-NP	O
.	.	0000	.	O	O

Cone	Cone	C500	NN	B-NP	O
electroretinograms	electroretinogram	E423	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
diminished	diminish	D523	VBN	I-VP	O
in	in	I500	IN	B-PP	O
amplitude	amplitude	A514	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
delayed	delay	D430	VBN	B-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
adults	adult	A343	NNS	I-NP	O
except	except	E213	IN	B-PP	O
one	one	O500	CD	B-NP	O
.	.	0000	.	O	O

Rod	Rod	R300	NN	B-NP	O
electroretinograms	electroretinogram	E423	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
or	or	O600	CC	O	O
near	near	N600	RB	B-ADJP	O
normal	normal	N654	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
amplitude	amplitude	A514	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
implicit	implicit	I514	JJ	I-NP	O
times	time	T520	NNS	I-NP	O
.	.	0000	.	O	O

Affected	Affect	A123	VBN	B-NP	O
asymptomatic	asymptomatic	A251	JJ	I-NP	O
children	child	C436	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
macular	macular	M246	JJ	B-NP	O
changes	change	C520	NNS	I-NP	O
,	,	0000	,	O	O
abnormal	abnormal	A156	JJ	B-NP	O
color	color	C460	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
contrast	contrast	C536	NN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
reduced	reduce	R323	VBD	B-VP	O
pattern	pattern	P365	NN	B-NP	O
and	and	A530	CC	I-NP	O
cone	cone	C500	NN	I-NP	O
electroretinograms	electroretinogram	E423	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSION	CONCLUSION	C524	NN	B-NP	O
These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
rds	rd	R320	NNS	I-NP	O
gene	gene	G500	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
expressed	express	E216	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
macular	macular	M246	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
evidence	evidence	E135	NN	B-NP	O
of	of	O100	IN	B-PP	O
primary	primary	P656	JJ	B-NP	O
cone	cone	C500	NN	I-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
preservation	preservation	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
rod	rod	R300	NN	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Anonymous	Anonymous	A520	JJ	B-NP	O
marker	marker	M626	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
within	within	W350	IN	B-PP	O
400	400	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
generate	generate	G563	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HFE	HFE	H100	NN	B-NP	O
)	)	0000	)	O	O

The	The	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
HFE	HFE	H100	NN	B-NP	O
)	)	0000	)	O	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
6p21	6p21	P000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
1	1	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
class	class	C420	NN	I-NP	O
I	I	I000	CD	B-NP	O
genes	gene	G520	NNS	I-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
precise	precise	P620	JJ	I-NP	O
physical	physical	P240	JJ	I-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
remained	remain	R530	VBN	I-VP	O
elusive	elusive	E421	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
controversial	controversial	C536	JJ	I-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
unambiguous	unambiguous	U512	JJ	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
crossover	crossover	C621	NN	I-NP	O
event	event	E153	NN	I-NP	O
within	within	W350	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
very	very	V600	RB	B-ADJP	O
difficult	difficult	D124	JJ	I-ADJP	O
;	;	0000	:	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
particularly	particularly	P632	RB	I-VP	O
hampered	hamper	H516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
variability	variability	V614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
and	and	A530	CC	O	O
age	age	A200	NN	B-NP	O
-	-	0000	HYPH	O	O
related	relate	R430	VBN	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
these	these	T200	DT	B-NP	O
practical	practical	P623	JJ	I-NP	O
considerations	consideration	C523	NNS	I-NP	O
,	,	0000	,	O	O
traditional	traditional	T635	JJ	B-NP	O
linkage	linkage	L520	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
could	could	C430	MD	B-VP	O
prove	prove	P610	VB	I-VP	O
of	of	O100	IN	B-PP	O
limited	limited	L530	JJ	B-NP	O
value	value	V400	NN	I-NP	O
in	in	I500	IN	B-PP	O
further	further	F636	RBR	O	O
refining	refine	R152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
extrapolated	extrapolate	E236	VBN	I-NP	O
physical	physical	P240	JJ	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
therefore	therefore	T616	RB	B-ADVP	O
embarked	embark	E516	VBD	B-VP	O
upon	upon	U150	IN	B-PP	O
a	a	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Brittany	Brittany	B635	NNP	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
66	66	0000	CD	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
yielding	yield	Y435	VBG	B-VP	O
151	151	0000	CD	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
and	and	A530	CC	O	O
182	182	0000	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
RFLP	RFLP	R141	NN	B-NP	O
-	-	0000	HYPH	O	O
typed	type	T130	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
battery	battery	B360	NN	I-NP	O
of	of	O100	IN	B-PP	O
probes	probe	P612	NNS	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
two	two	T000	CD	B-NP	O
newly	newly	N400	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
F	F	F000	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
located	located	L230	JJ	B-NP	O
150	150	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
250	250	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
telomeric	telomeric	T456	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
peak	peak	P200	NN	I-NP	O
of	of	O100	IN	B-PP	O
existing	exist	E235	VBG	B-NP	O
linkage	linkage	L520	NN	I-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
focused	focus	F230	VBD	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
i82	i82	I000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	SYM	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
interval	interval	I536	NN	I-NP	O
(	(	0000	(	O	O
approximately	approximately	A162	RB	B-NP	O
250	250	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
zone	zone	Z500	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
flanked	flank	F452	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
i97	i97	I000	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
positioned	position	P235	VBD	B-VP	O
30	30	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
i82	i82	I000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
F	F	F000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
found	find	F530	VBD	B-VP	O
250	250	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
markers	marker	M626	NNS	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
display	display	D214	VBP	B-VP	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
association	association	A235	NN	I-NP	O
with	with	W300	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
HFE	HFE	H100	NN	B-NP	O
resides	reside	R232	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
400	400	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
expanse	expanse	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
between	between	B350	IN	B-PP	O
i97	i97	I000	NN	B-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
F	F	F000	NN	I-NP	O
.	.	0000	.	O	O

Alternatively	Alternatively	A436	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
very	very	V600	RB	I-NP	O
tight	tight	T230	JJ	I-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	O	O
A3	A3	A000	NN	B-NP	O
and	and	A530	CC	O	O
allele	allele	A400	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
comprised	comprise	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
or	or	O600	CC	I-NP	O
founder	founder	F536	NN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
in	in	I500	IN	B-PP	O
Brittany	Brittany	B635	NNP	B-NP	O
,	,	0000	,	O	O
supports	support	S163	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
reside	reside	R230	VB	I-VP	O
immediately	immediately	I534	RB	B-ADJP	O
telomeric	telomeric	T456	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
locus	locus	L200	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
zone	zone	Z500	NN	I-NP	O
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
haplotypes	haplotype	H143	NNS	I-NP	O
possessing	possess	P252	VBG	B-VP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
A11	A11	A000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
frequency	frequency	F625	NN	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
F	F	F000	NN	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
allele	allele	A400	NN	B-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
supportive	supportive	S163	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
separate	separate	S163	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
,	,	0000	,	O	O
independently	independently	I531	RB	B-VP	O
arising	arise	A625	VBG	I-VP	O
mutant	mutant	M353	JJ	B-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
establishment	establishment	E231	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
likely	likely	L240	JJ	I-NP	O
"	"	0000	``	I-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
"	"	0000	``	O	O
centromeric	centromeric	C536	JJ	B-NP	O
boundary	boundary	B536	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
zone	zone	Z500	NN	I-NP	O
both	both	B300	CC	O	O
significantly	significantly	S251	RB	B-VP	O
contribute	contribute	C536	VBP	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
amount	amount	A530	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
required	require	R263	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
coding	coding	C352	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
constituting	constitute	C523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease

Genomic	Genomic	G520	JJ	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
relationship	relationship	R435	NN	I-NP	O
to	to	T000	TO	B-PP	O
EWSR1	EWSR1	E260	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
translocation	translocation	T652	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
location	location	L235	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
22	22	0000	CD	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
11	11	0000	CD	B-NP	O
;	;	0000	:	O	O
22	22	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q24	q24	Q000	NN	B-NP	O
;	;	0000	:	O	O
q12	q12	Q000	NN	B-NP	O
)	)	0000	)	O	O
translocation	translocation	T652	NN	B-NP	O
that	that	T300	WDT	B-NP	O
characterizes	characterize	C623	VBZ	B-VP	O
Ewing	Ewing	E520	NNP	B-NP	B-Disease
sarcoma	sarcoma	S625	NN	I-NP	I-Disease
and	and	A530	CC	O	O
related	related	R430	JJ	B-NP	O
neuroectodermal	neuroectodermal	N623	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
EWS	EWS	E200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
spans	span	S152	NNS	I-NP	O
about	about	A130	IN	B-NP	O
40	40	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
encoded	encode	E523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
17	17	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
7	7	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
encode	encode	E523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
EWS	EWS	E200	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
repeated	repeat	R130	VBN	I-NP	O
degenerated	degenerate	D256	VBD	B-VP	O
polypeptide	polypeptide	P413	NN	B-NP	O
of	of	O100	IN	B-PP	O
7	7	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
12	12	0000	CD	I-NP	O
residues	residue	R232	NNS	I-NP	O
rich	rich	R200	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
tyrosine	tyrosine	T625	NN	B-NP	O
,	,	0000	,	O	O
serine	serine	S650	NN	B-NP	O
,	,	0000	,	O	O
threonine	threonine	T650	NN	B-NP	O
,	,	0000	,	O	O
glycine	glycine	G425	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
glutamine	glutamine	G435	NN	B-NP	O
.	.	0000	.	O	O

Exons	Exon	E252	NNS	B-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
13	13	0000	CD	B-NP	O
encode	encode	E523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
RNA	RNA	R500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
glycine	glycine	G425	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
arginine	arginine	A625	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
motifs	motif	M312	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
mainly	mainly	M540	RB	I-VP	O
encoded	encode	E523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
8	8	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
14	14	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
16	16	0000	CD	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
features	feature	F362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
CpG	CpG	C120	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
island	island	I245	NN	I-NP	O
and	and	A530	CC	O	O
lacks	lack	L200	VBZ	B-VP	O
canonical	canonical	C524	JJ	B-NP	O
promoter	promoter	P653	NN	I-NP	O
elements	element	E453	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
TATA	TATA	T300	NN	B-NP	O
and	and	A530	CC	I-NP	O
CCAAT	CCAAT	C230	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
.	.	0000	.	O	O

Positions	Position	P235	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
22	22	0000	CD	B-NP	O
breakpoints	breakpoint	B621	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
for	for	F600	IN	B-PP	O
19	19	0000	CD	B-NP	O
Ewing	Ewing	E520	NNP	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
localized	localize	L242	VBN	I-VP	O
in	in	I500	IN	B-PP	O
introns	intron	I536	NNS	B-NP	O
7	7	0000	CD	B-NP	O
or	or	O600	CC	I-NP	O
8	8	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
18	18	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
10	10	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
1	1	0000	CD	B-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Norrie	Norrie	N600	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
:	:	0000	:	O	O
characterization	characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
and	and	A530	CC	O	O
possible	possible	P214	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Positional	Positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
experiments	experiment	E216	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
resulted	result	R243	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
pseudoglioma	pseudoglioma	P232	NN	B-NP	B-Disease
;	;	0000	:	O	O
NDP	NDP	N310	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
neurodevelopmental	neurodevelopmental	N631	JJ	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
and	and	A530	CC	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
encompassing	encompass	E525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
spans	span	S152	VBZ	B-VP	O
28	28	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
entirely	entirely	E536	RB	I-VP	O
contained	contain	C535	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Detailed	Detailed	D343	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Norrie	Norrie	N600	NNP	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
shows	show	S200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
heterogeneous	heterogeneous	H362	JJ	B-ADJP	O
,	,	0000	,	O	O
both	both	B300	CC	B-PP	O
in	in	I500	IN	I-PP	O
size	size	S200	NN	B-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
position	position	P235	NN	B-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
confined	confine	C515	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
eye	eye	E000	NN	I-NP	O
or	or	O600	CC	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
extensive	extensive	E235	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	I-NP	O
protein	protein	P635	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
comparison	comparison	C516	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
NDP	NDP	N310	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
related	related	R430	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
database	database	D312	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
homology	homology	H542	NN	B-NP	O
with	with	W300	IN	B-PP	O
cysteine	cysteine	C235	NN	B-NP	O
-	-	0000	HYPH	O	O
rich	rich	R200	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
immediate	immediate	I530	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	HYPH	I-NP	O
early	early	E640	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
implicated	implicate	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
NDP	NDP	N310	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
molecule	molecule	M424	NN	I-NP	O
related	relate	R430	VBN	B-VP	O
in	in	I500	IN	B-PP	O
function	function	F523	NN	B-NP	O
to	to	T000	TO	B-PP	O
these	these	T200	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
and	and	A530	CC	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pathway	pathway	P300	NN	I-NP	O
that	that	T300	WDT	B-NP	O
regulates	regulate	R243	VBZ	B-VP	O
neural	neural	N640	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
differentiation	differentiation	D165	NN	I-NP	O
and	and	A530	CC	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
Huntington	Huntington	H535	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
allele	allele	A400	NN	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
influences	influence	I514	VBZ	B-VP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
evaluated	evaluate	E143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
influenced	influence	I514	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
by	by	B000	IN	B-PP	O
comparing	compare	C516	VBG	B-VP	O
transmission	transmission	T652	NN	B-NP	O
patterns	pattern	P365	NNS	I-NP	O
of	of	O100	IN	B-PP	O
genetically	genetically	G532	RB	B-NP	O
linked	link	L523	VBN	I-NP	O
markers	marker	M626	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
D4S10	D4S10	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
against	against	A252	IN	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
information	information	I516	NN	B-NP	O
from	from	F650	IN	B-PP	O
21	21	0000	CD	B-NP	O
sibships	sibship	S121	NNS	I-NP	O
in	in	I500	IN	B-PP	O
14	14	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
tendency	tendency	T535	NN	I-NP	O
for	for	F600	IN	B-PP	O
sibs	sib	S120	NNS	B-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
similar	similar	S546	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
ages	age	A200	NNS	I-NP	O
to	to	T000	TO	B-VP	O
share	share	S600	VB	I-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
D4S10	D4S10	D200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
.	.	0000	.	O	O

Affected	Affect	A123	VBN	B-NP	O
sibs	sib	S120	NNS	I-NP	O
who	who	W000	WP	B-NP	O
inherited	inherit	I563	VBD	B-VP	O
different	different	D165	JJ	B-NP	O
D4S10	D4S10	D200	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
tended	tend	T530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
more	more	M600	RBR	B-NP	O
variable	variable	V614	JJ	I-NP	O
ages	age	A200	NNS	I-NP	O
at	at	A300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
modulated	modulate	M343	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
HD	HD	H300	NN	I-NP	B-Disease
allele	allele	A400	NN	I-NP	O
or	or	O600	CC	B-PP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
linked	link	L523	VBN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
investigation	investigation	I512	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
frequently	frequently	F625	RB	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
Isles	Isle	I242	NNPS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
study	study	S300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
Tay	Tay	T000	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
causing	cause	C252	VBG	B-VP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
donor	donor	D560	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
carriers	carrier	C620	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
Isles	Isle	I242	NNPS	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
more	more	M600	RBR	B-ADVP	O
frequently	frequently	F625	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Irish	Irish	I620	NNP	B-NP	O
,	,	0000	,	O	O
Scottish	Scottish	S232	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Welsh	Welsh	W420	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
English	English	E524	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
(	(	0000	(	O	O
63	63	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
31	31	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
tested	test	T230	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
blind	blind	B453	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
26	26	0000	CD	B-NP	O
American	American	A562	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
and	and	A530	CC	O	O
28	28	0000	CD	B-NP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
carriers	carrier	C620	NNS	B-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
British	British	B632	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
and	and	A530	CC	I-NP	O
none	none	N500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
controls	control	C536	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
positive	positive	P231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
six	six	S200	CD	I-NP	O
had	have	H300	VBD	B-VP	O
Irish	Irish	I620	JJ	B-NP	O
ancestry	ancestry	A523	NN	I-NP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
20	20	0000	CD	I-NP	O
other	other	O360	JJ	I-NP	O
(	(	0000	(	O	O
intron	intron	I536	NN	B-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
negative	negative	N231	JJ	B-ADJP	O
)	)	0000	)	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
carriers	carrier	C620	NNS	I-NP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
confirm	confirm	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
found	find	F530	VBN	I-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
intron	intron	I536	NN	I-NP	O
9	9	0000	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
British	British	B632	NNP	B-NP	O
Isles	Isles	I242	NNP	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-NP	O
Irish	Irish	I620	JJ	I-NP	O
,	,	0000	,	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
reinforce	reinforce	R516	VB	B-VP	O
the	the	T000	DT	B-NP	O
need	need	N300	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
such	such	S200	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
oncogenic	oncogenic	O525	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
bilateral	bilateral	B436	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
unilateral	unilateral	U543	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
12	12	0000	CD	B-NP	O
human	human	H500	JJ	I-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	B-ADJP	O
by	by	B000	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
technique	technique	T252	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
third	third	T630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
had	have	H300	VBD	B-VP	O
independent	independent	I531	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
neither	neither	N360	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
line	line	L500	NN	I-NP	O
,	,	0000	,	O	O
confirming	confirm	C516	VBG	B-VP	O
their	their	T600	PRP$	B-NP	O
true	true	T600	JJ	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
two	two	T000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
thirds	third	T632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
theory	theory	T600	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
.	.	0000	.	O	O

Point	Point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
C	C	C000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transitions	transition	T652	NNS	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
and	and	A530	CC	O	O
usually	usually	U240	RB	B-VP	O
resulted	result	R243	VBD	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
conversion	conversion	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
.	.	0000	.	O	O

Small	Small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
and	and	A530	CC	O	O
most	most	M230	RBS	B-VP	O
often	often	O135	RB	I-VP	O
created	create	C630	VBN	I-VP	O
a	a	A000	DT	B-NP	O
downstream	downstream	D523	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
.	.	0000	.	O	O

Deletions	Deletion	D435	NNS	B-NP	O
and	and	A530	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
affected	affect	A123	VBD	B-VP	O
splice	splice	S142	NN	B-NP	O
junctions	junction	J523	NNS	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
junctions	junction	J523	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
,	,	0000	,	O	O
supporting	support	S163	VBG	B-VP	O
a	a	A000	DT	B-NP	O
slipped	slip	S413	VBN	I-NP	O
-	-	0000	HYPH	I-NP	O
mispairing	mispaire	M216	VBG	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
.	.	0000	.	O	O

Point	Point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
generally	generally	G564	RB	B-ADVP	O
produced	produce	P632	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
perfect	perfect	P612	JJ	B-NP	O
homology	homology	H542	NN	I-NP	O
with	with	W300	IN	B-PP	O
endogenous	endogenous	E532	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
lay	lie	L000	VBP	B-VP	O
within	within	W350	IN	B-PP	O
14	14	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O

Aniridia	Aniridia	A563	NNP	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
malformation	malformation	M416	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
,	,	0000	,	O	O
chiefly	chiefly	C140	RB	B-VP	O
characterised	characterise	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
iris	iris	I620	NN	B-NP	B-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
blindness	blindness	B453	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
by	by	B000	IN	B-PP	O
positional	positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
smallest	small	S542	JJS	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
overlap	overlap	O164	NN	B-NP	O
of	of	O100	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

Subsequently	Subsequently	S125	RB	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Smalleye	Smalleye	S540	NNP	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
animal	animal	A540	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
six	six	S200	CD	B-NP	O
human	human	H500	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
paper	paper	P160	NN	I-NP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
four	four	F600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-ADJP	O
sporadic	sporadic	S163	JJ	I-ADJP	O
and	and	A530	CC	I-ADJP	O
familial	familial	F540	JJ	I-ADJP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
highlight	highlight	H242	VBP	B-VP	O
regions	region	R252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
at	at	A300	IN	B-PP	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
lesions	lesion	L252	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
will	will	W400	MD	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
arginine	arginine	A625	NN	I-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
by	by	B000	IN	B-PP	O
dideoxy	dideoxy	D320	NN	B-NP	O
fingerprinting	fingerprinting	F526	NN	I-NP	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
familial	familial	F540	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
variable	variable	V614	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
arginine	arginine	A625	NN	B-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
diabetes	diabete	D132	VBZ	B-VP	B-Disease
insipidus	insipidus	I521	NN	B-NP	I-Disease
of	of	O100	IN	B-PP	O
varying	vary	V652	VBG	B-NP	O
severity	severity	S163	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
responds	respond	R215	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
exogenous	exogenous	E252	JJ	B-NP	O
AVP	AVP	A100	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
members	member	M516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
method	method	M300	NN	I-NP	O
,	,	0000	,	O	O
called	call	C430	VBN	B-VP	O
dideoxy	dideoxy	D320	NN	B-NP	O
fingerprinting	fingerprinting	F526	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
an	an	A500	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
found	find	F530	VBN	B-VP	O
changes	change	C520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
codon	codon	C350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
from	from	F650	IN	B-PP	O
alanine	alanine	A450	NN	B-NP	O
to	to	T000	TO	B-PP	O
threonine	threonine	T650	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
should	should	S430	MD	B-VP	O
perturb	perturb	P636	VB	I-VP	O
cleavage	cleavage	C412	NN	B-NP	O
of	of	O100	IN	B-PP	O
mature	mature	M360	JJ	B-NP	O
AVP	AVP	A100	NN	I-NP	O
from	from	F650	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
precursor	precursor	P626	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	O	O
inhibit	inhibit	I513	VBP	B-VP	O
its	its	I320	PRP$	B-NP	O
secretion	secretion	S263	NN	I-NP	O
or	or	O600	CC	I-NP	O
action	action	A235	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Germinal	Germinal	G654	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
:	:	0000	:	O	O
implications	implication	I514	NNS	B-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counselling	counselling	C524	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
three	three	T600	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
generation	generation	G563	NN	I-NP	O
family	family	F540	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
two	two	T000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Immunohistochemical	Immunohistochemical	I523	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
and	and	A530	CC	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
transmitted	transmit	T652	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
grandfather	grandfather	G653	NN	I-NP	O
to	to	T000	TO	B-PP	O
his	his	H200	PRP$	B-NP	O
three	three	T600	CD	I-NP	O
daughters	daughter	D236	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
mother	mother	M360	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
grandfather	grandfather	G653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
germinal	germinal	G654	JJ	I-NP	O
mosaic	mosaic	M200	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
definition	definition	D153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
status	status	S320	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
possible	possible	P214	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
give	give	G100	VB	I-VP	O
accurate	accurate	A263	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
counselling	counselling	C524	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
prevent	prevent	P615	VB	I-VP	O
the	the	T000	DT	B-NP	O
birth	birth	B630	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
boy	boy	B000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
usefulness	usefulness	U214	NN	I-NP	O
of	of	O100	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
immunohistochemical	immunohistochemical	I523	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
hidden	hidden	H350	JJ	B-NP	O
germinal	germinal	G654	JJ	I-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
improve	improve	I516	VB	I-VP	O
genetic	genetic	G532	JJ	B-NP	O
counselling	counselling	C524	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
interval	interval	I536	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
:	:	0000	:	O	O
exclusion	exclusion	E242	NN	B-NP	O
of	of	O100	IN	B-PP	O
candidate	candidate	C530	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
EDH17B2	EDH17B2	E310	NN	I-NP	O
and	and	A530	CC	I-NP	O
RARA	RARA	R600	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
assigned	assign	A253	VBN	I-VP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q21	17q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

Candidate	Candidate	C530	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
include	include	I524	VBP	B-VP	O
EDH17B2	EDH17B2	E310	NN	B-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
estradiol	estradiol	E236	NN	B-NP	O
17	17	0000	CD	I-NP	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
hydroxysteroid	hydroxysteroid	H362	NN	B-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
II	II	I000	CD	I-NP	O
(	(	0000	(	O	O
17	17	0000	CD	B-NP	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
HSD	HSD	H230	NN	B-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
RARA	RARA	R600	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
retinoic	retinoic	R352	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
alpha	alpha	A410	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
typed	type	T130	VBN	I-VP	O
22	22	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17q12	17q12	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
two	two	T000	CD	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
EDH17B2	EDH17B2	E310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
trait	trait	T630	NN	I-NP	O
excludes	exclude	E243	VBZ	B-VP	O
RARA	RARA	R600	NN	B-NP	O
from	from	F650	IN	B-PP	O
further	further	F636	JJ	B-NP	O
consideration	consideration	C523	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
EDH17B2	EDH17B2	E310	NN	I-NP	O
map	map	M100	VBP	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
(	(	0000	(	O	O
between	between	B350	IN	B-PP	O
THRA1	THRA1	T600	NN	B-NP	O
and	and	A530	CC	I-NP	O
D17S579	D17S579	D200	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
recombination	recombination	R251	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
overlapping	overlap	O164	VBG	B-VP	O
PCR	PCR	P260	NN	B-NP	O
products	product	P632	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
EDH17B2	EDH17B2	E310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
affected	affected	A123	JJ	I-NP	O
women	woman	W500	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
uncover	uncover	U521	VB	I-VP	O
any	any	A500	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
variation	variation	V635	NN	I-NP	O
,	,	0000	,	O	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-SBAR	O
previously	previously	P612	RB	B-NP	O
described	describe	D261	VBN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
EDH17B2	EDH17B2	E310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Single	Single	S524	JJ	B-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
crossovers	crossover	C621	NNS	I-NP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
women	woman	W500	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
flanked	flank	F452	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
loci	locus	L200	NNS	I-NP	O
RARA	RARA	R600	NN	I-NP	O
and	and	A530	CC	I-NP	O
D17S78	D17S78	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cholesteryl	cholesteryl	C423	NN	I-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
.	.	0000	.	O	O

Plasma	Plasma	P425	NN	B-NP	O
HDL	HDL	H340	NN	I-NP	O
are	be	A600	VBP	B-VP	O
a	a	A000	DT	B-NP	O
negative	negative	N231	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
for	for	F600	IN	B-PP	O
atherosclerosis	atherosclerosis	A362	NN	B-NP	B-Disease
.	.	0000	.	O	O

Cholesteryl	Cholesteryl	C423	NN	B-NP	O
ester	ester	E236	NN	I-NP	O
transfer	transfer	T652	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
CETP	CETP	C310	NN	B-NP	O
;	;	0000	:	O	O
476	476	0000	CD	B-NP	O
amino	amino	A500	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
)	)	0000	)	O	O
transfers	transfer	T652	VBZ	B-VP	O
cholesteryl	cholesteryl	C423	NN	B-NP	O
ester	ester	E236	NN	I-NP	O
from	from	F650	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
lipoproteins	lipoprotein	L163	NNS	I-NP	O
.	.	0000	.	O	O

Subjects	Subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
CETP	CETP	C310	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
have	have	H100	VBP	B-VP	O
markedly	markedly	M623	RB	I-VP	O
elevated	elevate	E413	VBN	I-VP	O
HDL	HDL	H340	NN	B-NP	O
;	;	0000	:	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
have	have	H100	VBP	B-VP	O
only	only	O540	RB	B-NP	O
mild	mild	M430	JJ	I-NP	O
increases	increase	I526	NNS	I-NP	O
in	in	I500	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
two	two	T000	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
442	442	0000	CD	B-NP	O
D	D	D000	NN	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
,	,	0000	,	O	O
they	they	T000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
threefold	threefold	T614	JJ	B-NP	O
increases	increase	I526	NNS	I-NP	O
in	in	I500	IN	B-PP	O
HDL	HDL	H340	NN	B-NP	O
concentration	concentration	C525	NN	I-NP	O
and	and	A530	CC	O	O
markedly	markedly	M623	RB	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
plasma	plasma	P425	NN	I-NP	O
CETP	CETP	C310	NN	I-NP	O
mass	mass	M200	NN	I-NP	O
and	and	A530	CC	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
dominant	dominant	D530	JJ	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	O
and	and	A530	CC	I-NP	O
HDL	HDL	H340	NN	I-NP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
.	.	0000	.	O	O

Cellular	Cellular	C460	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
secretion	secretion	S263	NN	B-NP	O
of	of	O100	IN	B-PP	O
only	only	O540	RB	B-NP	O
30	30	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
type	type	T100	NN	I-NP	O
CETP	CETP	C310	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
coexpression	coexpression	C216	NN	B-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
type	type	T100	NN	I-NP	O
and	and	A530	CC	O	O
mutant	mutant	M353	JJ	B-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
inhibition	inhibition	I513	NN	B-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
type	type	T100	NN	I-NP	O
secretion	secretion	S263	NN	I-NP	O
and	and	A530	CC	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CETP	CETP	C310	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
during	during	D652	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
explains	explain	E214	VBZ	B-VP	O
why	why	W000	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
markedly	markedly	M623	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
HDL	HDL	H340	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
state	state	S300	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
active	active	A231	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
species	specie	S120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
CETP	CETP	C310	NN	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
multimeric	multimeric	M435	JJ	B-ADJP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
colchicine	colchicine	C425	NN	I-NP	O
era	era	E600	NN	I-NP	O
:	:	0000	:	O	O
the	the	T000	DT	B-NP	O
fate	fate	F300	NN	I-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
demonstrate	demonstrate	D523	VB	I-VP	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
prophylactic	prophylactic	P614	JJ	B-NP	O
colchicine	colchicine	C425	NN	I-NP	O
treatment	treatment	T635	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
natural	natural	N364	JJ	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
Mediterranean	Mediterranean	M365	JJ	I-NP	I-Disease
fever	fever	F160	NN	I-NP	I-Disease
(	(	0000	(	O	O
FMF	FMF	F510	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
presented	present	P625	VBN	I-VP	O
with	with	W300	IN	B-PP	O
6	6	0000	CD	B-NP	O
out	out	O300	IN	I-NP	O
of	of	O100	IN	I-NP	O
9	9	0000	CD	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
by	by	B000	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
represents	represent	R162	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
amyloidotic	amyloidotic	A543	JJ	I-NP	B-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
FMF	FMF	F510	NN	B-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
continuous	continuous	C535	JJ	B-NP	O
colchicine	colchicine	C425	NN	I-NP	O
treatment	treatment	T635	NN	I-NP	O
on	on	O500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
course	course	C620	NN	I-NP	O
.	.	0000	.	O	O

Considered	Consider	C523	VBN	B-VP	O
together	together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
present	present	P625	VBP	B-VP	O
an	an	A500	DT	B-NP	O
almost	almost	A452	RB	I-NP	O
complete	complete	C514	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
,	,	0000	,	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
behavioral	behavioral	B164	JJ	B-NP	O
picture	picture	P236	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
deletion	deletion	D435	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
isolated	isolate	I243	VBN	B-VP	O
by	by	B000	IN	B-PP	O
differential	differential	D165	JJ	B-NP	O
Alu	Alu	A400	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
fingerprint	fingerprint	F526	NN	I-NP	O
cloning	cloning	C452	NN	I-NP	O
.	.	0000	.	O	O

Differential	Differential	D165	JJ	B-NP	O
Alu	Alu	A400	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
fingerprint	fingerprint	F526	NN	I-NP	O
cloning	cloning	C452	NN	I-NP	O
was	be	W200	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
isolate	isolate	I243	VB	I-VP	O
a	a	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Xp11	Xp11	X100	NN	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
p11	p11	P000	NN	I-NP	O
.	.	0000	.	O	O

21	21	0000	CD	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
,	,	0000	,	O	O
cpXr318	cpXr318	C126	NN	B-NP	O
(	(	0000	(	O	O
DXS742	DXS742	D200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
detects	detect	D323	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
submicroscopic	submicroscopic	S152	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
(	(	0000	(	O	O
NDP	NDP	N310	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Combining	Combine	C515	VBG	B-VP	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
consensus	consensus	C525	NN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
map	map	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
the	the	T000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
order	order	O636	NN	I-NP	O
Xcen	Xcen	X250	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS14	DXS14	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS255	DXS255	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DXS426	DXS426	D200	NN	B-NP	O
,	,	0000	,	O	O
TIMP	TIMP	T510	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
DXS742	DXS742	D200	NN	O	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
[	[	0000	(	O	O
MAOB	MAOB	M100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
MAOA	MAOA	M000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
DXS7	DXS7	D200	NN	I-NP	O
]	]	0000	)	O	O
,	,	0000	,	O	O
NDP	NDP	N310	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
DXS77	DXS77	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS228	DXS228	D200	NN	I-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
DXS209	DXS209	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS148	DXS148	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
DXS196	DXS196	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
+	+	0000	SYM	B-NP	O
+	+	0000	SYM	B-VP	O
+	+	0000	SYM	B-NP	O
Xpter	Xpter	X136	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cpXr318	cpXr318	C126	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
subclone	subclone	S124	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
cosmid	cosmid	C253	NN	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
DXS7	DXS7	D200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
converted	convert	C516	VBN	I-VP	O
into	into	I530	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
tagged	tag	T230	VBN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
DXS742	DXS742	D200	NN	B-NP	O
,	,	0000	,	O	O
DSX7	DSX7	D200	NN	B-NP	O
,	,	0000	,	O	O
DXS77	DXS77	D200	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
MAOA	MAOA	M000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
integrated	integrate	I532	VBN	I-VP	O
into	into	I530	IN	B-PP	O
a	a	A000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
map	map	M100	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
Norrie	Norrie	N600	NNP	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O

Putative	Putative	P310	JJ	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
shares	share	S620	VBZ	B-VP	O
unexpected	unexpected	U521	JJ	B-NP	O
homology	homology	H542	NN	I-NP	O
with	with	W300	IN	B-PP	O
ABC	ABC	A120	NNP	B-NP	O
transporters	transporter	T652	NNS	I-NP	O
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
affecting	affect	A123	VBG	B-VP	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
males	male	M420	NNS	I-NP	O
either	either	E360	CC	B-PP	O
as	as	A200	IN	B-PP	O
cerebral	cerebral	C616	JJ	B-NP	B-Disease
ALD	ALD	A430	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
or	or	O600	CC	B-PP	O
as	as	A200	IN	B-PP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
AMN	AMN	A500	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
adults	adult	A343	NNS	B-NP	O
.	.	0000	.	O	O

Childhood	Childhood	C430	NN	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
form	form	F650	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
neurological	neurological	N642	JJ	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
between	between	B350	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

Central	Central	C536	JJ	B-NP	B-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
demyelination	demyelination	D545	NN	I-NP	I-Disease
progresses	progress	P626	VBZ	B-VP	O
rapidly	rapidly	R134	RB	B-ADVP	O
and	and	A530	CC	O	O
death	death	D300	NN	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

AMN	AMN	A500	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
at	at	A300	IN	B-PP	O
15	15	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
more	more	M600	RBR	I-NP	O
progressive	progressive	P626	JJ	I-NP	O
course	course	C620	NN	I-NP	O
.	.	0000	.	O	O

Adrenal	Adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
(	(	0000	(	O	O
Addisons	Addison	A325	NNS	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
)	)	0000	)	O	O
may	may	M000	MD	B-VP	O
remain	remain	R500	VB	I-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	RB	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
principal	principal	P652	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
abnormality	abnormality	A156	NN	I-NP	O
of	of	O100	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
VLCFA	VLCFA	V421	NN	B-NP	O
)	)	0000	)	O	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
impaired	impaired	I516	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
in	in	I500	IN	B-PP	O
peroxisomes	peroxisome	P625	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCFA	VLCFA	V421	NN	B-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
VLCFA	VLCFA	V421	NN	I-NP	O
-	-	0000	HYPH	O	O
CoA	CoA	C000	NN	B-NP	O
synthetase	synthetase	S532	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
use	use	U200	VBP	B-VP	O
positional	positional	P235	JJ	B-NP	O
cloning	cloning	C452	NN	I-NP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
partially	partially	P634	RB	B-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
85	85	0000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
segregated	segregate	S262	VBD	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Candidate	Candidate	C530	NN	B-NP	O
exons	exon	E252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
computer	computer	C513	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
and	and	A530	CC	O	O
used	use	U230	VBN	B-VP	O
to	to	T000	TO	B-VP	O
isolate	isolate	I243	VB	I-VP	O
complementary	complementary	C514	JJ	B-NP	O
DNAs	DNA	D520	NNS	I-NP	O
by	by	B000	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
connection	connection	C523	NN	I-NP	O
and	and	A530	CC	I-NP	O
screening	screening	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
libraries	library	L162	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deduced	deduce	D323	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
significant	significant	S251	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
peroxisomal	peroxisomal	P625	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
M	M	M000	NN	B-NP	O
(	(	0000	(	O	O
r	r	R000	NN	B-NP	O
)	)	0000	)	O	O
70K	70K	K000	NN	B-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
peroxisome	peroxisome	P625	NN	B-NP	O
biogenesis	biogenesis	B252	NN	I-NP	O
and	and	A530	CC	O	O
belongs	belong	B452	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
ATP	ATP	A310	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
cassette	cassette	C230	NN	B-NP	O
superfamily	superfamily	S161	NN	I-NP	O
of	of	O100	IN	B-PP	O
transporters	transporter	T652	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Targeted	Target	T623	VBN	B-NP	O
modification	modification	M312	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
apolipoprotein	apolipoprotein	A141	NN	I-NP	O
B	B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	B-NP	B-Disease
and	and	A530	CC	O	O
developmental	developmental	D141	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
codominant	codominant	C353	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
dramatic	dramatic	D653	JJ	I-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
apolipoprotein	apolipoprotein	A141	NN	B-NP	O
(	(	0000	(	O	O
apo	apo	A100	NN	B-NP	O
)	)	0000	)	O	O
B	B	B000	NN	B-NP	O
,	,	0000	,	O	O
cholesterol	cholesterol	C423	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
beta	beta	B300	SYM	O	O
-	-	0000	HYPH	O	O
migrating	migrate	M263	VBG	B-VP	O
lipoproteins	lipoprotein	L163	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
benefit	benefit	B513	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
mildly	mildly	M434	RB	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
protected	protect	P632	VBN	I-VP	O
from	from	F650	IN	B-PP	O
coronary	coronary	C656	JJ	B-NP	B-Disease
vascular	vascular	V246	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
gene	gene	G500	NN	B-NP	O
targeting	target	T623	VBG	B-VP	O
to	to	T000	TO	I-VP	O
generate	generate	G563	VB	I-VP	O
mice	mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
modified	modify	M313	VBN	I-NP	O
Apob	Apob	A100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
containing	contain	C535	VBG	B-VP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
display	display	D214	VBP	B-VP	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hallmarks	hallmark	H456	NNS	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	B-Disease
they	they	T000	PRP	B-NP	O
produce	produce	P632	VBP	B-VP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
apoB	apoB	A100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
apoB70	apoB70	A100	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
plasma	plasma	P425	NN	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
apoB	apoB	A100	NN	B-NP	O
,	,	0000	,	O	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
lipoproteins	lipoprotein	L163	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
total	total	T340	JJ	B-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
manifest	manifest	M512	VBP	B-VP	O
several	several	S164	JJ	B-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
occasionally	occasionally	O254	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	I-NP	B-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
plasma	plasma	P425	NN	I-NP	O
triglyceride	triglyceride	T624	NN	I-NP	O
concentrations	concentration	C525	NNS	I-NP	O
,	,	0000	,	O	O
fasting	fast	F235	VBG	B-VP	O
chylomicronemia	chylomicronemia	C452	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
reduced	reduce	R323	VBN	B-NP	O
high	high	H200	JJ	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
cholesterol	cholesterol	C423	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
unexpected	unexpected	U521	JJ	I-NP	O
finding	finding	F535	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
modified	modify	M313	VBN	I-NP	O
Apob	Apob	A100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
strongly	strongly	S365	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
exencephalus	exencephalus	E252	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
hydrocephalus	hydrocephalus	H362	NN	I-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
should	should	S430	MD	B-VP	O
help	help	H410	VB	I-VP	O
increase	increase	I526	VB	I-VP	O
our	our	O600	PRP$	B-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypobetalipoproteinemia	hypobetalipoproteinemia	H134	NN	B-NP	B-Disease
,	,	0000	,	O	O
atherogenesis	atherogenesis	A362	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
etiology	etiology	E342	NN	I-NP	O
of	of	O100	IN	B-PP	O
exencephalus	exencephalus	E252	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
hydrocephalus	hydrocephalus	H362	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
with	with	W300	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
mitochondrial	mitochondrial	M325	JJ	B-NP	I-Disease
very	very	V600	RB	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
CoA	CoA	C000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
.	.	0000	.	O	O

Palmitoyl	Palmitoyl	P453	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
CoA	CoA	C000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
skin	skin	S250	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
unidentified	unidentified	U535	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
fatty	fatty	F300	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
was	be	W200	VBD	B-VP	O
measured	measure	M263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
and	and	A530	CC	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
antibodies	antibody	A531	NNS	B-NP	O
against	against	A252	IN	B-PP	O
medium	medium	M350	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
,	,	0000	,	O	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
very	very	V600	RB	B-NP	O
-	-	0000	HYPH	I-NP	O
long	long	L520	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
acyl	acyl	A240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
dehydrogenases	dehydrogenas	D362	NNS	I-NP	O
(	(	0000	(	O	O
VLCAD	VLCAD	V423	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
month	month	M530	NN	I-NP	O
old	old	O430	JJ	I-NP	O
boys	boy	B200	NNS	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
judged	judge	J323	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
of	of	O100	IN	B-PP	O
very	very	V600	RB	B-NP	O
low	low	L000	JJ	I-NP	O
palmitoyl	palmitoyl	P453	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
CoA	CoA	C000	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
immunoreactivity	immunoreactivity	I562	NN	B-NP	O
toward	toward	T630	IN	B-PP	O
antibody	antibody	A531	NN	B-NP	O
raised	raise	R230	VBN	B-VP	O
to	to	T000	TO	B-PP	O
purified	purify	P613	VBN	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Chinese	Chinese	C520	JJ	B-NP	O
descent	descent	D253	NN	I-NP	O
and	and	A530	CC	I-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
new	new	N000	JJ	B-NP	O
base	base	B200	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
G6PD	G6PD	G130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
DNA	DNA	D500	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
glucose	glucose	G420	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
G6PD	G6PD	G130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
Asians	Asian	A252	NNPS	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
extensively	extensively	E235	RB	I-VP	O
investigated	investigate	I512	VBN	I-VP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
fill	fill	F400	VB	I-VP	O
this	this	T200	DT	B-NP	O
gap	gap	G100	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
sequenced	sequence	S252	VBD	B-VP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
43	43	0000	CD	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
Chinese	Chinese	C520	NNPS	I-NP	O
whose	whose	W200	WP$	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
well	well	W400	RB	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
biochemically	biochemically	B252	RB	B-ADVP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
for	for	F600	IN	B-PP	O
sequencing	sequencing	S252	NN	B-NP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
sequencing	sequencing	S252	NN	B-NP	O
procedure	procedure	P623	NN	I-NP	O
.	.	0000	.	O	O

From	From	F650	IN	B-PP	O
these	these	T200	DT	B-NP	O
43	43	0000	CD	I-NP	O
samples	sample	S514	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
five	five	F100	CD	B-NP	O
different	different	D165	JJ	I-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
1388	1388	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
(	(	0000	(	O	O
Arg	Arg	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
His	His	H200	NNP	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
1376	1376	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
Arg	Arg	A620	NN	B-NP	O
to	to	T000	TO	B-PP	O
Leu	Leu	L000	NN	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
1024	1024	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
C	C	C000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
Leu	Leu	L000	NN	B-NP	O
to	to	T000	TO	B-PP	O
Phe	Phe	P000	NN	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
392	392	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
G	G	G000	NN	B-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
(	(	0000	(	O	O
Gly	Gly	G400	NN	B-NP	O
to	to	T000	TO	B-PP	O
Val	Val	V400	NN	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
95	95	0000	CD	I-NP	O
from	from	F650	IN	B-PP	O
A	A	A000	NN	B-NP	O
to	to	T000	TO	B-PP	O
G	G	G000	NN	B-NP	O
(	(	0000	(	O	O
His	His	H200	NN	B-NP	O
to	to	T000	TO	B-PP	O
Arg	Arg	A620	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
five	five	F100	CD	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
over	over	O160	IN	B-NP	O
83	83	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
43	43	0000	CD	I-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
samples	sample	S514	NNS	I-NP	O
and	and	A530	CC	O	O
these	these	T200	DT	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Asians	Asian	A252	NNPS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
392	392	0000	CD	I-NP	O
and	and	A530	CC	O	O
cDNA	cDNA	C350	NN	B-NP	O
1024	1024	0000	CD	I-NP	O
are	be	A600	VBP	B-VP	O
new	new	N000	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
1376	1376	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
1388	1388	0000	CD	I-NP	O
account	account	A253	NN	I-NP	O
for	for	F600	IN	B-PP	O
over	over	O160	IN	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
43	43	0000	CD	I-NP	O
samples	sample	S514	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
indicating	indicate	I532	VBG	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
among	among	A520	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
Chinese	Chinese	C520	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
add	add	A300	VBP	B-VP	O
support	support	S163	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
notion	notion	N350	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
diverse	diverse	D162	JJ	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
account	account	A253	VB	I-VP	O
largely	largely	L624	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
much	much	M200	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Danish	Danish	D520	JJ	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
searched	search	S623	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
choroideremia	choroideremia	C636	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CHM	CHM	C500	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
12	12	0000	CD	B-NP	O
Danish	Danish	D520	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
CHM	CHM	C500	NNP	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
segregating	segregate	S262	VBG	I-VP	O
.	.	0000	.	O	O

Employing	Employ	E514	VBG	B-VP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
single	single	S524	JJ	B-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
(	(	0000	(	O	O
SSCP	SSCP	S210	NN	B-NP	O
)	)	0000	)	O	O
analysis	analysis	A542	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
,	,	0000	,	O	O
different	different	D165	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
interfere	interfere	I536	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
correct	correct	C623	JJ	I-NP	O
translation	translation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
predicting	predict	P632	VBG	B-VP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
or	or	O600	CC	O	O
no	no	N000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
at	at	A300	IN	B-ADVP	O
all	all	A400	DT	I-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Structure	Structure	S362	NN	B-NP	O
and	and	A530	CC	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
located	located	L230	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
putative	putative	P310	JJ	B-NP	O
serine	serine	S650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
threonine	threonine	T650	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
and	and	A530	CC	I-NP	O
murine	murine	M650	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
with	with	W300	IN	B-PP	O
each	each	E200	DT	B-NP	O
other	other	O360	JJ	I-NP	O
and	and	A530	CC	O	O
with	with	W300	IN	B-PP	O
known	know	K500	VBN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
from	from	F650	IN	B-PP	O
both	both	B300	DT	B-NP	O
species	specie	S120	NNS	I-NP	O
,	,	0000	,	O	O
led	lead	L300	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
predict	predict	P632	VB	I-VP	O
a	a	A000	DT	B-NP	O
translation	translation	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
determine	determine	D365	NN	B-VP	O
the	the	T000	DT	B-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
PCR	PCR	P260	NN	B-NP	O
assays	assay	A200	NNS	I-NP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
two	two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
and	and	A530	CC	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
represent	represent	R162	VBP	B-VP	O
an	an	A500	DT	B-NP	O
important	important	I516	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
further	further	F636	JJ	I-NP	O
understanding	understanding	U536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetics	genetic	G532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
biology	biology	B420	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemophilia	hemophilia	H514	NN	B-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
differential	differential	D165	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
bleeding	bleed	B435	VBG	I-NP	I-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
hemophilia	hemophilia	H514	NN	B-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
occasionally	occasionally	O254	RB	I-VP	O
confounded	confound	C515	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
close	close	C420	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
coagulation	coagulation	C243	NN	B-NP	O
factor	factor	F236	NN	I-NP	O
VIII	VIII	V000	CD	B-NP	O
and	and	A530	CC	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
vWF	vWF	V100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
describes	describe	D261	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
hemophilia	hemophilia	H514	NN	I-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
defective	defective	D123	JJ	B-NP	O
factor	factor	F236	NN	I-NP	O
VIII	VIII	V000	CD	I-NP	O
binding	binding	B535	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
factor	factor	F236	NN	B-NP	O
VIII	VIII	V000	CD	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

Polymerase	Polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
amplification	amplification	A514	NN	B-NP	O
and	and	A530	CC	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
were	be	W600	VBD	B-VP	O
employed	employ	E514	VBN	I-VP	O
to	to	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
exons	exon	E252	NNS	B-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
factor	factor	F236	NN	I-NP	O
VIII	VIII	V000	CD	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWF	vWF	V100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
Thr	Thr	T600	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
Met	Met	M300	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
28	28	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
recessive	recessive	R210	JJ	B-ADJP	O
because	because	B200	IN	B-SBAR	O
heterozygous	heterozygous	H362	JJ	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
clinically	clinically	C452	RB	B-ADJP	O
unaffected	unaffected	U512	JJ	I-ADJP	O
.	.	0000	.	O	O

Recombinant	Recombinant	R251	JJ	B-NP	O
vWF	vWF	V100	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
expressed	express	E216	VBN	I-VP	O
in	in	I500	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
vWF	vWF	V100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
processed	process	P623	VBN	I-VP	O
and	and	A530	CC	O	O
secreted	secrete	S263	VBN	B-VP	O
normally	normally	N654	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
functionally	functionally	F523	RB	B-ADJP	O
equivalent	equivalent	E214	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
vWF	vWF	V100	NN	I-NP	O
in	in	I500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
bind	bind	B530	VB	I-VP	O
to	to	T000	TO	B-PP	O
platelets	platelet	P434	NNS	B-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	NN	I-NP	O
failed	fail	F430	VBD	B-VP	O
to	to	T000	TO	I-VP	O
bind	bind	B530	VB	I-VP	O
factor	factor	F236	NN	B-NP	O
VIII	VIII	V000	CD	I-NP	O
,	,	0000	,	O	O
demonstrating	demonstrate	D523	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
functionally	functionally	F523	RB	I-VP	O
related	relate	R430	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
hemophilia	hemophilia	H514	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
recognized	recognize	R252	VBN	I-NP	O
class	class	C420	NN	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
bleeding	bleeding	B435	NN	I-NP	O
disorders	disorder	D263	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
call	call	C400	VBP	B-VP	O
"	"	0000	``	O	O
autosomal	autosomal	A325	JJ	B-NP	O
hemophilia	hemophilia	H514	NN	I-NP	B-Disease
.	.	0000	.	O	O

"	"	0000	``	O	O
We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
vWF	vWF	V100	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	O	O
under	under	U536	IN	B-PP	O
recognized	recognize	R252	VBN	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemophilia	hemophilia	H514	NN	B-NP	B-Disease
,	,	0000	,	O	O
especially	especially	E212	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	O	O
linked	link	L523	VBN	B-NP	O
transmission	transmission	T652	NN	I-NP	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
clear	clear	C460	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
papillary	papillary	P146	JJ	I-NP	B-Disease
cystadenoma	cystadenoma	C235	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
epididymis	epididymis	E135	NN	I-NP	I-Disease
.	.	0000	.	O	O

Papillary	Papillary	P146	JJ	B-NP	B-Disease
cystadenoma	cystadenoma	C235	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
epididymis	epididymis	E135	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
uncommon	uncommon	U525	JJ	I-NP	O
benign	benign	B525	JJ	I-NP	O
lesion	lesion	L250	NN	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
sporadically	sporadically	S163	RB	B-ADVP	O
or	or	O600	CC	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
disease	disease	D200	NN	B-NP	I-Disease
.	.	0000	.	O	O

Neither	Neither	N360	DT	B-NP	O
immunohistochemical	immunohistochemical	I523	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
nor	nor	N600	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
lesion	lesion	L250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
describe	describe	D261	VBP	B-VP	O
two	two	T000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
clear	clear	C460	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
papillary	papillary	P146	JJ	I-NP	B-Disease
cystadenoma	cystadenoma	C235	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
epididymis	epididymis	E135	NN	I-NP	I-Disease
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
initially	initially	I534	RB	I-VP	O
confused	confuse	C512	VBN	I-VP	O
with	with	W300	IN	B-PP	O
metastatic	metastatic	M323	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
lesions	lesion	L252	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
positive	positive	P231	JJ	B-NP	O
immunohistochemical	immunohistochemical	I523	JJ	I-NP	O
staining	staining	S352	NN	I-NP	O
for	for	F600	IN	B-PP	O
low	low	L000	JJ	B-NP	O
and	and	A530	CC	I-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
weight	weight	W230	NN	I-NP	O
keratins	keratin	K635	NNS	I-NP	O
(	(	0000	(	O	O
Cam	Cam	C500	NN	B-NP	O
5	5	0000	CD	I-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	O	O
AE1	AE1	A000	NN	B-NP	O
/	/	0000	SYM	B-NP	O
AE3	AE3	A000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
EMA	EMA	E500	NN	B-NP	O
,	,	0000	,	O	O
vimentin	vimentin	V535	NN	B-NP	O
,	,	0000	,	O	O
alpha	alpha	A410	SYM	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	B-VP	O
antitrypsin	antitrypsin	A536	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
alpha	alpha	A410	SYM	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
antichymotrypsin	antichymotrypsin	A532	NN	I-NP	O
.	.	0000	.	O	O

Each	Each	E200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
negative	negative	N231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
CEA	CEA	C000	NN	B-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
clear	clear	C460	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
papillary	papillary	P146	JJ	I-NP	B-Disease
cystadenoma	cystadenoma	C235	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
histologically	histologically	H234	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
because	because	B200	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
occur	occur	O260	VBP	B-VP	O
as	as	A200	IN	B-PP	O
components	component	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
complex	complex	C514	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
authors	author	A362	NNS	I-NP	O
analyzed	analyze	A542	VBD	B-VP	O
both	both	B300	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
cytosine	cytosine	C325	NN	I-NP	O
to	to	T000	TO	B-PP	O
thymine	thymine	T500	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
694	694	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
replacement	replacement	R142	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
sixth	sixth	S230	JJ	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
believed	believe	B413	VBN	I-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
VHL	VHL	V400	NN	B-NP	B-Disease
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
initiation	initiation	I535	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumorigenesis	tumorigenesis	T562	NN	B-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
cystadenomas	cystadenoma	C235	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
epididymis	epididymis	E135	NN	I-NP	I-Disease
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
isolated	isolate	I243	VBN	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
reveals	reveal	R142	VBZ	B-VP	O
allelic	allelic	A420	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
isolated	isolate	I243	VBN	I-NP	O
WASP	WASP	W210	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
Wiskott	Wiskott	W230	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
primary	primary	P656	JJ	I-NP	O
immunodeficiency	immunodeficiency	I531	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variability	variability	V614	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
SSCP	SSCP	S210	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
for	for	F600	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
19	19	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
boys	boy	B200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
or	or	O600	CC	O	O
attenuated	attenuate	A353	VBD	B-VP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
or	or	O600	CC	O	O
isolated	isolate	I243	VBN	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
19	19	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
WASP	WASP	W210	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
localized	localize	L242	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
three	three	T600	CD	I-NP	O
or	or	O600	CC	I-NP	O
terminal	terminal	T654	JJ	I-NP	O
three	three	T600	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
unique	unique	U520	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
case	case	C200	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
arginine	arginine	A625	NN	I-NP	O
at	at	A300	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
codon	codon	C350	NN	I-NP	O
86	86	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
boys	boy	B200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
boy	boy	B000	NN	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
thrombocytopenia	thrombocytopenia	T651	NN	B-NP	B-Disease
alone	alone	A450	RB	B-ADVP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
isolated	isolate	I243	VBN	I-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
leave	leave	L100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
reading	reading	R352	NN	I-NP	O
frame	frame	F650	NN	I-NP	O
intact	intact	I532	JJ	B-ADJP	O
,	,	0000	,	O	O
about	about	A130	RB	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
severe	severe	S160	JJ	I-NP	O
and	and	A530	CC	O	O
attenuated	attenuate	A353	VBD	B-VP	O
WAS	WAS	W200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
frameshifted	frameshifte	F652	VBN	B-NP	O
transcript	transcript	T652	NN	I-NP	O
and	and	A530	CC	O	O
premature	premature	P653	JJ	B-NP	O
translation	translation	T652	NN	I-NP	O
termination	termination	T653	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
therefore	therefore	T616	RB	B-ADVP	O
confirm	confirm	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
identify	identify	I353	VB	B-VP	O
WASP	WASP	W210	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
for	for	F600	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
mild	mild	M430	JJ	I-NP	O
presentations	presentation	P625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
do	do	D000	VBP	B-VP	O
not	not	N300	RB	I-VP	O
appear	appear	A160	VB	I-VP	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
WASP	WASP	W210	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
valuable	valuable	V414	JJ	I-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
distinguishing	distinguish	D235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
males	male	M420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
represent	represent	R162	VBP	B-VP	O
mild	mild	M430	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

WASP	WASP	W210	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Wiskott	Wiskott	W230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
recently	recently	R253	RB	I-VP	O
cloned	clone	C453	VBN	I-VP	O
from	from	F650	IN	B-PP	O
Xp11	Xp11	X100	NN	B-NP	O
.	.	0000	.	O	O

23	23	0000	CD	B-NP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Wiskott	Wiskott	W230	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Aldrich	Aldrich	A436	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WAS	WAS	W200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
developed	develop	D141	VBN	I-VP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
protocol	protocol	P632	NN	I-NP	O
for	for	F600	IN	B-PP	O
identifying	identify	I353	VBG	B-VP	O
WASP	WASP	W210	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
in	in	I500	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
,	,	0000	,	I-NP	O
nonsense	nonsense	N525	NN	I-NP	O
and	and	A530	CC	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
involve	involve	I514	VBP	B-VP	O
eight	eight	E230	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
12	12	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
creating	create	C635	VBG	B-VP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
lack	lack	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
detectable	detectable	D323	JJ	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
on	on	O500	IN	B-PP	O
Northern	Northern	N636	NN	B-NP	O
blots	blot	B432	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
Leu27Phe	Leu27Phe	L100	NN	B-NP	O
,	,	0000	,	O	O
Thr48Ile	Thr48Ile	T640	NN	B-NP	O
,	,	0000	,	O	O
Val75Met	Val75Met	V453	NN	B-NP	O
and	and	A530	CC	I-NP	O
Arg477Lys	Arg477Lys	A624	NN	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
and	and	A530	CC	O	O
no	no	N000	DT	B-NP	O
clinically	clinically	C452	RB	I-NP	O
evident	evident	E135	JJ	I-NP	O
immune	immune	I500	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
WASP	WASP	W210	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
site	site	S300	NN	I-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-NP	I-Disease
thrombocytopenia	thrombocytopenia	T651	NN	I-NP	I-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
WAS	WAS	W200	NNP	B-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
WAS	WAS	W200	NN	I-NP	B-Disease
patient	patient	P353	NN	I-NP	O
contained	contain	C535	VBD	B-VP	O
two	two	T000	CD	B-NP	O
independent	independent	I531	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
also	also	A420	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
leukocytes	leukocyte	L232	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
compensatory	compensatory	C515	JJ	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
valuable	valuable	V414	JJ	B-NP	O
information	information	I516	NN	I-NP	O
on	on	O500	IN	B-PP	O
amino	amino	A500	NN	B-NP	O
acids	acid	A232	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
function	function	F523	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
sites	site	S320	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
two	two	T000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
hot	hot	H300	JJ	B-ADJP	O
-	-	0000	HYPH	B-NP	O
spots	spot	S132	NNS	I-NP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
inter	inter	I536	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
generational	generational	G563	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
conserved	conserve	C526	VBN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
flanking	flank	F452	VBG	B-VP	O
markers	marker	M626	NNS	B-NP	O
amongst	amongst	A523	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CAG	CAG	C200	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
array	array	A600	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
microsatellite	microsatellite	M262	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
five	five	F100	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
observations	observation	O126	NNS	I-NP	O
.	.	0000	.	O	O

First	First	F623	RB	B-ADVP	O
,	,	0000	,	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
fo	fo	F000	VBP	B-VP	O
the	the	T000	DT	B-NP	O
array	array	A600	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
to	to	T000	TO	B-PP	O
68	68	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
84	84	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expansions	expansion	E215	NNS	B-NP	O
intermediate	intermediate	I536	VBP	B-VP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
between	between	B350	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
affected	affect	A123	VBN	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

Second	Second	S253	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
displays	display	D214	VBZ	B-VP	O
inter	inter	I536	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
generational	generational	G563	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenomenon	phenomenon	P500	NN	I-NP	O
of	of	O100	IN	B-PP	O
anticipation	anticipation	A532	NN	B-NP	O
.	.	0000	.	O	O

Third	Third	T630	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	B-VP	O
only	only	O540	RB	I-VP	O
inversely	inversely	I516	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
(	(	0000	(	O	O
r	r	R000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
738	738	0000	CD	I-NP	O
,	,	0000	,	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
[	[	0000	(	O	O
e	e	E000	NN	B-NP	O
.	.	0000	.	O	O
g	g	G000	NN	B-NP	O
.	.	0000	.	I-NP	O
pseudoexophthalmos	pseudoexophthalmo	P232	NNS	I-NP	O
and	and	A530	CC	O	O
pyramidal	pyramidal	P653	JJ	B-NP	O
signs	sign	S252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
large	large	L620	JJ	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
and	and	A530	CC	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
05	05	0000	CD	I-NP	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
]	]	0000	)	O	O
.	.	0000	.	O	O

Fourth	Fourth	F630	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
(	(	0000	(	O	O
16	16	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
contrasts	contrast	C536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
could	could	C430	MD	B-VP	O
exert	exert	E263	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
effect	effect	E123	NN	I-NP	O
either	either	E360	CC	B-PP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
(	(	0000	(	O	O
putatively	putatively	P314	RB	B-VP	O
excluded	exclude	E243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
or	or	O600	CC	O	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
gain	gain	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
effect	effect	E123	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
proposed	propose	P612	VBN	B-VP	O
for	for	F600	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
share	share	S600	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
uncommon	uncommon	U525	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
which	which	W200	WDT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
either	either	E360	CC	B-PP	O
of	of	O100	IN	B-PP	O
common	common	C500	JJ	B-NP	O
founders	founder	F536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
or	or	O600	CC	B-PP	O
of	of	O100	IN	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
pathologic	pathologic	P342	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
inter	inter	I536	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
generational	generational	G563	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
conserved	conserve	C526	VBN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
flanking	flank	F452	VBG	B-VP	O
markers	marker	M626	NNS	B-NP	O
amongst	amongst	A523	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CAG	CAG	C200	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
array	array	A600	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
'	'	0000	SYM	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
microsatellite	microsatellite	M262	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
five	five	F100	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
observations	observation	O126	NNS	I-NP	O
.	.	0000	.	O	O

First	First	F623	RB	B-ADVP	O
,	,	0000	,	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
fo	fo	F000	VBP	B-VP	O
the	the	T000	DT	B-NP	O
array	array	A600	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
14	14	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
to	to	T000	TO	B-PP	O
68	68	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
84	84	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
no	no	N000	DT	B-NP	O
subjects	subject	S123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expansions	expansion	E215	NNS	B-NP	O
intermediate	intermediate	I536	VBP	B-VP	O
in	in	I500	IN	B-PP	O
size	size	S200	NN	B-NP	O
between	between	B350	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
MJD	MJD	M230	NN	I-NP	B-Disease
affected	affect	A123	VBN	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

Second	Second	S253	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
displays	display	D214	VBZ	B-VP	O
inter	inter	I536	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
generational	generational	G563	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
male	male	M400	JJ	B-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
this	this	T200	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenomenon	phenomenon	P500	NN	I-NP	O
of	of	O100	IN	B-PP	O
anticipation	anticipation	A532	NN	B-NP	O
.	.	0000	.	O	O

Third	Third	T630	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	B-VP	O
only	only	O540	RB	I-VP	O
inversely	inversely	I516	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
(	(	0000	(	O	O
r	r	R000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
738	738	0000	CD	I-NP	O
,	,	0000	,	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
[	[	0000	(	O	O
e	e	E000	NN	B-NP	O
.	.	0000	.	O	O
g	g	G000	NN	B-NP	O
.	.	0000	.	I-NP	O
pseudoexophthalmos	pseudoexophthalmo	P232	NNS	I-NP	O
and	and	A530	CC	O	O
pyramidal	pyramidal	P653	JJ	B-NP	O
signs	sign	S252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
frequent	frequent	F625	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
large	large	L620	JJ	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
(	(	0000	(	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
001	001	0000	CD	I-NP	O
and	and	A530	CC	O	O
p	p	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
05	05	0000	CD	I-NP	O
respectively	respectively	R212	RB	B-ADVP	O
)	)	0000	)	O	O
]	]	0000	)	O	O
.	.	0000	.	O	O

Fourth	Fourth	F630	NNP	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
significantly	significantly	S251	RB	B-ADJP	O
more	more	M600	RBR	I-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
and	and	A530	CC	O	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
(	(	0000	(	O	O
16	16	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subject	subject	S123	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
contrasts	contrast	C536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
could	could	C430	MD	B-VP	O
exert	exert	E263	VB	I-VP	O
its	its	I320	PRP$	B-NP	O
effect	effect	E123	NN	I-NP	O
either	either	E360	CC	B-PP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
negative	negative	N231	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
(	(	0000	(	O	O
putatively	putatively	P314	RB	B-VP	O
excluded	exclude	E243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
or	or	O600	CC	O	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
gain	gain	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
effect	effect	E123	NN	I-NP	O
as	as	A200	IN	B-SBAR	O
proposed	propose	P612	VBN	B-VP	O
for	for	F600	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

Finally	Finally	F540	RB	B-ADVP	O
,	,	0000	,	O	O
Japanese	Japanese	J152	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
MJD	MJD	M230	NN	B-NP	B-Disease
share	share	S600	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
uncommon	uncommon	U525	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
which	which	W200	WDT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
either	either	E360	CC	B-PP	O
of	of	O100	IN	B-PP	O
common	common	C500	JJ	B-NP	O
founders	founder	F536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
or	or	O600	CC	B-PP	O
of	of	O100	IN	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
pathologic	pathologic	P342	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CAG	CAG	C200	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
MJD1	MJD1	M230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
megabase	megabase	M212	NN	I-NP	O
YAC	YAC	Y200	NN	I-NP	O
contig	contig	C532	NN	I-NP	O
that	that	T300	WDT	B-NP	O
spans	span	S152	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
Langer	Langer	L526	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8q24	8q24	Q000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
:	:	0000	:	O	O
use	use	U200	NN	B-NP	O
in	in	I500	IN	B-PP	O
refining	refine	R152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
trichorhinophalangeal	trichorhinophalangeal	T626	JJ	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
multiple	multiple	M431	JJ	B-NP	O
exostoses	exostosis	E232	NNS	I-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
TRPS1	TRPS1	T612	NN	B-NP	O
and	and	A530	CC	O	O
EXT1	EXT1	E230	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
constructed	construct	C523	VBN	I-VP	O
a	a	A000	DT	B-NP	O
physical	physical	P240	JJ	I-NP	O
map	map	M100	NN	I-NP	O
covering	cover	C165	VBG	B-VP	O
over	over	O160	IN	B-NP	O
4	4	0000	CD	I-NP	O
Mb	Mb	M100	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8q24	8q24	Q000	CD	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
and	and	A530	CC	O	O
used	use	U230	VBN	B-VP	O
this	this	T200	DT	B-NP	O
map	map	M100	NN	I-NP	O
to	to	T000	TO	B-VP	O
refine	refine	R150	VB	I-VP	O
the	the	T000	DT	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Langer	Langer	L526	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
composed	compose	C512	VBN	I-VP	O
of	of	O100	IN	B-PP	O
overlapping	overlap	O164	VBG	B-VP	O
YAC	YAC	Y200	NN	B-NP	O
clones	clone	C452	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	O	O
ordered	order	O636	VBN	B-VP	O
in	in	I500	IN	B-PP	O
relation	relation	R435	NN	B-NP	O
to	to	T000	TO	B-VP	O
sequence	sequence	S252	VB	I-VP	O
tagged	tag	T230	VBN	B-NP	O
sites	site	S320	NNS	I-NP	O
mapped	map	M130	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
Langer	Langer	L526	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
Giedion	Giedion	G350	NN	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
hybrids	hybrid	H163	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
overlap	overlap	O164	NN	B-NP	O
of	of	O100	IN	B-PP	O
Langer	Langer	L526	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
previously	previously	P612	RB	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
placed	place	P423	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
map	map	M100	NN	I-NP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
whose	whose	W200	WP$	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
define	define	D150	VBP	B-VP	O
the	the	T000	DT	B-NP	O
endpoints	endpoint	E531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
8	8	0000	CD	I-NP	O
breakpoint	breakpoint	B621	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
balanced	balanced	B452	JJ	I-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
8	8	0000	CD	B-NP	O
;	;	0000	:	O	O
9	9	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
q24	q24	Q000	NN	B-NP	O
.	.	0000	.	B-NP	O
11	11	0000	CD	I-NP	O
;	;	0000	:	O	O
q33	q33	Q000	CD	B-NP	O
.	.	0000	.	O	O
3	3	0000	CD	O	O
)	)	0000	)	O	O
translocation	translocation	T652	NN	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
trichorhinophalangeal	trichorhinophalangeal	T626	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
TRPS	TRPS	T612	NN	B-NP	B-Disease
I	I	I000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
located	locate	L230	VBN	I-VP	O
just	just	J230	RB	B-ADVP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
8q24	8q24	Q000	CD	B-NP	O
.	.	0000	.	O	O

11	11	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q24	q24	Q000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
exostoses	exostosis	E232	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
overlap	overlap	O164	VB	I-VP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LGS	LGS	L200	NN	I-NP	B-Disease
deletion	deletion	D435	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
EXT1	EXT1	E230	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
distal	distal	D234	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
TRPS1	TRPS1	T612	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
supporting	support	S163	VBG	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
Langer	Langer	L526	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Giedion	Giedion	G350	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
functional	functional	F523	JJ	B-NP	O
copies	copy	C120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
TRPS1	TRPS1	T612	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
EXT1	EXT1	E230	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
sample	sample	S514	NN	I-NP	O
of	of	O100	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
little	little	L340	JJ	B-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
contribution	contribution	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
enrolled	enrol	E564	VBN	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
and	and	A530	CC	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
80	80	0000	CD	B-NP	O
women	woman	W500	NNS	I-NP	O
in	in	I500	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
before	before	B160	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
35	35	0000	CD	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
who	who	W000	WP	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
selected	select	S423	VBN	I-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
family	family	F540	NN	B-NP	O
history	history	H236	NN	I-NP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
by	by	B000	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
involving	involve	I514	VBG	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
and	and	A530	CC	B-PP	O
with	with	W300	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
.	.	0000	.	O	O

Alterations	Alteration	A436	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
defined	define	D153	VBN	I-VP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
80	80	0000	CD	I-NP	O
women	woman	W500	NNS	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
rare	rare	R600	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
functional	functional	F523	JJ	I-NP	O
importance	importance	I516	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
39	39	0000	CD	I-NP	O
women	woman	W500	NNS	I-NP	O
who	who	W000	WP	B-NP	O
reported	report	R163	VBD	B-VP	O
no	no	N000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

None	None	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
variants	variant	V653	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
reference	reference	R165	NN	I-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
73	73	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
.	.	0000	.	O	O

Alterations	Alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
10	10	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
harboring	harbor	H616	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
women	woman	W500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
family	family	F540	NN	B-NP	O
histories	history	H236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
a	a	A000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
estimate	estimate	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Comprehensive	Comprehensive	C516	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
identifying	identify	I353	VBG	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
understanding	understand	U536	VBG	B-VP	O
their	their	T600	PRP$	B-NP	O
importance	importance	I516	NN	I-NP	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
needed	need	N300	VBN	I-VP	O
before	before	B160	IN	B-PP	O
testing	testing	T235	NN	B-NP	O
of	of	O100	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
undertaken	undertake	U536	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Novel	Novel	N140	JJ	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
variable	variable	V614	JJ	B-NP	O
expressivity	expressivity	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
185delAG	185delAG	D420	NN	I-NP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Thirty	Thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
seven	seven	S150	CD	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
four	four	F600	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
or	or	O600	CC	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Twelve	Twelve	T410	CD	B-NP	O
different	different	D165	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
and	and	A530	CC	I-NP	O
eight	eight	E230	CD	I-NP	O
previously	previously	P612	RB	B-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
descent	descent	D253	NNP	I-NP	O
carried	carry	C630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
shared	share	S630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
at	at	A300	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
spanning	span	S152	VBG	B-VP	O
approximately	approximately	A162	RB	B-NP	O
850	850	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
at	at	A300	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Expressivity	Expressivity	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
185delAG	185delAG	D420	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
varied	vary	V630	VBD	B-VP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
4184delTCAA	4184delTCAA	D432	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
independently	independently	I531	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
penetrance	penetrance	P536	NN	B-NP	O
was	be	W200	VBD	B-VP	O
complete	complete	C514	JJ	B-ADJP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
females	female	F542	NNS	B-NP	O
developing	develop	D141	VBG	B-VP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
or	or	O600	CC	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
male	male	M400	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
developing	develop	D141	VBG	B-VP	O
prostatic	prostatic	P623	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
penetrance	penetrance	P536	NN	B-NP	O
was	be	W200	VBD	B-VP	O
incomplete	incomplete	I525	JJ	B-NP	O
and	and	A530	CC	I-NP	O
only	only	O540	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
occurred	occur	O263	VBD	B-VP	O
,	,	0000	,	O	O
diagnosed	diagnose	D252	VBN	B-VP	O
at	at	A300	IN	B-PP	O
ages	age	A200	NNS	B-NP	O
38	38	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
81	81	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
10	10	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
6	6	0000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
665	665	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
nt	nt	N300	NN	I-NP	O
segment	segment	S253	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
and	and	A530	CC	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
were	be	W600	VBD	B-VP	O
invariant	invariant	I516	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
13	13	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
without	without	W300	IN	B-PP	O
coding	cod	C352	VBG	B-VP	O
-	-	0000	HYPH	B-NP	O
sequence	sequence	S252	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
series	series	S620	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
26	26	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
16	16	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
positive	positive	P231	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
,	,	0000	,	O	O
7	7	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
negative	negative	N231	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
(	(	0000	(	O	O
reflecting	reflect	R142	VBG	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
3	3	0000	CD	B-NP	O
not	not	N300	RB	B-VP	O
tested	test	T230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
other	other	O360	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
positive	positive	P231	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
13	13	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
without	without	W300	IN	B-PP	O
detected	detect	D323	VBN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
negative	negative	N231	JJ	B-NP	O
lod	lod	L300	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
glucose	glucose	G420	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
dehydrogenase	dehydrogenase	D362	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Orissa	Orissa	O620	NNP	I-NP	O
(	(	0000	(	O	O
44	44	0000	CD	B-NP	O
Ala	Ala	A400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Gly	Gly	G400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
tribal	tribal	T614	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
in	in	I500	IN	B-PP	O
India	India	I530	NNP	B-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
glucose	glucose	G420	NN	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
6	6	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
phosphate	phosphate	P213	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	O
G6PD	G6PD	G130	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
usually	usually	U240	RB	I-VP	O
found	find	F530	VBN	I-VP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
in	in	I500	IN	B-PP	O
areas	area	A620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
world	world	W643	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
malaria	malaria	M460	NN	B-NP	B-Disease
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
endemic	endemic	E535	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Africa	Africa	A162	NNP	B-NP	O
,	,	0000	,	O	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
Mediterranean	Mediterranean	M365	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Far	Far	F600	NNP	I-NP	O
East	East	E230	NNP	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
little	little	L340	JJ	B-NP	O
such	such	S200	JJ	I-NP	O
information	information	I516	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
available	available	A141	JJ	B-ADJP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
situation	situation	S350	NN	I-NP	O
in	in	I500	IN	B-PP	O
India	India	I530	NNP	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
extent	extent	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterogeneity	heterogeneity	H362	NN	B-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
several	several	S164	JJ	B-NP	O
different	different	D165	JJ	I-NP	O
Indian	Indian	I535	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
by	by	B000	IN	B-PP	O
screening	screen	S265	VBG	B-VP	O
for	for	F600	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
varies	vary	V620	VBZ	B-VP	O
between	between	B350	IN	B-NP	O
3	3	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	I-NP	O
15	15	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tribal	tribal	T614	JJ	I-NP	O
and	and	A530	CC	I-NP	O
urban	urban	U615	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

Remarkably	Remarkably	R562	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
unreported	unreported	U561	JJ	I-NP	O
deficient	deficient	D125	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
,	,	0000	,	O	O
G6PD	G6PD	G130	NN	B-NP	O
Orissa	Orissa	O620	NNP	I-NP	O
(	(	0000	(	O	O
44	44	0000	CD	B-NP	O
Ala	Ala	A400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Gly	Gly	G400	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
tribal	tribal	T614	JJ	B-NP	O
Indian	Indian	I535	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
urban	urban	U615	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
G6PD	G6PD	G130	NN	I-NP	O
Mediterranean	Mediterranean	M365	NN	I-NP	O
(	(	0000	(	O	O
188	188	0000	CD	B-NP	O
Ser	Ser	S600	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Phe	Phe	P000	NN	I-NP	O
)	)	0000	)	O	O
variant	variant	V653	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
KmNADP	KmNADP	K531	NN	I-NP	O
of	of	O100	IN	B-PP	O
G6PD	G6PD	G130	NN	B-NP	O
Orissa	Orissa	O620	NNP	I-NP	O
is	be	I200	VBZ	B-VP	O
fivefold	fivefold	F143	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
alanine	alanine	A450	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
replaced	replace	R142	VBN	I-VP	O
by	by	B000	IN	B-PP	O
glycine	glycine	G425	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
coenzyme	coenzyme	C525	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
bipolar	bipolar	B146	JJ	B-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
18	18	0000	CD	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
origin	origin	O625	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
18	18	0000	CD	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
origin	origin	O625	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
suggested	suggest	S230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
bipolar	bipolar	B146	JJ	B-NP	B-Disease
affective	affective	A123	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
(	(	0000	(	O	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
28	28	0000	CD	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
selected	select	S423	VBN	B-VP	O
for	for	F600	IN	B-PP	O
apparent	apparent	A165	JJ	B-NP	O
unilineal	unilineal	U545	JJ	I-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BPAD	BPAD	B130	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
31	31	0000	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
spanning	span	S152	VBG	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
18	18	0000	CD	I-NP	O
.	.	0000	.	O	O

Evidence	Evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
was	be	W200	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
-	-	0000	HYPH	I-NP	O
sib	sib	S100	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
pair	pair	P600	NN	I-NP	O
and	and	A530	CC	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
methods	method	M320	NNS	I-NP	O
under	under	U536	IN	B-PP	O
two	two	T000	CD	B-NP	O
definitions	definition	D153	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
-	-	0000	HYPH	I-NP	O
sibpair	sibpair	S160	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
excess	excess	E200	JJ	B-NP	O
allele	allele	A400	NN	I-NP	O
sharing	share	S652	VBG	B-VP	O
for	for	F600	IN	B-PP	O
markers	marker	M626	NNS	B-NP	O
on	on	O500	IN	B-PP	O
18p	18p	P000	NN	B-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
reported	report	R163	VBN	B-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
greatest	great	G632	JJS	I-NP	O
sharing	sharing	S652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
at	at	A300	IN	B-PP	O
D18S37	D18S37	D200	NN	B-NP	O
64	64	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
bipolar	bipolar	B146	JJ	B-NP	O
and	and	A530	CC	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
unipolar	unipolar	U514	JJ	I-NP	O
(	(	0000	(	O	O
RUP	RUP	R100	NN	B-NP	O
)	)	0000	)	O	O
sib	sib	S100	NN	B-NP	O
pairs	pair	P620	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
0006	0006	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
excess	excess	E200	JJ	B-NP	O
sharing	sharing	S652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternally	paternally	P365	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
maternally	maternally	M365	RB	B-ADVP	O
,	,	0000	,	O	O
transmitted	transmit	T652	VBN	B-NP	O
alleles	allele	A420	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-PP	O
three	three	T600	CD	B-NP	O
markers	marker	M626	NNS	I-NP	O
on	on	O500	IN	B-PP	O
18q	18q	Q000	NN	B-NP	O
at	at	A300	IN	B-PP	O
D18S41	D18S41	D200	NN	B-NP	O
,	,	0000	,	O	O
51	51	0000	CD	B-NP	O
bipolar	bipolar	B146	JJ	I-NP	O
and	and	A530	CC	I-NP	O
RUP	RUP	R100	NN	I-NP	O
sib	sib	S100	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
concordant	concordant	C526	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
paternally	paternally	P365	RB	B-NP	O
transmitted	transmit	T652	VBN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
21	21	0000	CD	B-NP	O
pairs	pair	P620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
discordant	discordant	D263	JJ	B-ADJP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0004	0004	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
loci	locus	L200	NNS	B-NP	O
on	on	O500	IN	B-PP	O
both	both	B300	CC	O	O
18p	18p	P000	NN	B-NP	O
and	and	A530	CC	I-NP	O
18q	18q	Q000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
strongest	strong	S365	JJS	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
11	11	0000	CD	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	O	O

e	e	E000	NN	B-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	NN	I-NP	O
,	,	0000	,	O	O
those	those	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
or	or	O600	CC	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fathers	father	F362	NNS	I-NP	O
sibs	sib	S120	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
affected	affect	A123	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
greatest	great	G632	JJS	I-NP	O
allele	allele	A400	NN	I-NP	O
sharing	share	S652	VBG	B-VP	O
(	(	0000	(	O	O
81	81	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
;	;	0000	:	O	O
P	P	P000	NN	B-NP	O
=	=	0000	JJ	B-NP	O
.	.	0000	.	I-NP	O
00002	00002	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
51	51	0000	CD	I-NP	O
;	;	0000	:	O	O
phi	phi	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-PP	O
D18S41	D18S41	D200	NN	B-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
support	support	S163	NN	I-NP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
of	of	O100	IN	B-PP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
18	18	0000	CD	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
parent	parent	P653	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
origin	origin	O625	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
operating	operate	O163	VBG	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
loci	locus	L200	NNS	B-NP	O
involved	involve	I514	VBN	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
precise	precise	P620	JJ	I-NP	O
location	location	L235	NN	I-NP	O
,	,	0000	,	O	O
require	require	R260	VB	B-VP	O
further	far	F636	JJR	B-NP	O
study	study	S300	NN	I-NP	O

A	A	A000	DT	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
for	for	F600	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
black	black	B420	JJ	B-NP	O
Americans	American	A562	NNPS	I-NP	O
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
causing	cause	C252	VBG	B-VP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
black	black	B420	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
who	who	W000	WP	B-NP	O
have	have	H100	VBP	B-VP	O
no	no	N000	DT	B-NP	O
galactose	galactose	G423	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
(	(	0000	(	O	O
GALT	GALT	G430	NN	B-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
in	in	I500	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
but	but	B300	CC	O	O
good	good	G300	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
We	We	W000	PRP	B-NP	O
discovered	discover	D216	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
T	T	T000	NN	I-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
base	base	B200	NN	B-NP	O
-	-	0000	HYPH	O	O
pair	pair	P600	NN	B-NP	O
1158	1158	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
serine	serine	S650	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
leucine	leucine	L250	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
135	135	0000	CD	I-NP	O
(	(	0000	(	O	O
S135L	S135L	S400	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
developed	develop	D141	VBD	B-VP	O
a	a	A000	DT	B-NP	O
method	method	M300	NN	I-NP	O
with	with	W300	IN	B-PP	O
which	which	W200	WDT	B-NP	O
to	to	T000	TO	B-VP	O
screen	screen	S265	VB	I-VP	O
populations	population	P143	NNS	B-NP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
galactose	galactose	G423	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
phosphate	phosphate	P213	NN	I-NP	O
uridyltransferase	uridyltransferase	U634	NN	I-NP	O
among	among	A520	IN	B-PP	O
erythrocytes	erythrocyte	E636	NNS	B-NP	O
,	,	0000	,	O	O
leukocytes	leukocyte	L232	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
transformed	transform	T652	VBN	B-NP	O
lymphoblasts	lymphoblast	L514	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
total	total	T340	JJ	B-NP	O
body	body	B300	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
of	of	O100	IN	B-PP	O
D	D	D000	NN	B-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
13C	13C	C000	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
galactose	galactose	G423	NN	I-NP	O
to	to	T000	TO	B-PP	O
13CO2	13CO2	C000	NN	B-NP	O
among	among	A520	IN	B-PP	O
three	three	T600	CD	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
for	for	F600	IN	B-PP	O
GALT	GALT	G430	NN	B-NP	O
(	(	0000	(	O	O
S135L	S135L	S400	NN	B-NP	O
/	/	0000	SYM	O	O
S135L	S135L	S400	NN	B-NP	O
,	,	0000	,	O	O
Q188R	Q188R	Q600	NN	B-NP	O
/	/	0000	SYM	I-NP	O
Q188R	Q188R	Q600	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Normal	Normal	N654	JJ	B-NP	O
/	/	0000	SYM	I-NP	O
Normal	Normal	N654	JJ	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
a	a	A000	DT	B-NP	O
48	48	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
S135L	S135L	S400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
among	among	A520	IN	B-PP	O
17	17	0000	CD	B-NP	O
black	black	B420	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
classic	classic	C420	JJ	B-NP	B-Disease
galactosemia	galactosemia	G423	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
black	black	B420	JJ	I-NP	O
Americans	American	A562	NNPS	I-NP	O
without	without	W300	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
S135L	S135L	S400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
84	84	0000	CD	B-NP	O
white	white	W300	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
G	G	G000	NN	B-NP	O
/	/	0000	SYM	O	O
G	G	G000	NN	B-NP	O
galactosemia	galactosemia	G423	NN	I-NP	B-Disease
nor	nor	N600	CC	B-PP	O
in	in	I500	IN	B-PP	O
87	87	0000	CD	B-NP	O
white	white	W300	JJ	I-NP	O
control	control	C536	NN	I-NP	O
subjects	subject	S123	NNS	I-NP	O
without	without	W300	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
whole	whole	W400	JJ	I-NP	O
body	body	B300	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
of	of	O100	IN	B-PP	O
D	D	D000	NN	B-NP	O
-	-	0000	HYPH	O	O
(	(	0000	(	O	O
13C	13C	C000	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
galactose	galactose	G423	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
S135L	S135L	S400	NN	B-NP	O
and	and	A530	CC	O	O
various	various	V620	JJ	B-NP	O
degrees	degree	D262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
enzyme	enzyme	E525	NN	B-NP	O
impairment	impairment	I516	NN	I-NP	O
among	among	A520	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
S135L	S135L	S400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALT	GALT	G430	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
galactosemia	galactosemia	G423	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
black	black	B420	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
GALT	GALT	G430	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
varies	vary	V620	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
S135L	S135L	S400	NN	B-NP	O
,	,	0000	,	O	O
they	they	T000	PRP	B-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
better	good	B360	JJR	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
than	than	T500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
who	who	W000	WP	B-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
Q188R	Q188R	Q600	NN	B-NP	O
when	when	W500	WRB	B-ADVP	O
both	both	B300	DT	B-NP	O
are	be	A600	VBP	B-VP	O
treated	treat	T630	VBN	I-VP	O
from	from	F650	IN	B-PP	O
infancy	infancy	I515	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
20	20	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
20	20	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
show	show	S000	VBP	B-VP	O
positive	positive	P231	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
17q12	17q12	Q000	CD	I-NP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
cosegregating	cosegregate	C262	VBG	B-VP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
1	1	0000	CD	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
generate	generate	G563	VB	I-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
truncated	truncate	T652	VBN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
88	88	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expected	expect	E212	VBN	I-NP	O
normal	normal	N654	JJ	I-NP	O
length	length	L523	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
altered	alter	A436	VBD	B-VP	O
the	the	T000	DT	B-NP	O
RING	RING	R520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Sequencing	Sequencing	S252	NN	B-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cDNA	cDNA	C350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
an	an	A500	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
or	or	O600	CC	I-NP	O
missing	missing	M252	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
8	8	0000	CD	I-NP	O
remaining	remaining	R520	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
reduced	reduce	R323	VBN	I-NP	O
quantity	quantity	Q530	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
transcript	transcript	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
unable	unable	U514	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
20	20	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
only	only	O540	RB	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
was	be	W200	VBD	B-VP	O
clearly	clearly	C464	RB	I-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
expected	expect	E212	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
clear	clear	C460	JJ	B-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Brca1	Brca1	B620	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	B-Disease
lethality	lethality	L343	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
neuroepithelial	neuroepithelial	N613	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
cloned	clone	C453	VBN	I-VP	O
and	and	A530	CC	O	O
shown	show	S500	VBN	B-VP	O
to	to	T000	TO	I-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
finger	finger	F526	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
some	some	S500	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
familial	familial	F540	JJ	I-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
in	in	I500	IN	B-PP	O
tumours	tumour	T562	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
carrying	carry	C652	VBG	B-VP	O
one	one	O500	CD	B-NP	O
nonfunctional	nonfunctional	N515	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
inhibit	inhibit	I513	VB	I-VP	O
the	the	T000	DT	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
of	of	O100	IN	B-PP	O
mammary	mammary	M560	JJ	B-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
examine	examine	E250	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
and	and	A530	CC	O	O
differentiation	differentiation	D165	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
generate	generate	G563	VB	I-VP	O
a	a	A000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
function	function	F523	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
created	create	C630	VBN	I-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
line	line	L500	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
Brca1	Brca1	B620	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Brca1	Brca1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
critical	critical	C632	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
development	development	D141	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
died	die	D300	VBD	B-VP	O
in	in	I500	IN	B-PP	O
utero	utero	U360	NN	B-NP	O
between	between	B350	IN	B-PP	O
10	10	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
13	13	0000	CD	I-NP	O
days	day	D200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
gestation	gestation	G235	NN	B-NP	O
(	(	0000	(	O	O
E10	E10	E000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
E13	E13	E000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Abnormalities	Abnormality	A156	NNS	B-NP	O
in	in	I500	IN	B-PP	O
Brca1	Brca1	B620	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
embryos	embryo	E516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
most	most	M230	RBS	B-ADJP	O
evident	evident	E135	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
neural	neural	N640	JJ	I-NP	O
tube	tube	T100	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
varying	vary	V652	VBG	B-NP	O
degrees	degree	D262	NNS	I-NP	O
of	of	O100	IN	B-PP	O
spina	spina	S150	NN	B-NP	B-Disease
bifida	bifida	B130	NN	I-NP	I-Disease
and	and	A530	CC	O	O
anencephaly	anencephaly	A521	RB	B-ADVP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
neuroepithelium	neuroepithelium	N613	NN	I-NP	O
in	in	I500	IN	B-PP	O
Brca1	Brca1	B620	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
embryos	embryo	E516	NNS	I-NP	O
appeared	appear	A163	VBD	B-VP	O
disorganized	disorganize	D262	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
rapid	rapid	R130	JJ	B-NP	O
proliferation	proliferation	P641	NN	I-NP	O
and	and	A530	CC	O	O
excessive	excessive	E210	JJ	B-NP	O
cell	cell	C400	NN	I-NP	O
death	death	D300	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	O
-	-	0000	HYPH	O	O
gene	gene	G500	NN	B-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
/	/	0000	SYM	I-NP	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	I-NP	B-Disease
.	.	0000	.	O	O

Adrenoleukodystrophy	Adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
X	X	X000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
inherited	inherit	I563	VBN	B-VP	I-Disease
metabolic	metabolic	M314	JJ	B-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
inborn	inborn	I516	JJ	I-NP	B-Disease
peroxisomal	peroxisomal	P625	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
demyelination	demyelination	D545	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
central	central	C536	JJ	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
peripheral	peripheral	P616	JJ	I-NP	I-Disease
nervous	nervous	N612	JJ	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
.	.	0000	.	O	O

Defective	Defective	D123	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
of	of	O100	IN	B-PP	O
saturated	saturate	S363	VBN	B-NP	O
very	very	V600	RB	I-NP	O
long	long	L520	JJ	I-NP	O
chain	chain	C500	NN	I-NP	O
fatty	fatty	F300	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
VLCFAs	VLCFA	V421	NNS	B-NP	O
;	;	0000	:	O	O
C22	C22	C000	NN	B-NP	O
0	0	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
C26	C26	C000	NN	I-NP	O
0	0	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
peroxisomes	peroxisome	P625	NNS	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCFAs	VLCFA	V421	NNS	B-NP	O
in	in	I500	IN	B-PP	O
leukoid	leukoid	L230	JJ	B-NP	O
areas	area	A620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
peripheral	peripheral	P616	JJ	B-NP	O
nerves	nerve	N612	NNS	I-NP	O
,	,	0000	,	O	O
adrenal	adrenal	A365	JJ	B-NP	O
gland	gland	G453	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
blood	blood	B430	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
recently	recently	R253	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
745	745	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acid	acid	A230	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
adrenomyeloneuropathy	adrenomyeloneuropathy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	O
AMN	AMN	A500	NN	I-NP	B-Disease
)	)	0000	)	O	O
from	from	F650	IN	B-PP	O
20	20	0000	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Eleven	Eleven	E415	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
five	five	F100	CD	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
insertion	insertion	I526	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
reverse	reverse	R162	JJ	I-NP	O
transcribed	transcribe	T652	VBN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
gene	gene	G500	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
de	de	D000	FW	B-NP	O
novo	novo	N100	FW	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
confirmed	confirm	C516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
by	by	B000	IN	B-PP	O
sequencing	sequence	S252	VBG	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
persons	person	P625	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
homolog	homolog	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11D	11D	D000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
cloned	clone	C453	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17q21	17q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
murine	murine	M650	JJ	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
clones	clone	C452	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
Brca1	Brca1	B620	NN	B-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
generating	generate	G563	VBG	B-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
library	library	L160	NN	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
probes	probe	P612	NNS	B-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
overlapping	overlap	O164	VBG	I-NP	O
mouse	mouse	M200	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
hybridized	hybridize	H163	VBD	B-VP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
exons	exon	E252	NNS	I-NP	O
9	9	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	O	O

Sequence	Sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
clones	clone	C452	NNS	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
exon	exon	E250	NN	I-NP	O
11	11	0000	CD	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
72	72	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
nucleic	nucleic	N242	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
but	but	B300	CC	O	O
only	only	O540	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
longest	long	L523	JJS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
clones	clone	C452	NNS	I-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11D	11D	D000	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
determined	determine	D365	VBN	B-VP	O
by	by	B000	IN	B-PP	O
two	two	T000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
color	color	C460	NN	I-NP	O
fluorescence	fluorescence	F462	NN	I-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
synteny	synteny	S535	NN	I-NP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17	17	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cohybridization	cohybridization	C163	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
probe	probe	P610	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
NF1	NF1	N100	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
comparative	comparative	C516	JJ	I-NP	O
study	study	S300	NN	I-NP	O
confirms	confirm	C516	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
between	between	B350	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
and	and	A530	CC	I-NP	O
humans	human	H520	NNS	I-NP	O
.	.	0000	.	O	O

Atelosteogenesis	Atelosteogenesis	A342	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
sulfate	sulfate	S413	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DTDST	DTDST	D323	NN	B-NP	O
)	)	0000	)	O	O
:	:	0000	:	O	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
series	series	S620	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
three	three	T600	CD	B-NP	O
chondrodysplasias	chondrodysplasia	C536	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Atelosteogenesis	Atelosteogenesis	A342	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
II	II	I000	CD	I-NP	I-Disease
(	(	0000	(	O	O
AO	AO	A000	NN	B-NP	B-Disease
II	II	I000	CD	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
neonatally	neonatally	N534	RB	I-NP	O
lethal	lethal	L340	JJ	I-NP	O
chondrodysplasia	chondrodysplasia	C536	NN	I-NP	B-Disease
whose	whose	W200	WP$	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
histological	histological	H234	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
resemble	resemble	R251	VBP	B-VP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
chondrodysplasia	chondrodysplasia	C536	NN	I-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
much	much	M200	RB	I-NP	O
less	less	L200	RBR	B-NP	O
severe	severe	S160	JJ	I-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
(	(	0000	(	O	O
DTD	DTD	D300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
similarity	similarity	S546	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
shared	shared	S630	JJ	I-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
lesions	lesion	L252	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
and	and	A530	CC	O	O
perhaps	perhaps	P612	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

DTD	DTD	D300	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
identified	identify	I353	VBN	I-NP	O
diastrophic	diastrophic	D236	JJ	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
sulfate	sulfate	S413	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DTDST	DTDST	D323	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
AOII	AOII	A000	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
have	have	H100	VBP	B-VP	O
DTDST	DTDST	D323	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
defective	defective	D123	JJ	B-NP	O
uptake	uptake	U132	NN	I-NP	O
of	of	O100	IN	B-PP	O
inorganic	inorganic	I562	JJ	B-NP	O
sulfate	sulfate	S413	NN	I-NP	O
and	and	A530	CC	O	O
insufficient	insufficient	I521	JJ	B-NP	O
sulfation	sulfation	S413	NN	I-NP	O
of	of	O100	IN	B-PP	O
macromolecules	macromolecule	M265	NNS	B-NP	O
by	by	B000	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
mesenchymal	mesenchymal	M252	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	FW	B-ADVP	O
vitro	vitro	V360	FW	I-ADVP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
recent	recent	R253	JJ	I-NP	O
observation	observation	O126	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
third	third	T630	JJ	I-NP	O
even	even	E150	RB	I-NP	O
more	more	M600	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
chondrodysplasia	chondrodysplasia	C536	NN	I-NP	B-Disease
,	,	0000	,	O	O
achondrogenesis	achondrogenesis	A253	NN	B-NP	O
type	type	T100	NN	I-NP	O
IB	IB	I100	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
DTDST	DTDST	D323	NN	B-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
chondrodysplasias	chondrodysplasia	C536	NNS	I-NP	B-Disease
of	of	O100	IN	B-PP	O
increasing	increase	I526	VBG	B-NP	O
severity	severity	S163	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
lesions	lesion	L252	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
transporter	transporter	T652	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
residual	residual	R234	JJ	I-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DTDST	DTDST	D323	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
and	and	A530	CC	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
61	61	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
:	:	0000	:	O	O
results	result	R243	NNS	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
international	international	I536	JJ	I-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
geographically	geographically	G261	RB	B-NP	O
diverse	diverse	D162	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
mutation	mutation	M350	NN	B-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	I-NP	O
mutation	mutation	M350	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
constructed	construct	C523	VBD	B-VP	O
a	a	A000	DT	B-NP	O
haplotype	haplotype	H143	NN	I-NP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
within	within	W350	IN	B-PP	O
or	or	O600	CC	O	O
immediately	immediately	I534	RB	B-VP	O
flanking	flank	F452	VBG	I-VP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
61	61	0000	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
selected	select	S423	VBN	B-VP	O
for	for	F600	IN	B-PP	O
having	have	H152	VBG	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Tests	Test	T232	NNS	B-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	I-NP	O
family	family	F540	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	O	O
significant	significant	S251	JJ	B-ADJP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
comparison	comparison	C516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
proportions	proportion	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
suggestive	suggestive	S231	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
069	069	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
57	57	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
presumed	presume	P625	VBN	B-VP	O
affected	affect	A123	VBD	B-VP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
1294	1294	0000	CD	I-NP	O
del	del	D400	NN	I-NP	O
40	40	0000	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
having	have	H152	VBG	B-VP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
individual	individual	I531	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
arisen	arise	A625	VBN	I-VP	O
9	9	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
170	170	0000	CD	I-NP	O
generations	generation	G563	NNS	I-NP	O
ago	ago	A200	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
general	general	G564	JJ	B-ADJP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
conservation	conservation	C526	NN	I-NP	O
across	across	A262	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
haplotype	haplotype	H143	NN	B-NP	O
differences	difference	D165	NNS	I-NP	O
most	most	M230	RBS	B-ADVP	O
often	often	O135	RB	I-ADVP	O
due	due	D000	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
tandem	tandem	T535	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
repeat	repeat	R130	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
likely	likely	L240	JJ	I-NP	O
instances	instance	I523	NNS	I-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
also	also	A420	RB	B-ADVP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
several	several	S164	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
instances	instance	I523	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
,	,	0000	,	I-NP	O
independent	independent	I531	JJ	I-NP	O
,	,	0000	,	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutational	mutational	M354	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
.	.	0000	.	O	O

Isolation	Isolation	I243	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
to	to	T000	TO	B-PP	O
mouse	mouse	M200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
large	large	L620	JJ	B-NP	O
part	part	P630	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
human	human	H500	JJ	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
genomic	genomic	G520	JJ	B-NP	O
P1	P1	P000	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contain	contain	C535	VBP	B-VP	O
most	most	M230	JJS	B-NP	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
not	not	N300	RB	B-NP	O
all	all	A400	DT	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-NP	O
coding	coding	C352	NN	I-NP	O
regions	region	R252	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
75	75	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
level	level	L140	NN	I-NP	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
identity	identity	I353	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
only	only	O540	RB	B-NP	O
58	58	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Brca1	Brca1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
and	and	A530	CC	O	O
used	use	U230	VBN	B-VP	O
to	to	T000	TO	B-VP	O
map	map	M100	VB	I-VP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	I-NP	O
Mus	Mus	M200	NNP	I-NP	O
m	m	M000	NN	I-NP	O
.	.	0000	.	O	O
musculus	musculus	M242	CC	O	O
Czech	Czech	C200	JJ	B-NP	O
II	II	I000	CD	I-NP	O
x	x	X000	SYM	I-NP	O
C57BL	C57BL	C140	NN	I-NP	O
/	/	0000	SYM	B-NP	O
KsJ	KsJ	K200	NN	I-NP	O
)	)	0000	)	O	O
F1	F1	F000	NN	B-NP	O
x	x	X000	SYM	B-NP	O
C57BL	C57BL	C140	NN	I-NP	O
/	/	0000	SYM	B-NP	O
KsJ	KsJ	K200	NN	I-NP	O
intersubspecific	intersubspecific	I536	JJ	I-NP	O
backcross	backcross	B262	NN	I-NP	O
to	to	T000	TO	B-PP	O
distal	distal	D234	JJ	B-NP	O
mouse	mouse	M200	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
highly	highly	H240	RB	B-ADJP	O
syntenic	syntenic	S535	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
17	17	0000	CD	I-NP	O
,	,	0000	,	O	O
coupled	couple	C143	VBN	B-VP	O
with	with	W300	IN	B-PP	O
Southern	Southern	S365	JJ	B-NP	O
and	and	A530	CC	I-NP	O
Northern	Northern	N636	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
,	,	0000	,	O	O
confirms	confirm	C516	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
we	we	W000	PRP	B-NP	O
isolated	isolate	I243	VBD	B-VP	O
the	the	T000	DT	B-NP	O
murine	murine	M650	JJ	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
rather	rather	R360	RB	B-CONJP	O
than	than	T500	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
related	related	R430	JJ	I-NP	O
RING	RING	R520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
isolation	isolation	I243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
Brca1	Brca1	B620	NN	I-NP	O
homologue	homologue	H542	NN	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
creation	creation	C635	NN	I-NP	O
of	of	O100	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
models	model	M342	NNS	I-NP	O
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Emerin	Emerin	E565	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
STA	STA	S300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
Xq28	Xq28	X200	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
Emery	Emery	E560	NNP	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
hitherto	hitherto	H363	RB	I-NP	O
unknown	unknown	U525	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
named	name	N530	VBN	B-VP	O
emerin	emerin	E565	NN	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
elucidate	elucidate	E423	VB	I-VP	O
the	the	T000	DT	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
raised	raise	R230	VBD	B-VP	O
two	two	T000	CD	B-NP	O
antisera	antiserum	A532	NNS	I-NP	O
against	against	A252	IN	B-PP	O
synthetic	synthetic	S532	JJ	B-NP	O
peptide	peptide	P130	NN	I-NP	O
fragments	fragment	F625	NNS	I-NP	O
predicted	predict	P632	VBN	B-VP	O
from	from	F650	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
both	both	B300	DT	B-NP	O
antisera	antiserum	A532	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
positive	positive	P231	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
staining	staining	S352	NN	I-NP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
,	,	0000	,	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
and	and	A530	CC	I-NP	O
smooth	smooth	S530	JJ	I-NP	O
muscles	muscle	M242	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
neuromuscular	neuromuscular	N652	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
in	in	I500	IN	B-PP	O
immunofluorescent	immunofluorescent	I514	JJ	B-NP	O
staining	staining	S352	NN	I-NP	O
of	of	O100	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
and	and	A530	CC	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
from	from	F650	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
34	34	0000	CD	I-NP	O
kD	kD	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
immunoreactive	immunoreactive	I562	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
antisera	antisera	A532	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	HYPH	I-NP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
equivalent	equivalent	E214	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
predicted	predict	P632	VBN	B-VP	O
for	for	F600	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
emerin	emerin	E565	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
muscle	muscle	M240	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Growth	Growth	G630	NN	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
and	and	A530	CC	O	O
tumour	tumour	T560	NN	B-NP	B-Disease
inhibition	inhibition	I513	NN	I-NP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
predispose	predispose	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
been	be	B500	VBN	I-VP	O
elusive	elusive	E421	JJ	B-ADJP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
retroviral	retroviral	R361	JJ	B-NP	O
transfer	transfer	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
inhibits	inhibit	I513	VBZ	B-VP	O
growth	growth	G630	NN	B-NP	O
in	in	I500	FW	B-PP	O
vitro	vitro	V360	FW	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
tested	test	T230	VBN	B-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
colon	colon	C450	NN	B-NP	B-Disease
or	or	O600	CC	O	I-Disease
lung	lung	L520	NN	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
or	or	O600	CC	O	O
fibroblasts	fibroblast	F161	NNS	B-NP	O
.	.	0000	.	O	O

Mutant	Mutant	M353	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
growth	growth	G630	NN	B-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
;	;	0000	:	O	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
portion	portion	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
inhibited	inhibit	I513	VBN	I-VP	O
by	by	B000	IN	B-PP	O
3	3	0000	CD	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Development	Development	D141	NN	B-NP	O
of	of	O100	IN	B-PP	O
MCF	MCF	M210	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
7	7	0000	CD	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
nude	nude	N300	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
inhibited	inhibit	I513	VBN	I-VP	O
when	when	W500	WRB	B-ADVP	O
MCF	MCF	M210	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
7	7	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
transfected	transfecte	T652	VBN	I-VP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
,	,	0000	,	B-NP	O
but	but	B300	CC	I-NP	O
not	not	N300	RB	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
,	,	0000	,	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
.	.	0000	.	O	O

Most	Most	M230	RBS	B-ADVP	O
importantly	importantly	I516	RB	I-ADVP	O
,	,	0000	,	O	O
among	among	A520	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
established	establish	E231	VBN	B-NP	O
MCF	MCF	M210	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
7	7	0000	CD	B-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
peritoneal	peritoneal	P635	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
retroviral	retroviral	R361	JJ	I-NP	O
vector	vector	V236	NN	I-NP	O
expressing	express	E216	VBG	B-VP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
significantly	significantly	S251	RB	B-VP	O
inhibits	inhibit	I513	VBZ	I-VP	O
tumour	tumour	T560	NN	B-NP	B-Disease
growth	growth	G630	NN	I-NP	O
and	and	A530	CC	O	O
increased	increase	I526	VBN	B-NP	O
survival	survival	S614	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

